<SEC-DOCUMENT>0001171843-16-008207.txt : 20160226
<SEC-HEADER>0001171843-16-008207.hdr.sgml : 20160226
<ACCEPTANCE-DATETIME>20160226162039
ACCESSION NUMBER:		0001171843-16-008207
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20151231
FILED AS OF DATE:		20160226
DATE AS OF CHANGE:		20160226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		161462146

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k_022616p.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML><HEAD>
     <TITLE></TITLE>
</HEAD>


<BODY STYLE="font: 10pt Times New Roman, Times, Serif">






<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>UNITED STATES</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Washington,&nbsp;D.C. 20549</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">________________________</p>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Form 10-K</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">________________________</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>



<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%; padding-right: 0.8pt; font-size: 10pt"><font style="font-size: 10pt">&#9746;</font></td>
    <td style="width: 96%; padding-right: 0.8pt; font-size: 10pt"><font style="font-size: 10pt"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>For the fiscal year ended December&nbsp;31, 2015</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>OR</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%; padding-right: 0.8pt; font-size: 10pt"><font style="font-size: 10pt">&#9744;</font></td>
    <td style="width: 96%; padding-right: 0.8pt; font-size: 10pt"><font style="font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Commission File Number 000-23186</b> &nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">________________________</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Exact name of registrant as specified in its charter)</b> </p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">________________________</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>



<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 47%; padding-right: 0.8pt; font-size: 10pt">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%; padding-right: 0.8pt; font-size: 10pt">&nbsp;</td>
    <td style="width: 52%; padding-right: 0.8pt; font-size: 10pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center; font-size: 10pt"><font style="font-size: 10pt"><b>DELAWARE</b></font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; font-size: 10pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center; font-size: 10pt"><font style="font-size: 10pt"><b>62-1413174</b></font></td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 1.6pt 0pt 0"><b>(State of other jurisdiction of</b></p>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 1.6pt 0pt 0"><b>incorporation or organization)</b></p></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; font-size: 10pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 1.6pt 0pt 0"><b>(I.R.S. employer</b></p>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 1.6pt 0pt 0"><b>identification no.)</b></p></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>4505 Emperor Blvd., Suite&nbsp;200, Durham, North Carolina 27703</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Address of principal executive offices)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(919)&nbsp;859-1302</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Registrant&#8217;s telephone number, including area code)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Securities registered pursuant to Section&nbsp;12(b) of the Act:</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 47%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 52%; padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 0.8pt; text-decoration: underline; text-align: center"><font style="font-size: 10pt"><b><u>Title of Each Class</u></b></font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-decoration: underline; text-align: center"><font style="font-size: 10pt"><b><u>Name of Each Exchange on Which Registered</u></b></font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt"><b>Common Stock, $.01&nbsp;Par Value</b></font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt"><b>The NASDAQ Global Select Market</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Securities registered pursuant to Section&nbsp;12(g) of the Act:</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Title of class</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>None</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">________________________</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>



<p style="font-size: 10pt; margin: 0pt 0">Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined
in Rule&nbsp;405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by a check mark if the registrant is not required to file reports pursuant
to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">Indicate by a check mark whether the registrant (1)&nbsp;has filed
all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months
(or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing
requirements for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by a check mark whether the registrant submitted electronically and posted
on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of
Regulation&nbsp;S-T (Section&nbsp;232.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that
the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">Indicate by check mark if disclosure of delinquent filers pursuant
to Item&nbsp;405 of Regulation&nbsp;S-K (Section&nbsp;229.405 of this chapter) is not contained herein, and will not be contained,
to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III
of this Form&nbsp;10-K or any amendment to this Form&nbsp;10-K.&nbsp;&nbsp;&#9744;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated
filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule&nbsp;12b-2 of the Exchange Act.
(Check one):</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 24%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 44%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 26%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 1%; padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">&#9746;</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">Accelerated&nbsp;filer</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">&#9744;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">Non-accelerated filer</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">&#9744;&nbsp;&nbsp;(Do not check if a smaller reporting company)</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">Smaller&nbsp;reporting&nbsp;company</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">&#9744;</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by a check mark whether the registrant is a shell company (as defined in Exchange
Act Rule 12b-2).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744; &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp; &#9746;.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">The Registrant estimates that the aggregate market value of the Common Stock on June&nbsp;30,
2015 (based upon the closing price shown on the NASDAQ Global Select Market on June&nbsp;30, 2015)&nbsp;held by non-affiliates
was $1,078,490,079.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The number of shares of Common Stock, par value $.01, of the Registrant outstanding
as of January&nbsp;31, 2016 was 73,629,816 shares.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Portions of the Registrant&#8217;s definitive Proxy Statement to be filed in connection
with the solicitation of proxies for its 2016 Annual Meeting of Stockholders are incorporated by reference into Items&nbsp;10,
11, 12, 13 and 14 under Part&nbsp;III hereof.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 100%; padding-right: 0.8pt; text-align: center">&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><u>TABLE OF CONTENTS</u></b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 97%; padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt"><b>PART&nbsp;I</b></font></td>
    <td style="width: 3%; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_001"><font style="font-size: 10pt">ITEM&nbsp;1.
    BUSINESS</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_001"><font style="font-size: 10pt">4</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_002"><font style="font-size: 10pt">ITEM&nbsp;1A.
    RISK FACTORS</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_002"><font style="font-size: 10pt">19</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_003"><font style="font-size: 10pt">ITEM&nbsp;1B.
    UNRESOLVED STAFF COMMENTS</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_003"><font style="font-size: 10pt">36</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_004"><font style="font-size: 10pt">ITEM&nbsp;2.
    PROPERTIES</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_004"><font style="font-size: 10pt">37</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_005"><font style="font-size: 10pt">ITEM&nbsp;3.
    LEGAL PROCEEDINGS</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_005"><font style="font-size: 10pt">37</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_006"><font style="font-size: 10pt">ITEM&nbsp;4.
    MINE SAFETY DISCLOSURES</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_006"><font style="font-size: 10pt">37</font></a></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt"><b>PART&nbsp;II</b></font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_007"><font style="font-size: 10pt">ITEM&nbsp;
    5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_007"><font style="font-size: 10pt">37</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_008"><font style="font-size: 10pt">ITEM&nbsp;6.
    SELECTED FINANCIAL DATA</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_008"><font style="font-size: 10pt">39</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_009"><font style="font-size: 10pt">ITEM&nbsp;7.
    MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_009"><font style="font-size: 10pt">39</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_010"><font style="font-size: 10pt">ITEM&nbsp;7A.
    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_010"><font style="font-size: 10pt">52</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_011"><font style="font-size: 10pt">ITEM&nbsp;8.
    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_011"><font style="font-size: 10pt">54</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_019"><font style="font-size: 10pt">ITEM&nbsp;9.
    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_019"><font style="font-size: 10pt">81</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_020"><font style="font-size: 10pt">ITEM&nbsp;9A.
    CONTROLS AND PROCEDURES</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_020"><font style="font-size: 10pt">81</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_021"><font style="font-size: 10pt">ITEM&nbsp;9B.
    OTHER INFORMATION</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_021"><font style="font-size: 10pt">81</font></a></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt"><b>PART&nbsp;III</b></font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_022"><font style="font-size: 10pt">ITEM&nbsp;10.
    DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_022"><font style="font-size: 10pt">82</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_023"><font style="font-size: 10pt">ITEM&nbsp;11.
    EXECUTIVE COMPENSATION</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_023"><font style="font-size: 10pt">82</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_024"><font style="font-size: 10pt">ITEM&nbsp;12.
    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_024"><font style="font-size: 10pt">82</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_025"><font style="font-size: 10pt">ITEM&nbsp;13.
    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_025"><font style="font-size: 10pt">82</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_026"><font style="font-size: 10pt">ITEM&nbsp;14.
    PRINCIPAL ACCOUNTING FEES AND SERVICES</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_026"><font style="font-size: 10pt">82</font></a></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt"><b>PART&nbsp;IV</b></font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_027"><font style="font-size: 10pt">ITEM&nbsp;15.
    EXHIBITS, FINANCIAL STATEMENT SCHEDULES</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_027"><font style="font-size: 10pt">83</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_028"><font style="font-size: 10pt">SIGNATURES</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_028"><font style="font-size: 10pt">84</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-decoration: none"><a href="#a_029"><font style="font-size: 10pt">INDEX TO EXHIBITS</font></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><a href="#a_029"><font style="font-size: 10pt">85</font></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 10pt"><font style="font-size: 10pt">EX-10.70</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 10pt"><font style="font-size: 10pt">EX-10.71</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 10pt"><font style="font-size: 10pt">EX-21</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 10pt"><font style="font-size: 10pt">EX-23</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 10pt"><font style="font-size: 10pt">EX-31.1</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 10pt"><font style="font-size: 10pt">EX-31.2</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 10pt"><font style="font-size: 10pt">EX-32.1</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 10pt"><font style="font-size: 10pt">EX-32.2</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 10pt"><font style="font-size: 10pt">EX-101</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PART I</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><a name="a_001"></a><font style="font-size: 10pt"><b>ITEM&nbsp;1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>BUSINESS</i></b></font></p>


<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Forward-Looking Statements</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">This report includes forward-looking statements within the meaning
of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created
in Section&nbsp;21E. In particular, statements about our expectations, beliefs, plans, objectives or assumptions of future events
or performance are contained or incorporated by reference in this report. All statements other than statements of historical facts
contained herein are forward-looking statements. We have based these forward-looking statements on our current expectations about
future events. While we believe these expectations are reasonable, forward-looking statements are inherently subject to risks and
uncertainties, many of which are beyond our control. Our actual results may differ materially from those suggested by these forward-looking
statements for various reasons, including those discussed in this report under the heading &#8220;Risk Factors.&#8221; Given these
risks and uncertainties, you are cautioned not to place undue reliance on our forward-looking statements. The forward-looking statements
included in this report are made only as of the date hereof. We do not undertake, and specifically decline, any obligation to update
any of these statements or to publicly announce the results of any revisions to any forward-looking statements to reflect future
events or developments. When used in the report, unless otherwise indicated, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221;
the &#8220;Company&#8221; and &#8220;BioCryst&#8221; refer to BioCryst Pharmaceuticals, Inc.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Our Business</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We are a biotechnology company that designs, optimizes and develops
novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on the treatment of rare diseases
in which significant unmet medical needs exist and align with our capabilities and expertise. We integrate the disciplines of biology,
crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process
known as structure-guided drug design. Structure-guided drug design is a drug discovery approach by which we design synthetic compounds
from detailed structural knowledge of the active sites of enzyme targets associated with particular diseases. We use X-ray crystallography,
computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure
and active site characteristics of the enzymes that control cellular biology. Enzymes are proteins that act as catalysts for many
vital biological reactions. Our goal generally is to design a compound that will fit in the active site of an enzyme and thereby
prevent its catalytic activity. Molecules from our discovery efforts which are commercially available or that are in development
are summarized in the table below:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="width: 18%; border-bottom: black 1pt solid; padding-right: 0.8pt"><font style="font-size: 10pt">Drug/Drug Candidate</font></td>
    <td style="width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 30%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt">Drug Class</font></td>
    <td style="width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 20%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt">Therapeutic</font><br>
<font style="font-size: 10pt">Area(s)</font></td>
    <td style="width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 12%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt">Phase</font></td>
    <td style="width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 16%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt">Rights</font></td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">RAPIVAB<sup>&#174;</sup></p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">(peramivir injection)</p></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Intravenous Neuraminidase Inhibitor</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Acute uncomplicated Influenza</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">Approved</p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">(US)</p></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0">Seqirus (worldwide, except Japan, Taiwan, Korea and Israel) BioCryst
retains U.S. stockpiling rights</p></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">RAPIACTA<sup>&#174;</sup></p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">(peramivir injection)</p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0"></p></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Intravenous Neuraminidase Inhibitor</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Uncomplicated seasonal influenza</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">Approved</p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">(Japan)</p></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">Shionogi</p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">(Japan &amp; Taiwan)</p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0"></p></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">PERAMIFLU<sup>&#174;</sup></p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">(peramivir injection)</p></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Intravenous Neuraminidase Inhibitor</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Uncomplicated seasonal influenza</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">Approved</p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">(Korea)</p></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">Green Cross</p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">(Korea)</p></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Avoralstat</font><br>
<font style="font-size: 10pt">(previously BCX4161)</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Oral Serine Protease Inhibitor Targeting Kallikrein</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Hereditary angioedema (&#8220;HAE&#8221;)</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Phase 2/3</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">BioCryst</p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">(worldwide)</p></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0">BCX7353</p>
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0"></p>
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0">&nbsp;</p></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0.8pt 0pt 0">Oral Serine Protease Inhibitor Targeting Kallikrein (intended to be a once-daily
treatment)</p>
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0"></p></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0">HAE</p></td>
    <td style="vertical-align: bottom"></td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0">Phase 2</p>
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0"></p></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">BioCryst</p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">(worldwide)</p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0"></p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0"></p></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">Other 2<sup>nd</sup> generation&nbsp;<br>
HAE compounds</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">Oral Serine Protease Inhibitors Targeting Kallikrein</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">HAE and other indications</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">Preclinical</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">BioCryst<br>
(worldwide)</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">BCX4430</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">RNA dependent-RNA Polymerase Inhibitor</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Filoviruses, including Ebola and Marburg viruses</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Phase 1</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">BioCryst</p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">(worldwide)</p></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 1.6pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Forodesine</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Oral Purine Nucleoside Phosphorylase Inhibitor</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Oncology</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">Preparing to file for regulatory approval</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">Mundipharma</p>
        <p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">(worldwide)</p></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"></p>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Business Strategy</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">Our business strategy is to create shareholder value by focusing
our discovery and development efforts on oral drugs for rare diseases for which a significant unmet medical need exists. We select
disease targets and product candidates in which a small molecule would offer a significant benefit over existing products or would
be the first to market. We strive to advance our product candidate portfolio from discovery to commercial markets efficiently by
utilizing a small group of talented and highly-skilled employees working in conjunction with strategic outsource partners. BioCryst
is unique in its approach to treat orphan diseases with small molecules utilizing crystallography and structure-guided drug design.
The principal elements of our strategy are:&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt"><i>Focusing on High Value-Added Structure-Guided Drug Design Technologies.</i> We utilize structure-guided drug design in order to most efficiently develop new therapeutic candidates. Structure-guided drug design is a process by which we design a product candidate through detailed analysis of the enzyme target, which the product candidate must inhibit in order to stop the progression of the disease or disorder. We believe that structure-guided drug design is a powerful tool for the efficient development of small-molecule product candidates that have the potential to be safe and effective. Our structure-guided drug design technologies typically allow us to design and synthesize multiple product candidates that inhibit the same enzyme target, with the goal of establishing broad patent protection and formulating compounds with competitive advantages.</font></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt"><i>Selecting Inhibitors that are Promising Product Candidates.</i> We start by selecting disease targets with well-understood biology and characteristics that fit with our ability to utilize structure-guided drug design capabilities to build potent and specific enzyme inhibitors. Next, we narrow our selection of these product candidates based on product characteristics, such as initial indications of safety and biologic activity on the target.</font></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt"><i>Developing our Product Candidates Efficiently.</i> An important element of our business strategy is to efficiently progress our product candidates through the development process. In order to accomplish this, we strive for disease targets with a defined clinical and regulatory pathway for approval. In addition, we control fixed costs and overhead by outsourcing with strategic partners and contractors or entering into license agreements with third parties, including the U.S. Government. We maintain a streamlined corporate infrastructure that focuses our expertise. By contracting with the U.S. Government and outsourcing certain aspects of our operations, we are able to control overhead costs and focus financial resources directly where they provide the most benefit and reduce our business risk.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">We are a Delaware corporation originally founded in 1986. Our corporate
headquarters is located at 4505 Emperor Blvd., Suite&nbsp;200, Durham, North Carolina 27703 and the corporate telephone number
is (919)&nbsp;859-1302. For more information about us, please visit our website at www.biocryst.com. The information on our website
is not incorporated into this Form&nbsp;10-K.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>RAPIVAB (peramivir injection)</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Peramivir is an intravenous neuraminidase inhibitor approved in
multiple countries for the treatment of patients with influenza, most recently in the United States as RAPIVAB<sup>&#174;</sup>.
Influenza is a seasonal virus with the highest infection rates generally observed in colder months.&nbsp;Intravenous (&#8220;i.v.&#8221;)
peramivir injection has also been approved in Japan (RAPIACTA<sup>&#174;</sup>) and Korea (PERAMIFLU<sup>&#174;</sup>). In the countries
for which peramivir is commercially available, influenza occurs primarily during the September to April timeframe.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">RAPIVAB was approved by the U.S. Food and Drug Administration
(&ldquo;FDA&rdquo;) on December 19, 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older
who have been symptomatic for no more than two days. In December 2013, we submitted a New Drug Application
(&ldquo;NDA&rdquo;) which contained data from over 2,700 subjects treated with peramivir in 27 clinical trials. We made
RAPIVAB available for commercial sale through agreements with specialty distributorships during the 2014-2015 influenza
season. On June 17, 2015, we announced that BioCryst licensed <FONT STYLE="font-size: 10pt">RAPIVAB (peramivir injection) for
the treatment of influenza to CSL Limited (&ldquo;CSL&ldquo;), a global biopharmaceutical company. RAPIVAB is being commercialized by a
subsidiary of CSL called Seqirus UK Limited (&ldquo;SUL&rdquo;), which specializes in influenza prevention through the
supply of seasonal and pandemic influenza vaccine to global markets. Under the terms of the agreement, SUL obtained worldwide
rights to commercialize RAPIVAB, with the exception of Japan, Korea, Taiwan and Israel. BioCryst retained all rights to
pursue pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL is responsible for government stockpiling
outside the U.S. With the out-license of RAPIVAB to SUL, a strategic and well-suited commercialization partner, our current
goals for RAPIVAB are to: (1) obtain a stockpiling procurement contract with the U.S. Government to realize the strategic
value of this program; (2) fulfill our post-approval development requirements, including conducting a pediatric trial; and
(3) submit a Marketing Authorization Application (&ldquo;MAA&rdquo;) and New Drug Submission (&ldquo;NDS&rdquo;) in the
European Union and Canada, respectively, to allow SUL the ability to commercialize the drug in those regions.</FONT></p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In January 2016, we filed a NDS with Health Canada for RAPIVAB as
an i.v. treatment for acute, uncomplicated influenza.</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">RAPIVAB was developed under a $234.8 million contract from the Biomedical
Advanced Research and Development Authority within the United States Department of Health and Human Services (&#8220;BARDA/HHS&#8221;),
which expired on June 30, 2014. See &#8220;Collaborations and In-License Relationships&#8212;BARDA/HHS&#8221; below for a further
discussion of this development contract.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In January 2010, our partner Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;)
received the first approval for peramivir injection and launched it in Japan under the commercial name RAPIACTA. It was initially
approved for the treatment of adults with uncomplicated seasonal influenza, as well as those at high-risk for complications associated
with influenza. In October 2010, Shionogi received approval for an additional indication to treat children and infants with influenza
in Japan. In August 2010, Green Cross Corporation (&#8220;Green Cross&#8221;) received marketing and manufacturing approval from
the Korean Food&nbsp;&amp; Drug Administration under the commercial name PERAMIFLU to treat patients with influenza A &amp; B viruses,
including pandemic H1N1 and avian influenza. In addition, we have a regional collaboration for the development and commercialization
of peramivir in Israel.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Hereditary Angioedema Drug Candidates</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i><u>Avoralstat</u>:</i> Avoralstat is our most advanced hereditary
angioedema (&#8220;HAE&#8221;) product candidate in a suite of molecules being developed as oral treatments for the prevention
of HAE attacks. Avoralstat is positioned to be the first oral prophylactic kallikrein inhibitor for the prevention of HAE attacks.
Avoralstat is a novel, selective inhibitor of plasma kallikrein in development as an orally-administered treatment for the prevention
of attacks in patients with HAE. By inhibiting plasma kallikrein, avoralstat suppresses bradykinin production. Bradykinin is the
mediator of acute swelling attacks in HAE patients. HAE is a rare, severely debilitating and potentially fatal genetic condition
that occurs in approximately 1 in 50,000 people. HAE symptoms include recurrent episodes of edema in various locations, including
the hands, feet, face, genitalia and airway. Airway swelling is particularly dangerous and can lead to death by asphyxiation. In
addition, patients often have bouts of excruciating abdominal pain, nausea and vomiting caused by swelling in the intestinal wall.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In December 2014 and January 2015, respectively, the FDA granted
avoralstat &#8220;Orphan Drug&#8221; designation and &#8220;Fast Track&#8221; designation for the treatment of HAE. Orphan drug
designation is granted by the FDA Office of Orphan Products Development to novel drugs intended for the safe and effective treatment
of a rare disease or condition that affects fewer than 200,000 patients in the U.S. This designation provides certain incentives,
including federal grants, tax credits, waiver of Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) filing fees, and a seven-year
marketing exclusivity period against competition once the product candidate is approved. The Fast Track designation process of
the FDA is designed to facilitate the development and expedite the review and approval of drugs intended to treat serious or life
threatening conditions and that address unmet medical needs. A drug that receives Fast Track designation is usually eligible for
more frequent written communication and meetings with the FDA to discuss the drug's development plan and the collection of appropriate
data supporting drug approval. In addition, the Committee for Orphan Medicinal Products (&#8220;COMP&#8221;) of the European Medicines
Agency (&#8220;EMA&#8221;) issued a positive opinion on the application for orphan drug designation for avoralstat for the treatment
of patients with HAE and the European Commission recently affirmed this designation. Orphan drug designation by the EMA provides
regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically
debilitating condition affecting no more than five in 10,000 persons in the European Union (&#8220;EU&#8221;).</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">On December 18, 2014, we announced the dosing of the first patient
in OPuS-2 (<B>O</B>ral <B>P</B>rophylaxi<B>S-2</B>), a blinded, randomized, placebo-controlled clinical trial of orally-administered
avoralstat in patients with HAE. OPuS-2 was a 12-week, three-arm, parallel cohort design trial to evaluate the efficacy and safety
of two doses of avoralstat, 300 mg and 500 mg, administered three-times daily compared with placebo. This trial was conducted
in the U.S. and select European countries, and it enrolled approximately 100 HAE patients. The primary goals of the trial were
to characterize the efficacy of avoralstat in reducing the frequency of angioedema attacks, and to evaluate the safety and tolerability
of 12 weeks of avoralstat treatment. The primary efficacy endpoint was angioedema attack frequency.</P>

<P STYLE="margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"><FONT STYLE="font-size: 10pt">On February 8, 2016, we announced
results from OPuS-2.</FONT> <FONT STYLE="font-size: 10pt">In the OPuS-2 study, HAE patients with a historical attack frequency
of greater than 0.45 attacks per week were randomized to treatment with either 500 mg or 300 mg of avoralstat, or placebo, administered
three times daily for 12 weeks. Thirty-eight subjects received avoralstat 500 mg, 36 subjects received avoralstat 300 mg, and 36
subjects received placebo. Treatment with 500 mg and 300 mg of avoralstat three times daily failed to demonstrate a statistically
significantly lower mean attack rate versus placebo. The mean (standard deviation) attack rates per week were 0.63 (0.57) on avoralstat
500 mg and 0.71 (0.66) on avoralstat 300 mg, compared to 0.61 (0.41) on placebo.</FONT> <FONT STYLE="font-size: 10pt">Statistically
significant improvements in duration of attacks and in the Angioedema Quality of Life total score were observed comparing the 500
mg three times a day avoralstat arm to placebo. Following the analysis of OPuS-2 results, the decision was made to discontinue
further development of softgel avoralstat formulation in order to focus development efforts on a novel solid dosage form of avoralstat
to achieve meaningfully better drug exposure. We expect additional avoralstat results from a relative bioavailability study testing
a novel solid dosage form of avoralstat by mid-year 2016. The primary goals of this study are to achieve meaningfully better drug
exposures and twice daily dosing. </FONT></P>



<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">On May 27, 2014, we announced positive results from a Phase 2a
proof of concept OPuS-1(<b>O</b>ral <b>P</b>rophylaxi<b>S-1</b>) clinical trial in patients with HAE. This clinical trial evaluated
400 mg of avoralstat administered three-times daily for 28 days in a randomized, placebo-controlled, two-period cross-over design.
Twenty-four HAE patients who had a high frequency of attacks (more than one per week) were enrolled. This study was designed to
provide proof of concept for oral kallikrein inhibition as a treatment strategy for HAE. The primary goals of the trial were to
estimate the degree of efficacy of avoralstat in reducing the frequency of angioedema attacks and to evaluate the safety and tolerability
of 28 days of avoralstat treatment. The OPuS-1 trial met its primary efficacy endpoint, several secondary endpoints as well as
other objectives established for the clinical trial. Each of the twenty-four patients dosed completed the trial. The primary efficacy
endpoint for the trial was the mean angioedema attack rate. Treatment with avoralstat demonstrated a statistically significant
mean attack rate reduction of 0.45 attacks per week versus placebo, p&lt; 0.001. The mean attack rate per week was 0.82 on avoralstat
treatment, compared to 1.27 on placebo. Oral administration of avoralstat was generally safe and well-tolerated, with an adverse
event profile similar to that observed for placebo. Patient dosing compliance in this trial was 98 percent.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><I><U>2nd generation HAE compounds:</U></I> The goal of our second
generation HAE discovery program is to discover and develop oral molecules for the prevention of HAE attacks which have a superior
selectivity and bioavailability profile while maintaining similar potency as compared to avoralstat. In December 2013, we announced
the selection of two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral
prophylactic treatments for HAE. Based on early preclinical development studies, these structurally different molecules have a
similar mechanism of action as avoralstat and have achieved the principal goal of improved bioavailability. Both BCX7353 and the
second compound had roughly five times better bioavailability than avoralstat. These compounds demonstrated sub-nanomolar potency
on the isolated enzyme and single digit nanomolar potency in suppressing kallikrein activity in an ex-vivo activated normal human
plasma kallikrein inhibition (&ldquo;aPKI&rdquo;) assay. Plasma concentrations of each of the optimized compounds exceeded the
aPKI assay EC80 concentration at 24 hours after a single oral dose of 10 mg/kg in rats, indicating potential for once-daily dosing.
In January 2015, we selected BCX7353 to advance into Phase 1 development as a once-daily, oral prophylactic HAE treatment. Given
the other advanced second generation molecule&rsquo;s inferior profile and similar molecular composition to BCX7353, we have chosen
only to advance BCX7353. In addition to BCX7353, we continue to work on and advance other second generation compounds that are
at an earlier stage. These molecules are in preclinical development and will be assessed for safety and efficacy in prophylactic
HAE treatment as well as for other potential indications. We will provide additional information on these molecules as we approach
an Investigational New Drug (&ldquo;IND&rdquo;) filing or we obtain data suggesting efficacy and safety surrounding these molecules
in potential HAE and other therapeutic indications.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><i><u>BCX7353</u></i>: BCX7353 is structurally different from avoralstat,
but has a similar mechanism of action targeting plasma kallikrein. On May 13, 2015, we announced the initiation of a Phase 1 clinical
trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 12pt 0 0">On October 8, 2015, we announced that the randomized, placebo-controlled,
Phase 1 clinical trial of orally-administered BCX7353 in healthy volunteers successfully met all of its objectives.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">In this Phase 1 clinical trial BCX7353 dose levels included
single doses of up to 1000mg, once-daily doses of up to 500 mg for seven days, and once-daily doses of 350 mg for 14 days. Plasma
levels increased in approximate proportion to dose, and drug exposure was not affected by dosing with food. The half-life of BCX7353
was estimated at 50-60 hours. After daily dosing, blood levels met or exceeded a predicted target therapeutic range throughout
the 24 hour dosing interval. Inhibition of the target enzyme, plasma kallikrein, was measured in a sensitive and specific bioassay.
Daily dosing with BCX7353 strongly inhibited plasma kallikrein at all four dose levels; the degree of inhibition was dose-related
(p &lt; 0.0001) and inhibition was sustained throughout the 24 hour dosing interval. This pharmacodynamic effect correlated strongly
to the achieved drug concentration (r = 0.91, p &lt; 0.0001).</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">Subsequently, cohorts of healthy Japanese volunteers were added
to the study to support development of BCX7353 in Japan under the &ldquo;Sakigake&rdquo; accelerated R&amp;D designation. Following assessment
of single oral doses of BCX7353 of 100mg (6 subjects) and 500 mg (6 subjects), 250 mg of BCX7353 was administered orally and daily
for seven days to ten subjects. Compared to Western subjects administered the same dose level, plasma drug levels in Japanese subjects
were moderately higher. Kallikrein inhibition on day seven of daily dosing with 250 mg in Japanese subjects was similar to that
seen at the 350 mg daily and 500 mg daily dose levels in Western subjects.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">The combined data from both Western and Japanese healthy volunteers
indicates that oral BCX7353 has been generally safe and well tolerated in a total of 96 treated healthy volunteers, 46 with singles
doses and 50 with multiple doses. No serious adverse events have been seen and no dose-limiting toxicity has been identified. There
have been no clinically significant laboratory abnormalities, ECG changes, or vital sign changes observed.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">In single dose subjects, 89% (31 of 35) of adverse events (AEs)
have been grade 1. The four grade 2 AEs observed were: nausea (1) and vomiting (1) occurring in one subject: hay fever (1) and
diarrhea (1 from Japanese cohort).</P>



<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">In multiple dose subjects, 90% (63 of 70) of adverse
events (AEs) have been grade 1. The six grade 2 AEs observed were: upper abdominal pain (1, discontinued from study); syncope
(1) headache (1) diarrhea (1) and upper abdominal pain (1) occurring on one subject (discounted from study), and
maculopapular rash. One grade 3 AE was observed, a cutaneous delayed-type hypersensitivity reaction. The two rash AE&rsquo;s
are described in more detail below.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">The incidence of drug-related skin rash across all multiple-dose
cohorts was 4% (2 of 50 subjects). One Japanese subject dosed at 250 mg daily for seven days developed a grade 2 maculopapular
skin rash following cessation of dosing, and one Western subject dosed at 500 mg daily for seven days developed a grade 3 hypersensitivity
reaction, described as a maculopapular skin rash, following cessation of dosing. Both AEs were assessed by the investigator as
drug-related. The Japanese subject received antihistamines and the Western subject received corticosteroids, and in both cases
the rash resolved within a few days.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">The safety, tolerability, drug exposure and on-target plasma
kallikrein inhibition results strongly support advancing the development program into a Phase 2 study in HAE patients. A Phase
2 trial (&ldquo;APeX-1&rdquo;) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of BCX7353
as a preventative treatment to reduce the frequency of attacks in HAE patients is expected to begin in 2016. The design of the
trial will be described when the APeX-1 protocol is approved by regulatory authorities and the clinical trial is initiated.</P>



<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">On October 27, 2015 The Japanese Ministry of Health Labor &amp;
Welfare (&ldquo;MHLW&rdquo;) announced that BioCryst&rsquo;s BCX7353 was one of six products designated under MLHW&rsquo;s new
Sakigake fast track review system. The Sakigake Designation System promotes R&amp;D in Japan, aiming at early market
availability for innovative pharmaceutical products. This designation provides for additional interactions with the regulatory
agency in Japan from early development through filing, prioritized development and review, and introduction of the product as
soon as possible to address a serious unmet medical need. We expect the results of APeX-1 to help us and the MHLW to determine
the regulatory pathway and timeline for BCX7353 in Japan.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>BCX4430</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">BCX4430 is a broad-spectrum antiviral (&ldquo;BSAV&rdquo;) research
program and is currently being developed under contracts with the National Institute of Allergy and Infectious Diseases (&ldquo;NIAID/HHS&rdquo;)
and the U.S.&nbsp;Department of Health and Human Services (&ldquo;BARDA/HHS&rdquo;). The objective of our BSAV program is to develop
BCX4430 as a broad-spectrum therapeutic for viruses that pose a threat to national health and security. The primary focus of the
program is treatment of hemorrhagic fever viruses. NIAID/HHS funding has supported BCX4430&rsquo;s development as a treatment
for Marburg virus and Ebola virus. In March 2014, BCX4430 was featured in an online <I>Nature</I> publication depicting successful
efficacy results in animal models of infection with Marburg virus and Ebola virus.&nbsp;BCX4430 completely protected cynomolgus
macaques from Marburg virus infection when administered by intramuscular (&ldquo;i.m.&rdquo;) injection 48 hours post-infection.&nbsp;Post-exposure
i.m. administration of BCX4430 also protected rodents against Marburg virus and Ebola virus infections.&nbsp;In addition, BCX4430
was shown to be active in vitro against a broad range of other RNA viruses, including the emerging viral pathogen Middle East
Respiratory Syndrome Coronavirus (&ldquo;MERS-CoV&rdquo;).&nbsp;The publication, which reported the protection of non-human primates
from filovirus disease by BCX4430, describes efficacy results generated from an ongoing collaboration between scientists in the
U.S. Army Medical Research Institute of Infection Diseases (&ldquo;USAMRIID&rdquo;) and us.&nbsp;BCX4430 has been shown to be
active against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses,
paramyxoviruses, coronaviruses and flaviviruses.&nbsp;In tests conducted at USAMRIID, BCX4430 protected animals against parenteral
exposures to Marburg, Ebola and Rift Valley Fever viruses and from exposures to aerosolized Marburg virus, an experimental condition
designed to mimic an exposure scenario that could result during a bioterrorist attack.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">On December 23, 2014, we announced results from a successful proof-of-concept
study of BCX4430 for the treatment of experimental Ebola virus infection in Rhesus macaques, conducted at USAMRIID. The primary
goal of the study was to assess the effect of BCX4430 treatment on survival through Day 41 in animals infected with Ebola virus.
Dosing of&nbsp;placebo or BCX4430 by i.m. injection was initiated 30-120 minutes after virus challenge and continued twice a day
(&#8220;BID&#8221;) for 14 days. Animals were dosed with either placebo, 16 mg/kg of BCX4430 BID or 25 mg/kg of BCX4430 BID. Survival
at day 41 in the 16 mg/kg BID group of BCX4430 treated animals was 4 of 6 (66.7%, p &lt; 0.001 compared to 0% survival in controls)
and 6 of 6 in the 25 mg/kg BID group (100%, p &lt; 0.001 compared to controls). The overall survival rate for BCX4430 treated animals
at day 41 was 10 of 12 (83%, p &lt; 0.001 compared to controls). Preliminary evaluation of the quantity of virus in the blood showed
an approximate 3-log reduction in Ebola virus RNA copies/mL of plasma, compared with control animals. This Rhesus macaque study
was conducted following the completion, in November 2014, of a dose-ranging study of BCX4430 for the experimental treatment of
cynomolgus macaques infected with Ebola virus. The cynomolgus macaque study was designed to evaluate whether BCX4430 showed a meaningful
benefit for survival in Ebola virus non-human primate (&#8220;NHP&#8221;) disease models and explore a dose range. In this study
BCX4430 demonstrated a statistically significant prolongation of survival for the animals at the highest dose regimen tested, but
no animals survived beyond 21 days.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">On December 15, 2014, we announced the dosing of the first subject
in a randomized, placebo-controlled Phase 1 clinical trial to evaluate i.m. administration of BCX4430 in healthy volunteers. The
main goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of BCX4430
administered via i.m. injection in healthy subjects. In part one of the study, subjects will receive a single dose of BCX4430;
and then subjects will receive BCX4430 for seven days in the second part of the study. Up to six single-dose cohorts and four multiple-dose
cohorts will be evaluated, with a total of up to 88 volunteers participating. This Phase 1 study is expected to continue in 2016.
&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><B>Forodesine</B></p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 12pt 0 0">Forodesine is a Purine Nucleoside Phosphorylase
(&ldquo;PNP&rdquo;) inhibitor in development by Mundipharma as a treatment for cancer under a world-wide license agreement.
PNP is a purine salvage pathway enzyme. High doses of PNP inhibitors could be useful in the treatment of hematological
malignancies. Mundipharma has received orphan drug status for forodesine, and following successful completion of a Phase 2
pivotal study in recurrent/refractory peripheral T-cell lymphoma patients in Japan, is preparing to file for regulatory
approval.</P>



<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">On November&nbsp;11, 2011, we entered into an Amended and Restated
License and Development Agreement (the &ldquo;Amended and Restated Agreement&rdquo;) with Mundipharma, amending and restating the
February&nbsp;1, 2006 exclusive, royalty-bearing Development and License Agreement for the development and commercialization of
forodesine for use in the field of oncology. Under the terms of the Amended and Restated Agreement, Mundipharma obtained worldwide
rights to forodesine, so Mundipharma controls the worldwide development and commercialization of forodesine and assumes all future
development and commercialization costs. The Amended and Restated Agreement is a multiple element arrangement for accounting purposes
in which we were required to deliver to Mundipharma both the worldwide rights to forodesine and the transfer of product data and
know-how to permit Mundipharma to develop and commercialize forodesine (the &ldquo;Knowledge Transfer&rdquo;). The world-wide license
rights were granted to Mundipharma upon execution of Amended and Restated Agreement and the Knowledge Transfer was completed in
the first quarter of 2012.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">We have licensed the PNP technology from Albert Einstein College
of Medicine of Yeshiva University (&#8220;AECOM&#8221;) and Industrial Research, Ltd. (&#8220;IRL&#8221;) and will owe sublicense
payments to AECOM/IRL based on the future milestone payments and royalties received by us from Mundipharma and any other partners
for which we out-license our PNP inhibitors. On November&nbsp;17, 2011, we amended our agreement with AECOM/IRL whereby AECOM/IRL
agreed to accept a reduction of one-half of the percentage of Net Proceeds (as defined in the license agreement) received by us
under our Amended and Restated Agreement with Mundipharma. This reduction does not apply to royalty payments made as a result of
sales of licensed products by our sub licensees.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Collaborations and In-License Relationships</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0"><I><U>U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;)</U>.
</I>In January 2007, BARDA/HHS awarded us a $102.6 million, four-year contract for the advanced development of peramivir for the
treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment
of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir
program and to increase funding by $77.2 million. On February&nbsp;24, 2011, we announced that BARDA/HHS had awarded us a $55.0
million contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients
hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to $234.8 million and
provided funding to support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013,
we submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired
on June 30, 2014 according to its terms.</p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">On March 31, 2015, we announced that BARDA/HHS awarded us a contract
for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This
BARDA/HHS contract includes a base contract of $13.3 million to support BCX4430 drug manufacturing, as well as $22.9 million in
additional development options that can be exercised by the government, bringing the potential value of the contract to $36.2 million.
As of December 31, 2015, a total of $16.3 million has been awarded under exercised options within this contract.</p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0"><I><U>National Institute of Allergy and Infectious Diseases
(&#8220;NIAID/HHS&#8221;)</U>. </I>In September 2013, NIAID/HHS contracted with us for the development of BCX4430 as a
treatment for Marburg, and subsequently, Ebola virus disease. NIAID/HHS, part of the National Institutes of Health, made an
initial award of $5.0 million to us. A total of $29.9 million of initial and option funding has been awarded under the
NIAID/HHS contract to date and total funding under the contract could be up to $34.0 million, if all contract options are
exercised. The goals of this contract, including amendments, are to file IND applications for i.v. and i.m. BCX4430 for the
treatment of Marburg virus disease, to conduct an initial Phase 1 human clinical trial, as well as to study BCX4430 as a
treatment for Ebola virus disease.</p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee
contracts. That is, we are entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions
that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic
assessments of progress and the continuation of the contract is based on our performance, the timeliness and quality of deliverables,
and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable
by the government at any time for breach or without cause.</p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"><i></i></p>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"><i><u>Seqirus UK Limited</u>.</i> On June 16, 2015, we and SUL,
a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the
laws of Australia, entered into a License Agreement (the "SUL Agreement") granting SUL and its affiliates worldwide rights
to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to
conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the "Territory").
RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan
and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the U.S. Food and Drug
Administration in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older who have been
symptomatic for no more than two days. We retain all rights and associated economics to procure pandemic stockpiling orders for
RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by
CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global
markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization
of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion. We will exercise sole
decision-making authority with regard to the development and commercialization of RAPIVAB outside of the Territory and are responsible
for all associated costs.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In December 2013, we submitted a NDA for RAPIVAB to the FDA. Under
the terms of the SUL Agreement, we are responsible for fulfilling all post-marketing approval commitments in connection with the
FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant
to potential rights to sell RAPIVAB in Canada and the EU, we are also responsible for regulatory filings and interactions with
the Health Canada and the European Medicines Agency  until marketing approval for RAPIVAB is obtained and assigned
to SUL. In accordance with the SUL Agreement, we and SUL formed a joint steering committee, composed of an equal number of representatives
from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory
and any additional development.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">Under the terms of the SUL Agreement, we received an upfront payment
of $33.7 million, and may receive up to $12.0 million in additional milestone payments related to the successful achievement of
regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication
in the EU and (iii) by Health Canada for an adult indication in Canada. We are also entitled under the SUL Agreement to receive
tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well
as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, we receive
tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined
as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory,
other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting
the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country
basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement
(the "Royalty Term"). We developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any future
milestone payments and/or royalties received by us from SUL.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">The term of the SUL Agreement shall continue on a country-by-country
basis until the expiration of the last-to-expire Royalty Term in any such country in the Territory. Either party may terminate
the SUL Agreement in its entirety if the other party breaches a payment obligation, otherwise materially breaches the SUL Agreement,
subject to applicable cure periods, or if the other party suffers an insolvency event. We may also terminate the SUL Agreement
if SUL or any of its affiliates seek to challenge the validity of our patents. Termination does not affect a party's rights which
have accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations
previously accrued. For all terminations exercised by us, the SUL Agreement provides for the termination of any sublicenses granted
by SUL to third parties, and in the case of termination by us for cause, the ceasing of SUL's activities with respect to RAPIVAB,
the discontinued use of all of our intellectual property and the termination of licenses and rights previously granted to SUL.
If requested by us, SUL shall also promptly sell to us all licensed product it then holds in stock, otherwise, SUL may continue
to sell such licensed product for designated periods.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"><i><u>Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;)</u>.</i>
On February&nbsp;28, 2007, we entered into a License, Development and Commercialization Agreement (as amended, supplemented or
otherwise modified, the &#8220;Shionogi Agreement&#8221;), an exclusive license agreement with Shionogi to develop and commercialize
peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. In October 2008, we and Shionogi
amended the Shionogi Agreement to expand the territory covered by the agreement to include Taiwan. Under the terms of the Shionogi Agreement, Shionogi obtained rights to injectable
formulations of peramivir in Japan in exchange for a $14.0&nbsp;million upfront payment. The license provided for development milestone
payments (up to $21.0&nbsp;million), which have all been paid, and for commercial milestone payments (up to $95.0&nbsp;million)
in addition to double-digit (between 10% and 20%) royalty payments on product sales of peramivir.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">Generally, all payments under the Shionogi Agreement are non-refundable
and non-creditable, but they are subject to audit. Shionogi is responsible for all development, regulatory, and marketing costs
in Japan. The term of the Shionogi Agreement is from February&nbsp;28, 2007 until terminated. Either party may terminate in the
event of an uncured breach. Shionogi has the right of termination without cause. In the event of termination, all license and rights
granted to Shionogi shall terminate and shall revert back to us. We developed peramivir under a license from the University of
Alabama Birmingham (&#8220;UAB&#8221;) and have paid sublicense payments to UAB on the upfront payments and will owe sublicense
payments on any future event payments and/or royalties received by us from Shionogi.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"><i><u>Shionogi Royalty Monetization and Non-Recourse Notes Payable</u></i>.
On March&nbsp;9, 2011, we completed a $30.0 million&nbsp;financing transaction to monetize certain future royalty and milestone
payments under the Shionogi Agreement, pursuant to which JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;) a wholly-owned subsidiary
of BioCryst, issued the PhaRMA Notes discussed below. We received net proceeds of $22.7 million&nbsp;from this transaction.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">As part of the transaction, we entered into a purchase and sale
agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby we transferred to Royalty Sub, among other things, (i)&nbsp;its
rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the
right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency
Hedge Agreement&#8221;) put into place by us in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese
yen and milestone payments will be paid in U.S. dollars. Our collaboration with Shionogi was not impacted by this transaction.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">On March 9, 2011, Royalty Sub completed a private placement to institutional
investors of $30.0 million in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#8220;PhaRMA Notes&#8221;).
The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#8220;Indenture&#8221;), by
and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable
from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by us to Royalty
Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&nbsp;per
annum, payable annually in arrears on September&nbsp;1st of each year (the &#8220;Payment Date&#8221;). We remain entitled to receive
any royalties and milestone payments related to sales of peramivir by Shionogi following repayment by Royalty Sub of the PhaRMA
Notes.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">Royalty Sub&#8217;s obligations to pay principal and interest on
the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except
to the extent of our pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. We may, but are not obligated
to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall
on, the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In September&nbsp;2013, Royalty Sub paid $1.8 million of interest
on the PhaRMA Notes from royalty payments received from RAPIACTA sales from the preceding four calendar quarters. This payment
resulted in an obligation shortfall of approximately $2.4 million associated with accrued interest due September&nbsp;3, 2013.
As stipulated under the PhaRMA Notes Indenture, if the amount available for payment on any Payment Date is insufficient to pay
all of the interest due on a Payment Date, the shortfall in interest will accrue interest at the interest rate applicable to the
PhaRMA Notes compounded annually. Accordingly, commencing in September&nbsp;2013, interest began to accrue at 14%&nbsp;per annum
on the interest shortfall of $2.4 million. In March, June and August of 2014, Royalty Sub paid additional interest of $446,000,
$1.9 million and $70,000, respectively, bringing the shortfall down to $222,000 as of September 30, 2014. Under the terms of the
Indenture, Royalty Sub&rsquo;s inability to pay the full amount of interest payable in September&nbsp;2013 by the next succeeding
Payment Date for the PhaRMA Notes, which was September&nbsp;1, 2014, constituted an event of default. Accordingly, we have classified
the PhaRMA Notes and related accrued interest as current liabilities on our balance sheet. As a result of the event of default
under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral
securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture
in respect of the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue
to us following repayment of the PhaRMA Notes and we might otherwise be adversely affected. Due to the non-recourse nature of the
PhaRMA Notes, in the event of any potential acceleration or foreclosure, we believe the primary impact to us would be the loss
of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, we may incur costs
associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure
or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub, we do not currently expect
the event of default on the PhaRMA Notes to have a significant impact on our future results of operations or cash flows. As of
December 31, 2015, the PhaRMA Notes remain in default.</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">The Indenture does not contain any financial covenants. The Indenture
includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of
Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters
typical for indentures used in structured financings of this type. The PhaRMA Notes are redeemable at the option of Royalty Sub
at any time at a redemption price equal to 100% of the outstanding principal balance of the PhaRMA Notes being redeemed, plus accrued
and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"><i><u>Foreign Currency Hedge</u>.</i> In connection with the issuance by Royalty Sub of the PhaRMA Notes, we entered into a Currency Hedge Agreement
to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency
Hedge Agreement, we have the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which we may be required
to pay a premium in each year from 2016 through 2020. A payment of $2.0 million&nbsp;will be required if, on May&nbsp;18 of the
relevant year, the U.S. dollar is worth 100 yen or less, as determined in accordance with the Currency Hedge Agreement.</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting
treatment; therefore, mark-to-market adjustments are recognized in our Consolidated Statement of Comprehensive Loss. Cumulative
mark-to-market adjustments resulted in a loss of $0.6 million and gains of $5.5 million and $5.3 million for the twelve months
ended December&nbsp;30, 2015, 2014 and 2013, respectively. In addition, a realized currency exchange gain of $1.6 million was recognized
in 2015 related to the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge. Thus, a resulting
$1.1 million net gain is recognized on our foreign currency derivative for 2015.We are also required to post collateral in connection
with the mark-to-market adjustments based on defined thresholds. As of December 31, 2015, no collateral was posted under the Currency
Hedge Agreement. We will not be required at any time to post collateral exceeding the maximum premium payments remaining payable
under the Currency Hedge Agreement. The maximum amount of hedge collateral we would be required to post is $9.8 million. We are
required to maintain a foreign currency hedge at 100 yen per dollar under the agreements governing the PhaRMA Notes.</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"><i><u>Green Cross</u>.</i> In June 2006, we entered into an agreement
with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is responsible
for all development, regulatory, and commercialization costs in Korea. We received a one-time license fee of $250,000. The license
provides that we will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean
government for stockpiling purposes. Furthermore, Green Cross will pay us a premium over its cost to supply peramivir for development
and any future marketing of peramivir products in Korea. Both parties have the right to terminate in the event of an uncured material
breach. In the event of termination, all rights, data, materials, products and other information would be transferred to us.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In August 2010, we announced that Green Cross had received marketing
and manufacturing approval from the Korean Food&nbsp;&amp; Drug Administration for i.v. peramivir, under the commercial name PERAMIFLU<sup>&#174;</sup>.
PERAMIFLU is intended to treat patients with influenza A&nbsp;&amp; B viruses, including pandemic H1N1 and avian influenza. Green
Cross received the indication of single dose administration of 300&nbsp;mg i.v. peramivir. Since PERAMIFLU&#8217;s approval, Green
Cross has been in pricing discussions with the Korean National Health Insurance Corporation and has yet to agree to a formulary
price. PERAMIFLU&#8217;s distribution to date has been limited to a case-by-case basis and significant sales have not occurred.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"><i><u>Other Peramivir Collaborations</u>.</i> In addition to our
collaborations with Shionogi and Green Cross, in March 2011 we entered into an arrangement with Neopharm Scientific Limited, granting
certain commercial and distribution rights for peramivir in Israel.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"><i><u>Mundipharma</u>.</i> In February 2006, we entered into an
exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine,
a PNP inhibitor, for use in oncology (the &#8220;Original Agreement&#8221;). Under the terms of the Original Agreement, Mundipharma
obtained rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a $10.0&nbsp;million up-front payment.
In addition, Mundipharma contributed $10.0&nbsp;million of the documented out-of-pocket development costs incurred by us in respect
of the current and planned trials as of the effective date of the agreement, and Mundipharma would conduct additional clinical
trials at their own cost up to a maximum of $15.0&nbsp;million. The Original Agreement provided for the possibility of future event
payments totaling $155.0&nbsp;million for achieving specified development, regulatory and commercial events (including certain
sales level amounts following a product&#8217;s launch) for certain indications. In addition, the Original Agreement provided that
we would receive royalties (ranging from single digits to mid teens) based on a percentage of net product sales, which varies depending
upon when certain indications receive NDA approval in a major market country and can vary by country depending on the patent coverage
or sales of generic compounds in a particular country. Generally, all payments under the Original Agreement were nonrefundable
and non-creditable, but they are subject to audit. We licensed forodesine and other PNP inhibitors from AECOM/IRL and will owe
sublicense payments to AECOM/IRL on all milestone payments and royalties received by us from Mundipharma.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">On November&nbsp;11, 2011, we entered into the Amended and Restated
Agreement with Mundipharma. Under the terms of this Amended and Restated Agreement, Mundipharma obtained worldwide rights to forodesine
in the field of oncology. Mundipharma will control the development and commercialization of forodesine and assume all future development
and commercialization costs. The Amended and Restated Agreement provides for the possibility of future event payments totaling
$15.0&nbsp;million for achieving specified regulatory events for certain indications. In addition, the Amended and Restated Agreement
provides that we will receive tiered royalties ranging from mid- to high-single digit percentages of net product sales in each
country where forodesine is sold by Mundipharma. These royalties are subject to downward adjustments based on the then-existing
patent coverage and/or the availability of generic compounds in each country. Generally, all payments under the Amended and Restated
Agreement are nonrefundable and non-creditable, but they are subject to audit.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">Mundipharma will also have a right of exclusive negotiations with
us for a limited period of time if they initiate negotiations for a specified backup PNP inhibitor. Otherwise, they will be able
to participate in the same negotiations process we enter into with another company for the backup PNP inhibitor. The Amended and
Restated Agreement will continue for the commercial life of the licensed products, but may be terminated by either party following
an uncured material breach by the other party or in the event the pre-existing third party license with AECOM/IRL expires. It may
be terminated by Mundipharma upon 60&nbsp;days written notice without cause or under certain other conditions as specified in the
Amended and Restated Agreement. If Mundipharma terminates the Amended and Restated Agreement, Mundipharma would no longer have
any rights in forodesine and the rights would revert back to us; provided, however, that in the event the we determine to subsequently
use the data developed under the Amended and Restated Agreement for development and commercialization of forodesine in the field
of oncology, then we would have to pay Mundipharma 150% of the cost of such data for such use.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"><I><U>Albert Einstein College of Medicine of Yeshiva University
and Industrial Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively)</U>.&nbsp;</I> In June 2000, we licensed
a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &ldquo;Licensors&rdquo;). The lead product candidate
from this collaboration is forodesine. We have obtained worldwide exclusive rights to develop and ultimately distribute it, or
any other, product candidates that might arise from research on these inhibitors. We have the option to expand our license agreement
with the Licensors to include other inventions in the field made by the investigators or employees of the Licensors. We agreed
to use commercially reasonable efforts to develop these drugs. In addition, we have agreed to pay certain milestone payments for
each licensed product (which range in the aggregate from $1.4 million to almost $4.0 million&nbsp;per indication) for future development
of these inhibitors, single digit royalties on net sales of any resulting product made by us, and to share approximately one quarter
of future payments received from other third-party partners, if any. In addition, we have agreed to pay annual license fees, which
can range from $150,000 to $500,000, that are creditable against actual royalties and other payments due to the Licensors. This
agreement may be terminated by us at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach
by the Licensors.</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In May 2010, we amended the license agreement through which we obtained
worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series
of PNP inhibitors, including forodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half
in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to
the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments we may receive in the future under our license
agreement with Mundipharma and (ii)&nbsp;royalties received from its sub licensees in connection with the sale of licensed products,
for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of
any resulting product made by us remains unchanged. At our sole option and subject to certain agreed upon conditions, any future
non-royalty payments due to be paid by us to the Licensors under the license agreement may be made either in cash, in shares of
our common stock, or in a combination of cash and shares.&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">On November&nbsp;17, 2011, we further amended our agreements with
the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined in the
license agreement) received by us under our Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL. &nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">On June&nbsp;19, 2012, we further amended our agreements with the
Licensors whereby the parties clarified the definition of the field with respect to PNP inhibition and the Licensors agreed to
grant an exclusive worldwide license of BCX4430 to us for any antiviral use.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"><i><u>The University of Alabama at Birmingham (&#8220;UAB&#8221;)</u>.</i>
We currently have agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements,
UAB performed specific research for us in return for research payments and license fees. UAB has granted us certain rights to any
discoveries in these areas resulting from research developed by UAB or jointly developed with us. We have agreed to pay single
digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. We
have completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable
for five-year terms throughout the life of the last patent and are terminable by us upon three months&#8217; notice and by UAB
under certain circumstances. Upon termination both parties shall cease using the other parties&#8217; proprietary and confidential
information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed
products. There is currently no activity between us and UAB on these agreements, but when we license this technology, such as in
the case of the Shionogi and Green Cross agreements, or commercialize products related to these programs, we will owe sublicense
fees or royalties on amounts it receives.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b>Government Contracts</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"><i><u>U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;)</u>.</i>
In January 2007, BARDA/HHS awarded us a $102.6 million four-year contract for the advanced development
of peramivir for the treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery
and the treatment of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend
the i.v. peramivir program and to increase funding by $77.2 million. On February&nbsp;24, 2011, we announced that BARDA/HHS had
awarded us a $55.0 million contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for
the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS
to $234.8 million and provided funding to support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S.
In December 2013, we submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS
contract expired on June 30, 2014 according to its terms.</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Under the defined scope of work in the contract with BARDA/HHS for
the development of peramivir, a process was undertaken to validate a U.S.-based manufacturer and the related method for producing
commercial batches of peramivir active pharmaceutical ingredient (&#8220;API&#8221;). As a required outcome of this validation
process, large quantities of peramivir API were produced. In accordance with our accounting practices, we recorded all costs associated
with this validation process as research and development expenses in our Consolidated Statements of Comprehensive Loss. Simultaneously,
revenue from the BARDA/HHS contract was also recorded in our Consolidated Statements of Comprehensive Loss in 2009. BARDA/HHS subsequently
reimbursed us for these costs and upon reimbursement from BARDA/HHS, the associated peramivir API became property of the U.S.&nbsp;Government.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Under the terms of the contract, if we determine the amount of peramivir
API produced under the contract is in excess of what is necessary to complete the contract, we can acquire any excess peramivir
API at cost to use for our own purposes. We believe that as a result of the manufacturing campaign described above, more peramivir
API has been produced than what was required to support U.S.&nbsp;regulatory approval. If we use any excess API for our other contracts
or activities, we will need to reconcile through an appropriate acquisition process with BARDA/HHS and to determine the appropriate
acquisition process remuneration for this API.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 31, 2015, we announced that BARDA/HHS awarded us a contract
for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This
BARDA/HHS contract includes a base contract of $13.3 million to support BCX4430 drug manufacturing, as well as $22.9 million in
additional development options that can be exercised by the government, bringing the potential value of the contract to $36.2 million.
As of December 31, 2015, a total of $16.3 million has been awarded under exercised options within this contract.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i><u>National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;)</u>.</i>
In September 2013, NIAID/HHS contracted with us for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS,
part of the National Institutes of Health, made an initial award of $5.0 million to the Company. The total funding under this contract
as of December 31, 2015 could be up to $34.0 million, if all contract options are exercised by NIAID/HHS, over a five year period.
The goals of this contract, including amendments, are to file IND applications for i.v. and i.m. BCX4430 for the treatment of Marburg
virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human clinical trial.
As of December 31, 2015, a total of $29.9 million has been awarded under exercised options within this contract. BCX4430 is the
lead compound in our BSAV research program.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee
contracts. That is, we are entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions
that are related to the development of BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments
of progress and the continuation of the contract is based on our performance, the timeliness and quality of deliverables, and other
factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable
by the government at any time for breach or without cause.</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Patents and Proprietary Information</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">Our success will depend in part on our ability to obtain and enforce
patent protection for our products, methods, processes and other proprietary technologies, preserve our trade secrets, and operate
without infringing on the proprietary rights of other parties, both in the United States and in other countries. We own or have
rights to certain proprietary information, proprietary technology, issued and allowed patents and patent applications which relate
to compounds we are developing. We actively seek, when appropriate, protection for our products, proprietary technology and proprietary
information by means of U.S.&nbsp;and foreign patents, trademarks and contractual arrangements. In addition, we rely upon trade
secrets and contractual arrangements to protect certain of our proprietary information, proprietary technology and products.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">The patent positions of companies like ours are generally uncertain
and involve complex legal and factual questions. Our ability to maintain and solidify our proprietary position for our technology
will depend on our success in obtaining effective patent claims and enforcing those claims once granted. We do not know whether
any of our patent applications or those patent applications that we license will result in the issuance of any patents. Our issued
patents and those that may issue in the future, or those licensed to us, may be challenged, invalidated, rendered unenforceable
or circumvented, which could limit our ability to stop competitors from marketing related products or the length of term of patent
protection that we may have for our products. In addition, the rights granted under any issued patents may not provide us with
competitive advantages against competitors with similar compounds or technology. Furthermore, our competitors may independently
develop similar technologies or duplicate any technology developed by us in a manner that does not infringe our patents or other
intellectual property. Because of the extensive time required for development, testing and regulatory review of a potential product,
it is possible that, before any of our product candidates or those developed by our partners can be commercialized, any related
patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the
patent.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">As of December&nbsp;31, 2015, we have been issued approximately
13 U.S.&nbsp;patents that expire between 2017 and 2030 and that relate to our HAE program compounds, neuraminidase inhibitor compounds
and PNP compounds. We have licensed a number of compounds protected by certain composition of matter patents from AECOM and IRL,
plus additional manufacturing patents, totaling 14 additional U.S. patents that expire between 2017 and 2029. Additionally, we
have approximately 12 Patent Cooperation Treaty or U.S.&nbsp;patent applications pending related to HAE program compounds, neuraminidase
inhibitor compounds, BSAV and PNP compounds. Our pending applications may not result in issued patents, our patents may not cover
the products of interest or may not be enforceable in all, or any jurisdictions and our patents may not provide us with sufficient
protection against competitive products or otherwise be commercially viable. After expiration of composition of matter patents
for our products and product candidates, we may rely on data exclusivity, or in some cases, method of use patents. The enforceability
of these patents varies from jurisdiction to jurisdiction and may not be allowed or enforceable in some territories where we may
seek approval. We may not have the funds to continue patent prosecution or to defend all of our existing patents in our current
patent estate and may selectively abandon patents or patent families worldwide or in certain territories.</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Our success is also dependent upon the skills, knowledge and experience
of our scientific and technical personnel, none of which is patentable. To help protect our rights, we require all employees, consultants,
advisors and partners to enter into confidentiality agreements, which prohibit the disclosure of confidential information to anyone
outside of BioCryst and, where possible, require disclosure and assignment to us of their ideas, developments, discoveries and
inventions. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information
in the event of any unauthorized use or disclosure or the lawful development by others of such information.<b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Competition</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">The pharmaceutical and biotechnology industries are intensely competitive.
Many companies, including biotechnology, chemical and pharmaceutical companies, are actively engaged in activities similar to ours,
including research and development of drugs for the treatment of rare medical conditions. Many of these companies have substantially
greater financial and other resources, larger research and development staffs, and more extensive marketing and manufacturing organizations
than we do. In addition, some of them have considerable experience in preclinical testing, clinical trials and other regulatory
approval procedures. In addition, there are also academic institutions, governmental agencies and other research organizations
that are conducting research in areas in which we are working. We expect to encounter significant competition for any of the pharmaceutical
products we plan to develop. Companies that successfully complete clinical trials, obtain required regulatory approvals and commence
commercial sales of their products may achieve a significant competitive advantage.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"><i><u>Antivirals</u>:</i> The pharmaceutical market for products that prevent or treat influenza is very competitive. Key competitive
factors for RAPIVAB (peramivir injection) include, among others, efficacy, ease of use, safety, price and cost-effectiveness, storage
and handling requirements and reimbursement. A number of neuraminidase inhibitors are currently available in the U.S.&nbsp;and/or
other counties, including Japan, for the prevention or treatment of influenza, including seasonal flu vaccines and F. Hoffmann-La
Roche Ltd.&rsquo;s (&ldquo;Roche&rdquo;) TAMIFLU<SUP>&reg;</SUP>, GlaxoSmithKline plc&rsquo;s (&ldquo;GSK&rdquo;) RELENZA<SUP>&reg;</SUP>
and Daiichi Sankyo Co., Ltd.&rsquo;s INAVIR<SUP>&reg;</SUP>. In addition, FUJIFILM Corporation&rsquo;s favipiravir, a polymerase
inhibitor, is approved in Japan. Roche&rsquo;s neuraminidase inhibitor is also approved for prophylaxis of influenza, and both
Roche and GSK have i.v. formulations in clinical trial development.</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In January 2011, GSK announced initiation of a multi-country Phase
3 study of i.v. zanamivir (the same active ingredient as in RELENZA) in hospitalized patients with influenza. The GSK study was
completed during the 2014-2015 flu season. In addition to these companies with neuraminidase inhibitors, there are other companies
working to develop additional antiviral drugs to be used against various strains of influenza. Currently, there are a number of
other companies developing potential new influenza therapies. Various government entities throughout the world are offering incentives,
grants and contracts to encourage additional investment into preventative and therapeutic agents against influenza, which may have
the effect of further increasing the number of our competitors and/or providing advantages to certain competitors.</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">BCX4430 is a product candidate in our BSAV research program and
is currently being developed under a contract with NIAID/HHS. The objective of our BSAV program is to develop BCX4430 as a broad-spectrum
therapeutic for viruses that pose a threat to national health and security. The U.S. Government is investing in a number of programs
intended to address gaps in its medical countermeasure plan. Due to the Ebola outbreak in West Africa in 2014, investment in medical
countermeasures has increased worldwide. Therapeutic products with potentially promising data to treat Ebola include FUJIFILM Corporation&rsquo;s
favipiravir (polymerase inhibitor), Tekmira Pharmaceuticals Corporation&rsquo;s TKM-Ebola (RNAi interference based) and Mapp Biopharmaceutical,
Inc.&rsquo;s ZMapp (antibody-based). Both TKM-Ebola and ZMapp have been used in Ebola patients. Gilead Sciences, Inc announced
in October 2015 that it had provided the investigational compound, GS-5734, to two patients with Ebola for compassionate use.</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><i></i></p>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><i><u>HAE</u>:</i> HAE is an autosomal dominant disease characterized
by painful, unpredictable, recurrent attacks of inflammation affecting the hands, feet, face, abdomen, urogenital tract, and the
larynx. The inflammation can be disfiguring, debilitating, or in the case of laryngeal attacks, life-threatening. Prevalence for
HAE is uncertain but is estimated to be approximately 1 case per 50,000 persons without known differences among ethnic groups and
is caused by deficient (Type I) or dysfunctional (Type II) levels of C1-Inhibitor (&#8220;C1-INH&#8221;), a naturally occurring
molecule that is known to inhibit kallikrein, bradykinin, and other serine proteases in the blood. If left untreated, HAE can result
in a mortality rate as high as 40% primarily due to upper airway obstruction. There are a number of licensed and developmental
therapies for HAE, including the following:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%; padding-right: 0.8pt"><font style="font-family: Symbol; font-size: 10pt">&#183;</font></td>
    <td style="width: 90%; padding-right: 0.8pt"><font style="font-size: 10pt">C1-INH therapy is available as an acute therapy (Berinert<sup>&#174;</sup>) and as a prophylactic therapy (Cinryze<sup>&#174;</sup>). These therapies are available intravenously and work by replacing the missing or malfunctioning C1-INH protein in patients.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font-family: Symbol; font-size: 10pt">&#183;</font></td>
    <td style="padding-right: 0.8pt"><P STYLE="margin: 0pt 0">Kallikrein Inhibition <B>-</B> Kalbitor<SUP>&reg;</SUP> (ecallantide)
is a specific recombinant plasma kallikrein inhibitor that halts the production of bradykinin and can be dosed subcutaneously
in an inpatient setting.</P>


</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font-family: Symbol; font-size: 10pt">&#183;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">Bradykinin receptor antagonist <b>-</b> Firazyr<sup>&#174;</sup> (icatibant) is a competitive antagonist of the bradykinin B2 receptor. Firazyr is approved for the treatment of acute attacks and is administered by subcutaneous administration.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font-family: Symbol; font-size: 10pt">&#183;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">Other medications - Prophylactic administration of synthetic attenuated androgens (generically available as danazol or stanozolol) has been utilized to reduce the frequency or severity of attacks. However, long-term use of danazol or stanozolol may result in virilization and arterial hypertension. Six-month liver function tests, annual lipid profiles, and biennial hepatic ultrasound are recommended because these medications increase production of C1-INH in the liver. </font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In addition to avoralstat, BCX7353 and our other second generation
compounds, there are a number of other HAE therapies in development. These include a prophylactic plasma derived C1-INH delivered
by subcutaneous injection in Phase 3 (CSL Behring); DX-2930/SHP643, a monoclonal antibody administered by subcutaneous injection
for prophylactic treatment of HAE in Phase 3 (Shire PLC); ISIS-PKK, a RNA-targeted antisense drug to inhibit prekallikrein for
prophylactic treatment of HAE in Phase 1 (ISIS Pharmaceuticals, Inc.); and two potential oral kallikrein inhibitors being developed
by KalVista and Global Blood Therapeutics, respectively.</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In order to compete successfully in these and other therapeutic
areas, we must develop proprietary positions in patented drugs for therapeutic markets that have not been satisfactorily addressed
by conventional research strategies and, in the process, expand our expertise in structure-based drug design. Our product candidates,
even if successfully tested and developed, may not be adopted by physicians over other products and may not offer economically
feasible alternatives to other therapies.</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Research and Development</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We initiated our research and development activities in 1986. We have
assembled a scientific research staff with expertise in a broad base of advanced research technologies including protein biochemistry,
X-ray crystallography, chemistry and pharmacology. Our research facilities, located in Birmingham, Alabama, include protein biochemistry
and organic synthesis laboratories, testing facilities, X-ray crystallography, computer and graphics equipment and facilities to
make product candidates on a small scale for early stage clinical trials. During the years ended December 31, 2015, 2014 and 2013,
our research and development expenses were $72.8 million, $51.8 million and $41.9 million, respectively.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Compliance</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We conduct our business in an ethical, fair, honest and lawful manner.
We act responsibly, respectfully and with integrity in our relationships with patients, health care professionals, collaborators,
governments, regulatory entities, stockholders, suppliers and vendors.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In order to ensure compliance with applicable laws and regulations,
our Chief Financial Officer, General Counsel and Vice President of Human Resources oversee compliance training, education, auditing
and monitoring; enforce disciplinary guidelines for any infractions of our corporate polices; implement new policies and procedures;
respond to any detected issues; and undertake corrective action procedures. Our controls address compliance with laws and regulations
that govern public pharmaceutical companies including, but not limited to, the following: federal and state law, such as the Sarbanes-Oxley
Act of 2002 and the U.S. Foreign Corrupt Practices Act of 1977; NASDAQ listing requirements; the regulations of the Financial Industry
Regulatory Authority; the Securities and Exchange Commission (&ldquo;SEC&rdquo;); the FDA; and the United States Department of
Health and Human Services. Our standard operating procedures are designed to provide a framework for corporate governance in accordance
with ethical standards and best legal practices.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>



<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->
<p style="font-size: 10pt; margin: 0pt 0"><b>Government Regulation</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The FDA regulates the pharmaceutical and biotechnology industries
in the U.S., and our product candidates are subject to extensive and rigorous domestic government regulations prior to commercialization.
The FDA regulates, among other things, the development, testing, manufacture, safety, efficacy, record-keeping, labeling, storage,
approval, advertising, promotion, sale and distribution of pharmaceutical products. In foreign countries, our products are also
subject to extensive regulation by foreign governments. These government regulations will be a significant factor in the production
and marketing of any pharmaceutical products that we develop. Failure to comply with applicable FDA and other regulatory requirements
at any stage during the regulatory process may subject us to sanctions, including:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">delays;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">warning letters;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">fines;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">product recalls or seizures;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">injunctions;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">penalties;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">refusal of the FDA to review pending market approval applications or supplements to approval applications;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">total or partial suspension of production;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">civil penalties;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">withdrawals of previously approved marketing applications;&nbsp;and</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">criminal prosecutions.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The regulatory review and approval process is lengthy, expensive
and uncertain. Before obtaining regulatory approvals for the commercial sale of any products, we or our partners must demonstrate
that our product candidates are safe and effective for use in humans. The approval process takes many years, substantial expenses
may be incurred and significant time may be devoted to clinical development.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Before testing potential product candidates in humans, we carry
out laboratory and animal studies to determine safety and biological activity. After completing preclinical trials, we must file
an IND, including a proposal to begin clinical trials, with the FDA. Thirty days after filing an IND, a Phase 1 human clinical
trial can start, unless the FDA places a hold on the trial.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Clinical trials to support a NDA are typically conducted in three
sequential phases, but the phases may overlap.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Phase 1&#8212;During Phase 1, the initial introduction of the drug
into healthy volunteers, the drug is tested to assess metabolism, pharmacokinetics and pharmacological actions and safety, including
side effects associated with increasing doses.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Phase 2&#8212;Phase 2 usually involves trials in a limited patient
population to: (1)&nbsp;assess the efficacy of the drug in specific, targeted indications; (2)&nbsp;assess dosage tolerance and
optimal dosage; and (3)&nbsp;identify possible adverse effects and safety risks.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Phase 3 (pivotal) &#8212;If a compound is found to be potentially
effective and to have an acceptable safety profile in Phase 2 evaluations, Phase 3 clinical trials, also called pivotal studies,
major studies or advanced clinical trials, are undertaken to further demonstrate clinical efficacy and to further test for safety
within an expanded patient population at geographically dispersed clinical trial sites. In general, the FDA requires that at least
two adequate and well-controlled Phase 3 clinical trials be conducted.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Initiation and completion of the clinical trial phases are dependent
on several factors including things that are beyond our control. For example, the clinical trials cannot begin at a particular
site until that site receives approval from its Institutional Review Board (&#8220;IRB&#8221;), which reviews the protocol and
related documents. This process can take from several weeks to several months. In addition, clinical trials are dependent on patient
enrollment, but the rate at which patients enroll in the study depends on:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">willingness of investigators to participate in a study;</font></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">ability of clinical sites to obtain approval from their IRB;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">the availability of the required number of eligible subjects to be enrolled in a given trial;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">the availability of existing or other experimental drugs for the disease we intend to treat;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">the willingness of patients to participate;&nbsp;and</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">the patients meeting the eligibility criteria.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Delays in planned patient enrollment may result in increased expense
and longer development timelines.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">After successful completion of the required clinical testing, generally
an NDA is submitted. Upon receipt of the NDA, the FDA will review the application for completeness. Within 60 days, the FDA will
determine if the application is sufficiently complete to warrant full review and will consider the application &#8220;filed&#8221;
at that time. Also upon receipt of the application, the FDA will assign a review priority to the application. Priority review applications
are usually reviewed within 8 months; standard review applications are usually reviewed within 12 months. The FDA will usually
refer NDAs for new molecular entities to an appropriate advisory committee for review and evaluation in regards to providing a
recommendation as to whether the application should be approved. The FDA is not bound to follow the recommendation of an advisory
committee.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Following the review of the application, which may include requests
for additional information from the sponsor and&nbsp;results from inspections of manufacturing and clinical sites, the FDA will
issue an &#8220;action letter&#8221; on the application. The action letter will either be an &#8220;approval letter,&#8221; in
which case the product may be lawfully marketed in the United States, or a &#8220;complete response letter.&#8221; A complete response
letter will state that the FDA cannot approve the NDA in its present form and, usually, will describe all of the specific deficiencies
that the FDA has identified in the application. The complete response letter, when possible, will include the FDA&#8217;s recommended
actions to place the application in a condition for approval. Deficiencies can be minor (e.g., labeling changes) or major (e.g.,
requiring additional clinical trials). A complete response letter may also be issued before the FDA conducts the required facility
inspection and/or reviews labeling, leaving the possibility that additional deficiencies in the original NDA could be subsequently
cited. An applicant receiving a complete response letter is permitted to resubmit the NDA addressing the identified deficiencies
(in which case a new two or six month review cycle will begin), or withdraw the NDA. The FDA may consider a failure to take action
within one year of a complete response letter to be a request to withdraw, unless the applicant has requested an extension of time
in which to resubmit. If the FDA approves an NDA, the marketing of the product will be limited to the particular disease states
and conditions of use that are described in the product label.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We and all of our contract manufacturers are also required to comply
with the applicable FDA current Good Manufacturing Practice, or cGMP, regulations during clinical development and to ensure that
the product can be consistently manufactured to meet the specifications submitted in an NDA. The cGMP regulations include requirements
relating to product quality as well as the corresponding maintenance of records and documentation. Manufacturing facilities must
be approved by the FDA before they can be used to manufacture our products. Based on an inspection, the FDA determines whether
manufacturing facilities are in compliance with applicable regulations. Manufacturing facilities in non-United States countries
that are utilized to manufacture drugs for distribution into the United States are also subject to inspection by the FDA. Additionally,
failure to comply with local regulatory requirements could affect production and availability of product in relevant markets.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Human Resources</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">As of January&nbsp;31, 2016, we had approximately 70&nbsp;employees,
of whom approximately 50 were engaged in the research and development function of our operations. Our research and development
staff, 24 of whom hold Ph.D. or M.D. degrees, have diversified experience in biochemistry, pharmacology, X-ray crystallography,
synthetic organic chemistry, computational chemistry, medicinal chemistry, clinical development and regulatory affairs.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Our employees are not represented by any collective bargaining agreements,
and we have never experienced a work stoppage. Employees are required to execute confidentiality and assignment of intellectual
property agreements. We consider our relations with our employees to be satisfactory.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Available Information</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">We have available a website on the Internet. Our address is www.biocryst.com.
We make available, free of charge, at our website our Annual Reports on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current
Reports on Form&nbsp;8-K, and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange
Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. We also make
available at our website copies of our audit committee charter, compensation committee charter, corporate governance and nominating
committee charter and our code of business conduct, which applies to all our employees as well as the members of our Board of Directors.
Any amendment to, or waiver from, our code of business conduct will be posted on our website.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b>Financial Information</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">For information related to our revenues, profits, net loss and total
assets, in addition to other financial information, please refer to the Financial Statements and Notes to Financial Statements
contained in this Annual Report. Financial information about revenues derived from foreign countries is included in Note&nbsp;1
to the Financial Statements contained in this Annual Report.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_002"></a>ITEM 1A. <i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><i>An investment in our stock involves risks. You should carefully
read this entire report and consider the following uncertainties and risks, which may adversely affect our business, financial
condition or results of operations, along with all of the other information included in our other filings with the Securities and
Exchange Commission, before deciding to buy our common stock.</i></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Risks Relating to Our Business</b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>We have incurred losses since our inception, expect to continue to incur
such losses, and may never be profitable.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Since our inception, we have not achieved sustained profitability.
We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development
efforts progress. We expect that such losses will fluctuate from quarter to quarter and losses and fluctuations may be substantial.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">To become profitable, we, or our collaborative partners, must successfully
manufacture and develop product candidates, receive regulatory approval, and successfully commercialize and/or enter into profitable
agreements with other parties. It could be several years, if ever, before we receive significant revenue from any current or future
license agreements or revenues directly from product sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Because of the numerous risks and uncertainties associated with developing
our product candidates and their potential for commercialization, we are unable to predict the extent of any future losses. Even
if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are
unable to achieve and sustain profitability, the market value of our common stock will likely decline.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Our success depends upon our ability to advance our products through
the various stages of development, especially through the clinical trial process.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">To receive the regulatory approvals necessary for the sale of our
product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate
is safe and effective. The development process and related regulatory process are complex and uncertain. Because of the cost and
duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show good results
in the clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable
commercial potential. We may suffer significant setbacks in pivotal pre-clinical studies and clinical trials (e.g. BCX4430, avoralstat,
BCX7353 and our other rare disease product candidates), even after earlier clinical trials show promising results. The development
of our product candidates, including our clinical trials, may not be adequately designed or executed, which could affect the potential
outcome and analysis of study results. Any of our product candidates may produce undesirable side effects in humans. The pre-clinical
and clinical data from our product candidates could cause us or regulatory authorities to interrupt, delay, modify or halt preclinical
or clinical trials of a product candidate. Undesirable or inconclusive data or side effects in humans could also result in the
FDA or foreign regulatory authorities refusing to approve the product candidate for any targeted indications. In addition, the
FDA or other regulatory agencies may determine that study data from our product candidates necessitates additional studies or study
designs which differ from our planned development strategy, and regulatory agencies may also require patient monitoring and testing
or may implement restrictions or other conditions on our development activities, any of which could materially impact the cost
and timing of our planned development strategy. We, our partners, the FDA or foreign regulatory authorities may suspend or terminate
clinical trials at any time if we or they believe the trial participants face unacceptable health risks. Clinical trials may fail
to demonstrate that our product candidates are safe or effective and have acceptable commercial viability. Regulatory authorities
may interrupt, delay or halt clinical trials for a product candidate for any number of reasons.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our ability to successfully complete clinical trials is dependent
upon many factors, including but not limited to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">our ability to find suitable clinical sites and investigators to enroll patients;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"></td></tr></table>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; width: 3%">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; width: 95%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><font style="font-size: 10pt">the ability to maintain contact with patients to provide complete data after treatment;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><font style="font-size: 10pt">our product candidates may not prove to be either safe or effective;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><font style="font-size: 10pt">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><font style="font-size: 10pt">formulation improvements may not work as expected, which could negatively impact commercial demand for our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><font style="font-size: 10pt">manufacturing or quality control problems could affect the supply of product candidates for our trials; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><font style="font-size: 10pt">delays or changes in our planned development strategy, the regulations or guidelines, or other unexpected conditions or requirements by governmental agencies.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Clinical trials are lengthy and expensive. We or our partners incur
substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that
the tests and trials will ever result in the commercial sale of a product. For example, clinical trials require adequate supplies
of drug and sufficient patient enrollment. Lack of adequate drug supply or delays in patient enrollment can result in increased
costs and longer development times. Even if we or our partners successfully complete clinical trials for our product candidates,
we or our partners might not file the required regulatory submissions in a timely manner and may not receive regulatory approval
for the product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>We focus on rare diseases, which may create additional risks and challenges.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Because we focus on developing drugs as treatments for rare diseases,
we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the
equivalent designations elsewhere in the world. Often, regulatory agencies have broad discretion in determining whether or not
to grant such designations. We cannot guarantee that we will be able to receive orphan drug status from the FDA or equivalent regulatory
designations elsewhere. We also cannot guarantee that we will obtain breakthrough therapy or fast track designation, which may
provide certain potential benefits such as more frequent meetings with the FDA to discuss the development plan, intensive guidance
on an efficient drug development program, and potential eligibility for rolling review or priority review. Even if we are successful
in obtaining any such designation by the FDA or other regulatory agency for our product candidates, such designations may not lead
to faster development or regulatory review or approval, and it does not increase the likelihood that our product candidates will
receive marketing approval. We may not be able to obtain or maintain such designations for our product candidates, and our competitors
may obtain these designations for their product candidates, which could impact our ability to develop and commercialize our product
candidates or compete with such competitors, which may adversely impact our business, financial condition or results of operations.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have received orphan and fast track designations for avoralstat
in the United States. Despite this designation; we may not experience a faster development, review or approval process compared
to the conventional FDA procedures. The FDA may withdraw fast track designation if it believes the designation is no longer supported
by data from our clinical development program. Although we have also received Sakigake designation for BCX7353 in Japan, we may
not experience a faster development, review or approval process compared to the conventional process.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Our clinical trials may not adequately show that our product candidates
are safe or effective.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Progression of our product candidates through the clinical development
process is dependent upon our trials indicating our product candidates have adequate safety and efficacy in the patients being
treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols. Failure to achieve
any of these endpoints in any of our programs, including avoralstat, BCX7353 and our other rare disease product candidates, could
result in delays in our trials or require the performance of additional unplanned trials. This could result in delays in the development
of our product candidates and could result in significant unexpected costs or the termination of programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>If our development collaborations with third parties, such as our development
partners and contract research organizations, fail, the development of our product candidates will be delayed or stopped.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We rely heavily upon third parties for many important stages of our
product candidate development, including but not limited to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">discovery of compounds that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"></td></tr></table>

<!-- Field: Page; Sequence: 20; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; width: 3%">&nbsp;</td>
    <td style="padding-right: 0.8pt; width: 95%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">licensing or designing of enzyme inhibitors for development as product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">execution of certain preclinical studies and late-stage development for our compounds and product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">management of our clinical trials, including medical monitoring and data management;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">execution of additional toxicology studies that may be required to obtain approval for our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">formulation improvement strategies and methods, including those for avoralstat; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our failure to engage in successful collaborations at any one of these
stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from
other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research
organizations that conduct our initial or late-stage clinical trials, conduct our toxicology studies, manufacture our starting
materials, drug substance and product candidates or manage our regulatory function breached their obligations to us or perform
their services inconsistent with industry standards and not in accordance with the required regulations, this would delay or prevent
both the development of our product candidates and the availability of any potential commercial product.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we lose our relationship with any one or more of these parties,
we could experience a significant delay in both identifying another comparable provider and then contracting for its services.
We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it
is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service
as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices
(&#8220;cGLP&#8221;), current Good Manufacturing Practices (&#8220;cGMP&#8221;) and current Good Clinical Practices (&#8220;cGCP&#8221;),
and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently,
if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates
could be delayed. If any of the foregoing risks are realized, our business, financial condition and results of operations could
be materially adversely affected.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Because we have limited manufacturing experience, we depend on third-party
manufacturers to manufacture our product, product candidates and the materials for our product candidates. Often, especially early
in the development and commercialization process, we have only one source for manufacturing. If we cannot rely on existing third-party
manufacturers, we will be required to incur significant costs and potential delays in finding new third-party manufacturers.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have limited manufacturing experience and only a small scale manufacturing
facility. We currently rely upon a very limited number of third-party manufacturers to manufacture the materials required for our
product, product candidates and most of the preclinical and clinical quantities of our product candidates. We depend on these third-party
manufacturers to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party
manufacturers, which may be the only manufacturer we have engaged for a particular product, may encounter difficulties with meeting
our requirements including but not limited to problems involving:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">inconsistent production yields;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">product liability claims or recalls of commercial product;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">difficulties in scaling production to commercial and validation sizes;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">interruption of the delivery of materials required for the manufacturing process;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">scheduling of plant time with other vendors or unexpected equipment failure;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">potential catastrophes that could strike their facilities or have an effect on infrastructure;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"></td></tr></table>

<!-- Field: Page; Sequence: 21; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; width: 3%">&nbsp;</td>
    <td style="padding-right: 0.8pt; width: 95%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">poor quality control and assurance or inadequate process controls; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies, particularly associated with RAPIVAB and planned studies for avoralstat, BCX7353 and BCX4430.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These contract manufacturers may not be able to manufacture
the materials required for our product candidates at a cost or in quantities necessary to make them commercially viable. We also
have no control over whether third-party manufacturers breach their agreements with us or whether they may terminate or decline
to renew agreements with us. To date, our third-party manufacturers have met our manufacturing requirements, but they may not continue
to do so. Furthermore, changes in the manufacturing process or procedure, including a change in the location where the drug is
manufactured or a change of a third-party manufacturer, may require prior review and approval in accordance with the FDA&#8217;s
cGMP and comparable foreign requirements. This review may be costly and time-consuming and could delay or prevent the launch of
a product. The FDA or similar foreign regulatory agencies may at any time implement new standards, or change their interpretation
and enforcement of existing standards for manufacture, packaging or testing of products. If we or our contract manufacturers are
unable to comply, we or they may be subject to regulatory action, civil actions or penalties any of which could be costly to the
Company and could result in a delay or shortage of product.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we are unable to maintain current manufacturing or other contract
relationships, or enter into new agreements with additional manufacturers on commercially reasonable terms, or if there is poor
manufacturing performance or failure to comply with any regulatory agency on the part of any of our third-party manufacturers,
we may not be able to complete development of, seek timely approval of, or market, our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our raw materials, drug substances, and product candidates are manufactured
by a limited group of suppliers, including some at a single facility. If any of these suppliers were unable to produce these items,
this could significantly impact our supply of product candidate material for further preclinical testing and clinical trials.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>We face intense competition, and if we are unable to compete effectively,
the demand for our products, if any, may be reduced.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The biotechnology and pharmaceutical industries are highly competitive
and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications
that we currently target. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational
pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than
we do, including greater financial resources, larger research and development staffs and more experienced marketing and manufacturing
organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining
FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of
product candidates more rapidly than we do. Companies that complete clinical trials, obtain required regulatory approvals, and
commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA
exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the licensing
of potential product candidates for desirable disease targets licensing of desirable product candidates, and development and marketing
of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical
companies. Competition may also arise from, among other things:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">other drug development technologies;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">methods of preventing or reducing the incidence of disease, including vaccines;&nbsp;and</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">new small molecule or other classes of therapeutic agents.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Developments by others may render our product candidates
or technologies obsolete or noncompetitive.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We and our partners are performing research on or developing products for the treatment of several disorders
including HAE and recurrent/refractory peripheral T-cell lymphoma, as well as broad spectrum antivirals that may be developed as
medical countermeasures. We expect to encounter significant competition for any of the pharmaceutical products we plan to develop.
Companies that complete clinical trials, obtain required funding or government support, obtain required regulatory approvals and
commence commercial sales or stockpiling orders of their products before their competitors may achieve a significant competitive
advantage. Such is the case with Eisai Co. Ltd.&rsquo;s TARGRETIN<SUP>&reg;</SUP> for cutaneous T-lymphoma; the current neuraminidase
inhibitors marketed by GSK and Roche for influenza; CINRYZE<SUP>&reg;</SUP>, KALBITOR<SUP>&reg;</SUP> and FIRAZYR<SUP>&reg;</SUP>,
marketed by Shire Pharmaceuticals, Inc. for HAE; and BERINERT<SUP>&reg;</SUP>, marketed by CSL for HAE. Therapeutic products with
potentially promising data to treat Ebola include Mapp Biopharmaceutical, Inc.&rsquo;s ZMapp (antibody-based) and Gilead Sciences,
Inc.&rsquo;s product currently under development (small molecule), both of which have been used in Ebola infected patients. Further,
several pharmaceutical and biotechnology firms, including major pharmaceutical companies and specialized structure-based drug design
companies, have announced efforts in the field of structure-based drug design and molecules in development in the fields of HAE
and in other therapeutic areas where we have discovery and development efforts ongoing. If one or more of our competitors&rsquo;
products or programs are successful, the market for our products may be reduced or eliminated.</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Compared to us, many of our competitors and potential competitors
have substantially greater:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">capital resources;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">research and development resources, including personnel and technology;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">regulatory experience;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">preclinical study and clinical testing experience;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">manufacturing and marketing experience;&nbsp;and</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">production facilities.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Any of these competitive factors could impede our funding efforts,
render technology and product candidates noncompetitive or eliminate or reduce demand for our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>We face risks related to our government-funded programs; if BARDA/HHS
or NIAID/HHS were to eliminate, reduce or delay funding from our contracts, this would have a significant negative impact on the
programs associated with such funding and could have a significant negative impact on our revenues and cash flows.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our projections of revenues and incoming cash flows are substantially
dependent upon BARDA/HHS and NIAID/HHS reimbursement for the costs related to our BCX4430 program. If BARDA/HHS or NIAID/HHS were
to eliminate, reduce or delay the funding for these programs or disallow some of our incurred costs, we would have to obtain additional
funding for continued development or regulatory registration for these product candidates or significantly reduce or stop the development
effort.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In contracting with BARDA/HHS and NIAID/HHS, we are subject to various
U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which
may limit our reimbursement or if we are found to be in violation could result in contract termination. If the U.S. Government
terminates any of its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract
schedule and terms, significant negative impact on our cash flows and operations could result.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Our government contracts with BARDA/HHS and NIAID/HHS have special contracting
requirements, which create additional risks of reduction or loss of funding.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have completed work under a contract with BARDA/HHS for
the development of our neuraminidase inhibitor, peramivir. We also have entered into contracts with BARDA/HHS and NIAID/HHS for
the development of BCX4430 as a treatment for diseases caused by RNA pathogens, including Marburg virus disease and Ebola virus
disease. In contracting with these government agencies, we are subject to various U.S. Government contract requirements, including
general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found
to be in violation, could result in contract termination. &nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">U.S. Government contracts typically contain a number of extraordinary
provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to
us as compared to competitors that do not rely on U.S. Government contracts. These risks include the ability of the U.S. Government
to unilaterally:</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">terminate or reduce the scope of our contract with or without cause;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">interpret relevant regulations (federal acquisition regulation clauses);</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">require performance under circumstances which may not be favorable to us;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">require an in process review where the U.S. Government will review the project and its options under the contract;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"></td></tr></table>

<!-- Field: Page; Sequence: 23; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; width: 3%">&nbsp;</td>
    <td style="padding-right: 0.8pt; width: 95%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">control the timing and amount funding, which impacts the development progress of our programs; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">audit and object to our contract-related costs and fees, including allocated indirect costs.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Our government contracts with BARDA/HHS and NIAID/HHS have termination
and audit provisions which create additional risks to us. </i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The U.S. Government may terminate its contracts with us either for
its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience
provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work
completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination
or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses
under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments
under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. Further,
if the U.S. Government terminates its contracts with us for its convenience, or if we default by failing to perform in accordance
with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As a U.S. Government contractor, we are required to comply with applicable
laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of
any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control systems
and policies, including those relating to our purchasing, property, estimating, compensation and management information systems.
Audits conducted by the U.S. Government for the completed BARDA/HHS contract have been performed and concluded through fiscal 2009;
all subsequent fiscal years are still open and auditable. Audits under the active BARDA/HHS and NIAID/HHS contracts may occur at
the election of the U.S. Government and have been concluded through fiscal 2013. Based on the results of its audits, the U.S. Government
may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment could impact the amount of
revenues reported on a historic basis and could impact our cash flows under the contracts prospectively. In addition, in the event
BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the allocated indirect cost rate
was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup any overpayment from us as a
result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties
and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines and
suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputation if
allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations, some of our costs may
not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject to an increased risk
of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared
to private sector commercial companies.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>If we fail to reach milestones or to make annual minimum payments or
otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional
remedies.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we are unable or fail to meet payment obligations, performance
milestones relating to the timing of regulatory filings, product supply obligations, post approval commitments for RAPIVAB, or
development and commercial diligence obligations; are unable or fail to make milestone payments or material data use payments in
accordance with applicable provisions; or fail to pay the minimum annual payments under our respective licenses, our licensors
may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate
or commercialization of the product would cease.&nbsp;&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>If we fail to obtain additional financing or acceptable partnership
arrangements, we may be unable to complete the development and commercialization of our product candidates or continue operations.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As our programs advance, our costs are likely to increase. Our current
and planned discovery activities, pre-clinical and clinical trials, the related development, manufacturing, regulatory approval
process requirements, and the additional personnel resources and testing required for supporting the development of our product
candidates will consume significant capital resources. Our expenses, revenues and cash utilization rate could vary significantly
depending on many factors, including: our ability to raise additional capital; the development progress of our collaborative agreements
for our product candidates; the amount of funding we receive from NIAID/HHS and BARDA/HHS for BCX4430 or from other new partnerships
with third parties for the development of our product candidates, including avoralstat, BCX7353 and our other rare disease product
candidates; the commercial success of peramivir achieved by our partners; the amount or profitability of any orders for RAPIVAB
or BCX4430 by any government agency or other party; the progress and results of our current and proposed clinical trials for our
most advanced product candidates, including avoralstat, BCX7353 and our other rare disease product candidates; the progress made
in the manufacture of our lead products and the progression of our other programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 24; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We expect that we will be required to raise additional capital to
complete the development and commercialization of our current product candidates and we may seek to raise capital at any time.
Additional funding, whether through additional sales of securities or collaborative arrangements with partners, including governmental
agencies in general and from any BARDA/HHS or NIAID/HHS contract specifically, may not be available when needed or on terms acceptable
to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable
than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or
rights of our existing stockholders. In addition, collaborative arrangements may require us to transfer certain material rights
to such corporate partners. Insufficient funds or lack of an acceptable partnership may require us to delay, scale-back or eliminate
certain of our research and development programs.&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">In order to continue future operations and continue our drug development
programs, we will be required to raise additional capital. In addition to seeking strategic partnerships, transactions and government
funding, we may decide to access the equity or debt markets or seek other sources to meet liquidity needs. Our ability to raise
additional capital may be limited and may greatly depend upon the success of ongoing development related to our current drug development
programs, including post approval studies for RAPIVAB,&nbsp;the progress, timeline and ultimate outcome of&nbsp;the avoralstat
development program (including, but not limited to, formulation trials, phase 3 trials, long-term human safety studies, and the
timing of carcinogenicity studies), the progress of BCX7353 and our other rare disease product candidates, funding for and continued
successful development of BCX4430, and the progress of our early discovery programs. In addition, constriction and volatility in
the equity and debt markets may restrict our future flexibility to raise capital when such needs arise. Furthermore, we have exposure
to many different industries, financing partners and counterparties, including commercial banks, investment banks and partners
(which include investors, licensing partners, and the U.S. Government) which may be unstable or may become unstable in the current
economic and political environment. Any such instability may impact these parties&rsquo; ability to fulfill contractual obligations
to us or they might limit or place burdensome conditions upon future transactions with us. Also, it is possible that suppliers
may be negatively impacted. Any such unfavorable outcomes in our current programs or unfavorable economic conditions could place
severe downward pressure on the price of our common stock and may decrease opportunities to raise capital in the capital or credit
markets, and further could reduce the return available on invested corporate cash, which, if severe and sustained, could have a
material and adverse impact on our results of operations and cash flows and limit our ability to continue development of our product
candidates.</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>If we fail to successfully commercialize or establish collaborative
relationships to commercialize certain of our product candidates, or if any partner terminates or fails to perform its obligations
under agreements with us, potential revenues from commercialization of our product candidates could be reduced, delayed or eliminated.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our business strategy is to increase the asset value of our product
candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with
third parties as appropriate. As needed, potential third-party relationships could include preclinical development, clinical development,
regulatory approval, marketing, sales and distribution of our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Currently, we have established collaborative relationships with Mundipharma
for the development and commercialization of forodesine and with each of Shionogi and Green Cross for the development and commercialization
of peramivir, in Japan, Taiwan and South Korea. Most recently we have established a collaborative relationship with Seqirus UK
Limited for RAPIVAB in the United States and countries other than Israel, Japan, Korea and Taiwan. The process of establishing
and implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, including post approval clinical commitments, a change in business strategy, a change of control or other reasons;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">our contracts for collaborative arrangements may expire;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">our partners may choose to pursue alternative technologies, including those of our competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">we may have disputes with a partner that could lead to litigation or arbitration;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">we do not have day to day control over the activities of our partners and have limited control over their decisions;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"></td></tr></table>

<!-- Field: Page; Sequence: 25; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; width: 3%">&nbsp;</td>
    <td style="padding-right: 0.8pt; width: 95%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">we or our partners may not devote sufficient capital or resources towards our product candidates; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">we or our partners may not comply with applicable government regulatory requirements.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we or our partners fail to fulfill our responsibilities in a timely
manner, or at all, our commercialization efforts related to that collaboration could be reduced, delayed or terminated, or it may
be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our partner. If
we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue further
development of one or more of our product candidates, undertake commercialization activities at our own expense or find alternative
sources of funding. Any delay in the development or commercialization of our product candidates would severely affect our business,
because if our product candidates do not progress through the development process or reach the market in a timely manner, or at
all, we may not receive additional future event payments and may never receive milestone, product sales or royalty payments.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>We do not have a great deal of experience in commercializing our products
or technologies, and our future revenue generation is uncertain.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not have a great deal of experience in commercializing our
products or technologies. We currently have limited marketing and commercial capability, no direct or third-party sales force
and limited distribution capabilities. We may be unable to establish or sufficiently increase these capabilities for products
we currently, or plan to, commercialize. In addition, our revenue from collaborative agreements may be dependent upon the status
of our preclinical and clinical programs. If we fail to advance these programs to the point of being able to enter into successful
collaborations, we will not receive any potential future event or other collaborative payments.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our ability to receive revenue from products we commercialize presents
several risks, including:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">we or our collaborators may fail to successfully complete clinical trials, or satisfy post-marketing commitments, sufficient to obtain and keep FDA marketing approval;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company and our products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">our ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">reimbursement is constantly changing, which could greatly affect usage of our products; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market and commercialize our approved drugs.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Commercialization of RAPIVAB by our partners
is subject to the potential commercialization risks described herein and numerous additional risks. Any potential revenue benefits
to us in the form of milestone payments, royalties or other consideration are highly speculative.</i></b> &nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Commercialization success of RAPIVAB is uncertain and is subject to
all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition,
commercialization of RAPIVAB is subject to further risks and may be negatively impacted by a number of factors, including, but
not limited to, the following:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">RAPIVAB may not prove to be adequately safe and effective for market approval in markets other than the United States;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"></td></tr></table>

<!-- Field: Page; Sequence: 26; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; width: 3%">&nbsp;</td>
    <td style="padding-right: 0.8pt; width: 95%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">necessary funding for post-marketing commitments and further development of RAPIVAB may not be available timely, at all, or in sufficient amounts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">flu prevention or pandemic treatment concerns may not materialize at all, or in the near future;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">advances in flu vaccines or other antivirals, including competitive i.v. antivirals, could substantially replace potential demand for RAPIVAB;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">a limited number of governmental entities are expected to be the primary potential stockpiling customers for RAPIVAB and if we are not successful at marketing RAPIVAB to these entities for any reason, we will not receive substantial revenues from stockpiling orders;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">government and third party payors may not provide sufficient coverage or reimbursement which would negatively impact the demand for RAPIVAB;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">the commercial demand and acceptance for RAPIVAB by healthcare providers and by patients may not be sufficient to result in substantial revenues of RAPIVAB to our partners and may result in little to no milestones or royalties to us;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">effectiveness of marketing efforts for RAPIVAB by our partners;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">market satisfaction with existing alternative therapies;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">perceived efficacy relative to other available therapies;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">disease prevalence;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">cost of treatment;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">pricing and availability of alternative products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">marketing and sales activities of competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">shifts in the medical community to new treatment paradigms or standards of care; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">relative convenience and ease of administration.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>We are subject to various federal and state laws related to RAPIVAB
and other products under development and, if we or our partners do not comply with these regulations, we could face substantial
penalties.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our or our partners activities related to RAPIVAB, or any of our
other products under development and following their regulatory approval, are subject to regulatory and law enforcement
authorities in addition to the FDA, including the Federal Trade Commission, the Department of Justice, and state and local
governments. In the case of our collaboration with SUL, although SUL is responsible for RAPIVAB marketing and
commercialization efforts, we continue to carry certain risks associated with RAPIVAB because we hold the RAPIVAB NDA. For
example, we are responsible for reporting adverse drug experiences, we have responsibility for certain post-approval studies,
we may have responsibilities and costs related to a recall or withdrawal of RAPIVAB from sale, we may incur liability
associated with RAPIVAB manufacturing contracted by us or in support of any of our partners, we are required to maintain
records and provide data and reports to regulatory agencies related to RAPIVAB (e.g. risk evaluation and mitigation
strategies, track and trace requirements, adverse events), and we may incur certain promotional regulatory and government
pricing risks, all of which could have a material adverse impact on our operations and financial condition. In addition, we
are now subject to the federal physician sunshine act and certain similar legislation in various states. We are subject to
various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including both federal and state
anti-kickback laws. Although we seek to comply with these statutes, it is possible that our practices, or those of our
distributors, might be challenged under anti-kickback or similar laws. Violations of the physician sunshine act and similar
state legislation or the fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and
civil monetary penalties, and future exclusion from participation in government healthcare programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have a number of outstanding post-marketing commitments to the
FDA that we retain, despite our partnership with SUL, which we may not complete successfully or on time for any number of reasons,
including but not limited to lack of funds to complete the studies and insufficient interest by appropriate sites, investigators
or study subjects. For example, as a condition of the approval of RAPIVAB, we are required to complete a pediatric patient study
of RAPIVAB and to submit the final results of this clinical trial to the FDA. Depending on the outcome of this clinical trial,
we may be unable to expand the indication for RAPIVAB or we may be required to include specific warnings or limitations on dosing
this product, which could negatively impact sales of RAPIVAB and negatively impact our relationship with our partner. We may be
subject to penalties if we fail to comply with post-approval legal and regulatory requirements and our products could be subject
to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies.
Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed or to
the other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore, the
approval of RAPIVAB and any other future product candidates may be subject to requirements for costly post-marketing testing and
surveillance to monitor its safety or efficacy.&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Advertising and promotion are subject to stringent FDA rules and oversight
and as the holder of the NDA we may be held responsible for any advertising and promotion conducted by our partner that is not
in compliance with the rules and regulations. In particular, the claims in all promotional materials and activities must be consistent
with the FDA approvals for approved products, and must be appropriately substantiated and fairly balanced with information on the
safety risks and limitations of the products. Adverse event information concerning approved products must be reviewed and as the
NDA holder of RAPIVAB we are required to make expedited and periodic adverse event reports to the FDA and other regulatory authorities.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, the research, manufacturing, distribution, sale and promotion
of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including
the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department
of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. Until we can
successfully transfer the pricing responsibilities to our partner, we remain responsible for pricing and rebate programs. Pricing
and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended,
and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply
Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially
subject to federal and state consumer protection and unfair competition laws.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If our operations with respect to RAPIVAB or our other products that
are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws described
above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties,
damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring
of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs
can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any
action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal
expenses and divert our management's attention from the operation of our business. Moreover, achieving and sustaining compliance
with all applicable federal and state fraud and abuse laws may be costly.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>We and our partners may be subject to
new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance and
adversely affect our or our partners ability to market our products, including RAPIVAB, obtain collaborators and raise
capital.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Patient Protection and Affordable Care Act, or PPACA, made extensive changes to the delivery of health
care in the U.S. The PPACA includes numerous provisions that affect pharmaceutical companies, some of which became effective immediately
and others of which will be taking effect over the next several years. For example, the PPACA seeks to expand health care coverage
to the uninsured through private health insurance reforms and an expansion of Medicaid. The PPACA will also impose substantial
costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid to Medicaid, new drug discounts that must
be offered to certain enrollees in the Medicare prescription drug benefit, an annual fee imposed on all manufacturers of brand
prescription drugs in the U.S., and an expansion of an existing program requiring pharmaceutical discounts to certain types of
hospitals and federally subsidized clinics. The PPACA also contains cost containment measures that could reduce reimbursement levels
for health care items and services generally, including pharmaceuticals. It also will require reporting and public disclosure of
payments and other transfers of value provided by pharmaceutical companies to physicians and teaching hospitals. We cannot predict
what effect the PPACA or other healthcare reform initiatives that may be adopted in the future will have on our business. Further,
it remains unclear whether there will be any changes made to provisions of the PPACA or other health care laws through acts of
Congress in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors
of health care services to contain or reduce costs of health care could result in decreased net revenues from our pharmaceutical
products and decrease potential returns from our development efforts. In addition, pharmaceutical and device manufacturers will
also be required to report and disclose investment interests held by physicians and their immediate family members during the preceding
calendar year. &nbsp;Failure to submit required information may result in civil monetary penalties for payments, transfers of value
or ownership or investment interests not reported in an annual submission. Compliance with the PPACA and state laws with similar
provisions is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. Because
of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could
be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business,
financial condition, results of operations and growth prospects.</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 28; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, there have been a number of other legislative and regulatory
proposals aimed at changing the pharmaceutical industry. In particular, legislation has been enacted in certain states and proposed
at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable
unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational
expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could face
a material adverse effect on our business, financial condition, results of operations and growth prospects.&nbsp; As a result of
these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change
our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of
operations.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Managed care organizations are increasingly challenging the prices
charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many managed
care organizations negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement
levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the managed care organization&#8217;s
patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months
before a particular payor initially reviews our product and makes a decision with respect to coverage. For example, third-party
payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of RAPIVAB or any other product
we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement
on a similar or preferred basis to competitive products, or at all which may have a material adverse effect on our business, financial
condition and results of operations. &nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>There are risks related to the potential government use or sale of peramivir
(RAPIVAB).</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">United States Government use or sale of RAPIVAB in emergency situations,
or otherwise, may result in the use of RAPIVAB outside of its approved use. To the extent that RAPIVAB is used as a treatment for
influenza by the U.S. Government or peramivir by any other government entity, there can be no assurance that it will prove to be
generally safe, well-tolerated and effective. Such government use of peramivir may create certain liabilities for us or our partners
in the case of government use outside of the U.S. There is no assurance that we or our manufacturers will be able to fully meet
the demand for peramivir in the event of additional orders. Further, we may not achieve a favorable price for additional orders
of RAPIVAB in the U.S. or peramivir in any other country. Our competitors may develop products that could compete with or replace
peramivir. We may face competition in markets where we have no existing intellectual property protection or are unable to successfully
enforce our intellectual property rights.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There is no assurance that the non-U.S. partnerships that we have entered into for peramivir will result
in any order for peramivir in those countries. There is no assurance that peramivir will be approved for any use or will achieve
market approval in additional countries. In the event that any emergency use or market approval is granted, there is no assurance
that any government order or commercialization of peramivir in any countries will be substantial or will be profitable to us. In
addition, the sale of peramivir, emergency use or other use of peramivir in any country may create certain liabilities for us and
our partners.</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>If we or our partners do not obtain and maintain governmental approvals
for our product candidates under development, we or our partners will not be able to sell these potential products, which would
significantly harm our business because we will receive no revenue.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We or our partners must obtain regulatory approval before marketing
or selling our future product candidates. If we or our partners are unable to receive regulatory approval and do not market or
sell our future product candidates, we will never receive any revenue from such product sales. In the United States, we or our
partners must obtain FDA approval for product candidates that we intend to commercialize. The process of preparing for and obtaining
FDA approval may be lengthy and expensive, and approval is never certain. Products distributed abroad are also subject to foreign
government regulation and export laws of the United States. Because of the risks and uncertainties in biopharmaceutical development,
our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval.
If the FDA delays regulatory approval of our product candidates, our management&#8217;s credibility, our value and our operating
results may suffer. Even if the FDA or foreign regulatory agencies approve a product candidate, the approval may limit the indicated
uses for a product candidate and/or may require post-approval studies.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 29; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The FDA regulates, among other things, the record keeping and storage
of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical
data and our manufacturing data at our facility. While we do store duplicate copies of most of our clinical data offsite and a
significant portion of our data is included in regular backups of our systems, we could lose important data if our facility incurs
damage, or if our vendor data systems fail, suffer damage or are destroyed. If we receive approval to market our potential products,
whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements
are wide ranging and govern, among other things:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">adverse drug experience reporting regulations;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">product promotion;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">product manufacturing, including good manufacturing practice requirements;&nbsp;and</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">product changes or modifications.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our failure to comply with existing or future regulatory requirements,
or our loss of, or changes to, previously obtained approvals, could have a material adverse effect on our business because we will
not receive product or royalty revenues if we or our partners do not receive approval of our products for marketing. &nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Royalties and milestone payments from Shionogi under our license agreement
with Shionogi (the &#8220;Shionogi Agreement&#8221;) will be required to be used by Royalty Sub to service its obligations under
its PhaRMA Notes, and generally will not be available to us for other purposes until Royalty Sub has repaid in full its obligations
under the PhaRMA Notes.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2011, our wholly-owned subsidiary Royalty Sub issued $30.0
million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone
payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and,
if approved for commercial sale, Taiwan, (ii) rights to certain payments under a Japanese yen/U.S. dollar foreign currency hedge
arrangement put into place by us in connection with the issuance of the PhaRMA Notes and (iii) the pledge by us of our equity interest
in Royalty Sub. Payments from Shionogi to us under the Shionogi Agreement will generally not be available to us for other purposes
until Royalty Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds will be required to be dedicated
to Royalty Sub&#8217;s debt service and not available to us for product development or other purposes. As of September 1, 2014,
the payments from Shionogi were insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in an
event of default with respect to the PhaRMA Notes. As a result of this event of default, the holders of the PhaRMA Notes may be
able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest
in Royalty Sub and may&nbsp;exercise other remedies available to them under the indenture or other documents related to&nbsp;the
PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following
repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might otherwise be adversely affected.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Because an event of default has occurred under the PhaRMA Notes, the
holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the
PhaRMA Notes and our equity interest in Royalty Sub, in which case we may not realize the benefit of future royalty payments that
might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#8217;s ability to service its payment obligations in
respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub, is subject to numerous risks.
Royalty Sub&#8217;s ability to service the PhaRMA Notes may be adversely affected by, among other things, changes in or any termination
of our relationship with Shionogi, reimbursement, regulatory, manufacturing and/or intellectual property issues, product returns,
product recalls, product liability claims and allegations of safety issues, as well as other factors. As Royalty Sub has been unable
to service its obligations under the PhaRMA Notes and an event of default has occurred under the PhaRMA Notes, the holders of the
PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and
our equity interest in Royalty Sub and may&nbsp;exercise other remedies available to them under the indenture&nbsp;or other documents
related to&nbsp;the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise
accrue to us following repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might otherwise be adversely affected.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"></p>

<!-- Field: Page; Sequence: 30; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>We may be required to pay significant premiums under the foreign currency
hedge arrangement entered into by us in connection with the issuance of the PhaRMA Notes. In addition, because our potential obligations
under the foreign currency hedge are marked to market, we may experience additional quarterly volatility in our operating results
and cash flows attributable to the foreign currency hedge arrangement.&nbsp;</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
we entered into a foreign currency hedge arrangement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. Under the foreign currency hedge agreement, we may be required to pay an annual premium in the
amount of $2.0 million in each May continuing through May 2020. Such payment will be required if, in May of the relevant year,
the spot rate of exchange for Japanese yen-U.S. dollars (determined in accordance with the foreign currency hedge arrangement)
is such that the U.S. dollar is worth 100 yen or less. We will be required to mark-to-market our potential obligations under the
currency hedge and post cash collateral, which may cause us to experience additional quarterly volatility in our operating results
and cash flows as a result. Additionally, we may be required to pay significant premiums or a termination fee under the foreign
currency hedge agreement entered into by us in connection with the issuance of the PhaRMA Notes. We are required to maintain a
foreign currency hedge at 100 yen per dollar under the agreements governing the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>If we fail to adequately protect or enforce our intellectual property
rights or secure rights to patents of others, the value of those rights would diminish.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our success will depend in part on our ability and the abilities of
our partners to obtain, protect and enforce viable intellectual property rights including but not limited to trade name, trademark
and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to
preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad.
The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual
questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#8220;USPTO&#8221;),
the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor
predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical
patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights
may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates
in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely
on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity
in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability
to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction
to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions.
The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We also rely on trade secrets to protect technology in cases when
we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain
the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our
ability to receive patent protection or protect our proprietary information may be imperiled.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>We may be involved in lawsuits to protect or enforce our patents, the
patents of our partners or our other intellectual property rights, which could be expensive, time consuming and unsuccessful</i></b>.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Competitors may infringe or otherwise violate our patents, the patents
of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to
file legal claims, which can be expensive and time-consuming and unsuccessful. An adverse result in any litigation or defense proceeding
could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties&#8217;
patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and
products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications
are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently
infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors
that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally
cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors,
we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country
or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be
available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with
the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive,
which would give our competitors access to the same intellectual property.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 31; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we or our partners are unable or fail to adequately initiate, protect,
defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish
to seek regulatory approval for our products, methods, processes and other technologies, the value of the product candidates to
produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use
of such products, processes, and other technologies, including but not limited to any trade name, trademark or commercial strategy
infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions
have issued to us a number of patents for our various inventions and we have in-licensed several patents from various institutions.
We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding
foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed
certain trademark and trade name applications worldwide. We cannot assure you as to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">the degree and range of protection any patents will afford against competitors with similar products;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">if and when patents will issue;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">if patents do issue we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents;&nbsp;or</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">If the USPTO or other foreign patent office upholds patents
issued to others or if the USPTO grants patent applications filed by others, we may have to:</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">obtain licenses or redesign our products or processes to avoid infringement;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">stop using the subject matter claimed in those patents;&nbsp;or</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">pay damages.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We may initiate, or others may bring against us, litigation
or administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign
patent office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application
could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any
such proceeding may be substantial whether or not we are successful.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our success is also dependent upon the skills, knowledge and experience,
none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants,
advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone
outside of our company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These
agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of
any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information
is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our product candidates
and any such events would significantly impair the value of such product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>We face an inherent risk of liability in the event that the use or misuse
of our products results in personal injury or death and our product liability insurance coverage may be insufficient.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If the use or misuse of peramivir or any other regulatory body-approved
products we or a partner may sell in the future harms people, we may be subject to costly and damaging product liability claims
brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product
candidates in clinical trials, including post marketing clinical studies, could also expose us to product liability claims. We
cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product
candidates and, therefore, the amount of insurance coverage we currently may not be adequate to cover all liabilities or defense
costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability
that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity
could be harmful to our business.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We face an inherent risk of product liability exposure related to
the testing of our product candidates in human clinical trials and will face even greater risks upon any commercialization by us
of our product candidates. We have product liability insurance covering our commercial sale of RAPIVAB and our clinical trials.
Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient
insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse
effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates
causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought
against us, with or without merit, could result in:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 32; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">withdrawal of clinical trial volunteers or patients;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">damage to our reputation and the reputation of our products, resulting in lower sales;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">regulatory investigations that could require costly recalls or product modifications;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">litigation costs;&nbsp;and</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">the diversion of management&#8217;s attention from managing our business.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Insurance coverage is increasingly more costly and difficult to obtain
or maintain.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">While we currently have insurance for our business, property, directors
and officers, and our products insurance is increasingly more costly and narrower in scope, and we may be required to assume more
risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we will be required
to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that is outside of our
insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an adverse effect on
our operations and financial position. Furthermore, any claims made on our insurance policies may impact our ability to obtain
or maintain insurance coverage at reasonable costs or at all.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><B><I>If our facility incurs damage or power is lost for
a significant length of time, or if we incur significant cost overruns or delays in the construction of our new research facility
in Birmingham, Alabama,<FONT STYLE="font-size: 10pt"> our business will suffer.</FONT></I></B></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We store clinical and stability samples at our facility that could
be damaged if our facility incurs physical damage or in the event of an extended power failure. We have backup power systems in
addition to backup generators to maintain power to all critical functions, but any loss of these samples could result in significant
delays in our drug development process.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, we store most of our preclinical and clinical data at
our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or failure of our computer
systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug
development process and any system failure could harm our business and operations.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">We also face the risk that the costs and time
required in connection with the construction of our new research facility in Birmingham, Alabama could exceed our current expectations.
If there is a significant cost overrun or significant delay in the completion of the construction, our business, financial condition,
and results of operations could be adversely affected.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>A significant disruption in our information technology systems or a
cyber-security breach could adversely affect our business.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are increasingly dependent on information technology systems to
operate our business. Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks
or intrusions, including by computer hackers, foreign governments, foreign companies or competitors, or may be breached by employee
error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction or interruption of critical information
technology systems could negatively impact operations.&nbsp;If our systems are damaged, fail to function properly or otherwise
become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions
or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results
of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant
legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data
security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information
technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and
any such events could adversely affect our business.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"></p>

<!-- Field: Page; Sequence: 33; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>If we fail to retain our existing key personnel or fail to attract and
retain additional key personnel, the development of our product candidates and commercialization of our products and the related
expansion of our business will be delayed or stopped.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are highly dependent upon our senior management and scientific
team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. Competition
for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract
and retain the required number of skilled and experienced management, commercial, operational and scientific personnel will harm
our business because we rely upon these personnel for many critical functions of our business.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>If because of our use of hazardous materials, we violate any environmental
controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our research and development involves the controlled use of hazardous
materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing
the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these
materials could occur. In the event of an accident, we could be liable for any damages that result and any liabilities could exceed
our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could
require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations. &nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Risks relating to investing in our common stock</b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Our existing principal stockholders hold a substantial amount of our
common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Several of our stockholders own greater than 5% of our outstanding
common stock. Our top ten stockholders own more than 50% of BioCryst and can individually, and as a group, influence our operations
based upon their concentrated ownership. These stockholders, if they act together, may be able to influence the outcome of matters
requiring approval of the stockholders, including the election of our directors and other corporate actions.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Our stock price has been, and is likely to continue to be, highly volatile,
which could result in the value of an investment in our common stock to decline significantly.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The market prices for securities of biotechnology companies in general
have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently,
and these fluctuations are often not related to our financial results. For the twelve months ended December 31, 2015, the 52-week
range of the market price of our stock was from $7.85 to $16.83 per share. The following factors, in addition to other risk factors
described in this section, may have a significant impact on the market price of our common stock:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%; padding-right: 0.8pt"><font style="font-size: 10pt">announcements of technological innovations or new products by us or our competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">developments or disputes concerning patents or proprietary rights;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">additional dilution through sales of our common stock or other derivative securities;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">status of new or existing licensing or collaborative agreements and government contracts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">announcements relating to the status of our programs;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">developments and announcements regarding new and virulent strains of influenza;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">we or our partners achieving or failing to achieve development milestones;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">publicity regarding certain public health concerns for which we are or may be developing treatments;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">regulatory developments in both the United States and foreign countries;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">public concern as to the safety of pharmaceutical products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">actual or anticipated fluctuations in our operating results;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"></td></tr></table>

<!-- Field: Page; Sequence: 34; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; width: 3%">&nbsp;</td>
    <td style="padding-right: 0.8pt; width: 95%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">changes in financial estimates or recommendations by securities analysts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">changes in the structure of healthcare payment systems, including developments in price control legislation;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">additions or departures of key personnel or members of our board of directors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">economic and other external factors or other disasters or crises; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">period-to-period fluctuations in our financial results.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Future sales and issuances of securities may dilute the ownership interests
of our current stockholders and cause our stock price to decline.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Future sales of our common stock by current stockholders into the
public market could cause the market price of our stock to fall. As of January&nbsp;31, 2016, there were 73,629,816 shares of
our common stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger
or acquisition. We may also sell, for our own account, shares of common stock or other equity securities, from time to time at
prices and on terms to be determined at the time of sale.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of January&nbsp;31, 2016, there were 11,022,560 stock options and
restricted stock units outstanding, 96,588 shares available for issuance under our Amended and Restated Stock Incentive Plan, and
497,204 shares available for issuance under our Employee Stock Purchase Plan. In addition, we could also make equity compensation
grants outside of our Stock Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future
stock options, stock appreciation rights and stock awards have been registered pursuant to registration statements on Form S-8.
&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If some or all of such shares are sold or otherwise issued into the
public market over a short period of time, our current stockholders&#8217; ownership interests may be diluted and the value of
all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices.
Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities
in the future at a time and price that our management deems acceptable, or at all.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>We have anti-takeover provisions in our corporate charter documents
that may result in outcomes with which you do not agree.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our board of directors has the authority to issue up to 4,800,000
shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without
further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may
adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third
parties to acquire a majority of our outstanding voting stock.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, our certificate of incorporation provides for staggered
terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors
and prevents our stockholders from acting by written consent. Our certificate also requires supermajority approval of any amendment
of these provisions. These provisions and other provisions of our by-laws and of Delaware law applicable to us could delay or make
more difficult a merger, tender offer or proxy contest involving us.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>We have never paid dividends on our common stock and do not anticipate
doing so in the foreseeable future.</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have never paid cash dividends on our stock. We currently intend
to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying cash
dividends on our common stock in the foreseeable future.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Information Regarding Forward-Looking Statements</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">This filing contains forward-looking statements within the meaning
of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created
in Section&nbsp;21E. All statements other than statements of historical facts contained in this filing are forward-looking statements.
These forward-looking statements can generally be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221;
&#8220;predicts,&#8221; &#8220;potential,&#8221; the negative of these words or similar expressions. Statements that describe our
future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions
containing these forward-looking statements are principally contained in &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as any amendments
we make to those sections in filings with the SEC. These forward-looking statements include, but are not limited to, statements
about:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 35; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="width: 95%; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">the initiation, timing, progress and results of our preclinical testing, clinical trials, and to the extent applicable, post-marketing commitments, for our HAE product candidates, RAPIVAB, BCX4430, and our&nbsp;&nbsp;other research and development efforts;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">the further preclinical development, clinical development, commercialization, or post marketing studies by either us or partners of our product candidates and products, including our HAE program, RAPIVAB, BCX4430, and early stage discovery programs;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">the potential funding from our contracts with NIAID/HHS and BARDA/HHS for the development of BCX4430;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">the potential for government stockpiling orders of RAPIVAB, additional regulatory approvals of RAPIVAB or milestones royalties or profit from commercial sales of RAPIVAB by us or our partners;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">the potential use of RAPIVAB as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">the implementation of our business model, strategic plans for our business, products, product candidates and technology;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">our ability to establish and maintain collaborations or out-license rights to our drug candidates;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">plans, programs, progress and potential success of our collaborations, including Seqirus UK Limited (&ldquo;SUL&rdquo;) for RAPIVAB, Mundipharma for forodesine and Shionogi and Green Cross for peramivir in their territories;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Royalty Sub&rsquo;s ability to service its payment obligations in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">the foreign currency hedge agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our products, product candidates and technology;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">our ability to operate our business without infringing the intellectual property rights of others;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">estimates of our expenses, revenues, capital requirements, annual cash utilization and our needs for additional financing;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">the timing or likelihood of regulatory filings or regulatory agreements, deferrals, and approvals;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">our ability to raise additional capital to fund our operations;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">our financial performance;&nbsp;and</FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">competitive companies, technologies and our industry.</FONT></TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">These statements relate to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking
statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those
listed under &#8220;Risk Factors.&#8221; Any forward-looking statement reflects our current views with respect to future events
and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry
and future growth. Except as required by law, we assume no obligation to update or revise these forward-looking statements for
any reason, even if new information becomes available in the future.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_003"></a>ITEM&nbsp;1B.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>UNRESOLVED STAFF COMMENTS</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">None.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 36; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_004"></a>ITEM&nbsp;2.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>PROPERTIES</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">We lease property in both Durham, North Carolina and
Birmingham, Alabama. Our headquarters, including our clinical and regulatory operations, are based in Durham, while our
principal research facility is located in Birmingham. We currently lease approximately 15,000 square feet in Durham through
June 30, 2020 and lease approximately 35,000 square feet in Birmingham through June&nbsp;30, 2016. We have recently leased an
additional approximate 32,000 square foot facility in Birmingham through 2027 to house our new research facility. In October
of 2015, we began construction of leasehold improvements on our new research facility and expect to move into the new
facility in the third quarter of 2016. We believe that our facilities are adequate for our current operations.</P>

<P STYLE="margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_005"></a>ITEM&nbsp;3.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>LEGAL PROCEEDINGS</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">None.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_006"></a>ITEM&nbsp;4.</b></font></td>
    <td style="width: 91%; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>MINE SAFETY DISCLOSURES</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Not applicable.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><b>PART&nbsp;II</b></p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_007"></a>ITEM&nbsp;5.</b></font></td>
    <td style="width: 91%; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Market Information</u></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Our common stock trades on the NASDAQ Global Select Market under the
symbol BCRX. The following table sets forth the low and high sales prices of our common stock as reported by the NASDAQ Global
Select Market for each quarter in 2015 and 2014:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; text-align: left">First quarter</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">7.85</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">12.71</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">7.46</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">13.33</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Second quarter</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8.50</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">16.43</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">7.29</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">12.86</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Third quarter</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">10.26</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">16.83</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">9.78</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">14.62</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Fourth quarter</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8.01</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">12.88</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">9.02</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">13.28</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The last sale price of the common stock on January&nbsp;29, 2016 as
reported by the NASDAQ Global Select Market was $6.97 per share.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Holders</u></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">As of January&nbsp;31, 2016, there were approximately 187 holders
of record of our common stock</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Dividends</u></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We have never paid cash dividends and do not anticipate paying cash
dividends in the foreseeable future.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 37; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Stock Performance Graph</u></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">This performance graph is not &#8220;soliciting material,&#8221; is
not deemed filed with the SEC and is not to be incorporated by reference in any filing by us under the Securities Act or the Exchange
Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. The
stock price performance shown on the graph is not necessarily indicative of future price performance.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 0.25in"><b>PERFORMANCE GRAPH FOR BIOCRYST</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Indexed Comparison Since 2010</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><img src="graph.jpg" alt=""></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Beginning<br> Investment<br> 12/31/10</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Investment<br> at 12/31/11</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Investment<br> at 12/31/12</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Investment<br> at 12/31/13</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Investment<br> at 12/31/14</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Investment<br> at 12/31/15</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-size: 10pt; text-align: left">BioCryst Pharmaceuticals, Inc.</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">100.00</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">47.78</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">27.47</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">147.00</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">235.20</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">199.61</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">NASDAQ Stock Market (U.S.)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">100.00</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">100.31</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">116.79</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">155.90</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">175.33</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">176.17</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">NASDAQ&nbsp;Pharmaceutical&nbsp;Stocks</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">100.00</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">117.48</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">134.31</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">182.23</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">221.99</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">234.05</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>



<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The above graph measures the change in a $100 investment in our common
stock based on its closing price of $5.17 on December&nbsp;31, 2010 and its year-end closing price thereafter. Our relative performance
is then compared with the CRSP Total Return Indexes for the NASDAQ Stock Market (U.S.) and NASDAQ Pharmaceutical Stocks.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Recent Sales of Unregistered Securities: None.</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Issuer Purchases of Equity Securities</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">There were no repurchases of our common stock or shares surrendered
to satisfy tax obligations during the fourth quarter of 2015.</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 38; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_008"></a>ITEM&nbsp;6.</b></font></td>
    <td style="width: 91%; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>SELECTED FINANCIAL DATA</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The selected Statement of Operations Data and Balance Sheet data
with respect to the years ended December&nbsp;31, 2015, 2014, 2013, 2012, and 2011 set forth below are derived from our consolidated
financial statements. The selected financial data set forth below should be read in conjunction with &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8221; contained in Item&nbsp;7 below and our consolidated
financial statements and the notes thereto appended to this annual report.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center">(In thousands, except per share amounts)</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">Statement of Operations Data:</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; text-align: left">Total revenues</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">48,257</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">13,608</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">17,331</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">26,293</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">19,643</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Cost of product sold</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,368</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Research and development expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">72,758</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">51,796</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">41,943</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">49,160</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">55,538</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">General and administrative expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,047</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,461</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,007</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,130</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,692</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Royalty expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">528</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">121</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">98</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">132</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Restructuring costs</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,759</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Loss from operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(39,444</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(45,771</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(30,717</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(33,888</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(49,587</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(43,019</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(45,189</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(30,108</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(39,081</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(56,948</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Basic and diluted net loss per share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.59</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.68</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.55</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(0.79</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(1.26</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Weighted average shares outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">72,901</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">66,773</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">55,216</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">49,474</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">45,144</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>


<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center">(In thousands)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Balance Sheet Data:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; font-size: 10pt; text-align: left">Cash, cash equivalents and investments</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">100,858</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">114,038</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">40,788</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">37,058</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">57,725</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Receivables</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,243</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,490</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,115</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,562</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,831</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,612</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">683</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">263</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">124,555</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">136,874</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48,866</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">57,439</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">82,208</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Long-term deferred revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,674</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,552</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,736</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,920</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,103</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Non-recourse notes payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30,000</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30,000</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30,000</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30,000</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30,000</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accumulated deficit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(510,917</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(467,898</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(422,709</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(392,601</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(353,520</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total stockholders&#8217; equity (deficit)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">47,724</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">75,635</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,126</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(454</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,806</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_009"></a>ITEM&nbsp;7.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><i>This Annual Report on Form&nbsp;10-K contains certain statements
of a forward-looking nature relating to future events or the future financial performance of BioCryst. Such statements are only
predictions and the actual events or results may differ materially from the results discussed in the forward-looking statements.
Factors that could cause or contribute to such differences include those discussed below and elsewhere in this report, as well
as those discussed in other filings made by BioCryst with the Securities and Exchange Commission.</i></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><i>The following Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;)
is intended to help the reader understand our results of operations and financial condition. MD&amp;A is provided as a supplement
to, and should be read in conjunction with, our audited financial statements and the accompanying notes to the financial statements
and other disclosures included in this Annual Report on Form&nbsp;10-K (including the disclosures under &#8220;Item&nbsp;1A. Risk
Factors&#8221;).</i></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Cautionary Statement</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The discussion herein contains forward-looking statements within the
meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221;
created in Section&nbsp;21E. Forward looking statements regarding our financial condition and our results of operations that are
based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted
within the United States (&#8220;U.S. GAAP&#8221;), as well as projections for the future. The preparation of these financial statements
requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses,
and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based
on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results
of our estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 39; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">We operate in a highly competitive environment that involves a
number of risks, some of which are beyond our control. We are subject to risks common to biotechnology and biopharmaceutical companies,
including risks inherent in our drug discovery, drug development and commercialization efforts, clinical trials, uncertainty of
regulatory actions and marketing approvals, reliance on collaborative partners, enforcement of patent and proprietary rights, the
need for future capital, competition associated with products, potential competition associated with our product candidates and
retention of key employees. In order for any of our product candidates to be commercialized, it will be necessary for us, or our
collaborative partners, to conduct clinical trials, demonstrate efficacy and safety of the product candidate to the satisfaction
of regulatory authorities, obtain marketing approval, enter into manufacturing, distribution and marketing arrangements, and obtain
market acceptance and adequate reimbursement from government and private insurers. We cannot provide assurance that we will generate
significant revenues or achieve and sustain profitability in the future. In addition, we can provide no assurance that we will
have sufficient funding to meet our future capital requirements. Statements contained in Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations and elsewhere in this report which are not historical facts are, or may constitute,
forward-looking statements. Forward-looking statements involve known and unknown risks that could cause our actual results to differ
materially from expected results. The most significant known risks are discussed in the section entitled &#8220;Risk Factors.&#8221;
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.&nbsp;We caution you not to place undue reliance on any forward-looking statements.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Our revenues are difficult to predict and depend on numerous factors,
including the prevalence and severity of influenza in regions for which peramivir has received regulatory approval, seasonality
of influenza, ongoing discussions with government agencies regarding future RAPIVAB and/or BCX4430 development and stockpiling
procurement, as well as entering into, or modifying, licensing agreements for our product candidates. Furthermore, revenues related
to our collaborative development activities are dependent upon the progress toward and the achievement of developmental milestones
by us or our collaborative partners.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Our operating expenses are also difficult to predict and depend
on several factors, including research and development expenses (and whether these expenses are reimbursable under government contracts),
drug manufacturing, and clinical research activities, the ongoing requirements of our development programs, and the availability
of capital and direction from regulatory agencies, which are difficult to predict. Management may be able to control the timing
and level of research and development and general and administrative expenses, but many of these expenditures will occur irrespective
of our actions due to contractually committed activities and/or payments.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As a result of these factors, we believe that period to period
comparisons are not necessarily meaningful and you should not rely on them as an indication of future performance. Due to all of
the foregoing factors, it is possible that our operating results will be below the expectations of market analysts and investors.
In such event, the prevailing market price of our common stock could be materially adversely affected.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Overview</u></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We are a biotechnology company that designs, optimizes and develops
novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on the treatment of rare diseases
in which significant unmet medical needs exist and align with our capabilities and expertise. We integrate the disciplines of biology,
crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process
known as structure-guided drug design.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Critical Accounting Policies and Estimates</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The accompanying discussion and analysis of our financial condition
and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared
in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments
that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities.
We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and
regularly discuss financial events, policies, and issues with members of our audit committee and our independent registered public
accounting firm. We routinely evaluate our estimates and policies regarding revenue recognition, administration, inventory and
manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses and any associated liabilities.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p>

<!-- Field: Page; Sequence: 40; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Recent Corporate Highlights</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>RAPIVAB (peramivir injection)</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 5.75pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">RAPIVAB was approved by the FDA on December 19, 2014 for the treatment of acute uncomplicated influenza
in adult patients who have been symptomatic for no more than two days. We have elected the &ldquo;Sell-Through&rdquo; revenue recognition
methodology and recognized approximately $0.6 million of RAPIVAB product sales in 2015. With the approval, commercial availability
and out-licensing collaboration of RAPIVAB, we have moved our focus to: (1) obtaining a stockpiling procurement contract with the
U.S. Government to realize the strategic value of this program; (2) fulfilling our post-approval development requirements, including
conducting a pediatric trial; and (3) submitting a MAA and a NDS in the European Union and Canada, respectively, to allow SUL (defined
below) the ability to commercialize the drug in those regions.</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On June 16, 2015, we and Seqirus UK Limited, a limited company organized
under the laws of the UK ("SUL") and a subsidiary of CSL, entered into a License Agreement (the "SUL Agreement")
granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the
treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies
together constituting the "Territory"). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is
currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment
in the world. We retain all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. government,
while SUL has the right to pursue government stockpiling outside the U.S.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by
CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global
markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization
of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion. We will exercise sole
decision-making authority with regard to the development and commercialization of RAPIVAB outside of the Territory and are responsible
for all associated costs.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, we are responsible for fulfilling
all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment we will transfer
ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the European
Union (&#8220;EU&#8221;), we are also responsible for regulatory filings and interactions with the Health Products and Food Branch
of Health Canada ("Health Canada") and the European Medicines Agency ("EMA") until marketing approval for RAPIVAB
is obtained and assigned to SUL. In accordance with the SUL Agreement, we and SUL formed a joint steering committee, composed of
an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization
of RAPIVAB in the Territory and any additional development.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, we received an upfront payment
of $33.7 million, and we may receive up to $12.0 million in additional milestone payments related to the successful achievement
of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult
indication in the EU and (iii) by Health Canada for an adult indication in Canada. We are also entitled under the SUL Agreement
to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales,
as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically,
we receive tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year
(defined as July 1 &#8211; June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in
the Territory, other than in the U.S., during a Contract Year, each subject to certain downward adjustments for circumstance or
events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and
expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years
from the date of the SUL Agreement (the "Royalty Term").&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b><i></i></b></p>

<!-- Field: Page; Sequence: 41; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b><i>HAE Program</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>Avoralstat</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"><FONT STYLE="font-size: 10pt">On December 18, 2014, we announced
the dosing of the first patient in OPuS-2 (<B>O</B>ral <B>P</B>rophylaxi<B>S-2</B>), a blinded, randomized, placebo-controlled
clinical trial of orally-administered avoralstat in patients with hereditary angioedema (&ldquo;HAE&rdquo;). OPuS-2 was a 12-week,
three-arm, parallel cohort design trial to evaluate the efficacy and safety of two doses of avoralstat, 300 mg and 500 mg, administered
three-times daily compared with placebo. This trial was conducted in the U.S. and select European countries. The primary efficacy
endpoint for the trial was the mean angioedema attack rate for each avoralstat dose group compared to placebo. On February 8, 2016,
we announced results from OPuS-2.</FONT> <FONT STYLE="font-size: 10pt">In the OPuS-2 study, HAE patients with a historical attack
frequency of greater than 0.45 attacks per week were randomized to treatment with either 500 mg or 300 mg of avoralstat, or placebo,
administered three times daily for 12 weeks. Thirty-eight subjects received avoralstat 500 mg, 36 subjects received avoralstat
300 mg, and 36 subjects received placebo. Treatment with 500 mg and 300 mg of avoralstat three times daily failed to demonstrate
a statistically significantly lower mean attack rate versus placebo. The mean (standard deviation) attack rates per week were 0.63
(0.57) on avoralstat 500mg and 0.71 (0.66) on avoralstat 300mg, compared to 0.61 (0.41) on placebo.</FONT> <FONT STYLE="font-size: 10pt">Statistically
significant improvements in duration of attacks and in the Angioedema Quality of Life total score were observed comparing the 500
mg three times a day avoralstat arm to placebo. Following the analysis of OPuS-2 results, the decision was made to discontinue
further development of softgel avoralstat formulation in order to focus development efforts on a novel solid dosage form of avoralstat
to achieve meaningfully better drug exposure. We expect additional avoralstat results from a relative bioavailability study testing
a novel solid dosage form of avoralstat by mid-year 2016. The primary goals of this study are to achieve meaningfully better drug
exposures and twice daily dosing.</FONT></P>



<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>BCX7353 and other 2nd generation HAE compounds</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">In January 2015, we selected BCX7353 to advance into Phase 1 development
as a once-daily, oral prophylactic HAE treatment. BCX7353 is structurally different from avoralstat, but has a similar mechanism
of action targeting plasma kallikrein. On May 13, 2015, we announced the initiation of a Phase 1 clinical trial to evaluate the
safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 12pt 0 0">On October 8, 2015, we announced that the randomized, placebo-controlled,
Phase 1 clinical trial of orally-administered BCX7353 in healthy volunteers successfully met all of its objectives.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">In this Phase 1 clinical trial BCX7353 dose levels included
single doses of up to 1000mg, once-daily doses of up to 500 mg for seven days, and once-daily doses of 350 mg for 14 days. Plasma
levels increased in approximate proportion to dose, and drug exposure was not affected by dosing with food. The half-life of BCX7353
was estimated at 50-60 hours. After daily dosing, blood levels met or exceeded a predicted target therapeutic range throughout
the 24 hour dosing interval. Inhibition of the target enzyme, plasma kallikrein, was measured in a sensitive and specific bioassay.
Daily dosing with BCX7353 strongly inhibited plasma kallikrein at all four dose levels; the degree of inhibition was dose-related
(p &lt; 0.0001) and inhibition was sustained throughout the 24 hour dosing interval. This pharmacodynamic effect correlated strongly
to the achieved drug concentration (r = 0.91, p &lt; 0.0001).</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">Subsequently, cohorts of healthy Japanese volunteers were added
to the study to support development of BCX7353 in Japan under the &ldquo;Sakigake&rdquo; accelerated R&amp;D designation. Following assessment
of single oral doses of BCX7353 of 100mg (6 subjects) and 500 mg (6 subjects), 250 mg of BCX7353 was administered orally and daily
for seven days to ten subjects. Compared to Western subjects administered the same dose level, plasma drug levels in Japanese subjects
were moderately higher. Kallikrein inhibition on day seven of daily dosing with 250 mg in Japanese subjects was similar to that
seen at the 350 mg daily and 500 mg daily dose levels in Western subjects.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">The combined data from both Western and Japanese healthy volunteers
indicates that oral BCX7353 has been generally safe and well tolerated in a total of 96 treated healthy volunteers, 46 with singles
doses and 50 with multiple doses. No serious adverse events have been seen and no dose-limiting toxicity has been identified. There
have been no clinically significant laboratory abnormalities, ECG changes, or vital sign changes observed.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">In single dose subjects, 89% (31 of 35) of adverse events (AEs)
have been grade 1. The four grade 2 AEs observed were: nausea (1) and vomiting (1) occurring in one subject: hay fever (1) and
diarrhea (1 from Japanese cohort).</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">In multiple dose subjects, 90% (63 of 70) of adverse
events (AEs) have been grade 1. The six grade 2 AEs observed were; upper abdominal pain (1, discontinued from study); syncope
(1) headache (1) diarrhea (1) and upper abdominal pain (1) occurring on one subject (discounted from study), and
maculopapular rash. One grade 3 AE was observed, a cutaneous delayed-type hypersensitivity reaction. The two rash AE&rsquo;s
are described in more detail below.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">The incidence of drug-related skin rash across all multiple-dose
cohorts was 4% (2 of 50 subjects). One Japanese subject dosed at 250 mg daily for seven days developed a grade 2 maculopapular
skin rash following cessation of dosing, and one Western subject dosed at 500 mg daily for seven days developed a grade 3 hypersensitivity
reaction, described as a maculopapular skin rash, following cessation of dosing. Both AEs were assessed by the investigator as
drug-related. The Japanese subject received antihistamines and the Western subject received corticosteroids, and in both cases
the rash resolved within a few days.</P>



<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b><i></i></b></p>

<!-- Field: Page; Sequence: 42; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b><i></i></b></p>
<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 12pt 0 0">The safety, tolerability, drug exposure and on-target plasma
kallikrein inhibition results strongly support advancing the development program into a Phase 2 study in HAE patients. A Phase
2 trial (&ldquo;APeX-1&rdquo;) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of BCX7353
as a preventative treatment to reduce the frequency of attacks in HAE patients is expected to begin in 2016. The design of the
trial will be described when the APeX-1 protocol is approved by regulatory authorities and the clinical trial is initiated.</P>



<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">On October 27, 2015 the Japanese Ministry of Health Labor &amp;
Welfare (&ldquo;MHLW&rdquo;) announced that BioCryst&rsquo;s BCX7353 was one of six products designated under MHLW&rsquo;s new
Sakigake fast track review system. The Sakigake Designation System promotes R&amp;D in Japan, aiming at early practical
application for innovative pharmaceutical products. This designation provides for additional interactions with the regulatory agency
in Japan from early development through filing, and prioritized development and review, with the aim of introduction of the product
as soon as possible to address a serious unmet medical need. We expect the results of APeX-1 to help us and the MHLW to determine
the regulatory pathway and timeline for BCX7353 in Japan.</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><B><I>Other 2<SUP>nd</SUP> generation&nbsp;HAE compounds</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">In addition to BCX7353, we have succeeded in inventing several
uniquely different plasma kallikrein inhibitor molecules from distinct structural classes. Accordingly, we have selected additional
drug candidates that have suitable pharmacologic properties to advance into preclinical development. The development of these candidates
for HAE or in other therapeutic areas is ongoing and additional disclosure on these compounds will occur as we near IND filings
of these compounds.</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</P>


<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0pt"><b><i>BCX4430</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">On December 15, 2014, we announced the dosing of the first subject
in a randomized, placebo-controlled Phase 1 clinical trial to evaluate i.m. administration of BCX4430 in healthy volunteers. The
main goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of BCX4430
administered via i.m. injection in healthy subjects. This Phase 1 study is expected to continue in 2016.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">On December 23, 2014, we announced results from a successful proof-of-concept
study of BCX4430 for the treatment of experimental Ebola virus infection in Rhesus macaques, conducted at USAMRIID. The primary
goal of the study was to assess the effect of BCX4430 treatment on survival through Day 41 in animals infected with Ebola virus.
Dosing of&nbsp;placebo or BCX4430 by i.m. injection was initiated 30-120 minutes after virus challenge and continued twice a day
for 14 days. The overall survival rate for BCX4430 treated animals at day 41 was 10 of 12 (83%, p &lt; 0.001 compared to controls).
Preliminary evaluation of the quantity of virus in the blood showed an approximate 3-log reduction in Ebola virus RNA copies/mL
of plasma, compared with control animals. This Rhesus macaques study was conducted following the completion, in November 2014,
of a dose-ranging study of BCX4430 for the treatment of cynomolgus macaques infected with Ebola virus. The cynomolgus macaques
study was designed to evaluate whether BCX4430 showed a meaningful benefit for survival in Ebola virus NHP disease models. In this
study, BCX4430 demonstrated a statistically significant prolongation of survival for the animals at the highest dose regimen tested,
but no animals survived beyond 21 days.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Results of Operations</u></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Year Ended December&nbsp;31, 2015 Compared to 2014</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Total 2015 revenues increased to $48.3 million as compared to 2014
revenues of $13.6 million. The increase in 2015 was primarily due to recognizing revenue associated with the SUL out-licensing
transaction, RAPIVAB product revenue and increased collaboration revenue associated with BCX4430 development. The 2015 revenue
consisted of $5.7 million of RAPIVAB product revenue and $21.8 million of collaborative revenue related to the SUL Agreement, $2.4
million of royalty revenue from SUL, Shionogi and Green Cross associated with sales of peramivir in the United States, Japan and
Korea, $16.3 million of reimbursement of collaborative expenses from BARDA/HHS and NIAID/HHS related to the development of peramivir
and BCX4430, and $1.4 million associated with collaborative revenue amortization from other corporate partnerships. In addition,
we recorded approximately $618,000 of RAPIVAB revenue under the &ldquo;Sell-Through&rdquo; revenue recognition methodology, but
going forward will recognize all future commercial RAPIVAB sales as royalty revenue under one of our partnership arrangements.
RAPIVAB was available for commercial sale on December 26, 2014. The 2014 revenue consisted of $3.0 million of royalty revenue from
Shionogi and Green Cross associated with sales of peramivir in Japan and Korea, $9.4 million of reimbursement of collaborative
expenses from BARDA/HHS related to the development of peramivir, $1.2 million associated with collaborative revenue amortization
from other corporate partnerships and $33,000 of RAPIVAB revenue. With the expiration of BARDA/HHS peramivir contract, unless we
enter into new government contracts, all significant and future reimbursement of collaborative expenses will be under the NIAID/HHS
and BARDA/HHS BCX4430 development contracts. Our RAPIVAB product revenue will be difficult to predict because of volatility in
prevalence, timing and severity of influenza season to season.</P>



<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Research and Development (&ldquo;R&amp;D&rdquo;) expenses increased to $72.8 million in 2015 from $51.8
million in 2014. 2015 R&amp;D expenses, compared with 2014, reflect increased spending on our HAE programs and slightly higher
spending on our RAPIVAB program. In addition, our 2014 equity compensation expense allocated to R&amp;D increased due to the vesting
of two underlying milestones under previously issued performance-based stock options for the successful outcome of OPuS-1 and RAPIVAB
approval in the U.S.</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The following table summarizes our R&amp;D expenses for the
periods indicated (amounts are in thousands).</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">R&amp;D expenses by program:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; font-size: 10pt; padding-left: 10pt">Avoralstat</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">27,769</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">19,005</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">15,442</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 10pt">BCX7353</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,819</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Other 2nd generation HAE compounds</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,320</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,681</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 10pt">BCX4430</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,400</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,060</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,318</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 10pt">Peramivir</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,690</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,898</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,627</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other research, preclinical and development costs</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,760</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,152</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,556</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total R&amp;D expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">72,758</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">51,796</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">41,943</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt"></p>


<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 43; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">R&amp;D expenses include all direct and indirect expenses and are
allocated to specific programs at the point of development of a lead product candidate. Direct expenses are charged directly to
the program to which they relate and indirect expenses are allocated based upon internal direct labor hours dedicated to each respective
program. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct laboratory studies,
develop manufacturing processes, manufacture the product candidates, conduct and manage clinical trials, as well as other costs
related to our clinical and preclinical studies. Indirect R&amp;D expenses consist of lab supplies and services, facility expenses,
depreciation of development equipment and other overhead of our research and development efforts. R&amp;D expenses vary according
to the number of programs in clinical development and the stage of development of our clinical programs. Later stage clinical programs
tend to cost more than earlier stage programs due to the longer length of time of the clinical trials and the higher number of
patients enrolled in these clinical trials.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Selling, General and administrative (&ldquo;SG&amp;A&rdquo;) expenses
increased to $13.0 million in 2015 compared to $7.5 million in 2014. The increase of $5.5 million is primarily associated with
increased marketing and medical affairs activities associated with our HAE programs, as well as unrestricted grants awarded to
the U.S. and international HAE patient advocacy groups.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Interest expense, related to the non-recourse notes issued in conjunction
with the peramivir royalty monetization transaction in March 2011, increased slightly to $5.2 million in 2015 as compared to $5.0
million in 2014. In addition, a mark to market loss of $0.6 million was recognized in 2015 related to the foreign currency hedge
entered into in conjunction with the royalty monetization transaction, compared to a mark to market gain of $5.5 million in 2014,
both resulting from changes in the U.S. dollar/Japanese yen exchange rate during the respective years. In addition, a realized
currency exchange gain of $1.6 million was recognized in 2015 related to the exercise of a U.S. dollar/Japanese yen currency option
under our foreign currency hedge. Thus, a resulting $1.1 million net gain is recognized on our foreign currency derivative for
2015. We entered into a foreign currency hedge agreement to hedge changes in the value of the Japanese yen relative to the U.S.
dollar. The currency hedge does not qualify for hedge accounting treatment and therefore mark to market adjustments are recognized
in our Consolidated Statements of Comprehensive Loss. Although we cannot predict the future yen/dollar exchange rate, the applicable
foreign currency rates moved such that we currently have no collateral posted; however, it is possible that collateral will be
required in 2016 or the future. We are unable to predict future changes in the yen/dollar exchange rate or increases/decreases
in our hedge loss associated with the currency hedge agreement.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Year Ended December&nbsp;31, 2014 Compared to 2013</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Total 2014 revenues decreased to $13.6 million as compared to 2013
revenues of $17.3 million. The 2014 revenue consisted of $3.0 million of royalty revenue from Shionogi and Green Cross associated
with sales of peramivir in Japan and Korea, $9.4 million of reimbursement of collaborative expenses from BARDA/HHS and NIAID/HHS
related to the development of peramivir and BCX4430, and $1.2 million associated with collaborative revenue amortization from other
corporate partnerships. In addition, we recorded approximately $33,000 of RAPIVAB revenue under the &#8220;Sell-Through&#8221;
revenue recognition methodology. RAPIVAB was available for commercial sale on December 26, 2014. The decrease in total revenues
was primarily the result of the June 2014 BARDA/HHS peramivir contract expiration associated with completion of development activities
under this contract. The 2013 revenue consisted of $2.6 million of royalty revenue from Shionogi and Green Cross associated with
sales of peramivir in Japan and Korea, $13.5 million of reimbursement of collaborative expenses from BARDA/HHS related to the development
of peramivir and $1.2 million associated with collaborative revenue amortization from other corporate partnerships. With the expiration
of BARDA/HHS peramivir contract, unless we enter into new government contracts, all significant and future reimbursement of collaborative
expenses will be under the NIAID/HHS BCX4430 development contract. In addition, we expect RAPIVAB product sales to increase in
future years when the product is available prior to the beginning of the influenza season and for a longer period of time within
a fiscal year. However, our RAPIVAB product revenue will be difficult to predict because of volatility in prevalence, timing and
severity of influenza season to season in the United States and because we will not incur substantial commercialization expenses
to promote it.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">R&amp;D expenses increased to $51.8 million in 2014 from $41.9 million
in 2013. 2014 R&amp;D expenses, compared with 2013, reflect increased spending on our HAE and BCX4430 programs which were partially
offset by the wind-down of peramivir development activities and the expiration of the BARDA/HHS development contract. In addition,
our 2014 equity compensation expense allocated to R&amp;D increased due to the vesting of two underlying milestones under previously
issued performance-based stock options for the successful outcome of OPuS-1 and RAPIVAB approval in the U.S. In 2013, we recognized
approximately $5.0 million of R&amp;D costs related to a write-off of deferred collaboration costs associated with our PNP licensing
agreement with AECOM/IRL. This write-off, and related R&amp;D expenses, was allocated to the ulodesine program and represents the
majority of 2013 ulodesine expense represented in the table below.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 44; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 12pt 0 0">SG&amp;A expenses increased to $7.5 million in 2014 compared
to $6.0 million in 2013. The increase of $1.5 million is primarily due to RAPIVAB distribution expenses and unrestricted grants
awarded to U.S. and international HAE patient advocacy groups. We expect our future SG&amp;A expenses to increase due to increases
in administrative expenses associated with corporate growth in preparation for future NDA and other regulatory filings and for
product commercialization.</P>



<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Interest expense, related to the non-recourse notes issued in conjunction
with the peramivir royalty monetization transaction in March 2011, increased slightly to $5.0 million in 2014 as compared to $4.8
million in 2013. In addition, a mark to market gain of $5.5 million was recognized in 2014 related to the foreign currency hedge
entered into in conjunction with the royalty monetization transaction, compared to a mark to market gain of $5.3 million in 2013,
both resulting from changes in the U.S. dollar/Japanese yen exchange rate during the respective years.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Cash expenditures have exceeded revenues since our inception and
we expect our 2016 operating expenses to exceed our 2016 revenues. Our operations have principally been funded through public offerings
and private placements of equity securities; cash from collaborative and other research and development agreements, including U.S.
Government contracts for peramivir and BCX4430; and to a lesser extent, the PhaRMA Notes financing. To date, we have been awarded
a BARDA/HHS peramivir development contract totaling $234.8 million, which expired on June 30, 2014, a NIAID/HHS BCX4430 development
contract totaling $34.0 million, which is ongoing, and a BARDA/HHS BCX4430 development contract totaling $36.2 million, which is
also ongoing. The total amount of NIAID/HHS and BARDA/HHS funding obligated under awarded options in the active contracts is $29.9&nbsp;million
and $16.3 million, respectively. Most recently, we completed a successful public offering in June 2014 of 11.5 million shares of
common stock at a price of $10.00 per share, which provided net proceeds to us of approximately $107.8 million. This financing
and the recently completed SUL out-licensing transaction provides us liquidity through mid-2017. We may issue securities through
private placement transactions or registered public offerings pursuant to a registration statement filed with the SEC. In addition
to the above, we have received funding from other sources, including other collaborative and other research and development agreements;
government grants; equipment lease financing; facility leases; research grants; and interest income on our investments.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of December&nbsp;31, 2015, we had net working capital of $1.5 million, a decrease of approximately
$30.6 million from $32.1 million at December&nbsp;31, 2014. The decrease in working capital was principally due to our normal operating
expenses associated with the development of our product candidates and the reclassification of our non-recourse notes payable to
current liabilities. Our principal sources of liquidity at December&nbsp;31, 2015 were approximately $28.9 million in cash and
cash equivalents; approximately $70.3 million in investments considered available-for-sale, and approximately $5.5 million in U.S.
Government receivables. We anticipate our cash and investments will fund our operations through mid-2017.</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We intend to contain costs and cash flow requirements by closely managing
our third party costs and headcount, leasing scientific equipment and facilities, contracting with other parties to conduct certain
research and development projects and using consultants. We expect to incur additional expenses, potentially resulting in significant
losses, as we continue to pursue our research and development activities and begin to build a commercial infrastructure. We may
incur additional expenses related to the filing, prosecution, maintenance, defense and enforcement of patent and other intellectual
property claims and additional regulatory costs as our clinical programs advance through later stages of development. The objective
of our investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient
to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies,
and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our
investments.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We extended or executed additional lease obligations in 2015 for our
Birmingham, Alabama operations which increased the obligations by $5.6 million and extended the new obligations out to 2027. These
operating lease obligations encompass future rental obligations of our Birmingham operating facilities.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We plan to finance our needs principally from the following:</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">lease or loan financing and future public or private equity financing;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">our existing capital resources and interest earned on that capital;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">payments under existing and executing new contracts with the U.S. Government; and</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">payments under collaborative and licensing agreements with corporate partners.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 45; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As our programs continue to advance, our costs will increase. Our
current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements and
additional personnel resources and testing required for the continuing development of our product candidates will consume significant
capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could vary significantly depending
on many factors, including our ability to raise additional capital, the development progress of our collaborative agreements for
our product candidates, the amount and timing of funding we receive from existing U.S. Government contracts for BCX4430, the amount
of funding or assistance, if any, we receive from new U.S. Government contracts or other new partnerships with third parties for
the development and or commercialization of our product candidates, the progress and results of our current and proposed clinical
trials for our most advanced product candidates, the progress made in the manufacturing of our lead product candidates and the
progression of our other programs.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">With the funds available at December 31, 2015, we believe these
resources will be sufficient to fund our operations through mid-2017. Our future liquidity needs, and ability to address those
needs, will largely be determined by the success of our product candidates and key development and regulatory events in the future.
In order to continue our operations substantially beyond mid-2017, we will need to: (1)&nbsp;successfully secure or increase U.S.
Government funding of our programs, including procurement contracts; (2)&nbsp;out-license rights to certain of our products or
product candidates, pursuant to which we would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt
financings or from other sources; (4)&nbsp;obtain additional product candidate regulatory approvals, which would generate revenue
and cash flow; (5)&nbsp;reduce spending on one or more research and development programs; and/or (6)&nbsp;restructure operations.
We may issue securities through private placement transactions or registered public offerings pursuant to a registration statement
filed with the SEC.</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Our long-term capital requirements and the adequacy of
our available funds will depend upon many factors, including:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">our ability to perform under our government contracts and receive reimbursement, and receive stockpiling procurement contracts;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">the magnitude of work under our government contracts;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">the progress and magnitude of our research, drug discovery and development programs;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">changes in existing collaborative relationships or government contracts;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">our ability to negotiate favorable development and marketing strategic alliances for certain product candidates or a decision to build or expand internal development and commercial capabilities;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">successful commercialization of marketed products by either us or a partner;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">the scope and results of preclinical studies and clinical trials to identify and develop product candidates;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">our ability to engage sites and enroll subjects in our clinical trials;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">the scope of manufacturing of our product candidates to support our preclinical research and clinical trials;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">increases in personnel and related costs to support the development and commercialization of our product candidates;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">the scope of manufacturing of our drug substance and product candidates required for future NDA filings;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">competitive and technological advances;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">the time and costs involved in obtaining regulatory approvals;&nbsp;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">post-approval commitments for RAPIVAB and other products that receive regulatory approval; and</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><font style="font-size: 10pt">the costs involved in all aspects of intellectual property strategy and protection including the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 46; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">We expect that we will be required to raise additional capital
to complete the development and commercialization of our current product candidates and we may seek to raise capital in the future.
Additional funding, whether through additional sales of equity or debt securities, collaborative or other arrangements with corporate
partners or from other sources, including governmental agencies in general and existing government contracts specifically, may
not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities,
with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect
of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements
may require us to transfer certain material rights to such corporate partners. Insufficient funds may require us to delay, scale
back or eliminate certain of our research and development programs. Our future working capital requirements, including the need
for additional working capital, will be largely determined by the advancement of our portfolio of product candidates as well as
rate of reimbursement by U.S. Government agencies of our BCX4430 expenses and any future decisions regarding the future of the
RAPIVAB and BCX4430 programs, including those relating to stockpiling procurement. More specifically, our working capital requirements
will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our product candidates;
obtaining funding from collaborative partners; the cost, timing and outcome of regulatory reviews, regulatory investigations, and
changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the timing and terms of
business development activities; the rate of technological advances relevant to our operations; the efficiency of manufacturing
processes developed on our behalf by third parties; and the level of required administrative support for our daily operations.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Financial Outlook for 2016</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">Based upon our development plans, expected operations and our awarded
government contracts, we expect 2016 operating cash usage to be in the range of $55 to $75 million, and expect our total 2016 operating
expenses to be in the range of $78 to $98 million. Our operating expense range excludes equity-based compensation expense due to
the difficulty in accurately projecting this expense as it is significantly impacted by the volatility and price of the Company&rsquo;s
stock, as well as vesting of the Company&rsquo;s outstanding performance-based stock options. Our operating cash forecast excludes
any impact of our royalty monetization, hedge collateral posted or returned, and any other non-routine cash outflows or inflows.
Our ability to remain within our operating expense and operating cash target ranges is subject to multiple factors, including unanticipated
or additional general development and administrative costs and other factors described under the Risk Factors located elsewhere
in this report.</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">As of December&nbsp;31, 2015, we are not involved in any unconsolidated
entities or off&#8211;balance sheet arrangements.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Contractual Obligations</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In the table below, we set forth our enforceable and legally binding
obligations and future commitments and obligations related to all contracts that we are likely to continue regardless of the fact
that they are cancelable as of December&nbsp;31, 2015. Some of the amounts we include in this table are based on management&#8217;s
estimates and assumptions about these obligations, including their duration, the possibility of renewal, anticipated actions by
third parties, and other factors. Because these estimates and assumptions are necessarily subjective, the obligations we will actually
pay in future periods may vary from those reflected in the table.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="19" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Payments Due by Period<BR> (In thousands)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Contractual Obligations</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Less&nbsp;Than<BR> 1&nbsp;Year</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">1-3&nbsp;Years</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">3-5&nbsp;Years</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">More&nbsp;Than<BR> 5&nbsp;Years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-size: 10pt; text-align: left">Operating lease obligations</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">6,908</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">651</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,741</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,471</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3,045</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Purchase obligations(1)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">34,137</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">34,137</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Contingent license obligations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">225</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">450</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">425</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">900</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Non-recourse notes payable(2)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">57,396</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,946</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,400</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">38,050</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100,441</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">45,959</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,591</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">39,946</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,945</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 4%; padding-right: 0.8pt"><font style="font-size: 10pt">(1)</font></td>
    <td style="width: 96%; padding-right: 0.8pt"><font style="font-size: 10pt">Purchase obligations include commitments related to clinical development, manufacturing and research operations and other purchase commitments.</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">(2)</font></td>
    <td style="padding-right: 0.8pt"><font style="font-size: 10pt">Assumes the PhaRMA Notes will be repaid at maturity and the related interest costs will accrue and be paid annually through maturity. This assumption is based on the unpredictable nature of the royalty payments from Shionogi, which are designated for both principal and interest payments on the PhaRMA Notes.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 47; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Under the Currency Hedge Agreement, we have the right to purchase
dollars and sell yen at a rate of 100 yen per dollar for which we may be required to pay a premium in each year from 2016 through
2020. A payment of $2.0 million will be required if, during the relevant year, the dollar is worth 100 yen or less. As of December&nbsp;31,
2015, we have no hedge collateral posted against the Currency Hedge Agreement. Because the posting of additional collateral and
payment of annual premiums is contingent on the value of the yen relative to the dollar and other factors, such payments have been
excluded from the foregoing table.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In addition to the above, we have committed to make potential future
&#8220;sublicense&#8221; payments to third-parties as part of in-licensing and development programs. Payments under these agreements
generally become due and payable only upon achievement of certain developmental, regulatory and/or commercial milestones. Because
the achievement of these milestones is neither probable nor reasonably estimable, such contingencies have not been recorded on
our balance sheet.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Critical Accounting Policies</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We have established various accounting policies that govern the application
of U.S. GAAP, which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve
significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities.
Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management
are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the
nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which
could have a material impact on the carrying values of assets and liabilities and the results of operations.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">While our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements included in this Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2015, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating
our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial
statements.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Inventory</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Our inventories consist of RAPIVAB finished goods and work in process,
which are valued at the lower of cost or market using the first-in, first-out (i.e., FIFO) method. Cost includes materials, labor,
overhead, shipping and handling costs. Our inventories are subject to expiration dating. We regularly evaluate the carrying value
of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition,
we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in
addition to the quantification of such reserve, requires us to utilize significant judgment. In connection with the FDA approval
of RAPIVAB in December 2014, we began capitalizing costs associated with the production of RAPIVAB commercial inventories.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Accrued Expenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We enter into contractual agreements with third-party vendors who
provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts
are subject to milestone-based invoicing and services are completed over an extended period of time. We record liabilities under
these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and
purchase orders, communicating with our applicable personnel to identify services that have been performed and estimating the level
of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual cost. The majority
of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of
each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of our estimates
with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and product candidates;&nbsp;and</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">professional fees.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 48; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We base our expenses related to clinical trials on our estimates of
the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and
manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to
contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful
enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over
which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services
or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have
begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Revenue Recognition</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We recognize revenues from collaborative and other research and development
arrangements and product sales. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive
evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#8217;s
price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 23pt"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 23pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and
research and development fees are recognized as revenue when the earnings process is complete and we have no further continuing
performance obligations or we have completed the performance obligations under the terms of the agreement. Fees received under
licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by
management based on the terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables,
we evaluate whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as
a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Under certain of our license agreements, we receive royalty payments
based upon our licensees&#8217; net sales of covered products. We recognize royalty revenues when we can reliably estimate such
amounts and collectability is reasonably assured. Royalty revenue paid by Shionogi on their product sales is subject to returns.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element,
each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting.
This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer. The consideration that
is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.
The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective
evidence of fair value, (ii) third-party evidence of selling price (&#8220;TPE&#8221;) and (iii) best estimate of selling price
(&#8220;BESP&#8221;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold
by us on a stand-alone basis. In most cases we expect to use TPE or BESP for allocating consideration to each deliverable. The
consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the
consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the
use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another
performance obligation.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, we entered into a License Agreement (the "SUL Agreement")
granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize
RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments,
and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii)
regulatory support to obtain Canadian and EU marketing approvals. We received an upfront payment of $33.7 million from SUL of which
$7.0 million was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21.8
million of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately
$3.7 million of the upfront payment was allocated to the sale of inventory and was recognized in the third quarter when the inventory
transfer was completed. Approximately $1.2 million of the revenue from the SUL Agreement will be recognized ratably over the expected
period of involvement in these regulatory support activities.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement
of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured
at the inception of the SUL Agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying
these revenue recognition criteria are recorded as deferred revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Under the terms of the SUL Agreement, we may receive up to $12.0
million in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i)
by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult
indication in Canada. We evaluated each event based payment under the provisions of ASU 2010-17, <i>Milestone Method of Revenue
Recognition</i>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone
under the milestone method of accounting. No event based payments were achieved during the periods presented.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 49; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related
to research and development costs are recorded as revenue in the income statement rather than as a reduction in expenses. Under
our contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct and indirect costs are incurred.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Product Sales</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We recognize revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership
have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the
Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement
exists, title has passed, the price was fixed and determinable, and collectability is reasonably assured. Product sales are recognized
net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, prior to completion of the
SUL transaction, we sold RAPIVAB to specialty distributors, who, in turn, sell to physician offices, hospitals and federal, state
and commercial health care organizations.</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare
and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are
recorded as reductions to revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived
from historical experience adjusted to reflect known changes in the factors that impact such reserves.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We utilize data from external sources to help estimate gross-to-net
sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. External sourced data includes, but is not limited
to, information obtained from specialty distributors with respect to their inventory levels and sell-through to customers, and
information from third-party suppliers of market research data to the pharmaceutical industry.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">We have categorized and described more fully the following significant
sales deductions, all of which involve estimates and judgments, which we consider to be critical accounting estimates, and requires
us to use information from external sources.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Rebates and Chargebacks</i>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based
on statutory discounts to RAPIVAB&#8217;s selling price.&nbsp;As it can take up to nine months or more for information to be received
on actual usage of RAPIVAB in Medicaid and other governmental programs, we maintain reserves for amounts payable under these programs
relating to RAPIVAB sales.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials
between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers
covered under federally qualified programs.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based
on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment
experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices
and statutory or negotiated prices), changes in prescription demand patterns and utilization of our product through public benefit
plans, and the levels of RAPIVAB inventory in the distribution channel. We acquire prescription utilization data from third-party
suppliers of market research data to the pharmaceutical industry. We update our estimates and assumptions each period and record
any necessary adjustments to reserves. Settlements of rebates and chargebacks typically occur within nine months from point of
sale. To the extent actual rebates and chargebacks differ from our estimates, additional reserves may be required or reserves may
need to be reversed, either of which would impact current period product revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Discounts and Sales Incentives</i>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 22.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory
Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with our specialty distributors, we provide an IMA fee
based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in our individual contracts. We track sales
to our specialty distributors each period and accrue a liability relating to the unpaid portion of these fees by applying contractual
rates to such sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Product Returns</i>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 22.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We do not record a product return allowance as we do not offer the
ability to return goods once a bona fide shipment has been accepted by a specialty distributor.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i></i></b></p>

<!-- Field: Page; Sequence: 50; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Our research and development costs are charged to expense when incurred.
Advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed.
Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs,
clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of
various administrative and facilities related costs. Most of our manufacturing and clinical and preclinical studies are performed
by third-party CROs. Costs for studies performed by CROs are accrued by us over the service periods specified in the contracts
and estimates are adjusted, if required, based upon our on-going review of the level of services actually performed.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, we have license agreements with third parties, such
as AECOM, IRL, and UAB, which require fees related to sublicense agreements or maintenance fees. We expense sublicense payments
as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized
over the related revenue recognition period. We expense maintenance payments as incurred.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments paid
to our academic partners upon receipt of consideration from various commercial partners, and other consideration to our academic
partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt
of such payments or modifications from our commercial partners and are being expensed in proportion to the related revenue being
recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We group our R&amp;D expenses into two major categories: direct external
expenses and indirect expenses. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct
laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials,
as well as other costs related to our clinical and preclinical studies. These costs are accumulated and tracked by program. Indirect
expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our
research and development efforts. These costs apply to work on our clinical and preclinical candidates as well as our discovery
research efforts.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">All share-based payments, including grants of stock option awards
and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based on their fair values.
Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense
on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related
assumptions for the model requires judgment, including estimating the life of an award, the stock price volatility, and the expected
term. We utilize the Black-Scholes option-pricing model to value our awards and recognize compensation expense on a straight-line
basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest requires judgment, and to
the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative
adjustment in the period estimates are revised. In addition, we have outstanding performance-based stock options for which no compensation
expense is recognized until &#8220;performance&#8221; has occurred. Significant management judgment is also required in determining
estimates of future stock price volatility and forfeitures to be used in the valuation of the options. Actual results, and future
changes in estimates, may differ substantially from our current estimates.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Foreign Currency Hedge</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In connection with our issuance of the PhaRMA Notes, we entered into
a foreign Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to
the U.S.&nbsp;dollar. Under the Currency Hedge Agreement, we have the right to purchase dollars and sell yen at a rate of 100 yen
per dollar for which we may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement
remains in effect. A payment of $2.0&nbsp;million will be required if, on May&nbsp;18 of the relevant year, the U.S. dollar is
worth 100 yen or less as determined in accordance with the Currency Hedge Agreement. In conjunction with establishing the Currency
Hedge Agreement, we will be required to post collateral to the counterparty, which may cause us to experience additional quarterly
volatility in our financial results. We will not be required at any time to post collateral exceeding the maximum premium payments
remaining payable under the Currency Hedge Agreement. In establishing the hedge, we provided initial funds of approximately $2.0&nbsp;million
to support our potential hedge obligations. As of December 31, 2015, the maximum amount of hedge collateral we may be required
to post is $9.8 million.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting
treatment and therefore mark to market adjustments will be recognized in our Consolidated Statements of Comprehensive Loss. Mark
to market adjustments are determined by quoted prices in markets that are not actively traded and for which significant inputs
are observable directly or indirectly, representing the Level 2 in the fair value hierarchy as defined by generally accepted accounting
principles (&ldquo;U.S. GAAP&rdquo;). The Company is also required to post collateral in connection with the mark to market adjustments
based on defined thresholds. As of December&nbsp;31, 2015, no collateral was posted under the agreement.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i></i></b></p>

<!-- Field: Page; Sequence: 51; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Tax</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We account for uncertain tax positions in accordance with U.S. GAAP.
Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities
and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation allowance against all potential
tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting of certain net operating losses
carried forward, before they expire. The valuation allowance is based on estimates of taxable income in each of the jurisdictions
in which we operate and the period over which our deferred tax assets will be recoverable.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Impact of Inflation</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We do not believe that our operating results have been materially
impacted by inflation during the past three years. However, we cannot be assured that our operating results will not be adversely
affected by inflation in the future. We will continually seek to mitigate the adverse effects of inflation on the services that
we use through improved operating efficiencies and cost containment initiatives.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Recent Accounting Pronouncements</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Note&nbsp;11 to the Consolidated Financial Statements included in
Item&nbsp;8 of this Annual Report on Form&nbsp;10-K discusses accounting pronouncements recently issued or proposed but not yet
required to be adopted.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_010"></a>ITEM&nbsp;7A.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Interest Rate Risk</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">We are subject to interest rate risk on our investment portfolio
and borrowings under our PhaRMA Notes.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We invest in marketable securities in accordance with our investment
policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs
and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit
exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions,
commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest
in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment
to fluctuate.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our investment exposure to market risk for changes in interest rates
relates to the increase or decrease in the amount of interest income we can earn on our portfolio, changes in the market value
due to changes in interest rates and other market factors as well as the increase or decrease in any realized gains and losses.
Our investment portfolio includes only marketable securities and instruments with active secondary or resale markets to help ensure
portfolio liquidity. A hypothetical 100 basis point drop in interest rates along the entire interest rate yield curve would not
significantly affect the fair value of our interest sensitive financial instruments. We generally have the ability to hold our
fixed-income investments to maturity and therefore do not expect that our operating results, financial position or cash flows will
be materially impacted due to a sudden change in interest rates. However, our future investment income may fall short of expectations
due to changes in interest rates, or we may suffer losses in principal if forced to sell securities which have declined in market
value due to changes in interest rates or other factors, such as changes in credit risk related to the securities&#8217; issuers.
To minimize this risk, we schedule our investments to have maturities that coincide with our expected cash flow needs, thus avoiding
the need to redeem an investment prior to its maturity date. Accordingly, we do not believe that we have material exposure to interest
rate risk arising from our investments. Generally, our investments are not collateralized. We have not realized any significant
losses from our investments.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We do not use interest rate derivative instruments to manage exposure
to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk
and reinvestment risk. We reduce default risk by investing in investment grade securities.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i></i></p>

<!-- Field: Page; Sequence: 52; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Foreign Currency Risk</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The majority of our transactions occur in U.S. dollars and we do not
have operating subsidiaries or investments in foreign countries. Therefore, we are not subject to significant foreign currency
exchange risk in our normal operations.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
we entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative
to the U.S. dollar. Under the Currency Hedge Agreement, we are required to post collateral based on our potential obligations under
the Currency Hedge Agreement as determined by periodic mark-to-market adjustments. Provided the Currency Hedge Agreement remains
in effect, we may be required to pay an annual premium in the amount of $2.0&nbsp;million from May&nbsp;2016 through May&nbsp;2020.
Such payment will be required if, in May of the relevant year, the spot rate of exchange for Japanese yen-U.S. dollars (determined
in accordance with the Currency Hedge Agreement) is such that the U.S. dollar is worth 100 yen or less.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 53; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_011"></a>ITEM&nbsp;8.</b></font></td>
    <td style="width: 91%; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_012"></a>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="balance-sheet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">ASSETS</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">28,899</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">54,540</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Restricted cash</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,612</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">150</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,664</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">18,232</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Receivables from collaborations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,243</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,849</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Receivables from product sales</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,641</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,612</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">683</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Prepaid expenses and other current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,870</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,172</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Deferred collaboration expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">90</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">76</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Total current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">65,990</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">89,343</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">47,683</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">41,116</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Property and equipment, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,149</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">207</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">265</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">177</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,468</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,031</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total assets</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">124,555</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">136,874</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accounts payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">9,307</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,849</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16,237</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,329</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,746</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,029</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,163</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,481</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred product sales revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,605</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Non-recourse notes payable</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,000</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,000</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Total current liabilities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">64,453</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">57,293</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,674</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,552</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred rent</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">329</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">394</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Lease financing obligation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,375</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Stockholders&#8217; equity:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Preferred stock, $0.001 par value; shares authorized&nbsp;&#8212;&nbsp;5,000; no shares outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock, $0.01&nbsp;par value; shares authorized&nbsp;&#8212;&nbsp;200,000; shares issued and outstanding&nbsp;&#8212;&nbsp;73,355 in 2015 and 71,955 in 2014</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">734</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">720</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Additional paid-in capital</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">558,113</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">542,943</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accumulated other comprehensive loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(206</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(130</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(510,917</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(467,898</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">47,724</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">75,635</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total liabilities and stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">124,555</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">136,874</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 54; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_013"></a>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="income"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 61%; font-size: 10pt; text-align: left; padding-left: 10pt">Product sales, net</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">6,291</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">33</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Royalty revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,386</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,025</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,562</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Collaborative and other research and development</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,580</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,550</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,769</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Total revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48,257</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,608</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,331</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Cost of products sold</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,368</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Research and development</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">72,758</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">51,796</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">41,943</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Selling, general and administrative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,047</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,461</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,007</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">Royalty</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">528</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">121</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">98</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total operating expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,701</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">59,379</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">48,048</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Loss from operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(39,444</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(45,771</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(30,717</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest and other income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">535</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">93</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">93</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,200</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(4,998</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(4,778</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Gain on foreign currency derivative</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,090</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,487</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,294</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(43,019</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(45,189</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(30,108</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Basic and diluted net loss per common share</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.59</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.68</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.55</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Weighted average shares outstanding</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">72,901</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">66,773</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">55,216</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Unrealized loss on available for sale investments</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(76</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(134</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(23</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Comprehensive loss</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(43,095</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(45,323</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(30,131</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b></b></p>

<!-- Field: Page; Sequence: 55; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 6pt"><b><a name="a_014"></a>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 6pt"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="cash-flows"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Operating activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 61%; font-size: 10pt; text-align: left">Net loss</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(43,019</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(45,189</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(30,108</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Depreciation, amortization, and impairment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">180</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">177</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">304</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Loss (gain) on disposal of property and equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(47</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock-based compensation expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,705</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,177</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,368</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Amortization of debt issuance costs</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">439</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">439</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">439</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of foreign currency derivative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">564</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,487</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,294</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Receivables</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,247</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(7,375</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,447</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(929</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(683</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Prepaid expenses and other assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,207</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,943</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(620</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Deferred collaboration expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(102</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">59</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,133</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,393</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,818</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,049</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Deferred revenue</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,199</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,429</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,103</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Net cash used in operating activities:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(13,116</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(38,551</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(26,530</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investing activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Acquisition of property and equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,122</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(106</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(30</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from sale of property and equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">50</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Change in restricted cash</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,462</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">157</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Purchases of investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(53,830</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(73,875</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(23,974</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Sales and maturities of investments</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">42,410</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">34,000</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,330</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Net cash used in investing activities:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(18,004</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(39,980</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(3,467</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Financing activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Sale of common stock, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">106,600</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">23,633</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Exercise of stock options</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,124</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,997</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,333</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Employee stock purchase plan sales</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">355</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">310</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">124</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Receipt of foreign currency derivative
    collateral</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,180</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Net cash provided by financing activities:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">5,479</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">111,907</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">30,270</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">(Decrease) increase in cash and cash equivalents</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(25,641</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">33,376</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">273</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of year</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">54,540</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,164</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,891</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.25pt">Cash and cash equivalents at end of year</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">28,899</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">54,540</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">21,164</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 56; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_015"></a><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217;
EQUITY (DEFICIT)</B></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="stockholders-equity"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common<BR> Stock</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Additional<BR> Paid-In<BR> Capital</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated<BR> Other<BR> Comprehensive<BR> (Loss) Income</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated<BR> Deficit</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<BR> Stockholders&rsquo;<BR> Equity&nbsp;(Deficit)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-size: 10pt; font-weight: bold">Balance at Decembe<font style="font-size: 10pt">r 31, 2012</font></TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">509</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">391,611</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">27</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(392,601</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(454</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(30,108</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(30,108</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Other comprehensive loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(23</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(23</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">Exercise of stock options, 563 shares, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,327</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,333</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Employee stock purchase plan sales, 89&nbsp;shares, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">123</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">124</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock, 7,547 shares, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">75</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,559</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,634</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Stock-based compensation expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,368</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,368</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">Balance at December&nbsp;31, 2013</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">591</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">420,988</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">4</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(422,709</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(1,126</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(45,189</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(45,189</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Other comprehensive loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(134</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(134</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">Exercise of stock options, 1,314 shares, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,984</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,997</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Employee stock purchase plan sales, 49&nbsp;shares, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">309</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">310</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock, 11,500 shares, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">115</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">106,485</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">106,600</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Stock-based compensation expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,177</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,177</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">Balance at December&nbsp;31, 2014</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">720</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">542,943</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(130</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(467,898</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">75,635</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(43,019</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(43,019</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Other comprehensive loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(76</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(76</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">Exercise of stock options, 1,359 shares, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,110</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,124</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Employee stock purchase plan sales, 41&nbsp;shares, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">355</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">355</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Stock-based compensation expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,705</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,705</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">Balance at December&nbsp;31, 2015</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">734</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">558,113</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(206</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(510,917</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">47,724</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>
</div>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 57; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b><a name="a_016"></a>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note&nbsp;1&nbsp;&#8212; Significant Accounting Policies and Concentrations of Risk</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>The Company</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biotechnology
company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of
diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its
capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina.
The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop
small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative
cash flows from operations since inception.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Based on its current operating plans, the Company expects it has sufficient
liquidity, with its existing cash, restricted cash and investments of $100,858, to continue its planned operations through mid-2017.
The Company&rsquo;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product
candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017
it will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts;
(2)&nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash
milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources; (4)&nbsp;obtain additional
product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on one or more research
and development programs; and/or (6)&nbsp;restructure operations. The Company may issue securities through private placement transactions
or registered public offerings pursuant to a registration statement filed with the SEC.&nbsp;&nbsp;Additionally, the Company retains
the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares,
stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities
and Exchange Commission (&ldquo;SEC&rdquo;) on November&nbsp;6, 2013. The Company will continue to incur operating losses and negative
cash flows until revenues reach a level sufficient to support ongoing operations.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Basis of Presentation</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Beginning in March 2011, the consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;). Royalty Sub was formed
in connection with a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 3, Royalty Monetization,
for a further description of this transaction. All intercompany transactions and balances have been eliminated.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company&#8217;s consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Such consolidated financial
statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects,
the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than
normal recurring adjustments.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Reclassifications</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Long term deferred rent as of December 31, 2014 has been reclassified
to conform to the 2015 presentation.</P>



<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held
in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities
of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to
the short-term nature of these items.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Restricted Cash</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Restricted cash as of December 31, 2015 reflects $150 the Company
is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program,
$59 in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes
(defined in Note 3) and $1,403 the Company is required to maintain as collateral for a letter of credit associated with the lease
execution and build-out of its new Birmingham research facilities.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></p>

<!-- Field: Page; Sequence: 58; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></p>

<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>



<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Investments</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance
with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment
policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow
requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government
agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable
debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments,
municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s
investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years
and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market
risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize
this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the
need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to
interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company
has not realized any significant losses from its investments.<b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale.
Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be
other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments
for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary
declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in
the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions
recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature
at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from
the balance sheet date are classified as long-term. At December 31, 2015, the Company believes that the costs of its investments
are recoverable in all material respects.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#8217;s
investments by type. The estimated fair value of the Company&#8217;s fixed income investments are classified as Level 2 in the
fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted
prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets
that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br> Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br> Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br> Unrealized<br> Gains</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br> Unrealized<br> Losses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br> Fair Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">26,557</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">88</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(99</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">26,546</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,820</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">184</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(41</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,963</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,884</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(72</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,838</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,261</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">293</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(212</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>
<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2014</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br> Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br> Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br> Unrealized<br> Gains</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br> Unrealized<br> Losses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br> Fair Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">20,307</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">22</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(23</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">20,306</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,152</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">151</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(47</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,261</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Commercial paper</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,838</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(63</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,781</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,297</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">179</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(133</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#8217;s
investments at December&nbsp;31, 2015 and 2014.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 67%; font-size: 10pt; text-align: left">Maturing in one year or less</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">22,664</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">18,232</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">28,395</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">25,459</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,288</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">15,657</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 59; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>



<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Receivable from Collaborations</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the
Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables
from Shionogi and Seqirus UK Limited (&#8220;SUL&#8221;), and product sales to SUL. These receivables are evaluated to determine
if any reserve or allowance should be established at each reporting date. At December&nbsp;31, 2015 and 2014, the Company had the
following receivables.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">5,536</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">5,536</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Shionogi&nbsp;&amp; Co. Ltd.</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">469</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">469</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">210</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">238</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">679</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,564</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,243</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2014</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; width: 52%">U.S. Department of Health and Human Services</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">2,778</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">2,778</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Shionogi&nbsp;&amp; Co. Ltd.</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,071</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,071</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,071</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,778</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,849</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and
Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of
indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates
are subject to audit by the U.S. Government.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Receivables from Product Sales</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the
Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established
at each reporting date.</P>

<P STYLE="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Inventory</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">At December&nbsp;31, 2015 and 2014, the Company&rsquo;s inventory
consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under
the first-in, first-out (&ldquo;FIFO&rdquo;) method, or market. The Company expenses costs related to the production of inventories
as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected
to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize
subsequent costs related to the production of inventories.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">During 2014, in connection with the FDA approval of RAPIVAB, the Company
began capitalizing costs associated with the production of RAPIVAB inventories.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company&#8217;s inventory consisted of the following:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><P STYLE="margin: 0">Work in process</P>


</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1,612</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">267</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished goods</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">416</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net inventories</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,612</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">683</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i></i></b></p>

<!-- Field: Page; Sequence: 60; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i></i></b></p>
<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>
<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Property and Equipment</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed
using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of
three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures
are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the remaining
lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded
at its fair value, less depreciation. The building is being depreciated over a period of ten years equal to the term of the related
lease</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its
property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets
may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from
the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover
the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed
of are reported at the lower of carrying amount or fair value less cost to sell.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Patents and Licenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company seeks patent protection on all internally developed
processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as
recoverability of such expenditures is uncertain.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Accrued Expenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party
vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these
contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records
liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of
the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel
to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost
incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service
providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of
each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the
accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses
include:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><font style="font-size: 10pt">professional fees.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its
estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that
conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation,
vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors
such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company
estimates the time period over which services will be performed and the level of effort expended in each period. If the actual
timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 61; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></p>
<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>&nbsp;</b></p>


<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">Accrued expenses were comprised of the following:</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 67%; font-size: 10pt; text-align: left">Compensation and benefits</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">424</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">2,105</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Development costs</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,398</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,232</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">549</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">397</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Professional fees</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">242</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">238</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Duties and taxes</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">102</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">75</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,522</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,282</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Total accrued expenses</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">16,237</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,329</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">As of December 31, 2015 and 2014, the carrying value of accrued
expenses approximates their fair value due to their short-term settlement.</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Income Taxes</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The liability method is used in the Company&#8217;s accounting for
income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting
and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect
when the differences are expected to reverse.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><B><I>Accumulated Other Comprehensive Loss</I></B></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Accumulated other comprehensive loss is comprised of unrealized gains
and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Amounts reclassified
from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive
Loss. During 2015, realized gains of $13 were reclassified out of accumulated other comprehensive loss. No reclassifications out
of accumulated other comprehensive loss were recorded during 2014.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Revenue Recognition</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research
and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable
and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery
has occurred or services have been rendered; (iii)&nbsp;the seller&#8217;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability
is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and
research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing
performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received
under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined
by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result
of changes in the estimated revenue period are recognized prospectively.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#8217;s license agreements, the Company
receives royalty payments based upon its licensees&#8217; net sales of covered products. The Company recognizes royalty revenues
when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element,
each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting.
This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer. The consideration that
is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.
The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective
evidence of fair value, (ii) third-party evidence of selling price (&#8220;TPE&#8221;) and (iii) best estimate of selling price
(&#8220;BESP&#8221;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold
by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each
deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered,
limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables
requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset,
or another performance obligation.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 62; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, the Company entered into a License Agreement (the &ldquo;SUL
Agreement&rdquo;) granting Seqirus UK Limited (&ldquo;SUL&rdquo;) and its affiliates worldwide rights, excluding Israel, Japan,
Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments,
including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three
deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&ldquo;EU&rdquo;)
marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent
upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to
the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated
to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately
$1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support
activities.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement
of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured
at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these
revenue recognition criteria are recorded as deferred revenue.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company may receive up to
$12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i)
by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food
Branch of Health Canada (&#8220;Health Canada&#8221;) for an adult indication in Canada. The Company evaluated each event based
payment under the provisions of ASU 2010-17, <i>Milestone Method of Revenue Recognition</i>, and determined that each event based
payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event
based payments were achieved during the periods presented.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related
to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a
reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within
the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious
Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><i>Product Sales</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenue for sales of RAPIVAB when title and
substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment
from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when
there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability
is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates.
In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to
physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the SUL
worldwide license of RAPIVAB, SUL will be primarily responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales,
and the Company&rsquo;s commercial sales will be minimal.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare
and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are
recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived
from historical experience adjusted to reflect known changes in the factors that impact such reserves.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate
gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes,
but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through
to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with
authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following
significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting
estimates, and require it to use information from external sources.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><i></i></p>

<!-- Field: Page; Sequence: 63; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><i></i></p>
<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><i>Rebates and Chargebacks</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based
on statutory discounts to RAPIVAB&#8217;s selling price.&nbsp;As it can take up to nine months or more for information to be received
on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under
these programs relating to RAPIVAB sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the
differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid
by eligible customers covered under federally qualified programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based
on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment
experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices
and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#8217;s product through
public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization
data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions
each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within
nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#8217;s estimates, additional
reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Discounts and Sales Incentives</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory
Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with the Company&#8217;s specialty distributors, the
Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual
contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of
these fees by applying the contractual rates to such product sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Product Returns</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does
not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the years ended December&nbsp;31:</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; font-size: 10pt; text-align: left">Product sales, net</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">6,291</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">33</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Royalty revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,386</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,025</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,562</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">U.S. Department of Health and Human Services</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16,337</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,366</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,585</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Green Cross Corporation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">132</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Shionogi (Japan)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,184</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,184</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,184</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,927</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,580</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,550</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,769</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">48,257</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">13,608</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">17,331</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Advertising</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response
advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred. Advertising and
product promotion expenses were $103 and $290 for the years ended December&nbsp;31, 2015 and 2014, respectively.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Research and Development Expenses</i></b></p>



<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s research and development costs are charged to
expense when incurred. Research and development expenses include all direct and indirect development costs related to the development
of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for
future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related
goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel
costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials
and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s
manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued
by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s
on-going review of the level of services actually performed.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 64; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>
<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties,
such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;),
and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance
fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which
case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments
as incurred.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid
to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration
paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred
without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion
to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with
the associated revenue.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Stock-Based Compensation</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">All share-based payments, including grants of stock option awards
and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on
their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value
of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is
recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding
performance-based stock options for which no compensation expense is recognized until &#8220;performance&#8221; has occurred.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Interest Expense and Deferred Financing Costs</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Interest expense for the years ended December&nbsp;31, 2015, 2014
and 2013 was $5,200, $4,998 and $4,778, respectively, and relates to the issuance of the PhaRMA Notes. Costs directly associated
with the issuance of the PhaRMA Notes have been capitalized and are included in other non-current assets on the Consolidated Balance
Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate
method. Amortization of deferred financing costs included in interest expense was $439 for each of the years ended December&nbsp;31,
2015, 2014 and 2013.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Currency Hedge Agreement</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to
market adjustments are recognized in the Company&rsquo;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market
adjustments for the years ended December&nbsp;31, 2015, 2014 and 2013 resulted in a loss of $564 and gains of $5,487 and $5,294,
respectively. Mark to market adjustments are determined by a third party pricing model which uses quoted prices in markets that
are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair
value hierarchy as defined by U.S. GAAP. In addition, a realized currency exchange gain of $1,654 was recognized in 2015 related
to the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge. The Company is also required to
post collateral in connection with the mark to market adjustments based on defined thresholds. As of December 31, 2015 and December&nbsp;31,
2014, no hedge collateral was posted under the agreement.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Net Loss Per Share</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common
shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented
herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be
issued under the Company&rsquo;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share
for the years ended December&nbsp;31, 2015, 2014, and 2013 does not include 3,524, 3,991 and 1,430 respectively, of potential common
shares as their impact would be anti-dilutive.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Use of Estimates</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP
requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results
could differ from those estimates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 65; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><b></b></p>
<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><b>Significant Customers and Other Risks</b><i>&nbsp;</i></p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Significant Customers</i></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Prior to the SUL Agreement, the Company relied primarily on three
specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted
for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&rsquo;s outstanding
receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact
the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent
to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide
basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will
be made by the Company&rsquo;s partners and the Company will be reliant on these partners to generate sales and remit cash to
satisfy receivables.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company&#8217;s primary source of revenue that has an underlying
cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with
BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development
costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the
Company&#8217;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS
peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&#8217;s
future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from
the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest,
and then the principal, on the Company&#8217;s non-recourse notes payable. Payment of the interest and the ultimate repayment of
principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#8217;s
drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform
their services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Risks from Third Party Manufacturing and Distribution Concentration</i>
&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 22.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical
ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays
in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling
of RAPIVAB.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Credit Risk</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 22.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially
subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess
cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits.
The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities
that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio
of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables
discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which
there is no assumed credit risk.</p></div><p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Note&nbsp;2&nbsp;&#8212; Property and Equipment</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Property and equipment consisted of the following at December&nbsp;31:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 67%; font-size: 10pt; text-align: left">Furniture and fixtures</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">718</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">542</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Office equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,122</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,115</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Software</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,427</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,423</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Laboratory equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,004</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,786</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Leased equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">63</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">63</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Leasehold improvements</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,610</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,303</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Construction in progress</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,821</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Building</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,589</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">19,354</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,232</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation and amortization</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(14,205</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(14,025</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Property and equipment, net</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,149</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">207</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 66; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>
<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Depreciation and amortization expense for the years ended December&nbsp;31,
2015, 2014 and 2013 was $180, $177 and $304, respectively.</p></div><p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Note 3&#8212; Royalty Monetization</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt"><i>Overview</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, the Company completed a $30,000&nbsp;financing
transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi
licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received
net proceeds of $22,691&nbsp;from the transaction after transaction costs of $4,309&nbsp;and the establishment of a $3,000&nbsp;interest
reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account
has been fully utilized with the September 2012 interest payment.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">As part of the transaction, the Company entered into a purchase and
sale agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things,
(i)&nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the
right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency
Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi
in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#8217;s collaboration with Shionogi was not impacted
as a result of this transaction.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 6pt"><i>Non-Recourse Notes Payable</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, Royalty Sub completed a private placement to
institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#8220;PhaRMA
Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#8220;Indenture&#8221;),
by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are
payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the
Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest
at 14%&nbsp;per annum, payable annually in arrears on September&nbsp;1st of each year. The Company remains entitled to receive
any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. &nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Royalty Sub&#8217;s obligations to pay principal and interest on
the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except
to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company
may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion
pay any interest shortfall on, the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In September&nbsp;2013, Royalty Sub paid $1,844 of interest on
the PhaRMA Notes from royalty payments received from RAPIACTA<SUP>&reg;</SUP> sales from the preceding four calendar quarters.
This payment resulted in an obligation shortfall of approximately $2,356 associated with accrued interest due September&nbsp;3,
2013. As stipulated under the PhaRMA Notes Indenture, if the amount available for payment on any Payment Date is insufficient to
pay all of the interest due on a Payment Date, the shortfall in interest will accrue interest at the interest rate applicable to
the PhaRMA Notes compounded annually. Accordingly, commencing in September&nbsp;2013, the Company began accruing interest at 14%&nbsp;per
annum on the interest shortfall of $2,356. In March, June and August of 2014, Royalty Sub paid additional interest of $446, $1,882
and $70, respectively, bringing the 2013 shortfall down to $222 as of September 30, 2014. Under the terms of the Indenture, Royalty
Sub&rsquo;s inability to pay the full amount of interest payable in September&nbsp;2013 by the next succeeding Payment Date for
the PhaRMA Notes, which was September&nbsp;1, 2014, constituted an event of default. Accordingly, the PhaRMA Notes and related
accrued interest have been classified as current liabilities on the December 31, 2014 balance sheet. As a result of the event of
default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the
collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under
the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments
that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to
the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the
Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In
addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be
required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of
Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact
on the Company&rsquo;s future results of operations or cash flows. As of December 31, 2015, the PhaRMA Notes remain in default.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 67; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p><p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Indenture does not contain any financial covenants. The Indenture
includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of
Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters
typical for indentures used in structured financings of this type.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of December&nbsp;31, 2015, the aggregate fair value of the PhaRMA
Notes was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified
as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The PhaRMA Notes are redeemable at the option of Royalty Sub at any
time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid
interest through the redemption date on the PhaRMA Notes being redeemed.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Foreign Currency Hedge</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen
at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided
the Currency Hedge Agreement remains in effect. A payment of $1,950&nbsp;will be required if, on May&nbsp;18 of the relevant year,
the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting
treatment; therefore mark to market adjustments are recognized in the Company&rsquo;s Consolidated Statement of Comprehensive
Loss. Cumulative mark to market adjustments in 2015, 2014 and 2013 resulted in a loss of $564 and gains of $5,487 and $5,294 respectively.
In addition, a realized currency exchange gain of $1,654 was recognized in 2015 related to the exercise of a U.S. dollar/Japanese
yen currency option under our foreign currency hedge. The Company is also required to post collateral in connection with the mark
to market adjustments based on defined thresholds. As of December&nbsp;31, 2015 and 2014, no collateral was posted under the Currency
Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining
payable under the Currency Hedge Agreement. As of December 31, 2015, the maximum amount of hedge collateral the Company may be
required to post is $9,750.</P>



<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p></div><p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Note&nbsp;4&nbsp;&#8212; Lease Obligations and Other Contingencies</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company has the following minimum payments under operating lease
obligations that existed at December&nbsp;31, 2015:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: left">2016</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">651</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">2017</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">871</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">2018</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">870</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">2019</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">820</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">651</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: left">Thereafter</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,045</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total minimum payments</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,908</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


</div>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">The obligations in the preceding table are primarily related
to the Company&rsquo;s leases for buildings in Birmingham, Alabama and Durham, North Carolina. The lease for the Company&rsquo;s
headquarters in Durham, North Carolina expires June&nbsp;30, 2020. The lease for the existing facility in Birmingham, Alabama currently
expires on June&nbsp;30, 2016; however, in 2015, the Company leased an additional approximate 32,000 square feet in Birmingham
to house its new research facility. The Company began construction on leasehold improvements for its new research facility in 2015
and this lease obligates the Company for $4,839 of lease payments into 2027. Rent expense for operating leases was $664, $633,
and $526 in 2015, 2014, and 2013, respectively.</P>

<P STYLE="font-size: 10pt; text-indent: 0.25in; margin: 12pt 0 0"><I>Lease Financing Obligation</I></P>

<P STYLE="font-size: 10pt; text-indent: 24.5pt; margin: 12pt 0 0">Based on the terms of the lease agreement for the new research
facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed
the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset
of $1,589, representing the Company&rsquo;s leased portion of the building and recorded a corresponding liability. Upon completion
of leasehold improvement construction, the Company will not meet the sale-leaseback criteria for de-recognition of the building
asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected
duration of the lease, and rental payments will be treated as principal and interest payments on the lease financing obligation
liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease and
or construction in process.</P>



<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 68; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></p>
<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>
<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">At December 31, 2015, the lease financing obligation balance
was $2,375 and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments
under the lease financing obligation are $4,839.</P>



<P STYLE="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></p></div><p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Note&nbsp;5&nbsp;&#8212; Stockholders&#8217; Equity</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Sales of Common Stock</i></b></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">On March 3, 2015, the Company filed a $150,000 shelf registration
statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell
securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time
to time at prices and on terms to be determined at the time of sale. The Company intends to file a post-effective amendment to
this registration statement, which will allow for its use by the Company when declared effective by the SEC&rsquo;s staff.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">On November&nbsp;6, 2013, the Company filed a $125,000 shelf registration
statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows us to
sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from
time to time at prices and on terms to be determined at the time of sale. On June 3, 2014, the Company issued 11,500 shares of
common stock for gross proceeds of $115,000 under this $125,000 shelf registration statement. Net proceeds were approximately $107,800
after deducting underwriting discounts and offering expenses. The Company has $10,000 remaining under this shelf registration statement</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In August 2013, the Company completed a public offering of 4,600
shares of its common stock at a price of $4.40 per share, which included the underwriters&#8217; over-allotment allocation of an
additional 600 shares. Net proceeds were approximately $18,500 after deducting underwriting discounts and offering expenses. Shares
of common stock in this offering were sold under the $70,000 shelf registration statement declared effective in July 2011.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In June 2011, the Company entered into an At Market Issuance Sales
Agreement (the &#8220;ATM Agreement&#8221;) with McNicoll, Lewis&nbsp;&amp; Vlak (&#8220;MLV&#8221;) pursuant to which the Company
was able to sell $70,000 in shares of its common stock at current market prices under a Form S-3 registration statement with MLV
acting as the sales agent. During 2012, the Company sold an aggregate of 4,516 shares of common stock at an average per share price
of $4.08 pursuant to the ATM Agreement for net proceeds of $17,805. During 2013, the Company sold an aggregate of 2,883 shares
of common stock at an average per share price of $1.85 pursuant to the Agreement for net proceeds of $5,218.</p></div><p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Note&nbsp;6&nbsp;&#8212; Stock-Based Compensation</b></p>

<p style="font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Stock Incentive Plan</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">As of December&nbsp;31, 2015, the Company had two stock-based employee
compensation plans, the Stock Incentive Plan (&#8220;Incentive Plan&#8221;) and the Employee Stock Purchase Plan (&#8220;ESPP&#8221;),
both which were amended and restated in March 2014 and approved by the Company&#8217;s stockholders in May 2014. Stock-based compensation
expense of $9,705 ($9,485 of expense related to the Incentive Plan, $220 of expense related to the ESPP) was recognized during
2015, while $10,177 ($9,963 of expense related to the Incentive Plan, $214 of expense related to the ESPP) was recognized during
2014, and $4,368 ($4,253 of expense related to the Incentive Plan, $115 of expense related to the ESPP) was recognized during 2013.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">The Company accounts for stock-based compensation in accordance
with FASB authoritative guidance regarding share-based payments. Total stock-based compensation was allocated as follows:</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left">Research and development</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">7,580</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">8,906</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">3,664</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,125</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,271</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">704</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total stock-based compensation expense</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,705</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,177</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,368</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 69; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p><p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company grants stock option awards and restricted stock unit
awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are
granted with an exercise price equal to the market price of the Company&#8217;s stock at the date of grant. Commencing March&nbsp;1,
2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013,
the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully
vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively.
These awards vest upon successful completion of specific development milestones. As of December 31, 2015, 75% of the August 2013
grants have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which
vesting occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of
2014, and (3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered
BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of December&nbsp;31, 2015, 25%
of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation
expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to
non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5
to 10&nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in
the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive
Plan.<b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Related activity under the Incentive Plan is as follows:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Awards<br> Available</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options<br> Outstanding</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br> Average<br> Exercise<br> Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt">Balance at December&nbsp;31, 2012</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">2,815</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">8,073</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">6.09</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(310</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards cancelled</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">53</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(3,277</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,277</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3.05</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(563</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2.37</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock option awards cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,801</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,801</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">7.22</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Balance at December&nbsp;31, 2013</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,082</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,986</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.99</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Plan amendment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,750</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(593</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards cancelled</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,965</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,965</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10.99</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,258</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.78</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock option awards cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">88</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(88</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">8.83</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Balance at December&nbsp;31, 2014</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,362</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,605</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6.21</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(163</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards cancelled</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,217</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,217</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11.52</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,118</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4.36</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock option awards cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">33</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(33</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">9.87</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance at December&nbsp;31, 2015</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">16</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,671</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">7.50</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">For stock option awards granted under the Incentive Plan during
2015, 2014 and 2013, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions
noted in the table below. The weighted average grant date fair value of these awards granted during 2015, 2014 and 2013 was $7.72,
$8.02, and $1.28, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using
a straight-line expense attribution method. The following explanations describe the assumptions used by the Company to value the
stock option awards granted during 2015, 2014, and 2013. The expected life is based on the average of the assumption that all outstanding
stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised
at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The
expected volatility represents the volatility over the most recent period corresponding with the expected life. The Company has
assumed no expected dividend yield, as dividends have never been paid to stockholders and will not be for the foreseeable future.
The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining
term equal to the expected term.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p>

<!-- Field: Page; Sequence: 70; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p><p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Weighted Average Assumptions for Stock Option Awards Granted under the
Incentive Plan</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; text-align: left">Expected Life</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">5.5</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">5.5</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right">4.7</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected Volatility</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">81</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">87</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">84</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1.6</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1.6</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.7</td><td style="font-size: 10pt; text-align: left">%</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The total intrinsic value of stock option awards exercised under the
Incentive Plan was $10,117 during 2015, $8,522 during 2014, $738 and during 2013. The intrinsic value represents the total proceeds
(fair market value at the date of exercise, less the exercise price, times the number of stock option awards exercised) received
by all individuals who exercised stock option awards during the period.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The following table summarizes, at December&nbsp;31, 2015, by price
range: (1)&nbsp;for stock option awards outstanding under the Incentive Plan, the number of stock option awards outstanding, their
weighted average remaining life and their weighted average exercise price; and (2)&nbsp;for stock option awards exercisable under
the Plan, the number of stock option awards exercisable and their weighted average exercise price:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>




<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <td style="font-size: 10pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="9" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><font style="font-size: 10pt">Outstanding</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><font style="font-size: 10pt">Exercisable</font></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2"><font style="font-size: 10pt"><b><u>Range</u></b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"><font style="font-size: 10pt">Number</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><font style="font-size: 10pt">Weighted
    <br>
    Average <br>
    Remaining <br>
    Life</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><font style="font-size: 10pt">Weighted
    <br>
    Average <br>
    Exercise <br>
    Price</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"><font style="font-size: 10pt">Number</font></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><font style="font-size: 10pt">Weighted
    <br>
    Average <br>
    Exercise <br>
    Price</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"><font style="font-size: 10pt">0</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 3%"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"><font style="font-size: 10pt">3</font></td><td style="width: 2%; font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 12%; font-size: 10pt; text-align: right"><font style="font-size: 10pt">1,826</font></td><td style="width: 2%; font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="width: 14%; font-size: 10pt; text-align: right"><font style="font-size: 10pt">6.4</font></td><td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="width: 2%; font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 14%; font-size: 10pt; text-align: right"><font style="font-size: 10pt">1.51</font></td><td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="width: 2%; font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="width: 14%; font-size: 10pt; text-align: right"><font style="font-size: 10pt">1,322</font></td><td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="width: 2%; font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 14%; font-size: 10pt; text-align: right"><font style="font-size: 10pt">1.55</font></td><td style="width: 1%; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">3</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">6</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">2,792</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">6.1</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">4.63</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">2,329</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">4.53</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">6</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">9</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">1,153</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">4.5</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">7.10</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">1,070</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">7.13</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">9</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">12</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">3,728</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">8.1</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">11.07</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">714</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">11.45</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">12</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><font style="font-size: 10pt">15</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">1,077</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">6.4</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">12.44</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">374</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">12.65</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><font style="font-size: 10pt"><b>&nbsp;</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><font style="font-size: 10pt">15</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><font style="font-size: 10pt">18</font></td><td style="font-size: 10pt; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1.1pt; border-bottom: Black 1pt solid"><font style="font-size: 10pt">95</font></td><td style="font-size: 10pt; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">9.5</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">15.39</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><font style="font-size: 10pt">&#8212;</font></td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; padding-bottom: 1.1pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">&#8212;</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><font style="font-size: 10pt">0</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><font style="font-size: 10pt">to</font></td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><font style="font-size: 10pt">18</font></td><td style="font-size: 10pt; padding-bottom: 2.25pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 2.25pt; border-bottom: Black 2.25pt double"><font style="font-size: 10pt">10,671</font></td><td style="font-size: 10pt; padding-bottom: 2.25pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">6.7</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; padding-bottom: 2.25pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">$</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">7.50</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; padding-bottom: 2.25pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><font style="font-size: 10pt">5,809</font></td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td><td style="font-size: 10pt; padding-bottom: 2.25pt"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">$</font></td><td style="font-size: 10pt; text-align: right"><font style="font-size: 10pt">5.70</font></td><td style="font-size: 10pt; text-align: left"><font style="font-size: 10pt">&nbsp;</font></td></tr>
</table></div>



<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The weighted average remaining contractual life of stock option
awards exercisable under the Incentive Plan at December&nbsp;31, 2015 was 5.0 years.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The aggregate intrinsic value of stock option awards outstanding
and exercisable under the Incentive Plan at December&nbsp;31, 2015 was $28,511. The aggregate intrinsic value represents the value
(the period&#8217;s closing market price, less the exercise price, times the number of in-the-money stock option awards) that would
have been received by all stock option award holders under the Incentive Plan had they exercised their stock option awards at the
end of the year.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The total fair value of the stock option awards vested under the
Incentive Plan was $4,492 during 2015, $2,844 during 2014, and $3,483 during 2013.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of December&nbsp;31, 2015, the number of stock option awards
vested and expected to vest under the Incentive Plan is 9,633. The weighted average exercise price of these stock option awards
is $7.51 and their weighted average remaining contractual life is 6.6&nbsp;years.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 71; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p><p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following table summarizes the changes in the number and weighted-average
grant-date fair value of non-vested stock option awards during 2015:</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-Vested<br> Stock Option<br> Awards</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<br> Grant-Date Fair<br> Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 67%; font-size: 10pt">Balance December&nbsp;31, 2014</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 13%; font-size: 10pt; text-align: right">4,385</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">4.27</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock option awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,217</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7.72</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Stock option awards vested</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,711</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2.63</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Stock option awards forfeited</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(28</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6.39</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance December&nbsp;31, 2015</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,863</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6.40</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">As of December&nbsp;31, 2015, there was approximately $18,607 of total
unrecognized compensation cost related to non-vested employee stock option awards and restricted stock units granted by the Company.
That cost is expected to be recognized as follows: $7,023 in 2016, $6,010 in 2017, $3,891 in 2018, and $1,683 in 2019.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><b><i>Employee Stock Purchase Plan</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company has reserved a total of 1,475&nbsp;shares of common stock
to be purchased under the ESPP, of which 497&nbsp;shares remain available for purchase at December&nbsp;31, 2015. Eligible employees
may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price
during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates
and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">There were 41, 49 and 89 shares of common stock purchased under the
ESPP in 2015, 2014, and 2013, respectively, at a weighted average price per share of $8.65, $6.29, and $1.39, respectively. Expense
of $220, $214, and $115, related to the ESPP was recognized during 2015, 2014, and 2013, respectively. Compensation expense for
shares purchased under the ESPP related to the purchase discount and the &#8220;look-back&#8221; option were determined using a
Black-Scholes option pricing model. The weighted average grant date fair values of shares granted under the ESPP during 2015, 2014,
and 2013, were $4.93, $4.41, and $1.27, respectively.&nbsp;</p></div><p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note&nbsp;7&nbsp;&#8212; Income Taxes</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company has incurred net losses since inception and, consequently,
has not recorded any U.S.&nbsp;Federal and state income tax expense or benefit. The differences between the Company&#8217;s effective
tax rate and the statutory tax rate in 2015, 2014, and 2013 are as follows:</p></div>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-size: 10pt; text-align: left">Income tax benefit at federal statutory rate (35%)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(15,057</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(15,816</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(10,538</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">State and local income taxes net of federal tax benefit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(819</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,286</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(839</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Permanent items</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">560</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">258</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">738</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Rate change</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,012</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,892</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Expiration of attribute carryforwards</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">330</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">373</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">242</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Research and development tax credits</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(10,454</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(748</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,206</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Orphan drug credit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,307</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Other</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(218</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(115</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,144</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,339</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,312</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,567</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Income tax expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


</div>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company recognizes the impact of a tax position in its financial
statements if it is more likely than not that the position will be sustained on audit based on the technical merits of the position.
The Company has concluded that it has an uncertain tax position pertaining to its research and development and orphan drug credit
carryforwards. The Company has established these credits based on information and calculations it believes are appropriate and
the best estimate of the underlying credit. Any changes to the Company&rsquo;s unrecognized tax benefits are offset by an adjustment
to the valuation allowance and there would be no impact on the Company&rsquo;s financial statements. The Company does not expect
its unrecognized tax benefits to change significantly over the next 12 months.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 72; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>


<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">A reconciliation of the beginning and ending amount of unrecognized
tax benefits is as follows:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-size: 10pt">Balance at January&nbsp;1,</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">472</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">284</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Additions to current period tax positions</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,616</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">176</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Additions to prior period tax positions</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Reductions to prior period tax provisions</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">Balance at December&nbsp;31,</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,085</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">472</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


</div>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><FONT STYLE="background-color: white">The Company&rsquo;s ability
to utilize the net operating loss and tax credit carryforwards in the future may be subject to substantial restrictions in the
event of past or future ownership changes as defined in Section&nbsp;382 of the Internal Revenue Code of 1986, as amended and similar
state tax law.</FONT></P>



<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Significant components of the Company&#8217;s deferred tax assets
and liabilities are as follows:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Deferred tax assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left; padding-left: 10pt">Net federal and state operating losses</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">142,836</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">135,922</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Research and development credits</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">48,551</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">38,096</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Fixed assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,054</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,073</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Deferred revenue</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,240</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,798</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Stock-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,605</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,086</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,590</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,178</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Total deferred tax assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">207,876</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">187,153</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Deferred tax liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Foreign currency derivative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,668</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,285</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,668</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,285</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(205,208</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(184,868</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net deferred tax assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


</div>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The majority of the Company&rsquo;s deferred tax assets relate
to net operating loss and research and development carryforwards that can only be realized if the Company is profitable in future
periods. It is uncertain whether the Company will realize any tax benefit related to these carryforwards. Accordingly, the Company
has provided a full valuation allowance against the net deferred tax assets due to uncertainties as to their ultimate realization.
The valuation allowance will remain at the full amount of the deferred tax assets until it is more likely than not that the related
tax benefits will be realized. The Company&rsquo;s valuation allowance increased by $20,339 in 2015, $17,312 in 2014, and $8,567
in 2013.&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of December&nbsp;31, 2015, the Company had federal operating
loss carryforwards of $386,219, state operating loss carryforwards of $373,454, and research and development and orphan drug credit
carryforwards of $48,551, which will expire at various dates from 2016 through 2035. The federal losses begin to expire in 2018,
the state losses begin to expire in 2016 and the research and development contracts begin to expire in 2018.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company&rsquo;s federal and state operating loss carryforwards
include $15,655 of excess tax benefits related to a deduction from the exercise of stock options. The tax benefit of these deductions
has not been recognized in deferred tax assets. If utilized, the benefits from these deductions will be recorded as adjustments
to additional paid-in capital.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Tax years 2012-2014 remain open to examination by the major taxing
jurisdictions to which the Company is subject. Additionally, years prior to 2012 are also open to examination to the extent of
loss and credit carryforwards from those years. The Company recognizes interest and penalties accrued related to unrecognized tax
benefits as components of its income tax provision. However, there were no provisions or accruals for interest and penalties in
2015, 2014, and 2013.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p>

<!-- Field: Page; Sequence: 73; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p>

<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>


<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Note&nbsp;8&nbsp;&#8212; Employee 401(k) Plan</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In January 1991, the Company adopted an employee retirement plan (&#8220;401(k)
Plan&#8221;) under Section&nbsp;401(k) of the Internal Revenue Code covering all employees. Employee contributions may be made
to the 401(k) Plan up to limits established by the Internal Revenue Service. Company matching contributions may be made at the
discretion of the Board of Directors. The Company made matching contributions of $366, $361, and $313, in 2015, 2014, and 2013,
respectively.</p></div><p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Note&nbsp;9&nbsp;&#8212; Collaborative and Other Research and Development
Contracts</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><I>U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;).
</I>In January 2007, the U.S.&nbsp;Department of Health and Human Services (&ldquo;BARDA/HHS&rdquo;) awarded the Company a $102,661,
four-year contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development
shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract
modification was awarded to extend the i.v. peramivir program and to increase funding by $77,191. On February&nbsp;24, 2011, the
Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended to fund completion of the Phase 3 development
of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract
award from BARDA/HHS to $234,852 and provided funding to support the filing of a NDA to seek regulatory approval for i.v. peramivir
in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December
2014. The BARDA/HHS contract expired on June 30, 2014.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">On March 31, 2015, the Company announced that the Biomedical Research
and Development Authority within the U.S. Department of Health and Human Services&rsquo; Office of the Assistant Secretary for
Preparedness and Response awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases
caused by RNA pathogens, including filoviruses.&nbsp;This BARDA/HHS contract includes a base contract of $13,314 to support BCX4430
drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the
potential value of the contract to $36,169. As of September 30, 2015, a total of $16,300 has been awarded under exercised options
within this contract.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><i>National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;).</i>
In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease.
NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this
contract as of December 31, 2015 could be up to $34,002, if all contract options are exercised by NIAID/HHS, over a five year period.
The goals of this contract, including amendments, are to file IND applications for intravenous and intramuscular BCX4430 for the
treatment of Marburg virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human
clinical trial. As of December 31, 2015, a total of $29,875 has been awarded under exercised options within this contract. BCX4430
is the lead compound in the Company&#8217;s BSAV research program.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee
contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions
that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic
assessments of progress and the continuation of the contract is based on the Company&#8217;s performance, the timeliness and quality
of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These
contracts are terminable by the government at any time for breach or without cause.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"><i>Seqirus UK Limited (&#8220;SUL&#8221;).</i> On June 16, 2015,
the Company and Seqirus UK Limited ("SUL"), a limited company organized under the laws of the United Kingdom and a subsidiary
of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the "SUL Agreement")
granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the
treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies
together constituting the "Territory"). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is
currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment
in the world and was approved by the U.S. Food and Drug Administration in December 2014 for the treatment of acute uncomplicated
influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and
associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue
government stockpiling outside the U.S.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's
subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets.
SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization
of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 74; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In December 2013, the Company submitted a New Drug Application ("NDA")
for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval
commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility
for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory
filings and interactions with the Health Canada and the European Medicines Agency ("EMA") until marketing approval for
RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee,
composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the
commercialization of RAPIVAB in the Territory and any additional development.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company received an upfront
payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory
milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in
the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive
tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well
as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the
Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract
Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the
Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events
impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire,
on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from
the date of the SUL Agreement (the "Royalty Term"). The Company developed RAPIVAB under a license from UAB and will owe
sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><i>Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;).</i> In
February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in
Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi
obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and
will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In
October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include
Taiwan. Shionogi has commercially launched
peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Green Cross Corporation (&#8220;Green Cross&#8221;).</i> In
June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms
of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company
received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale
of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross
will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products
in Korea.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;).</i>
In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development
and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#8220;PNP&#8221;) inhibitor, for use in oncology (the
&#8220;Original Agreement&#8221;). Under the terms of the Original Agreement, Mundipharma obtained rights to forodesine in markets
across Europe, Asia, and Australasia in exchange for a $10,000 up-front payment.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 75; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>&nbsp;</b></p>


<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company deferred revenue recognition of the $10,000 up-front
payment that was received from Mundipharma in February&nbsp;2006 because the Company was involved in the continued development
of forodesine. Amortization of this revenue commenced in February&nbsp;2006 and was initially scheduled to end in October&nbsp;2017,
which is the date of expiration for the last-to-expire patent covered by the agreement. The Company also deferred revenue recognition
of a $5,000 payment received from Mundipharma in connection with the initiation of a clinical trial in 2007. Amortization of this
deferred revenue commenced in 2007 and was initially scheduled to end in October&nbsp;2017. Under its agreement with AECOM/IRL,
the Company paid sublicense payments related to these upfront cash payments received from Mundipharma. Expense recognition of these
sublicense payments was deferred and recognized under the same term as the related deferred revenue.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">On November&nbsp;11, 2011, the Company entered into the Amended
and Restated License and Development Agreement (the &#8220;Amended and Restated Agreement&#8221;) with Mundipharma, amending and
restating the Original Agreement. Under the terms of the Amended and Restated Agreement, Mundipharma obtained worldwide rights
to forodesine. Commencing on November&nbsp;11, 2011, Mundipharma controls the development and commercialization of forodesine and
assumes all future development and commercialization costs. The Amended and Restated Agreement provides for the possibility of
future event payments totaling $15,000 for achieving specified regulatory events for certain indications and tiered royalties ranging
from mid to high single-digit percentages of net product sales in each country where forodesine is sold by Mundipharma. These royalties
are subject to downward adjustments based on the then-existing patent coverage and/or the availability of generic compounds in
each country.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Amended and Restated Agreement is a multiple element arrangement
for accounting purposes, in which the Company is required to deliver to Mundipharma both the worldwide rights to forodesine in
the field of oncology and the transfer of product data and know-how to permit Mundipharma to develop and commercialize forodesine
(the &ldquo;Knowledge Transfer&rdquo;). The Company accounted for these elements as a combined unit of accounting as they do not
have stand-alone value to Mundipharma. The worldwide license rights were granted to Mundipharma on November&nbsp;11, 2011 and the
Knowledge Transfer was completed during the first quarter of 2012.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Albert Einstein College of Medicine of Yeshiva University and Industrial
Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively).</i> In June 2000, the Company licensed a series of potent
inhibitors of PNP from AECOM and IRL, (collectively, the &#8220;Licensors&#8221;). The lead product candidates from this collaboration
are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or
any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement
to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially
reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed
product (which range in the aggregate from $1,400 to almost $4,000&nbsp;per indication) for future development of these inhibitors,
single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future
payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which
can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement
may be terminated by the Company at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach by
the Licensors.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2010, the Company amended the licensee agreement through which
the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from
research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed
to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed
PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments the Company
may receive in the future under its license agreement dated February&nbsp;1, 2006 with Mundipharma and (ii)&nbsp;royalties received
from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect.
The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In consideration for these modifications in 2010, the Company issued
to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally,
at the Company&#8217;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid
by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination
of cash and shares.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;17, 2011, the Company further amended its agreements
with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined)
received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On June&nbsp;19, 2012, the Company further amended its agreements
with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to
exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 76; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>


<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">At its sole option and subject to certain agreed upon conditions,
any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash,
in shares of the Company&#8217;s common stock, or in a combination of cash and shares.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">On January 6, 2014, the Carbohydrate Chemistry Research Team from
Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#8220;VUW&#8221;)
to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts
relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst
is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties,
the terms and conditions of the contracts are substantially the same</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>The University of Alabama at Birmingham (&#8220;UAB&#8221;).</i>
The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements,
UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain
rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company
has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other
third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year
terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company
upon three months&#8217; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other
parties&#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall
resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements,
but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes
products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</p></div><p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Note&nbsp;10&nbsp;&#8212; Quarterly Financial Information (Unaudited)</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">First</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Second</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Third</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fourth</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">2015 Quarters</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; padding-left: 10pt">Revenues</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">6,826</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">25,842</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">10,987</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">4,602</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Net (Loss) Income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(15,164</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,901</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(14,621</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(18,135</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Basic net (loss) income per share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.21</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.07</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.20</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.25</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Diluted net (loss) income per share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.21</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.06</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.20</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.25</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">2014 Quarters</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">3,458</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1,466</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">3,238</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5,446</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Net Loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(10,137</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(14,649</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(8,731</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(11,672</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Basic and diluted net loss per share</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.17</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.23</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.12</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(0.16</td><td style="font-size: 10pt; text-align: left">)</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>&nbsp;</b></p></div><p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0 0pt 0pt"><b>Note&nbsp;11&nbsp;&#8212; Recent Accounting Pronouncements</b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">In November 2015, the Financial Accounting Standards Board (&#8220;FASB&#8221;)
issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2015-17, <i>Balance Sheet Classification of Deferred Taxes</i>, requiring
all deferred tax assets and liabilities, and any related valuation allowance, to be classified as noncurrent on the balance sheet.
The classification change for all deferred taxes as noncurrent simplifies entities&#8217; processes as it eliminates the need to
separately identify the net current and net noncurrent deferred tax asset or liability in each jurisdiction and allocate valuation
allowances. We elected to prospectively adopt the accounting standard in the beginning of our fourth quarter of fiscal 2015. Adoption
of this standard had no impact on the Company&#8217;s consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In April 2015, the FASB issued ASU No.2015-03, <i>Simplifying the
Presentation of Debt Issuance Costs</i>. This standard amends existing guidance to require the presentation of debt issuance costs
in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is
effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect
this standard will have a material impact on its consolidated financial statements.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 77; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b>BIOCRYST PHARMACEUTICALS, INC.<br>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0"><b>&nbsp;</b></p>


<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In August 2014, the FASB issued ASU No. 2014-15 &#8211; <i>Presentation
of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue
as a Going Concern,</i> which defines management&#8217;s responsibility to evaluate, at each annual and interim reporting period,
whether there are conditions or events that raise substantial doubt about an entity&#8217;s ability to continue as a going concern
within one year after the date the financial statements are issued and to provide related footnote disclosures in certain circumstances.
In connection with each annual and interim period, management must assess if there is substantial doubt about the company&#8217;s
ability to continue as a going concern within one year after the issuance date.&nbsp; Disclosures are required if conditions give
rise to substantial doubt.&nbsp;This standard is effective for all companies in the first annual period ending after December 15,
2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact this standard
will have on its financial statements and disclosures.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In May 2014, the FASB issued ASU 2014-09 &ndash; <I>Revenue from
Contracts with Customers</I>, which provides a single, comprehensive revenue recognition model for all contracts with customers.
The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers
in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.
This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising
from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to
obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which
will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January
1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method.
The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&nbsp;</p></div><p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 78; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_017"></a>Report of Independent Registered Public Accounting Firm</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">The Board of Directors and Stockholders</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We have audited the consolidated balance sheets of BioCryst Pharmaceuticals,
Inc. as of December 31, 2015 and 2014, and the related consolidated statements of comprehensive loss, stockholders&#8217; equity
and cash flows for each of the three years in the period ended December&nbsp;31, 2015. These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We conducted our audits in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe
that our audits provide a reasonable basis for our opinion.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In our opinion, the financial statements referred to above present
fairly, in all material respects, the consolidated financial position of BioCryst Pharmaceuticals, Inc. at December&nbsp;31, 2015
and 2014, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December&nbsp;31,
2015, in conformity with U.S.&nbsp;generally accepted accounting principles.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We also have audited, in accordance with the standards of the Public
Company Accounting Oversight Board (United States), BioCryst Pharmaceuticals, Inc.&rsquo;s internal control over financial reporting
as of December&nbsp;31, 2015, based on criteria established in <I>Internal Control-Integrated Framework</I> issued by the Committee
of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated February 26, 2016 expressed an unqualified
opinion thereon.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%">/s/&nbsp;Ernst&nbsp;&amp; Young LLP</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Raleigh, North Carolina</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>February 26, 2016</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>


<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 79; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><a name="a_018"></a><b>Report of Independent Registered Public Accounting
Firm</b></p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">The Board of Directors and Stockholders</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We have audited BioCryst Pharmaceuticals, Inc.&#8217;s internal control
over financial reporting as of December&nbsp;31, 2015, based on criteria established in <i>Internal Control-Integrated Framework</i>
issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) (the COSO criteria). BioCryst Pharmaceuticals,
Inc.&#8217;s management is responsible for maintaining effective internal control over financial reporting, and for its assessment
of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal
Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial
reporting based on our audit.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We conducted our audit in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit
included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists,
testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such
other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our
opinion.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">A company&#8217;s internal control over financial reporting is a process
designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial
reporting includes those policies and procedures that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&nbsp;provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations
of management and directors of the company; and (3)&nbsp;provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial
statements.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
or procedures may deteriorate.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In our opinion, BioCryst Pharmaceuticals, Inc. maintained, in all
material respects, effective internal control over financial reporting as of December&nbsp;31, 2015, based on the COSO criteria.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We also have audited, in accordance with the standards of the Public
Company Accounting Oversight Board (United States), the consolidated balance sheets of BioCryst Pharmaceuticals, Inc. as of December&nbsp;31,
2015 and 2014, and the related consolidated statements of comprehensive loss, stockholders&#8217; equity, and cash flows for each
of the three years in the period ended December&nbsp;31, 2015 of BioCryst Pharmaceuticals, Inc. and our report dated February 26,
2016 expressed an unqualified opinion thereon.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%">/s/&nbsp;Ernst&nbsp;&amp; Young LLP</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Raleigh, North Carolina</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>February 26, 2016</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 80; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><a name="a_019"></a><b>ITEM&nbsp;9.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">None.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_020"></a>ITEM&nbsp;9A.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>CONTROLS AND PROCEDURES</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0 0pt 4.5pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 4.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">We maintain a set of disclosure controls and procedures that are designed
to ensure that information relating to BioCryst Pharmaceuticals, Inc. required to be disclosed in our periodic filings under the
Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized and reported in
a timely manner under the Exchange Act of 1934. We carried out an evaluation as required by paragraph (b)&nbsp;of Rule&nbsp;13a-15
or Rule&nbsp;15d-15 under the Exchange Act, under the supervision and with the participation of management, including our Chief
Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and
procedures (as defined in Rule&nbsp;13a-15(e) or Rule&nbsp;15d-15 under the Exchange Act). Based upon that evaluation, the Chief
Executive Officer and Chief Financial Officer concluded that, as of December&nbsp;31, 2014, our disclosure controls and procedures
are effective. We believe that our disclosure controls and procedures will ensure that information required to be disclosed in
the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the Securities and Exchange Commission, and include controls and procedures designed to ensure
that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our
Chairman and Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><b>Management&#8217;s Report on Internal Control Over Financial Reporting</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 4.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Management of BioCryst Pharmaceuticals, Inc. is responsible for establishing
and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal control
over financial reporting. As defined by the Securities and Exchange Commission, internal control over financial reporting is a
process designed by, or under the supervision of our principal executive and principal financial officers and effected by our Board
of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of the financial statements in accordance with U.S.&nbsp;GAAP.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Our internal control over financial reporting is supported by written
policies and procedures that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
our transactions and dispositions of our assets; (2)&nbsp;provide reasonable assurance that transactions are recorded as necessary
to permit preparation of the financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being
made only in accordance with authorizations of our management and directors; and (3)&nbsp;provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect
on the financial statements.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
or procedures may deteriorate.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In connection with the preparation of our annual financial statements,
management has undertaken an assessment of the effectiveness of our internal control over financial reporting as of December&nbsp;31,
2015, based on criteria established in Internal Control&nbsp;&#8212; Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (2013 Framework) (the COSO Framework). Management&#8217;s assessment included an evaluation
of the design of our internal control over financial reporting and testing of the operational effectiveness of those controls.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Based on this assessment, management has concluded that as of December&nbsp;31,
2015, our internal control over financial reporting was effective. Management believes our internal control over financial reporting
will provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with U.S. GAAP.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Ernst&nbsp;&amp; Young LLP, the independent registered public accounting firm that audited our financial
statements included in this report, has issued an attestation report on the Company&rsquo;s internal control over financial reporting,
a copy of which appears on page&nbsp;80 of this annual report.</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Changes in Internal Control over Financial Reporting</b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">There have been no changes in our internal control over financial
reporting that occurred during the quarter ended December&nbsp;31, 2015 that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_021"></a>ITEM&nbsp;9B.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>OTHER INFORMATION</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">None.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 6pt">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 81; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PART&nbsp;III</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_022"></a>ITEM&nbsp;10.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The information required by this item is set forth under the captions
<i>&#8220;Items to be Voted on&nbsp;&#8212; 1. Election of Directors,&#8221; &#8220;Executive Officers,&#8221; &#8220;Section&nbsp;16(a)
Beneficial Ownership Reporting Compliance&#8221;</i> and <i>&#8220;Corporate Governance&#8221;</i> in our definitive Proxy Statement
for the 2016 Annual Meeting of Stockholders and incorporated herein by reference.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_023"></a>ITEM&nbsp;11.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>EXECUTIVE COMPENSATION</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The information required by this item is set forth under the captions
<i>&#8220;Compensation Discussion and Analysis,&#8221; &#8220;Summary Compensation Table,&#8221; &#8220;Grants of Plan-Based Awards
in 2015,&#8221; &#8220;Outstanding Equity Awards at December&nbsp;31, 2015,&#8221; &#8220;2015 Option Exercises and Stock Vested,&#8221;
&#8220;Potential Payments Upon Termination or Change in Control,&#8221; &#8220;2015 Director Compensation,&#8221; &#8220;Compensation
Committee Interlocks and Insider Participation&#8221;</i> and <i>&#8220;Compensation Committee Report&#8221;</i> in our definitive
Proxy Statement for the 2016 Annual Meeting of Stockholders and incorporated herein by reference.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_024"></a>ITEM&nbsp;12.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The information required by this item is set forth under the captions
<i>&#8220;Equity Compensation Plan Information&#8221;</i> and &#8220;<i>Security Ownership of Certain Beneficial Owners and Management&#8221;</i>
in our definitive Proxy Statement for the 2016 Annual Meeting of Stockholders and incorporated herein by reference.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_025"></a>ITEM&nbsp;13.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The information required by this item is set forth under the captions
<i>&#8220;Certain Relationships and Related Transactions&#8221;</i> and &#8220;<i>Corporate Governance&#8221;</i> in our definitive
Proxy Statement for the 2016 Annual Meeting of Stockholders and incorporated herein by reference.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_026"></a>ITEM&nbsp;14.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>PRINCIPAL ACCOUNTING FEES AND SERVICES</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The information required by this item is set forth under the caption
<i>&#8220;2. Ratification of Appointment of Independent Registered Public Accountants&#8221;</i> in our definitive Proxy Statement
for the 2016 Annual Meeting of Stockholders and incorporated herein by reference.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>


<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 82; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PART&nbsp;IV</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><a name="a_027"></a>ITEM&nbsp;15.</b></font></td>
    <td style="width: 91%; padding-top: 12pt; padding-right: 0.8pt"><font style="font-size: 10pt"><b><i>EXHIBITS, FINANCIAL STATEMENT SCHEDULES</i></b></font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><i>(a)&nbsp;Financial Statements</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">The following financial statements appear in Item&nbsp;8 of this Form&nbsp;10-K:</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Page&nbsp;in<br> Form&nbsp;10-K</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; font-size: 10pt; text-align: left"><a href="#a_012">Consolidated Balance Sheets at December&nbsp;31, 2015 and 2014</a></td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right"><a href="#a_012">54</a></td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><a href="#a_013">Consolidated Statements of Comprehensive Loss for the years ended December&nbsp;31, 2015, 2014 and 2013</a></td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"><a href="#a_013">55</a></td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><a href="#a_014">Consolidated Statements of Cash Flows for the years ended December&nbsp;31, 2015, 2014 and 2013</a></td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"><a href="#a_014">56</a></td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><a href="#a_015">Consolidated Statements of Stockholders&#8217; Equity for the years ended December&nbsp;31, 2015, 2014 and 2013</a></td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"><a href="#a_015">57</a></td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><a href="#a_016">Notes to Consolidated Financial Statements</a></td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"><a href="#a_016">58</a></td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><a href="#a_017">Report of Independent Registered Public Accounting Firm on Consolidated Financial Statements</a></td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"><a href="#a_017">79</a></td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><a href="#a_018">Report of Independent Registered Public Accounting Firm on Internal Control</a></td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"><a href="#a_018">80</a></td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">No financial statement schedules are included because the information
is either provided in the consolidated financial statements or is not required under the related instructions or is inapplicable
and such schedules therefore have been omitted.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt">(b)&nbsp; <i>Exhibits.</i> See Index of Exhibits.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>


<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 83; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_028"></a><b>SIGNATURES</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized on February 26, 2016.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td nowrap colspan="2">BIOCRYST PHARMACEUTICALS, INC.</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="width: 33%">&nbsp;</td>
    <td style="width: 34%">&nbsp;</td>
    <td style="width: 4%">By:</td>
    <td style="width: 29%; border-bottom: Black 1pt solid">/s/&nbsp;Jon P. Stonehouse</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>Jon P. Stonehouse</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><i>Chief Executive Officer</i></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
</table>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt">Pursuant to the requirements of the Securities Exchange Act
of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated
on February 26, 2016:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 33%">&nbsp;</td>
    <td style="width: 34%">&nbsp;</td>
    <td style="width: 33%; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="text-align: center"><b><u>Signature</u></b></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><b><u>Title(s)</u></b></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="border-bottom: Black 1pt solid">/s/&nbsp;Jon P. Stonehouse</td>
    <td>&nbsp;</td>
    <td style="text-align: center">President, Chief Executive Officer and Director</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>(Jon P. Stonehouse)</td>
    <td>&nbsp;</td>
    <td style="text-align: center">(Principal Executive Officer)</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="border-bottom: Black 1pt solid">/s/&nbsp;Thomas R. Staab II</td>
    <td>&nbsp;</td>
    <td nowrap style="text-align: center">Senior Vice President, Chief Financial Officer and Treasurer</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>(Thomas R. Staab II)</td>
    <td>&nbsp;</td>
    <td nowrap style="text-align: center">(Principal Financial Officer and Principal Accounting Officer)</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="border-bottom: Black 1pt solid">/s/ George B. Abercrombie</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Director</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>(George B. Abercrombie)</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="border-bottom: Black 1pt solid">/s/&nbsp;Fred E. Cohen</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Director</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>(Fred E. Cohen, M.D., D. Phil)</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="border-bottom: Black 1pt solid">/s/ Stanley C. Erck</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Director</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>(Stanley C. Erck)</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="border-bottom: Black 1pt solid">/s/ Nancy Hutson</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Director</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>(Nancy Hutson, Ph.D.)</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="border-bottom: Black 1pt solid">/s/ Robert A. Ingram</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Director</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>(Robert A. Ingram)</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="border-bottom: Black 1pt solid">/s/&nbsp;Kenneth B. Lee, Jr.</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Director</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>(Kenneth B. Lee, Jr.)</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="border-bottom: Black 1pt solid">/s/&nbsp;Sanj K. Patel</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Director</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>(Sanj K. Patel)</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="border-bottom: Black 1pt solid">/s/&nbsp;Charles A. Sanders</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Director</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>(Charles A. Sanders,&nbsp;M.D.)</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
</table>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0 0pt 12pt"></p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 84; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 12pt 0 0"><b><a name="a_029"></a>INDEX TO EXHIBITS</b></p>

<p style="font-size: 10pt; margin: 0; text-indent: 0.5in"></p>


<p style="font-size: 10pt; margin: 6pt 0.8pt 0 0"></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td><b><u>Number</u></b></td>
    <td>&nbsp;</td>
    <td><b><u>Description</u></b></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">3.1</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed December 22, 2006.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">3.2</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed July 24, 2007.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">3.3</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed May 8, 2014.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">3.4</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed November 4, 2008.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">3.5</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.2 to the Company&#8217;s Form 8-K filed May 8, 2014.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">3.6</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amended and Restated Bylaws of Registrant effective October 29, 2008. Incorporated by reference to Exhibit 3.2 to the Company&#8217;s Form 8-K filed November 4, 2008.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">4.1</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Indenture, dated as of March 9, 2011 by and between JPR Royalty Sub LLC and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit 4.3 of the Company&#8217;s Form 10-Q filed May&nbsp;6, 2011.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.1&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amended and Restated Stock Incentive Plan dated March 29, 2012. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K, filed May 25, 2012.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.2&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amended and Restated Stock Incentive Plan dated March 8, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed May 5, 2014.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.3&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amended and Restated Employee Stock Purchase Plan dated March 29, 2012. Incorporated by reference to the Company&#8217;s Form 8-K, filed May 25, 2012.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.4&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amended and Restated Employee Stock Purchase Plan dated March 8, 2014. Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed May 5, 2014.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.5</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Form of Notice of Grant of Non-Employee Director Automatic Stock Option and Stock Option Agreement. Incorporated by reference to Exhibit 10.4 of the Company&#8217;s Form 10-K filed March 4, 2008.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.6&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Form of Notice of Grant of Stock Option and Stock Option Agreement. Incorporated by reference to Exhibit 10.5 of the Company&#8217;s Form 10-K filed March 4, 2008.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 9%"><font style="font-size: 10pt">10.7&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 90%"><font style="font-size: 10pt">Form of Notice of Grant of Stock Option and Stock Option Agreement.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.7 of the Company&#8217;s Form 10-K filed March 2, 2015.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 7%"><font style="font-size: 10pt">10.8&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 92%"><font style="font-size: 10pt">Form of Notice of Grant of Restricted Stock Unit Award and Restricted Stock Unit Agreement.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.8 of the Company&#8217;s Form 10-K filed March 2, 2015.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.9&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Annual Incentive Plan. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed March 12, 2012.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.10&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Executive Relocation Policy. Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form&nbsp;10-K filed March 4, 2008.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.11&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amended and Restated Employment Letter Agreement dated February 14, 2007, by and between the Company and Jon P. Stonehouse. Incorporated by reference to Exhibit 10.12 to the Company&#8217;s Form 10-K for the year ended December 31, 2006, filed March 14, 2007.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.12&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Thomas R. Staab II, dated May 23, 2011. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed May 25, 2011.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 6pt 0 0">&nbsp;</p>

<!-- Field: Page; Sequence: 85; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 6pt 0 0"></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.13&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and William P. Sheridan dated June 12, 2008. Incorporated by reference to Exhibit 10.27 of the Company&#8217;s Form 10-Q filed August 8, 2008.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.14&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Yarlagadda S. Babu dated April 27, 2012.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.15&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Alane P. Barnes dated August 8, 2013.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 7%"><font style="font-size: 10pt">10.16&amp;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 92%"><font style="font-size: 10pt">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Lynne Powell dated December 30, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.16 of the Company&#8217;s Form 10-K filed March 2, 2015.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.17#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Agreement dated January 3, 2007, between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services, as amended by Amendment number 1 dated January 3, 2007 and Amendment number 2 dated May 11, 2007. Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed August 9, 2007. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.18</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services, dated October 2, 2007. Incorporated by reference to Exhibit 10.6 of the Company&#8217;s Form 10-K filed March 4, 2008.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.19</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #4 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated April 3, 2008. Incorporated by reference to Exhibit 10.29 of the Company&#8217;s Form 10-Q filed August 8, 2008.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.20</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #5 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated July 2, 2008. Incorporated by reference to Exhibit 10.30 of the Company&#8217;s Form 10-Q filed August 8, 2008.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.21</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #6 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated August&nbsp;18, 2008. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed November&nbsp;7, 2008.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.22</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #7 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated November&nbsp;17, 2008. Incorporated by reference to Exhibit 10.12 of the Company&#8217;s Form 10-K filed March&nbsp;6, 2009.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.23</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #8 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated March 13, 2009. Incorporated by reference to Exhibit&nbsp;10.13 of the Company&#8217;s Form 10-K filed March 9, 2010.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.24</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #9 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services dated September 18, 2009. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed November 6, 2009.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.25</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #10 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated October 15, 2009. Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 10-Q filed November 6, 2009.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.26</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #11 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated February 23, 2011. Incorporated by reference to Exhibit 10.25 of the Company&#8217;s Form 10-K filed March 15, 2011.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.27</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Stop-Work Order from U.S. Department of Health and Human Services, dated March 26, 2013, relating to Agreement dated January 3, 2007 between the Company and the U.S. Department of Health and Human Services. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed May 9, 2013.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.28</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #13 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated February 15, 2012.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.29</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #14 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated June 4, 2013. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed June 5, 2013.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.30#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #15 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated September 5, 2013. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed November 8, 2013. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.31</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #16 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated December 17, 2013. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed December 23, 2013.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.32</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #17 to the Agreement between the Company and the U.S. Department of Health &amp; Human Services, dated February 21, 2014. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed February 26, 2014.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 6pt 0 0"></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 86; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.33</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Order for Supplies or Services from the U.S. Department of Health &amp; Human Services, dated November 4, 2009. Incorporated by reference to Exhibit 10.16 of the Company&#8217;s Form 10-K filed March 9, 2010.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.34</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #18 to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated March 28, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed April 3, 2014.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.35</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #19 to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated April 29, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed May 2, 2014.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.36</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #20 to the Agreement to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated May 30, 2014. . Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed June 5, 2014.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.37#</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">License, Development and Commercialization Agreement dated as of February 28, 2007, by and between the Company and Shionogi &amp; Co., Ltd. Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Form 10-Q filed May 10, 2007. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.38#</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">First Amendment to License, Development and Commercialization Agreement, effective as of September 30, 2008, between the Company and Shionogi &amp; Co., Ltd. Incorporated by reference to Exhibit 10.19 to the Company&#8217;s Form 10-K filed March 6, 2009. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.39</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Riverchase Business Park Warehouse Lease dated July 12, 2000 between RBP, LLC an Alabama Limited Liability Company and the Registrant for office/warehouse space. Incorporated by reference to Exhibit 10.8 to the Company&#8217;s Form 10-Q for the second quarter ending June 30, 2000 filed August 8, 2000.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.40</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Third Amendment to Lease Agreement dated August 7, 2007, by and between Riverchase Capital LLC, a Florida limited liability company, Stow Riverchase, LLC, a Florida limited liability company, as successor landlord to RBP, LLC and the Company. Incorporated by reference to Exhibit 10.4 of the Company&#8217;s Form 10-Q filed August 9, 2007.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.41</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Fourth Amendment to the Lease Agreement dated February 1, 2012, by and between Riverchase Capital LLC, a Florida limited liability company, Stow Riverchase, LLC, a Florida limited liability company, as successor landlord to RBP, LLC and the Company. Incorporated by reference to Exhibit 10.27 of the Company&#8217;s Form 10-K filed March 11, 2013.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 7%"><font style="font-size: 10pt">10.42</font></td>
    <td>&nbsp;</td>
    <td style="width: 92%"><font style="font-size: 10pt">Fifth Amendment to Lease Agreement dated January 15, 2015, by and between Riverchase Capital LLC, a Florida limited liability company, Stow Riverchase, LLC, a Florida limited liability company, as successor landlord to RBP, LLC and the Company.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.42 of the Company&#8217;s Form 10-K filed March 2, 2015.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.43</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Stock and Warrant Purchase Agreement dated as of August 6, 2007, by and among BioCryst Pharmaceuticals, Inc. and each of the Investors identified on the signature pages thereto. Incorporated by reference to Exhibit 4.1 of the Company&#8217;s Form 8-K filed August 7, 2007.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.44</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Stock Purchase Agreement, dated as of February&nbsp;17, 2005, by and among BioCryst Pharmaceuticals, Inc., Baker Bros. Investments, L.P., Baker Biotech Fund II, L.P., Baker Bros. Investments II, L.P., Baker Biotech Fund&nbsp;II (Z), L.P., Baker/Tisch Investments, L.P., Baker Biotech Fund III, L.P., Baker Biotech Fund&nbsp;I, L.P., Baker Biotech Fund&nbsp;III (Z), L.P. and 14159, L.P. Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Form 8-K filed February&nbsp;17, 2005.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.45#</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Development and License Agreement dated as of February 1, 2006, by and between BioCryst Pharmaceuticals, Inc. and Mundipharma International Holdings Limited. Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K/A filed May 2, 2006. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.46#</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amended and Restated Development and License Agreement, dated as of November 11, 2011, by and between BioCryst Pharmaceuticals, Inc. and Mundipharma International Corporation Limited. Incorporated by reference to Exhibit 10.32 to the Company&#8217;s Form 10-K filed March 6, 2012. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.47#</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">License Agreement dated as of June 27, 2000, by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., as amended by the First Amendment Agreement dated as of July 26, 2002 and the Second Amendment Agreement dated as of April 15, 2005. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed November 30, 2005. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

</table>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 87; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.48#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Third Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of December&nbsp;11, 2009. Incorporated by reference to Exhibit 10.33 to the Company&#8217;s Form 10-K filed March&nbsp;9, 2010. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.49#</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Fourth Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of May 5, 2010. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed August 6, 2010. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.50#</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Fifth Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of November 17, 2011. Incorporated by reference to Exhibit 10.36 to the Company&#8217;s Form 10-K filed March 6, 2012. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.51#</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Sixth Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of June 19, 2012. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed August 8, 2012. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.52</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Novation Agreement among Albert Einstein College of Medicine of Yeshiva University, BioCryst Pharmaceuticals, Inc., Mundipharma International Corporation Limited, Callaghan Innovation Research Limited, and Victoria Link Limited, dated May 18, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.6 to the Company&#8217;s Form 10-Q filed August 7, 2015.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.53</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Novation Agreement among Albert Einstein College of Medicine of Yeshiva University, BioCryst Pharmaceuticals, Inc., Callaghan Innovation Research Limited, and Victoria Link Limited, dated June 24, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.7 to the Company&#8217;s Form 10-Q filed August 7, 2015.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.54</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Purchase and Sale Agreement, dated as of March 9, 2011 between BioCryst Pharmaceuticals, Inc. and JPR Royalty Sub LLC. Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q filed May 6, 2011.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.55</font></td>
    <td>&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Pledge and Security Agreement, dated as of March 9, 2011 between BioCryst Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 10-Q filed May 6, 2011.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.56</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Confirmation of terms and conditions of ISDA Master Agreement, dated as of March 7, 2011, between Morgan Stanley Capital Services Inc. and BioCryst Pharmaceuticals, Inc. dated as of March 9, 2011. Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Form 10-Q filed May 6, 2011.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.57#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Agreement, dated as of September&nbsp;12, 2013, between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases. Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 10-Q filed November&nbsp;8, 2013. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.58#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #1 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated December 26, 2013.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.51 to the Company&#8217;s Form 10-K filed on March 10, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.59#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #2 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated January 24, 2014.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.52 to the Company&#8217;s Form 10-K filed on March 10, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.60#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2014. Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Form 10-Q filed on August 8, 2014.&nbsp;&nbsp;&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.61#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #4 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2014. Incorporated by reference to Exhibit 10.6 to the Company&#8217;s Form 10-Q filed on August 8, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.61#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #5 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated August 11, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.62#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #6 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated August 27, 2014.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 6pt 0 0">&nbsp;</p>

<!-- Field: Page; Sequence: 88; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 6pt 0 0"></p>

<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.63#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #8 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 17, 2014.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.64#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #9 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated October 29, 2014.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Form 10-Q filed on November 7, 2014.&nbsp;&nbsp;(Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.65#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #10 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated February 13, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.66#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #11 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated March 19, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.67#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #12 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 12, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.68#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #13 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.69#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #14 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 16, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed on November 6, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">(10.70)</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #15 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated November 16, 2015.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">(10.71)&#8224;</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #16 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated December 18, 2015. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.72#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, dated March 27, 2015. &nbsp;Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on May 8, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.73#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #1 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated June 2, 2015.&nbsp;&nbsp;Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed on August 7, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.74#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #2 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated July 8, 2015. &nbsp;Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed on November 6, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.75#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated August 25, 2015. &nbsp;Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed on November 6, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">10.76#</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">License Agreement by and between BioCryst Pharmaceuticals, Inc. and Seqirus UK Limited, dated as of June 16, 2015. &nbsp;Incorporated by reference to Exhibit 10.8 to the Company&#8217;s Form 10-Q filed on May 8, 2015.&nbsp; (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0"></p>

<!-- Field: Page; Sequence: 89; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0"></p>


<p style="font-size: 10pt; margin: 6pt 0 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td>(21)</td>
    <td>&nbsp;</td>
    <td>Subsidiaries of the Registrant.</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 7%"><font style="font-size: 10pt">(23)</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 92%"><font style="font-size: 10pt">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">(31.1)</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">(31.2)</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">(32.1)</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Certification pursuant to 18&nbsp;U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">(32.2)</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Certification pursuant to 18&nbsp;U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">(101)</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%"><font style="font-size: 10pt">Financial statements from the Annual Report on Form 10-K of BioCryst Pharmaceuticals, Inc. for the year ended December 31, 2015, formatted in XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, (iv) Consolidated Statements of Stockholders&#8217; Equity and (v) Notes to Consolidated Financial Statements.</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&#8224;</td>
    <td>&nbsp;</td>
    <td>Confidential treatment requested.</td></tr>
<tr style="vertical-align: top">
    <td>#</td>
    <td>&nbsp;</td>
    <td>Confidential treatment granted.</td></tr>
<tr style="vertical-align: top">
    <td>&amp;</td>
    <td>&nbsp;</td>
    <td>Management contracts.</td></tr>
<tr style="vertical-align: top">
    <td>(&nbsp;)</td>
    <td>&nbsp;</td>
    <td>Filed herewith.</td></tr>
</table>
<p style="font-size: 10pt; margin: 6pt 0.8pt 0 0; text-indent: 0.5in"></p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0; text-align: center">90</p>

<!-- Field: Rule-Page --><div align="CENTER" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.70
<SEQUENCE>2
<FILENAME>exh_1070.htm
<DESCRIPTION>EXHIBIT 10.70
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.70</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="exh1070_1.jpg"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="exh1070_2.jpg"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="exh1070_3.jpg"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="exh1070_4.jpg"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.71
<SEQUENCE>3
<FILENAME>exh_1071.htm
<DESCRIPTION>EXHIBIT 10.71
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: right">EXHIBIT 10.71</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh1071_1.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid; text-align: left"><P STYLE="margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; text-align: left">&nbsp;</DIV>


    <!-- Field: /Page -->




<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh1071_2.jpg" ALT=""></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid; text-align: left"><P STYLE="margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; text-align: left">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh1071_3.jpg" ALT=""></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%; text-align: left">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>4
<FILENAME>exh_21.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><B>Exhibit 21</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 24pt 0 0"><B>Subsidiaries of the Registrant</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom"><B>Subsidiary</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 42%; text-align: center"><B>Jurisdiction of</B><BR>
    <FONT STYLE="font-size: 10pt"><B>Incorporation</B></FONT></TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>JPR Royalty Sub LLC</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Delaware</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>BioCryst UK Limited</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">United Kingdom</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>5
<FILENAME>exh_23.htm
<DESCRIPTION>EXHIBIT 23
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><B>Exhibit 23</B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Consent of Independent Registered Public Accounting Firm</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">We consent to the incorporation by reference in the following Registration Statements:</P>

<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statements (Form&nbsp;S-8 Nos.&nbsp;333-120345, 333-39484 and 333-30751) pertaining to the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan, as amended and restated as of March&nbsp;8, 2004;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-8 No.&nbsp;333-90582) pertaining to the BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-8 No.&nbsp;333-136703) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, which amended and restated the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan as of May&nbsp;17, 2006;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-3 No.&nbsp;333-145638) pertaining to the registration of up to 8,140,000&nbsp;shares of common stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-8 No.&nbsp;333-145627) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan as amended and restated effective March 2007 and Employment Letter Agreement dated April&nbsp;2, 2007 between BioCryst Pharmaceuticals, Inc. and David McCullough;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-3 No.&nbsp;333-153084) for the registration of 3,335,408&nbsp;shares of BioCryst Pharmaceuticals, Inc. common stock and 3,159,895 warrants to purchase common stock of BioCryst Pharmaceuticals, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-8 No.&nbsp;333-152570) pertaining to the BioCryst Pharmaceutical, Inc. Stock Incentive Plan, as amended and restated effective February&nbsp;28, 2008 and the BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan, as amended and restated effective February&nbsp;28, 2008;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-8 No.&nbsp;333-167830) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated effective March&nbsp;31, 2010 and the BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan, as amended and restated effective March&nbsp;31, 2010;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form&nbsp;S-8 No.&nbsp;333-176096) pertaining to the BioCryst Pharmaceutical, Inc. Stock Incentive Plan, as amended and restated effective February&nbsp;17, 2011;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form S-3 No. 333-192117) for the registration of up to $125 million of BioCryst Pharmaceuticals, Inc. common stock, preferred stock, depository shares, stock purchase contracts, warrants or units;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Registration Statement (Form S-8 No. 333-187193) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan and Employee Stock Purchase Plan, each as amended and restated effective March 29, 2012;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Registration Statement (Form S-8 No. 333-195869) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan and Employee Stock Purchase Plan, each as amended and restated effective March 8, 2014;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 92%; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Registration Statement (Form S-8 No. 333-202466) for the registration of up to $150 million of BioCryst Pharmaceuticals, Inc. common stock, preferred stock, depositary shares, stock purchase contracts, warrants or units;</FONT></TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">of our reports dated February 26, 2016 with respect to the consolidated financial statements
of BioCryst Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of BioCryst Pharmaceuticals,
Inc. included in this Annual Report (Form 10-K) of BioCryst Pharmaceuticals, Inc. for the year ended December&nbsp;31, 2015.</P>

<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%">/s/&nbsp;Ernst&nbsp;&amp; Young LLP</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Raleigh, North Carolina</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>February 26, 2016</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exh_311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><B>Exhibit&nbsp;31.1</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 24pt 0 0 24pt"><B>CERTIFICATIONS</B></P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0 12pt">I, Jon P. Stonehouse, certify that:</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 6pt">1.&nbsp;I have reviewed this annual report on Form&nbsp;10-K
of BioCryst Pharmaceuticals, Inc.;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 6pt">2.&nbsp;Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 6pt">3.&nbsp;Based on my knowledge, the financial statements, and
other financial information included in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 6pt">4.&nbsp;The registrant&rsquo;s other certifying officer(s) and
I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f) for
the registrant and have:</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 23pt">a)&nbsp;designed such disclosure controls and procedures, or
caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 23pt">b)&nbsp;designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 23pt">c)&nbsp;evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 23pt">d)&nbsp;disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant&rsquo;s internal control over financial reporting;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 6pt">5.&nbsp;The registrant&rsquo;s other certifying officer(s) and
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 23pt">a)&nbsp;all significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 23pt">b)&nbsp;any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid">/s/&nbsp;Jon P. Stonehouse</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Jon P. Stonehouse</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP>Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0.25in 0 0 0.25in">Date: February 26, 2016</P>

<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exh_312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><B>Exhibit&nbsp;31.2</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 24pt 0 0 24pt"><B>CERTIFICATIONS</B></P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0 12pt">I, Thomas R. Staab II, certify that:</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 6pt">1.&nbsp;I have reviewed this annual report on Form&nbsp;10-K
of BioCryst Pharmaceuticals, Inc.;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 6pt">2.&nbsp;Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 6pt">3.&nbsp;Based on my knowledge, the financial statements, and
other financial information included in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 6pt">4.&nbsp;The registrant&rsquo;s other certifying officer(s) and
I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f) for
the registrant and have:</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 23pt">a.&nbsp;designed such disclosure controls and procedures, or
caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 23pt">b.&nbsp;designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 23pt">c.&nbsp;evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 23pt">d.&nbsp;disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant&rsquo;s internal control over financial reporting;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 6pt">5.&nbsp;The registrant&rsquo;s other certifying officer(s) and
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 23pt">a.&nbsp;all significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 6pt 0 0 23pt">b.&nbsp;any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid">/s/&nbsp;Thomas R. Staab II</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Thomas R. Staab II</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP>Chief Financial Officer and Treasurer<BR>
(Principal Financial Officer)</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0.25in 0 0 0.25in">Date: February 26, 2016</P>

<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exh_321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><B>Exhibit&nbsp;32.1</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>CERTIFICATION PURSUANT TO</B> &nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>18&nbsp;U.S.C. SECTION&nbsp;1350,</B> &nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>AS ADOPTED PURSUANT TO</B> &nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0">In connection with the Annual Report of BioCryst Pharmaceuticals, Inc.
(the &ldquo;Company&rdquo;) on Form&nbsp;10-K for the period ending December&nbsp;31, 2015 as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;Report&rdquo;),&nbsp;I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify,
pursuant to 18&nbsp;U.S.C. &sect;&nbsp;1350, as adopted pursuant to &sect;&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to
the best of my knowledge:</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0 0 0 23pt">(1)&nbsp;The Report fully complies with the requirements of section&nbsp;13(a)
or 15(d) of the Securities Exchange Act of 1934;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0 0 0 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0 0 0 23pt">(2)&nbsp;The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0 0 0 23pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 61%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 39%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; margin: 0; border-bottom: black 1pt solid">/s/&nbsp;Jon P. Stonehouse</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; margin: 0 1.6pt 0 0">Jon P. Stonehouse</P>
        <P STYLE="font-size: 10pt; margin: 0 1.6pt 0 0">Chief Executive Officer</P>
        <P STYLE="font-size: 10pt; margin: 0 1.6pt 0 0; text-indent: 0.5in">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0">February 26, 2016</P>

<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0">This certification is furnished with this Report on Form&nbsp;10-K pursuant
to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed
by the Company for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).
Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended,
or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>exh_322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><B>Exhibit&nbsp;32.2</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>CERTIFICATION PURSUANT TO</B> &nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>18&nbsp;U.S.C. SECTION&nbsp;1350,</B> &nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>AS ADOPTED PURSUANT TO&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0">In connection with the Annual Report of BioCryst Pharmaceuticals, Inc.
(the &ldquo;Company&rdquo;) on Form&nbsp;10-K for the period ending December&nbsp;31, 2015 as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;Report&rdquo;),&nbsp;I, Thomas R. Staab, II, Chief Financial Officer of the Company,
certify, pursuant to 18&nbsp;U.S.C. &sect;&nbsp;1350, as adopted pursuant to &sect;&nbsp;906 of the Sarbanes-Oxley Act of 2002,
that, to the best of my knowledge:</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0 0 0 23pt">(1)&nbsp;The Report fully complies with the requirements of section&nbsp;13(a)
or 15(d) of the Securities Exchange Act of 1934;&nbsp;and</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0 0 0 23pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0 0 0 23pt">(2)&nbsp;The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0 0 0 23pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 61%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 39%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; margin: 0; border-bottom: black 1pt solid">/s/&nbsp;Thomas R. Staab II&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; margin: 0 1.6pt 0 0">Thomas R. Staab II&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0 1.6pt 0 0">Chief Financial Officer and Treasurer&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0 1.6pt 0 0">(Principal Financial Officer)</P>
        <P STYLE="font-size: 10pt; margin: 0 1.6pt 0 0; text-indent: 0.5in">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0">February 26, 2016</P>

<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0">This certification is furnished with this Report on Form&nbsp;10-K pursuant
to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed
by the Company for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).
Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended,
or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>bcrx-20151231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 05:41PM UTC 2016-02-26--><xbrli:xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:bcrx="http://www.biocryst.com/20151231" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="bcrx-20151231.xsd" xlink:type="simple"/>
  <bcrx:AccruedDevelopmentCosts contextRef="i_2015-12-31_FairValueByLiabilityClassAxis-DevelopmentCostMember" decimals="-3" id="c3656364" unitRef="iso4217-usd">10398000</bcrx:AccruedDevelopmentCosts>
  <bcrx:AccruedDevelopmentCosts contextRef="i_2014-12-31_FairValueByLiabilityClassAxis-DevelopmentCostMember" decimals="-3" id="c3656365" unitRef="iso4217-usd">4232000</bcrx:AccruedDevelopmentCosts>
  <bcrx:AccruedExpensesPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4073313">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt; &lt;tr&gt; &lt;td style="width: 5%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to Clinical Research Organizations (&amp;#x201c;CROs&amp;#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt; &lt;tr&gt; &lt;td style="width: 5%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt; &lt;tr&gt; &lt;td style="width: 5%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&amp;nbsp;and&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt; &lt;tr&gt; &lt;td style="width: 5%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;professional fees.&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: center; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;Accrued expenses were comprised of the following:&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Compensation and benefits&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;424&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;2,105&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Development costs&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;10,398&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,232&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Inventory&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;549&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;397&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Professional fees&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;242&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;238&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Duties and taxes&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;102&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;75&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,522&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,282&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Total accrued expenses&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;16,237&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;11,329&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;As of December 31, 2015 and 2014, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:AccruedExpensesPolicyTextBlock>
  <bcrx:AccruedInventoryExpense contextRef="i_2015-12-31" decimals="-3" id="c3656366" unitRef="iso4217-usd">549000</bcrx:AccruedInventoryExpense>
  <bcrx:AccruedInventoryExpense contextRef="i_2014-12-31" decimals="-3" id="c3656367" unitRef="iso4217-usd">397000</bcrx:AccruedInventoryExpense>
  <bcrx:AdvanceNoticePeriodForTerminationOfAgreement contextRef="d_2015-01-01_2015-12-31_TypeOfArrangementAxis-AECOMAndIRLMember" id="c3657094">P60D</bcrx:AdvanceNoticePeriodForTerminationOfAgreement>
  <bcrx:AnnualLicenseFeeMaximum contextRef="i_2015-12-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c3657093" unitRef="iso4217-usd">500000</bcrx:AnnualLicenseFeeMaximum>
  <bcrx:AnnualLicenseFeeMinimum contextRef="i_2015-12-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c3657092" unitRef="iso4217-usd">150000</bcrx:AnnualLicenseFeeMinimum>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c3656284" unitRef="iso4217-usd">88000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c3656289" unitRef="iso4217-usd">184000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c3656294" unitRef="iso4217-usd">21000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31" decimals="-3" id="c3656299" unitRef="iso4217-usd">293000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2014-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c3656304" unitRef="iso4217-usd">22000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2014-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c3656309" unitRef="iso4217-usd">151000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2014-12-31_InvestmentTypeAxis-CommercialPaperMember" decimals="-3" id="c3656314" unitRef="iso4217-usd">6000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2014-12-31" decimals="-3" id="c3656319" unitRef="iso4217-usd">179000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue contextRef="i_2015-12-31" decimals="-3" id="c3656325" unitRef="iso4217-usd">28395000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue contextRef="i_2014-12-31" decimals="-3" id="c3656326" unitRef="iso4217-usd">25459000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;22,664&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;18,232&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;28,395&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;25,459&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Maturing after two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;19,288&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;15,657&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,348&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears contextRef="i_2015-12-31" decimals="-3" id="c3656327" unitRef="iso4217-usd">19288000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears contextRef="i_2014-12-31" decimals="-3" id="c3656328" unitRef="iso4217-usd">15657000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears>
  <bcrx:AveragematurityForPortfolioInvestments contextRef="d_2015-01-01_2015-12-31_RangeAxis-MaximumMember" id="c3656781">P1Y180D</bcrx:AveragematurityForPortfolioInvestments>
  <bcrx:AveragematurityPeriodOfHighQualityMarketableSecurities contextRef="d_2015-01-01_2015-12-31_RangeAxis-MaximumMember" id="c3656704">P1Y180D</bcrx:AveragematurityPeriodOfHighQualityMarketableSecurities>
  <bcrx:CollaborationAgreementAdditionalPaymentsReceived contextRef="i_2015-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-3" id="c3657060" unitRef="iso4217-usd">29875000</bcrx:CollaborationAgreementAdditionalPaymentsReceived>
  <bcrx:CollaborativeAgreementAdditionalContractValue contextRef="d_2009-09-01_2009-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c3657041" unitRef="iso4217-usd">77191000</bcrx:CollaborativeAgreementAdditionalContractValue>
  <bcrx:CollaborativeAgreementAdditionalContractValue contextRef="d_2011-02-01_2011-02-24_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c3657042" unitRef="iso4217-usd">55000000</bcrx:CollaborativeAgreementAdditionalContractValue>
  <bcrx:CollaborativeAgreementAdjustedContractValue contextRef="d_2007-01-01_2011-02-24_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c3657044" unitRef="iso4217-usd">234852000</bcrx:CollaborativeAgreementAdjustedContractValue>
  <bcrx:CollaborativeAgreementContractValue contextRef="d_2007-01-01_2007-01-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c3657037" unitRef="iso4217-usd">102661000</bcrx:CollaborativeAgreementContractValue>
  <bcrx:CollaborativeAgreementPeriodOfcontract contextRef="d_2015-01-01_2015-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" id="c3657056">P5Y</bcrx:CollaborativeAgreementPeriodOfcontract>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656043" unitRef="iso4217-usd">39580000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656044" unitRef="iso4217-usd">10550000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656045" unitRef="iso4217-usd">14769000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c3656383" unitRef="iso4217-usd">16337000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c3656384" unitRef="iso4217-usd">9366000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2013-01-01_2013-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c3656385" unitRef="iso4217-usd">13585000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-12-31_CounterpartyNameAxis-GreenCrossCorporationMember" decimals="-3" id="c3656386" unitRef="iso4217-usd">132000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-12-31_CounterpartyNameAxis-GreenCrossCorporationMember" id="c3656387" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2013-01-01_2013-12-31_CounterpartyNameAxis-GreenCrossCorporationMember" id="c3656388" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-12-31_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c3656389" unitRef="iso4217-usd">1184000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-12-31_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c3656390" unitRef="iso4217-usd">1184000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2013-01-01_2013-12-31_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c3656391" unitRef="iso4217-usd">1184000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-12-31_CounterpartyNameAxis-CSLMember" decimals="-3" id="c3656392" unitRef="iso4217-usd">21927000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-12-31_CounterpartyNameAxis-CSLMember" id="c3656393" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2013-01-01_2013-12-31_CounterpartyNameAxis-CSLMember" id="c3656394" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656395" unitRef="iso4217-usd">39580000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656396" unitRef="iso4217-usd">10550000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656397" unitRef="iso4217-usd">14769000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CommonStockToBeIssuedValue contextRef="i_2014-06-30" decimals="-3" id="c3656866" unitRef="iso4217-usd">70000000</bcrx:CommonStockToBeIssuedValue>
  <bcrx:ConcentrationOfMarketRiskPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4074462">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Significant Customers and Other Risks&lt;/div&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Prior to the SUL Agreement, the Company relied primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&amp;#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&amp;#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&amp;#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&amp;#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#x2019;s ability to complete its drug development activities.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/div&gt; &amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Credit Risk&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&amp;#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:ConcentrationOfMarketRiskPolicyTextBlock>
  <bcrx:CurrencyHedgeAgreementPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4074459">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Currency Hedge Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the years ended December&amp;nbsp;31, 2015, 2014 and 2013 resulted in a loss of $564 and gains of $5,487 and $5,294, respectively. Mark to market adjustments are determined by a third party pricing model which uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. In addition, a realized currency exchange gain of $1,654 was recognized in 2015 related to the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of December 31, 2015 and December&amp;nbsp;31, 2014, no hedge collateral was posted under the agreement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:CurrencyHedgeAgreementPolicyTextBlock>
  <bcrx:DeferredCollaborationExpenseAssets contextRef="i_2015-12-31" decimals="INF" id="c3655994" unitRef="iso4217-usd">265000</bcrx:DeferredCollaborationExpenseAssets>
  <bcrx:DeferredCollaborationExpenseAssets contextRef="i_2014-12-31" decimals="INF" id="c3655995" unitRef="iso4217-usd">177000</bcrx:DeferredCollaborationExpenseAssets>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656122" unitRef="iso4217-usd">102000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656123" unitRef="iso4217-usd">-59000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656124" unitRef="iso4217-usd">-5133000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DescriptionOfCompanyPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4073303">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#x201c;Company&amp;#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash, restricted cash and investments of $100,858, to continue its planned operations through mid-2017. The Company&amp;#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017 it will need to: (1)&amp;nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&amp;nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&amp;nbsp;raise additional capital through equity or debt financings or from other sources; (4)&amp;nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&amp;nbsp;reduce spending on one or more research and development programs; and/or (6)&amp;nbsp;restructure operations. The Company may issue securities through private placement transactions or registered public offerings pursuant to a registration statement filed with the SEC.&amp;nbsp;&amp;nbsp;Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) on November&amp;nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:DescriptionOfCompanyPolicyTextBlock>
  <bcrx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656602" unitRef="iso4217-usd">4307000</bcrx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount>
  <bcrx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount contextRef="d_2014-01-01_2014-12-31" id="c3656603" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount contextRef="d_2013-01-01_2013-12-31" id="c3656604" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear contextRef="d_2015-01-01_2015-12-31" decimals="0" id="c3656957" unitRef="iso4217-usd">7023000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour contextRef="d_2015-01-01_2015-12-31" decimals="0" id="c3656963" unitRef="iso4217-usd">1683000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree contextRef="d_2015-01-01_2015-12-31" decimals="0" id="c3656961" unitRef="iso4217-usd">3891000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo contextRef="d_2015-01-01_2015-12-31" decimals="0" id="c3656959" unitRef="iso4217-usd">6010000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo>
  <bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts contextRef="d_2015-01-01_2015-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-3" id="c3657055" unitRef="iso4217-usd">34002000</bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656596" unitRef="iso4217-usd">330000</bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards>
  <bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656597" unitRef="iso4217-usd">373000</bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards>
  <bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656598" unitRef="iso4217-usd">242000</bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards>
  <bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4074458">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Interest Expense and Deferred Financing Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Interest expense for the years ended December&amp;nbsp;31, 2015, 2014 and 2013 was $5,200, $4,998 and $4,778, respectively, and relates to the issuance of the PhaRMA Notes. Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other non-current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $439 for each of the years ended December&amp;nbsp;31, 2015, 2014 and 2013.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock>
  <bcrx:Interestreserve contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="0" id="c3656792" unitRef="iso4217-usd">3000000</bcrx:Interestreserve>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2015-12-31_BalanceSheetLocationAxis-LongTermLiabilitiesMember_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c3656849" unitRef="iso4217-usd">2375000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2015-12-31" decimals="INF" id="c3656019" unitRef="iso4217-usd">2375</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2014-12-31" id="c3656020" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:LongtermInvestmentMaturityMinimum contextRef="d_2015-01-01_2015-12-31_RangeAxis-MinimumMember" id="c3656707">P1Y</bcrx:LongtermInvestmentMaturityMinimum>
  <bcrx:MaturityOfInvestments contextRef="d_2015-01-01_2015-12-31_RangeAxis-MaximumMember" id="c3656697">P3Y</bcrx:MaturityOfInvestments>
  <bcrx:MaturityPeriodOfHighQualityMarketablesecurities contextRef="d_2015-01-01_2015-12-31_RangeAxis-MaximumMember" id="c3656703">P3Y</bcrx:MaturityPeriodOfHighQualityMarketablesecurities>
  <bcrx:MaturityperiodOfShortTermInvestment contextRef="d_2015-01-01_2015-12-31_RangeAxis-MinimumMember" id="c3656705">P90D</bcrx:MaturityperiodOfShortTermInvestment>
  <bcrx:MaturityperiodOfShortTermInvestment contextRef="d_2015-01-01_2015-12-31_RangeAxis-MaximumMember" id="c3656706">P1Y</bcrx:MaturityperiodOfShortTermInvestment>
  <bcrx:MaximumAggregateOfferingPrice contextRef="i_2015-03-03" decimals="-3" id="c3656852" unitRef="iso4217-usd">150000000</bcrx:MaximumAggregateOfferingPrice>
  <bcrx:MaximumAggregateOfferingPrice contextRef="i_2013-11-06" decimals="-3" id="c3656854" unitRef="iso4217-usd">125000000</bcrx:MaximumAggregateOfferingPrice>
  <bcrx:MaximumAmountOfCollateralRequiredToPost contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c3656835" unitRef="iso4217-usd">9750000</bcrx:MaximumAmountOfCollateralRequiredToPost>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c3656740" unitRef="iso4217-usd">12000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" decimals="-3" id="c3657068" unitRef="iso4217-usd">12000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-01-01_2015-12-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c3657089" unitRef="iso4217-usd">4000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMinimum contextRef="d_2015-01-01_2015-12-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c3657088" unitRef="iso4217-usd">1400000</bcrx:MilestonePaymentMinimum>
  <bcrx:NumberOfMilestonesAchieved contextRef="d_2015-01-01_2015-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c3656901" unitRef="xbrli-pure">3</bcrx:NumberOfMilestonesAchieved>
  <bcrx:NumberOfStockbasedCompensationPlans contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c3656878" unitRef="xbrli-pure">2</bcrx:NumberOfStockbasedCompensationPlans>
  <bcrx:PaymentsForModificationOfLicenseAgreement contextRef="d_2010-05-01_2010-05-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c3657100" unitRef="iso4217-usd">90000</bcrx:PaymentsForModificationOfLicenseAgreement>
  <bcrx:PercentageOfCarryingAmountInExcessOfFairValue1 contextRef="i_2015-12-31_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" decimals="INF" id="c3657222" unitRef="xbrli-pure">0.5</bcrx:PercentageOfCarryingAmountInExcessOfFairValue1>
  <bcrx:PercentageOfCommonStockSharesBeginning contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c3656968" unitRef="xbrli-pure">0.85</bcrx:PercentageOfCommonStockSharesBeginning>
  <bcrx:PercentageOfCommonStockSharesEnding contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c3656969" unitRef="xbrli-pure">0.85</bcrx:PercentageOfCommonStockSharesEnding>
  <bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c3656967" unitRef="xbrli-pure">0.15</bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum>
  <bcrx:PeriodOfAgreement contextRef="d_2015-01-01_2015-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" id="c3657105">P25Y</bcrx:PeriodOfAgreement>
  <bcrx:PotentialMilestonePaymentsReceivable contextRef="i_2011-11-11_TypeOfArrangementAxis-MundipharmaMember" decimals="-3" id="c3657082" unitRef="iso4217-usd">15000000</bcrx:PotentialMilestonePaymentsReceivable>
  <bcrx:PrivatePlacementOfSeniorSecuredNotes contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="0" id="c3656795" unitRef="iso4217-usd">30000000</bcrx:PrivatePlacementOfSeniorSecuredNotes>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2015-01-01_2015-09-30_TypeOfArrangementAxis-ASPRBARDAContractMember" decimals="-3" id="c3657051" unitRef="iso4217-usd">16300000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-3" id="c3657053" unitRef="iso4217-usd">5000000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:ReceiptPaymentOfForeignCurrencyDerivativeCollateral contextRef="d_2015-01-01_2015-12-31" id="c3656163" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:ReceiptPaymentOfForeignCurrencyDerivativeCollateral contextRef="d_2014-01-01_2014-12-31" id="c3656164" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:ReceiptPaymentOfForeignCurrencyDerivativeCollateral contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656165" unitRef="iso4217-usd">5180000</bcrx:ReceiptPaymentOfForeignCurrencyDerivativeCollateral>
  <bcrx:RemainingAggregateOfferingPrice contextRef="i_2013-11-06" decimals="-3" id="c3656861" unitRef="iso4217-usd">10000000</bcrx:RemainingAggregateOfferingPrice>
  <bcrx:RenewablePeriodOfAgreement contextRef="d_2015-01-01_2015-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" id="c3657106">P5Y</bcrx:RenewablePeriodOfAgreement>
  <bcrx:RequiredForeignCurrencyHedgePerDollar contextRef="i_2014-12-31_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c3656826" unitRef="iso4217-jpy">100</bcrx:RequiredForeignCurrencyHedgePerDollar>
  <bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="0" id="c3656790" unitRef="iso4217-usd">22691000</bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet>
  <bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember" decimals="0" id="c3656693" unitRef="iso4217-usd">30000000</bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized>
  <bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized contextRef="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="0" id="c3656789" unitRef="iso4217-usd">30000000</bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized>
  <bcrx:RoyaltyMonetizationTextBlock contextRef="d_2015-01-01_2015-12-31" id="s131701">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 3&amp;#x2014; Royalty Monetization&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 6pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Overview&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 6pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On March&amp;nbsp;9, 2011, the Company completed a $30,000&amp;nbsp;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691&amp;nbsp;from the transaction after transaction costs of $4,309&amp;nbsp;and the establishment of a $3,000&amp;nbsp;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;As part of the transaction, the Company entered into a purchase and sale agreement dated as of March&amp;nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&amp;nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&amp;nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &amp;#x201c;Currency Hedge Agreement&amp;#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&amp;#x2019;s collaboration with Shionogi was not impacted as a result of this transaction.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 6pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Non-Recourse Notes Payable&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On March&amp;nbsp;9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &amp;#x201c;PhaRMA Notes&amp;#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&amp;nbsp;9, 2011 (the &amp;#x201c;Indenture&amp;#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&amp;nbsp;per annum, payable annually in arrears on September&amp;nbsp;1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. &amp;nbsp;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;Royalty Sub&amp;#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&amp;#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;In September&amp;nbsp;2013, Royalty Sub paid $1,844 of interest on the PhaRMA Notes from royalty payments received from RAPIACTA&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;&amp;reg;&lt;/div&gt; sales from the preceding four calendar quarters. This payment resulted in an obligation shortfall of approximately $2,356 associated with accrued interest due September&amp;nbsp;3, 2013. As stipulated under the PhaRMA Notes Indenture, if the amount available for payment on any Payment Date is insufficient to pay all of the interest due on a Payment Date, the shortfall in interest will accrue interest at the interest rate applicable to the PhaRMA Notes compounded annually. Accordingly, commencing in September&amp;nbsp;2013, the Company began accruing interest at 14%&amp;nbsp;per annum on the interest shortfall of $2,356. In March, June and August of 2014, Royalty Sub paid additional interest of $446, $1,882 and $70, respectively, bringing the 2013 shortfall down to $222 as of September 30, 2014. Under the terms of the Indenture, Royalty Sub&amp;#x2019;s inability to pay the full amount of interest payable in September&amp;nbsp;2013 by the next succeeding Payment Date for the PhaRMA Notes, which was September&amp;nbsp;1, 2014, constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the December 31, 2014 balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&amp;#x2019;s future results of operations or cash flows. As of December 31, 2015, the PhaRMA Notes remain in default.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 67; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;As of December&amp;nbsp;31, 2015, the aggregate fair value of the PhaRMA Notes was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Foreign Currency Hedge&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950&amp;nbsp;will be required if, on May&amp;nbsp;18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark to market adjustments in 2015, 2014 and 2013 resulted in a loss of $564 and gains of $5,487 and $5,294 respectively. In addition, a realized currency exchange gain of $1,654 was recognized in 2015 related to the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of December&amp;nbsp;31, 2015 and 2014, no collateral was posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of December 31, 2015, the maximum amount of hedge collateral the Company may be required to post is $9,750.&lt;/div&gt;&lt;/div&gt;</bcrx:RoyaltyMonetizationTextBlock>
  <bcrx:RoyaltyTerm contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" id="c3657069">P10Y</bcrx:RoyaltyTerm>
  <bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-19">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;210&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;238&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;679&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5,564&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,243&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; width: 52%"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;3,849&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock>
  <bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;6,291&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;33&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,386&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,025&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,562&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;16,337&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;9,366&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;13,585&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;132&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Shionogi (Japan)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,184&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,184&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,184&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,927&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;39,580&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;10,550&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;14,769&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;48,257&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;13,608&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;17,331&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock>
  <bcrx:SecuritiesOffered contextRef="d_2013-11-06_2013-11-06" decimals="0" id="c3656691" unitRef="iso4217-usd">10000000</bcrx:SecuritiesOffered>
  <bcrx:ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount contextRef="i_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="0" id="c3656974" unitRef="iso4217-usd">25000</bcrx:ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember" id="c3656918">P1Y</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656448" unitRef="xbrli-shares">3277000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656469" unitRef="xbrli-shares">1965000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656487" unitRef="xbrli-shares">2217000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
  <bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage contextRef="d_2015-01-01_2015-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c3656914" unitRef="xbrli-pure">0.25</bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage contextRef="d_2015-01-01_2015-12-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c3656916" unitRef="xbrli-pure">1</bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656454" unitRef="xbrli-shares">1801000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
  <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656475" unitRef="xbrli-shares">88000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
  <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656493" unitRef="xbrli-shares">33000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
  <bcrx:StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter contextRef="d_2013-08-01_2013-08-31" decimals="-3" id="c3656864" unitRef="xbrli-shares">600000</bcrx:StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter>
  <bcrx:StockIssuedDuringPeriodValueForModificationOfLicenseAgreement contextRef="d_2010-05-01_2010-05-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c3657099" unitRef="iso4217-usd">5911000</bcrx:StockIssuedDuringPeriodValueForModificationOfLicenseAgreement>
  <bcrx:TransactionCosts contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="0" id="c3656791" unitRef="iso4217-usd">4309000</bcrx:TransactionCosts>
  <bcrx:UpfrontPaymentsReceivableAmount contextRef="d_2006-02-01_2006-02-28_TypeOfArrangementAxis-MundipharmaMember" decimals="-3" id="c3657075" unitRef="iso4217-usd">10000000</bcrx:UpfrontPaymentsReceivableAmount>
  <dei:AmendmentFlag contextRef="d_2015-01-01_2015-12-31" id="c-15">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2015-01-01_2015-12-31" id="c-4">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2015-01-01_2015-12-31" id="c-14">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2015-01-01_2015-12-31" id="c-13">2015</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2015-01-01_2015-12-31" id="c-12">2015-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2015-01-01_2015-12-31" id="c-11">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2015-01-01_2015-12-31" id="c-2">0000882796</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2016-01-31" decimals="INF" id="c-9" unitRef="xbrli-shares">73576471</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2015-01-01_2015-12-31" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="d_2015-01-01_2015-12-31" id="c-5">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="i_2015-06-30" decimals="0" id="c-10" unitRef="iso4217-usd">1078490079</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="d_2015-01-01_2015-12-31" id="c-1">BIOCRYST PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="d_2015-01-01_2015-12-31" id="c-7">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2015-01-01_2015-12-31" id="c-8">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="d_2015-01-01_2015-12-31" id="c-3">bcrx</dei:TradingSymbol>
  <us-gaap:AccountsPayableCurrent contextRef="i_2015-12-31" decimals="INF" id="c3656001" unitRef="iso4217-usd">9307000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="i_2014-12-31" decimals="INF" id="c3656002" unitRef="iso4217-usd">2849000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember" decimals="INF" id="c3655978" unitRef="iso4217-usd">6243000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember" decimals="INF" id="c3655979" unitRef="iso4217-usd">3849000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember" id="c3655980" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember" decimals="INF" id="c3655981" unitRef="iso4217-usd">5641000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2015-12-31" decimals="INF" id="c3656003" unitRef="iso4217-usd">16237000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2014-12-31" decimals="INF" id="c3656004" unitRef="iso4217-usd">11329000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2015-12-31" decimals="-3" id="c3656368" unitRef="iso4217-usd">242000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2014-12-31" decimals="-3" id="c3656369" unitRef="iso4217-usd">238000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2015-12-31" decimals="-3" id="c3656419" unitRef="iso4217-usd">14205000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2014-12-31" decimals="-3" id="c3656420" unitRef="iso4217-usd">14025000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2015-12-31" decimals="INF" id="c3656028" unitRef="iso4217-usd">-206000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2014-12-31" decimals="INF" id="c3656029" unitRef="iso4217-usd">-130000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2015-12-31" decimals="INF" id="c3656026" unitRef="iso4217-usd">558113000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2014-12-31" decimals="INF" id="c3656027" unitRef="iso4217-usd">542943000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656209" unitRef="iso4217-usd">4368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656212" unitRef="iso4217-usd">4368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656244" unitRef="iso4217-usd">10177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656247" unitRef="iso4217-usd">10177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656274" unitRef="iso4217-usd">9705000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656277" unitRef="iso4217-usd">9705000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdvertisingExpense contextRef="d_2015-01-01_2015-12-31" decimals="0" id="c3656747" unitRef="iso4217-usd">103000</us-gaap:AdvertisingExpense>
  <us-gaap:AdvertisingExpense contextRef="d_2014-01-01_2014-12-31" decimals="0" id="c4072789" unitRef="iso4217-usd">290000</us-gaap:AdvertisingExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-12-31" decimals="0" id="c3656880" unitRef="iso4217-usd">9705000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="0" id="c3656881" unitRef="iso4217-usd">9485000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="0" id="c3656882" unitRef="iso4217-usd">220000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-12-31" decimals="0" id="c3656884" unitRef="iso4217-usd">10177000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-IncentivePlanMember" decimals="0" id="c3656885" unitRef="iso4217-usd">9963000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="0" id="c3656886" unitRef="iso4217-usd">214000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2013-01-01_2013-12-31" decimals="0" id="c3656888" unitRef="iso4217-usd">4368000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2013-01-01_2013-12-31_PlanNameAxis-IncentivePlanMember" decimals="0" id="c3656889" unitRef="iso4217-usd">4253000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2013-01-01_2013-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="0" id="c3656890" unitRef="iso4217-usd">115000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c3656430" unitRef="iso4217-usd">7580000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c3656431" unitRef="iso4217-usd">8906000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2013-01-01_2013-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c3656432" unitRef="iso4217-usd">3664000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c3656433" unitRef="iso4217-usd">2125000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c3656434" unitRef="iso4217-usd">1271000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2013-01-01_2013-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c3656435" unitRef="iso4217-usd">704000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2015-01-01_2015-12-31" decimals="0" id="c3670022" unitRef="iso4217-usd">439000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2013-01-01_2013-12-31" decimals="0" id="c3670023" unitRef="iso4217-usd">439000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2014-01-01_2014-12-31" decimals="0" id="c3656755" unitRef="iso4217-usd">439000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656768" unitRef="xbrli-shares">3524000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656769" unitRef="xbrli-shares">3991000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656770" unitRef="xbrli-shares">1430000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AreaOfRealEstateProperty contextRef="i_2015-12-31" decimals="INF" id="c4072886" unitRef="utr-sqft">32000</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:Assets contextRef="i_2015-12-31" decimals="INF" id="c3655998" unitRef="iso4217-usd">124555000</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2014-12-31" decimals="INF" id="c3655999" unitRef="iso4217-usd">136874000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2015-12-31" decimals="INF" id="c3655988" unitRef="iso4217-usd">65990000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2014-12-31" decimals="INF" id="c3655989" unitRef="iso4217-usd">89343000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31" decimals="-3" id="c3656329" unitRef="iso4217-usd">70347000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2014-12-31" decimals="-3" id="c3656330" unitRef="iso4217-usd">59348000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c3656287" unitRef="iso4217-usd">26546000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c3656292" unitRef="iso4217-usd">21963000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c3656297" unitRef="iso4217-usd">21838000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2014-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c3656307" unitRef="iso4217-usd">20306000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2014-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c3656312" unitRef="iso4217-usd">27261000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2014-12-31_InvestmentTypeAxis-CommercialPaperMember" decimals="-3" id="c3656317" unitRef="iso4217-usd">11781000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" id="c3656285" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" id="c3656290" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c3656295" unitRef="iso4217-usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31" decimals="-3" id="c3656300" unitRef="iso4217-usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2014-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" id="c3656305" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2014-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c3656310" unitRef="iso4217-usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2014-12-31_InvestmentTypeAxis-CommercialPaperMember" id="c3656315" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2014-12-31" decimals="-3" id="c3656320" unitRef="iso4217-usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c3656286" unitRef="iso4217-usd">99000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c3656291" unitRef="iso4217-usd">41000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c3656296" unitRef="iso4217-usd">72000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31" decimals="-3" id="c3656301" unitRef="iso4217-usd">212000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2014-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c3656306" unitRef="iso4217-usd">23000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2014-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c3656311" unitRef="iso4217-usd">47000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2014-12-31_InvestmentTypeAxis-CommercialPaperMember" decimals="-3" id="c3656316" unitRef="iso4217-usd">63000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2014-12-31" decimals="-3" id="c3656321" unitRef="iso4217-usd">133000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c3656283" unitRef="iso4217-usd">26557000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c3656288" unitRef="iso4217-usd">21820000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c3656293" unitRef="iso4217-usd">21884000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31" decimals="-3" id="c3656298" unitRef="iso4217-usd">70261000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2014-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c3656303" unitRef="iso4217-usd">20307000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2014-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c3656308" unitRef="iso4217-usd">27152000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2014-12-31_InvestmentTypeAxis-CommercialPaperMember" decimals="-3" id="c3656313" unitRef="iso4217-usd">11838000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2014-12-31" decimals="-3" id="c3656318" unitRef="iso4217-usd">59297000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="i_2015-12-31" decimals="-3" id="c3656323" unitRef="iso4217-usd">22664000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="i_2014-12-31" decimals="-3" id="c3656324" unitRef="iso4217-usd">18232000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="i_2015-12-31" decimals="INF" id="c3655976" unitRef="iso4217-usd">22664000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="i_2014-12-31" decimals="INF" id="c3655977" unitRef="iso4217-usd">18232000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="i_2015-12-31" decimals="INF" id="c3655990" unitRef="iso4217-usd">47683000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="i_2014-12-31" decimals="INF" id="c3655991" unitRef="iso4217-usd">41116000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-17">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;26,557&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;88&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(99&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;26,546&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,820&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;184&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(41&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,963&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,884&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(72&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,838&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,261&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;293&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(212&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;20,307&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;22&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(23&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;20,306&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;27,152&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;151&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(47&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;27,261&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Commercial paper&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11,838&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;6&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(63&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11,781&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,297&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;179&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(133&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,348&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31" decimals="INF" id="c3655972" unitRef="iso4217-usd">28899000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2014-12-31" decimals="INF" id="c3655973" unitRef="iso4217-usd">54540000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2013-12-31" decimals="-3" id="c3656173" unitRef="iso4217-usd">21164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2012-12-31" decimals="-3" id="c3656174" unitRef="iso4217-usd">20891000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656169" unitRef="iso4217-usd">-25641000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656170" unitRef="iso4217-usd">33376000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656171" unitRef="iso4217-usd">273000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4073306">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="d_2015-01-01_2015-12-31" id="c4073307">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Restricted cash as of December 31, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $59 in royalty revenue paid by Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;) designated for interest on the PhaRMA Notes (defined in Note 3) and $1,403 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2015-01-01_2015-12-31" id="s131716">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;9&amp;nbsp;&amp;#x2014; Collaborative and Other Research and Development Contracts&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;U.S.&amp;nbsp;Department of Health and Human Services (&amp;#x201c;BARDA/HHS&amp;#x201d;). &lt;/div&gt;In January 2007, the U.S.&amp;nbsp;Department of Health and Human Services (&amp;#x201c;BARDA/HHS&amp;#x201d;) awarded the Company a $102,661, four-year contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir program and to increase funding by $77,191. On February&amp;nbsp;24, 2011, the Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to $234,852 and provided funding to support the filing of a NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired on June 30, 2014.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;On March 31, 2015, the Company announced that the Biomedical Research and Development Authority within the U.S. Department of Health and Human Services&amp;#x2019; Office of the Assistant Secretary for Preparedness and Response awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&amp;nbsp;This BARDA/HHS contract includes a base contract of $13,314 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $36,169. As of September 30, 2015, a total of $16,300 has been awarded under exercised options within this contract.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;).&lt;/div&gt; In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this contract as of December 31, 2015 could be up to $34,002, if all contract options are exercised by NIAID/HHS, over a five year period. The goals of this contract, including amendments, are to file IND applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human clinical trial. As of December 31, 2015, a total of $29,875 has been awarded under exercised options within this contract. BCX4430 is the lead compound in the Company&amp;#x2019;s BSAV research program.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&amp;#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;).&lt;/div&gt; On June 16, 2015, the Company and Seqirus UK Limited (&amp;quot;SUL&amp;quot;), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &amp;quot;SUL Agreement&amp;quot;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &amp;quot;Territory&amp;quot;). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the U.S. Food and Drug Administration in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 74; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In December 2013, the Company submitted a New Drug Application (&amp;quot;NDA&amp;quot;) for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency (&amp;quot;EMA&amp;quot;) until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company received an upfront payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement (the &amp;quot;Royalty Term&amp;quot;). The Company developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;).&lt;/div&gt; In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Green Cross Corporation (&amp;#x201c;Green Cross&amp;#x201d;).&lt;/div&gt; In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Mundipharma International Holdings Limited (&amp;#x201c;Mundipharma&amp;#x201d;).&lt;/div&gt; In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&amp;#x201c;PNP&amp;#x201d;) inhibitor, for use in oncology (the &amp;#x201c;Original Agreement&amp;#x201d;). Under the terms of the Original Agreement, Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a $10,000 up-front payment.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 75; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; text-align: center; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Company deferred revenue recognition of the $10,000 up-front payment that was received from Mundipharma in February&amp;nbsp;2006 because the Company was involved in the continued development of forodesine. Amortization of this revenue commenced in February&amp;nbsp;2006 and was initially scheduled to end in October&amp;nbsp;2017, which is the date of expiration for the last-to-expire patent covered by the agreement. The Company also deferred revenue recognition of a $5,000 payment received from Mundipharma in connection with the initiation of a clinical trial in 2007. Amortization of this deferred revenue commenced in 2007 and was initially scheduled to end in October&amp;nbsp;2017. Under its agreement with AECOM/IRL, the Company paid sublicense payments related to these upfront cash payments received from Mundipharma. Expense recognition of these sublicense payments was deferred and recognized under the same term as the related deferred revenue.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;On November&amp;nbsp;11, 2011, the Company entered into the Amended and Restated License and Development Agreement (the &amp;#x201c;Amended and Restated Agreement&amp;#x201d;) with Mundipharma, amending and restating the Original Agreement. Under the terms of the Amended and Restated Agreement, Mundipharma obtained worldwide rights to forodesine. Commencing on November&amp;nbsp;11, 2011, Mundipharma controls the development and commercialization of forodesine and assumes all future development and commercialization costs. The Amended and Restated Agreement provides for the possibility of future event payments totaling $15,000 for achieving specified regulatory events for certain indications and tiered royalties ranging from mid to high single-digit percentages of net product sales in each country where forodesine is sold by Mundipharma. These royalties are subject to downward adjustments based on the then-existing patent coverage and/or the availability of generic compounds in each country.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Amended and Restated Agreement is a multiple element arrangement for accounting purposes, in which the Company is required to deliver to Mundipharma both the worldwide rights to forodesine in the field of oncology and the transfer of product data and know-how to permit Mundipharma to develop and commercialize forodesine (the &amp;#x201c;Knowledge Transfer&amp;#x201d;). The Company accounted for these elements as a combined unit of accounting as they do not have stand-alone value to Mundipharma. The worldwide license rights were granted to Mundipharma on November&amp;nbsp;11, 2011 and the Knowledge Transfer was completed during the first quarter of 2012.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&amp;#x201c;AECOM&amp;#x201d; and &amp;#x201c;IRL&amp;#x201d; respectively).&lt;/div&gt; In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &amp;#x201c;Licensors&amp;#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000&amp;nbsp;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60&amp;nbsp;days advance notice or in the event of material uncured breach by the Licensors.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&amp;nbsp;any milestone payments the Company may receive in the future under its license agreement dated February&amp;nbsp;1, 2006 with Mundipharma and (ii)&amp;nbsp;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;In consideration for these modifications in 2010, the Company issued to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally, at the Company&amp;#x2019;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination of cash and shares.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On November&amp;nbsp;17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On June&amp;nbsp;19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.&amp;nbsp;&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 76; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;          &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company&amp;#x2019;s common stock, or in a combination of cash and shares.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&amp;#x201c;VUW&amp;#x201d;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;).&lt;/div&gt; The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months&amp;#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&amp;#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2014-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c3657212" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2015-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c3657213" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c3657220" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c3657221" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2015-01-01_2015-12-31" id="s131702">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;4&amp;nbsp;&amp;#x2014; Lease Obligations and Other Contingencies&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company has the following minimum payments under operating lease obligations that existed at December&amp;nbsp;31, 2015:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 87%; font-size: 10pt; text-align: left"&gt;2016&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;651&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;2017&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;871&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;2018&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;870&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;2019&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;820&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;2020&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;651&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left"&gt;Thereafter&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;3,045&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total minimum payments&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,908&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;      &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;The obligations in the preceding table are primarily related to the Company&amp;#x2019;s leases for buildings in Birmingham, Alabama and Durham, North Carolina. The lease for the Company&amp;#x2019;s headquarters in Durham, North Carolina expires June&amp;nbsp;30, 2020. The lease for the existing facility in Birmingham, Alabama currently expires on June&amp;nbsp;30, 2016; however, in 2015, the Company leased an additional approximate 32,000 square feet in Birmingham to house its new research facility. The Company began construction on leasehold improvements for its new research facility in 2015 and this lease obligates the Company for $4,839 of lease payments into 2027. Rent expense for operating leases was $664, $633, and $526 in 2015, 2014, and 2013, respectively.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 0.25in; margin: 12pt 0 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Lease Financing Obligation&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 12pt 0 0"&gt;Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of $1,589, representing the Company&amp;#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company will not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease and or construction in process.&lt;/div&gt;        &lt;!-- Field: Page; Sequence: 68; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;      &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;At December 31, 2015, the lease financing obligation balance was $2,375 and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease financing obligation are $4,839.&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2015-12-31" decimals="INF" id="c3657132" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2014-12-31" decimals="INF" id="c3657133" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2015-12-31" decimals="0" id="c3657134" unitRef="xbrli-shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2014-12-31" decimals="0" id="c3657135" unitRef="xbrli-shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="i_2015-12-31" decimals="0" id="c3657136" unitRef="xbrli-shares">73355000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2014-12-31" decimals="0" id="c3657137" unitRef="xbrli-shares">71955000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2015-12-31" decimals="0" id="c3657138" unitRef="xbrli-shares">73355000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2014-12-31" decimals="0" id="c3657139" unitRef="xbrli-shares">71955000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2011-07-13" decimals="-3" id="c3656867" unitRef="iso4217-usd">70000000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2015-12-31" decimals="INF" id="c3656024" unitRef="iso4217-usd">734000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2014-12-31" decimals="INF" id="c3656025" unitRef="iso4217-usd">720000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656089" unitRef="iso4217-usd">-43095000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656090" unitRef="iso4217-usd">-45323000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656091" unitRef="iso4217-usd">-30131000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4073315">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accumulated Other Comprehensive Loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&amp;#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During 2015, realized gains of $13 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded during 2014.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="d_2015-01-01_2015-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_ProductOrServiceAxis-RAPIVABMember" decimals="1" id="c3656773" unitRef="xbrli-pure">0.9</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4073304">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Beginning in March 2011, the consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&amp;#x201c;Royalty Sub&amp;#x201d;). Royalty Sub was formed in connection with a $30,000&amp;nbsp;financing transaction the Company completed on March&amp;nbsp;9, 2011. See Note 3, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201c;U.S. GAAP&amp;#x201d;). Such consolidated financial statements reflect all adjustments that are, in management&amp;#x2019;s opinion, necessary to present fairly, in all material respects, the Company&amp;#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:CostOfGoodsSold contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656050" unitRef="iso4217-usd">1368000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656051" unitRef="iso4217-usd">1000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2013-01-01_2013-12-31" id="c3656052" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CostsAndExpenses contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656062" unitRef="iso4217-usd">87701000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656063" unitRef="iso4217-usd">59379000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656064" unitRef="iso4217-usd">48048000</us-gaap:CostsAndExpenses>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="INF" id="c3656796" unitRef="xbrli-pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="i_2013-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="INF" id="c3656805" unitRef="xbrli-pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DeferredCostsCurrent contextRef="i_2015-12-31" decimals="INF" id="c3655986" unitRef="iso4217-usd">90000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredCostsCurrent contextRef="i_2014-12-31" decimals="INF" id="c3655987" unitRef="iso4217-usd">76000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="i_2015-12-31" decimals="-3" id="c3656641" unitRef="iso4217-usd">2668000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="i_2014-12-31" decimals="-3" id="c3656642" unitRef="iso4217-usd">2285000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="i_2015-12-31" decimals="INF" id="c3656017" unitRef="iso4217-usd">329000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="i_2014-12-31" decimals="INF" id="c3656018" unitRef="iso4217-usd">394000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRevenue contextRef="i_2006-02-28_DeferredRevenueArrangementTypeAxis-UpfrontPaymentMember_TypeOfArrangementAxis-MundipharmaMember" decimals="-3" id="c3657076" unitRef="iso4217-usd">10000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="i_2007-12-31_DeferredRevenueArrangementTypeAxis-ClinicalTrial2007Member_TypeOfArrangementAxis-MundipharmaMember" decimals="-3" id="c3657079" unitRef="iso4217-usd">5000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueAdditions contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c3656737" unitRef="iso4217-usd">3740000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueAdditions contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c3656739" unitRef="iso4217-usd">1223000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2015-12-31_DeferredRevenueArrangementTypeAxis-DeferredCollaborativeRevenueMember" decimals="INF" id="c3656007" unitRef="iso4217-usd">2163000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2014-12-31_DeferredRevenueArrangementTypeAxis-DeferredCollaborativeRevenueMember" decimals="INF" id="c3656008" unitRef="iso4217-usd">1481000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2015-12-31_DeferredRevenueArrangementTypeAxis-DeferredProductSalesMember" id="c3656009" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2014-12-31_DeferredRevenueArrangementTypeAxis-DeferredProductSalesMember" decimals="INF" id="c3656010" unitRef="iso4217-usd">5605000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2015-12-31" decimals="INF" id="c3656015" unitRef="iso4217-usd">9674000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2014-12-31" decimals="INF" id="c3656016" unitRef="iso4217-usd">3552000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="i_2015-12-31" decimals="-3" id="c3656628" unitRef="iso4217-usd">4240000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="i_2014-12-31" decimals="-3" id="c3656629" unitRef="iso4217-usd">3798000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsGross contextRef="i_2015-12-31" decimals="-3" id="c3656634" unitRef="iso4217-usd">207876000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross contextRef="i_2014-12-31" decimals="-3" id="c3656635" unitRef="iso4217-usd">187153000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="i_2015-12-31" id="c3656645" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="i_2014-12-31" id="c3656646" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="i_2015-12-31" decimals="-3" id="c3656622" unitRef="iso4217-usd">142836000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="i_2014-12-31" decimals="-3" id="c3656623" unitRef="iso4217-usd">135922000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOther contextRef="i_2015-12-31" decimals="-3" id="c3656632" unitRef="iso4217-usd">2590000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther contextRef="i_2014-12-31" decimals="-3" id="c3656633" unitRef="iso4217-usd">1178000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="i_2015-12-31" decimals="-3" id="c3656626" unitRef="iso4217-usd">1054000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="i_2014-12-31" decimals="-3" id="c3656627" unitRef="iso4217-usd">1073000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="i_2015-12-31" decimals="-3" id="c3656624" unitRef="iso4217-usd">48551000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="i_2014-12-31" decimals="-3" id="c3656625" unitRef="iso4217-usd">38096000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="i_2015-12-31" decimals="-3" id="c3656630" unitRef="iso4217-usd">8605000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="i_2014-12-31" decimals="-3" id="c3656631" unitRef="iso4217-usd">7086000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2015-12-31" decimals="-3" id="c3656643" unitRef="iso4217-usd">205208000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2014-12-31" decimals="-3" id="c3656644" unitRef="iso4217-usd">184868000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains contextRef="i_2015-12-31" decimals="-3" id="c3656639" unitRef="iso4217-usd">2668000</us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains>
  <us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains contextRef="i_2014-12-31" decimals="-3" id="c3656640" unitRef="iso4217-usd">2285000</us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3657030" unitRef="iso4217-usd">366000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3657031" unitRef="iso4217-usd">361000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3657032" unitRef="iso4217-usd">313000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656785" unitRef="iso4217-usd">180000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656786" unitRef="iso4217-usd">177000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656787" unitRef="iso4217-usd">304000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DerivativeForwardExchangeRate1 contextRef="i_2015-09-30_CurrencyAxis-JapanYenMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c3656822" unitRef="xbrli-pure">100</us-gaap:DerivativeForwardExchangeRate1>
  <us-gaap:DerivativeGainOnDerivative contextRef="d_2014-01-01_2014-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="0" id="c3656761" unitRef="iso4217-usd">5487000</us-gaap:DerivativeGainOnDerivative>
  <us-gaap:DerivativeGainOnDerivative contextRef="d_2013-01-01_2013-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="0" id="c3656762" unitRef="iso4217-usd">5294000</us-gaap:DerivativeGainOnDerivative>
  <us-gaap:DerivativeGainOnDerivative contextRef="d_2015-01-01_2015-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="0" id="c4072810" unitRef="iso4217-usd">1654000</us-gaap:DerivativeGainOnDerivative>
  <us-gaap:DerivativeLossOnDerivative contextRef="d_2015-01-01_2015-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="0" id="c3656760" unitRef="iso4217-usd">564000</us-gaap:DerivativeLossOnDerivative>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2015-01-01_2015-12-31" id="s131705">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;6&amp;nbsp;&amp;#x2014; Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock Incentive Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;As of December&amp;nbsp;31, 2015, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (&amp;#x201c;Incentive Plan&amp;#x201d;) and the Employee Stock Purchase Plan (&amp;#x201c;ESPP&amp;#x201d;), both which were amended and restated in March 2014 and approved by the Company&amp;#x2019;s stockholders in May 2014. Stock-based compensation expense of $9,705 ($9,485 of expense related to the Incentive Plan, $220 of expense related to the ESPP) was recognized during 2015, while $10,177 ($9,963 of expense related to the Incentive Plan, $214 of expense related to the ESPP) was recognized during 2014, and $4,368 ($4,253 of expense related to the Incentive Plan, $115 of expense related to the ESPP) was recognized during 2013.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;The Company accounts for stock-based compensation in accordance with FASB authoritative guidance regarding share-based payments. Total stock-based compensation was allocated as follows:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended December&amp;nbsp;31,&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;Research and development&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;7,580&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;8,906&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;3,664&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,125&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,271&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;704&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total stock-based compensation expense&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;9,705&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;10,177&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,368&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;      &lt;!-- Field: Page; Sequence: 69; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;          &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&amp;#x2019;s stock at the date of grant. Commencing March&amp;nbsp;1, 2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of December 31, 2015, 75% of the August 2013 grants have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which vesting occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014, and (3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of December&amp;nbsp;31, 2015, 25% of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5 to 10&amp;nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;Related activity under the Incentive Plan is as follows:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Awards&lt;br /&gt; Available&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Options&lt;br /&gt; Outstanding&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 55%; font-size: 10pt"&gt;Balance at December&amp;nbsp;31, 2012&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,815&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;8,073&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;6.09&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock awards granted&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(310&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock awards cancelled&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;53&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards granted&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(3,277&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;3,277&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;3.05&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards exercised&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(563&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2.37&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Stock option awards cancelled&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,801&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(1,801&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;7.22&lt;/td&gt;      &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;Balance at December&amp;nbsp;31, 2013&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,082&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;8,986&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;4.99&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Plan amendment&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;3,750&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock awards granted&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(593&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock awards cancelled&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards granted&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(1,965&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,965&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;10.99&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards exercised&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(1,258&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;4.78&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Stock option awards cancelled&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;88&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(88&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;8.83&lt;/td&gt;      &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;Balance at December&amp;nbsp;31, 2014&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2,362&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;9,605&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;6.21&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock awards granted&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(163&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock awards cancelled&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards granted&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(2,217&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2,217&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;11.52&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards exercised&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(1,118&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;4.36&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Stock option awards cancelled&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;33&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(33&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;9.87&lt;/td&gt;      &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance at December&amp;nbsp;31, 2015&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;16&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;10,671&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right"&gt;7.50&lt;/td&gt;      &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;For stock option awards granted under the Incentive Plan during 2015, 2014 and 2013, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during 2015, 2014 and 2013 was $7.72, $8.02, and $1.28, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following explanations describe the assumptions used by the Company to value the stock option awards granted during 2015, 2014, and 2013. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the volatility over the most recent period corresponding with the expected life. The Company has assumed no expected dividend yield, as dividends have never been paid to stockholders and will not be for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining term equal to the expected term.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 70; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted Average Assumptions for Stock Option Awards Granted under the Incentive Plan&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;Expected Life&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5.5&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5.5&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;4.7&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Volatility&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;81&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;87&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;84&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Dividend Yield&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-Free Interest Rate&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1.6&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1.6&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;0.7&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The total intrinsic value of stock option awards exercised under the Incentive Plan was $10,117 during 2015, $8,522 during 2014, $738 and during 2013. The intrinsic value represents the total proceeds (fair market value at the date of exercise, less the exercise price, times the number of stock option awards exercised) received by all individuals who exercised stock option awards during the period.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The following table summarizes, at December&amp;nbsp;31, 2015, by price range: (1)&amp;nbsp;for stock option awards outstanding under the Incentive Plan, the number of stock option awards outstanding, their weighted average remaining life and their weighted average exercise price; and (2)&amp;nbsp;for stock option awards exercisable under the Plan, the number of stock option awards exercisable and their weighted average exercise price:&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;        &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td colspan="9" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Outstanding&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Exercisable&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td colspan="2"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; text-decoration: underline;"&gt;Range&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Number&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Life&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Number&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 1%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;0&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; width: 3%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,826&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.4&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1.51&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,322&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1.55&lt;/div&gt;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;2,792&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.1&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;4.63&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;2,329&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;4.53&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;9&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,153&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;4.5&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;7.10&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,070&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;7.13&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;9&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3,728&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;8.1&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;11.07&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;714&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;11.45&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,077&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.4&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12.44&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;374&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12.65&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;18&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right; padding-bottom: 1.1pt; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;95&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;9.5&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15.39&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;0&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;18&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right; padding-bottom: 2.25pt; border-bottom: Black 2.25pt double"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;10,671&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.7&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;7.50&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;5,809&lt;/div&gt;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;5.70&lt;/div&gt;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The weighted average remaining contractual life of stock option awards exercisable under the Incentive Plan at December&amp;nbsp;31, 2015 was 5.0 years.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The aggregate intrinsic value of stock option awards outstanding and exercisable under the Incentive Plan at December&amp;nbsp;31, 2015 was $28,511. The aggregate intrinsic value represents the value (the period&amp;#x2019;s closing market price, less the exercise price, times the number of in-the-money stock option awards) that would have been received by all stock option award holders under the Incentive Plan had they exercised their stock option awards at the end of the year.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The total fair value of the stock option awards vested under the Incentive Plan was $4,492 during 2015, $2,844 during 2014, and $3,483 during 2013.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;As of December&amp;nbsp;31, 2015, the number of stock option awards vested and expected to vest under the Incentive Plan is 9,633. The weighted average exercise price of these stock option awards is $7.51 and their weighted average remaining contractual life is 6.6&amp;nbsp;years.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 71; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The following table summarizes the changes in the number and weighted-average grant-date fair value of non-vested stock option awards during 2015:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Non-Vested&lt;br /&gt; Stock Option&lt;br /&gt; Awards&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted Average&lt;br /&gt; Grant-Date Fair&lt;br /&gt; Value&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 67%; font-size: 10pt"&gt;Balance December&amp;nbsp;31, 2014&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;4,385&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;4.27&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Stock option awards granted&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2,217&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;7.72&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Stock option awards vested&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(1,711&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2.63&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Stock option awards forfeited&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(28&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;6.39&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance December&amp;nbsp;31, 2015&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,863&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6.40&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;As of December&amp;nbsp;31, 2015, there was approximately $18,607 of total unrecognized compensation cost related to non-vested employee stock option awards and restricted stock units granted by the Company. That cost is expected to be recognized as follows: $7,023 in 2016, $6,010 in 2017, $3,891 in 2018, and $1,683 in 2019.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Employee Stock Purchase Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company has reserved a total of 1,475&amp;nbsp;shares of common stock to be purchased under the ESPP, of which 497&amp;nbsp;shares remain available for purchase at December&amp;nbsp;31, 2015. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;There were 41, 49 and 89 shares of common stock purchased under the ESPP in 2015, 2014, and 2013, respectively, at a weighted average price per share of $8.65, $6.29, and $1.39, respectively. Expense of $220, $214, and $115, related to the ESPP was recognized during 2015, 2014, and 2013, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &amp;#x201c;look-back&amp;#x201d; option were determined using a Black-Scholes option pricing model. The weighted average grant date fair values of shares granted under the ESPP during 2015, 2014, and 2013, were $4.93, $4.41, and $1.27, respectively.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasic contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c3656656" unitRef="iso4217-usd-per-xbrli-shares">-0.21</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2015-04-01_2015-06-30" decimals="INF" id="c3656657" unitRef="iso4217-usd-per-xbrli-shares">0.07</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2015-07-01_2015-09-30" decimals="INF" id="c3656658" unitRef="iso4217-usd-per-xbrli-shares">-0.20</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2015-10-01_2015-12-31" decimals="INF" id="c3656659" unitRef="iso4217-usd-per-xbrli-shares">-0.25</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c3656080" unitRef="iso4217-usd-per-xbrli-shares">-0.59</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c3656081" unitRef="iso4217-usd-per-xbrli-shares">-0.68</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2013-01-01_2013-12-31" decimals="INF" id="c3656082" unitRef="iso4217-usd-per-xbrli-shares">-0.55</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2014-01-01_2014-03-31" decimals="INF" id="c3656673" unitRef="iso4217-usd-per-xbrli-shares">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2014-04-01_2014-06-30" decimals="INF" id="c3656674" unitRef="iso4217-usd-per-xbrli-shares">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2014-07-01_2014-09-30" decimals="INF" id="c3656675" unitRef="iso4217-usd-per-xbrli-shares">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2014-10-01_2014-12-31" decimals="INF" id="c3656676" unitRef="iso4217-usd-per-xbrli-shares">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c3656660" unitRef="iso4217-usd-per-xbrli-shares">-0.21</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2015-04-01_2015-06-30" decimals="INF" id="c3656661" unitRef="iso4217-usd-per-xbrli-shares">0.06</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2015-07-01_2015-09-30" decimals="INF" id="c3656662" unitRef="iso4217-usd-per-xbrli-shares">-0.20</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2015-10-01_2015-12-31" decimals="INF" id="c3656663" unitRef="iso4217-usd-per-xbrli-shares">-0.25</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4074460">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&amp;#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the years ended December&amp;nbsp;31, 2015, 2014, and 2013 does not include 3,524, 3,991 and 1,430 respectively, of potential common shares as their impact would be anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2015-01-01_2015-12-31" decimals="2" id="c4082779" unitRef="xbrli-pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2014-01-01_2014-12-31" decimals="2" id="c4082780" unitRef="xbrli-pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2013-01-01_2013-12-31" decimals="2" id="c4082781" unitRef="xbrli-pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c3656362" unitRef="iso4217-usd">424000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2014-12-31" decimals="-3" id="c3656363" unitRef="iso4217-usd">2105000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i_2015-12-31" decimals="0" id="c3656956" unitRef="iso4217-usd">18607000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions contextRef="d_2015-01-01_2015-12-31" decimals="0" id="c3657018" unitRef="iso4217-usd">15655000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions>
  <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c3656982" unitRef="iso4217-usd-per-xbrli-shares">8.65</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
  <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c3656983" unitRef="iso4217-usd-per-xbrli-shares">6.29</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
  <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased contextRef="d_2013-01-01_2013-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c3656984" unitRef="iso4217-usd-per-xbrli-shares">1.39</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="d_2015-01-01_2015-12-31" id="c3656100" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656101" unitRef="iso4217-usd">-27000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656102" unitRef="iso4217-usd">47000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656074" unitRef="iso4217-usd">1090000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656075" unitRef="iso4217-usd">5487000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656076" unitRef="iso4217-usd">5294000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember" decimals="-3" id="c3657047" unitRef="iso4217-usd">13314000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember" decimals="-3" id="c3657049" unitRef="iso4217-usd">22855000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember" decimals="-3" id="c3657050" unitRef="iso4217-usd">36169000</us-gaap:GovernmentContractReceivable>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2015-01-01_2015-12-31" id="s131711">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;7&amp;nbsp;&amp;#x2014; Income Taxes&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Company has incurred net losses since inception and, consequently, has not recorded any U.S.&amp;nbsp;Federal and state income tax expense or benefit. The differences between the Company&amp;#x2019;s effective tax rate and the statutory tax rate in 2015, 2014, and 2013 are as follows:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;Income tax benefit at federal statutory rate (35%)&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(15,057&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(15,816&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(10,538&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;State and local income taxes net of federal tax benefit&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(819&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(1,286&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(839&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Permanent items&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;560&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;258&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;738&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Rate change&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,012&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;22&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,892&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Expiration of attribute carryforwards&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;330&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;373&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;242&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Research and development tax credits&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(10,454&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(748&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(1,206&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Orphan drug credit&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;4,307&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;Other&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(218&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(115&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,144&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;20,339&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;17,312&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;8,567&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Income tax expense&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Company recognizes the impact of a tax position in its financial statements if it is more likely than not that the position will be sustained on audit based on the technical merits of the position. The Company has concluded that it has an uncertain tax position pertaining to its research and development and orphan drug credit carryforwards. The Company has established these credits based on information and calculations it believes are appropriate and the best estimate of the underlying credit. Any changes to the Company&amp;#x2019;s unrecognized tax benefits are offset by an adjustment to the valuation allowance and there would be no impact on the Company&amp;#x2019;s financial statements. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 72; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 70%; font-size: 10pt"&gt;Balance at January&amp;nbsp;1,&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;472&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;284&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Additions to current period tax positions&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2,616&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;176&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Additions to prior period tax positions&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;12&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reductions to prior period tax provisions&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(3&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance at December&amp;nbsp;31,&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;3,085&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;472&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;div style="display: inline; background-color: white"&gt;The Company&amp;#x2019;s ability to utilize the net operating loss and tax credit carryforwards in the future may be subject to substantial restrictions in the event of past or future ownership changes as defined in Section&amp;nbsp;382 of the Internal Revenue Code of 1986, as amended and similar state tax law.&lt;/div&gt;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Significant components of the Company&amp;#x2019;s deferred tax assets and liabilities are as follows:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred tax assets:&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Net federal and state operating losses&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;142,836&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;135,922&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Research and development credits&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;48,551&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;38,096&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Fixed assets&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,054&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,073&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Deferred revenue&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;4,240&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;3,798&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock-based compensation&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;8,605&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;7,086&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt"&gt;Other&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,590&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,178&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;207,876&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;187,153&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Foreign currency derivative&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2,668&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2,285&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total deferred tax liabilities&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2,668&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2,285&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(205,208&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(184,868&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Net deferred tax assets&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The majority of the Company&amp;#x2019;s deferred tax assets relate to net operating loss and research and development carryforwards that can only be realized if the Company is profitable in future periods. It is uncertain whether the Company will realize any tax benefit related to these carryforwards. Accordingly, the Company has provided a full valuation allowance against the net deferred tax assets due to uncertainties as to their ultimate realization. The valuation allowance will remain at the full amount of the deferred tax assets until it is more likely than not that the related tax benefits will be realized. The Company&amp;#x2019;s valuation allowance increased by $20,339 in 2015, $17,312 in 2014, and $8,567 in 2013.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;As of December&amp;nbsp;31, 2015, the Company had federal operating loss carryforwards of $386,219, state operating loss carryforwards of $373,454, and research and development and orphan drug credit carryforwards of $48,551, which will expire at various dates from 2016 through 2035. The federal losses begin to expire in 2018, the state losses begin to expire in 2016 and the research and development contracts begin to expire in 2018.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s federal and state operating loss carryforwards include $15,655 of excess tax benefits related to a deduction from the exercise of stock options. The tax benefit of these deductions has not been recognized in deferred tax assets. If utilized, the benefits from these deductions will be recorded as adjustments to additional paid-in capital.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;Tax years 2012-2014 remain open to examination by the major taxing jurisdictions to which the Company is subject. Additionally, years prior to 2012 are also open to examination to the extent of loss and credit carryforwards from those years. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as components of its income tax provision. However, there were no provisions or accruals for interest and penalties in 2015, 2014, and 2013.&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2015-01-01_2015-12-31" id="c3656608" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2014-01-01_2014-12-31" id="c3656609" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2013-01-01_2013-12-31" id="c3656610" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4073314">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The liability method is used in the Company&amp;#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2015-01-01_2015-12-31" decimals="0" id="c3657004" unitRef="iso4217-usd">20339000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2014-01-01_2014-12-31" decimals="0" id="c3657006" unitRef="iso4217-usd">17312000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2013-01-01_2013-12-31" decimals="0" id="c3657008" unitRef="iso4217-usd">8567000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656593" unitRef="iso4217-usd">1012000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656594" unitRef="iso4217-usd">22000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656595" unitRef="iso4217-usd">1892000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656584" unitRef="iso4217-usd">-15057000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656585" unitRef="iso4217-usd">-15816000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656586" unitRef="iso4217-usd">-10538000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656590" unitRef="iso4217-usd">560000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656591" unitRef="iso4217-usd">258000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656592" unitRef="iso4217-usd">738000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656605" unitRef="iso4217-usd">-218000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656606" unitRef="iso4217-usd">-115000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656607" unitRef="iso4217-usd">1144000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656587" unitRef="iso4217-usd">-819000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656588" unitRef="iso4217-usd">-1286000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656589" unitRef="iso4217-usd">-839000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656599" unitRef="iso4217-usd">10454000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656600" unitRef="iso4217-usd">748000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656601" unitRef="iso4217-usd">1206000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656125" unitRef="iso4217-usd">14393000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656126" unitRef="iso4217-usd">6818000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656127" unitRef="iso4217-usd">-2049000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656128" unitRef="iso4217-usd">1199000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656129" unitRef="iso4217-usd">4429000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656130" unitRef="iso4217-usd">-1103000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656109" unitRef="iso4217-usd">-564000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656110" unitRef="iso4217-usd">5487000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656111" unitRef="iso4217-usd">5294000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656116" unitRef="iso4217-usd">929000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656117" unitRef="iso4217-usd">683000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2013-01-01_2013-12-31" id="c3656118" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656119" unitRef="iso4217-usd">-1207000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656120" unitRef="iso4217-usd">1943000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656121" unitRef="iso4217-usd">620000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656113" unitRef="iso4217-usd">-3247000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656114" unitRef="iso4217-usd">7375000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656115" unitRef="iso4217-usd">-2447000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656141" unitRef="iso4217-usd">1462000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656142" unitRef="iso4217-usd">-1000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656143" unitRef="iso4217-usd">-157000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2015-01-01_2015-12-31" id="c4073312">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patents and Licenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:InterestAndOtherIncome contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656068" unitRef="iso4217-usd">535000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656069" unitRef="iso4217-usd">93000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656070" unitRef="iso4217-usd">93000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestExpense contextRef="d_2015-01-01_2015-12-31_LongtermDebtTypeAxis-PhaRMANotesMember" decimals="0" id="c3656752" unitRef="iso4217-usd">5200000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2014-01-01_2014-12-31_LongtermDebtTypeAxis-PhaRMANotesMember" decimals="0" id="c3656753" unitRef="iso4217-usd">4998000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2013-01-01_2013-12-31_LongtermDebtTypeAxis-PhaRMANotesMember" decimals="0" id="c3656754" unitRef="iso4217-usd">4778000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656071" unitRef="iso4217-usd">5200000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656072" unitRef="iso4217-usd">4998000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656073" unitRef="iso4217-usd">4778000</us-gaap:InterestExpense>
  <us-gaap:InterestPaid contextRef="d_2013-09-01_2013-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="0" id="c3656802" unitRef="iso4217-usd">1844000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid contextRef="d_2014-03-01_2014-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="0" id="c3656808" unitRef="iso4217-usd">446000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid contextRef="d_2014-06-01_2014-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="0" id="c3656809" unitRef="iso4217-usd">1882000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid contextRef="d_2014-08-01_2014-08-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="0" id="c3656810" unitRef="iso4217-usd">70000</us-gaap:InterestPaid>
  <us-gaap:InterestPayableCurrent contextRef="i_2015-12-31" decimals="INF" id="c3656005" unitRef="iso4217-usd">6746000</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrent contextRef="i_2014-12-31" decimals="INF" id="c3656006" unitRef="iso4217-usd">6029000</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="i_2013-09-03_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="0" id="c3656804" unitRef="iso4217-usd">2356000</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="i_2014-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_StatementScenarioAxis-Shortfall2013Member" decimals="0" id="c3656812" unitRef="iso4217-usd">222000</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="i_2015-12-31" id="c3656356" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="i_2014-12-31" decimals="-3" id="c3656357" unitRef="iso4217-usd">416000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryNet contextRef="i_2015-12-31" decimals="INF" id="c3655982" unitRef="iso4217-usd">1612000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="i_2014-12-31" decimals="INF" id="c3655983" unitRef="iso4217-usd">683000</us-gaap:InventoryNet>
  <us-gaap:InventoryPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4073310">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;At December&amp;nbsp;31, 2015 and 2014, the Company&amp;#x2019;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&amp;#x201c;FIFO&amp;#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;During 2014, in connection with the FDA approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s inventory consisted of the following:&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of December&amp;nbsp;31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style=" margin: 0"&gt;Work in process&lt;/div&gt; &lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;267&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;416&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Net inventories&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;683&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2015-12-31" decimals="-3" id="c3656354" unitRef="iso4217-usd">1612000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2014-12-31" decimals="-3" id="c3656355" unitRef="iso4217-usd">267000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InvestmentPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4073308">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At December 31, 2015, the Company believes that the costs of its investments are recoverable in all material respects.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The following tables summarize the fair value of the Company&amp;#x2019;s investments by type. The estimated fair value of the Company&amp;#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;26,557&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;88&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(99&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;26,546&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,820&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;184&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(41&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,963&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,884&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(72&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,838&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,261&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;293&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(212&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;20,307&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;22&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(23&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;20,306&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;27,152&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;151&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(47&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;27,261&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Commercial paper&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11,838&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;6&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(63&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11,781&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,297&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;179&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(133&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,348&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The following table summarizes the scheduled maturity for the Company&amp;#x2019;s investments at December&amp;nbsp;31, 2015 and 2014.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;22,664&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;18,232&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;28,395&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;25,459&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Maturing after two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;19,288&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;15,657&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,348&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:InvestmentsAndCash contextRef="i_2015-12-31" decimals="0" id="c3656679" unitRef="iso4217-usd">100858000</us-gaap:InvestmentsAndCash>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2015-12-31" decimals="INF" id="c3656034" unitRef="iso4217-usd">124555000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2014-12-31" decimals="INF" id="c3656035" unitRef="iso4217-usd">136874000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2015-12-31" decimals="INF" id="c3656013" unitRef="iso4217-usd">64453000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2014-12-31" decimals="INF" id="c3656014" unitRef="iso4217-usd">57293000</us-gaap:LiabilitiesCurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656166" unitRef="iso4217-usd">5479000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656167" unitRef="iso4217-usd">111907000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656168" unitRef="iso4217-usd">30270000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656150" unitRef="iso4217-usd">-18004000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656151" unitRef="iso4217-usd">-39980000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656152" unitRef="iso4217-usd">-3467000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656131" unitRef="iso4217-usd">-13116000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656132" unitRef="iso4217-usd">-38551000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656133" unitRef="iso4217-usd">-26530000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c3656186" unitRef="iso4217-usd">-30108000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656187" unitRef="iso4217-usd">-30108000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c3656221" unitRef="iso4217-usd">-45189000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656222" unitRef="iso4217-usd">-45189000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c3656256" unitRef="iso4217-usd">-43019000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656257" unitRef="iso4217-usd">-43019000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c3656652" unitRef="iso4217-usd">-15164000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c3656653" unitRef="iso4217-usd">4901000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c3656654" unitRef="iso4217-usd">-14621000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-10-01_2015-12-31" decimals="-3" id="c3656655" unitRef="iso4217-usd">-18135000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c3656669" unitRef="iso4217-usd">-10137000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c3656670" unitRef="iso4217-usd">-14649000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c3656671" unitRef="iso4217-usd">-8731000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-10-01_2014-12-31" decimals="-3" id="c3656672" unitRef="iso4217-usd">-11672000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="d_2015-01-01_2015-12-31" id="s131719">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;11&amp;nbsp;&amp;#x2014; Recent Accounting Pronouncements&lt;/div&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0"&gt;In November 2015, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) No. 2015-17, &lt;div style="display: inline; font-style: italic;"&gt;Balance Sheet Classification of Deferred Taxes&lt;/div&gt;, requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as noncurrent on the balance sheet. The classification change for all deferred taxes as noncurrent simplifies entities&amp;#x2019; processes as it eliminates the need to separately identify the net current and net noncurrent deferred tax asset or liability in each jurisdiction and allocate valuation allowances. We elected to prospectively adopt the accounting standard in the beginning of our fourth quarter of fiscal 2015. Adoption of this standard had no impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;In April 2015, the FASB issued ASU No.2015-03, &lt;div style="display: inline; font-style: italic;"&gt;Simplifying the Presentation of Debt Issuance Costs&lt;/div&gt;. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect this standard will have a material impact on its consolidated financial statements.&amp;nbsp;&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 77; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;      &lt;div style=" font-size: 10pt; text-align: center; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;In August 2014, the FASB issued ASU No. 2014-15 &amp;#x2013; &lt;div style="display: inline; font-style: italic;"&gt;Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a Going Concern,&lt;/div&gt; which defines management&amp;#x2019;s responsibility to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about an entity&amp;#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management must assess if there is substantial doubt about the company&amp;#x2019;s ability to continue as a going concern within one year after the issuance date.&amp;nbsp; Disclosures are required if conditions give rise to substantial doubt.&amp;nbsp;This standard is effective for all companies in the first annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact this standard will have on its financial statements and disclosures.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;In May 2014, the FASB issued ASU 2014-09 &amp;#x2013; &lt;div style="display: inline; font-style: italic;"&gt;Revenue from Contracts with Customers&lt;/div&gt;, which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <us-gaap:NotesPayableCurrent contextRef="i_2015-12-31" decimals="INF" id="c3656011" unitRef="iso4217-usd">30000000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableCurrent contextRef="i_2014-12-31" decimals="INF" id="c3656012" unitRef="iso4217-usd">30000000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableFairValueDisclosure contextRef="i_2013-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" decimals="0" id="c3656820" unitRef="iso4217-usd">30000000</us-gaap:NotesPayableFairValueDisclosure>
  <us-gaap:OperatingIncomeLoss contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656065" unitRef="iso4217-usd">-39444000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656066" unitRef="iso4217-usd">-45771000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656067" unitRef="iso4217-usd">-30717000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="i_2015-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c3656839" unitRef="iso4217-usd">4839000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="i_2014-12-31" decimals="-3" id="c3656429" unitRef="iso4217-usd">6908000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="i_2014-12-31" decimals="-3" id="c3656423" unitRef="iso4217-usd">651000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="i_2014-12-31" decimals="-3" id="c3656427" unitRef="iso4217-usd">651000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="i_2014-12-31" decimals="-3" id="c3656426" unitRef="iso4217-usd">820000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="i_2014-12-31" decimals="-3" id="c3656425" unitRef="iso4217-usd">870000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="i_2014-12-31" decimals="-3" id="c3656424" unitRef="iso4217-usd">871000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="i_2014-12-31" decimals="-3" id="c3656428" unitRef="iso4217-usd">3045000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656841" unitRef="iso4217-usd">664000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656842" unitRef="iso4217-usd">633000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656843" unitRef="iso4217-usd">526000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2015-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" decimals="0" id="c3657010" unitRef="iso4217-usd">386219000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2015-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" decimals="0" id="c3657011" unitRef="iso4217-usd">373454000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c3656372" unitRef="iso4217-usd">4522000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2014-12-31" decimals="-3" id="c3656373" unitRef="iso4217-usd">4282000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2015-12-31" decimals="INF" id="c3655996" unitRef="iso4217-usd">5468000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2014-12-31" decimals="INF" id="c3655997" unitRef="iso4217-usd">6031000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c3656190" unitRef="iso4217-usd">-23000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656192" unitRef="iso4217-usd">-23000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c3656225" unitRef="iso4217-usd">-134000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656227" unitRef="iso4217-usd">-134000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c3656260" unitRef="iso4217-usd">-76000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656262" unitRef="iso4217-usd">-76000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656086" unitRef="iso4217-usd">-76000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656087" unitRef="iso4217-usd">-134000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656088" unitRef="iso4217-usd">-23000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities contextRef="d_2015-01-01_2015-09-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c3656825" unitRef="iso4217-usd">1950000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656144" unitRef="iso4217-usd">53830000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656145" unitRef="iso4217-usd">73875000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656146" unitRef="iso4217-usd">23974000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656135" unitRef="iso4217-usd">5122000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656136" unitRef="iso4217-usd">106000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656137" unitRef="iso4217-usd">30000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="d_2015-01-01_2015-12-31" id="s131715">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;8&amp;nbsp;&amp;#x2014; Employee 401(k) Plan&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;In January 1991, the Company adopted an employee retirement plan (&amp;#x201c;401(k) Plan&amp;#x201d;) under Section&amp;nbsp;401(k) of the Internal Revenue Code covering all employees. Employee contributions may be made to the 401(k) Plan up to limits established by the Internal Revenue Service. Company matching contributions may be made at the discretion of the Board of Directors. The Company made matching contributions of $366, $361, and $313, in 2015, 2014, and 2013, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2015-12-31" decimals="INF" id="c3657126" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2014-12-31" decimals="INF" id="c3657127" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2015-12-31" decimals="0" id="c3657128" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2014-12-31" decimals="0" id="c3657129" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2015-12-31" decimals="0" id="c3657130" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2014-12-31" decimals="0" id="c3657131" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="i_2015-12-31" decimals="INF" id="c3656022" unitRef="iso4217-usd">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="i_2014-12-31" decimals="INF" id="c3656023" unitRef="iso4217-usd">0</us-gaap:PreferredStockValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2015-12-31" decimals="INF" id="c3655984" unitRef="iso4217-usd">4870000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2014-12-31" decimals="INF" id="c3655985" unitRef="iso4217-usd">6172000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="d_2015-01-01_2015-12-31" id="c4073305">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Reclassifications&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Long term deferred rent as of December 31, 2014 has been reclassified to conform to the 2015 presentation.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2014-06-03_2014-06-03" decimals="-3" id="c3656858" unitRef="iso4217-usd">115000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2013-08-01_2013-08-31" decimals="-3" id="c3656865" unitRef="iso4217-usd">18500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2012-01-01_2012-12-31" decimals="-3" id="c3656872" unitRef="iso4217-usd">17805000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2015-01-01_2015-12-31" id="c3656154" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656155" unitRef="iso4217-usd">106600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656156" unitRef="iso4217-usd">23633000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656876" unitRef="iso4217-usd">5218000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="d_2014-06-03_2014-06-03" decimals="-3" id="c3656860" unitRef="iso4217-usd">107800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c3656733" unitRef="iso4217-usd">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_StatementScenarioAxis-ContingentUponEuMarketingApprovalMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c3656734" unitRef="iso4217-usd">7000000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" decimals="-3" id="c3657067" unitRef="iso4217-usd">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember" decimals="-3" id="c3657074" unitRef="iso4217-usd">250000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656147" unitRef="iso4217-usd">42410000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656148" unitRef="iso4217-usd">34000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656149" unitRef="iso4217-usd">20330000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleOfFurnitureAndFixtures contextRef="d_2015-01-01_2015-12-31" id="c3656138" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromSaleOfFurnitureAndFixtures contextRef="d_2014-01-01_2014-12-31" id="c3656139" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromSaleOfFurnitureAndFixtures contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656140" unitRef="iso4217-usd">50000</us-gaap:ProceedsFromSaleOfFurnitureAndFixtures>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656157" unitRef="iso4217-usd">5124000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656158" unitRef="iso4217-usd">4997000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656159" unitRef="iso4217-usd">1333000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockPlans contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656160" unitRef="iso4217-usd">355000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656161" unitRef="iso4217-usd">310000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656162" unitRef="iso4217-usd">124000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2015-01-01_2015-12-31" id="s131699">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;2&amp;nbsp;&amp;#x2014; Property and Equipment&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Property and equipment consisted of the following at December&amp;nbsp;31:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Furniture and fixtures&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;718&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;542&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Office equipment&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,122&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,115&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;Software&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,427&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,423&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Laboratory equipment&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;6,004&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5,786&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Leased equipment&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;63&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;63&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Leasehold improvements&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5,610&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5,303&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Construction in progress&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2,821&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Building&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,589&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;19,354&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;14,232&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less accumulated depreciation and amortization&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(14,205&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(14,025&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Property and equipment, net&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5,149&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;207&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;        &lt;!-- Field: Page; Sequence: 66; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Depreciation and amortization expense for the years ended December&amp;nbsp;31, 2015, 2014 and 2013 was $180, $177 and $304, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="-3" id="c3861185" unitRef="iso4217-usd">1589000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" decimals="-3" id="c3656401" unitRef="iso4217-usd">718000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" decimals="-3" id="c3656402" unitRef="iso4217-usd">542000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember" decimals="-3" id="c3656403" unitRef="iso4217-usd">1122000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember" decimals="-3" id="c3656404" unitRef="iso4217-usd">1115000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember" decimals="-3" id="c3656405" unitRef="iso4217-usd">1427000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember" decimals="-3" id="c3656406" unitRef="iso4217-usd">1423000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" decimals="-3" id="c3656407" unitRef="iso4217-usd">6004000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" decimals="-3" id="c3656408" unitRef="iso4217-usd">5786000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LeasedEquipmentMember" decimals="-3" id="c3656409" unitRef="iso4217-usd">63000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-LeasedEquipmentMember" decimals="-3" id="c3656410" unitRef="iso4217-usd">63000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="-3" id="c3656411" unitRef="iso4217-usd">5610000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="-3" id="c3656412" unitRef="iso4217-usd">5303000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember" decimals="-3" id="c3656413" unitRef="iso4217-usd">2821000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember" id="c3656414" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" decimals="-3" id="c3656415" unitRef="iso4217-usd">1589000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" id="c3656416" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31" decimals="-3" id="c3656417" unitRef="iso4217-usd">19354000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2014-12-31" decimals="-3" id="c3656418" unitRef="iso4217-usd">14232000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2015-12-31" decimals="-3" id="c3656421" unitRef="iso4217-usd">5149000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2014-12-31" decimals="-3" id="c3656422" unitRef="iso4217-usd">207000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4073311">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the remaining lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period of ten years equal to the term of the related lease&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-23">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Furniture and fixtures&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;718&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;542&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Office equipment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,122&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,115&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Software&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,427&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,423&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Laboratory equipment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;6,004&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,786&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Leased equipment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;63&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;63&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Leasehold improvements&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,610&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,303&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Construction in progress&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,821&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Building&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,589&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;19,354&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;14,232&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less accumulated depreciation and amortization&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(14,205&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(14,025&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Property and equipment, net&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5,149&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;207&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2015-01-01_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" id="c3656720">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2015-01-01_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" id="c3656721">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2015-01-01_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" id="c3656722">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2015-01-01_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" id="c3656723">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="d_2015-01-01_2015-12-31" id="s131717">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;10&amp;nbsp;&amp;#x2014; Quarterly Financial Information (Unaudited)&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;First&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Second&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Third&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fourth&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;2015 Quarters&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="width: 48%; font-size: 10pt; padding-left: 10pt"&gt;Revenues&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;6,826&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;25,842&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;10,987&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;4,602&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Net (Loss) Income&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(15,164&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;4,901&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(14,621&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(18,135&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Basic net (loss) income per share&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(0.21&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;0.07&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(0.20&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(0.25&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Diluted net (loss) income per share&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(0.21&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;0.06&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(0.20&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(0.25&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; font-weight: bold"&gt;2014 Quarters&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Revenues&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;3,458&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,466&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;3,238&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5,446&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Net Loss&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(10,137&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(14,649&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(8,731&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(11,672&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Basic and diluted net loss per share&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(0.17&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(0.23&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(0.12&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(0.16&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" id="c3656331" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c3656332" unitRef="iso4217-usd">5536000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c3656333" unitRef="iso4217-usd">5536000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c3656334" unitRef="iso4217-usd">469000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" id="c3656335" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c3656336" unitRef="iso4217-usd">469000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-CSLLimitedMember" decimals="-3" id="c3656337" unitRef="iso4217-usd">210000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-CSLLimitedMember" decimals="-3" id="c3656338" unitRef="iso4217-usd">28000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-CSLLimitedMember" decimals="-3" id="c3656339" unitRef="iso4217-usd">238000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" decimals="-3" id="c3656340" unitRef="iso4217-usd">679000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" decimals="-3" id="c3656341" unitRef="iso4217-usd">5564000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31" decimals="-3" id="c3656342" unitRef="iso4217-usd">6243000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" id="c3656343" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c3656344" unitRef="iso4217-usd">2778000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c3656345" unitRef="iso4217-usd">2778000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c3656346" unitRef="iso4217-usd">1071000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" id="c3656347" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c3656348" unitRef="iso4217-usd">1071000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" decimals="-3" id="c3656349" unitRef="iso4217-usd">1071000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" decimals="-3" id="c3656350" unitRef="iso4217-usd">2778000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2014-12-31" decimals="-3" id="c3656351" unitRef="iso4217-usd">3849000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4073309">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivable from Collaborations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi and Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At December&amp;nbsp;31, 2015 and 2014, the Company had the following receivables.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;210&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;238&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;679&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5,564&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,243&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; width: 52%"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;3,849&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Product Sales&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="d_2014-01-01_2014-12-31" decimals="0" id="c3657215" unitRef="iso4217-usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="d_2015-01-01_2015-12-31" decimals="0" id="c3656728" unitRef="iso4217-usd">13000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656053" unitRef="iso4217-usd">72758000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656054" unitRef="iso4217-usd">51796000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656055" unitRef="iso4217-usd">41943000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2015-01-01_2015-12-31" id="c4074456">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#x2019;s on-going review of the level of services actually performed.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#x201c;AECOM&amp;#x201d;), Industrial Research, Ltd. (&amp;#x201c;IRL&amp;#x201d;), and the University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&amp;#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="i_2015-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember" decimals="0" id="c3656702" unitRef="iso4217-usd">1403000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CertificatesOfDepositMember" decimals="0" id="c3656699" unitRef="iso4217-usd">150000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember" decimals="0" id="c3656700" unitRef="iso4217-usd">59000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31" decimals="INF" id="c3655974" unitRef="iso4217-usd">1612000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2014-12-31" decimals="INF" id="c3655975" unitRef="iso4217-usd">150000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2015-12-31" decimals="INF" id="c3656030" unitRef="iso4217-usd">-510917000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2014-12-31" decimals="INF" id="c3656031" unitRef="iso4217-usd">-467898000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c4074455">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;nbsp;persuasive evidence of an arrangement exists; (ii)&amp;nbsp;delivery has occurred or services have been rendered; (iii)&amp;nbsp;the seller&amp;#x2019;s price to the buyer is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Under certain of the Company&amp;#x2019;s license agreements, the Company receives royalty payments based upon its licensees&amp;#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &amp;#x201c;stand-alone value&amp;#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&amp;#x201c;TPE&amp;#x201d;) and (iii) best estimate of selling price (&amp;#x201c;BESP&amp;#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: center; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In June 2015, the Company entered into a License Agreement (the &amp;#x201c;SUL Agreement&amp;#x201d;) granting Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;) and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&amp;#x201c;EU&amp;#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&amp;#x201c;Health Canada&amp;#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, &lt;div style="display: inline; font-style: italic;"&gt;Milestone Method of Revenue Recognition&lt;/div&gt;, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&amp;#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#x201d;BARDA/HHS&amp;#x201d;) and the National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Sales&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&amp;nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be primarily responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales, and the Company&amp;#x2019;s commercial sales will be minimal.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Rebates and Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&amp;#x2019;s selling price.&amp;nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&amp;#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&amp;#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Discounts and Sales Incentives&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Discounts and other sales incentives primarily consist of Inventory Management Agreement (&amp;#x201c;IMA&amp;#x201d;) Fees. Per contractual agreements with the Company&amp;#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Returns&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recorded the following revenues for the years ended December&amp;nbsp;31:&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;6,291&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;33&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,386&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,025&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,562&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;16,337&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;9,366&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;13,585&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;132&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Shionogi (Japan)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,184&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,184&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,184&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,927&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;39,580&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;10,550&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;14,769&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;48,257&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;13,608&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;17,331&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Advertising&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred. Advertising and product promotion expenses were $103 and $290 for the years ended December&amp;nbsp;31, 2015 and 2014, respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:Revenues contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c3656735" unitRef="iso4217-usd">21777000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656398" unitRef="iso4217-usd">48257000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656399" unitRef="iso4217-usd">13608000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656400" unitRef="iso4217-usd">17331000</us-gaap:Revenues>
  <us-gaap:RoyaltyExpense contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656059" unitRef="iso4217-usd">528000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656060" unitRef="iso4217-usd">121000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656061" unitRef="iso4217-usd">98000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyRevenue contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656379" unitRef="iso4217-usd">2386000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656380" unitRef="iso4217-usd">3025000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656381" unitRef="iso4217-usd">2562000</us-gaap:RoyaltyRevenue>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656376" unitRef="iso4217-usd">6291000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656377" unitRef="iso4217-usd">33000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2013-01-01_2013-12-31" id="c3656378" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SalesRevenueNet contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656046" unitRef="iso4217-usd">48257000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656047" unitRef="iso4217-usd">13608000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656048" unitRef="iso4217-usd">17331000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c3656648" unitRef="iso4217-usd">6826000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c3656649" unitRef="iso4217-usd">25842000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-07-01_2015-09-30" decimals="-3" id="c3656650" unitRef="iso4217-usd">10987000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-10-01_2015-12-31" decimals="-3" id="c3656651" unitRef="iso4217-usd">4602000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c3656665" unitRef="iso4217-usd">3458000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2014-04-01_2014-06-30" decimals="-3" id="c3656666" unitRef="iso4217-usd">1466000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2014-07-01_2014-09-30" decimals="-3" id="c3656667" unitRef="iso4217-usd">3238000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2014-10-01_2014-12-31" decimals="-3" id="c3656668" unitRef="iso4217-usd">5446000</us-gaap:SalesRevenueNet>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Compensation and benefits&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;424&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;2,105&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Development costs&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;10,398&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,232&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Inventory&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;549&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;397&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Professional fees&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;242&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;238&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Duties and taxes&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;102&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;75&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,522&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,282&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Total accrued expenses&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;16,237&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;11,329&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-32">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred tax assets:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Net federal and state operating losses&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;142,836&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;135,922&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Research and development credits&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;48,551&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;38,096&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Fixed assets&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,054&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,073&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Deferred revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,240&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,798&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock-based compensation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;8,605&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;7,086&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,590&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,178&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Total deferred tax assets&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;207,876&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;187,153&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Foreign currency derivative&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2,668&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2,285&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total deferred tax liabilities&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2,668&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2,285&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(205,208&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(184,868&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Net deferred tax assets&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;Income tax benefit at federal statutory rate (35%)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(15,057&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(15,816&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(10,538&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;State and local income taxes net of federal tax benefit&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(819&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(1,286&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(839&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Permanent items&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;560&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;258&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;738&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Rate change&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,012&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;22&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,892&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expiration of attribute carryforwards&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;330&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;373&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;242&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Research and development tax credits&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(10,454&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(748&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(1,206&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Orphan drug credit&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,307&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(218&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(115&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,144&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;20,339&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;17,312&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;8,567&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Income tax expense&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-25">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended December&amp;nbsp;31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;Research and development&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;7,580&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;8,906&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;3,664&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,125&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,271&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;704&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total stock-based compensation expense&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;9,705&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;10,177&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,368&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-24">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 87%; font-size: 10pt; text-align: left"&gt;2016&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;651&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;871&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;2018&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;870&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;2019&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;820&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;2020&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;651&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left"&gt;Thereafter&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;3,045&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total minimum payments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,908&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of December&amp;nbsp;31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style=" margin: 0"&gt;Work in process&lt;/div&gt; &lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;267&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;416&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Net inventories&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;683&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-33">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;First&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Second&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Third&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fourth&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;2015 Quarters&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 48%; font-size: 10pt; padding-left: 10pt"&gt;Revenues&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;6,826&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;25,842&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;10,987&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;4,602&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Net (Loss) Income&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(15,164&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,901&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(14,621&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(18,135&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Basic net (loss) income per share&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(0.21&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.07&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(0.20&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(0.25&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Diluted net (loss) income per share&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(0.21&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.06&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(0.20&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(0.25&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;2014 Quarters&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Revenues&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,458&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,466&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,238&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,446&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Net Loss&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(10,137&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(14,649&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(8,731&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(11,672&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Basic and diluted net loss per share&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(0.17&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(0.23&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(0.12&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(0.16&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-26">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Awards&lt;br /&gt; Available&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Options&lt;br /&gt; Outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-size: 10pt"&gt;Balance at December&amp;nbsp;31, 2012&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,815&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;8,073&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;6.09&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(310&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;53&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(3,277&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,277&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3.05&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(563&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2.37&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,801&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(1,801&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;7.22&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;Balance at December&amp;nbsp;31, 2013&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,082&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;8,986&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4.99&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Plan amendment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,750&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(593&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(1,965&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,965&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;10.99&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(1,258&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4.78&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;88&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(88&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;8.83&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Balance at December&amp;nbsp;31, 2014&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,362&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;9,605&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;6.21&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(163&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(2,217&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,217&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;11.52&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(1,118&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4.36&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;33&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(33&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;9.87&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance at December&amp;nbsp;31, 2015&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;16&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;10,671&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right"&gt;7.50&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-29">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Non-Vested&lt;br /&gt; Stock Option&lt;br /&gt; Awards&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted Average&lt;br /&gt; Grant-Date Fair&lt;br /&gt; Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 67%; font-size: 10pt"&gt;Balance December&amp;nbsp;31, 2014&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;4,385&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;4.27&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,217&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;7.72&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Stock option awards vested&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(1,711&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2.63&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Stock option awards forfeited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(28&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;6.39&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance December&amp;nbsp;31, 2015&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,863&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6.40&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-27">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-size: 10pt; text-align: left"&gt;Expected Life&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5.5&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;5.5&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;4.7&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Volatility&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;81&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;87&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;84&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Dividend Yield&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-Free Interest Rate&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1.6&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1.6&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.7&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-31">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 70%; font-size: 10pt"&gt;Balance at January&amp;nbsp;1,&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;472&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;284&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Additions to current period tax positions&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,616&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;176&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Additions to prior period tax positions&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;12&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reductions to prior period tax provisions&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(3&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance at December&amp;nbsp;31,&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;3,085&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;472&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656056" unitRef="iso4217-usd">13047000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656057" unitRef="iso4217-usd">7461000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656058" unitRef="iso4217-usd">6007000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656103" unitRef="iso4217-usd">9705000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656104" unitRef="iso4217-usd">10177000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656105" unitRef="iso4217-usd">4368000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" id="c3656893">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember" id="c3656895">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656445" unitRef="xbrli-shares">53000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656484" unitRef="xbrli-shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656442" unitRef="xbrli-shares">310000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656463" unitRef="xbrli-shares">593000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656481" unitRef="xbrli-shares">163000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c3656994" unitRef="iso4217-usd-per-xbrli-shares">4.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c3656995" unitRef="iso4217-usd-per-xbrli-shares">4.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2013-01-01_2013-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c3656996" unitRef="iso4217-usd-per-xbrli-shares">1.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2015-01-01_2015-12-31" decimals="3" id="c3656505" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2014-01-01_2014-12-31" decimals="3" id="c3656506" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2013-01-01_2013-12-31" decimals="3" id="c3656507" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2015-01-01_2015-12-31" decimals="3" id="c3656502" unitRef="xbrli-pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2014-01-01_2014-12-31" decimals="3" id="c3656503" unitRef="xbrli-pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2013-01-01_2013-12-31" decimals="3" id="c3656504" unitRef="xbrli-pure">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2015-01-01_2015-12-31" decimals="3" id="c3656508" unitRef="xbrli-pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2014-01-01_2014-12-31" decimals="3" id="c3656509" unitRef="xbrli-pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2013-01-01_2013-12-31" decimals="3" id="c3656510" unitRef="xbrli-pure">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c3656971" unitRef="xbrli-shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="i_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c3656965" unitRef="xbrli-shares">1475000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c3656966" unitRef="xbrli-shares">497000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2012-12-31" decimals="-3" id="c3656439" unitRef="xbrli-shares">2815000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2013-12-31" decimals="-3" id="c3656457" unitRef="xbrli-shares">1082000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2014-12-31" decimals="-3" id="c3656478" unitRef="xbrli-shares">2362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2015-12-31" decimals="-3" id="c3656496" unitRef="xbrli-shares">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2013-12-31" decimals="INF" id="c3656459" unitRef="iso4217-usd-per-xbrli-shares">4.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2014-12-31" decimals="INF" id="c3656480" unitRef="iso4217-usd-per-xbrli-shares">6.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2015-12-31" decimals="INF" id="c3656498" unitRef="iso4217-usd-per-xbrli-shares">7.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="0" id="c3656934" unitRef="iso4217-usd">10117000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-IncentivePlanMember" decimals="0" id="c3656936" unitRef="iso4217-usd">8522000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="d_2013-01-01_2013-12-31_PlanNameAxis-IncentivePlanMember" decimals="0" id="c3656938" unitRef="iso4217-usd">738000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656455" unitRef="xbrli-shares">1801000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656476" unitRef="xbrli-shares">88000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656494" unitRef="xbrli-shares">33000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2013-01-01_2013-12-31" decimals="INF" id="c3656456" unitRef="iso4217-usd-per-xbrli-shares">7.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c3656477" unitRef="iso4217-usd-per-xbrli-shares">8.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c3656495" unitRef="iso4217-usd-per-xbrli-shares">9.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656580" unitRef="xbrli-shares">28000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656449" unitRef="xbrli-shares">3277000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656470" unitRef="xbrli-shares">1965000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656488" unitRef="xbrli-shares">2217000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="-3" id="c3656897" unitRef="xbrli-shares">1032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="-3" id="c3656898" unitRef="xbrli-shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656576" unitRef="xbrli-shares">2217000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c3656927" unitRef="iso4217-usd-per-xbrli-shares">7.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c3656928" unitRef="iso4217-usd-per-xbrli-shares">8.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2013-01-01_2013-12-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c3656929" unitRef="iso4217-usd-per-xbrli-shares">1.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c3656577" unitRef="iso4217-usd-per-xbrli-shares">7.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="0" id="c3678544" unitRef="iso4217-usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2012-12-31" decimals="-3" id="c3656440" unitRef="xbrli-shares">8073000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2013-12-31" decimals="-3" id="c3656458" unitRef="xbrli-shares">8986000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2014-12-31" decimals="-3" id="c3656479" unitRef="xbrli-shares">9605000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2015-12-31" decimals="-3" id="c3656497" unitRef="xbrli-shares">10671000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2012-12-31" decimals="INF" id="c3656441" unitRef="iso4217-usd-per-xbrli-shares">6.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-28">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="9" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Outstanding&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Exercisable&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="2"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; text-decoration: underline;"&gt;Range&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Number&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Remaining &lt;br /&gt; Life&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Number&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 1%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; width: 3%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,826&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.4&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1.51&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,322&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1.55&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;2,792&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.1&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;4.63&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;2,329&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;4.53&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;9&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,153&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;4.5&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;7.10&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,070&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;7.13&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;9&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;3,728&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;8.1&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;11.07&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;714&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;11.45&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;1,077&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.4&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12.44&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;374&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;12.65&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;18&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right; padding-bottom: 1.1pt; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;95&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;9.5&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;15.39&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;to&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;18&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right; padding-bottom: 2.25pt; border-bottom: Black 2.25pt double"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;10,671&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;6.7&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;7.50&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;5,809&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;5.70&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="i_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c3656952" unitRef="xbrli-shares">9633000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c3656953" unitRef="iso4217-usd-per-xbrli-shares">7.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656460" unitRef="xbrli-shares">3750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2013-01-01_2013-12-31" decimals="INF" id="c3656453" unitRef="iso4217-usd-per-xbrli-shares">2.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c3656474" unitRef="iso4217-usd-per-xbrli-shares">4.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c3656492" unitRef="iso4217-usd-per-xbrli-shares">4.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2013-01-01_2013-12-31" decimals="INF" id="c3656450" unitRef="iso4217-usd-per-xbrli-shares">3.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c3656471" unitRef="iso4217-usd-per-xbrli-shares">10.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c3656489" unitRef="iso4217-usd-per-xbrli-shares">11.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2015-01-01_2015-12-31" id="c4074457">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; has occurred.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" decimals="-1" id="c4072561" unitRef="xbrli-shares">1550</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" decimals="-1" id="c4072568" unitRef="xbrli-shares">4530</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" decimals="-1" id="c4072575" unitRef="xbrli-shares">7130</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" decimals="-1" id="c4072582" unitRef="xbrli-shares">11450</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" decimals="-1" id="c4072589" unitRef="xbrli-shares">12650</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" id="c4072596" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2015-12-31" decimals="-1" id="c4072603" unitRef="xbrli-shares">5700</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" decimals="-1" id="c4072558" unitRef="xbrli-shares">6400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" decimals="-1" id="c4072565" unitRef="xbrli-shares">6100</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" decimals="-1" id="c4072572" unitRef="xbrli-shares">4500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" decimals="-1" id="c4072579" unitRef="xbrli-shares">8100</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" decimals="-1" id="c4072586" unitRef="xbrli-shares">6400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" decimals="-1" id="c4072593" unitRef="xbrli-shares">9500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2015-12-31" decimals="-1" id="c4072600" unitRef="xbrli-shares">6700</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" decimals="INF" id="c4072557" unitRef="iso4217-usd-per-xbrli-shares">1826</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" decimals="INF" id="c4072564" unitRef="iso4217-usd-per-xbrli-shares">2792</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" decimals="INF" id="c4072571" unitRef="iso4217-usd-per-xbrli-shares">1153</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" decimals="INF" id="c4072578" unitRef="iso4217-usd-per-xbrli-shares">3728</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" decimals="INF" id="c4072585" unitRef="iso4217-usd-per-xbrli-shares">1077</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" decimals="INF" id="c4072592" unitRef="iso4217-usd-per-xbrli-shares">95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c4072599" unitRef="iso4217-usd-per-xbrli-shares">10671</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharePrice contextRef="i_2013-08-31" decimals="INF" id="c3656863" unitRef="iso4217-usd-per-xbrli-shares">4.40</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="i_2012-12-31" decimals="INF" id="c3656871" unitRef="iso4217-usd-per-xbrli-shares">4.08</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="i_2013-12-31" decimals="INF" id="c3656875" unitRef="iso4217-usd-per-xbrli-shares">1.85</us-gaap:SharePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" decimals="INF" id="c3656892" unitRef="xbrli-pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember" decimals="INF" id="c3656894" unitRef="xbrli-pure">0.5</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2015-01-01_2015-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c3656899" unitRef="xbrli-pure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2015-01-01_2015-12-31" id="c3656499">P5Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2014-01-01_2014-12-31" id="c3656500">P5Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2013-01-01_2013-12-31" id="c3656501">P4Y255D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="i_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="0" id="c3656945" unitRef="iso4217-usd">28511000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MinimumMember" id="c3656919">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember" id="c3656920">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-IncentivePlanMember" id="c3656943">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2014-12-31" decimals="-3" id="c3656574" unitRef="xbrli-shares">4385000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31" decimals="-3" id="c3656582" unitRef="xbrli-shares">4863000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c3656581" unitRef="iso4217-usd-per-xbrli-shares">6.39</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="i_2014-12-31" decimals="INF" id="c3656575" unitRef="iso4217-usd-per-xbrli-shares">4.27</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="i_2015-12-31" decimals="INF" id="c3656583" unitRef="iso4217-usd-per-xbrli-shares">6.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-IncentivePlanMember" id="c3656954">P6Y219D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="0" id="c3656946" unitRef="iso4217-usd">4492000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-IncentivePlanMember" decimals="0" id="c3656948" unitRef="iso4217-usd">2844000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2013-01-01_2013-12-31_PlanNameAxis-IncentivePlanMember" decimals="0" id="c3656950" unitRef="iso4217-usd">3483000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656578" unitRef="xbrli-shares">1711000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c3656579" unitRef="iso4217-usd-per-xbrli-shares">2.63</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" decimals="INF" id="c4072560" unitRef="iso4217-usd-per-xbrli-shares">1322</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" decimals="INF" id="c4072567" unitRef="iso4217-usd-per-xbrli-shares">2329</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" decimals="INF" id="c4072574" unitRef="iso4217-usd-per-xbrli-shares">1070</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" decimals="INF" id="c4072581" unitRef="iso4217-usd-per-xbrli-shares">714</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" decimals="INF" id="c4072588" unitRef="iso4217-usd-per-xbrli-shares">374</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" id="c4072595" unitRef="iso4217-usd-per-xbrli-shares" xs:nil="true"/>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2015-12-31" decimals="INF" id="c4072602" unitRef="iso4217-usd-per-xbrli-shares">5809</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" id="c4072559">P1Y186D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" id="c4072566">P4Y229D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" id="c4072573">P7Y36D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" id="c4072580">P11Y25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" id="c4072587">P12Y160D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" id="c4072594">P15Y142D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2015-01-01_2015-12-31" id="c4072601">P7Y182D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2015-01-01_2015-12-31" id="s131690">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;1&amp;nbsp;&amp;#x2014; Significant Accounting Policies and Concentrations of Risk&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#x201c;Company&amp;#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash, restricted cash and investments of $100,858, to continue its planned operations through mid-2017. The Company&amp;#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017 it will need to: (1)&amp;nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&amp;nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&amp;nbsp;raise additional capital through equity or debt financings or from other sources; (4)&amp;nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&amp;nbsp;reduce spending on one or more research and development programs; and/or (6)&amp;nbsp;restructure operations. The Company may issue securities through private placement transactions or registered public offerings pursuant to a registration statement filed with the SEC.&amp;nbsp;&amp;nbsp;Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) on November&amp;nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Beginning in March 2011, the consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&amp;#x201c;Royalty Sub&amp;#x201d;). Royalty Sub was formed in connection with a $30,000&amp;nbsp;financing transaction the Company completed on March&amp;nbsp;9, 2011. See Note 3, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201c;U.S. GAAP&amp;#x201d;). Such consolidated financial statements reflect all adjustments that are, in management&amp;#x2019;s opinion, necessary to present fairly, in all material respects, the Company&amp;#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Reclassifications&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Long term deferred rent as of December 31, 2014 has been reclassified to conform to the 2015 presentation.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Restricted cash as of December 31, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $59 in royalty revenue paid by Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;) designated for interest on the PhaRMA Notes (defined in Note 3) and $1,403 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 58; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;          &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At December 31, 2015, the Company believes that the costs of its investments are recoverable in all material respects.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The following tables summarize the fair value of the Company&amp;#x2019;s investments by type. The estimated fair value of the Company&amp;#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2015&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair Value&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;26,557&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;88&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(99&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;26,546&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;21,820&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;184&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(41&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;21,963&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,884&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(72&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,838&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,261&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;293&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(212&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair Value&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of U.S. Government and its agencies&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;20,307&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;22&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(23&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;20,306&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;27,152&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;151&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;5&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(47&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;27,261&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Commercial paper&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11,838&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;6&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(63&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11,781&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,297&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;179&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(133&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,348&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The following table summarizes the scheduled maturity for the Company&amp;#x2019;s investments at December&amp;nbsp;31, 2015 and 2014.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;22,664&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;18,232&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;28,395&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;25,459&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Maturing after two years&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;19,288&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;15,657&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;59,348&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;      &lt;!-- Field: Page; Sequence: 59; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;          &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;    &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivable from Collaborations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi and Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At December&amp;nbsp;31, 2015 and 2014, the Company had the following receivables.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;210&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;238&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;679&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5,564&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,243&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;    &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; width: 52%"&gt;U.S. Department of Health and Human Services&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,071&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,778&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;3,849&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Product Sales&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;At December&amp;nbsp;31, 2015 and 2014, the Company&amp;#x2019;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&amp;#x201c;FIFO&amp;#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;During 2014, in connection with the FDA approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s inventory consisted of the following:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of December&amp;nbsp;31,&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;&lt;div style=" margin: 0"&gt;Work in process&lt;/div&gt; &lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;267&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;416&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Net inventories&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;683&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;      &lt;!-- Field: Page; Sequence: 60; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the remaining lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period of ten years equal to the term of the related lease&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patents and Licenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt;       &lt;tr&gt;     &lt;td style="width: 5%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 2%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 92%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to Clinical Research Organizations (&amp;#x201c;CROs&amp;#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/div&gt;&lt;/td&gt;    &lt;/tr&gt;    &lt;tr&gt;     &lt;td style="padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt;       &lt;tr&gt;     &lt;td style="width: 5%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 2%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 92%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/div&gt;&lt;/td&gt;    &lt;/tr&gt;    &lt;tr&gt;     &lt;td style="padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt;       &lt;tr&gt;     &lt;td style="width: 5%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 2%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 92%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&amp;nbsp;and&lt;/div&gt;&lt;/td&gt;    &lt;/tr&gt;    &lt;tr&gt;     &lt;td style="padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt;       &lt;tr&gt;     &lt;td style="width: 5%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 2%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 92%; padding-right: 0.8pt"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;professional fees.&lt;/div&gt;&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 61; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; text-align: center; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;Accrued expenses were comprised of the following:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 67%; font-size: 10pt; text-align: left"&gt;Compensation and benefits&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;424&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;2,105&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Development costs&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;10,398&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;4,232&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;Inventory&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;549&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;397&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Professional fees&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;242&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;238&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Duties and taxes&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;102&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;75&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,522&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,282&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Total accrued expenses&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;16,237&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;11,329&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;As of December 31, 2015 and 2014, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The liability method is used in the Company&amp;#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accumulated Other Comprehensive Loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&amp;#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During 2015, realized gains of $13 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded during 2014.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;nbsp;persuasive evidence of an arrangement exists; (ii)&amp;nbsp;delivery has occurred or services have been rendered; (iii)&amp;nbsp;the seller&amp;#x2019;s price to the buyer is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Under certain of the Company&amp;#x2019;s license agreements, the Company receives royalty payments based upon its licensees&amp;#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &amp;#x201c;stand-alone value&amp;#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&amp;#x201c;TPE&amp;#x201d;) and (iii) best estimate of selling price (&amp;#x201c;BESP&amp;#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&amp;nbsp;&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 62; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; text-align: center; margin: 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In June 2015, the Company entered into a License Agreement (the &amp;#x201c;SUL Agreement&amp;#x201d;) granting Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;) and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&amp;#x201c;EU&amp;#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&amp;#x201c;Health Canada&amp;#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, &lt;div style="display: inline; font-style: italic;"&gt;Milestone Method of Revenue Recognition&lt;/div&gt;, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&amp;#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#x201d;BARDA/HHS&amp;#x201d;) and the National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Sales&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&amp;nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be primarily responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales, and the Company&amp;#x2019;s commercial sales will be minimal.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&amp;nbsp;&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 63; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Rebates and Chargebacks&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&amp;#x2019;s selling price.&amp;nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&amp;#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&amp;#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Discounts and Sales Incentives&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Discounts and other sales incentives primarily consist of Inventory Management Agreement (&amp;#x201c;IMA&amp;#x201d;) Fees. Per contractual agreements with the Company&amp;#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Returns&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recorded the following revenues for the years ended December&amp;nbsp;31:&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;6,291&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;33&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2,386&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;3,025&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2,562&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;16,337&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;9,366&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;13,585&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Green Cross Corporation&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;132&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Shionogi (Japan)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,184&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,184&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,184&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Seqirus UK Limited&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,927&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;39,580&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;10,550&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;14,769&lt;/td&gt;      &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;48,257&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;13,608&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;17,331&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Advertising&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred. Advertising and product promotion expenses were $103 and $290 for the years ended December&amp;nbsp;31, 2015 and 2014, respectively.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#x2019;s on-going review of the level of services actually performed.&amp;nbsp;&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 64; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#x201c;AECOM&amp;#x201d;), Industrial Research, Ltd. (&amp;#x201c;IRL&amp;#x201d;), and the University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&amp;#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; has occurred.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Interest Expense and Deferred Financing Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Interest expense for the years ended December&amp;nbsp;31, 2015, 2014 and 2013 was $5,200, $4,998 and $4,778, respectively, and relates to the issuance of the PhaRMA Notes. Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other non-current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $439 for each of the years ended December&amp;nbsp;31, 2015, 2014 and 2013.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Currency Hedge Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the years ended December&amp;nbsp;31, 2015, 2014 and 2013 resulted in a loss of $564 and gains of $5,487 and $5,294, respectively. Mark to market adjustments are determined by a third party pricing model which uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. In addition, a realized currency exchange gain of $1,654 was recognized in 2015 related to the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of December 31, 2015 and December&amp;nbsp;31, 2014, no hedge collateral was posted under the agreement.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&amp;#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the years ended December&amp;nbsp;31, 2015, 2014, and 2013 does not include 3,524, 3,991 and 1,430 respectively, of potential common shares as their impact would be anti-dilutive.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&amp;nbsp;&lt;/div&gt;      &lt;!-- Field: Page; Sequence: 65; Value: 3 --&gt;      &lt;!-- Field: /Page --&gt;        &lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Significant Customers and Other Risks&lt;/div&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Prior to the SUL Agreement, the Company relied primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&amp;#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&amp;#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&amp;#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&amp;#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#x2019;s ability to complete its drug development activities.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/div&gt; &amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Credit Risk&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&amp;#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3657145" unitRef="xbrli-shares">89000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3657160" unitRef="xbrli-shares">49000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3657175" unitRef="xbrli-shares">41000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c3656976" unitRef="xbrli-shares">41000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c3656977" unitRef="xbrli-shares">49000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2013-01-01_2013-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c3656978" unitRef="xbrli-shares">89000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3657150" unitRef="xbrli-shares">7547000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3657165" unitRef="xbrli-shares">11500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2014-06-03_2014-06-03" decimals="-3" id="c3656857" unitRef="xbrli-shares">11500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2013-08-01_2013-08-31" decimals="-3" id="c3656862" unitRef="xbrli-shares">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2012-01-01_2012-12-31" decimals="-3" id="c3656870" unitRef="xbrli-shares">4516000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656874" unitRef="xbrli-shares">2883000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3657140" unitRef="xbrli-shares">348000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3657155" unitRef="xbrli-shares">1314000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3657170" unitRef="xbrli-shares">1359000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656452" unitRef="xbrli-shares">563000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656473" unitRef="xbrli-shares">1258000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656491" unitRef="xbrli-shares">1118000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3656198" unitRef="iso4217-usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656199" unitRef="iso4217-usd">123000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656202" unitRef="iso4217-usd">124000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3656233" unitRef="iso4217-usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656234" unitRef="iso4217-usd">309000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656237" unitRef="iso4217-usd">310000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656269" unitRef="iso4217-usd">355000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656272" unitRef="iso4217-usd">355000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3656203" unitRef="iso4217-usd">75000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656204" unitRef="iso4217-usd">23559000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656207" unitRef="iso4217-usd">23634000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3656238" unitRef="iso4217-usd">115000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656239" unitRef="iso4217-usd">106485000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656242" unitRef="iso4217-usd">106600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3656193" unitRef="iso4217-usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656194" unitRef="iso4217-usd">1327000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656197" unitRef="iso4217-usd">1333000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3656228" unitRef="iso4217-usd">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656229" unitRef="iso4217-usd">4984000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656232" unitRef="iso4217-usd">4997000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3656263" unitRef="iso4217-usd">14000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656264" unitRef="iso4217-usd">5110000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656267" unitRef="iso4217-usd">5124000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockholdersEquity contextRef="i_2012-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3656178" unitRef="iso4217-usd">509000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2012-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656179" unitRef="iso4217-usd">391611000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2012-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c3656180" unitRef="iso4217-usd">27000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2012-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c3656181" unitRef="iso4217-usd">-392601000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2012-12-31" decimals="-3" id="c3656182" unitRef="iso4217-usd">-454000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3656213" unitRef="iso4217-usd">591000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656214" unitRef="iso4217-usd">420988000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c3656215" unitRef="iso4217-usd">4000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c3656216" unitRef="iso4217-usd">-422709000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31" decimals="-3" id="c3656217" unitRef="iso4217-usd">-1126000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3656248" unitRef="iso4217-usd">720000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656249" unitRef="iso4217-usd">542943000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c3656250" unitRef="iso4217-usd">-130000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c3656251" unitRef="iso4217-usd">-467898000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31" decimals="-3" id="c3656252" unitRef="iso4217-usd">75635000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c3656278" unitRef="iso4217-usd">734000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c3656279" unitRef="iso4217-usd">558113000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c3656280" unitRef="iso4217-usd">-206000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c3656281" unitRef="iso4217-usd">-510917000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31" decimals="-3" id="c3656282" unitRef="iso4217-usd">47724000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2015-01-01_2015-12-31" id="s131704">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note&amp;nbsp;5&amp;nbsp;&amp;#x2014; Stockholders&amp;#x2019; Equity&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Sales of Common Stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company intends to file a post-effective amendment to this registration statement, which will allow for its use by the Company when declared effective by the SEC&amp;#x2019;s staff.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;On November&amp;nbsp;6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows us to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. On June 3, 2014, the Company issued 11,500 shares of common stock for gross proceeds of $115,000 under this $125,000 shelf registration statement. Net proceeds were approximately $107,800 after deducting underwriting discounts and offering expenses. The Company has $10,000 remaining under this shelf registration statement&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;In August 2013, the Company completed a public offering of 4,600 shares of its common stock at a price of $4.40 per share, which included the underwriters&amp;#x2019; over-allotment allocation of an additional 600 shares. Net proceeds were approximately $18,500 after deducting underwriting discounts and offering expenses. Shares of common stock in this offering were sold under the $70,000 shelf registration statement declared effective in July 2011.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;In June 2011, the Company entered into an At Market Issuance Sales Agreement (the &amp;#x201c;ATM Agreement&amp;#x201d;) with McNicoll, Lewis&amp;nbsp;&amp;amp; Vlak (&amp;#x201c;MLV&amp;#x201d;) pursuant to which the Company was able to sell $70,000 in shares of its common stock at current market prices under a Form S-3 registration statement with MLV acting as the sales agent. During 2012, the Company sold an aggregate of 4,516 shares of common stock at an average per share price of $4.08 pursuant to the ATM Agreement for net proceeds of $17,805. During 2013, the Company sold an aggregate of 2,883 shares of common stock at an average per share price of $1.85 pursuant to the Agreement for net proceeds of $5,218.&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="i_2015-12-31_TaxCreditCarryforwardAxis-ResearchMember" decimals="0" id="c3657012" unitRef="iso4217-usd">48551000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxesPayableCurrent contextRef="i_2015-12-31" decimals="-3" id="c3656370" unitRef="iso4217-usd">102000</us-gaap:TaxesPayableCurrent>
  <us-gaap:TaxesPayableCurrent contextRef="i_2014-12-31" decimals="-3" id="c3656371" unitRef="iso4217-usd">75000</us-gaap:TaxesPayableCurrent>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2014-12-31" decimals="-3" id="c3656611" unitRef="iso4217-usd">472000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2013-12-31" decimals="-3" id="c3656612" unitRef="iso4217-usd">284000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2015-12-31" decimals="-3" id="c3656619" unitRef="iso4217-usd">3085000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="d_2015-01-01_2015-12-31" id="c3656615" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656616" unitRef="iso4217-usd">12000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="i_2015-12-31" decimals="0" id="c3686251" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="i_2014-12-31" decimals="0" id="c3657023" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="i_2013-12-31" decimals="0" id="c3657024" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656613" unitRef="iso4217-usd">2616000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656614" unitRef="iso4217-usd">176000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UseOfEstimates contextRef="d_2015-01-01_2015-12-31" id="c4074461">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c3656083" unitRef="xbrli-shares">72901000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2014-01-01_2014-12-31" decimals="-3" id="c3656084" unitRef="xbrli-shares">66773000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2013-01-01_2013-12-31" decimals="-3" id="c3656085" unitRef="xbrli-shares">55216000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="utr-sqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="iso4217-jpy">
    <xbrli:measure>iso4217:JPY</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="d_2006-02-01_2006-02-28_TypeOfArrangementAxis-MundipharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-02-01</xbrli:startDate>
      <xbrli:endDate>2006-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-06-01</xbrli:startDate>
      <xbrli:endDate>2006-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2007-01-01_2007-01-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>
      <xbrli:endDate>2007-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2007-01-01_2011-02-24_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>
      <xbrli:endDate>2011-02-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2009-09-01_2009-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-09-01</xbrli:startDate>
      <xbrli:endDate>2009-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2010-05-01_2010-05-31_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-05-01</xbrli:startDate>
      <xbrli:endDate>2010-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-02-01_2011-02-24_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>
      <xbrli:endDate>2011-02-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2012-01-01_2012-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_CounterpartyNameAxis-CSLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_CounterpartyNameAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_LongtermDebtTypeAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-08-01_2013-08-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>
      <xbrli:endDate>2013-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>
      <xbrli:endDate>2013-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-09-01_2013-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-11-06_2013-11-06">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-11-06</xbrli:startDate>
      <xbrli:endDate>2013-11-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_CounterpartyNameAxis-CSLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_CounterpartyNameAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_LongtermDebtTypeAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-03-01_2014-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-03-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-04-01_2014-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-06-01_2014-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-06-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-06-03_2014-06-03">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-06-03</xbrli:startDate>
      <xbrli:endDate>2014-06-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-07-01_2014-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-08-01_2014-08-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-08-01</xbrli:startDate>
      <xbrli:endDate>2014-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-10-01_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-10-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-09-30_TypeOfArrangementAxis-ASPRBARDAContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:August2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:StockOptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest50PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_ProductOrServiceAxis-RAPIVABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_CounterpartyNameAxis-CSLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_CounterpartyNameAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_LongtermDebtTypeAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange01Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange02Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange03Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange04Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange05Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange06Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_StatementScenarioAxis-ContingentUponEuMarketingApprovalMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">bcrx:ContingentUponEuMarketingApprovalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-16</xbrli:startDate>
      <xbrli:endDate>2015-06-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-07-01_2015-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-10-01_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2006-02-28_DeferredRevenueArrangementTypeAxis-UpfrontPaymentMember_TypeOfArrangementAxis-MundipharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:UpfrontPaymentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2006-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2007-12-31_DeferredRevenueArrangementTypeAxis-ClinicalTrial2007Member_TypeOfArrangementAxis-MundipharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:ClinicalTrial2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2007-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-07-13">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-07-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-11-11_TypeOfArrangementAxis-MundipharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-11-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2012-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2012-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2012-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2012-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2012-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-08-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-09-03_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-11-06">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-11-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_StatementScenarioAxis-Shortfall2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">bcrx:Shortfall2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bcrx:CollaborationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_DeferredRevenueArrangementTypeAxis-DeferredCollaborativeRevenueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredCollaborativeRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_DeferredRevenueArrangementTypeAxis-DeferredProductSalesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredProductSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_FairValueByLiabilityClassAxis-DevelopmentCostMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bcrx:DevelopmentCostMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_InvestmentTypeAxis-CommercialPaperMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-LeasedEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LeasedEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_CurrencyAxis-JapanYenMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">bcrx:JapanYenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bcrx:CollaborationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-CSLLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-CSLLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-CSLLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_BalanceSheetLocationAxis-LongTermLiabilitiesMember_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:LongTermLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_DeferredRevenueArrangementTypeAxis-DeferredCollaborativeRevenueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredCollaborativeRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_DeferredRevenueArrangementTypeAxis-DeferredProductSalesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredProductSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_FairValueByLiabilityClassAxis-DevelopmentCostMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bcrx:DevelopmentCostMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LeasedEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LeasedEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange01Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange02Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange03Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange04Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange05Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange06Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_TaxCreditCarryforwardAxis-ResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-01-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>bcrx-20151231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 05:41PM UTC 2016-02-26--><xsd:schema xmlns:bcrx="http://www.biocryst.com/20151231" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biocryst.com/20151231">
  <xsd:import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-roles/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-roles-2015-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20151231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20151231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20151231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20151231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.biocryst.com/20151231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-comprehensive-loss" roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-comprehensive-loss">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity" roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity-parentheticals" roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk" roleURI="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-furniture-and-equipment" roleURI="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 2 - Furniture and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-royalty-monetization" roleURI="http://www.biocryst.com/20151231/role/statement-note-3-royalty-monetization">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 3 - Royalty Monetization</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-lease-obligations-and-other-contingencies" roleURI="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 4 - Lease Obligations and Other Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity" roleURI="http://www.biocryst.com/20151231/role/statement-note-5-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 5 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockbased-compensation" roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 6 - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-income-taxes" roleURI="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 7 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-employee-401k-plan" roleURI="http://www.biocryst.com/20151231/role/statement-note-8-employee-401k-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 8 - Employee 401(k) Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-collaborative-and-other-research-and-development-contracts" roleURI="http://www.biocryst.com/20151231/role/statement-note-9-collaborative-and-other-research-and-development-contracts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 9 - Collaborative and Other Research and Development Contracts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-quarterly-financial-information-unaudited" roleURI="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 10 - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-recent-accounting-pronouncements" roleURI="http://www.biocryst.com/20151231/role/statement-note-11-recent-accounting-pronouncements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Document - Note 11 - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.biocryst.com/20151231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" roleURI="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-furniture-and-equipment-tables" roleURI="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 2 - Furniture and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-lease-obligations-and-other-contingencies-tables" roleURI="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 4 - Lease Obligations and Other Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockbased-compensation-tables" roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 6 - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-income-taxes-tables" roleURI="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 7 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-quarterly-financial-information-unaudited-tables" roleURI="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 10 - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" roleURI="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-fair-value-of-the-companys-investments-by-type-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Statement - Note 1 - Fair Value of the Company's Investments by Type (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-scheduled-maturity-for-the-companys-investments-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Statement - Note 1 - Scheduled Maturity for the Company's Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-summary-of-receivables-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-1-summary-of-receivables-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Statement - Note 1 - Summary of Receivables (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-inventory-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-1-inventory-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Statement - Note 1 - Inventory (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-accrued-expenses-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-1-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Statement - Note 1 - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-summary-of-revenues-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-1-summary-of-revenues-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Statement - Note 1 - Summary of Revenues (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-furniture-and-equipment-details-textual" roleURI="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 2 - Furniture and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-furniture-and-equipment-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Statement - Note 2 - Furniture and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-royalty-monetization-details-textual" roleURI="http://www.biocryst.com/20151231/role/statement-note-3-royalty-monetization-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 3 - Royalty Monetization (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-lease-obligations-and-other-contingencies-details-textual" roleURI="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 4 - Lease Obligations and Other Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-minimum-payments-under-operating-lease-obligations-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-4-minimum-payments-under-operating-lease-obligations-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Statement - Note 4 - Minimum Payments under Operating Lease Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity-details-textual" roleURI="http://www.biocryst.com/20151231/role/statement-note-5-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 5 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockbased-compensation-details-textual" roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 6 - Stock-Based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockbased-compensation-allocation-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-allocation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Statement - Note 6 - Stock-based Compensation Allocation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stock-incentive-plan-activities-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stock-incentive-plan-activities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Statement - Note 6 - Stock Incentive Plan Activities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Statement - Note 6 - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Statement - Note 6 - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Statement - Note 6 - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-income-taxes-details-textual" roleURI="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 7 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Statement - Note 7 - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" roleURI="http://www.biocryst.com/20151231/role/statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Statement - Note 7 - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Statement - Note 7 - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-7-components-of-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Statement - Note 7 - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-employee-401k-plan-details-textual" roleURI="http://www.biocryst.com/20151231/role/statement-note-8-employee-401k-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 8 - Employee 401(k) Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-collaborative-and-other-research-and-development-contracts-details-textual" roleURI="http://www.biocryst.com/20151231/role/statement-note-9-collaborative-and-other-research-and-development-contracts-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 9 - Collaborative and Other Research and Development Contracts (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-quarterly-financial-information-unaudited-details" roleURI="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Statement - Note 10 - Quarterly Financial Information (Unaudited) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="bcrx_AECOMAndIRLMember" name="AECOMAndIRLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ASPRBARDAContractMember" name="ASPRBARDAContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AccruedDevelopmentCosts" name="AccruedDevelopmentCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AccruedExpensesPolicyTextBlock" name="AccruedExpensesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AccruedInventoryExpense" name="AccruedInventoryExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_AdditionalDevelopmentOptionsMember" name="AdditionalDevelopmentOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" name="AdvanceNoticePeriodForTerminationOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AgreementMember" name="AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMaximum" name="AnnualLicenseFeeMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMinimum" name="AnnualLicenseFeeMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_August2013Member" name="August2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesAccruedInterest" name="AvailableForSaleSecuritiesAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" name="AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" name="AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AveragematurityForPortfolioInvestments" name="AveragematurityForPortfolioInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" name="AveragematurityPeriodOfHighQualityMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BaseContractMember" name="BaseContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BirminghamResearchFacilityMember" name="BirminghamResearchFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLLimitedMember" name="CSLLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLMember" name="CSLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ClinicalTrial2007Member" name="ClinicalTrial2007Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborationAgreementAdditionalPaymentsReceived" name="CollaborationAgreementAdditionalPaymentsReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_CollaborationReceivablesMember" name="CollaborationReceivablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementAdditionalContractValue" name="CollaborativeAgreementAdditionalContractValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementAdjustedContractValue" name="CollaborativeAgreementAdjustedContractValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementContractValue" name="CollaborativeAgreementContractValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementPeriodOfcontract" name="CollaborativeAgreementPeriodOfcontract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAndOtherResearchAndDevelopment" name="CollaborativeAndOtherResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" name="CollaborativeAndOtherResearchAndDevelopmentRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollateralForCreditMember" name="CollateralForCreditMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CommonStockToBeIssuedValue" name="CommonStockToBeIssuedValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" name="ConcentrationOfMarketRiskPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ContingentUponEuMarketingApprovalMember" name="ContingentUponEuMarketingApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CurrencyDomain" name="CurrencyDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CurrencyHedgeAgreementMember" name="CurrencyHedgeAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CurrencyHedgeAgreementPolicyTextBlock" name="CurrencyHedgeAgreementPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_December2014Member" name="December2014Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DeferredCollaborationExpenseAssets" name="DeferredCollaborationExpenseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" name="DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DeferredCollaborativeRevenueMember" name="DeferredCollaborativeRevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DeferredProductSalesMember" name="DeferredProductSalesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DescriptionOfCompanyPolicyTextBlock" name="DescriptionOfCompanyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DevelopmentCostMember" name="DevelopmentCostMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" name="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange01Member" name="ExercisePriceRange01Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange02Member" name="ExercisePriceRange02Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange03Member" name="ExercisePriceRange03Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange04Member" name="ExercisePriceRange04Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange05Member" name="ExercisePriceRange05Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange06Member" name="ExercisePriceRange06Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" name="ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_GreenCrossCorporationMember" name="GreenCrossCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_IncentivePlanMember" name="IncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" name="IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" name="InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_Interestreserve" name="Interestreserve" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_JPRRoyaltySubLLCMember" name="JPRRoyaltySubLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_JapanYenMember" name="JapanYenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" name="LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LeaseFinancingObligationNetOfCurrent" name="LeaseFinancingObligationNetOfCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_LeasedEquipmentMember" name="LeasedEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_LongTermLiabilitiesMember" name="LongTermLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LongtermInvestmentMaturityMinimum" name="LongtermInvestmentMaturityMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityOfInvestments" name="MaturityOfInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" name="MaturityPeriodOfHighQualityMarketablesecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityperiodOfShortTermInvestment" name="MaturityperiodOfShortTermInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaximumAggregateOfferingPrice" name="MaximumAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MaximumAmountOfCollateralRequiredToPost" name="MaximumAmountOfCollateralRequiredToPost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MilestonePaymentMaximum" name="MilestonePaymentMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMinimum" name="MilestonePaymentMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_MundipharmaMember" name="MundipharmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_NumberOfMilestonesAchieved" name="NumberOfMilestonesAchieved" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_NumberOfStockbasedCompensationPlans" name="NumberOfStockbasedCompensationPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PaymentsForModificationOfLicenseAgreement" name="PaymentsForModificationOfLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" name="PercentageOfCarryingAmountInExcessOfFairValue1" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesBeginning" name="PercentageOfCommonStockSharesBeginning" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesEnding" name="PercentageOfCommonStockSharesEnding" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" name="PercentageOfSalaryToPurchaseCommonStockMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PeriodOfAgreement" name="PeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_PhaRMANotesMember" name="PhaRMANotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PotentialMilestonePaymentsReceivable" name="PotentialMilestonePaymentsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PrivatePlacementOfSeniorSecuredNotes" name="PrivatePlacementOfSeniorSecuredNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" name="ProceedsFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RAPIVABMember" name="RAPIVABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" name="ReceiptPaymentOfForeignCurrencyDerivativeCollateral" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" name="RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RemainingAggregateOfferingPrice" name="RemainingAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_RenewablePeriodOfAgreement" name="RenewablePeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RequiredForeignCurrencyHedgePerDollar" name="RequiredForeignCurrencyHedgePerDollar" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" name="RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" name="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" name="RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyMonetizationMember" name="RoyaltyMonetizationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyMonetizationTextBlock" name="RoyaltyMonetizationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyReceivableMember" name="RoyaltyReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyTerm" name="RoyaltyTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" name="ScheduleOfReceivablesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" name="ScheduleOfRevenuesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SecuritiesOffered" name="SecuritiesOffered" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" name="ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" name="SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ShionogiAndCoLtdMember" name="ShionogiAndCoLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Shortfall2013Member" name="Shortfall2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter" name="StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" name="StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_StockOptionsAndRestrictedStockMember" name="StockOptionsAndRestrictedStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_TransactionCosts" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_UABMember" name="UABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_USDepartmentOfHealthAndHumanServicesMember" name="USDepartmentOfHealthAndHumanServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_UpfrontPaymentMember" name="UpfrontPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_UpfrontPaymentsReceivableAmount" name="UpfrontPaymentsReceivableAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest25PercentEachYearUntilFullyVestedMember" name="Vest25PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest50PercentEachYearUntilFullyVestedMember" name="Vest50PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" name="VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-accrued-expenses-details" name="statement-statement-note-1-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" name="statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-inventory-details" name="statement-statement-note-1-inventory-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" name="statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" name="statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-summary-of-receivables-details" name="statement-statement-note-1-summary-of-receivables-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-summary-of-revenues-details" name="statement-statement-note-1-summary-of-revenues-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-details" name="statement-statement-note-10-quarterly-financial-information-unaudited-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-tables" name="statement-statement-note-10-quarterly-financial-information-unaudited-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-furniture-and-equipment-details" name="statement-statement-note-2-furniture-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-furniture-and-equipment-tables" name="statement-statement-note-2-furniture-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-4-lease-obligations-and-other-contingencies-tables" name="statement-statement-note-4-lease-obligations-and-other-contingencies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-4-minimum-payments-under-operating-lease-obligations-details" name="statement-statement-note-4-minimum-payments-under-operating-lease-obligations-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" name="statement-statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" name="statement-statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-6-stock-incentive-plan-activities-details" name="statement-statement-note-6-stock-incentive-plan-activities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-6-stockbased-compensation-allocation-details" name="statement-statement-note-6-stockbased-compensation-allocation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-6-stockbased-compensation-tables" name="statement-statement-note-6-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" name="statement-statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" name="statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" name="statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-7-income-taxes-tables" name="statement-statement-note-7-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" name="statement-statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>bcrx-20151231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 05:42PM UTC 2016-02-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:href="bcrx-20151231.xsd#statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20151231.xsd#statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets" xlink:href="bcrx-20151231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="bcrx_DeferredCollaborationExpenseAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:href="bcrx-20151231.xsd#statement-consolidated-statements-of-comprehensive-loss" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-cash-flows" xlink:href="bcrx-20151231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:label="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:label="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-inventory-details" xlink:href="bcrx-20151231.xsd#statement-note-1-inventory-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-inventory-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-accrued-expenses-details" xlink:href="bcrx-20151231.xsd#statement-note-1-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AccruedDevelopmentCosts" xlink:label="bcrx_AccruedDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AccruedInventoryExpense" xlink:label="bcrx_AccruedInventoryExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="bcrx_AccruedDevelopmentCosts" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="bcrx_AccruedInventoryExpense" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:href="bcrx-20151231.xsd#statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>bcrx-20151231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 05:42PM UTC 2016-02-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-11-recent-accounting-pronouncements" xlink:href="bcrx-20151231.xsd#statement-note-11-recent-accounting-pronouncements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-11-recent-accounting-pronouncements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited" xlink:href="bcrx-20151231.xsd#statement-note-10-quarterly-financial-information-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-document-and-entity-information" xlink:href="bcrx-20151231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="bcrx-20151231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:href="bcrx-20151231.xsd#statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:href="bcrx-20151231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment" xlink:href="bcrx-20151231.xsd#statement-note-2-furniture-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-3-royalty-monetization" xlink:href="bcrx-20151231.xsd#statement-note-3-royalty-monetization" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-3-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Shortfall2013Member" xlink:label="bcrx_Shortfall2013Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_Shortfall2013Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_CurrencyDomain" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies" xlink:href="bcrx-20151231.xsd#statement-note-4-lease-obligations-and-other-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LongTermLiabilitiesMember" xlink:label="bcrx_LongTermLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bcrx_LongTermLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-5-stockholders-equity" xlink:href="bcrx-20151231.xsd#statement-note-5-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-5-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation" xlink:href="bcrx-20151231.xsd#statement-note-6-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes" xlink:href="bcrx-20151231.xsd#statement-note-7-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-8-employee-401k-plan" xlink:href="bcrx-20151231.xsd#statement-note-8-employee-401k-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-8-employee-401k-plan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-9-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20151231.xsd#statement-note-9-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-9-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ClinicalTrial2007Member" xlink:label="bcrx_ClinicalTrial2007Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_UpfrontPaymentMember" xlink:label="bcrx_UpfrontPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_UpfrontPaymentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_ClinicalTrial2007Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20151231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:href="bcrx-20151231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-tables" xlink:href="bcrx-20151231.xsd#statement-note-2-furniture-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies-tables" xlink:href="bcrx-20151231.xsd#statement-note-4-lease-obligations-and-other-contingencies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-tables" xlink:href="bcrx-20151231.xsd#statement-note-6-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes-tables" xlink:href="bcrx-20151231.xsd#statement-note-7-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited-tables" xlink:href="bcrx-20151231.xsd#statement-note-10-quarterly-financial-information-unaudited-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaturityOfInvestments" xlink:label="bcrx_MaturityOfInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_SecuritiesOffered" xlink:label="bcrx_SecuritiesOffered" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsAndCash" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SecuritiesOffered" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityOfInvestments" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityForPortfolioInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-2-furniture-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-3-royalty-monetization-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-3-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-3-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Shortfall2013Member" xlink:label="bcrx_Shortfall2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_Shortfall2013Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_CurrencyDomain" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_Interestreserve" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPaid" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-4-lease-obligations-and-other-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LongTermLiabilitiesMember" xlink:label="bcrx_LongTermLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bcrx_LongTermLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-5-stockholders-equity-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-5-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-5-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CommonStockToBeIssuedValue" xlink:label="bcrx_CommonStockToBeIssuedValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RemainingAggregateOfferingPrice" xlink:label="bcrx_RemainingAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter" xlink:label="bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RemainingAggregateOfferingPrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CommonStockToBeIssuedValue" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-6-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NumberOfMilestonesAchieved" xlink:label="bcrx_NumberOfMilestonesAchieved" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfMilestonesAchieved" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-7-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-8-employee-401k-plan-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-8-employee-401k-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-8-employee-401k-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-9-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-9-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-9-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ClinicalTrial2007Member" xlink:label="bcrx_ClinicalTrial2007Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAgreementAdditionalContractValue" xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAgreementAdjustedContractValue" xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAgreementPeriodOfcontract" xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PaymentsForModificationOfLicenseAgreement" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PotentialMilestonePaymentsReceivable" xlink:label="bcrx_PotentialMilestonePaymentsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_UpfrontPaymentMember" xlink:label="bcrx_UpfrontPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_UpfrontPaymentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_ClinicalTrial2007Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementPeriodOfcontract" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyTerm" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivable" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:href="bcrx-20151231.xsd#statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:href="bcrx-20151231.xsd#statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="bcrx-20151231.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20151231.xsd#statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-summary-of-revenues-details" xlink:href="bcrx-20151231.xsd#statement-note-1-summary-of-revenues-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-details" xlink:href="bcrx-20151231.xsd#statement-note-2-furniture-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LaboratoryEquipmentMember" xlink:label="bcrx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LeasedEquipmentMember" xlink:label="bcrx_LeasedEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LeasedEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stock-incentive-plan-activities-details" xlink:href="bcrx-20151231.xsd#statement-note-6-stock-incentive-plan-activities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-stock-incentive-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:href="bcrx-20151231.xsd#statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:href="bcrx-20151231.xsd#statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:href="bcrx-20151231.xsd#statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:label="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:href="bcrx-20151231.xsd#statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets" xlink:href="bcrx-20151231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredCollaborativeRevenueMember" xlink:label="bcrx_DeferredCollaborativeRevenueMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredProductSalesMember" xlink:label="bcrx_DeferredProductSalesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="bcrx_CollaborationReceivablesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_DeferredCollaborativeRevenueMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_DeferredProductSalesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="bcrx_DeferredCollaborationExpenseAssets" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:href="bcrx-20151231.xsd#statement-consolidated-statements-of-comprehensive-loss" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-cash-flows" xlink:href="bcrx-20151231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:label="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:label="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20151231.xsd#statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-summary-of-receivables-details" xlink:href="bcrx-20151231.xsd#statement-note-1-summary-of-receivables-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-inventory-details" xlink:href="bcrx-20151231.xsd#statement-note-1-inventory-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-inventory-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-accrued-expenses-details" xlink:href="bcrx-20151231.xsd#statement-note-1-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AccruedDevelopmentCosts" xlink:label="bcrx_AccruedDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AccruedInventoryExpense" xlink:label="bcrx_AccruedInventoryExpense" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DevelopmentCostMember" xlink:label="bcrx_DevelopmentCostMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bcrx_DevelopmentCostMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AccruedDevelopmentCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AccruedInventoryExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-allocation-details" xlink:href="bcrx-20151231.xsd#statement-note-6-stockbased-compensation-allocation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-allocation-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:href="bcrx-20151231.xsd#statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited-details" xlink:href="bcrx-20151231.xsd#statement-note-10-quarterly-financial-information-unaudited-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:href="bcrx-20151231.xsd#statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange01Member" xlink:label="bcrx_ExercisePriceRange01Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange02Member" xlink:label="bcrx_ExercisePriceRange02Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange03Member" xlink:label="bcrx_ExercisePriceRange03Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange04Member" xlink:label="bcrx_ExercisePriceRange04Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange05Member" xlink:label="bcrx_ExercisePriceRange05Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange06Member" xlink:label="bcrx_ExercisePriceRange06Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange01Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange02Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange03Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange04Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange05Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange06Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>bcrx-20151231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 05:41PM UTC 2016-02-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CustomerConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_AgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a License Agreement (the "Agreement") granting rights to develop, manufacture and commercialize RAPIVAB&#174;.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AgreementMember" xlink:to="bcrx_AgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="bcrx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementsignificantaccountingpoliciespolicies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciesandconcentrationsofrisktables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueProductLineMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Product Line [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueProductLineMember" xlink:to="us-gaap_SalesRevenueProductLineMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-2-furniture-and-equipment-tables" xlink:label="bcrx_statement-statement-note-2-furniture-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-furniture-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2furnitureandequipmenttables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-furniture-and-equipment-tables" xlink:to="bcrx_statement-statement-note-2-furniture-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-4-lease-obligations-and-other-contingencies-tables" xlink:label="bcrx_statement-statement-note-4-lease-obligations-and-other-contingencies-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-4-lease-obligations-and-other-contingencies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote4leaseobligationsandothercontingenciestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-4-lease-obligations-and-other-contingencies-tables" xlink:to="bcrx_statement-statement-note-4-lease-obligations-and-other-contingencies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityperiodOfShortTermInvestment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of Short Term Investment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity period of short term investment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityperiodOfShortTermInvestment" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-6-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-6-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-6-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6stockbasedcompensationtables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-6-stockbased-compensation-tables" xlink:to="bcrx_statement-statement-note-6-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-7-income-taxes-tables" xlink:label="bcrx_statement-statement-note-7-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-7-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7incometaxestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-7-income-taxes-tables" xlink:to="bcrx_statement-statement-note-7-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_LongtermInvestmentMaturityMinimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Investment Maturity, Minimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents long term investment maturity minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LongtermInvestmentMaturityMinimum" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-tables" xlink:label="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote10quarterlyfinancialinformationunauditedtables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-tables" xlink:to="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1fairvalueofthecompanysinvestmentsbytypedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:to="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:label="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1scheduledmaturityforthecompanysinvestmentsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:to="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-summary-of-receivables-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1summaryofreceivablesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:to="bcrx_statement-statement-note-1-summary-of-receivables-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]</link:label>
    <link:label xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred revenue from upfront payment allocated to the regulatory support for the Canadian and EU marketing approvals, portion to be recognized ratably over the expected period of involvement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-inventory-details" xlink:label="bcrx_statement-statement-note-1-inventory-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-inventory-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1inventorydetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-inventory-details" xlink:to="bcrx_statement-statement-note-1-inventory-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-accrued-expenses-details" xlink:label="bcrx_statement-statement-note-1-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1accruedexpensesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-accrued-expenses-details" xlink:to="bcrx_statement-statement-note-1-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDeferredRevenue</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]</link:label>
    <link:label xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred revenue from the sale of inventory to be recognized when the inventory transfer is complete.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-summary-of-revenues-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1summaryofrevenuesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:to="bcrx_statement-statement-note-1-summary-of-revenues-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL [Member]</link:label>
    <link:label xlink:label="bcrx_CSLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited (&#8220;CSL&#8221;) and its affiliates.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLMember" xlink:to="bcrx_CSLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-2-furniture-and-equipment-details" xlink:label="bcrx_statement-statement-note-2-furniture-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-furniture-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2furnitureandequipmentdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-furniture-and-equipment-details" xlink:to="bcrx_statement-statement-note-2-furniture-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-6-stockbased-compensation-allocation-details" xlink:label="bcrx_statement-statement-note-6-stockbased-compensation-allocation-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-6-stockbased-compensation-allocation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6stockbasedcompensationallocationdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-6-stockbased-compensation-allocation-details" xlink:to="bcrx_statement-statement-note-6-stockbased-compensation-allocation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:label="bcrx_statement-statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-4-minimum-payments-under-operating-lease-obligations-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote4minimumpaymentsunderoperatingleaseobligationsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:to="bcrx_statement-statement-note-4-minimum-payments-under-operating-lease-obligations-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:label="bcrx_statement-statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6weightedaverageassumptionsforstockoptionawardsgrantedtoemployeesanddirectorsundertheincentiveplandetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:to="bcrx_statement-statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_SecuritiesOffered" xlink:label="bcrx_SecuritiesOffered" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SecuritiesOffered-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SecuritiesOffered</link:label>
    <link:label xlink:label="bcrx_SecuritiesOffered-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Offered</link:label>
    <link:label xlink:label="bcrx_SecuritiesOffered-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents securities offered for sale.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SecuritiesOffered" xlink:to="bcrx_SecuritiesOffered-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-6-stock-incentive-plan-activities-details" xlink:label="bcrx_statement-statement-note-6-stock-incentive-plan-activities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-6-stock-incentive-plan-activities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6stockincentiveplanactivitiesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-6-stock-incentive-plan-activities-details" xlink:to="bcrx_statement-statement-note-6-stock-incentive-plan-activities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:label="bcrx_statement-statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6changesinthenumberandweightedaveragegrantdatefairvaluedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:to="bcrx_statement-statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:label="bcrx_statement-statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6numberofstockoptionawardsexercisableandtheirweightedaverageexercisepricedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:to="bcrx_statement-statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:label="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7differencesbetweenthecompanyseffectivetaxrateandthestatutorytaxratedetailsparentheticals</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:to="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:label="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7differencesbetweenthecompanyseffectivetaxrateandthestatutorytaxratedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:to="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:label="bcrx_statement-statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-7-components-of-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7componentsofdeferredtaxassetsandliabilitiesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:to="bcrx_statement-statement-note-7-components-of-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:label="bcrx_statement-statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7reconciliationofbeginningandendingamountofunrecognizedtaxbenefitsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:to="bcrx_statement-statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities</link:label>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity Period of High Quality Marketable Securities</link:label>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NotesToFinancialStatements" xlink:label="bcrx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatements" xlink:to="bcrx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-details" xlink:label="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote10quarterlyfinancialinformationunauditeddetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-details" xlink:to="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdvertisingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdvertisingExpense</link:label>
    <link:label xlink:label="us-gaap_AdvertisingExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="bcrx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</link:label>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Royalty and Milestone Revenue Recognized</link:label>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue recognition royalty and milestone revenue recognized.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UAB [Member]</link:label>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UAB</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UABMember" xlink:to="bcrx_UABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AECOM and IRL [Member]</link:label>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AECOM and IRL</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AECOMAndIRLMember" xlink:to="bcrx_AECOMAndIRLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAgreementAdditionalContractValue" xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementAdditionalContractValue</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Additional Contract Value</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative agreement additional contract value during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:to="bcrx_CollaborativeAgreementAdditionalContractValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Department of Health and Human Services [Member]</link:label>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States department of health and human services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of High Quality Marketable Securities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAgreementAdjustedContractValue" xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementAdjustedContractValue</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Adjusted Contract Value</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement adjusted contract value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:to="bcrx_CollaborativeAgreementAdjustedContractValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents proceeds from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AmortizationOfFinancingCosts</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Financing Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AveragematurityForPortfolioInvestments</link:label>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity for Portfolio Investments</link:label>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity for portfolio investments during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AveragematurityForPortfolioInvestments" xlink:to="bcrx_AveragematurityForPortfolioInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Receivable [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents royalty receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyReceivableMember" xlink:to="bcrx_RoyaltyReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RAPIVABMember</link:label>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repesents RAPIVAB product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RAPIVABMember" xlink:to="bcrx_RAPIVABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral for Credit [Member]</link:label>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollateralForCreditMember" xlink:to="bcrx_CollateralForCreditMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter" xlink:label="bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter" xlink:type="locator"/>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter</link:label>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares for over Allotment Option Exercised by Underwriter</link:label>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock issued during period shares for over allotment option exercised by underwriter.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter" xlink:to="bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DeferredCollaborationExpenseAssets</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred collaboration expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseAssets" xlink:to="bcrx_DeferredCollaborationExpenseAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LaboratoryEquipmentMember" xlink:label="bcrx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label xlink:label="bcrx_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to laboratory equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LaboratoryEquipmentMember" xlink:to="bcrx_LaboratoryEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LeasedEquipmentMember" xlink:label="bcrx_LeasedEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LeasedEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leased Equipment [Member]</link:label>
    <link:label xlink:label="bcrx_LeasedEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to leased equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LeasedEquipmentMember" xlink:to="bcrx_LeasedEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CommonStockToBeIssuedValue" xlink:label="bcrx_CommonStockToBeIssuedValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CommonStockToBeIssuedValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CommonStockToBeIssuedValue</link:label>
    <link:label xlink:label="bcrx_CommonStockToBeIssuedValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock to be Issued, Value</link:label>
    <link:label xlink:label="bcrx_CommonStockToBeIssuedValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the value of equity to be issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CommonStockToBeIssuedValue" xlink:to="bcrx_CommonStockToBeIssuedValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueAdditions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueAdditions</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueAdditions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Additions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnDispositionOfAssets1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossOnDispositionOfAssets1</link:label>
    <link:label xlink:label="us-gaap_GainLossOnDispositionOfAssets1-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on disposal of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PaymentsForModificationOfLicenseAgreement" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PaymentsForModificationOfLicenseAgreement</link:label>
    <link:label xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Modification of License Agreement</link:label>
    <link:label xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents payments for modifications of license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement</link:label>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, for Modification of License Agreement</link:label>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock issued during period value for modification of license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyTerm</link:label>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Term</link:label>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of time between the date of the Agreement and its expiration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyTerm" xlink:to="bcrx_RoyaltyTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance Notice Period for Termination of Agreement</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents advance notice period for termination of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Revenues</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL Limited [Member</link:label>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited which is a company organized under the laws of Australia.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLLimitedMember" xlink:to="bcrx_CSLLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedProfessionalFeesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:label="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:to="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAccruedLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Text Block]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationTextBlock" xlink:to="bcrx_RoyaltyMonetizationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of Agreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PeriodOfAgreement" xlink:to="bcrx_PeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RenewablePeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewable Period of Agreement</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents renewable period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RenewablePeriodOfAgreement" xlink:to="bcrx_RenewablePeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireProductiveAssets</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_UpfrontPaymentsReceivableAmount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payments Receivable Amount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents upfront payments receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UpfrontPaymentsReceivableAmount" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_UpfrontPaymentMember" xlink:label="bcrx_UpfrontPaymentMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UpfrontPaymentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment [Member]</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining upfront payment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UpfrontPaymentMember" xlink:to="bcrx_UpfrontPaymentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards</link:label>
    <link:label xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration of attribute carryforwards</link:label>
    <link:label xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income tax reconciliation income tax expense benefit expiration of carryforwards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:to="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMaximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Maximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMaximum" xlink:to="bcrx_MilestonePaymentMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:label xlink:label="us-gaap_RoyaltyRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ClinicalTrial2007Member" xlink:label="bcrx_ClinicalTrial2007Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ClinicalTrial2007Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial 2007 [Member]</link:label>
    <link:label xlink:label="bcrx_ClinicalTrial2007Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Clinical Trial 2007.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ClinicalTrial2007Member" xlink:to="bcrx_ClinicalTrial2007Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents National Institute of Allergy and Infectious Diseases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PotentialMilestonePaymentsReceivable" xlink:label="bcrx_PotentialMilestonePaymentsReceivable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PotentialMilestonePaymentsReceivable</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Receivable</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents potential milestone payments receivable based on possibility of future event payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PotentialMilestonePaymentsReceivable" xlink:to="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Shortfall2013Member" xlink:label="bcrx_Shortfall2013Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Shortfall2013Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shortfall 2013 [Member]</link:label>
    <link:label xlink:label="bcrx_Shortfall2013Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the 2013 interest shortfall.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Shortfall2013Member" xlink:to="bcrx_Shortfall2013Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentGross</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SalesRevenueNet</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMinimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Minimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMinimum" xlink:to="bcrx_MilestonePaymentMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange01Member" xlink:label="bcrx_ExercisePriceRange01Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange01Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 01 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange01Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the first exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange01Member" xlink:to="bcrx_ExercisePriceRange01Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborationAgreementAdditionalPaymentsReceived</link:label>
    <link:label xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Additional Payments Received</link:label>
    <link:label xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaboration agreement additional payments received.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:to="bcrx_CollaborationAgreementAdditionalPaymentsReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net federal and state operating losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Receivable From Awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents expected receivable from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange05Member" xlink:label="bcrx_ExercisePriceRange05Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange05Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 05 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange05Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the fifth exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange05Member" xlink:to="bcrx_ExercisePriceRange05Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange04Member" xlink:label="bcrx_ExercisePriceRange04Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange04Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 04 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange04Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the fourth exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange04Member" xlink:to="bcrx_ExercisePriceRange04Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange03Member" xlink:label="bcrx_ExercisePriceRange03Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange03Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 03 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange03Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the third exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange03Member" xlink:to="bcrx_ExercisePriceRange03Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange02Member" xlink:label="bcrx_ExercisePriceRange02Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange02Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 02 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange02Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the second exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange02Member" xlink:to="bcrx_ExercisePriceRange02Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange06Member" xlink:label="bcrx_ExercisePriceRange06Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange06Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 06 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange06Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the sixth exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange06Member" xlink:to="bcrx_ExercisePriceRange06Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMaximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Maximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual maximum license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMaximum" xlink:to="bcrx_AnnualLicenseFeeMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BirminghamResearchFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Birmingham Research Facility [Member]</link:label>
    <link:label xlink:label="bcrx_BirminghamResearchFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the Birmingham Research Facility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BirminghamResearchFacilityMember" xlink:to="bcrx_BirminghamResearchFacilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RestrictedCashAndCashEquivalents</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMinimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Minimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent minimum annual license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMinimum" xlink:to="bcrx_AnnualLicenseFeeMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment, Office Equipment and Software [Member]</link:label>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to laboratory equipment, office equipment and software.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock option awards forfeited (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeLossOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Loss on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeGainOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum payments</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan sales</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan sales, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueServicesNetAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development revenues:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_SalesRevenueServicesNetAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByLiabilityClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeForwardExchangeRate1</link:label>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Forward Exchange Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeForwardExchangeRate1" xlink:to="us-gaap_DerivativeForwardExchangeRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CollateralAlreadyPostedAggregateFairValue</link:label>
    <link:label xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestAndOtherIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value; shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 73,355 in 2015 and 71,955 in 2014</link:label>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsAndCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InvestmentsAndCash</link:label>
    <link:label xlink:label="us-gaap_InvestmentsAndCash-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and Cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaturityOfInvestments" xlink:label="bcrx_MaturityOfInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityOfInvestments</link:label>
    <link:label xlink:label="bcrx_MaturityOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity of Investments</link:label>
    <link:label xlink:label="bcrx_MaturityOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maturity of investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityOfInvestments" xlink:to="bcrx_MaturityOfInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AccruedInventoryExpense" xlink:label="bcrx_AccruedInventoryExpense" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedInventoryExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AccruedInventoryExpense</link:label>
    <link:label xlink:label="bcrx_AccruedInventoryExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label xlink:label="bcrx_AccruedInventoryExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of accrued inventory expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedInventoryExpense" xlink:to="bcrx_AccruedInventoryExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AccruedDevelopmentCosts" xlink:label="bcrx_AccruedDevelopmentCosts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AccruedDevelopmentCosts</link:label>
    <link:label xlink:label="bcrx_AccruedDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development costs</link:label>
    <link:label xlink:label="bcrx_AccruedDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedDevelopmentCosts" xlink:to="bcrx_AccruedDevelopmentCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDerivativeAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DevelopmentCostMember" xlink:label="bcrx_DevelopmentCostMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DevelopmentCostMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Cost [Member]</link:label>
    <link:label xlink:label="bcrx_DevelopmentCostMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DevelopmentCostMember" xlink:to="bcrx_DevelopmentCostMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent upon EU Marketing Approval [Member]</link:label>
    <link:label xlink:label="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information about the contingent proceed which is upon EU marketing approval.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ContingentUponEuMarketingApprovalMember" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mundipharma [Member]</link:label>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Mundipharma.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MundipharmaMember" xlink:to="bcrx_MundipharmaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_JapanYenMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen [Member]</link:label>
    <link:label xlink:label="bcrx_JapanYenMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Japanese Yen.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JapanYenMember" xlink:to="bcrx_JapanYenMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentContractReceivable</link:label>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Contract Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest Upon Successful Completion of Specific Development Milestones [Member]</link:label>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vesting upon successful completion of specific development milestones.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2014 [Member]</link:label>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of December 2014.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_December2014Member" xlink:to="bcrx_December2014Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2013 [Member]</link:label>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of August 2013.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_August2013Member" xlink:to="bcrx_August2013Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 25% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 25% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 50% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 50% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConcentrationRiskPercentage1</link:label>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Carrying Amount in Excess of Fair Value</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of carrying amount in excess of fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyDomain" xlink:to="bcrx_CurrencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AreaOfRealEstateProperty</link:label>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:label="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount</link:label>
    <link:label xlink:label="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orphan drug credit</link:label>
    <link:label xlink:label="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents orphan drug credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:to="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockPlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan sales</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of common stock, net</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OfficeEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SoftwareDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenue</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesRentExpenseNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesRentExpenseNet</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesRentExpenseNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards exercised (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsReceivableNetCurrent</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TradeAccountsReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAccountsReceivableMember" xlink:to="us-gaap_TradeAccountsReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivableTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledRevenuesMember" xlink:to="us-gaap_BilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnbilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledRevenuesMember" xlink:to="us-gaap_UnbilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-vested stock option awards (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-vested stock option awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesBillingStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_ReceivablesBillingStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards vested (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards forfeited (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards vested (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeContractTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards Available (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards Available (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan amendment (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable Number (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Weighted Average Remaining Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Number (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upper Exercise Price Range (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized loss on available for sale investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Dividend Yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award first vesting period after grant date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReceivablesNetCurrent</link:label>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherComprehensiveIncomeLossNetOfTax</link:label>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased</link:label>
    <link:label xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestPayableCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shionogi and Co. Ltd [Member]</link:label>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shionogi &amp; Co. Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShionogiAndCoLtdMember" xlink:to="bcrx_ShionogiAndCoLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development revenues</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative and other research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of schedule of revenues from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DepreciationDepletionAndAmortization</link:label>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents available for sale securities accrued interest.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueCurrent</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BuildingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConstructionInProgressMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Quarterly Financial Information [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities Fair Value [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of available for sale securities debt maturities fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing after one year through two years</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents available for sale securities debt maturities after one through two years fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Receivables from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure representing receivables from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromLicenseFeesReceived</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PhaRMA Notes Member]</link:label>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PhaRMA notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PhaRMANotesMember" xlink:to="bcrx_PhaRMANotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JPR Royalty Sub LLC [Member]</link:label>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents JPR Royalty Sub LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JPRRoyaltySubLLCMember" xlink:to="bcrx_JPRRoyaltySubLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to prior period tax positions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NotesPayableCurrent</link:label>
    <link:label xlink:label="us-gaap_NotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-recourse notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to current period tax positions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAgreementPeriodOfcontract" xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementPeriodOfcontract</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Period of Contract</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement period of contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementPeriodOfcontract" xlink:to="bcrx_CollaborativeAgreementPeriodOfcontract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EarningsPerShareDiluted</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net (loss) income per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestPaid</link:label>
    <link:label xlink:label="us-gaap_InterestPaid-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborationReceivablesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Receivables [Member]</link:label>
    <link:label xlink:label="bcrx_CollaborationReceivablesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents receivables from collaborations for reimbursable research and development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborationReceivablesMember" xlink:to="bcrx_CollaborationReceivablesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PrivatePlacementOfSeniorSecuredNotes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement of Senior Secured Notes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents private placement of senior secured notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredCollaborativeRevenueMember" xlink:label="bcrx_DeferredCollaborativeRevenueMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborativeRevenueMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Collaborative Revenue [Member]</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborativeRevenueMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents revenue deferred under collaborative arrangements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborativeRevenueMember" xlink:to="bcrx_DeferredCollaborativeRevenueMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharePrice</link:label>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredProductSalesMember" xlink:label="bcrx_DeferredProductSalesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredProductSalesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Product Sales [Member]</link:label>
    <link:label xlink:label="bcrx_DeferredProductSalesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred revenue related to product sales.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredProductSalesMember" xlink:to="bcrx_DeferredProductSalesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeRelatedLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxCreditCarryforwardAmount</link:label>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Royalty And Milestone Revenue Recognized, Net</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents revenue recognition royalty and milestone revenue recognized, net.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInRestrictedCash</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred collaboration expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:label="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receipt of foreign currency derivative collateral</link:label>
    <link:label xlink:label="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the receipt or payment of foreign currency derivatives.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:to="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementContractValue</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Contract Value</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement contract value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementContractValue" xlink:to="bcrx_CollaborativeAgreementContractValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EarningsPerShareBasic</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net (loss) income per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxesPayableCurrent</link:label>
    <link:label xlink:label="us-gaap_TaxesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Duties and taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAmountOfCollateralRequiredToPost</link:label>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Amount of Collateral Required to Post</link:label>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maximum amount of collateral required to post.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_HedgingDesignationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RemainingAggregateOfferingPrice" xlink:label="bcrx_RemainingAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RemainingAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RemainingAggregateOfferingPrice</link:label>
    <link:label xlink:label="bcrx_RemainingAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining Aggregate Offering Price</link:label>
    <link:label xlink:label="bcrx_RemainingAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the remaining aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RemainingAggregateOfferingPrice" xlink:to="bcrx_RemainingAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NondesignatedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NondesignatedMember" xlink:to="us-gaap_NondesignatedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeCategorizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAggregateOfferingPrice</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAggregateOfferingPrice" xlink:to="bcrx_MaximumAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementMember" xlink:to="bcrx_CurrencyHedgeAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RequiredForeignCurrencyHedgePerDollar</link:label>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Required Foreign Currency Hedge Per Dollar</link:label>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignExchangeContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignExchangeContractMember" xlink:to="us-gaap_ForeignExchangeContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_Interestreserve</link:label>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Reserve</link:label>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest reserve established as part of the royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Interestreserve" xlink:to="bcrx_Interestreserve-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty monetization transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationMember" xlink:to="bcrx_RoyaltyMonetizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Green Cross Corporation [Member]</link:label>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Green Cross Corporation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GreenCrossCorporationMember" xlink:to="bcrx_GreenCrossCorporationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_TransactionCosts</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction Costs</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents transaction costs associated with royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TransactionCosts" xlink:to="bcrx_TransactionCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Contract [Member]</link:label>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BaseContractMember" xlink:to="bcrx_BaseContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASPRBARDA Contract [Member]</link:label>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The potential value of the ASPR/BARDA Contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ASPRBARDAContractMember" xlink:to="bcrx_ASPRBARDAContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Development Options [Member]</link:label>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The additional development options that can be exercised by the Government.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdditionalDevelopmentOptionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan [Member]</link:label>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanMember" xlink:to="bcrx_IncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan, (ESPP).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeStockPurchasePlanMember" xlink:to="bcrx_EmployeeStockPurchasePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Company [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The description of company policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options and Restricted Stock [Member]</link:label>
    <link:label xlink:label="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock options and restricted stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockOptionsAndRestrictedStockMember" xlink:to="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CertificatesOfDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Market Risk [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents concentration of market risk policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense and Deferred Financing Costs [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest expense and deferred financing costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit at federal statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents currency hedge agreement policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in shares)</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award options forfeitures in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate change</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing after two years</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents debt maturities after two years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationOtherAdjustments</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued expenses policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedExpensesPolicyTextBlock" xlink:to="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LongTermLiabilitiesMember" xlink:label="bcrx_LongTermLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LongTermLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Liabilities [Member]</link:label>
    <link:label xlink:label="bcrx_LongTermLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents long term liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LongTermLiabilitiesMember" xlink:to="bcrx_LongTermLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employee Directors [Member]</link:label>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents non-employee directors of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NonEmployeeDirectorsMember" xlink:to="bcrx_NonEmployeeDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommercialPaperMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NotesPayableFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in shares)</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share based compensation arrangement by share based payment award options grants in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NumberOfMilestonesAchieved" xlink:label="bcrx_NumberOfMilestonesAchieved" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NumberOfMilestonesAchieved-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_NumberOfMilestonesAchieved</link:label>
    <link:label xlink:label="bcrx_NumberOfMilestonesAchieved-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Milestones Achieved</link:label>
    <link:label xlink:label="bcrx_NumberOfMilestonesAchieved-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of milestones achieved.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfMilestonesAchieved" xlink:to="bcrx_NumberOfMilestonesAchieved-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of performance awards that remain unvested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueNoncurrent</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrencyAxis" xlink:to="us-gaap_CurrencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Salary to Purchase Common Stock, Maximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of salary to purchase common stock maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_NumberOfStockbasedCompensationPlans</link:label>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Stock-based Compensation Plans</link:label>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of stock based compensation plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfStockbasedCompensationPlans" xlink:to="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease financing obligation</link:label>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Financing Obligation, Net of Current</link:label>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Financing obligation as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income taxes net of federal tax benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit at federal statutory rate (35%)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationNondeductibleExpense</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesEnding</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Ending</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares ending.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesEnding" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesBeginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Beginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares beginning.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesBeginning" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRentCreditNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>bcrx-20151231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 05:41PM UTC 2016-02-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-11-recent-accounting-pronouncements" xlink:href="bcrx-20151231.xsd#statement-note-11-recent-accounting-pronouncements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-11-recent-accounting-pronouncements" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited" xlink:href="bcrx-20151231.xsd#statement-note-10-quarterly-financial-information-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-document-and-entity-information" xlink:href="bcrx-20151231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="bcrx-20151231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:href="bcrx-20151231.xsd#statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:href="bcrx-20151231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment" xlink:href="bcrx-20151231.xsd#statement-note-2-furniture-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-3-royalty-monetization" xlink:href="bcrx-20151231.xsd#statement-note-3-royalty-monetization" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-3-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Shortfall2013Member" xlink:label="bcrx_Shortfall2013Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_Shortfall2013Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies" xlink:href="bcrx-20151231.xsd#statement-note-4-lease-obligations-and-other-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LongTermLiabilitiesMember" xlink:label="bcrx_LongTermLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="bcrx_LongTermLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-5-stockholders-equity" xlink:href="bcrx-20151231.xsd#statement-note-5-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-5-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation" xlink:href="bcrx-20151231.xsd#statement-note-6-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes" xlink:href="bcrx-20151231.xsd#statement-note-7-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-8-employee-401k-plan" xlink:href="bcrx-20151231.xsd#statement-note-8-employee-401k-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-8-employee-401k-plan" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-9-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20151231.xsd#statement-note-9-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-9-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ClinicalTrial2007Member" xlink:label="bcrx_ClinicalTrial2007Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_UpfrontPaymentMember" xlink:label="bcrx_UpfrontPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_UpfrontPaymentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_ClinicalTrial2007Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20151231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:href="bcrx-20151231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-tables" xlink:href="bcrx-20151231.xsd#statement-note-2-furniture-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-2-furniture-and-equipment-tables" xlink:label="bcrx_statement-statement-note-2-furniture-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-furniture-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies-tables" xlink:href="bcrx-20151231.xsd#statement-note-4-lease-obligations-and-other-contingencies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-4-lease-obligations-and-other-contingencies-tables" xlink:label="bcrx_statement-statement-note-4-lease-obligations-and-other-contingencies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-4-lease-obligations-and-other-contingencies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-tables" xlink:href="bcrx-20151231.xsd#statement-note-6-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-6-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-6-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-6-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes-tables" xlink:href="bcrx-20151231.xsd#statement-note-7-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-7-income-taxes-tables" xlink:label="bcrx_statement-statement-note-7-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-7-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited-tables" xlink:href="bcrx-20151231.xsd#statement-note-10-quarterly-financial-information-unaudited-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-tables" xlink:label="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaturityOfInvestments" xlink:label="bcrx_MaturityOfInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_SecuritiesOffered" xlink:label="bcrx_SecuritiesOffered-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsAndCash-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SecuritiesOffered-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityOfInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityForPortfolioInvestments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-2-furniture-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-3-royalty-monetization-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-3-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-3-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Shortfall2013Member" xlink:label="bcrx_Shortfall2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_Shortfall2013Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_Interestreserve-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPaid-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-4-lease-obligations-and-other-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LongTermLiabilitiesMember" xlink:label="bcrx_LongTermLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="bcrx_LongTermLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-5-stockholders-equity-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-5-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-5-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CommonStockToBeIssuedValue" xlink:label="bcrx_CommonStockToBeIssuedValue-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RemainingAggregateOfferingPrice" xlink:label="bcrx_RemainingAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter" xlink:label="bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RemainingAggregateOfferingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CommonStockToBeIssuedValue-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-6-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NumberOfMilestonesAchieved" xlink:label="bcrx_NumberOfMilestonesAchieved-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfStockbasedCompensationPlans-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfMilestonesAchieved-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-7-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-8-employee-401k-plan-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-8-employee-401k-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-8-employee-401k-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-9-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20151231.xsd#statement-note-9-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-9-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ClinicalTrial2007Member" xlink:label="bcrx_ClinicalTrial2007Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAgreementAdditionalContractValue" xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAgreementAdjustedContractValue" xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAgreementPeriodOfcontract" xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PaymentsForModificationOfLicenseAgreement" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_PotentialMilestonePaymentsReceivable" xlink:label="bcrx_PotentialMilestonePaymentsReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_UpfrontPaymentMember" xlink:label="bcrx_UpfrontPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_UpfrontPaymentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_ClinicalTrial2007Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementAdditionalContractValue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementAdjustedContractValue-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementPeriodOfcontract-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborationAgreementAdditionalPaymentsReceived-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyTerm-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:href="bcrx-20151231.xsd#statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:label="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:href="bcrx-20151231.xsd#statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:label="bcrx_statement-statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-4-minimum-payments-under-operating-lease-obligations-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="bcrx-20151231.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20151231.xsd#statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:label="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-summary-of-revenues-details" xlink:href="bcrx-20151231.xsd#statement-note-1-summary-of-revenues-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-details" xlink:href="bcrx-20151231.xsd#statement-note-2-furniture-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LaboratoryEquipmentMember" xlink:label="bcrx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LeasedEquipmentMember" xlink:label="bcrx_LeasedEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-2-furniture-and-equipment-details" xlink:label="bcrx_statement-statement-note-2-furniture-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-furniture-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LeasedEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n7" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stock-incentive-plan-activities-details" xlink:href="bcrx-20151231.xsd#statement-note-6-stock-incentive-plan-activities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-stock-incentive-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-6-stock-incentive-plan-activities-details" xlink:label="bcrx_statement-statement-note-6-stock-incentive-plan-activities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-6-stock-incentive-plan-activities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:href="bcrx-20151231.xsd#statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:label="bcrx_statement-statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:href="bcrx-20151231.xsd#statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:label="bcrx_statement-statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n7" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:href="bcrx-20151231.xsd#statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:label="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:label="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:href="bcrx-20151231.xsd#statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:label="bcrx_statement-statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets" xlink:href="bcrx-20151231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets-1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredCollaborativeRevenueMember" xlink:label="bcrx_DeferredCollaborativeRevenueMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredProductSalesMember" xlink:label="bcrx_DeferredProductSalesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="bcrx_CollaborationReceivablesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_TradeAccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_DeferredCollaborativeRevenueMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_DeferredProductSalesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="bcrx_DeferredCollaborationExpenseAssets-1" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:href="bcrx-20151231.xsd#statement-consolidated-statements-of-comprehensive-loss" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense-n7" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-cash-flows" xlink:href="bcrx-20151231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-n8" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:label="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:label="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-n7" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfFurnitureAndFixtures" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash-n7" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n7" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20151231.xsd#statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n7" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-summary-of-receivables-details" xlink:href="bcrx-20151231.xsd#statement-note-1-summary-of-receivables-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-inventory-details" xlink:href="bcrx-20151231.xsd#statement-note-1-inventory-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-inventory-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-inventory-details" xlink:label="bcrx_statement-statement-note-1-inventory-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-inventory-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-1-accrued-expenses-details" xlink:href="bcrx-20151231.xsd#statement-note-1-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-1-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AccruedDevelopmentCosts" xlink:label="bcrx_AccruedDevelopmentCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_AccruedInventoryExpense" xlink:label="bcrx_AccruedInventoryExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_DevelopmentCostMember" xlink:label="bcrx_DevelopmentCostMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-1-accrued-expenses-details" xlink:label="bcrx_statement-statement-note-1-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="bcrx_DevelopmentCostMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AccruedDevelopmentCosts-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AccruedInventoryExpense-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxesPayableCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-allocation-details" xlink:href="bcrx-20151231.xsd#statement-note-6-stockbased-compensation-allocation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-allocation-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-6-stockbased-compensation-allocation-details" xlink:label="bcrx_statement-statement-note-6-stockbased-compensation-allocation-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-6-stockbased-compensation-allocation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:href="bcrx-20151231.xsd#statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:label="bcrx_statement-statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-7-components-of-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains-n7" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-n7" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n7" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited-details" xlink:href="bcrx-20151231.xsd#statement-note-10-quarterly-financial-information-unaudited-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-details" xlink:label="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-10-quarterly-financial-information-unaudited-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20151231/role/statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:href="bcrx-20151231.xsd#statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20151231/role/statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange01Member" xlink:label="bcrx_ExercisePriceRange01Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange02Member" xlink:label="bcrx_ExercisePriceRange02Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange03Member" xlink:label="bcrx_ExercisePriceRange03Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange04Member" xlink:label="bcrx_ExercisePriceRange04Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange05Member" xlink:label="bcrx_ExercisePriceRange05Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_ExercisePriceRange06Member" xlink:label="bcrx_ExercisePriceRange06Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20151231.xsd#bcrx_statement-statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:label="bcrx_statement-statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange01Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange02Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange03Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange04Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange05Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange06Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-2" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>graph.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graph.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Z D8# 2(  A$! Q$!_\0
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M1EH6C!')WJ3_ "(JO U_-;QR^9;#>H;'EMQD9_O4 7J*J[;_ /YZVW_?IO\
MXJC;?_\ /6V_[]-_\50!:HJKMO\ _GK;?]^F_P#BJ-M__P ];;_OTW_Q5 %J
MBJNV_P#^>MM_WZ;_ .*HVW__ #UMO^_3?_%4 6J*J[;_ /YZVW_?IO\ XJC;
M?_\ /6V_[]-_\50!:HJKMO\ _GK;?]^F_P#BJ-M__P ];;_OTW_Q5 %JBJNV
M_P#^>MM_WZ;_ .*HVW__ #UMO^_3?_%4 6J*J[;_ /YZVW_?IO\ XJC;?_\
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M #UMO^_3?_%4 6J*J[;_ /YZVW_?IO\ XJC;?_\ /6V_[]-_\50!:HJKMO\
M_GK;?]^F_P#BJ-M__P ];;_OTW_Q5 %JBJNV_P#^>MM_WZ;_ .*HVW__ #UM
MO^_3?_%4 6J*J[;_ /YZVW_?IO\ XJC;?_\ /6V_[]-_\50!:HJKMO\ _GK;
M?]^F_P#BJ-M__P ];;_OTW_Q5 %JBJNV_P#^>MM_WZ;_ .*HVW__ #UMO^_3
M?_%4 6J*J[;_ /YZVW_?IO\ XJC;?_\ /6V_[]-_\50!:HJKMO\ _GK;?]^F
M_P#BJ-M__P ];;_OTW_Q5 %JBJNV_P#^>MM_WZ;_ .*HVW__ #UMO^_3?_%4
M 6J*J[;_ /YZVW_?IO\ XJC;?_\ /6V_[]-_\50!:HJKMO\ _GK;?]^F_P#B
MJ-M__P ];;_OVW_Q5 %JBF1^8$'FE2_<J,"GT %%%% #7C21&1U#*PP5(R"*
M/+0X^4<=.*=10 W8N<XY/7WI0H'3@#M2T4 ,E_U+_P"Z:BL?^0?;?]<E_D*E
ME_U+_P"Z:BL?^0?;?]<E_D* +%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%85_XBCCN6L--@;4-0'6.(_)%
M[NW1?IUIJ+EL)R2W-'4]1@TK3YKVY)$42Y.!R?85S?A[QW::K+)!>^59S;B8
M]S_*Z]AD]ZO6_A^2ZF6]UZX6\G4[D@ Q!#]%[GW-)90>&39SQI!9I"TS[UE"
M_,<]1GMZ5?-1@N66YF^=M-:(Z%'610R,&4]"#D4ZN/DTWPS"Q>RU*2P?UL[A
M@/\ OGD?I41U+4[,#['K,6I(.B7%FX;_ +Z0?TK+GI=)HKF:W1VM%<W9>)+U
MT)O=$NH]HR7ARX/X$ U&GC:QEN#!%"XESC;+(L9_\>-3SKIKZ7?Z#YXG445D
MK?:I* T6F1!3T9KD$?H*7=KC_P#+*PC^KLW]*7M%T3^X=S5HK*$&M/\ >O+2
M/_<A)_F:#I^I./GUAQ_US@4?XT<[Z1?]?,9JT5E?V/*W^MU6^;_=<+_(4'0+
M5O\ 63WDA_VKAOZ4<T_Y?Q U"RKU8#ZFH7O;6/.^YA7ZN*I#P_I8ZVH<^KLS
M?S-$^@:?+;/%%;Q0LPQYB1@L/IFDW4MHD+4FTW4X=3A>2'HCE"#[=#^-7JQ]
M)T%-)FDDCNI)%=<,C 8]C6Q3I.;BN?<%?J%%%%:#"BLS7M;MO#^DS:A=[C'&
M0H5>K,QPHYX&2>IXK/N_&%G806$]U:7\45Y,L!D,'$+L^Q0_/&6XXSV/0T =
M'17,-X\T*,ZAYERZK8Q2RR.4X98W,;E<=<.-OOQCBM?2-7MM9M9)[8L/*F>W
ME1QAHY$.&4]N#Z4 79?]2_\ NFHK'_D'VW_7)?Y"I)F587W,!\IZGVJ&REC%
MA;@NO^J7O["@"U13/-C_ .>B_G1YL?\ ST7\Z 'T4SS8_P#GHOYT>;'_ ,]%
M_.@!]%,\V/\ YZ+^='FQ_P#/1?SH ?13/-C_ .>B_G1YL?\ ST7\Z 'T4SS8
M_P#GHOYT>;'_ ,]%_.@!]%,\V/\ YZ+^='FQ_P#/1?SH ?13/-C_ .>B_G1Y
ML?\ ST7\Z 'T4SS8_P#GHOYT>;'_ ,]%_.@!]%,\V/\ YZ+^='FQ_P#/1?SH
M ?13/-C_ .>B_G1YL?\ ST7\Z 'T4SS8_P#GHOYT>;'_ ,]%_.@!]%,\V/\
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M3_GU@_[]BC[#:?\ /K!_W[%6** *_P!AM/\ GU@_[]BC[#:?\^L'_?L58HH
MK_8;3_GU@_[]BC[#:?\ /K!_W[%6** *_P!AM/\ GU@_[]BC[#:?\^L'_?L5
M8HH K_8;3_GU@_[]BC[#:?\ /K!_W[%6** *_P!AM/\ GU@_[]BC[#:?\^L'
M_?L58HH K_8;3_GU@_[]BC[#:?\ /K!_W[%6** *_P!AM/\ GU@_[]BC[#:?
M\^L'_?L58HH K_8;3_GU@_[]BC[#:?\ /K!_W[%6** *_P!AM/\ GU@_[]BC
M[#:?\^L'_?L58HH K_8;3_GU@_[]BC[#:?\ /K!_W[%6** *_P!AM/\ GU@_
M[]BC[#:?\^L'_?L58HH K_8;3_GU@_[]BC[#:?\ /K!_W[%6** *_P!AM/\
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M:1/J6H:3I3I:I9QW%XP_=6D$09S_ /$CW-5(O#<VKRK/KB0QP@[DL+8 (/\
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M?./_ +_?_6H\Z]_Y\X_^_P!_]:K5% %7SKW_ )\X_P#O]_\ 6H\Z]_Y\X_\
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M^M5JB@"KYU[_ ,^<?_?[_P"M1YU[_P ^<?\ W^_^M5JB@"KYU[_SYQ_]_O\
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M#%=3'MY<#'/XD4?VK=O_ *G2+HCUD*I_,U3_ .$2A/WM7UICZF]:C_A$;?\
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M]-'V ?\ /S=?]_30!;HJI]@'_/S=?]_31]@'_/S=?]_30!;HJI]@'_/S=?\
M?TT?8!_S\W7_ ']- %NBJGV ?\_-U_W]-'V ?\_-U_W]- %NBJGV ?\ /S=?
M]_31]@'_ #\W7_?TT 6Z*J?8!_S\W7_?TT?8!_S\W7_?TT 6Z*J?8!_S\W7_
M ']-'V ?\_-U_P!_30!;HJI]@'_/S=?]_31]@'_/S=?]_30!;HJI]@'_ #\W
M7_?TT?8!_P _-U_W]- %NBJGV ?\_-U_W]-'V ?\_-U_W]- %NBJGV ?\_-U
M_P!_31]@'_/S=?\ ?TT 6Z*J?8!_S\W7_?TT?8!_S\W7_?TT 6Z*J?8!_P _
M-U_W]-'V ?\ /S=?]_30!;HID<?EH%W,V.[')I] !1110 4444 %%%% #)?]
M2_\ NFHK$?Z!;?\ 7)?Y"I9?]2_^Z:BL?^0?;?\ 7)?Y"@"5XUD0HZJRG@JP
MR#6)-X3L1(9]/>;3;@\[[1]JD^Z?=/Y5O44U)QV8G%/<YTR^)=+_ -;#!JT
M_BB/E38_W3\I_#%6+3Q3IEQ,+>:1[.Z_YX7:^6WX9X/X&MG%07=C:W\)BN[:
M*>,_PR*&JN:+^)?<39K9D^X'I2YKG3X8DLCOT74[BQ](7/FP_P#?+=/P-']K
MZUIW&J:29XAUN+ [QCU*'YA^&:.2_P +#FM\2.BHK.T[7=,U3BTO(WD'6,_*
MZ_53S6AD5+36C*33V%HHS12&%(12T4 (!2T44 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !115+4M4M-*LVN;J78@.% &6=NRJ.YH2;T0F[%BXN(;:W
MDGGD6.)!EG8X %<U_I?BT_\ +6TT/\5DNQ_[*GZFI+?3+S7KA+[6HS%:H=UO
MIV>!Z-)ZGVZ"ND"@< 8 Z5=U#;?\B-9[[#(+>*U@2""-8XD&U448"BI:**@T
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***Y+Q3KVIZ3K^C6L'V>"RO',9N9U
MRC2X.V)B.4W=CW(Q]0#K:*\XU/QOK&A_\)'<ZE8S1):0O+I]M):@+,H<('\U
M7.?O*2I"D UT_A/79==L[\SH%FL=0GL795P)/+; 8#MD$?CF@#=E_P!2_P#N
MFHK'_D'VW_7)?Y"ENIEAA;<'.01\J%NWL*K65]$+&W!2?(C7_E@_H/:@#0HJ
MM]OA_N7'_@._^%'V^'^Y<?\ @._^% %FBJWV^'^Y<?\ @._^%'V^'^Y<?^ [
M_P"% %FD(JO]OA_N7'_@._\ A1]OA_N7'_@._P#A0!6U#0M,U3YKNSC>0=)
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MX#O_ (4 6:*K?;X?[EQ_X#O_ (4?;X?[EQ_X#O\ X4 6:*J_;HO[EQ_X#O\
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M?[EQ_P" [_X4?;X?[EQ_X#O_ (4 6:*K?;X?[EQ_X#O_ (4?;X?[EQ_X#O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***ANKNWL;=KBZFCAA3EI)&
M"J/J30!-134=9%#*05(R"#D$4Z@!DO\ J7_W345C_P @^V_ZY+_(5++_ *E_
M]TU%8_\ (/MO^N2_R% %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 3%&!2T4 ,EACGB>*5 \;@JRL,@BJ>E:-8Z+;-!8P^
M6C,68DY)/N?:K]%.[M85E>X4444AA1110 4444 %%%% !1110 4444 %%%%
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ML.^C37Y5BHN(W2,-^!Q^E0^+_$&M65IX?N($NM.DN]7BLI[=1%*[Q.&)VY!
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>*$CC08"@= !4U% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exh1071_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1071_1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X1?=17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#(Z
M,3@@,38Z-#4Z,S<      Z !  ,    !  $  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !:G
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MITG]*[<RAS?T3/>H8/4!59OMOR+#2Q[6P^N0 [](ZS[3U#+WM^C_ #C?T?\
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M<0V&-!,@@X9B1_:;MW;?9_I$E.J,T.,"IY^#J_\ TJH7=2KH:'VU6AKB&C:
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MY+=KG4O>X5C;!_G;&_:MVQOO][5 Y62 =N?D.:#+W#TG@-EHW_HLMMNQC_\
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M'S]"=/BI=TE/_]G_[1QZ4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M                .$))30/M       0 2P    !  $!+     $  3A"24T$
M)@      #@             _@   .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))300*       !   X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      -'    !@             #CP   L     ) &4 > !H
M #$ ,  W #$ 7P Q     0                         !
M  +    #CP                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   #CP    !29VAT;&]N9P   L     &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   X\     4F=H
M=&QO;F<   +      W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     3_P        .$))3004       $     3A"24T$
M#      6PP    $   !\    H    70  .B    6IP 8  '_V/_@ !!*1DE&
M  $"  !( $@  /_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
MH !\ P$B  (1 0,1 ?_=  0 "/_$ 3\   $% 0$! 0$!          ,  0($
M!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"
M!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,'
M)9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'
M!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T
M\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]43I(5[L
MEK6G'8RQT^X6.+!M@_1<QEWNW[/S4E)4EDMZS<0=U+&P7B0;W:L&X_\ :*O=
M_P!__P &F_;5VXPRLMU<T_IQ[0'N=_VDV[]*_8DIUDZR#UK(%;3Z->\B2)R(
M'S^Q?]]2'6L@L#Q36=P#F[79#@0?I:C!_P Q)3KI+''6\@M+O0J _-]V1J1!
MU_4/H_RU-O5\ATD45D?F'=?K^]_VB_K)*=5)8[>MY);K0P62!$Y.W4@3O.!_
MWU._K62T[1CLWC1[2<@09.WW# =]+:DIUTEENZRUK7 :VL]I9Z=X;OX]/U10
M_P!N_P#PGI?S?Z7TU$]8R]Q:,=A=+ ).0!+^V_[#M_M_]N>FDIUDEDGJ^8"?
MU9I$C9_21(/TI_4'?1_Z?\A7,2[.M(=?3774YNYCF6/<Z3M]KZK<?'V?G)*;
M)(! )B=!^5+6?+Q4+?IT_P!<_P#4/1$E/__0]55?-=6VB;+7TMGZ=8).GN[-
ML]J.J^?BNR\8TML-))!#V[@01[FZU/IL^G^[8DIY]_76R[T[7.K'T7G*K;+9
M^F6^B=G[R3.N-+-SKG R('VEITG]*[<RAS?T3/>H8/4!59OMOR+#2Q[6P^N0
M [](ZS[3U#+WM^C_ #C?T?\ T%>;UZI]?JAV3&@ G$U+@T@?SFW_  B2E-NZ
MB[_ 90!X/JZ$2W;Q1^[O0+NI7U/+'"YKY(:UV0&N) :YS=OV?\UCU>JZQ@.I
M9;;U X[G $UV/QRYN[^;WNH%U7Z3Z3/TBI67XSG;K^JTVUOW&HLN.+&_^<8_
MTO59>_;L^E^DI24K'ZADWV%C&W/AI=[,@.<1^:=GH-]KG*5N9ET#=DMNH;(]
MS[X&P']+;_1_\$W9[?SU>Q<?)V^OC6;V7M819]H-@<UHVUN:;,:S\S\]O\Y_
MA$K6=1&0PNR!215:=YVVC0U?29Z.-]'Z7TTE.4>MM!_G7D2>,ELQ!,^^EC?^
MFC'JF&]K!^T;:;-SO5VN]2&@/V.EU&WZ1H=]'_@T2G/NM=6UG6L=QM^C&/&[
M<=C-A-_[ZT#B]7[9U?)B:.W_ &\DIJMQ\N#/4\PGL?L[1V_\*_O(-^=B4UBD
M]4O^UD;02T!Q<":WO%'H;/I,L]FQ:]>/DA@%N4YS^Y:QC1\FN;9_U:!;A]19
MM^R98#0XN>RVMI+MSM[@RU@9Z/\ 6]&])3B"SH[&M!ZI;)W[WD[06O!MJN]/
M;LV-<]O_ !OYZV^CTFG'+3;?:2=T7L],MW$NV-&QC>_O_G$S*>L"Q^^YAJ,>
MD&D!PT]WJ...YK_=^XRM6<9F2W=Z[MTQMU:?C]"FA)3.SZ=7]<_]2]34+/IU
M>;S_ -2]$24__]'U5"R,FC%K]2]^QDQ)GPW=OY+455.IY&5CXOJXK!9:'-&T
MM>_VDP_V42_Z*2GCV]0QO2K#['14\V5DL<P D;-WK-Q/SW;ZO4_PKZZ_]*D>
MH4/UL<X[B+&D/?Z9:X/?]ELVXC?3LKV;/\)=_I+UNCK'5@]H=C.<UPWDLQ[C
M#2&Q[G/8W?ZCO]?34?VOUL.DX["T D@4W[SMV?0;#O=;ZGZ)CO\ 1W?I/T22
MFWA];Z(W&:RJT4LK$>F^06@$-]T[MOTV?]N5HYZUTH$@Y+ 1((,Z$#<9_LJC
M^U.LM,''#BTD/BF\-]LN=L?JYWJM8[TOT?\ HO\ 2;%=P+^IWEMM]==>.ZL>
MTA[+A8/:_=78/YK=OV?G[$E,J^L=-M>UE5PL>X$M8UKBXAIVO+6M;N=L=]-.
M[(8<NM^RW:*[ 3Z5G)-4?F?R5<224@^UU?NV_P#;5G_I-,[-H8W<_>UHY)KL
MCP_<5A5NH%@Q@7P&>I5N+N(]6OE)37=]8.C,;N?E,8"0 72-2T6-^D/]&[?_
M %$O^</1"-PS*MIT#ITT\U4&995ZPIZAA8]0N?L9:)+03N+7$9%7N=9ZCV?\
M&G;U#+D;NJ].V_G!K2#!/MVN.4[_  ?\E)3<KZYTFVP5U93'V.T:QLEQ)!=[
M6@;OS7*W5<RV=@<-O.YKF\_\8UJHGJ&)R.JT0>/=7_Y)6L2UEH<69+,D"-6;
M8'_;9*2F=O\ .4_US_U%B(H6@%]/D\_]0]$24__2]55/JMF!7B[L^KUZ X>S
MTS;[AJUWI-:]WM_JJXJ75FV'%!9NECVN<&,;8XM'TO9<'-24U&8'0(W,Z9C@
M.8:]*J!-;@)J<-W\VYO^#<BBGI37ML&#4+*R',?MIW-< &-<UV_VNV,8U537
M:)'I@NU /V.!(^D[GZ+OS4P;<0V&-!,@@X9B1_:;MW;?9_I$E.J,T.,"IY^#
MJ_\ TJH7=2KH:'VU6AKB&C: \DF?S*76/_-61D8-.3+;L;>RW;O;]F>#+ [9
M[JKZ]FW=_@T)W1L(A[QB_P X-KB*;1H(_G-N4W\UOM_/24[%?6L6U[&,KOW6
M$ALU/:) GW/>&LK_ .N.5G[5/^#=][/_ $HL"WI.%8\%V.XM#2T$TV:@N?NV
M.9D?GLL]S_S_ .<_FOT:@[I.)8S;]GUD.V^E8(< *O<RO,][OH_3_P!'<DIZ
M(Y1'^"?][/\ TH@9>07U!@8ZLNLK >2P@$O9M=I8Y8E?1,!H%K<02)F:;B?:
M9;M;]J>U$HZ-TPAWVC$>X@EH].I]?MD_SK++;MW/TTE,.HFZEEF3=;1Z0M-8
MW:A[V^IOLR&-Q,QU=FYOIU^_^:?Z?Z)_\]6;E.<'/%V-L9O:2"9T8ZVO_O,W
M?S>_9M_\'_FU<'2\&O*KR*,2ZDUZRZIS_=.QI_1/]VR/_5O^#N4,MMKO]5PH
M>QGZ)SJ&TB3N&YWK"_>W>&I*9548.12'L&$ZIQ) =C[=1-?T++&N5_$:UC"Q
MIJ+09#:6[0"=72-S_I*B<'(C:'XKG@ $NJ:3('NW;=JO8=#:6&"PO('J>FUK
M6[@/S=C6N_._PB2DEGTZOZY_ZEZ(A6GWT^;S_P!18BI*?__3]567]8=OV%NX
M$_I60&S).O[C+'K40,RNZRDLI@.=H7$EI (/NK<&V;;/[*2GCJ[<%Q#]U?J.
M#1#H+AZ8'O\ 5]+>QVOJ,M9^?7_(4JK\&M]-;;@-HECB0PMW>YXV^FW]':UC
M-O\ VZNB;@Y[7-<2QX:(V/L):=-OO;Z#=R*:LX:BC%)' EW_ *324\O79A;6
MM):^"'![3JT@EU>VST=S?=Z>_9;Z?J^I_.?GFK;Z@!8'6"OV!];"]H!#6V5M
M?51[+/8S]S]!9_HUIW]4RJ'FN[%Q*R&C1][&^Z&N-.UP^FQMO_%_]N*-?7<A
MK&FC'Q=KR&@-R*Q^D/M95[3])S4E-.OIGKUAY:R@.!&RX_I&QN9^=C;MNWW5
M?Z+_  ?\ZB.Z8\SN=2_<[>YKKGF(D^VUV.ZSW.LLWJX.O9+GFL,QMPT:/M#?
M<=-S& 3[V[OH*'_.'*-HK%6-J2)^TLX&N_;.[Z'Z1)34=T1CBZ3CN#@&D_1W
MQ/ON:S';N>WZ/_#*3^EN<[>\8SB1&W>="0^7;G8WOV>H_P!/<Q6W=?S&?SE.
M,P0"TG)K$[AOK[^W?7NL2_YPY)L<QM>*_88<6Y+)&NR7,=M<WWG8DIHMZ.UL
M"MU$,(<QHL<P @GVC;CG9].S],S_ +;2'1F-K]$''%;0 TEY<>:WO#MV-_-O
MLJ_F_H*\WKV>]YKJQ:+7@[=K,FN=QG:W:[8_W['[/ZBT:W]5>QKG54UN< 2Q
MSG$M/[I+6N;[?Y*2G"9TH,M]0#&WN: ^PV6%Q):6WN_F6_SKG_O?HUK=$Q_0
M;D3Z0-E@?MI+BT#:UC6^YE>W;LVMVM^@K$]4_<H_SG_^01J#DG=]H#&_N^F2
M?\[<UJ2E[/IU?US_ -2]$0[3[ZO-Y_ZAZ(DI_]3U55\REMU;6D./NGVM8X\'
M_3M>Q6%6SK&UU->Z-N]K9+W5B7GTJ_=4U[O=8]C$E.,W]AC'Q/M3+VVNQP6[
M3>TN!VA[W-I<W?9ZCO\ "?IO]'^C4/4^JN]@G(+B?:-^49)\??M_._/5=]^+
MMQ:[A:+ZZ&A[6YE(>T%GJ?K#+K6V;O3_ $GZ/_!6)5W]/KW/'JP!+OUN@P/W
MO;9^]ML_\$24VO7^K#1]+( 'N^GD]O#W^]BD<KZM[!_2-NID?:9T&UV]S3O_
M .W%7QF8MQ].FK(OM:)](9-#GM#8:7-#;?WG?35VKI#K&;W5WM+B99;D>X#5
MNUWILL;L_/9^D24J.BNEGHY;M\$>W*(Y+F['_FM=_(=_-_\ !*&WH0(/V?-)
M(W?1RSH"?S4=G2KV-#6NO@"&C[78 !Y-;6&IZ^F9#';M][M0Z'9EA&AW;8V_
M124UPSH;&@?9\X-:>=N8>-?[:=[.A:O?7E  R3.4 "1^[N]O_?%H^C>?\$?_
M &(L_N3>CD?Z(_\ L3;_ ')*<\LZ"'AAKR@^8VSE<N/'TMO_ *3_ .+4/3^K
MS=SA7E'DF#E. ^E.T!Y:WZ7YJT_0R!Q4?_8FW^Y+T<C_ $1_]B;?[DE-&I_0
M\5YBC*<8((?7DWM$NV_GB^OZ;?\ 6M:>"_%LK-F-4:F.,'=6:B2/;]![6/\
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M2DDDDE(WSZM7A)G[E/NHN9-C'S]"=/BI=TE/_]D .$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P R     0 X0DE-! 8
M      < "     $! /_A.65H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY4
M8WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B
M('@Z>&UP=&L](C,N,2XQ+3$Q,2(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB
M:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.GAA<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M;6TO(CX*(" @(" @(" @/'AA<$U-.D1O8W5M96YT240^=75I9#HQ034Q-C$P
M14$R1#9%-3$Q03DV.4)!0D1&0S5%.3,T-3PO>&%P34TZ1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AA<$U-.DEN<W1A;F-E240^=75I9#HQ0C4Q-C$P14$R1#9%
M-3$Q03DV.4)!0D1&0S5%.3,T-3PO>&%P34TZ26YS=&%N8V5)1#X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAA<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX87 Z0W)E871E1&%T93XR
M,#$V+3 R+3$X5#$V.C0U+3 X.C P/"]X87 Z0W)E871E1&%T93X*(" @(" @
M(" @/'AA<#I-;V1I9GE$871E/C(P,38M,#(M,3A4,38Z-#4Z,S<M,#@Z,# \
M+WAA<#I-;V1I9GE$871E/@H@(" @(" @(" \>&%P.DUE=&%D871A1&%T93XR
M,#$V+3 R+3$X5#$V.C0U.C,W+3 X.C P/"]X87 Z365T861A=&%$871E/@H@
M(" @(" @(" \>&%P.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#4S(@
M5VEN9&]W<SPO>&%P.D-R96%T;W)4;V]L/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT
M<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF
M;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T
M;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@
M(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XS/"]P:&]T;W-H;W Z0V]L
M;W)-;V1E/@H@(" @(" @(" \<&AO=&]S:&]P.DAI<W1O<GDO/@H@(" @(" @
M(" \<&AO=&]S:&]P.DE#0U!R;V9I;&4^<U)'0B!)14,V,3DV-BTR+C$\+W!H
M;W1O<VAO<#I)0T-0<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B
M/@H@(" @(" @(" \=&EF9CI/<FEE;G1A=&EO;CXQ/"]T:69F.D]R:65N=&%T
M:6]N/@H@(" @(" @(" \=&EF9CI84F5S;VQU=&EO;CXS,# P,# P+S$P,# P
M/"]T:69F.EA297-O;'5T:6]N/@H@(" @(" @(" \=&EF9CI94F5S;VQU=&EO
M;CXS,# P,# P+S$P,# P/"]T:69F.EE297-O;'5T:6]N/@H@(" @(" @(" \
M=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L=71I;VY5;FET/@H@
M(" @(" @(" \=&EF9CI.871I=F5$:6=E<W0^,C4V+#(U-RPR-3@L,C4Y+#(V
M,BPR-S0L,C<W+#(X-"PU,S L-3,Q+#(X,BPR.#,L,CDV+#,P,2PS,3@L,S$Y
M+#4R.2PU,S(L,S V+#(W,"PR-S$L,C<R+#,P-2PS,34L,S,T,S([1CDR-D(R
M-T9&0D0Y.#,Y1$$T.#5$0T5$.38P-D$Q-S$\+W1I9F8Z3F%T:79E1&EG97-T
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z97AI9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\B/@H@(" @(" @(" \97AI9CI0
M:7AE;%A$:6UE;G-I;VX^-S T/"]E>&EF.E!I>&5L6$1I;65N<VEO;CX*(" @
M(" @(" @/&5X:68Z4&EX96Q91&EM96YS:6]N/CDQ,3PO97AI9CI0:7AE;%E$
M:6UE;G-I;VX^"B @(" @(" @(#QE>&EF.D-O;&]R4W!A8V4^,3PO97AI9CI#
M;VQO<E-P86-E/@H@(" @(" @(" \97AI9CI.871I=F5$:6=E<W0^,S8X-C0L
M-# Y-C L-# Y-C$L,S<Q,C$L,S<Q,C(L-# Y-C(L-# Y-C,L,S<U,3 L-# Y
M-C0L,S8X-C<L,S8X-C@L,S,T,S0L,S,T,S<L,S0X-3 L,S0X-3(L,S0X-34L
M,S0X-38L,S<S-S<L,S<S-S@L,S<S-SDL,S<S.# L,S<S.#$L,S<S.#(L,S<S
M.#,L,S<S.#0L,S<S.#4L,S<S.#8L,S<S.38L-#$T.#,L-#$T.#0L-#$T.#8L
M-#$T.#<L-#$T.#@L-#$T.3(L-#$T.3,L-#$T.34L-#$W,C@L-#$W,CDL-#$W
M,S L-#$Y.#4L-#$Y.#8L-#$Y.#<L-#$Y.#@L-#$Y.#DL-#$Y.3 L-#$Y.3$L
M-#$Y.3(L-#$Y.3,L-#$Y.30L-#$Y.34L-#$Y.38L-#(P,38L,"PR+#0L-2PV
M+#<L."PY+#$P+#$Q+#$R+#$S+#$T+#$U+#$V+#$W+#$X+#(P+#(R+#(S+#(T
M+#(U+#(V+#(W+#(X+#,P.S<Q.44T-3A#-#=%0CDY13(W1C=!-3@V,#8W,#=%
M0C!!/"]E>&EF.DYA=&EV941I9V5S=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_X@Q824-#
M7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3
M+4A0("
M         !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B
M:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0
M !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #
MU    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER
M:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M       2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q
M.38V+3(N,0
M                6%E:(        /-1  $    !%LQ865H@
M         %A96B        !OH@  ./4   .06%E:(        &*9  "WA0
M&-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                          !D
M97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(
M9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$
M '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
M $P)5@!0    5Q_G;65A<P         !                         H\
M   "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H
M "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4
MF@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$-
M 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!
MJ0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G
M G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#
M6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q
M!'X$C 2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%
MQ075!>4%]@8&!A8&)P8W!D@&609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]
M!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(
M^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<
M"O,+"PLB"SD+40MI"X +F NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-
M#0TF#4 -6@UT#8X-J0W##=X-^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>
M#WH/E@^S#\\/[! )$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2
M!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.
M%/ 5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7
M]Q@;&$ 891B*&*\8U1CZ&2 911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[
M&V,;BANR&]H< APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>
MZ1\3'SX?:1^4'[\?ZB 5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O
M(MTC"B,X(V8CE"/"(_ D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<F
MZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV
M*VDKG2O1+ 4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O
M_C U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38
M-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ
M-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B
M/^) (T!D0*9 YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%
MFD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:
M2^),*DQR3+I- DU*39--W$XE3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92
M,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+
M61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@
M!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]
M9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O
M'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X
M=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_
MA'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$
MB&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1
M/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IH
MFM6;0INOG!R<B9SWG62=TIY GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D
M5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K JMUJ^FL7*S0K42MN*XM
MKJ&O%J^+L "P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV ;9YMO"W:+?@N%FX
MT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8
MP]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.
MML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQ
MVG;:^]N W 7<BMT0W9;>'-ZBWRG?K^ VX+WA1.',XE/BV^-CX^OD<^3\Y83F
M#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_
M\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^
MW/]M____[@ .061O8F4 9$     !_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,#
M 0$! 0$! 0$! 0$" @$" @,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P/_P  1" ./ L # 1$  A$! Q$!_]T ! !8
M_\0!H@    8" P$             !P@&!00) PH" 0 + 0  !@,! 0$
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MNS]GYOMGH;!]D8[;>]\6^[YNP<[D*W<_W5.U;BL"]#CTR>+CF9O)434_NO=
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M[\J*APZ_;,7"#ID.(S#5QR>H ^-@UK$7]U[J-%_PI6_E!RP33_Z>^T(_#/'
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MA,9B*&H@K88O"^2HA4"$ F(>Z]T3_>'\NWXF=FXS=$W=O\Q ]F[^Q/PUW?\
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MY*&6I5<J6@BEQSB=6< -"0X])O[]U[J9'VSU7- M3#V9U_+3/&TJ5$>\MN/
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MJE<OMC+]'8ZN_E<[<BW1O3K^7?FZ-LY2?9>7JNL]N;>S&\\I1["J#2XG<<V
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M[KWOW7NO>_=>Z][]U[I+[W>&/9>[WJ2PITVOGWG*(9'$*XFK,I2-7C9V" V
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M>Z;5^!_P=6CFQZ_#7XIKCZBHAK*B@7X[]0BCGJZ='B@JIJ8;/\,M1#'(RH[
MLJL0" 3[]U[K''\"?@Q")5A^%_Q.A$\+TTXB^.G3Z":GE96D@E"[. DAD9%+
M*;J2!<<>_=>ZX'X"_!0J$/PK^)94,6"GXY=/%0S*JLP']S;!F50"?R /?NO=
M='X!_!(_7X5?$HV%A?XX=.FP_H+[-]^Z]UKC[GQ]33;NDGRWPV^,G6.VZ[NO
MOWKSN;;,?\INC[#R/Q,PW7N2[E;XMUV&W-BMD_8]VX7Y7XO9^VEK,O31UU+1
M3Y<&C^R6MI_L_=>Z*I4;X^3==@<?4TO\L+XLX+<VY>T9=L[[VM6_RNX<=3?'
MO"46*ZSEHOM^Q6ZTW=@>Q:/=F?W1N[&O-38C)RX--FI75)>FFD6?W7NK>_Y>
M_P 4OBKV5\GOY@%1OSXE?&O*+24WP.RN,Q.4^+NQMIX3#UF\?AGL'=NZ9ML]
M;[NVM49GKFCRVY\M52U&*J_\OI:L21U3-,C'W[KW5M'^R"?!*UO]DJ^)5OZ?
M[+CT[;_WC??NO=43_P TGK#IWXH]T;2R'0_P^^(^Z=E3_#/Y;=I]V=-8#XI_
M%;-=KX3%]<9[JK$[4^1726&SO5%7F-X[LZFW/VM/FLYMW)553A<UM_&UABI?
MO:>U1[KW1:^U=P=5]3]#P=B=??"SX>]Q;QDW#@^T,ALA?B#\9H<GE?B7\*MC
M=?I\_P#NNHQ>,V-A!0[@[5[FR>;VACZA8*:AQ,WVDE/' *>H0>Z]UL6[2^"W
M\L[L_:6V.PMI?##X3[NVAOC;N,W1MC<>,^.71N6Q6>V[N6./<6-R>/R%-LZH
MI:VAR0KEJD>-W1V?6";W]^Z]T^'^6K_+J9F9O@5\,BSQ) Q/Q@Z3NT,:HB1$
M_P!R+F-%C  ^E@/?NO=1*?\ EC?RW*5:A*;^7_\ "J!*OQ?=)%\7.D46H\$2
MPP^8#8X#^*% JW^B@#W[KW7&/^6)_+;A69(?Y?OPIB6IM]PL?Q;Z043696'D
M V/9K,@//Y ]^Z]T\P?RYOY?--*L]/\ !?X>0S)*DZ2Q_&?I='66./Q)(K+L
MH$.D7I!^H7CW[KW0H]6?%;XQ=&;DR^\>D_CIT5T]NS<&*&"SVYNK>I=@]?Y[
M-X1:U,DN(RV7VG@,37Y'&+D8EJ!!-(\0F4/IU"_OW7NA[]^Z]U[W[KW7O?NO
M=<)%9XY%20Q.R,J2J%8QL5(60*X9&*$WL00?S[]U[KDM[#4;M;DCZ7_-O?NO
M==^_=>Z*SUU!4K\M_D[5R2L]--UE\9*6GC9X?V9*6?O6:H5(ED:H$+_>HPD=
M51W+*I)1[>Z]T:;W[KW7O?NO=>]^Z]U[W[KW7__3W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71 /U]^Z]UZPXX^@L/\ 6XX_WCW[
MKW15/DK\R.D?B9N/XZ[?[JRV1VW!\FNYJ/HC8>YQ10S[6PV_\KMS.9_;\>]\
MG)602[=PV?JL*N,IZ[Q3PIDJRF2<PQ.TT?NO=%P3^<#\"J3I_<G;NYNZ\'LN
M3:VR.YNP\MU1N:JQ5/W:FVNC,KV-CMW/#UKC\KD<O-E\M3]59JOPU!J6MR6-
MI7J4B$<508?=>Z6O6G\T+X5]C2[9H*CNS8W7^=W_ +TW9LWK/;&_=[;"H=Q=
MC_W32@DDW+MC&X'=FXRFW,\F3@7&_P 0:AKYYW%,U+'4D0GW7NG^'^9I_+RJ
M=J5&^:+YI_&FMVA2;F39TNXJ#MW9M?B1N&3"0;F^TCJJ/*SI/2Q;;G7(RU<>
MJCAH U1)*L*.X]U[I-+_ #,?CFO6V*[9JEWM0;)S'S9W!\"Z?*U6%Q'AI^X=
MM=M;GZ:R6Y<C/#N*:CH>K!NG:57.N6>43+C]$STR,QC7W7NE;B?YEO\ +YSN
M"I=SX?YH?&K([=KMYXOKZBS=+V_LJ3&UF[LW14.3Q.+I*H9?Q5,5?B\G3U<=
M4A:C-)*LWE\7K]^Z]T6K:O\ / _EZ[HWUAMFOVY%M3';AS_9>VL1V'OB7;FU
MNOWRO3])V'6]C0YC*Y#<JY3:2;?I^N*DHV8HJ#^("MI&HQ.C3M![KW1D-Z_S
M)/A-UWW?N7X^[T^0O76W>Q=C=<[F[.W[2Y3<6+I<7L;!;7S_ %QMNHQ.Z\G)
M5K'B-XY>N[6PCXS$.OWV1IZH20(X,8?W7NA&Z\^:OQ'[;[ Q/5/5_P D.FNP
M.R<]LBD['PFR-H[_ -N9W<F6V16T&/RL&X<?C,?7SSU5)_"<M2U;H@,T5+41
MS.BQNK'W7NBW=[?S:_A-TI+3;?Q?;&W.[.S:KY%=4_%L=1=-;IV1N/?E#VYV
MYO#([+PN.SE-E=T8+$8/#8#*8'*?QBNJ:M(J"3%U-*=5:JTS>Z]T_P"ZOYG'
MQEV;NON#8^=RF9HMU]*?*7H_XE[HP$\NSJ?,93?O?D'2M1M+=6UL55;QI\CF
M.NL)'WOB&S5>8HJJ@6EKF%+(L"F3W7NE@_\ ,K^ *;:?>#?,'X_';$>\$V%)
MG5[(V])C4W.^%_O*('G2K;3B1M@'*-DR/X8N+4UAJ!3*91[KW1/O^'Y_@%1=
M@TO76Z-S[VV1DCO";9V:S6ZMOX2EVWM:=,G\E<329O.Y'';IR<_\"RM9\7\N
MM*U'#5U4IS.(7P!JBI6C]U[JX':>Z]L;\VMMS>^RMP8?=>SMX8+$[HVINC;V
M0I<O@=Q[;SU!3Y7"9W"96AEFHLEB<MC:J*>GGA=XY8I%9200??NO=*#W[KW7
MO?NO=>]^Z]U[W[KW7O?NO= [\B.K*CO/H'N_I.DSL.UZCN+J'LKJR'<U1BY,
MW!MR3L'9F:VDN>FPL.3PDN8CQ!R_W!I5K*1I_'H$T=]8]U[JOK ?%/\ FH[9
MPF VWB/YG/2,&&V[MK$X&A@?^7?BIIT.'ABQ],PGF^43,U*<731AE?5*:C4^
MO01&/=>ZG0_&W^;<'ION?YH70C1B@ K!3_RY,;%(^6T+JEI6F^5,RPXLR7M$
MXDFTV_=O<GW7NLK_ !N_FS%AX_YH'1:I]S,3Y/Y<^(=S1:)OMD!7Y2(HK%D,
M?D>QC90X5%)4K[KW7%?C=_-I^\D+_P T#HC^'?<5!B1?Y<V*&0%&8_\ )$DG
M/RE:E:K27_.N(@CKPJJ>??NO=1)OC9_-Z\A^W_FB?'D1?:N )_Y;U(\OWQ0^
M)RT?RQB3[,26+)I\A7@.#S[]U[J+_LMG\X?15_\ 8TCXV^0F+^'G_AM>/QQ*
M)3YQ7+_LWFNI9J>P0QM"%DY(8>GW[KW7!/C;_.."%)/YHWQC9KNXEC_EJ2(]
M]&F.)@WS#EC,(?U-90Y^@8>_=>ZER_'#^<#+/42+_- ^-E/"\KM3T\'\MRZP
M17011M)4_+NHED<*&U,3RQ%@ +'W7NL4_P ;/YPA1OMOYHWQO27R1Z34?RVH
MI8Q#HD\H9(OEO3N96DT%2& 5=0(8D$>Z]U+3XW_S=F2D$_\ - ^/"RI RUK4
MW\N&F2.>H\M2RRTZS_+*H>!/$T*E27Y1B"-0T^Z]US@^-O\ -O 'W7\T/H-S
MK]7VW\N/&Q#1]PY-O-\JI[.*32+\CR@M;20H]U[I%=M?'3^:G3=:]I5.2_F9
M])Y';\'7>]YJC%Q_R\\119.LI8]M9EYJ0Y2/Y.2PTTD\05!*M.WC.IM+<*/=
M>Z,#_*.2E3^5E_+G6B\?VO\ LDOQC,/B%D"-TYM!K#^I!)!/Y//OW7NK#O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U"QU$N-H:2@2HK:M*2".!:G(U4M=73B-=(DJ
MZR=FFJ9V_M.Q+,?K[]U[J;[]U[IGS>W=O[EHIL;N/!8?<&.J(C!44&;QE%E:
M*> STU489J6O@G@EB-31PR:64CR1(WU52/=>Z>/IP/?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U J\7C,A48RKK\=0UM5A:R3(X>IJZ2GJ:C$Y"6@K<5+78V::-Y*&
MLEQ>2J:9I8BKM3U$D9.B1@?=>ZG^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z];\_D>_=>ZZL/^(_UA_0?T''OW7NJE=S?#;YT[*^57RF^0?Q5^5'QO
MZ_VS\J<[U)N/=&R.Z_BYO[MW-;;RG4?3>U>I,?\ P+=6U/DGU/128_-P;?>K
MFAFQK/"[J$D:[W]U[J1_HJ_G8>"8_P"SG?R[_N@:7[=/]D5[T^V96$_WIF?_
M &=;RHT9$7AT@A[MJTV%_=>Z9*OH;^<=79&+.Y#Y4_RT,GG::D;$T^1KO@)W
M1+6KA:Z"<97&KE)/F9+7P4E1/+I,"'Q2QNQ<7-C[KW3(WQN_G"/+#/)\E_Y7
M$D]/B<M@:>=_Y>W<3308//U(K,]AH9#\QM46*S=6HEJZ<$0U,@#2*S<^_=>Z
M45#T]_.PQE)38_&_+[^6SC\?111T])04/P2[UHZ.EIX@%CIZ:F@^9Z0T\**+
M!54 #Z>_=>Z4;]=_SJ&H/ME^57\N".M^[BG_ (F/AA\AV;[5!.):'[)OF9]O
M:<R(?+?6OBL!ZC[]U[KA%UU_.J1U:3Y7?RX)D!!:,_"[Y#1AA9P5UI\S=2@E
M@;_7T_XGW[KW3Y%LO^<DAC,GR+_ENS:8J9) ?B-\E(Q+)#2RPU$WH^8]X_O*
MEUF*@D1Z-"W4D^_=>Z;?]'_\Z+S1R?[-#_+?\2Q(DE/_ +)M\BM,LBTHA:;R
M_P"SE^2/74@S:1< G1^GGW[KW1C_ ([;>^=^(W3N*I^5_:WQ6W[LZ?"K'M/%
M= =(=J=79_&[A;)^66JS^8[ [V[6H<MADQ!,$<$%'2S^<"5I2+I[]U[HWWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HH_651'+\R/E;"J!7INK?BJLC#1ZS+
M+WY*ILIU^E6 ]7^PX]^Z]T;CW[KW7O?NO=>]^Z]U[W[KW7__U-_CW[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$0^9O1G
MQQ[ZW;\:-H_(K?6W\-C\EO3M[:.S>K=PUN'HH^^,SV/\=NT]D9W8N+;(SPU\
MF=P&SLO7[CHSCKUT%3ADGC*^+6/=>ZHSV9_(W^/N\.D-J=J4?\S#>78WQVV=
MU%VU!2=G;TP>T<MBZ>#.=<?)OJ#N;L++[XRNZJ';U+@Y*+NS-93+M5T(JES^
M,DJ:G)/32-21>Z]T//7W\F/KCLA^R<]LSYY9[=^![6[3EI_EQ3[)ZPZXIZ'L
MG=74'=.'[UVCL_:67@KLAENEAL;N.CGER<>,J:U<GA:J.AC%(T$-;[]U[J;W
M-_PGTV_VKU]@.M<5\O\ ?6QML4_QLZ1^,6\L)C>M</4;?WCMKIKH#/=$TFZ7
MP]#O+ -C]VUO\:&9H4GGK\9C:ORH]'6-)%/3^Z]TN*+X(_%*3X;;"^.U!\U,
M'/LT_P R[L'L#$=E3)M>JJ=R_(S/=T]KU.<^-]#%+N00-O+$[YS61PQ3[B?)
MM58QU>%I&=1[KW3#OW^07MW<N'ZKH-I?*O<NR,MU7T[\7NC\-NN/J+;&5W51
M[:^-_260Z2?<&U=ST>Z-O[GV3O?>.-JXZPO15QPL;+)2Y+%YJF:..#W7N@0J
M/Y2_QE[IWOVAL3 ?S(ML[@W;V-NOO_:V7VAMG;W6F5W-3[5[@V-\G<?GM@8V
MF3?-;)D=][*':62RD^32GD 7;31U..BCDG\?NO=+S?G\DO$=G=AY.D[7_F!?
MWI^2^]\AV!\BZGQ=-[&VM6Y+,TO:GQ/W5@][4/6N#[ I,O'U;U_O#HO%XJOI
MHZ[R5M/N/P)DZ&KB@J']U[HR7Q _DQ8#XB_);KCY#[;^1><R5)L3K[,;7RW7
MNV^I-A]68SL'<NY=O5>$S%9O;);,J(8=R;$Q]?7RY?"8O)4%?N'%Y0KKW%54
M:_9GW7N@)ZA_EW_%[;V_MT=A4/SQEW=UW_+C[XJ]QQ[:AVULC$83XW;=VMV;
MO/Y==G=1]O=FPRS5V^\S'N??$,^4S-344T^(Q.+2EJJ1J]ZRLD]U[I1=J?R_
M_P"7)\G^T=Z-GOD1UCG^Y_G'\A?C=\YNL=P8?'=79/N&LZKV+UMLVGVQL7I?
M>%;!D]SU75O96T?C1G*]J^CD\8IVR+)$R1.7]U[H%I/^$U6P9NKZOK*/YD]D
MX_#YW%T6QMW)ANK]DXS%;RZOVMUCFNL.N$W%1)EY<EG.V=D8W-3U46X:[(5>
M!%145)I-NT(EC,'NO=&KZ9_DG[.Z7[TZY[=QGR'W#N' ]?9S<.\DV-G>L]H-
M5Y??&5C^:&)P^?;>U-D(<CC:;;FV/FMF:6&D@I=,E1B:2IUIKFA/NO=6L_&7
MI7#_ !F^.?17QUPNY*_=>'Z(ZBZ[ZCQ>YLU!0T66SN-Z\VGB]JT&7R='CUCH
M:2KR%)B5E=(QH5F(!(Y/NO="!N3L?8NS]P=?[4W1NG$8/<?:NXLGM+KG#9"I
M$-=O'<F&VEN'?F4P^#A()JZRAV?M/)9&118+34<C7X /NO=1ME=I=>=C4>ZL
MALC=V&W'0[(WMO#KC=E7CZF]/@=\=?Y&7$;UVU7RS+$D>1VUDX'@JP"5BD1@
M6X/OW7NFWISNCJ[Y ];;9[@Z:WEB]_\ 6>\H<A5;4WEA4K%P^X*+&9>OP55D
M,5)74M'-5XTY/%SI#4JA@J$021.\3([>Z]U!RG?O2^&["P'4^1[+VC#V5N>L
MP-!A-E19:&KW#55.Z=M]@[PVR):"C^XEH(-P[:ZJW'5T,U1XHJJ/#U(B9F32
M?=>Z%H2QFQ$B$'D$,"#?Z6(^M[>_=>Z#3M_NCJGH+KO.=M=S;\V[UQUKMJ7#
MP9[>FYZT4."Q<^X,YCMM82&KJ]+A)<IN#+TM' MB9*B=$'J8#W[KW2!ZH^77
MQI[S7;C=1=R;,[ 3=>*[$S.%DV[6SU<3T74NX-N;6[*3)2-31QX');+S^[L9
M35U%7FFK(FK8SXBAU#W7NC#FH@5F1IHE=(_,Z&10R0W9?,ZDZEBU*1J/%P??
MNO==1U-/,D<D,\4J31I+"\4BR)-%(%9)8F0D2QLK@AEN""/?NO=8H\A03)!)
M#6TDJ53O'3/%4PR)4R1)+))'3LCD321QP.S!;D!"3P#[]U[J9[]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[H,.[3IZ8[=:P-NL-_&Q^AMM3+&QMS;W[K
MW10OY2%%'COY6?\ +FHXIIJB.'X1?%_3+4*B3,).F=G2V98RRC07L.3P!?GW
M[KW5AGOW7NBLU'S;^)]+%O>:I[UV+ O6_P @=K_%;?"RUM4DNW?D-O3([=Q6
MU>J:V!J03MN?.5^[,?' L:O ?N-1D"QRE/=>Z#;&_P SOX"Y;L38/5%!\H^L
MY=^=GT&TLCL;#RU>5I:;.0[^K,QCMBT_\?J\5!MS&93>F1P-738FBK*NGK,C
M40^*GBDD9%;W7NE;VY\__AMT+W#@^@^X_D#L;KOMC<-)M"OH=L;D?+4<--1[
M_P YD=M;(J<]N1<7)M3:T.[-P8BHH\>V3KJ,551$4CU,5!]U[I@S/\RGX'[>
MW5W'LC-_*'JW&;IZ!P>\]Q]L8FKRU5'+MC%=;RI3=BO!4&A-'N6MZ_JY4@SE
M)B9*ZKQ%0ZQ5<4,C!3[KW0[]#?(OI+Y/;&?LCH7L; ]E;.@S60VU7Y/"FLIZ
MG#;CQ24TV0V_N'"9:DQV>VYG*6EKJ>=J2OI:>H--4PS!#%-$[>Z]TH.I.Y.J
M^^MDTO9'3&_]K]F["KLSNG;]%N[9V5ILU@:O,[*W-EMF[JQ]/D*1G@FGPFY\
M%5T<VDE1+ UB5L3[KW0E>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[HI76CLWS&^5BEU8)U;\5PJ -JCU3]^,0]YI%)8FX
MLJ<?@_4^Z]T;7W[KW7O?NO=>]^Z]U[W[KW7_U=_CW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5I?S!_@UGOFWN?XMT:Y
M_#[5V?TGOOLWM&LW=#DLSCNRM@=IKU)N/ = =G]3OC*0TK;HZW[3R5+EI?NJ
MNDC>FIVA(GCEEA;W7NJ"LE_(=_F [RP>T<#OC=7Q-EJ,-\7=X]*;GSF+WSV5
M08_=QWS\>OD)LW-[+S.!CZ?EW ^T)/D'VQCMU+_#,_@L(*+'12S8.JS-/%7>
M_=>Z'A_Y-?S/J=W8G<M)7= [?R W",YUCN>E[J[IJ-P_"RBH_D;FNU=UXCIF
MDCV)%CNR$[^Z3JL=UUG37282+'8W%QH5KZ!4HQ[KW0(=J?R#?F35=48'J7J7
M<?0V)V_-U/TI4;BI*WNKM?%F#Y>;1^+E1U=OSY*T$^5ZL[ QM?F*OM?PY:3)
M-BX=V5R4M)5463PE7&[-[KW5B.YOY8/R8S/PNV5T)0[GZBI.T-O_ ,ROMGYF
MUN=BS^Z(L.FR=\=R=W]J8:&7-+M5LO6]B4L'9&/AJ6^UC@$\<FB=E19']U[H
MBF[OY#/RJVYA.E]I=+9;J>DVSL.C^+FZ<CC\KWIVAAL+%\B-A=()L/O3O?/[
M5CZRSE-O3<&^MY8VDK/XOCJS;&[U:-:RAR6/F,\,WNO=(3*_\)_OEO/DMSSX
M:/H###%Y_P"3.W.E<E!V_P!G02; Q'<.$^3,^V>V8<-1;&B@PN2&[M_[3_B6
M&HJF:I%%2-,*N:6E2FD]U[H6^^/Y,WSM^0';V_/D+FZOH':F[>T]V]DY3?&R
M,#W=O',TV5Z6SO<7Q=[ QWQGFWOO+X];GP,FUMY;?ZJW*F6J9-I5&(3)UL,=
M1B\A0UE9H]U[HTO<7\K#Y3[O^"7P<^-N'R_7>^\K\=\?W+1;[ZO[4[Z[+;8O
M\?W_ + [#VWT+V'A^W<%U+%NO=&<^'.YMT8[(;9I3MO"0E:%30-C:BCQ\L7N
MO=+[;?\ *N[NVK\(^V?A]M?>_6^QJ[Y+?.S=?<7?_;FVFJ*C<63Z!W/VA2[]
MW'D\1A=Q[-SNW]P]M[[P6TL9@:_$YN"IP2T.3K1//6)$(:GW7NB)]@?R+?GG
MFMR9G![3^2/3]#LWK_KCL?ICX_\ 9U7D=Q;>[;_T6;LPGS.RF"PF]=N[-ZNQ
MFP]HU>*S7RL;:KM@4DH8-K4WGIJ2.2".AE]U[IHW9_*%[=Z7Z1WIVMV9U-MW
MN:796)ZGQO7/QOZYW%O7O^IV]LK*?,^I[-[VZ8P..V-T3TU#1=1=A=29K[',
MQ;+V1%44E%59&GI,)64IJ(,A[KW3U_*Z_E\_(K;O?WP[E[;V+V=U3U%UGTSE
M/EUW!U+GL1NR+K;!?+1NQ?D)U]\4]I;8W;N2H@GS&X-G?%SO25]RX:G25\)6
M[1P,>3\=8?MT]U[H9*[^2U\B>POFMV]W7VUE/CWE^B.U.^J;>>^=B46XMTR2
M]N]=87Y6[)[UVG!OK:%+U+@I)\OA.MMNR;:FQV=W7NVBJ*AYUII<?AJIL8/=
M>ZG_ !'_ ).7R6Z.^4WQ*[<['K/CWO/&_';>F4W34=T'?_;&?[PQO6:?%[LK
MXW[,^*VRML[DV3)MA.J=GUV<QNY(*[^+XTK-4U,(Q[2Q"JJ?=>Z@]P_R*^T.
MV^Q?E'OS+[IZ0K\QV?OB?=O1V?S5;V%)D>KH=X?S!=P?);M$+!CL)2IBL]NS
MH+*_W6GJ*5JE:JHFGH9B<9-.TWNO=%[Z[_X3X?++8&'W)MO$=Y=8X+)R_'W)
M=7;>[)V[V#V#BJ:7"YSX];$ZJJ_CMF^N<3U-A]P3]-4N]-GUN0&5DWI4TRTV
M8:KIMKT^622>3W7NA'K?Y''R,R.\.RMU]:[?^('Q!_TH[2KW3']";^[UR$77
M53_HJ^:?6N,Z?Q%36[0VW59'858WR&VU4Y'(8S^[=!218JKBPN QO@H=?NO=
M*'*_R>OFS3[8WMMGK.M^*G5>V>]LC@J_.==8/LSNJEV?\2\#L_Y;=8?)+;VP
M>A<GM3K+:>YM^8FI3;FX'-1'-L(XK,9^H>AC2,J_OW7NC"]%?RN_E'U5_+DS
M_P 4ZG</153V!1_+SH;Y%]<[<J=U[MJMA8_:/2_<_P ?^U<IL?>G9^*ZCP&2
MSF3WO6]0Y25<C3;%IY8#EX5K_P"*5J5N4K/=>Z#SY1_RC?E9\C=P=Y]LY?+?
M'%-X?("7(Y?>/3^/WIOV@V#B)\5NGX60;)V]B=[9CIS<>)WG//LGXK557GLG
MNK8N4PV4RF2BH9]MST*>>+W7N@(JOY$7RY&4[0RTW;/1VY]T[MZ2QVPJ3?60
MW1OO"4FXJ!^E.BNIZWHC.[ 3JK<-;3=3;?J^I:S(8FLRFY]TX2.6IH)9-G&:
M*M-3[KW3!@OY"WS<Q];L.EQ/R"ZBZK?:_7?RNZ^Q79>QMX;VSNZNM-K=Z9#Y
M9Y+:&U-A[0_T-]?[;Q9VW4?(W'H:_:M3L'&0TV*J4EP=>R81\3[KW2MZX_D5
M_);8O9/QH[ VQEOCMU[#TUWEMGL[^[H[$["[%Q.P*;%YCX_S[]RNR-N0]'=7
M=?Y/*]KXGJ&MUTN#PO7F5QE=5PO6;BS=)-E**M]U[K:W]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]T%O>+%.E.X'6-YF7JWL!EBC\?DE*[3RY$<?E>.
M+6Y%AJ95N>2![]U[HI/\I4$?RMOY<X,\%0?]DB^+W[U-/45$#_\ &&-F_P";
MFJGDGD"_0ZF-B+#BWOW7NK"/?NO=:RN]OY'W?V[/D3OKM8=S=2Q]>;]^>6+^
M=&X.O&AWI3R9?L/K;Y)[;W-TMFZ^N@PSQOE]N_&7/;MP.0HV\E!4;B@PLRLU
M.LTM/[KW3WM+^4)\L\/U7VQ\;LEO3XX+U/\ )#9_Q)VAVGV/29_L7(]D]=4/
MQSW=N3<^X:OK'8U9UC0;:W1NK<J9&D7#9BOSN&.#R,;5YI*EHHH#[KW1@OFI
M_*S[:^3'?7R-[WVUVK_ X]X;*^%.$V)TW-VCV;MGIKO"A^-_97:^_>TNJOEE
MLO:F.2AS77_9F-WS2XO&9&B.0R>'833B,PM/15GNO=!QVA_+2^;6_/BGNSX0
MX;</Q)PW4.T]C_)[;?5_:F>D["W'W3V76]RYG,Y3KMMU5S; @G^/-?@(]TU1
MW?G]OY7=N2W564JO'3T457-''[KW2QVG_+D^=.S>O/E=/US\KTZ5WU\ANR,]
MNW#]:4>]LC\C]ET\.\NE>K^B,ON#M?Y*=^],S_)[L'<FT,5LN?<&VZ7%U.VZ
M;'U,%%BFF>A5IE]U[HU/\MSX%[P_EZ4W=O3^/[9KNV/CUN7)]7;WZBJ]X4FV
M<9V7MG>%'UU0];=KX3.XO8.Q]C;"BVM7T?7NV\IC:BCIS75F3K\M-7ZZA_N:
MGW7NK.O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]T4;K*82?,KY81"JJ9C!U;\5%:FF: P49DE[\D"4@C F5)@VM_(22Y-
MN/?NO=&Y]^Z]U[W[KW7O?NO=>]^Z]U__UM_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4U?S2.MI=Y=U? O=>[OCIV_
M\G>@>NMT?)C(=U=;=2;0GW]4U;[FZ#RFVNN7SVTH\OA8,C33;LK/'1R2S1QT
MM84E+QJKN/=>ZJ1^)70?RBZ*[;S/8'RX^-?<O9F3VUA?C/N;KL5OQNWA\N.P
MAM7K39VX,O@>M\3WYA^\<!A=C]D;)H*G";=S$DV"S<,^?Q+US5&0\\DP]U[H
MY/\ +_RWSD^$_:&Y,Q\YMB[@W!L?^8-NKKOM3%5W66Y]V]P'H[Y6=Q=H_P!U
M\[UKV)@MQ;?V;/UGB)-A;[VO2-0[=ILGM[#4FP,I6&<F2623W7NDK\U.@>]]
MT=\?-".EZ"^078'RN[:WIT?7?RQ_EOLRDJ,CU#\7=F;9V5U?05%)/ONGW9]E
M\>8=A=P8[=>Y-\4%?2TD?8F)KHZ>.',B48Z'W7NJJ]O_  K_ )D73O<N9^1?
M6/6_RDW_ /(7*;R[]W3LK+=I;(Z_W#MK&]@;F[K_ )FJ8'?&XYSM#96)HFSF
MV-C]1Y1)Y)T@D@S>)I)8FQ'\+H*3W7NCIS]Q?SEG[3Z%HNGLK_,';HI-S[9K
M,1NGY1_$?IP]B=H[DR?9VSJ3M78O>FV.KMEX*3KOJ';&P:BO3;V=W$>NJB8R
M5]3'45QHL5]W[KW0Q_S-ZO\ FD]@]G_-'IWHN/Y:R[!W/U)V3MCK_ =8]7];
M+T+DN@*WX49O,2;EVSW#6;?F["D^7.>^9;Q;7I<-19J.J&V)I)(<=&/#DE]U
M[H3?G-T-\^9(OB9LGX5;"J(.NOY;_2/77?\ %D-P;ZRW7-5WSW)M"?%X/!]-
M[*VGU?LNMV[V5N6/J7KW=6(S6!RE+M[;L]5V'0/#-#) OA]U[HKO;?R$_FE8
MW;79^_J]_P"95UM@H^P.U]X?(IMG?''H?,8?HK8N&I>Z\[\4,?\ #9-S[0RV
MY=^[5W'0X[8</:OW=#NF##T:9*2MKL16S5"K[KW7+#=W?S2/D?LCJ':&2ZT[
M][#P-77;*[NW?O:?IKKA.HNQ]G;MR_P)[5^/DW7^\:FEQ.W=QY';E3)OW(U-
M+%44B8BHIIH\M/31PTS)[KW1<&VK_-G[>V#T'EN\]I?.+-Y3JGM"3-;U[(HN
MK]H[9[HWKU[C?E-_+AW5F]O4&TL5UOA]P;>P(IL?V-5_W6DGSM#DO[NR2TF5
MS&W:>ADD]U[I=[(?^>'LWI[:/6FP-G_*?KKLS$]3]=[(IMN8KKCH&@^.77G0
M5=TKUK3T.X]C5,6"JVA^9.V_D?5YNFR6-J)*O%T6VHY'EH1C(:6<>Z]T;WH>
M;^;ILC^8)TSLS?U5\N.S/BQLOMOOOJ:HS^]*'IS$;/W;T%0;R[KDZ\[T[1[
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MJFGIZ=Q3Q1T..RLC>Z]T;_\ F@?S"^S?B1\B?@AW1UEO>FWE\0*GICY*=O\
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M"]P%="2R/J'7NXBNA(%:=VO] @+D_07]^Z]T$'\M'_MW'_+_ /\ Q2;XJ?\
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M/=^],!LSKJJV7M/IGY=5.$KMG[AZ6WYT;V7M+LO,;(V-_+UP>W>U!L#>74F
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M[.H:3);&7*M3;=FCG&>QU?#.IIC.((I T_B6Y]^Z]T.NO^<U_P J_P#+%_\
M.SY5?_4/OW7NO:_YS7_*O_+%_P#.SY5?_4/OW7NO:_YS7_*O_+%_\[/E5_\
M4/OW7NO:_P"<U_RK_P L7_SL^57_ -0^_=>Z0G:6Q/YQG:W6/8_5V4J?Y:6'
MQO9.PMX;!R&7QL_RAGR.*HMX[>R.W:G)T,%9CWI)ZR@AR+2QQRCQNZ!6X)]^
MZ]TG>A.H?YPOQ]Z'Z2Z"VUE/Y:N;P/1_4O6_4&%W#G!\H1E\WANM=EXC96-S
M&4H\?!2T4&3R-+AHJB>.)O$)&9$L"&7W7NAF_P"QQ^BH;_L6=Y%4"EAM\I=$
MK">,&2HJ;W@5J9F(18I-,B :B'+1^Z]U$5_YSAU:J7^6&MFLA6O^5;:DTJ=3
M XY/&VLL-(+"P!OS8>Z]UP>7^="&41T7\L"1-+%F?*?*V%@_]E51<1.&4CZM
MJ!']#]??NO=85G_G4EG#XO\ E=*@>T;+GOE@[/'I'K=#MN,1OJN-(9A87U<V
M'NO=1)*K^=LIC\."_E7R@C]TR;L^6T!C.NG \:KLNH\P\;RMR4]4:+])"T7N
MO=<TJ_YV8JT$FW_Y64E$#$9)4W?\M(JMU(=IHT@;8\T49#*JJQD8$,6*C2%?
MW7NL9R7\[@!V79?\JYV2NFDCB/9ORVB%1C5\7V]&\XZDF-'73#R!ZD1SQQ64
MB"2Y ]U[I1#-_P XS[?)R-UG_+0%69G?#4H[R^4AIUIV$AC@R=>?CR)'FB.A
M6EBI@LG+"-.%]^Z]U[$9S^<8L% <]UA_+0FJ?M%7*)B.]OE)30"N0%7FH)*W
MXYU<AI*@D.(Y$#PVT:Y;^0>Z]U+FS'\WV5ZK[?KS^6W01M#6+1B;N7Y/9=XJ
MAJ.):"6J*=$819X8J_7)-&@C:2'3&KHUY/?NO=,<%=_.BB%ZG;'\K^N8P5!T
MP;Z^5N*"5/TI4UR==9DR0>F\C:5;UV"^B\GNO= GVG\G/YM74W:_QGZBS'2W
M\O',YGY0;^WOUWM3-87NWY(+C=L9?8O3O8O=63K]ST60Z.I:J3"S;<ZYJ*6.
M6DDFJ#6U,5X!$'D7W7N@][[^;W\T?X\[PZ_ZYW5UQ_+LW/V7V7)+%L[K?K7?
M'S-WYO3.1O6UT5'DOX=A_CO]C@L=)3X^HL]?50K.U#5M \@@D5/=>ZA?&[YP
M?S6?EI0]RS=2]5?R]=MYGH'L[)=1=J;1[?W3\U^O-V;6W[1;5VIO X'(87/_
M !XQLPACVYNNFKDKZ<U-+5QU$:1A0#,?=>Z1'3'\Q?\ F9=Y=?=5=@8>E_E"
M=>U7:GQXH?E91=6]C_(WY.4O:."Z-JL9%6U>[<YA\1TG5TD%%AVCF-54P/4T
MR*ITLZQM(WNO=&;KN[OYOM'UC)W7-A?Y0E'U%1;$JNTLCV'6?(CY9C:L77,.
MWY=V?WQ.:/QWAI*;;]/M@+725;EHS3*TGI4C3[KW049_YO?S(=HX3L/<&[-Z
M_P DK!8CJG/;)VQV)D<E\IOE%0T^R=P=K4&"SG5.&W$L_09DHZ_?N"W1CI\2
MATG+)61/3 APOOW7ND5AOYE/SAW705N4VIVW_(WRN/V[A*#>.Y9J?Y9?*.KD
M78V4K]NXO'[JH*:/X]05']W*O(;PP\:95%JJ G+41U6JZ<R>Z]TN>D_Y@_S;
M[DJ]N[;V3OW^2AVIO#=^8SV&VIB^O/FM\AZ:LW'D-L[;I=U9O%X7;U3\9MQ9
M;*5U!MR1\J3#(P?&7G16BADE]^Z]U$V]_,]^26[<OB\#MGL[^2?G<OG-P83:
MF%HL;\_^\:J3,;FW+74N-V[@<6\?Q,,-?E<]69"E6CAB9WJ164SQADJ8&D]U
M[ITZO_F/_+'NO=,FR.IMW_R;>P-X0XK<N<GVUMOYR_(2NS-/AMG3/3;JRM50
M#XAK/2X_;U1$Z5<T@5(6C<,08WT^Z]U&VW_,K^4^\<WL;;6T]Z?R:]R;@[,R
MZX+8.&PGSC^0^3R6ZLM)D</BH*/%4E)\0)9I7JJ[<>,2%F"I.,K0O&S)64S2
M^Z]T]U?\PCYAT$U5!7;B_DZ4DU%V35]/U4=1\X_D)"T/9=!X!7;082?$-?\
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MS2^0,,516)+"TE$::3X8-/$)H)65)"=*21%FNK*![KW4+_25_.K>)I4^)/\
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M'P6[):G'2[(7;VZ,1V=L_;./QFZ*+*T=6F8U5]3(RU&1J']^Z]T3Z+_A/?\
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M_+M6;"U^5EV_2YFD^?GP>JL+5;@IJ9:RKP='E4[.6EJ\I34K"5Z=3YUB(<H
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M^Z]U7+MC^:I\Z]R8G;?9^?ZHZ2ZNV1T'U=_+\WC\R.K=T;5[&K.W=[9CYO\
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M3Q^UL33;_P!EXW=FU<)7TN,^WI(4GP5#JUK$ZR>Z]TA]S_R;OC+O/M3N#?\
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MU[KWOW7NO>_=>Z][]U[KWOW7NJNOE<T7_#E?\IR,LPG,GSJEC6U1XVAC^/\
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M%@??NO=>B_G>_P ON64PC</R=C(\EY9O@#\](:?]I68VJ)/C:L1UZ;)8^LD
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M'Q(B5Q3D#)=R;3PS@533K'JCS%;0R(5-,WD# &$%3)I#IJ]U[J-F?YX/\H;
MF-:[^8K\49S+)-$O\&[7V_N,!H%B9S(VWILHL,;"8:'<JDA#!"Q5K>Z]TW_\
M/I_R?OK_ ,.(_&'ZU8_YF%1_\H4"5$W'AO9XW B/TG>Z1:W!4>Z]U&'\]_\
MD\%'?_AP_P"-6E&12#O4AR9->DI&:(22*-!U%00O%[7%_=>ZX?\ #\7\G?\
M[V'?&W_T,9/_ *@]^Z]U[_A^+^3O_P![#OC;_P"AC)_]0>_=>Z]_P_%_)W_[
MV'?&W_T,9/\ Z@]^Z]U[_A^+^3O_ -[#OC;_ .AC)_\ 4'OW7NO?\/Q?R=_^
M]AWQM_\ 0QE_^M_OW7NO?\/Q?R=_^]AWQM_]#&3_ .H/?NO=>_X?B_D[_P#>
MP[XV_P#H8R?_ %![]U[KW_#\7\G?_O8=\;?_ $,9/_J#W[KW7O\ A^+^3O\
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M-.O\QWX6F* Q+*W^S&=7 J9RZQV4[D#O<H;V!M^;7'OW7NLO_#Q/\J,%%/\
M,;^%@,D=-*G_ #D=U7RE80*<W_O-8%RPN#RO]JWOW7NC(?'_ .8_Q/\ E=)N
MB+XR?(_I7O\ DV3!@:C>*]0=D;5[ .UX=T1Y"7;K9_\ NQD\D,4<S'BJDTXG
MT-)]O( +HUO=>Z,E[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*9TZRM\H/F(
M!413%*KH)6B2?S/2$]8RL()TO_DTCJPE"?E)%?\ M>_=>Z-G[]U[KWOW7NO>
M_=>Z][]U[K__U]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]T7S?_Q)^*O;&Z*K>_:?QF^/O9F]*V&DIZS=_8/3/7.\]T55/04OV-!3
MU.X-Q[;R66G@H:']F%&F*Q0^A0%X]^Z]TC7^ GP3D:-Y/A7\2I'BJ(*N%I/C
MCTZS155*---4QL=FDI44Z\1N/4@^A'OW7NN*_ 'X(+(LJ_"CXD+*CB1)5^-_
M3@D20>&SJXV9J5Q]O'R#?]M?]2+>Z]UCE_E]_ JHBCIY_A'\1)X(I)9HH)OC
M9TS)#%-.5,\L<;[+*)),5&M@+M87]^Z]U@?^7E\ 9 @D^#?P]<1IXXP_QFZ6
M81QW+>- =DG2FIB;#BY]^Z]UP_X;M_E^_P#>"_PZX-Q_SC)TI]?Z_P#'D_7W
M[KW7C_+M_E^GZ_!?X='_ %_C)TI^/_))]^Z]UFG_ )>_P&JC$:KX/_$&I,%-
M#10&H^-/3$QAHZ9=%-21&393>.FIT-DC%E0< #W[KW6#_ANS^7Y_W@M\.?\
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MZNH/F[OG,83X9?RUL%MWIZOWKV-T1MS=^8[-.X^GMI9S-=%;#VUN_<F6R?\
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M</AY<GFLQ54N/H8J[.9>GI4:1@&GFC0$,RW]U[HIGS+^=GP@^4'R1_E*]?\
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M?)X>CW3V#CH-J4>U<ME^K8Y\AO'<U37A\%7P14]3&?=>Z,7V%\\OYSVU^O\
M/[JV]\#>L\O71;&Z0WI@VGV5\A,G%2KV_N&39V2P.:V3LBIW;VME-S];5.T,
MMN#<.,QF&GKL/@=Q8*.KBAJ(J]V]U[H3/D?_ #!OYAG5GR9H^L^NOA1G=[=,
M_P"B7JG>F:[#QO1WR'W_ %.(WON."ISO9>RJ?/;#IFVAG)MG8'$RTT,=->J;
M)Y*EC*2R124T_NO=%.RG\TO^;%FH*7#57P"W[M:BS_7^U4S=9M_XI_+V7=^
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MR/)U=5/1Y"EA7W7NAT[W^7O\RS:W</Q3W!TY\0M^;PHNV/C5\=LQW9@9>O\
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M$M-@>Z,;L#_0-O'[_&X'-[8H=V]74\V4SLE(U---DZ?$0QBKD64^Z]TH<?\
M\*D.J,I6S8*@^(V]J_<^+V]NW>>>Q]'W[TE'BZ/:.V=O5L\53@LWELCB?[[;
MLR&[<55TK[=Q%/5YFDP4/\=D@-'K2/W7NCT?!S^<U@_FE7?)_+XSI&7:^ROC
M9T)BNWJK%[?[,VYV7VYO/.T6[N]=J[VVOM386WJ&C@S>+I)^G$3$Y."M,=?5
M9"&)DC,T=O=>Z#OXU_SZMD?(?Y$]#]!Q_'JNVS!W=N"EVK3=AX[O'KO?6 H<
MWG^OM^]D;3EVYC\#10U^^-O38O8LN*S5? :5<%N8S8V2.=Z9Y7]U[I&=\_\
M"C;HGX_]T=K]1[L^/W8S4_5'REIOC7D-UOOSK>C.;7&0U8WYO''[0_B=7NO$
MU6#J:=)\+BLM3X\;JQ,RUU#6!%>-?=>Z>/CI_/%QG>WR^Z!ZNBVQLJ'J?Y.[
M:Q.V=G46V^S=A[NW?UYVBS=Y[LHL]N/)XW,P'=&VM[;)V#CL95XNFQ]-D-G[
MIBJ:"M-1*ZA?=>Z=^\OY_P!U)TGV]VWU/+T)O#>=;U5VKOOK69]O]C[!AW)E
MY^H\?EJKL/'U.R<A)!EML=F[JGH(CU?M6ODCJ^T:*H-5C*B&."H6/W7NI'QT
M_GMX_P"2.YNH-M;2^'/:T)[TW_M_K;K[<%#O_96Z]J'=V:VQUOVWDMJ;LW#M
MBER&/V?O78OQVW=G-X;AQ=8ROC&VC78OR2U<U(9?=>Z3_P T/YTFYMC]H]C?
M%+XX]?;>P?=F'^1/2WQSQ?;7<&X<(=A;1K^PNP.H=E[QWEO#K_\ BF W!B:>
MA3N3&2;.3)5M%C]YQ19"JIJI(\;)#4>Z]TE_DW_.ZWQ\2OGSAOC#V=L78.7Z
MJZVDVQM?NS=NW,Y0XCL?>63[!ZZ^-N=PG9'7G7.XMQ-D,7MC;N[^W\E2?P&"
M;/Y#,I2Z*:L$U'4(_NO=#QAOYXO6N:^ ^'^=0Z&WE@\;N7NW-]*[?Z[W-V5U
M9CHILEB-IY[L>#+9WL_'YS,;$VL^8V+MZ6FI\=6RQUZ;TEAVU,D5;)Y1[KW5
M9&9_X4*?(W:GR1S&3S6Q>E,Q\:8^RNT=OXCIK;^X-B8_Y*P878^[-C]3;<P^
M]-S;Z[OV=LKKK<&<W#O@;@R<V7HH:;'O2QX:G:KDJXZ@>Z]U;)5_SE-DXSX*
M]=_.K-=![TQ.U>UOD@/CQLGKZ3L3K#+;HDJ(^QMS=:U^[\SE=MYS.;<AI,7E
M]DY>6>AQM1EJB.FI!.6%*9:B#W7NB)9K_A1QMR;O#:C[+Z@R>ZNC]O=?;V;N
MK9.W\UU[FNZZ#?M1C/B[FM@9'954.Q*/$;@H<'4=VY3#Y_;D5%_&HY<54Y&&
M22GH:JG3W7NF"N_X4U[ W7BL'/L3H;<6UMR#;N_NPH-O;G["Z5W7B.Q</L/H
M+L7MR?9-/N7;'9,==L"2M-#@9I,^^,S$=,K55,:!AIJE]U[H2=O_ /"D/K2;
M,[XZ\WS\==T;+['VSD]][=I<GC.T^H]Y=7T^;H.Z-R=*=;5V;S[;KVMN)=E;
MARVW)<CG]PT^,EV_MF@DIFJJX"NHVE]U[JP'H'^91)NS^73MWYL]J[0VS69.
M/9_0QSF.ZIW[LG)[5W!O;N':73@FK5K:W=F0I^F-G8GLGM.6AKUW=D8JO!8;
M&R9.M8TS1N_NO= EU3_.YV;WI\'?G7\W=A?'3LS;^R_A<N^-J?PW>.YNM<O6
M=B=L[!VZF4W-M^BI.MMW;SJL+LK Y#+XGS9RJ\:5.-K9*JGB84TJ#W7NGG9G
M\VA<S\A>L/C\^W,1NO(T?R2Q_P ,^[<WMML+!E*GN7);#[AR<W8NT.NZ'?\
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M5B/BMV=LO<NZ^J.J^SMO8S$5GQ-Q>2R_7_:^%VSO?:L517X7O08>AK4V]O\
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M.4HL2[=+Y"NK-P5D=+08G#5U'75.BEF\@]U[H8MI_P X?;G4_P#+L^'GR_\
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ME>X7EILS@J['5]# XCEH%H7<1U9]U[H'^C_YQ?4G=&0Z[RN[/BIUIL:KV?\
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MMK]I?*3I.GWMM^@KJC+.L>YMOY*;(T#1_:U5+![KW0.[,_FP;^W2GREH,?\
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M=VWMSMCJOKCO+;.3J:?!O'6QT.YH12/+(*V*G]U[HO>_?YCW\N#9G;'>&/\
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MAK^VL-A<;B.G-M;8SYQ^:FR.V=O;^H(,U0S"BQ5%2901I/,C3*ONO=!UM_\
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MS<HC#Z:;_7W7NLO^S7_S'D69I?Y3N7DT4]XDHOF]\<)I9ZTL56("LCQ\4="
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MNO>_=>ZZO_K_ .V)_P!Z]^Z]UW[]U[KWOW7NNK_Z_P#MC[]U[KOW[KW75_\
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MY0BR#W7ND]E/@S\,<YE8\WFOBI\>\ME(L)_=R.JR/46Q*PC!B2KD3&F*?!O
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M;RDPN'^,N2KH<#E*;,4DL=1I: I5P'R$3Q%O=>Z[W#\R_P"8%M*MDHMU9?\
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M #B3Z2LCNGCY)\=[^JP]U[J"O87\\ M4@_%G^6;&JP@TA/S*^24ADG0Q:UF
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M=J*P_P L=F^6%HI UQX2-5N;\^_=>ZDQ_,+Y9FGEDE_E4_*Z.I6618J8=V?
MN1980"8I34+\L0D32$6*$77_ !]^Z]U%J_F/\O8I0M)_*=^5U9$8XF,I[T^
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MD)!_XP[\>'FB/V\DJB2FC^4;U US1&&X4J'LS$1LKGW7NNJ?^:+V'/)31O\
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M[SS>#PN%V?68O?=+F*/:67Q^YJDTB54V-9)O=>Z7G;'\VWN3XI_"'XL_*'Y
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MQF'I(<)6U=(TE4)$J9!8'W7NA,W+_,PVK2=#YWMG:/1W;FXM[[/^8O6WP<[
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MY]T[:@ZY;'5&1PNV.L\=14$--'2TL0!E>.298GC]U[HZ'_#R?\MC_O)B@_\
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MU3;]I]Q[=IJ/ 4U'M+^-;PEGRN;QV&CH<;N.LGJ)LK35C33%_=>Z1FVNVO\
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MISYD27R+[KW01[N_F%=@8'Y&3_%# _&NEWAW9E\3L2+8V-Q?<]'!M>KW;4[
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M;N+K'MK)YB+KV.LCW%UUO/O_ #VXZ"@@,6'GW+%19*LIJFH@D,_NO=#IMO\
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MV!D.ROCK)D?D/O?I>I^18V5LV#MUM@8WJ&/Y%=-=-8\Y+([IZIV]O?$=HYO
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M3![]Z]H)M_\ 7D$/=&V]K4G<FVZ[#4F1;%X2HEV_'10XN@I8*9X_=>Z#K?\
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MSD\IC9(1*TT%,N.E\6??^$CW7NFO-_\ "AGX,;;^./2ORBSFVN_,5UKWSO\
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MR#$? 7HP+6/%*[T\M7%D=V9&DJ)DCGE1RT5B'!01G5K]U[II?X1?.J<!*O\
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M@:[K?:&]Z?>6U<=G.UJ//[@PFY]F[EQ3P2P4=775$$OV19:A!XO=>Z#7LCY
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M7E):V1'EBI8Z"5Y62,7/NO='UI]E?S(O[K[:WC+_ #._AZ=H9S%ONBAW75_
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M1Q P K<#M3<O0??&]:^C@D2JVSDLOG=E8(U3U:HF0^W>H1W*3Z/=>Z9MF?\
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MX/KSKO<W4\38NKWQ@L5%6QY5JVG7'OADK$AIO=>Z0LO\[3^>1N+H3/=D])=
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M=AZ+.;NKZF\U91.M)CHI#&\,*^_=>Z*]BO@]\YNM:KXC[V^,/16=^-64^/\
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M9IDGJZ\U?NO=&V_E)UV3^&=?V#_*![KWI7Y3?/QEKLON_P"'FY]W08C%Y/Y
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M-E=L[+VO\]^S_FS\/*BMI-S_ -_.BLAV;B,<M3B\QN>NS+29_+8+*3Y*FIY
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M:S'+7,D#2_+ZE)EHY0U-,I "SA0"RMJ'NO=-W^SQ?)@V/_#37SE(/T(W_P#
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M87)Y3=,55-G9VQF4PM'0FBR?NO=$N_G7]7=B;?[#WW2;;V_UCW9W-_,=_P!
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M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5K?#M%'S9_FW.%4.WR3^-:LX
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M>O\ ;[KDJ>9OC=\$^O=G[VK::OH13P,=U]X]L?(C#XFHQT\CO&])A4FN$;R
M@CW[KW0R?%;^7-\>OBINK)]L8VH[+[Q^2&Y,$FV]W_*;Y+]AYWNCOW<."#QS
MR[>H]V[DD_AVP]H354:RM@]L4&$PQ=5)I254CW7NCZ>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI+Z_[AJNDM^_\
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M@>+2%:/QLFD>.UQH:-K"W&DV^GOW7NF;/;3VMNK"Y3;>Z-MX'<FW<Y2FAS>
MS^(Q^8PF8HF;6:/*XK(T]309&E+"_CFC=+_CW[KW3A/B<94_<?<4%).:H0"I
M>6GC>2H^V+-2F:1E+R-2LY,1))C)NMO?NO=2_!#IB4QJ1  (2WJ:.R>.Z.UW
M!*&Q-[D'W[KW2)W=UAUUO[:^YMD[RV3MK<>T]Y8?<&W]U8'*8BCGQV=PVZZ4
M4.YL=D8?$//3YZD41U8)O.JKK)TBWNO=$S_FF8;$0?RROY@?AQ>.B^T^$_R<
M:D\=%3I]LU-T?O:"G:GTQCPM!"Q1"MBJD@6!/OW7NCB=?8O$S;(V;4R8Z@DK
M*G8NU*6JJ7I(&J:BDCPE-XJ:HG,?EEIT%0^E&)4!VX]1O[KW2QJ\-B*^0S5V
M+Q];,U!68IIJNCIZF9L7D#$<AC6EFC>1J"N,">:$GQRZ%U V'OW7NLR8['Q1
MQ11T5+'% J)#&E/$L<*1I'%&D2*H6-8XHD10H "HH'  ]^Z]U#FV[@*F>BJ:
MC"8F>IQJPKCJB;'4DL^/2FEBGIDH9GA:2D2GG@1XQ&5".BD6(!]^Z]U@.U=L
M-]_JVY@F&5R<6:R@;$T!&2S-/%3P09?( TY%;E(8:2)$J)=4RK$@#646]U[K
M.-O8!:M:\83$"N1942M&-HQ5JLU6^0F5:D0^95FKY&G8!K-,Q<^HD^_=>Z<Z
M>G@I8(:6EABIZ:FBC@IZ>"-(H(((4$<4,,485(HHHU"JJ@!0 !Q[]U[K+[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNC_ ,2/]['OW7NB6?R[
MZAZOX<=,U,E0]6]13;VF>JDB:&2H:3LC>+&9X72-HFD)N5*J1>UO?NO='4]^
MZ]U[W[KW7O?NO=8S*@D6(ZM;HSK^W(4LC(I!E"^)7NXLI.HBY (!M[KW7__7
MW^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]T6_+;)^4U1D<I-A?D%U1B\3/E*VHQ%!7?'#,Y>OQN)EKY)Z#&5N4C[^Q4
M&4JJ.@98)*E:2F$[*9!%&3I'NO=)_P#T>_,L4K1#Y.]*M4A#%%5/\4L_RI6F
M!J*B!/DNB25BLDI71XH;2*#&=!+>Z]UQFZ]^9QA,5/\ )[I*-S2"G%1-\4-P
MS3"<02+]_:/Y-P4YJ&G*N4\?ALI4+S<>Z]T5_P"7'R)[X^'^T*#=&\.Y=O\
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M]#B:RJA7S4QTQF/W7NEWO?X&?\*-LU\QZGYS=9=G?RK.AN[,_P#'W%_'#?\
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M_P!DYZYWWL#=';^S]];@WMV929>GHML5XH\#CHME]7]:=,4LU-B:VI^Y_O\
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M(-H=;[9S>^-O5>V<-N/=>Y#A\\V)H,#E,G%5K(E)-*9X46,!V5A[KW5(5#\
M/EEUWLJ*@^#G\QG:O4_2=-N'9/9.%Q>'^0NT8]DA,&W:VYOF/782GVW\=LKU
MGM':>T>[-T;5K(,7C<'_  *JP&-J\/60X):UY']U[H2.J/B7_,MS.P]AY'M?
M^8SM;=W6^&>/&]@=B[!^3.Z*:'*[8H>SMTUFX=K9#<$/4287/[R:">EIZC<J
M56""I/)@DQ=-2T%+42>Z]T$>Q/Y<7\S/J^HPFR^D_P"85U3U/G\MV!UIO3L+
M9VP>R0*#M3*]:=1].]=]E;@PNQ<UT5FJ+K^EZ]WUM>6OSV!Q= ])V)C\S3T&
M5J=MO!33^_=>Z=LM\+N\%Z-J=J9;YC?&/;?R_P!D_P QNO\ E5ENPHODSE1F
M\/N+._$>I^/$M;EMSY;KP;@V[N^EW!6#<?\ <Z?!SXNKVW2+MTU:02?>Q^Z]
MT8_9GQZ^1'R+^'55L_LGOW']I[LS_P Q]G]A;4Z?[_W_ +?J\;VS\<>C=^8O
M<F-^//<]7UID.PL31[@[?ZYVS-G]P1T*;BQ7DGIA68Z2C%93GW7NBI]8?RK/
MD]UUVINO)IV/\3-L;OWOU+O3X\9')[7W^^/W1UYM'NS=LF47 ].[(PG2.R/]
M&6_.LNHMP;B% <37TFV=W2TE!4R;>QE?$^:C]U[J];X&[+[2Z1^+7671??>\
MNNMU;_Z+IUZ8CW1LG=E;GH,[LW:U9_!.FJG=AS6"VY78CLO*=:'"KF:$QU"O
ME3)+!43QSQGW[KW1P\;D\;F:*#)8C(4.5QU4'--7XVK@KJ*H$<CPR&"JI9)8
M)1'-&R-I8V92#R#[]U[J=[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KQ_P")'^]^
M_=>Z)Q_+TG-3\'/BI4M$\#5'1VP:AH)"K20--@Z:1H9&225&DB+:6(=@2."1
MS[]U[HX_OW7NO>_=>Z][]U[KWOW7NO_3W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW17/F
MYT5N#Y/_ !!^2GQRVID-K8?<7>?3&_\ JK$9O>M!4Y3;&!J]\[>K=NIG\IC:
M.&>JKA@EKS5PQ1J&>>%!J3]:^Z]U4]O;^4;WU1;X^/\ OKI/NW8>WZ?XV[;W
MCM7:_6O8>/R.YM@]G8GY.8[LN3YKGN1L3MC%9G<%?V)F-Q[:BVW-3O$F/H]J
MTTE9'43FWOW7NDOT#_*)[W^*/Q'V9\=]M=B;%[/I-E_+#XL?)S-IB,#3[<SO
M9B=:[.V+LCL39VXH=SL=AY1.O<OL7#;IV'+/3T:5TNW,?0YI7J!4Y6L]U[I3
M_&O^2SOWH#Y1?'SO[+?)F#MB#I/L7Y ;XR-1O'8M.N\-YIW94=P9&NJ=Q5<%
M5-1YG?E?N#MRHRLF?#T+XNK.1CAIJN#*(F-]U[IME_DL[BR^R_BWUAN;*?'F
M?"?'GN<[JWGV[MG8V?V[W[\@-@5V,[]H,S/OC<==_>+"8_>^8K.[Y,GD*>:'
M+TF1R\=74?=4L59]M#[KW3)U9_*B^0?1';$>;VOF.L*S&=N_,WJ'Y!9_<FR*
M2HVO5?&W9/2W>'?/<M5L/9RK!MZ'<6RNP^LNV<CL!*5\=5Y"FJ=Q5GW$TV$:
MG@Q/NO=#MN3^55N/*_('=/=>#JNHL##N/Y?=9?+6BI)TW1N?=FV][=5[JBW9
ME\S@][[PQ&XMR8O_ &8FEQ^-P6Y]NT=52;=VS1X>FJL*CM+54<_NO=!OV1_*
M'[A[4[>[$[9;?G1O3T6Z_D[\>/D2W7W6>W-XY/:W8M3TEV'!OK3W=/D9=N3[
MSWI]WF=TRPY=H9!D)]SB.LA%/A<*E)[KW5H7P@^,U;\4>F\WUM6U>V6.?[C[
MG[8I<#LS'4^/VEL6@[8[#SF]Z+K_ &W)!A=MME,+L^GRPHJ>KEQU#)+%& 85
M"B_NO='"]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=8Y4:1-*RO"=2-KC"%K(ZN4_<1UTR!=+<7TDV(-B/=>ZR>
M_=>Z][]U[KWOW7NO>_=>Z)A_+HI*NA^!GP_I:ZHAJZN+X[]4B>IIZE:R&9VV
MABWUI4J2LUPPN?Z\>_=>Z.?[]U[KWOW7NO>_=>Z;\E35M3254>/R+8RMDH:V
MGHZLTT-;#2UD\6FDKY*27Q_=&AF <1&1$D!*M]01[KW7_]3?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UX_0_P"^_P"*>_=>Z*O\&J2*@^&7
MQ5I((Z>**#X^=1JD=+#'3TZWV-A'/BABIZ6.,$M>PC7GFWY/NO=&H]^Z]U[W
M[KW7O?NO=,^5P&)S=1@ZK)TK5$^V\PN?PSBIJH!299<;DL0M4R4T\*50&/R]
M1'XYA)%>37IUJC+[KW7_U=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW426NIH:NEH9'<55;'4RTZ"&9D>.C\'W#/,L9@A*?<I8.RE[^D&QM
M[KW4OW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1ZL
MRBDJC ;3"GF,) !M*(V\9L2 ?7;@FWOW7NBY?#)73X@_%E9%"S?[+MTN9PJ)
M&/.>N=N&<Z(R40F4DV!('X/OW7NC*^_=>Z][]U[KWOW7NO>_=>Z__];?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6-HD:6.8@^2
M-9$0AW"A92A>Z!@CG]L6)!*\VM<W]U[K)[]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K!JJ?N=/
MCA^T\&KR^5_N/N?);Q^#P^/P^+G7Y-6KC3;GW[KW6?W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M-V8J9:/$92L@\/GI<=75,/W#B.G\L%-++'YY"5"0ZU&HW%EO[]U[HN/PCK)L
MC\,?B1D:C[;[C(?&7HBOJ?LY!+1_<5O5VUJJ?[.4/():3RRGQ,&8,EC<_7W[
MKW1G_?NO=>]^Z]U[W[KW3;4/5ID\<L-%)44DL=:E;6"MCABQY1(9*8M1,-=8
M]5("@9>8@#?AO?NO=?_7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=)K<\R3;1W',8Y1&VWLT6CD1H9=(Q]4&5D<!D) X]^Z]T6[X!&)O@C\
M*6A5EA/Q)^.!A5SJ=8CTYLTQJ[?VF5+ G\GW[KW1MO?NO=>]^Z]U[W[KW4'*
M93&X3&Y'-9K(T.(P^(H:O*9;+92KIZ#&XO&T%/)5UV1R-=5R14M%0T5+$\DT
MTCK''&I9B "??NO=?__0W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4*BJ:J
MH-8*G'SX\4];+34[3S4<PR%-&D31Y& 4E14&&"=G90DWCF!0ZD *D^Z]U-]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6-4D$DC-*6C8)HB**/$
M5U:R''J;R7'!^EN/K[]U[K)[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z3N\.-I;H)^@V[F_P#W65/O
MW7NBT?R_D:/X&_"6-U9'3XC?&Y'1@0RLO3>S RL#R&4BQ'OW7NC<^_=>Z][]
MU[KWOW7NL4T,-3#+3U$4<]//&\,\$R++#-%(I22*6-PR21R(2&4@@@V/OW7N
MO__1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW6-Y8T>*-W"O,S)$IO=V1&D8#_$(A/^P]^Z]UD]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U@AD:R1SM"*KQ^22**36 +V+)
MJ6.1HP>-14>_=>ZS^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NHXI
MP*IJKRSW:G6G\'D_R8!9&D\PBMQ.=6DM?E0![]U[J1[]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z2^]^-E[OM<'^Z^?Y'!'^XFK^A'T/
MOW7N@I^*-/!2?%OXUTM+!#34M-T#TY3TU-3QI#!3P0]=[<CA@@AC"QQ0Q1J%
M55 "J ![]U[H?O?NO=>]^Z]U[W[KW7O?NO=?_]+?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>M[]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN.E=6O2NO3IUV&K3>^G
M5]=-^;>_=>ZY>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z2^]_\ CR]W
M_P#AKY__ -U-7[]U[H+_ (L_]DQ?'+_Q _4/_OOMO>_=>Z'CW[KW7O?NO=>]
M^Z]U[W[KW7__T]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2
M([-R='A>M^P<SD93#C\3LC=>3KIECDE:*CH,#7U55*(HE>64QP1,=*@LUK $
M^_=>Z#CXH5$-7\6OC55T[^2GJN@>G*B!RK)KAFZ[VY)$^APKKJ1@;$ C\^_=
M>Z'[W[KW7O?NO=>]^Z]U[W[KW7__U-_CW[KW7O?NO=8*:FIZ.!*:EACIZ>+5
MXX8D6.- S,[!44 "[L3_ *Y]^Z]UG]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6+R_O>'QR_YKR^73
M^S^LKX]=_P#.\7M;Z>_=>ZR^_=>Z"'Y!+KZ%[N34J:^H>REU.=*+JV9FAJ=N
M;*+W)_I[]U[I&_#==/Q#^*RW!T_&_HY;J;J;=8[7%U/Y!_'OW7NC(>_=>Z][
M]U[KWOW7NH.2J*REH*JHQ] V4K88B]/CUJ8:-JN2X B%54?L0D@WU-QQ[]U[
MK__5W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6.0R@+XE1SK0,'<H!&6'D92$?4ZK<JI
ML">"1]??NO=9/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW01?($7Z%[N%@;]1=DBQ^AOLW-"QX/'^P/O
MW7NF7XM4XH_C)\<Z18H8%I>B.HJ=8:;5]O"(.O\ ;T0B@UPT[^&,+9;QH=(%
MU'T'NO=#O[]U[KWOW7NO>_=>Z9GQ,S;@@SHS>82GAP]7B6VZDM%_=^HFJ:VB
MK$S4\+4+9(YFC2D:")DJD@\$\@>)VT.GNO=?_];?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]TF=Z;8I=[;.W9LRNJ)Z2BW=MG/;8K*JE$;5-
M-2Y_%U6*J*BG697A,\,-660.I74!<$>_=>Z[V9M;';'V?M/96(+G$[/VU@MK
M8PR)#'(<=M_%TN)HB\=/'#3HYIJ1;A$5 >% %A[]U[I2^_=>Z][]U[KWOW7N
MO>_=>Z__U]_CW[KW7O?NO=-U!6U-9+DXZC$U^+6@R+T5+-6R8Z2/,4RTE)4+
MEL>,?7ULD5#)-4O %J5IZGR0.3$(S&[^Z]TX^_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__0W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exh1071_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1071_2.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X1?_17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#(Z
M,3@@,38Z-#8Z,#$      Z !  ,    !  $  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !;)
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M4W3V[HV6_NH?V#J1O=2QS :VM<"<C+^B]S_SO7^E^B24[R2Y@7VES::[#N$
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MT!SMP<_)HO9Z?MWV.9_HT];[,?$<!CLH$T.W[2[=M>R-[\:FEOL_J?X1&O\
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MR+&V;B7656>QV19Z[O<[^NQ)35Q<#IY.W$S<5Q?+2*VXI)T<]V_9B?Z,6?\
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M_^T<G%!H;W1O<VAO<" S+C  .$))300E       0
M #A"24T#[0      $ $L     0 ! 2P    !  $X0DE-!"8       X
M        /X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))
M30/S       )           ! #A"24T$"@       0  .$))32<0       *
M  $          CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8
M 0"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M     3A"24T#^       <   _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #1P    8              X\   +     "0!E '@ :  Q #  -P Q %\
M,@    $                          0             "P    X\
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   X\
M4F=H=&QO;F<   +     !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   ./     %)G:'1L;VYG   "P
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M#     $_\        #A"24T$%       !     $X0DE-! P     %N4    !
M    ?    *    %T  #H@   %LD &  !_]C_X  02D9)1@ ! @  2 !(  #_
M[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1
M"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( *  ? ,!(@ "$0$#
M$0'_W0 $  C_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $%
M 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "
M$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:B
MLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9V
MAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q
M$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"
MTD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&
MUN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /54DEB]1R:G7/8&VLR"-K'M
M^U^G#76-'J'!9Z+?<V[V^MZB2G:27,G*M#6-!-@L^B=G4'_1#JKAOA_I6.>/
MT>_W^G_I/YU-0^ZVQM+)#G/#6G;U"MH#=]FUUC]K&^]_\[OV)*>G26*[IO5G
M.:[=5H1Q?E-T]NZ-EO[J']@ZD;W4L<P&MK7 G(R_HO<_\[U_I?HDE.\DN8%]
MI<VFNP[A  <>H$DN;K)/TO;_ (/_ -&J5MMK6,9^E.\!["!U)T EW\YL&YEN
MZO\ FK7^I_VXDIZ5)<L_(N:#ZKW@,82"QO4A](L#/H_2_P!;/WU8PFY^6XW5
M.:YP&^+'9M;)<7>G^ARG-K>SV^^O8DIZ%)8K,?JV1758YN.UOTMM=E]9)UT<
MZIWZ1G\FQ)O3>J #<:W$-C^D9423W#K7;F;#^<DIVDES;O7IS&8=M@#QKL%N
M<"YHA[]ENY]=NW>SW^_T_P";6KTFZJRMS:A9Z8VO:ZQ]KR=TC_M8&W_X-)3>
M+@(GN8'Q3H=IAU?F_P#@Y$24_P#_T/550SG_ &#&LR0^]S \?H:16YTV/#/9
MZK?=[[-W\XKZJ=4(&!:30W)T'Z%[7/:X[A&ZNFK)M=M^E[*'I*<9GUHQ'/V%
MV<QW[KJJ@=WYE<;?YRW_  34SOK3AM;+GYC7EK7-K+,<.=)^BW=[/;4ZO(^G
M_,VU*Q1BY%])>SIN!()@6,LJ]P;+?9=B-L_G?;OV_P W_P!MHMW3;Y'H].Z<
M?8)WS].3[?;C_P WM]/W)*:K?K-AO$LLS'0Z';:Z3M;(;ZS]K?YKW,_SU ?6
M/ ]6RQKLUS]C)<VNIVYH>]HVM:T_S>ZRRSV_S:NMZ=DAQ_R=TYK"WM).[_V&
M;N:I-Z98:VN?@8 O#XT!+6LC\UWH->ZS_,24Y[_K!T[*8[&RF9CJK'>C=7;3
M4YON.W9:QC7_ /;?\XJOV[ZL^Y_V.X-LWD/].H>J:X:YS?=NL]K_ .Q_P:VQ
MT^T"7=.P'/GL2!V_.^S/2_9]A$OZ9@$SQN[?G>[['_)8DIS&]5Z+6_U:J\@6
M5VOAS:ZA#B'BR\.<&U[;JL=^[_"?Z7_"HK/K+BV.8UKLS=8X- #,<D[CL9_6
MW_\ !JX>GVEKA^RNGS$@%Y(+ICW?J7^C<_WIZ.GNWUV/Z5@5.K=[2UVYS=NM
M3ZG?8V?G)*0U=1-5+V-HZD&T-&P>@PE_ BOV>?\ A/33CJUAW31U-NT3KCL,
MF6MVMVL=^]_4]BNNNZV&2W%QG.D^W[0\:1[?=]D4G6]7_-Q\<Z$_S[^8;#?Z
M+^]ZC=W]O_@TE.>>KV2P>AU3W-#C^K,]LG;M?^C^DWZ?L5_IMGKL?E$9#7/_
M $>W)8*W0PN@MK:ROVN]1.VWJY+-V-C@%WZ0B]Y(;IJS]4;O=_)_1JXDI';]
M*O\ K_P<B(5PEU7D_P#@Y%24_P#_T?54DDDE-#/LZI4RLXK1:\V$.VUAP##]
M'<+,K%]S&_N/_2?Z.M-0.M6UM?9=34Z3NK?CD& 6_P"CSK6_FO\ \)^>LG*P
MFY%OJL>UG\Z'3?=438++8]2JACV6-_-W[F6[%&O#IH%EUSFN:ZL,+#?;< [U
M&AMC6WL8S=97_./;Z>S^6RQ)3MBKK$?TK&/M(_H[_I2=KOZ7]';M]B1JZQVR
M<8#3G'?X>_\ [5JA;@=%MR#<W-=4+(+::K6BO3:W=6S:?:_V?0_\^6*(Z=TA
MK1'4K0UD GUF=_H;SL_._P"FDIT15UB7SDXT&=GZ!^FOLW?K?O\ 9])/Z75Y
M;&3C[0[WS0^2W31OZU[7_P I9O[,Z0YH+.I7;-T@MO:1!.WT]Y:[<W>?;[O^
M#4<S#PK&,QL:QIL%(/K>HZMSMME.Y[\C&&[U7LW>[9_UOTDE.F*NL@"<K')@
M@G[.\28&UW]+_?WJ)IZYH/M6-Q!=]G>"#V=M^U.W-_D?]-8?[-<(F]LM>'%I
MS+R"!M]G\U[6V>YS_;8IU8.0+*]UM<!P+W-RWZ@EN]GI.P]KZ_;^B8^S?^9Z
MR2G:]'K,C]:QXG4?9W_1_=_I?TOY2?T^L2/UC'C<9_0OG;IL_P"U/TV^_<L[
M[+TS*IJL&8_&.UP/HV!L@N/TVV-L]W\OZ:3NF].<(;U.]GM#=+*^1^?+JG>]
MZ2G0]/K?N_6,4Z';^@L&OYN[]:<KRJ8/H[\@4$>F'M VF1_-UE6TE(K_ *57
M]?\ [ZY$G6(\Y[*%OTJ_Z_\ !R(DI__2]522224X[^J58N""VVDV"Q[;&/L(
M< 7O!VMIKR;-[?\ BE&KJ].3TTOMNJ:\/:T0\@D!S/<?M%>*_=_UI3>,EV!6
M,2[8[<\/K K)<#80[^D>WV^].UV0,!QRG[3NK:VL^F-H%C1N_0G9[I;[=R2G
M!;90*R'&MC>&L#&D;_87/G]B#;^C8_W[/3_2_P#%^D465N=L<]IL>UK&V/8Q
MH:TAOV9C+/V-MVNV>G>R[^C?^>U5DXE+GDFHUN,65_JXG<;7-J+R]K?TGH^S
MT?5>RO\ XM&;E=!%;K_LM'I"6^HW(:\:!U@;['';[?S'?Z5)2&BO"RK]+J8;
ML:76-JKVU,]K7,^T=)8WU/\ NIZVS_A%J5LZ=2]F-CYE=#?3+WW4FECG$/KD
MO:ROT/TNW;9MI3T-+<IN0.EFJP3%HO9KNW;C8P/]V[?[=W[Z-ZF3D6@//V#(
M-;N',L+6BQGCNJ_3,_D_HTE*8[%8XD]7<^01#K*(&A;N&VIOT4FG&!;_ )8>
M=O8V4:\?2_1?R45M&9+C^T2X%I#1Z=>A(=M?Q^9N;_F)5XV:'L+NHE[01N;Z
M=0W<:2&^U)3''S<.S%I_7*ZRTAQV6,U )_1NW;_8CUYN$!M.778?$O9/_0VH
M>)N?A8_IW"J(<Z(=N;K[/=_U2MLAK8-F\_O.VS_T U)2'$LKMLR'U/:]OJ ;
MFD$:,K_=5E5\;^>RC_PC?_/=2L)*17?2J_K_ /?7(J%=.^F/W_\ OKT5)3__
MT_54DDDE.!>\MP ['8"0;/5W8SK-P+W;G>H;,.MNWW^_UDF7AW3R_(J+ 34&
M-^RO; #V>\EC\MKF.]G^&_\ ,'O9F6X-/HGTG,-CA%SJ][0YSG[6T[7/L]OL
MW?010W+IPW"P.MM)IWCUBZ#O9HSU/H/=N_\ /:2G- PA6[9U*AS #ZFZO)>
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M![7UOVEA8YOYS%8&/C:L_9E?N'N;%.H)[C=^\HW&RVXU^E94#2V#6]C2(?\
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MS7427U@C;#/4T;M]WI[MG\M'KZ=A@>_'H<[Q;4UO_DTE,L5C669#6 -;ZHT
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M &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
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M<&%C:V5T(&5N9#TB=R(_/O_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __
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M6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@ , P$
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M3NWYI['W/MS+9^C_ (?M_$]?4F'AVS7U)2MJ,O53G,4R8U*=<94>Z]T"^/\
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M%ZQ^,N%W%V7MS>='TKC]J[X[FW?Y]_\ 6/S,V5\*=R0[@PF!ZSR^[=W4F_\
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MV3VEMS'XNH+R,9L=04],^J&&-%]U[H*^L>JOBHV#SFS>K.FNH<+MKKK<&_\
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ML*++U%$DF]-E;WFJH\IEJ:BR>/IY%]U[K%F>B_EOV#L7&4?:/7W4_P# C/\
M$G9F[]@[B^1G4O8>>R^$Z+^-/;G7F>WU#CMP[QI>E\E3[F[LWAC*ADW)'N"6
MGP;0YBGQ$VX*6GIJ/W7NL_3_ ,$>],9M/HS=?;N^.O\ <_>>R=Q?!3:.\.PL
MI\C*3+Q5'0/6'0)ZW^5&&A%/F:/#UV$W[D:RMQN7B6ACJ-V4$=/4UR2O3P0P
M>Z]T9QOBYG*K^7Y_+%ZCQ^QNI-H]E?#_ +!^.F8W!MJH[-Z_S5#U[5=>[(W?
MU?F^U]C[ICS<>W\Y-A=P9Z'>-)2"6*IKZ.%Z,)%6L(T]U[J7_+XZ3[,^/FY.
MQ,WNV/K?H_"U7Q;ZHZAS&TZSY.TW9N-[_P#EOM',=B9#L/Y59;/T&3_C6'J.
MP:;/XRGJ,K6I3;ORRL6KJ:%J&EU^Z]TGOY6/2?;WQQ[;[.W9W7GNM^N]C]C_
M !ZZ)P.2VIA>V.K\GBLW\C]L;C[+RG9N^8<;MW<^Y\W73Y3 [LQE)1[GS^<S
MFZ]T45)'59F>&J1*=/=>Z:MB[,^6^'^+FQ?@9LVA^)G6DG4G7W;^P]M?->J[
MMVUGS7U_^C/L3:74?9716P=M21=E]=]][GS^],=7[GS>4TQ8!/XV:(YB:JI'
M;W7N@BV3\&JG??:_6,V[=J]/=.?#P[S7(]B_$2B^3V(WMM^;-X/XE=R=3Y[L
M^KJ-M9RCQ>?/9O;N]-I,M )9*B5MKT^X,DM/E:AZ>'W7ND3L/^7Y\J<3UKN'
M)T?:O5VW?EAVEA.O:/L'N>B[]I7S^5W#L#^4GE/C!42[AW!B%ESU953?(W,.
M9LC M974T52,Y$IGC75[KW2:WE\$>X\ZO:&6Z^Z;V%U=TOO'NC=&[!\0-I?)
M;I;+5]+D)?A+U+TYUOV=DMT[PJ=S=9[=FZ\[-V3GC%38Y3DL/%EX,]CUFKJ7
M[<^Z]T+V[_Y;G<>]-IYU]V[DV+OKLK=O8O977>_^Q-S]]_WDE[!^,V:_E52_
M'F@V_NC)5-+M^GR.-W)\PTQ6Y<ICUPU))490KGIJ85+7]^Z]T$_;_P "/F3O
M_J[=^Q:?K_9NV-B9C&[J'7^VI>^-B9')=$[_ *?X"?$?H#JP0'-;UJ^K]D;=
MVWVUUONZN&?PV*W!NO!2""IPM+3MDZRJ7W7NKMO@5L3=70O7W<5+W=N_9W][
M^RN]-U=S+7+O; 963(XK=6Q^M:&KRV2KJ:K$/W3[CP]:DT@)1R%D!TR*/?NO
M=5Q8GX(=K;K^/G\N;JC)[PZZVINWXO\ Q*^3F R68I>WC54'7'RNW%MCK3$_
M''L>BH-KYU8=_8CK_>>&RV21Y4JDHJJ"GD6/S:=/NO=%IVI_+T^:V!ZQ78N7
MV'/GMD9_LCX^5'8/5F[^U^F-WU-;E^O^C^XMM]@=Q[2ZV._-M=.;Y3?O;>Y<
M!)E\IOO-9+.;@I<?_>*?;46XJ"E1_=>Z4?QT_E@?(NDW5UQ2_*/$[9W:=T8G
M^7G#\E-\5'>%)D:SLV@^+WQV^3G5O:FP-YU&+W!BMV[VB?<&\]ISA)X9L?G\
M6C_?$F"2G?W7NNZC^6M\K]G]=[3V?LZMJ<YMZKZO^%U7\E^L?]-F [%W/\A.
MSNKNR/D57=NPY*E[EWW2[$WG70;'W?L*H,6Y,A28C<^&PD&)J:A(J&FC]^Z]
MT+/7/\NKY X?"]0;HWIFOXUV9U;GOY>N.VOG-V_(D[VRFRNL^L/E)V5NKY;[
M+BR]/#M; U<U?\<=Z4FT<C'#C;9G%4<6%$]934L4\ONO=#AM7XD=ZO\ RL_C
M_P# #96'V!T-N#([DVWUCWMF]N;NV3NO$;,Z"P6_]Q;KW_V#L?%15%1C=\'N
M;%[=IL1'B:N&)H8MTU!K8@M'+&_NO=$T[5^'WR9Z^WCM_P"+E9UZGRBV",7_
M #'M^_'+=.V>Q<#\?MI[*R'>=%\=>Q-I;BWCMFDW'3X#:4GQ_P#D3N_<T.W4
M@GJZZ@PM5!D\+2-58UH%]U[IGVW\-/E?VM5?)6CP6V(Z3?DVZOGCU;VE\D-Z
M]K18X?+C![AZ/H^J]A=8T?6U?5U%5M#:</=M;'NZ"1J:GP6*_@9JZ)Y*K-U>
MGW7NC4T/PU^46,[:HMW;XZMV[WW)-N#)R])[ERWRFW5UM0?$RNHOG+\C.[,O
MOFO;:V97=643LWIGL+:5.5VU!5Y"I3 ?W9R24^&<R#W7NBO]7_RU_EQ#OGKC
M>G8G46RZW:.Q^VO@'VMD^K*CLO8M!33]K=*[R[UI/D#VYMF&FWEOV3*Y>?;W
M9F&JJ/<.YMQY#>6\<=B#'E#25(AH5]U[H3<)\"?F]M_#; P#4IS_ &YB\9\=
M:ND^3\_R$$5)UWU%UM\4</UOV]\33M2;<$F6R<O9';6"R;?=TF-GV_EH]U+F
M\C519'#TT)]U[HY7PH^"F^>G]L=U].=FNF%Z8[L^$?Q-ZSW5B\1VGE]T9')_
M).DZX[>V'\N>PI<A69B?,4.[MX4N8VT*G.4\ZOFYJ&.K:0U,;O[]U[JNC&?R
MYOYIF>VOV*.Q.U,+69W?_1/8.^ZVDP?=&0H_M/F-U_UGNGX9_'7$8;*)6&;'
M=?;H^->4H=ZYJH$BQ)OBC'EB,@\Q]U[I=[[_ )5O<-?0_)BIZTZCVSL+>V I
M/FUG_BOO#$=OT6,67M[NKYE[,^2G3/:..7'9I)MH5^!V[A:>AJCE(5>EJ,9/
M"BR4]:QG]U[HXO\ ,:^"O:/R9^0F*WOL?8F.W%MO='Q!W'\>=P;NAW]3;-W%
MM')57RM^-_<,7V+-DL9FJ:ERO7^R=S1Q9+#N:ZDR IU.C7'-%[KW1&^]OY9O
MSMFSN[MO]65&\H.E*7?GRZC^.6QNO>X=J8K(=&Y+MO<W4.Y.HNVZ#/\ 9N?D
M'7>(V^F+W+#25V!H<WN?9#321XO$5E+E:B*+W7NK<>^^MOD%L7Y1=$?+;J?J
M:/Y)R[2^.?;/QLWYUO0[^VAUSO;$3]B[SZ@["QO9^TLWO^?!;(SF.ES/5AQ^
M=HZBHQ]=%25,-50K4O%-12^Z]T1;-?#CYT;N[#VUOC</5W4VR^S,YD?B?N;K
MOL?I;L^? ]:?!;';([GSF^OE!UOM;8>3AQF6WY5=K["JFH,EE,9C6IM\Y/,U
M4643'8RDHT'NO=)+KS^5GW'L# =/[@P>V(*+M_9.Q_Y8]?EL_!W;N6L6@[BZ
MH^3N?SOS/WW2&MW#545;NC<_QK;'[<JLH8!4;CP\*X82-21B'W[KW29ZW_E(
M]W[,VCU9EJ#'4N$[EVKU_P#RZ,OF]]4G<6YLEFL?\A>JOESG-W?+KL:&2LW!
M6XS+;FW#\9*FFVZ^0G#G-X>.+" ?91)3I[KW2?Z__ES_ #LVSNOKJKKL-G,G
MG$^.E5U?O[?.;^3_ -I1X.DJ_BQVAU9+2]1]F;8BB[BZO[%J>R\OAR:#(8+L
M+8%R^[(12;@C6E3W7NN&UO@%_,%Q'5-5L;:^SJC9^S:.L[&KSLG)=S839>].
MT]C9?(_!^?>G4V_:?K/?.[NH>N-Q=U;<ZD[ P./S>R1B<0(,B<GE,?B,CEJY
MI/=>Z=LQ_+'^66]E[ESM-M4]<[>'4O===\(^HJCO&M?(_$SLW<';O5FY^J</
M#7;8S^3VG393:M-L_.9W&28^LR>$VM%N&? X^7['R^;W7NMC_9&<W7GL=EJG
M>&R)MAU]%N[>&%Q>-FW!B-R'-;6PNX\EC-I[T2LPO^3T$6]MOTM/E%Q\UJO'
M"J^VJ!Y8W]^Z]TLO]]]/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW13_ ) 5])3=W?!BAFEJ4JLE\A^P5HXHHYVIIC2?$'Y,U-0*R2.1
M88ECA4M'Y%<%[!;'GW[KW1L/?NO=>]^Z]U[W[KW7O?NO=?_0W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW1&OYGE;B\=_+<^?M=FZB6EQ--\,/D[)7U$+3I
M+%3CI?>@9HVIH:B=6)(%U1B+WM;W[KW3#UM\$?@!6]0=>YO*?#'XBR4$W6NS
MLE69#,_'OIBH HEVYC\BU7DLC4[,CBE6*YFDF?2NJ[FWOW7NI\WP?_EA919*
MNH^(GP/R"YF&EJY:F7H3X_U2Y2GKHDQU%4O,^U)!6PUD,ZP1.2RR*X1200/?
MNO=1G^!?\K;'3_P63X9_ :AJJ3)RPG%/\>OCU35%-F9\?%)/$:%MHI+#DYL4
MJ,RZ1*U. 3Z+>_=>Z[K?Y=7\KC&Y*APN1^#'P)H,QDXIY\9B:WXT?'RER60@
MI1>IFH:"?9<=55Q4Z\NT:,$'UM[]U[J31?RW/Y8F34MC?@;\$\@HIX*HM0_&
M'H&J I:EIUIJDM!LB0""H:FD$;_I<QM8G2;>Z]UZ;^6S_+%QWV]'5? SX+4C
M) K4]/5_&/H6.3[=ZJ&D5XDJ-E>0Q25U7'&"+@RRJOZF /NO=9\A_+;_ )9M
M#XY\K\"_@U2?=U*T\4^1^,'0L!JJR59)5A26JV0IGJI4B=@H)=@I/X/OW7NH
MK?RY?Y8,$7G?X*?!"&"6!)?,WQFZ CBEIIIO#')Y#LI4>"6H30IN59Q8<CW[
MKW7'+_RY/Y7N I8J[/?!/X&X6BJ*JFH8*O+_ !E^/V-I9ZVM;11T<516;*AB
MEJJM^(XP2\AX4'W[KW4P_P MC^6=')+3'X$_!I)494GIS\7NA5D5_":A%EB_
MN0&#_;L7 (OH-QQS[]U[J$G\N;^5Y)4+1Q_!3X&25;R-"E*GQF^/S5#S+1MD
M6B6!=E&5I%QZF<J!<0@O^GGW[KW3=!_+]_E35--25E-\*/Y?=129#R?8U4'Q
MS^.DM-6^&1HI?M)X]GM%4^*52K:"VE@0>??NO=.A_EQ?RP!DI<,?@C\#QF(*
M-LA/B3\9/C__ !*''J8U:NEH?[D_=1T:M*@,I0("PYY'OW7NO3?RXOY8%,E'
M+4?!'X'P1Y"6."@DF^,GQ_B2NFF:-(8:-WV2JU,LK3(%5-18N+?4>_=>ZX8[
M^7-_*\R\U93XGX*? S*5&.K:W'9"#'?&;X_5LU#D,;+%!D:&LBIME2O35M!-
M,B3Q.%>)G4, 2/?NO=.__#8W\MK_ +U]?"/_ -)4Z*_^P3W[KW6.7^6%_+7F
M1HY/Y?/PD*-IN!\5NC$)TLKKZDV*K"S*/SS[]U[K)_PV-_+:_P"]?7PC_P#2
M5.BO_L$]^Z]U[_AL;^6U_P!Z^OA'_P"DJ=%?_8)[]U[KM?Y9'\MQ&#+_ "^_
MA(K*0RLOQ5Z+#*0;@@C8@((/OW7NN<O\LS^7!,VJ;^7]\)Y6M;5)\5^C'(%R
MU@6V*>+L3_KGW[KW6/\ X;&_EM?]Z^?A'_Z2IT5_]@GOW7NN/_#8G\MDN'/\
MOOX3%@GC4-\5^C2B)K,A"1G8QC2[DDD $D^_=>ZK%_G.? KX$=3_ ,L#YA=A
M;$^#_P 2MF[JVQUSBZS%[KV;\<.F-M[EV^)M];2HJ[*XK,XS:F+R5))1XZIF
M>04]1'/-"'B2[.%/NO=6<T_\LG^6TIAJJ?\ E_?"E&6"%:>1/BUT@IAA0O+$
M( -CCP%6E)NNDW/OW7NN0_EB_P ML-J7^7Y\)UO&T15?BST>(V1VC<JT0V,(
MF]42D$@D6X^I]^Z]U(A_EH?RY*82"F^ GPLIA,@CF%/\7.D(!-&'201S"+8Z
M>6,2QJP5K@,H/U ]^Z]TW9#^73_+-HJC'465^#'P;I:O*S24V)I,C\:>AH:C
M)5%- ]3+3XZGJMF+)634]+&TC)$&9(U+$  GW[KW3G!_+6_EUP15"4OP0^'-
M/%6H%J/M?C7TW )H[JZKJAV<A6/6H<!2!KN_ZB2?=>ZQ?\-G_P NGRO,/@C\
M0$DEDJ9IO'\<^I(UFEJX*BFJI9HX]IK'-)-!52*S,";.??NO=<X?Y:7\NJ!#
M&GP/^'C1E0C)-\;>GZA6"R>52ZU&SY0[+)R&-V!_/OW7NN3_ ,M7^70ZE9/@
M1\+Y%8*"LGQ?Z2=6T$% 0^R"#H*@K_0@6^@]^Z]UB/\ +=_EPKY8&^"'PK A
M@+30M\9>D (J8AR3+$=E62G(9KW 4W/^/OW7NN$'\M7^7%+*:^G^!_PSE,],
MM)Y(OC7TS)2O2Q2*ZQ)"NSFI-$<L0M9;@C_7]^Z]UW7?RW?Y;T%-+59/X'_"
MF*DIO\HFJ*_XR]'K30:+?Y1++4[*$412P]9(M8<^_=>Z:<C_ "W_ .6)/#)#
MDO@O\&Q#$Z12K+\;^BJ<0RR0&.)&8;/C:&5J?A!<'2!;Z"WNO=1Z7^6+_*_@
MD2*D^!/P@26-H$2.+XV])&5)/0( @&T#(LK^)1<>I[6-_?NO=-[_ ,K?^5?D
M)8G'P&^#T\E*T6,B^W^.G2Z^*;&I%II---M51]S3JB%U(\A(#-<\^_=>Z@C^
M4M_*I>"2AC_E_?"_QP@4DL<70/5BRQ&6:J;Q/)'MX5$<TTM1*"2P=OTFX50/
M=>ZXU7\HO^535U%JC^7Q\,VJ!*\QC7H#K")VF=GF>26*+;Z>5F\AOJ!])M^G
MCW[KW6%/Y0/\J=/%/'_+Y^'@4SK+"Z]$]=>)J@NA5D7^"&)Y&>%?P;Z%']D6
M]U[K,/Y0?\JYGD3_ (;\^(<C'U31/T;U_*&\T;QAYX7PS*Y>/4 6!-AQ]/?N
MO=81_)__ )4R,G_8O;X=%I(GI8A)T/US)K@91Y*:-9,&P:+0HN@%A8&W ]^Z
M]UQ/\GW^5('GF_X;U^'221EVJ)$Z'ZYC,9<_<OY"F#7Q ZM9' YO;W[KW42J
M_DX?RI:N9'J/@)\5_+(PFB$?56V:?68B\FJ.*GIHE94,Q)L+<B_T'OW7NO'^
M35_*D=JC_L7]\5B\LB22D=2[7\B2+018\-$PI-=*6HXUU>/1K<F0W=BQ]U[J
M(?Y,7\IR".FC;X ?%F(15T]5 [=7;>2>2LK9(Y9$>I:$5%2C&!1'"[/'&@T(
MJK<>_=>ZDK_)E_E2*M(@_E^_%@K0ZA3JW4^VI -4HF?SAZ5ONBT@N3+K)^AX
M]^Z]UX_R9?Y4QEDE'\O_ .+D;RDE_#U5MZ!2IEBG\(2&GCC6E66!2(0!$MN%
M )O[KW79_DS?RJ"TQ_V0+XPVJ"AFC'5^"$#F-YY$/VXA$"E6J7Y"CTD+]  /
M=>ZKVZM_E8?RZ\K_ #1_F#UMDOAAT/D.M]D?#CX29_:6R*SJ[;]7L;;FY=[]
MB?,+&[MS^)I9Z22FQNZ=QXO9N+@JI(],M338^$L3XE(]U[JPM?Y-'\JA0H'P
M ^+MEJEK!?JK;I/G6FGI!J)IB6A\-2UXC>(OI<KK167W7NH5)_)9_E/T-.M+
M!\ /C(8E9V'W'6V)K);R1)"UZBL$]0P\:"P+6#7868D^_=>Z;JO^2)_*4K9J
M>>?X _'#R4U?-DHO!LB.DC^ZJ)EGD\L-)4PPU%-Y%&F"16@1?2J!21[]U[ID
M/\B/^4">?]D Z Y_ZL.5_P#KS[]U[K/'_(M_E%PQF*'X%=$PQ&>&I,4.*S<4
M1J:<DT]28TSBH:FG)_;DMK3^R1[]U[J<O\D#^4\GF"?!WII!4QM#4A(-RH*B
M%F5FAJ NX@)XF9 2K74D VX'OW7NG=?Y,7\K]? %^'O7*_:(8Z33D]\+]I&8
MO"4I;;L'VR&#T632-'I^G'OW7NN-5_)@_EB5E--2R_$C9,<=1&T3O2;E[(H*
ME586)@K:'>M-64LEOH\<B.OX/OW7NN<?\F3^6+&GC7XC[%9?5S)N#L2:3U7)
M_=FWD\IM?CGC\6]^Z]UZ+^3)_+%A4*GQ'V,0#>\NX>Q)WO8#_.3;RDDM9?I>
MU^?J3[]U[K'#_)=_E=T[M+3_  YZUIY758Y)*?(;V@DDC1F=$D>+=2,Z(TC$
M D@%C;ZGW[KW72_R9/Y7-")GC^'_ %I1+4SM-4/'E-[4PJ:J<A7FJ&3=D8GJ
M9C8%FN[?DGW[KW72?R9?Y7<R1/%\1.N9(M*>,19K?1IY8HE984:./=_AJ(8-
M1,:L&5&Y4 @'W[KW3=/_ "2OY7E1*)G^*F%C/C6-XJ3LKNJAI)E3(29-#4T-
M'V3!1U4B5,I4/)&[""T%_"HC'NO=39_Y+O\ *_9%,OQ-V=&D4<B:TW?V?3>F
M77J,LD6^HC(X\ATLQ+)8:2-*V]U[I.C^1I_*T$\U3!\87I9:B&6GE-!WC\C:
M"-H)YEJ9(EAHNWH(8T,BBP51I4!190![]U[KB_\ (R_E;R223S?&K)3RRBI$
MLM3\@?DW4.QK(1!4L7G[FD8230@*S?JLHYX%O=>Z<L?_ "3?Y:6+:J;%="[K
MQSU<"4=:V/\ DQ\JZ-JJE4Q2)2U1IN[XS/3JT2,(WNH*J;<#W[KW2!^ ?0?6
M/QC^?G\PGI;I+#[DVKU5MSI3X#YK"[1S'8_9'8.,Q&<W'#\I*;-5.%;L7>&Z
MZS$)6X[;N.BDB@9(RE)$ 0JA![KW5RWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[HE/R425_DC_+N\<<[K%\B>W9IVB>T4,(^%WR9@$E2GC;7$9ZA$7E;2.OU
M^GOW7NCK>_=>Z][]U[KWOW7NO>_=>Z__T=_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U7M_-IO_ ,->?S"[$@_[)G\CA<?X]4;I!^H(/!_((/Y'OW7ND1_,
MUZZF[3_ET[NZ<I*'N^2'LA>B-CS9OX[;(;L7LK8E'4]E]>U)[$BZSH\=6CL'
M9.QVQRY#<^WTA5<QMN"NHE*>8$>Z]UJU[L^"WRB^3O97P7V-VM\=<7LVES/R
MT_F#XCM?Y1]?_!3LK!=>[YZB[?\ C=UITQUM\I>S?CINNDQF,Z'WUV7O?:V0
M6CQU4V&H\/G:"'=+XZ."=:BN]U[H2NR_@".E?YD/8:9SX^_)/Y'_ !'ZB^%G
MQ9Z SV1R_P 6^U>X=_\ S&RW5>UZZ@R^V-J]X;4VI3T6U.WWW'+M:IJMSH^.
MQ9H*.MH$R>.BIBJ>Z]T?;XH=%R8_>W\P':?\S[X@=T]Z?*?O;YM+O3K#L7!]
M/[E[:VYG_CAE<MM6I^.N*Z6^1N+H4V#TYM/H&?$5U5D,=7[AVS-M[Q^62.26
MHC63W7NBU?'_ *U[\H?CK_-C^-_3O1O=_5_;O\Q/^:7\LL9UCO7-=4=H=&)C
MOB'NC;N)S%9VHN_]R=95^"ZHVA6;2ASF'V?45\*1RY[,QI30Q322O%[KW2#V
M[V!\D?D-L?\ D-;U^5GP_P#D^W</P>^3&Z]N?++*93XD]\[LJQUYLG82;3V#
MWO>#JRMR&YMM[XR-'@\N[T$53-_&Z::=(0:='7W7NK&OYV.[.T/FO_)7[[?J
MKXM=[5.^][=W;*VMU'UEENCNRLOW5F=L=<?)+ 4]7VW3]5-M#%]A=>4^XM@[
M1RN7I!D:6BJ$PE3&LDBM6)&WNO=5??+K^6#W-T]V%_+\Q7Q7VOAOE'O#L_NK
MYY?)[>"=R_%?L'&?#3J"7Y-=#;;V[UIT[E.L<!-5)T/U#F>PJ9X<-B\SGC+A
M-SUSY6O"QI.OOW7NE+\4.A-U;0J_B%N+YU?$/Y7]J?$GJW^4IO?XY;4Z7[FZ
M5["[UW9U9\Y,+V?+4]O8O(;$V]L_.55%D.XM@Y-*#KC>JXN/'2;:--B*>MIZ
MBGFC?W7NE1M;X)_S$/C!U-_)F^;N(ZNC[?\ G_L/%[C^&7R:V%ONJR.Y,D.C
M_DM7[UP/1.=[<W=B*#<<E1/\0,!G<919S+U!)_AR-2U$K4\!/OW7NGWY._R]
M=M=8_,[.]1["ZK^3T?16&_D>;C^,&:[C^-70V\J_>N4[XWS\G]K9W=.Z-J;K
MP.U)-G[A[FSG7N4RF>S&,@JUJ<IA6KL5%(AJ!"ONO= 9F?CIWO7TWQ5V?O3X
MTT7:E+UA_.G^"6\<?\HNAOA%VQT32=T?''K3KK</^D_MGMKX[S;"?']-S];[
MES^(Q>[LC!0X_ [GG41PK5-B:B=/=>Z%#IKXT?)ZEZW^+G6>0Z+[?QO\V_:/
M\VW*=P?(GY@9KK/?$6+J>@Z3LW?.2WMVGF_DW4X2DV=OKH'L/XXC';0Q^T8,
MU5PY)Q%C1C8Y*<^'W7NG/X]_"+Y)]&=R?&GM[K'K3>^^/A/WE\I^\.\>\_C9
MV)UYOG$=A_%;Y4]30?*7.]:]Q]%[4WO@\75=8[-[NP5-A<9]S!2)10Y8XR2%
MC%-0>#W7NC<_R/>A.WNG?D+OVFW#UUN+>74.&^*FR=O[ ^4';?QPWE\3ODYM
MC)YKL6?<F2^(WR6VIF:#![1^1O9^P(8_XC5=C8BGK99)1)]WD)FRD,,'NO=;
M//OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ-_GMTTM7_ "J/
ME1#3T\%54Z>DI:2GJA(:.6KIOD9U#4TB5YB#2KCS4Q+]PRK(5AU'0]M#>Z]U
M;B+VYX/Y -Q<F_!XN/?NO==^_=>Z\?H;?7\>_=>ZUC<1U!MBL^8?\U^@_F6_
M'#M_O+<7=F\,!@_ACN_$]&;Z[IP65^)59L!L1M?K+XV[LP^W-R[$Z6[(VAN^
MLK)]PK/7[;JY,S5P9:K=H(_NX_=>Z+9\@/F/_.KV%1_+;&=1[6[MJMU[%W5V
M9AML;7P_Q=HMZ[<ZDQFU_F'TEL#XJ8WIVK3K"HJN\J;O'XFYK=FY-W3-5;J%
M$M$E='+AGA:B?W7ND:G<_P#-,WMN?I;M+?79/S1Q=?TGU[_.9I]E9G ?$6.B
MH.R-X]=5&W8/A?E^W-FTOQUJMOX^I[9ZVW*LN+JZC#4E'71XZ*+%&FKJ^N:;
MW7NECV/\Q?YR?5.W_P"6UN3 [Q^1'>^Y/D#@.DN^_DYMF@^!..V[LCJ[$[Y[
M#^.O778G1N>S.W^N\KNS$-LFFS6Z9GQ590[?SL+5CY1\XT5%2XJ7W7NN^P>Y
M?YG_ '=U!E,MOOLKYH=9;ZPO\R;XS[;[TZ+ZJ^'&1Q+_ !WZJVW\N]]XZOS/
M1?;5/UGF7^2?5&YNF<=L?-O3P4^XXXZRGJ*O)UM1C<D^*]^Z]T:W^:1\6^Y>
M\/G1M_N#XAU6XMN?,;XI?#1>U>I:VLVEFX^H?D&T?;=?C^P?BGWAN./"TFQ-
MUXSMWK:KJ*&EQ%1DH:F@FK/NHTAIGGE7W7N@)Z2[]_F/_'+>'PGZ:V=TOV3M
MSHS9G2O\OZ4]'[9Z(J<WL[='1FZ?CQVSOW^8)V#OG?)V7+G-F]V]#=GX#!8'
M;&VDW!B*FJR%32P38S*29<RQ>Z]UL)[B[1VQWK\']R]MY3K;L+;NU.U/CIGM
MV3=4]I];Y&+M#'XS=NQ:RKAV;O/JFCI]Q93^]Q6M6FGP\,=;,]0WB19&(!]U
M[K3._EG?'#L;JSL'^4;F.\_C;O5L1U)\*/Y@V)[WQ61^#W;VV<[L7?\ NW.[
MB?8NT.]MRY[&[DH^Q^PMW8_[F+;\;TN*G%%+'#%!(:M6D]U[H*_@M\;/D/UD
M_P#)GS'9WQY[PQ]-T_T+_-@QG=F$V+\4^WNN.\.G=_=A8?M:3I:@[![5SN.S
MF%RW<&]YYZ)NN:JKQ^(.&JC NJ4/%(/=>Z,UL'X5[J[3V-G/A;W9L//[WZ/S
M^Y?@[U)U=\\^KOB3VU\6/D/M*;;&[NULA1[,[?Z]K-C38:C[SZ-C--6;A[%H
M$&/EH:V&CS64J9*^U'[KW3AWWT1W)1?#+Y/=6?S!OC;V_P!J_,_,?+3$=1[*
M^0WQ6Z![K[*H<SLG8?2WQXQ=#_,KSN#ZF I\UV#0;+I9_P"$R5]2E:F]<G7T
M,4-&E3G6I_=>ZLD[G^!_PYS'RYD^:V^/CC\DJ+'[-^&&Y.^/DINNFH^[MQ_(
M3N'?GR P.#Z:ZOZ#HL3L'<643*[PVEU3L_=6.W#@=KPQM2U&6QBU%2*>HDE;
MW7NJ?)-E]+O\#>ANN*OXR_S(MM=AS?/#>G<G7F*Z_P#CS\K5F^ /6#=I[+[U
MW5M+H#:51]M2+D\=BJ'']5[=SVZEI(JG<&1S64@>#!4K22>Z]T87;O5'RJHO
MG%_,3W9V1LKO[;F-JL9_->RO=V[#@^V\)2[MZD[!?XX9+^6YM'8V_MH555'V
M+F<+EL7D*?;>(V[D<C)A*.GRU/IACJZFG?W7NL^\]M[G[)^)'\DWK78/3'>>
M1^=_QVV%_+X[:QM)O[XX?)/^!;\79G9..VEW)TM!\E\=E,1MSXM[HVE]AGLO
MV'5YRAISE\'34%,]3*%HD7W7NBH[>ZI^>J[R^0F>R6P>\4V2F[NK<7_,ZES>
MR>SX<5VADHOYR/9^_=PUM-1YG%U4O:>!H/@Q6X,Y1L'%E85ZNK*6AE#X\FG'
MNO=3>INF?YD&.[)^ "9_9/<"[_HL/\0JSXEY3/[6[!27I[I?#_/WY#;I[[P^
MY<G78^CQNPJRC^*-9MBGW91YN>BFR6RI,;CI?N9HH:=?=>ZL=^/O1'6_:GPO
M_FXQ]J=6_(7NK&;-_F<_)/O_ ..75.Y<S\E]KYONS!3]?X'K3XA:-[9#+8/L
MKLOJ3,Y*>U&\65J*&%:-)JC7'3JK>Z]U)ZW^,6VOB#\V,)TE_,/V]OWMCXC]
M3_RY.D^L?A3O&NVKVAV;TO-W91Q21?*VKI\=MO#[A3'_ "V[+W_7562V[75
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M/T?VEN;8M5BH(*C$=N]19N!JS([:J:LR5-'')+%:!?/[]U[JR_XP?S$?B?\
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M)9ZBNIL9W#2P5]88I33K/,KS1T5J56%,!$/=>Z[3^3O_ "[8H\1#%T3G8H<
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MDL<YE[/[FD:;S2O.[RL_8K-)/YI&99"3(A9M+"YO[KW7.#^5!\ *=$CA^/\
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M[P23%SM44$R_,[YH^:F>2>*JJ%CE_P!F!UB*KJ81)*M],CDDBY/OW7NH\_\
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M::IIY%Y5T9E(^A]^Z]U/]^Z]U HLKB\D];'CLE05\F-JY,?D8Z*LIZIZ"OB
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MZWOQ;^M_?NO==*RM?2RMI8JVD@V8&Q4V^C _4>_=>Z\647)90!>]R!:WUO\
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MBQ\%719NG-#%%,3&S>Z]UK[[,^7/8FU/D/\ /3<W?5?_ 'KZ-_FT?!C<G:>
MH*3,5_9&)^./>6TMG]B[!Z?^/^^,%!L7 GK'<>X^FY<3BZ_#UB5E3_>7&J\M
M0Z3K)[]U[H'/Y+N#ZOZ][>ZWPWSPV3L+%=:[U_EL?'#:O7F1VGB1MGI:7=GQ
MA[8W!VUN[:OS;V)6UM?E<O\ +;:>^\!2/MS*Y9$Q.:P&/B@HJ9WK*6)_=>Z
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MGRCVEWMD4[![IJ-I]%[5ZRW/\?\ K1NTMP8_=.;H^D>S,;68C>N+J:3$X66
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MW7O?NO=-6=_CG\#S/]V!BCN3^%9'^[PSIK%P9SGV<W\)&9;'JU>N*-?X_N#
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M6"HHFA$U=++YX_=>Z4OQ ^"?R:^&>%[2^-VQ-Y=%[O\ B;V#\F>TNYL/NC>
M[$3O3:75'=F?GW?V+TP^U\+2T&T=Q;G7-9&MIL1O%]PTHI*:I6:?#5,D(B?W
M7NBJ=7?R=ODGL_IKX0?$+/\ =/4<OQP_EX?(+>7R.Z7WY@L?NENX.U]SX?\
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M:_F#=:=&=1838'1VZ<)\H-@[+^2F'ZL[NVKW-T9N[;%1M3OOY;;O[:F^,_\
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M^!A)^@@^_=>ZXT_S:^&=7,*>E^7'QCJ:@NB""G[[ZJFF9Y55XD$4>[&<M(C
MJ+7(((]^Z]U E^=WP@@U^?YD?%2'QZ2_E^0_4,>C6TJ+KU[P&G4\#@7^I1A^
M#[]U[J+_ +/W\%!]?FG\2Q_Y<=TY_P#9G[]U[K,OST^#3I)(OS.^*!CB*"60
M?(KI\I&9"502,N\2J%V4@7M<CW[KW6(?/KX*,;+\T_B6Q_P^1W3I_P!C;^^5
M_?NO=>_V?KX*\_\ .:7Q,]/ZO^<C>G/3_K_[_/CZ>_=>ZY+\^/@L]M'S0^)S
MW94&GY&=.M=V-E46WD;LQ^@^I]^Z]UV?GO\ !=69#\T/B<'0Z60_(SIX,I_H
MRG>0()_Q]^Z]UW_L^OP9_P"\SOBA]2/^RB^GOJ/J/^/R^H]^Z]US_P!GQ^#O
MC28?,OXI&)W,:2#Y$=0>-I%4.T:O_?'2SA#<@&]N??NO=</]GU^#-R/]G.^*
M%UO<?[,7T]<6O>X_OE<6M[]U[K)-\[_@]3^'S_,KXIP_<0I44_F^0_4,?GIY
M"ZQSPZ]X+Y89&C8*RW4D'G@^_=>Z]#\\/@]4S14]/\R?BG/43R)%#!#\B.H9
M9II9#:..**/>+/([GZ  D_CW[KW4N'YP?"VHKH<93_+WXO3Y*H6-X,?#W_U/
M+6S)+2_>Q/%2)NUJB19:+]Y2JD-%ZQZ>??NO=/N.^7'Q2RXJVQ/R<^/>3%!5
M5-%7'']T=;UHHJVC)%9259IMRRBFJJ0@B6-]+QD>H#W[KW4O_9J?C!]PM(/D
M=T,:II7@6F'<'7GW#3QSU-,\*P_WB\AE2HHIHRMKAXG7ZJP'NO=93\H_C,JR
MLWR)Z*58/%YV/;G7X$'GDFBA\Q.X;1^66GD5;VU-&P%RIM[KW7!?E/\ &)X8
M*A/D;T.U/51O+2SKV]U\T-3%&5#R02C<)2:-"PN5) N+^_=>Z]_LTWQC_P F
M_P"<C.B!]Z\$=)_QE[K[_*I*J22&FCI_]_%^^]3-$R1A+EV4@7(/OW7NH3?+
MCXI)(T3_ ";^/:2K&\S1MW1UNKK#'I\DS(=RAA%'K&IB+"X]^Z]UEF^6/Q9I
MP&J/DKT! IB><--W)US$I@CE,+S ON1;Q),-!;Z!N#S[]U[J0_RF^,<<WV\G
MR,Z(2H,XIA3OV]U\L_W)2GD%/XFW"'\YCJHFT6U6D4V]0O[KW7&H^5/Q@I$\
ME5\C^AJ:/R>'R5'<'7D*"8LJ"+5+N)5\I=@-/UN1[]U[K$_RO^+<:+))\DN@
MD1U=U=^X^NE1D0 NRLVY "J!A<_07]^Z]UCC^6OQ5E)6/Y,?'V1E5G94[GZX
M=@B$!W(7<ILJDBY_'OW7NHC?,7XC)"*E_E-\<5IS'',*AN[^LEA,4LJ012B4
M[G"&.2:545KV+, .2![]U[K!!\SOA]56-+\K?C74@U,=&#3]Z]73 U<I18J4
M>/=37J)&D4*GZB6%AR/?NO=.(^6WQ4*QN/DS\?"DR/+"P[GZW*RQQP/5221M
M_>6SHE+&TA(N!&I8\ GW[KW7%?ES\46J8*-?DY\>FJZH2-34H[IZV-34+% U
M3*T$ W,99ECIE,C:0;("QXY]^Z]UQH_EY\3\C5PT&/\ D]\>*^MJ%=X*.C[J
MZUJJJ=(P#(\-/#N9YI%C##454@7Y]^Z]TH?]F/\ CQ_S_GIC_P!&CL?_ .OG
MOW7NLC?(GX_)'#*_>G3B15"NT$C=G;)6.=8Y&AD:%SFPLBQS(R,5O9@0>1[]
MU[KQ^17Q^4%CWITX$"Q.7/9VR0H2<$PL2<YPLP4Z3]&_'OW7NN+?(SX^*$9^
M]NFE$BZXRW9^R '34R%D)SEF4.A%QQ<$?CW[KW68_(3H,1R2GN_J 11-3K+*
M>R]EB.-JM'DI5=_XUI1JE(V,8-M84D7L??NO=>B^0?0E076G[OZAG,:AY!#V
M5LN0HA94#.$S1*JSNJ@GBY _/OW7NLH[]Z*8L%[IZF++&LS*.Q]G%EA:>.E6
M4@9GB-JJ9(PQX,C!?J0/?NO=36[KZ<2>EI6[9ZS6IKI?!14S;\VHL]7,06$-
M+$<L)*B4J"=* FP^GOW7NL5'WCTMD*E**@[>ZOK:R2IFHHZ6D[ VE4U,E93Q
M-/44B00Y=Y7J8($+O&!J5020 +^_=>Z5G]]=F_\ /6[9^E_^+]BOH/J?^!?T
M'OW7NL4^^]CTL+U%3O+:M/!%;R3S[BQ$4,89UC!>62L5$O(P47/)-OK[]U[K
M+_?39W_/6;9_\_V+_P#JKW[KW7CO79HM?=NV1?Z7SV*YXOQ_E?\ 3W[KW77]
M]=FW _O;MBY^@_CV*N;?6P^[N;>_=>Z[_OKLZ]O[V[9O_3^/8J_^V^Z]^Z]U
MW_?39W_/6;:_\_N+_P#JKW[KW77]]-G?\]9MG^G_ !?L7^?I_P I7Y]^Z]UW
M_?/9W_/6;:_I_P 7W%__ %5[]U[KW]\]G?\ /6;:_P#/[B__ *J]^Z]U[^^>
MSO\ GK-M?^?W%_\ U5[]U[KE_?':("L=U;;TM<JW\<QEF"FS%3]U8Z2>?Z>_
M=>Z[_O?M.Y7^]&W=2IK8?QO&W":/)K(^YN$\?JO]+<_3W[KW70WCM$JS#=6W
M"JZ0S#.8PJNHV74?NK#41Q_7W[KW66#=6UZIG2FW)@:AXXVFD6#,8Z9DB5E5
MI76.H8K&K. 6/ )']??NO=3TRN+EJ31QY+'R58\]Z5*RG>I'VRPO4W@60RC[
M=*B,OQZ!(I-M0O[KW4U'215>-E=' 9'1@RLIY#*RDA@1^1[]U[KE[]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)
M!V^\:_/+X4*T$,COU%\S/%,\T:2TY7_9<2YAB8%YS*OI8*1I')X]^Z]T=_W[
MKW7O?NO=>]^Z]U[W[KW7_]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:\7\M'X:?$'O^O\ YF&\>]?BG\=.
MXMX1_P WKYW8@;N[4Z7ZU[!W+/BL?O#;YQU#_&MT[:RF5BQV.2LDC@IVE,<=
MV= !(??NO=<_YP75WPM_EY?"W<?RSZU_EU_R\MV9W8?8/2NTLIMGL;XH]<5>
M,S>T>P.RMO; K:3%5NU\1@Z_"YK"3;DAR<%0Z5\)CH9(#3,TR2P^Z]U3=V1\
MH^GNK,/\<\EW5_*R_E5_'#8W>'=OSIZD3N7O3X+Y+!;)W7L3XR[(I>PNN/DE
ML[KO)0[6[*V]USWO_$X<.F(RR39"GJH#74]364]1'#'[KW0GCO\ VEN+=/Q1
MI\5_)0_E\MNKY)_RO>X_G:.B:GXL[$S';-7NSJO#[MEV[U9M7=5+2X_%-@^Z
M%I,)D<5+48*?*8ZDK31M35M9+&T7NO=('>7RZZ-3X>;G^5_QB_EZ?RC_ ).4
M.PN_\'M#?O76+^#\_4':.W-I;;Z"WYWUWO0[WZNWQDJS<G7O;'5,/5F>AHAY
M<WAMP8W3DJ:4?:U5&/=>Z-9U5\L_Y>W:GR?^0=1MWX#?R^*/^7]TC_+TG^<F
MTNRG^*76]3V_W%28[/3[4W%08&M2D@V/@,5BM^XS+X"*F./R%;6Y?%M'%):<
M&+W7NBU[I^1&S^DNVLOT#\J_Y47\K?K3>'9F2Z#VI\7^V\)\+\-F.I:_O/>6
M$Z#W[W+\5NU<37YRFSM+VSLKK[ONE?!Y&/(8BBR]9AIK49^Z2GI_=>ZG]?\
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M[%VMA^QL8[8/'^7<-3#7TQ%'Y',2>Z]T8S^6U\/_ .4[\X]@?)G?NY/Y57Q
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M%_"WL8SULGQJPF)W)W#M[9NX,MUQC]E;MSVS\'N"@KYZ:BR;Q4V,K$R$C14
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M+.ID5V!C@T&)@K8$AKH8 :U:YT+^_=>Z8,A_)A^ 75F)I-T?WD[5ZJZCZ?\
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MWU_<C:FP*NMPW]U=F;.@H*+(8'96/\M.Z3(LT1:/QAV4^Z]T6#!?]OXNT/\
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MNDOD#/2XO?D>;^*FV9\)M"LVZN0+9/'1Y2OHZZ*F*43HTDL7NO=6LG=_\X
MD?'[^7 ; D#_ &;GY,7-A<"Y^%EKG_;>_=>ZXG>/\X+0C#X]?RX2S&+5'_LW
M?R6#1AV02$M_LEFAO &)-OU:>.2/?NO==2[Q_G!QIJC^//\ +AJ'UPKXD^7G
MR5C.B29(Y9=<GPL"V@B8R$?5@ND<D>_=>ZC56^/YQ4&O[?XV?RY:[2:33X_F
M'\CJ;R">>2.IMY_A;Z&HH464WXD#Z5Y!]^Z]TDJCM7^=?$\BP_##^7A5*CQK
M&Z_.KO*#RJ\6MY LGPK)18G]%CRQY''OW7NHW^EK^=M_WA+_ "\O_2\>[O\
M[BGW[KW7O]+7\[;_ +PE_EY?^EX]W?\ W%/OW7NN:=M_SL@6\OPD_E[$:#I$
M?SR[K!UW&DL7^%)&@"]P.??NO=*P=R_S=(X*1I?@=\,*F=$C&0CI/Y@_8\0G
MD*E9'Q_W/P;588UE8-:5F/C4BY8CW[KW42G[B_G!M6DU'P4^$*8\2U5E7^8#
MV>*QH)*:F;'@2#X/RP^6FJ3**DE ' 7Q@6U-[KW4P]U?S;6I8ID^ GP]CG>0
M-)1S?S"]]O+% HJV:-I(O@_]L9Y L*J5=D#,2>/T^Z]UGF[G_FSCQ+!\"OAV
MS$WFE?\ F%;_ /$%=S&BHG^R,I('A#B1_J&1&"^HJ/?NO=05[I_F[RTL2K\!
MOAI35TDD[/+4?S">P)**"&,U20I)%3_"!ZAYYS%&X9&90D@! 8,%]U[J+DN[
M?YP-#0Q24?P ^&F9KC,(YH*'^83ORG58]$\S3C^*?"B@0(1$L0'D9_+*IT^,
M.R^Z]U5]MKMO^:;/_-E[=W[3_ #X\_Z:*?\ EP=!;:R77<_SNR3;*Q>QJOY-
M?(#+X7/C?4/QCJ_N-VYG+4N2I#B?L:2""GQPJONZ@S^&'W7NK&:WY#_SG(?M
MC2?RT?B95AY*1ZE5_F+9=&B@-/++6P!I_B33J*H3:(D<>2-7!)#H0X]U[KT?
MR3_G)M3D/_*X^,B51IY)E=OYDQ\"RQ, *1H4^)$CF:I56,;"3QKJ76P(/OW7
MNG"/Y&_SA/N5@E_EB?&80O!3R&NC_F0RF&&5K&H@:G;XABIEEC!-K:4)'ZR.
M??NO=13\F/YQ'EC0?RK?CEXY/"6F/\R^ETP>4*9!(@^(>MFIBQ#Z P8J=.H6
M)]U[J8?DE_-]$J(/Y7/QS,9I(Y7G_P"')X="UDC!6I0A^(8D*0!@SR6L55M
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M93*Y7/.^8Q>/RV1IL'@XIL[N1=H8*MJLU+BJ +796''-24[QS3)(ONO=!O\
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MC9_7\FQNI.I7[2EK-B=)9&IZ8S70F0[-ZSI\CAJS/4W:.2Z_W1EC+DLMD,M
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MZC2-.J(UXM6E7]U[JLWYR?(C^8%O/Y:_RCZO>W\L<;!W#MGY<]D[FV!M:O\
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M)8U$8,920O+JL8V4IXU":3J$@+7-QIT_0WX]U[K+:_U]^Z]U[W[KW7O?NO=
MS\C7>/X]=\21LR2)TSV@Z.A*LCKLC.,K*PY#*PN#_7W[KW17/Y23,_\ *Q_E
MO.QNS?!;XHLQ/Y9NC=CDG_8D^_=>ZL)]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=% SV2G_P!GYZHP_P!Q1?;#
MX@?(+)"D_>_B/G/<_P 9J4U'_ K[?[+QC3_F->O^W;T^_=>Z-_[]U[KWOW7N
MO>_=>Z][]U[K_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=4N?\)\\4^)_E2]"JXE'\1[*^76:7RFG-X\O\
MQ>^ZY#']O-,!$5E](?3*!PZJUP/=>ZNC]^Z]U57\Z/YEV/\ ACGNW)ZC8:[P
MV5\;OC)B/D3W14PU[4^=R&6[@[+R/2'QDZEV6-0QV/S/8_9F"RDN6RN0\D&'
MQ./5DI:AZM7I_=>Z#7<O\U')_$;N^J^/_P#,1VGM7:6ZMS]4[![BZBW+\5-O
M=X=ZXG=-'O3M_;W0>0ZOR^T:+KJ;?%)OK ]J;SP5)05]/338[<%-F(6$>/JP
M*.3W7N@Q[*_GK=)9_#=B4/QJH\U-D=H]3=#]G+W#W+T[W6O2VV,OW#\IJCXR
M3]4]E[;V/MZ3MS:O8.+W;MK.8HK/CZ>AI<_1O!4SK%2U3+[KW1LNQ_YOGPBZ
MJJM]T^\=X]A0+L?<>/VU356(Z=[+W%3]CU,_=F-^-V<R73XP.V\A4]HX/9/?
M>7I=I9FKQ$=1'1YFIIXAY%J:9YO=>Z>M^_S#=L9?^7=\B?GA\;=M'? Z)V%W
M[N.LZY[HAW;T;F,=N[XVU^Z<9VKL#L'&9?:>5W;LC=>VJ_962@-#4XU7FJXH
MHGDIXYC4Q>Z]T[=??,_/9+OOXT=7]@;?VMBMI_,[XPGN_P"/N>P-3D?XQ#OS
MKO ;.W1W9UEO2DR=2R3J=J=E8C,;:K:.*+RTV/RT-8B20TTE1[KW5@ZQQH9&
M1$1I7\DI50IDDT)'KD( +OXXU6YYLH'T'OW7NJ@?Y_*22_R</G_%"H>:3HZ>
M.%&"LKS/NO;*Q*5>Z,&D(%FN#]""/?NO='-^0_RRZD^&'4'7^_.[ZO<B4>Z-
MP;7ZRVYB=G;6KMU[FW)O7(;5SFYGQ.%V_A85>JJ:?;6SLK7^&(+).E$:>DCG
MJY::EF]U[JKOYY_S)?BI1]?_ .EG975VV^UODI\7-_\ :N4ZHQG?71G9FK8^
M[^A^R>D^O/DO2;)R-#M],W@>U<?L3N3&5."6EEA.?@K8DIY*B(U$7OW7NC [
MA_G;_"#$8*6KQ=3W7N?>-#M3NW<^Y>I\7T1V=3=I]<R=!S[@QN^<%VULC+;>
MH,[UCE(MP[;GH$;*PPT\4DD,]1)!23Q5#^Z]U H?YW_PKQ>W<)D^USW#T]G*
MSXSK\G,WM[=G3'9<KX?;.*ZKVIW-OW;6/JJ3;'W6Z-Q=?=>;TQV5KVHZ1J1Z
M*I#12M+'4PP>Z]T(^'_F[_$+<./QU5@(N^LUE)-Z;KVAN?96*^.W;E?V1UO0
M[-W#U[MG,;^[(ZWIML2;XVKU\V4[8VU]M7R4#RU,.662.%DI:\TGNO=#9\:O
MY@GQ9^7'9_=G4/1/87]\-Y="U\-+O-(\95PX;)8^7<&Y-GG<>S\]:3%[EV_#
MO#9V4QCS0R"19J,3>,TE515-3[KW1T_?NO=>]^Z]UZWY_/\ OO\ BGOW7NO6
M']/?NO=>L#]1?W[KW7K ?CW[KW7K _4?X?[ _4?['W[KW7O?NO==$ _4 _Z_
MOW7N@;[B^.O0GR%H]O8_O;IKK/N"BVED:K+;7I^Q]EX#=\>WLE7T38W(5>&_
MCE#6'&RY''.:>H\105$)T2:EX]^Z]T+5!04&*H:+%XNBI,;C,;24U!CL=04T
M-'0T%#1PI3TE%14E.D=/2TE+3QK''&BJB(H50  /?NO=2_?NO=>]^Z]U[W[K
MW5-?\PX0R_S$?Y'-/+#%(6^57RCJ4E:15FC:C^#?>$B+''YEE>-IF1V(1E#1
MJ&9=0#^Z]U8?\L?D)A?BC\:^[?D?N#"5^Y\9TYUWN+>YVQBI8Z?([GR&+HG_
M ()MJBJYDD@H9]P9N6GHQ42*T=/YO(X*J1[]U[JFSMC^=1V+T=E^V^G^P.F>
MGHOD!\9<5WWO+N]:OMO<VS.G][[8Z'Z'Z.^1\NTOC]NW<.P:K);C[?[ ZX[T
M@_AN'R<--%33[>R4LLSTQBD'NO=&;W7_ #*-_P!-5T.]MB]/[?W%TAN/Y6_
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M]U[W[KW7O?NO=>]^Z]T1K/1M_P .5]52^G1_LC7?\?ZTUZO]/GQI;_-ZO)I
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M1FW<O15.V-E2&AEK*FLK)LB)6FK//4J)_?NO=$O[BZG_ )A78W\SM_FUM[X
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M-I'\G3^9PAM>\V.^&,2\LJ6U/\PP+W>]OZ G\'W[KW7,?S+^_F:)1_)U_F;
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M8M:UR/?NO=<!_,KWHW@*_P KW^:$4FJ!3EFZ;Z$C,18E%EEC?Y-"1(#+8%R
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MJ^L]B=X?PI,2FYNWJ]?B=O3<F]HL+64T"9.CV_!+XF,.0>H]U[J#F=K34/\
M(.^>6WZO&[YWQ5;@_F+][9'KO(YKJO=.S-W;\V]GOGWM_.X'?^T]@8;;V S&
M'H\_UI+49:!,9CJ2BIZ$S1+"E*DD/OW7NGOM#O#NCXN]G=];S_EDXK?G4/\
M+U[*W#\7]EY_M;/](]W;IZ=Z:[MRE'\E,IW!VAT%U3F.K>Q<U2=;9>FP'76
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MP^>9:>$2R)'YJB0,4AB#E?)-(%)"B[&QX]^Z]UF]^Z]T4OY\Z1\%/FH3PO\
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M(V)L_IO[]U[HWWS;^6&_?BS'\:J/KWJ/:7;VXODI\E-I_&;!8S=W;64ZDQ^
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M=1T57U1+F,IN/X4_)FBR6Y-\5U1X5@V,*;^/)-)4HL7NO=%WR/S<_FG5_?\
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M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H-\QMW?L_9VR]UX+?\
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M0_$'M3N"GZPZM_F]?S3-S4^T^R.]NL>Y<Y_PZO@MFQ;"ROQ]V#2;_P!XYO\
MNONY*'?N_MJTLE:U%5Y3:U/+18MH*B:NEBI8%?W[KW0A9#X]?RY]O;;V]N;<
M7_"@3YZX[;N[GW-!M7-9S^;K38>#*2[3R&.QV[(L?+IQK5DNULAN&ACKO,LC
M41J(!-I60:O=>Z?/E5\5ML?%FHZT3+_*S^>9VIM'L+=/7.P\OOGKGYY4@H-H
MR]A]B[4ZYV2*;&[@S&U-W[_W-79_-T#SX[:E#ELL,'35=?4*Q>7[WW7NGGO_
M .%</QZ[<^,G7.,^7W\Z[LO+?)S?F[^O=N9S;?\ ,*PM+A,%N_:?7>Z^Z,M'
MNG%=A1XOQTF?V3UKE6@.,I)::FDI13Q1TK55Y/=>Z)[B-V_%3<?P+ZT^>^#_
M )A'\[^CP^^>W,!T-MGI0?-'!#N8_('>._HNM*+KK<.)W503["AKL>U2,P\E
M7DCB$V_IR2+)JCU^Z]T9'Y-]*UWQL[%VEUQ6_*?^=]V)D]R_'GMSY&+7;!^:
MW0\-)2;3^/!V@.X<+D(][XK;%5)NO&1]A8.2EBI$DH\D:UU@FB^WD'OW7N@(
MW)N[IV@Z4V5W]U]\W/YXG;_5N]^A/D=\B<WF,'\NNF-I[QZ@V_\ %JDVWD>Z
MNO=][%[ PNR\EB^S]DIGXZ88AXZR2:I\R-.UH)6]U[HP/1?0>([7[PD^-F]?
MGM_/*Z'[NK.F,?\ (#9^T>T_E1TE78CLKJ*OR5!M[([NZ[WKUEL/>VU\W6;)
MW%FJ&DS>+GJ:3)XZ:LII'II*2>.9_=>Z#C:6S,)7]]=@='9OYG?SM=OTW5'<
M>Z.E.R>Q-P_.KXR2;?VEF<5U/0=W_P"DC+;=Q5(.P(.FJ?KG=>+K:C<)Q24F
M(JZB.FKZ>***J=?=>Z''_1A\&JK9]3V'2_\ "@?YE#8:[NQFP6W?2?S).E9]
MLTN],GMVGW30;97-/L&IHCF:_; ;*B"25V^Q:2H 6! 8_=>Z*YN#=WQOQ?5'
MSBWO)_,B_FT5G:GP4ROR/F[*^+]+_,!Z<A[TW#L3XYYNEHMP]B;=VK18=JJD
MZYR5+5PU>.KZQJ>LEIY!'+Y)F2)_=>Z.+/T/\3,,,]%O7^>#\[=EYK:M)U[7
M;WVMO+^8EUGMS,]=U>_*K%4NU<7N>CJ=D8ZKQ=9N3+5\5 D57?RU-0(HPLC1
M@>Z]UAV?TG\-MX[9W;O+:'\^3YN[ZVKUS@<'N??NXL%_,3ZIS.*VS@-YY"KQ
M6TLMN2LP&P!!B:7,Y>)J+'D^'[JLB$%I)BR-[KW24W1UQ\%]BX7<>1S/\_#Y
MQU<FW^JMQ=I9/$XW^8OU=F]U5NQL1L*I[*K-ZX?;>)V)-EJ]H]C0R9:D2B@^
MWJ*5E=89(_&![KW1B>J?Y=.UN\>I^N.V>L_YKG\VO.;&[)VIA=_[3W/1_+K;
M$DN:V]NW$4^3Q9JHCU#54%/)3458J/#''&\$ZLKDRJ2/=>Z$"'^4ODH%A0?S
M2/YNLBQ2F1Q-\L]IR&H1F1O!,[=+>18AI(!C,;V<^KA=/NO=>?\ E,Y9G=E_
MFF_S=8U9V98T^5VRBD:LQ(C0R='R2%$!L"S,UAR2>??NO=0Y_P"477U,+P2_
MS3_YOXC>1I6\'R[VO22ZV8NVFHI.EH*A$)/Z%<(!P !Q[]U[JMOY3?RS\AM_
M^8/_ "K-C'^8G_,QW%+OO/\ S+\.]=U?)C:]?V!UY#M/XW5&5EJ.L,Q#U-14
M^'K-SO-'09AJBEKON<8SQKXB2_OW7NK)E_E'9)$D1?YJ'\WW3,49]7RWVE(U
MTBBA7QR2=)O)"/' MPA4,VIC=W=F]U[J1_PTQE_^]J'\W?\ ]*LV/_\ :,]^
MZ]U[_AIC+_\ >U#^;O\ ^E6['_\ M&>_=>Z]_P -,9?_ +VH?S=__2K=C_\
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M75Q]+B_U^OX^E_?NO==W']??NO=>O_Q3_B/][]^Z]UUJ ^I _P!B/?NO==W
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M/L?,T&-^07Q*V!M'Y,T7Q@[%WQ@,GG*J+L^IH]O[=VJFWMQ90UU5E8YJ6O\
M+/4UXGD]U[HTW\M#?8;Y2?S -L[%[=WA\DNCX]N?'7M3J3L#$?*+*?+?8.XZ
M_=-+W'C=\U*;USZ8S;_57=V^,UM>"LS&PL \6T\'B!AY*%*=*B6_NO=([Y4_
M)OLO=_=_\F[<F2Q7R!^%F;[+^?\ OGK'>OQX[5[,V'M#(=D]?X_X_=NY,U&]
M,%U3VEOS8>^L%/O'#X,8:":NJI&K:^*%88ZFIIP_NO=$[Q'<])7]O_*GK'XE
M_P P_=G?%5\G\!LCXG;)PF\.^*?NC<N4^4FZ>V<]AODK\N^KMHX/.23=%=2=
M"]-;@:BHX,#!AML9.OVY(V-HQ'01U=;[KW4O9>\^BLSOWYB=>=;_ ,SW/]D]
M/2]1]?['I=F]L_S+<;UME^Z?D7UOV+]COW?.R^XMCMNC>/Q+Z7RM-FL%L*<;
M0H,##N?(TU8F+H/%1??5_NO=2]G_ "+P?;GQ-Z&WM\JOE)\B.@.H_BQ\,.N<
MKWSV2G<5)U9WSW7WQW7N:NV[M/8-#V;@<E@J/-UV]^O^EI\EA<ICZVBSV8P6
M_P#%9'[NE>MFG'NO=%QV)\E.^MLTOQ_V]7_-[=7=?:_66U?A#3?&*#9_>$_9
M&VOD]O/NG^95V+U=\LMC;JW'L_-)MGY@;B^/'QKQ>(V+N'-R09&EQ+05>X8W
MI:BI6L]^Z]T8WMWY=]\;'ZJ^876W4OR.@^]WM_.VA^)F4[\[2[BK8Z#XK= [
MV^/_ %?V1FU3LLX[=</36,J]U8?);/V]D):!Z;!Y?/AJ6)JZ.+W[KW5Y/\N+
MM[$]]_!WXV]PX/8NZ^M<7OWKNFS-/L[>F_=U]JYK',N4R=#55L/:&^:NMW?V
M/MS<%7229+"Y[(N*G+X>KI:MDB\HB3W7NBF_"BJ%5_-D_G8*(-'V.4_EV4)F
M8!7FT_%K*5ND#4S/#']]Z6(4$LP NI)]U[JXOW[KW7O?NO=%@^:N6S>%^)/R
M*K]L=Z8/XR;H'4F\Z/:_R$W/205FVNG-S93$5&+V]V!N%*J&HIJ?![<S%9!4
M5=3(A2D@5YR0([CW7NM0?J#Y24V6_ER]4X/(?S(.]?CS\J=E]OY7IWKG&;O^
M7>V8.H\MWEMC;O4V_=\]]9CNG=FX\AG>W_AUL[K=:K+R;/W-5S-2Y/<59MN6
M@FSC8:&#W7NKL/YC?>>0W_O/X5YOX]?-78%7UEMCY(;'P?>/QZZ&^0AZZ^2?
M?$FYNXNO.G FP\OL;<.1R>X<5TUGMPUL^ZMD56/CBRD/W%/45=)54T&GW7NJ
MP<=\]_FDV"D;8W?]<G<'RG-7LCOG+[_W!44G5?P"[1RG\RS-_&O9XI,/N;:N
M\Z3H=QTG#F=HXZ&KPM539#<F"Q>:K:.LEEK)JOW7NCG9WY^[6[)^$?\ +YQ7
M6_:N_.@\/W7\LNG^J?E54;T^1E5NOY"]5]"[AW;WWA)-YYSO3-YA=_8;97R&
M[;Z@I,)M;?VC%Q93"YM(\3)022TRTONO=%AZE_F-_,C?/9O\J/9W8&[>_>N]
MF;QR7>O7.<[8?I#(2;/^4<-=\<OD/7];_*?-;PJJ2@V)GNM^HMM8C9^[,I0-
M]K1-7U.5RU:K4.+II1[KW5KO\I#M"E[!RGRYI-F_-C(?,'H_'=D;$R70\G8/
M:>U.VN\-L[3KMDC"[TWOO;,;=IZ'([;Z][B[6VSFZ_8^&R5/"\6$H6K:-4QU
M?20P^Z]U<Q[]U[KWOW7NB&?S3ZHT7\L?^8G5B"FJC3_!OY7RBGK(O/2S%.B=
M]G1/#J7R1G\BXO[]U[H=_BE3QTGQ=^-M+#Y/#3=!].T\7EEEGE\</7FW8T\D
M\SR332:5%W=F9CR23[]U[H?/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1-Y99F_F"T$!F3[>'X;Y>5:=9F,AFJ
M.[,(CS34Y8JJ!*55C< $DN"386]U[HY'OW7NO>_=>Z][]U[KWOW7NO_4W^/?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
M$G?T@BZ([KE+2H(^I.QY"].95G4)L[,L6A: &<2K:ZE!JO:W/OW7NJ\OY$<G
MD_D]?R\&^TCHK?&C8\?AB5D5_"M;%]X0Q),F0T>=S]&>0D<'W[KW5M'OW7N@
MSR/6&T(>PZ[N[%;7IY^V_P#1Q/UO_%TS&2PT>Y-ITF7J-T8/:VY(Z:2?$Y&D
MQ.XZJIEQU75T5748C^)5WVI1*VK2?W7NJ*>YOYB?PM[Z_E_='_/#?/6_9E-D
MND/E[MG#]9_%O [[IMC;U'S+VUO:OZ\V]L+<=1B9Z/:^XL)38+<U3N2IDJ/N
M<3)M*LDKY()CIB]^Z]T9S='\U_8.!Q?:'=51\?MUY/X:]"=\R_&?NOY64^XM
MG-C]I]A;=WU0=5[VW1MCK*H";VWUTAUCV9FTP^6W'2^"I+)4U6/QM=0P25/O
MW7NL&&_FHXK#9;:N3[Q^+&Y^KNEM]?+?=7PNH>^]O;^ZY[2V5M_Y%X/LK</3
M])1=D87$/@]Z;3V=OK?FUGQ^)W$N/KJ42S4PR0QPFBU>Z]T=3L3O':>UOE9\
M<OBYG.GZO+S=Q;0[D[:V/V9+_<Z7:6U]P])TVUJ'/8N##S5D^[(-W5&([)B:
M.MCHH*1:6IDC6JD=I84]U[H<ML=3[(VEOOL/LW%8RHDWYVBVW8]W[ERF3R.6
MR%1B-HT,]!M;;&*.0J:B';^TL#]]65-/C*%*>C6OR-95M&U35U$LGNO="/[]
MU[JES^>_,8OAIU6%DJ0\GS]_EZHE-3Z--<R_+?JR<4E2TE1!&L)\/D4MK7RQ
MI<#]:^Z]U<]+!#.$$T,4PC8N@EC20(Y1XRZ:P=+&.1EN.=+$?0GW[KW4?^&X
M[6TGV%%Y'5E>3[6#6ZNCQNK-X]3*\<K*0?J&(_)]^Z]UE^TI?":;[:G^W-[P
M>&/PG5?5>+3H.J_/'/OW7NL28W'QPT]/'044=/2#320)2P+#2K;3IIXE0)"-
M/%E X]^Z]UU)B\;*TK2XZAD:>>.JG:2DIW::IAC$,-1*6C)DGBA 17-V5> ;
M>_=>ZX_PG%6"_P ,Q]ED651]G3665%T+(!X["14X!^H''OW7NO#$XH *,9CP
M!6C) "BI@!D1:U> (["M&D?N_P"<X^OOW7NN28O&1K$D>.H8T@J?O852DIU6
M&L*E#5Q*L8$=248CR"S6-K^_=>ZX08C$TLJU%-B\=3SH9&2:"BIHI4:4%92L
MD<2NID5B&L>0>??NO=./OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZJ-^5G_;WK^47_XB'^9K_P"\1\8O?NO=6VS00U,,
ME/40Q5$$R-%-!-&DL,L;@J\<D;ADD1E-B"""/?NO=0/X'A;0C^#XNU/J^W'\
M/I+0:I7G;PCPVBU3R,YTVN[$_4GW[KW7.7#XF>2*6;%XZ:6G2*."26BII)(8
MX"6@CB=XBT:0LQ* $!2>/?NO=9IJ"AJ)X*F>CI9JFEE6:EJ):>*2>FF2*I@2
M6"9D,D,BP5LR!E((29U^CL#[KW4)MN[?>GK:1\'AVI,E22T&1I6QE$:>OH9U
M9)Z*MA,'CJJ2='*O'(&1@2""#[]U[KIMNX!WH)&PF(:3%0T]/BW.-HR^,@I'
MCDI8<>YAU445-)"C1K$5",BD6('OW7NN. VUMS:E"V+VMM_";:QCU537-CL!
MBJ##T+5M9)Y:NL:DQT%-3M554OJDD*ZW;EB3[]U[K-7X/"Y6>FJLGB,9D*JB
M_P" 536T%)5U%'_E5'6_Y)//#))3_P"68^GF]!'[L$;_ *D4CW7NH=#M+:N,
M%+_#=M8#'?8DM1&@P^/HS1L8)Z4M2FFIXC3L::JECNFD^.1E^C$'W7ND]6]2
M=59.@K<5DNM.O\AB\E)CILEC:[9NW*J@R$N'J8:W$R5U'/C7IJN3%UE/'-3-
M(K&"6-732R@CW7NG+*]>[%SU/64>>V=M;.4%?6T&2J\?F-NX;)4,^1QF/CQ.
M/KYJ6KH98IJVCQD*4\4KAI(H$6-"J +[]U[K-2;%V50';IH-H;8H3M".KAVF
M:/ 8JE.UX<A%X:^+;A@I$.#BKH?1,M+XA*ILUQ[]U[IO'5W6BXO<6#'7FQAA
M=WR&7=F(_NE@/X9N>4S25!DW%0?P_P"TS<AGE=RU4DI+L6O<D^_=>Z6L$$--
M##34T,5/3T\4<$$$$:10P0Q((XH88HPJ111(H554 *!8>_=>ZIF^"GVQ_FR?
MSR7CBI(ZD;Q_EZ13O!&$GEB3XC1- U4QDD>1A)+*%/I3ZV4'43[KW5SWOW7N
MO>_=>ZA9'&X_,8^MQ.6H:/*8O)4L]#D<;D*:"MH*^BJHFAJJ.MHZE):>JI:F
M%RDD<BLCH2&!!(]^Z]T#&#^+_P ;-M;=V=M' ?'_ *6Q&U^O*&7&;"V_0]7[
M)@Q&R\=49!<O446U:!,(*? TM1E4%3(E*L2O4 2$%Q?W[KW6/8WQ@^/W7&?K
M-W;0ZCV-CMY5V_.Q^S9M[5& H,MO6+?/;E:M=V-GZ#=N7AKMP8N?=1BB@J8Z
M:HAA-)3PTX000QQK[KW2SR'4'4V6H=^8S*]7]=Y/&]IS0U'9V/R.RMM5U%V-
M/3TL%#3S;\I:K&2P;OE@H:6*%&R"U#+%&J A5 'NO=(*H^*?QSK=Y[RW]D^F
M]@YG<>_^K]H]*;K;.;=Q^:PV4ZFV+DLCF-K]>MMC)PU6VX-K8W*966?[6.D6
M.601>34((1'[KW0IYOK_ &'N6BQV-W%LK:>?QV'H<CC,309K;F'RE%C,;F,+
M4[;R^/QU+74<\%%0Y7;M9-CZF&)4CGH9G@<-$S(?=>ZA;(ZLZRZS&57K?KK8
MG7ZYV6DGS:[(VCM_:BYB?'P-2T$V57 X^@&0EH:9S'"TVMHXR54@<>_=>Z7G
MOW7NO>_=>Z(-_-85'_E@?S&%D=DC;X,?+ .Z()&5?]!.^[E4+Q!B/Z:A_K^_
M=>Z,'\6_^R9/CI?Z_P"@GJ+_ -]_M[^H'OW7NAV]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$L:M=OYB<..(A\
M<'PLJ:T$*14%ZKO*E@8._C :%11C2-9LQ;@7!;W7NCI^_=>Z][]U[KWOW7NO
M>_=>Z__5W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]T"'R:6G?XV_(-*LJ*5^D.V%J2TC1**=MAY\3%I5CE:-1&3=@K
M$?6Q^GOW7NM?'^4E_-3^+72?\LSX+=5;DV=\PLKN39WQHZTQN;JM@? ;YG;Z
MVE+D4Q1^^?!;QVKTMG=L;IH!6^15R&-K*G'U3 O!(4( ]U[JQ67^='\/H8Y9
M9-A_.M8X8XY'<_RW_G8%T.@=V#'H "U./\Y>VD@_7W[KW3=7?SI_B.\%31T6
MR?G5196HI*@8Z2I_EI_.VL6&H:&44]7)CEZ*HY:VG@E36\:RQ%U1EUK^H>Z]
MU0?DNN/@55]:]C4%-V]_,2QO9>^NL?C5USG=SU?\J7YQU&W:;>_3.Y]N5^2^
M0.U^G5ZVI-OXKM;MK9G4VSMI9_)M7.6Q>&:%$=,A+'%[KW0\[JW1\-MP[*[A
M^.:=C_/7&_"#N_Y#-\D^X?CMC?Y3/SEDWGN;=FZNP,=VYV1UKUWW16=9U#[*
M^/\ V#VKBERV5PHV_5YVDIZNKH:'-T]+4*L/NO=<L%OWXI9B? X+O7N7Y[]B
M=![3^86\_G-0?'[:'\HGYI]4X_=O>^\.X<IW9M?%;QW:W5V^=S[FZWZQ[ S\
MU?C=O4TN,^[E@A_B537PP) ?=>Z/EV5\\OBMV%\M?C%\F:?<GS%P>.^/'7_=
MFVUZ]D_E:_/7*_WM'?5!L>#/M5[P'46-;;^8V\=@8S[6%,95Q@_=K(TGFC,'
MNO=&AG_G+?#^"2HC79GSBJ!!,(EDIOY<?SNDCJ5-/)/YZ5C\?%,D :/Q7(4^
M5E%K&X]U[KBG\Y?X@/I_WY/SE2\7E]?\N'YW@J?V_P!I@/CX;3>L\?3TGGCW
M[KW54O\ -^_F>?&SO'XN=7[9V?M#Y>8W+8KYR?!?=<L>^O@K\PNOJ6MQ6UOD
MEL;<.6IL/E-Y=*X7$9?<4E!C)$H<3!4/D\K5-'3T4$\[JGOW7NK4!_.A^(7E
M,;=??/&.S.IDD_EM?.^.,% QYU?'X."Q6P!%[FUO?NO=<Y/YSWQ!2*.0;"^=
MDA?3^U%_+>^=K2IJ0L3(G^R_@#21I/)LQ]^Z]UP?^=#\042)_P"X'SO<RAR8
MD_EN?.TRPZ7TJ)T/Q_&@R 77ZW'OW7NN:?SG/B-+/'3P]=_/*5Y-&DI_+<^=
MF@:HQ(^IFZ 4#PJ3K_H5/U]^Z]UQ;^<]\1A)-&.N?GHY@,OD*?RV_G6R!8"1
M)(&_T V*#3>_]/?NO=3!_.-^*S+K7JWY]E?M*2ON/Y;?SHM]E7SI3453_P R
M%_S5542*B_FYY '/OW7NHY_G,_$M)(XY>M?GM"TDJP@R?RV_G6%$C"-K,1T$
M=-EE4G_!O?NO=>F_G.?$&"J^SDV)\Z1(N@RL/Y</SL:.!)2_B>=A\?R8TEC3
M6MQRA!]^Z]TWQ?SM/A/+4+3C;WS4352O6>5_Y=WSE$*TZ%@'8CH%G59  5.G
M20Z\B_OW7NN(_G:_"EJ:HJ8MM?-B9::K:EEBA_EV_.228!85G^[*+T'9*1HV
M!#,5//TM[]U[K%)_.Y^%43K"=J?-\U!5&DI5_ET_.7[FG$JEH1/$W0:LAF"O
MHM<-H;^GOW7NI*?SK/AS(=";%^=;SZI%-,G\N'YTM4@1,T<DAA'01;QI,C1D
M_AT8'Z>_=>ZE_P##TGPO$T43;;^:B1O2_<5%6_\ +L^=2TE!,HC^YQU?*?C[
M>#(T4TJ131V94D=5U&X]^Z]TH,=_.%^&61>%!0_+RC,B,\WWO\O7YY1?8Z5G
M]-<L7QRF:!FEIVC'!_<]/];>Z]T\K_-M^%S"$K6?*$BI -.1_+_^?)$X,;3#
MPV^-!\MX5+^F_I!/T]^Z]U#3^;S\+#"]1)+\J:>%:V2B22H_E^_/6-)C',T+
M5$+?[+:5>E]#L&N&T(QMQ;W[KW7.'^;S\)9] CR7R<,DCNB0_P"R"?/0S,R2
M-'947XUL3K*W7\D$'W[KW62/^;C\,98O+&WRJ=?$DBA?Y??SX)=B\D<L"V^-
M>DSTSQD2"X"G\GW[KW7D_FX_#&04IB?Y52K5&1=4?\OOY\,E.8TD+"I8?&JT
M9\L9BXU?N^G_ !]^Z]U%7^;U\-9' BI/EQ-$RLR547\O7YZO32**F2G5HY1\
M;_6LJ()D-K&%U;\V]^Z]U6G\E/YDWQ=W#_,__E@]C8O_ &9!]M]<]9?S#Z+<
M\=1\)OF;C=R/-N[9?0E)@1@=F93H&EW?O"@FEP%0]748>BK(<6H@>NDIHYXS
M)[KW5E47\WOX:S/ICH_ERT?EJ(A4C^7K\]33,U/]R&*R#XWDE9)*?0O%R[J#
M:YM[KW4B'^;K\,I:F6E=?E?3M"GE:2H_E\_/=8FB+SHLJ,GQL=C&YIR02 ""
M/\;>Z]TP1_SG?@H],:Z3)?*&FH&J:NCI,A4? 7YVQT62JJ"<TU9!CJD?')HZ
MF6FG5T=;AD:-P0"OOW7NDXW\\_\ EP1Z?-V'WU 9(HIX!-\'?G$GW%--2+4Q
M54!_V74K)3R.3"K V,RD#TC5[]U[K)_P^?\ RUK"_:G=BD@$J?A%\Y;J2+E3
MI^.!%U^AL3S[]U[KE'_/,_EK22)&O:W= 9W5 7^$OSCC0,S!07DD^.*QQH">
M68A5')('OW7NN4?\\K^6Q),L"]K=SJ[2+'>3X4?.&&)69@NJ2>7XYI!%&";E
MV8*HY)MS[]U[IY'\ZW^7&6T_Z8>R@?*L5V^)OS 0:F:1-89NA@#"#$;R?H4%
M22 RD^Z]UR/\ZS^7&&5/],79%VU6(^)_R^* (\B$O(.AS'&+QDC41J!!%PRD
M^Z]UG/\ .D_ERK)XCW/OZ]W&L?%OY9F'T+*Q_?'1OALPA.DZO62H6Y90?=>Z
MS4W\YW^7/53R4R=U;VB>-#(SU?QD^5=%3D*Q72E55])0TTDA(X57+,.0"#[]
MU[K G\ZG^6NT,4\W?^X*%9(Z5WCROQY^3>)J:5JXA:*GR%)DNFJ6IQM;5M<1
M03I'-)I;2ITM;W7NL%1_.R_EG4S1I+\A\QY)I)(H88^@/DM+--+&LKB.*&+I
MUY97G2!VA"@F94)34 3[]U[K#)_.X_EF)-'2#Y![@GKY!&PQE)\=OD_699(Y
MW5*::?$TO3$V1IX*S6&@D>)4FC(="R>KW[KW55?PW_FJ_ W9?\RC^;YV1G^Z
MLQ3[*[HWG\(,AUWFZ7I;Y 9E<S!M'XP4&T]QFLH<5U1593:S8S.1-%XLI#2&
M5$>:(R0J[I[KW5L$'\ZG^6Y/2QU@[UW9!#*X1/O/C9\IJ&;_ (&C'N[T]9TI
M!41Q4]4P$SLH6%6#.54@^_=>ZP_\/:?RR%HH,A-\DJNEHZFE2MAGKNC?D90J
MU+(L3K.PK.HX6C33,A)8"VM;_47]U[K%-_.[_E?4Y9:CY/) R:-2S]-_(&%E
M\BEH]2R=4J5\BJ2M_J!Q[]U[J#5_ST/Y56/@IZJO^6.+H:6K>:.EJ:WJGO>E
MIZJ2FFFIJF.FGGZNCBG>FJ*>2.0(24DC96LRD#W7NF[_ (?G_E*?]YC;8_\
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MC9^;ZX#T6-Q<I_A^/\T526$T?W ]U[H%>]/E3_,I_EY=S[0WQVKV%ANR=M[
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M6UU!\JLWU7A<RVV,EBNG=X[G;>,=-3T])35&/KZF+*9J8S20&CD]U[IK[?\
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M+,M.XD3H7N98HI7C3SE.O=QB-@Z-*(XYB."PU 'E1]/?NO=%0_DQ_P#;I?\
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MNR_9?+J'2M2^NH_E[?/&)&%/++$H5C\<R&:I$0>(?5T=3Q>P]U[I*9?^=W\
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MW[KW52G\U[M'.]5S?RZJG"=L[FZHHNP/YE?QXZHW_4;?[$RNP*3=O5F[]O\
M9-;O+:6XI*#+XN#(X3(2[?HGE,EY:?Q_MR1B237[KW1*/F7_ #3_ /0Y\GNS
MM[?'++;%[>I]C?#_ &)3X"CW-WAV=B.E=S[]W!_,1VE\5=ZXI]B8"BK=BS;I
MV?N/<'VZ;NHH:VO<+/CT9X*>:-O=>ZP;!_G7]T;B^1/3/QTS?7_QBIMPP=C9
M[K[O?.)W)'@<5V*F-^8?='Q)JLY\0\?N#._WKW_D]H5'4M/G\KMX8W-Y4+GZ
M6CG..C5<C-[KW2M^<?\ ,8[1^&WR,^:%=L;;^+WG5=>]6_$#.'$;W[<WIN/9
M>UMA[GV=\QMY;T[!PWQXQ=5CLRV9P==TY!'N639PKLLVV9QG*BEK(\(]%)[K
MW1I/E;_,LJNE^Y^B>J]A5OQRH*#L/HZC^2^8W9\ANULWU9M[L'K,]D;"V/D=
MD]!YRCVWEHMS=K4F W;5;@%--35,C0TU!2"B;^*&KH?=>ZK1VE_/\[[['W5+
MUKUQT?\ &3<&]]Q]^=3=<=?9NN[KWYC-A9/K_N;H[Y+=M87>0,'7^1WOFZ/:
M=;\;JFBFR1Q6)ILZN7I)*:EI(7CJ)O=>Z7N+_G\9_,=+[P^1%+UST%3;7V+T
MYLK/YWHS/]TYC;?R0KM_[V^*/5WR5QV]-K[:JMLU.$S7QQAJ^T#C:W/R/2#&
M8? 9#,SSDC^'1>Z]T5OYE_S$/DOO+:';6_,=VW5_'S?NT?A%\C6DVK\??D)M
M7LWJRLW/UI\Y_@[MSJ_N?:^=V%GLY@\1N_<_77<N0Q>:HVKLE5XJEKY*(S$I
MKE]U[HY>1_GF[WKNV]Z==X?I?I?$;4W#\GLE\/.H=U;P^2>S\1N;:/:NU?D3
M-T-NW-?(SKC"UF5[(Z]V5D\1 =PX6OCQ<$,L]7C,5YY)LI35B^Z]T?G^2YVC
MOGN7^6I\<NP>S.R<IVYOW*S=RX_<_8&9W55;UR6<KMM=^=I;:@67=5;#2UN<
MIL7CL1!24M1+!3/)201'P0@B)/=>ZM)]^Z]U[W[KW5/G\O?(?Q/Y_P#\[BH\
M7A$'RT^->-">5)@QQ7P7^/\ 0F;7'Z5,YAU:/U1WTMR#[]U[JX/W[KW7O?NO
M==6_U_\ ;GW[KW7=O]?_ &Y]^Z]U@J)X*6GJ*JIGBIJ>GAEJ*BHJ)!'!3PPQ
MM)+--([HD<,4:EF)(  N2/?NO=:>WQD^9GRWW/V=V%\3^X/FQV'DNV>T/G!U
M1M'>W;_6R]99SH?;WQO[*V%V-V5M7M+X6=M3[+EH]IXWL6HZ^Q6R*C YFFR4
M&'K\Q!/CI*NMJIJN?W7NMD#^79W1V1\B?A#\9^Z^W8Z+_2-V%U?ALUN?(8RE
MAQ^.W+51RU6/I-ZT./I;45!2;[QE%!FD@@ IX5KPD0$84>_=>Z.A[]U[KWOW
M7NO>_=>Z][]U[JL3^=1_VZ1_F-_^*>=Z_P#O!Y?W[KW5A?7G_'@;'_\ #/VS
M_P"Z6B]^Z]TL/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW16\?_ -EK;L_\5;Z]_P#?L]G>_=>Z-)[]U[KWOW7N
MO>_=>Z][]U[K_]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW11/Y@;R1? OYN2PU#T<L?Q$^2;Q5<9(DI9$Z:WHR5"
M%60AX& 86(-Q]??NO=5&?R\OYO/Q)ZZ^ ?P?Z_W%MCYCSY_8_P 1/C?M#.3[
M:_E__-C=NW)LOMKI[9V%R4N W7MCH?*[:W-A9*VB<TN0QU54T-9 5E@EDB=6
M/NO='"_X>K^&/_/)?.+_ --O_/3_ .YY]^Z]TD-O?S;_ .7SLW);FRVT.G/E
MUMG*[\SK;CWQE=M_RO?FS@Z_=FX6I$IFW'NVMQ_QOHZO<68:FIHX/NJEJBIT
M!5U:!Q[KW0.]6_/W^5QT]0SX_9W1'S#%)09K>N2VI'F/Y8GS3S%3LG$[_P U
MDMU;DV1L#(UGQK.0VWUY/N3<&1J*?#+,M)2R5T\<2I3&.-/=>Z$:;^9__+7R
M5!O#%S?'+Y/9+']D>CL;%3_RIOF-/1[X3(Y.>LJ6WS2U/QJ^TW6LF6R\T\WW
MGW)>>HDD 9W8M[KW33/_ #+OY9\^+VW@ZCXF?)VIQNWL>NTMI[=F_E.?*R2B
MV_MA&%9%C<!0R_'3^&XC;?W.EEHZ8Q@2L&\(Y8>Z]TO*K^<3\*1MN7:LW1?S
MEGVE-B*W 3[;/\L_YC';TV!7'U5--AI<-/T:F,DP];C8FA^W,1A,+Z754U6]
MU[H((_YB7P&Q/:'6G9N'^+W\P\U/4/7V8Z^ZDQ6W_P"7#\O,1UAU3A-UY"GI
MMPY/9VQJ?I_#XO"[DW5C*2"@DKXJ22>+#TC4L!IXYZJ.I]U[H<8_YUOQ@EJQ
M1Q]#_P Q=W6?P5#C^7)\P E'JFFABEJE/5 F1)_MY&10C2$(05#>GW[KW56?
M\T'^:]\;>YL'\%\=A^I_FUB(=@_S0?A;V=N$;V^#/R7VA_$MN;$W9N3<-;1;
M3;<O7-)!NC=]9#11RT&$HEJ<QD5)6FIGD23Q>Z]T>W??\V;^7UV-6I-V=\,?
MFKORMP](U%!5;[_E8_(W=-1CJ%ZNDKEI*>3/]05]11TM16K'.(QI0R1*Y 8(
M3[KW4&L_FI?RZGJXDF^#OS*K<I''@L3!3'^5-\A'KQ38>@?![=H8?NNG8RM/
MAL.RTU'$& IZ658H5"ZD'NO=*/;?\U'X!8&MPNY]F?#CYIXK<.V=O9K![:K=
ML_RKODWB\_@MK9+,4N0SF"P&2H>E:1\5@LON6L,E3205$=/-7(TLJEBCO[KW
M2<?^:Y_+J;<$>XZ3X4?,O)[G@W'4[_I=P4?\JOY#-G!O6>DJ'K]V4V4J>GJ;
M)1[K>G:1)LCK6H=6:\Q0L??NO=/F^_YNWP([2HJ:#L7XB_-[LW';7KX\SAHM
MY_RO/DKNZCQF;=6IJ2MPT&Y>H*Q,9EIX6D6.<+ VA7!<7 ;W7NF7.?S<O@#G
M\Q69/=/PD^<>7ST]0JY/)[A_E;?(#*9=ZBGIZ/' U];7=755;++3T>-IX/4S
M,L5/&@XC4#W7NI^V?YL_\NZ'<&.KZ?XB_,G9E?A<SF=TX?=,_P#*S^3,#XG<
MV9QS8;,9W&5>V>ELMG:#<&X,0YI:BLBB2:HIB8II-'I]^Z]U&C_FK?RWZBG-
M-/\ #SY>4],^YLIO)Z:I_E5?)9X#O#/RQSYW=K14_2%1$=S9B6DADK*^QJZE
MEC+NY7T^Z]TZX#^:O_+?PM;M+<>'^+/RTVKN';>"W!MO;=90_P JSY68[/[&
MV[G<RM=G=NXK)X;H*0X?#;GKYGR%328ZH:FJ75WJ%\Y"M[KW3KL'^;)_+NZI
MQJ8WK#XX_+KK?'9_)"IS>)V'_*T^7>SZ2EJ=,W^Y?/TFW?C[CJ.O<#C7!]Y4
M?N#TVU6]U[H1*3^=G\-ZBECGGV)\[<=,XD+4-9_+A^<SU4.B1T02/0="UU$?
M,BAUT3-Z6&K2UU'NO=9O^'KOAH8@XV5\Z&E*!A2C^6_\[3/K*W\%_P#9?O 9
M=7I_7HO_ &K<^_=>ZR?\/5_#'_GDOG%_Z;>^>G_W/'OW7NO?\/5_#'_GDOG%
M_P"FW_GI_P#<\^_=>ZQ#^=?\-"^@[+^<ZKJ=?*?Y<'SM\=E6-E:R_'\RZ92Y
M5?3>Z&X TEO=>ZR_\/5_#'_GDOG%_P"FW_GI_P#<\^_=>ZQ)_.O^&;2,C;+^
M<\:K>TK_ ,N#YVF-[, -(C^/[RC4#<:E''UL>/?NO=81_.S^'!CE?^X'SOUH
M(_'!_P -P_.3RU+/;4D)_P! _A#0DV;R.@/]DM[]U[J2O\ZOX;N[Q)LGYT/+
MK6.&,?RW_G=KJI75=$4 /Q^%G>5O&/)H]8_U-F/NO=<T_G1_$:2=Z=>M_GGY
M(H9*B6_\N#YQ_M00S31SR.HZ(,@6&.%I6LI]' N]U'NO=5J]G?S2/CGG_P";
M1\-NWJ'8GS/7:NSOA9\T=HY3#5_P1^7=#O*3/;Q[,^+-9BFV]L*IZ=CWEN3'
MB#;C+D<E144^+Q;S44=540RU,:'W7NK+(_YTGP]FEDB@V)\ZYO$^F1X_Y<'S
MKTJJTU1532D/T LGCIX:20OZ=7H.D,.??NO=1O\ AZ[X<F.KD38?SLD^U(.E
M/Y</SGU5$;2)$)H2_0BHL?DD _=,;?X>_=>Z#??_ /-;_EQ]MT^.QW:OQS^5
M_9./P>4>IPU-V%_*O^7^\Z'&5-7CIJ:JS6+IMP_';*+0,]-*U)*\:1U+ARNE
MHB6]^Z]TDI?Y@_\ *7R>/Q$>3^(/=TL.'QL6#P^+R7\H3Y5U9P>&HLW4;GI,
M3CX%^+U528_$P[DKILA%! PA6OEDG"B9F8^Z]TH,3_,>_E9;9J-LY7;_ ,:>
M^L+D-D[BW)N+9E7@_P"4U\OL;DMH[DWA3Q+N_=&UY\?\7J>HP&5W7$JQ9&MI
M&AJ*[1IF9P/?NO=<]Q?S$_Y4'9.X:W<6^/C[V[O+=>5I\%G*S/;T_E2_+C<6
MX<PNV)I,3MNLFRN9^+5?DLA+MN#(N**1W;[.GG81,@<J?=>Z$'<G\T#^6[OK
M+[,S6\M@=\[LS&P,S4YCKK/[I_EI?-'/5NSMP1VIOXML?+97XQUE5M[,UJ4:
MB*HH'AFD2-1J]( ]U[H&8_G3_):H:F>:G^.68IGHZ_+Y.HR,'\ISY.01TF2I
MWK\C6Y&6K7XH1M#6UT^3J91,;2225$K,09')]U[I64W\Q/\ D_XBNGJ,;U?N
M:CJTZX7J]LCC?Y8GROII)NG<AJI'Z_CJJ?XL132=930R$/B/^+6T1/[)!M[]
MU[H/7^=/\A^HPF)VQ/TYMEMM83:]3L/![?G_ )6WR1."P^R<CFZO<^1VCB\4
M?B<:#'[5JMQU$F3J*"&-*62MF^X:,S-J]^Z]T\YO^9!_)"JI^PTW=L:ECF[3
M3;>)[7.Z/Y9_R=+]C_P QY'9V'["-?\ %>63>#XF*ECJ\7!D?N? B++ %T@C
MW7NA#V+_ #B_Y274^T*#:76&Y-W==;#Q55618;:^P?@7\O\ :.TZ6JK:D9/*
MC$83 ?&K&XBFFDJLD:FJ$<2.SS&1KL]S[KW2CG_GO?RS8;:>V>Y*B\HB_P G
M^%_S6DL":@>4D_'M1X1X 2?Z2IQR;>Z]U)_X?5_EEZ(W_P!,G;-W:-3'_LFG
MS8\D?D(!:0?[+QI"Q7N]B; 'W[KW55GP5_FX? ;JSY?_ ,W'>^Y.T>SCM?N?
MY8]2;SZ^K<;\5/E9F<AE,10_%KJ7;.:?*8'!],97-;2EQNY\/5TJ09F#'UE3
M%$M3' :>6-S[KW5I,'\]_P#EFS3R0MVQW-3B.62(3U'PN^:R4\@C%Q-$Z_'M
MV>&7^P;7/Y ]^Z]U(3^>O_+,>>6 ]P]N(L2QLM0_PR^; IIC)J]$,@^/!9GC
MT^H$+:X]^Z]UT_\ /;_EA0PB:J[N[/HD,1E;[SX=?-6G,:(JM*9#)\> B^$,
M-9N0OY/OW7ND[+_PH,_E)PP-5/\ )S<PI(Q,]16'XN_+Q:2EBII335$]34/T
M*L4,,%:! [$V6=EC-F-O?NO=1'_X4*_R@)86+_*O)R4\M*U0Q?XT?+-H9*%B
MT;U#%NB#&](2K*7-TN"+\'W[KW1/-H_S#O\ A,Q@=I]J];;-H>C(-C=W;DQ.
M[NV=@XSX(?(*NVMOO.X)\>^W:K.;6/QQJ<5+2;>J\7%48ZDC@2CH:LR3P11S
M3322>Z]T;+#?\*!_Y-6$P=!C=O\ R@?$[:P5%28?%T.(^,'RKH,%AL=CJ2&F
MH,3CZ:BZ%BQ^.H<?0QQQPT\82.*$*%4+8>_=>ZF2?\*(_P"3S$[12_+>NBD0
MZ7CD^-_RQ1T8?561NB@RG_ ^_=>Z\/\ A1)_)X9'D7Y;UQCC*+(X^-_RP*(T
MFOQJ[#HK2ID\;:0?KI-OI[]U[K*W_"AS^3^K*C_+')HSTRUJ*_QK^6:,]&\1
MG2K56Z)!:E: :Q(/04]5[<^_=>ZP_P#01)_)WT>3_9NJC3K*$?[+K\J_("%#
M7\7^@[R^/FVK3IOQ>_OW7NB"_P T[^>-_*W^0'\M_P";_3'4_P HJK</9/9'
MQF[9VILK;[='_(W;/\=W%E=K5M/B\.,WNSJ'![>H3DZIEAU557!$0Y!8?7W[
MKW6SYL, ;&V8   -I[=  01@ 8>CX" L$'^%S;W[KW2K]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%(Q5;42?.
M_?N.:&E6EHOB1U'6Q5"5T<M;+49/N/NR"HAJ<8$$U%2P1XF)H)V8K5/)*B@&
MG8GW7NC;^_=>Z][]U[KWOW7NO>_=>Z__U=_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$Z_F(W_ .&_OG/I-F_V3KY-
M:3;58_Z%=[6.D\&Q_'OW7NF;^68U*_\ +?\ Y?S44*TU&WPG^*[4M.M4:T00
M-T9L4Q1?>,D9J?&A UE5U6O8>_=>Z.][]U[KWOW7NO>_=>ZKK_F?O4[<^*N^
M^V7[J[_ZHQG3>$S>](-M_'#=6'V'V#W3OVKQS;6ZFZFCWE7;<W%E:&#>'8>?
MH:"GHZ%(7K\E5TJRNT<9BD]U[HRGQ2V#V;U=\:>B>ONZ]_9SM+N+:?56RL1V
MKV%N/)+F,ONWL:'!4;[US$^22"F6K@J-QR5(IVT+_DRQC\>_=>Z,![]U[KWO
MW7NO>_=>ZI__ )OUQC_Y:)5K2#^;_P#!+QKI+-)?<N[UF1;S0Q@K3%V);4 J
MG2I?3[]U[K+\[^U-\T_S;^ /QMW-V3N;H_XH][XGY)9CL[L'9^]\YU3GNP.W
M.L]I;6RO4?1,/<>V<MM[<?7$6;QV4SFX3%CLA0Y#<(P)I8I3!#50R^Z]U4QA
MOYO_ ,S.@=MU>'QM-TW\C^H=D=A?*_(]7=H]L;HW32]T_*KXV](?-'I/XS];
MT'4V<VG FS^Q>T-VTO=K4.(W$:>II]R5.WO/)%++4O/)[KW3[U3_ #5.\<0V
MT^U>]MX=>;Y[33;7\P/;&*QFT][;XV/U+U=3[/\ YE7Q_P#BMM[<'R)Z>P.=
MW!MU]L]4[<WQ3YW^/5C+N;$[3HJN&>2$U]3DI?=>Z479W\^'Y*]<[HW5MX=0
M?'7+8KHREWU6=I;SJMR;YP^#[PQ'6GSKZD^'>6W/\<6&0R5%C,-NNG[:2N@&
M4K,N,3F\)DL:)<FL(J#[KW1D/GW\U>U.M_GE2=9YB'.4_P =^BM@_$3L.;J_
M9'>V;Z)[E^2^_P#Y1?)C/='Q9OKV+;FU<GG>\=H]"M@:%LCL6GSNV*7+U>69
M<C+71-24;>Z]TKMX]V[M^4/\P+XG]<UE%\S_ (<;=WCTC_,#VCN7K/?78E3T
MON'L7([ PWQV@V!V_LC9O5_;>[=OYN/:R]KY^3$9BKB%2*RC=GB9:*G9?=>Z
MD_RRMV]Z=L=D8SJGNGLCN')]A_RQ=M=D?&?Y(97(;R[$7:/R.[[WCNUI>M>U
M-R19;(O@^PA5_'#!XS>D<,PG_@M?V%# HB-!3A?=>Z)+V;\@=_\ 76POG%VM
MT_\ +_M_+?+3I/\ F;Y[I+XF_'+)]ZYKMC!=]X=\OT7-3?%R7H7<^=W(^Y,)
MN)]_[AI7S%!34NXMLP7K!D8:'%1I%[KW1C_Y;$7S8[,^2^:[3PO=6[-Q_$KK
MSY$?S(.ENY:?M'Y$U'=S=C1;#^0>9V7\7=O=8['KL;GJ_JO+].X7;\L&6RKY
MBD;<>+DAJ)XZZ2J2:+W7N@/[T[ZWQUUMOYS=J=-?,WN6H^673G\R&7J#XL_&
M+(=RGM#;W<TF7H/C[/)\8C\?]QPY"OW!MO<U7V)N!HJO&PP9?:L#BLBR4=!B
MPB^Z]THJ#^?#W$<%VIW9FNE.CJ7X[='_ "%V7MCNNFVIVN.ROD1TS\>\IWMO
MWH#>V]NRNG-D9'*9S:N^=H;CV]ALB:+*PXJ6IQ^6K33453'B&J:[W7N@G^27
M\W'Y=9S;7S%^-G8NR.E/CENW87PR[;R6[<O@_D14]3?)S97:N:^$NZ/E'L3?
M/3&P:W<3;_W)MC:LLU%MNLK,?!]O'F\3EJD9>'[5<?)[KW0T=P_SJ^Y^D-L]
MFY7:_6G4_9.%ZRQGR5ZYH-L9?<VZH.W=L;U^)GQGV_W_ )3N3NP4-5E*>+I/
MMS&/-3XZ>FHZ:HHQF,%5R5E4,FT$'NO=)?M+^=W\N.KL7VT:_JKX:YFMZ'QG
MRUW7NW=F"[8[(R75W9VV_C9COB+OK'X_IW<Z8&*LK,SG]K_*J+;60GKJ<08[
M=F%JI/$\"&C/NO=+BI_G5_(;'=^[:^-U;UK\2(M_;>[][7ZO[/R^>[ZEZZV7
MOS";%[/Z/V=C\+\?LCOV;%9S<G9M-MGN?[ZMQT>/S-;556/IXJ;&K!D?N:'W
M7NB\5?\ .]^8/8,/4>-IO]E*Z&7L/Y%?':GAWA)F=T[IQF/Z0J_G[WQ\.^WJ
M/>LF]:G:6,Q4N>K^CJ>JBKJ>2!Z3%9QH86&0>GFA]U[H[W\P/^<=NSX:_+IO
MC]A,)T!F]KTO7%%69.KWGOK*8'=V$['WGTM\FNT^NTW$]16X;'4.W\OE^@Z+
M%Q8[&TN;KZ],VT\U5BG2@I\I[KW5;'>O\]SY =C_ !;^0O4.8Q/1OQ\[RW/\
M;-U=F;4[KV;VYV#AMF;,VGN[^7'M?YC;1VIL[=JOM?<B?*JIRN^!B\#!!5P4
M,CXRIK$2H%-]M4^Z]UM2?$W.U^Z/BO\ &C<V5S%;N')[B^/W36=R.?R5=+E,
MAG*_+]<[<R%9F*_)SRSS9&MR=14--+.[NTSN7+$F_OW7NC ^_=>ZJ%[FJ)#_
M #OO@C2OI:&/X _/6:%0\8>*>H[;^':32LBL9BKQ4B*-8"$@E22& ]U[JWKW
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TG_L]Q#= KUS
M-$VTWP34LFWWQ;_Q./<*9 30YBGSB5ZQB@EQLCP34DE*Y\B121RI^XLGNO=*
M#W[KW7O?NO=>]^Z]U[W[KW5+'\LIW/SF_GA1EV,:_.'J1U34="N_Q!Z25W5;
MZ0SK&H)^I"B_T'OW7NKI_?NO=8TD+M(#&Z!'"JSZ+2C0K%D"NSA59BIU!3=3
M8$6)]U[K)[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK
M*_G/^$?RG?YASU&H0P_$ON>ID:-4>6-:79^1J/+"DG[;3P^+4@;TEP+\>_=>
MZL6VI-'4;7VW/#)+-%/@,/-%-.D<<TL<F.IG22:.(F*.5U8%E4Z038<>_=>Z
M?_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW16,.%D^;78I!D#4?Q8Z8$@,+K$RY+MKOHPF.H6$1SR*<5)K1Y"T0
M*E% D<GW7NC3^_=>Z][]U[KWOW7NO>_=>Z__UM_CW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$X_F*$+_+[^=3$:@/AQ
M\G"5O;4!TGO<D7N+7_UQ[]U[K!_+AI30_P O+X'41K?XB:3X9?%^F_B&AXQ6
M^#I'8\7W8CDB@D05&G6 R(POR ;CW[KW1SO?NO=$2[U_F&]$] [CWQM;<U!O
M[<V9V1NCIGJW^'[#V]1;AR6\._\ Y!SK)U'\==B8N3,T&0W!VUN/;DL.>J83
M'!B</@:J"MR%?30R$I[KW3EL+^8'\;MPKV7B^S]X8OXQ;_Z7WGC-@]L=9?)#
M=O777FZ-F;CSVS\?O_;9_BD6]<UL;=> W3LW)ID,;E<'E\ECJN&.=5F\M-4Q
MQ>Z]TS;H^;GQ@WCV=%T-MNIVAWQO?:GR5ZUZ4[$VIB-T]223=1;\S.QI>YMI
M;XRF*[!WEMVIW'!M=<52E5VS#F<]1Y=6$-(9J"K-/[KW0\Y+Y5?%_"X:MW%F
M/DAT+BMO8S,9S;N1SV3[@Z^H<-C]P;8QJYG<N"KLK5[BBHJ7,[>P["KKJ621
M9Z2F(EE54.KW[KW25^0WS Z=^.>R^N-U[@R%;OC*]W;NV]U]T%L#K>7!YW>7
M>>^=UX^HS.!P'79R6;PFU9Z6? T<^2J<OD<ICL%C\9 ]55UL,.EF]U[I4=4_
M(7;/:._NU^I9=O[FV%VKTQ_<BMWML'>*X)LJFV.R<)49C8N]\)D-L9O<> SN
MTMPSXG+8U*F"K9XLK@Z^FEC0PJTGNO=#[[]U[JFW^<8*@Q?RMA3N$/\ P\C\
M&3,6/I,"U?8S2J5N"Y8#T@7LUC] 3[]U[HSGRU^3WQ<ZU[/Z"^,/RXV-C*O9
M'RVSE=L[K?>':.!ZZW+T)G>V=O*,YB.JMU4FY,Y6Y?$[SS5/3K486HK,'_!Z
MNL,5)%7BODBIV]U[H$]GT7PZ[8^2O5_RH[ DCZB["ZGRG>?P.^.G3G<.7^/.
M.VCEMQ=>=NXBEWSN_I+:V/7<FY%WFV\NOJ3'8VIQV8HZZ#'4:Q?PZG%43/[K
MW1M=D47P>[:W1NI.MZ3XJ=F[UQN(W/1;X38]/U'O/=-!@>S<IFX=Z4>ZUP"9
M++TV(["S4>13*1UFF'+52U(G$L@E]^Z]T4-._P#X=;FW)D]L[(^$.8[5Z@ZM
M[:VK\*<[WGLWH;IK)],['WA!V-AMK2==X?&Y;/8SL3-=7]4=H;A2FSN0V_MN
MOVU@,Q%5DR^2DK'A]U[J1G?YBWP2R7QC[M^>78.T/M\=\"NQ.X^IM]XG=NQM
MD9KN_J;N;JS/C8NZ>N-C_;9C-8ZDW-N[*344&(FQF9BH<G2Y"FE>HCA,C1^Z
M]U"H_P"8=\5=S_)#K_:O8WQN[(V3V/5=I=3?'39_=/877'4N;H]K]W]T=!I\
ME^NNG$W3M7?>\NPMNYC+]5[IEG-7'0+@:?(3U%))7+*S:_=>Z.OV9\E^B.B>
M[?C_ -';SRM-M[M#YA[NWQA.LJ.DQ:!-T[CZUZ[DW9GJK<>3B$24LB;7P5/0
M4DU07DJ:@TU)'?TA?=>Z!_L3MS^7%\/*K>>_-U9GXI]-[PV')B%WD^'I^JMM
M=F8.;M#/X7&8P97&XE*+=]&=YYK<=$S-,B+5?<+,Y93K]^Z]TX=!=^_$?;U%
MOC:>T:#I'XTC%[\[C^VV5%N_X^;4;L3;O4-1/0[P[VP6#ZRWIEH)MCRXW"RU
M-16Y)*/*8VDHW_B=-1F(H/=>Z+MB?EK_ "ZNKMZ[XW3M[K?H38O>^4;Y$9W8
M8VI4?%W$=B?([ ]2;?VWO/=^]]F]C;?WK#@H,5V//NVBBHI-U9O"5-35R,]>
ME.B22K[KW1O-M;Z^)(PF\\QETZ ZUS^^]D;1[J[_ -G[AS73-'N:DQ6Y</B&
MQ>Y>\'P6:R>'S,=*E;3T29JKK*[&SLJ"EK)HFB=O=>Z$ZEV9\>^ZJ>@[8H]J
M=-]MTN]-E4N"Q?9<&#V5OV#=G7-3D4S]%A\?O-*7+1Y[9%1EE6MBIXZF6@:H
M F52XU>_=>Z#?OOX7=!]_P#4_=/4^8V?B]@0]^=3-T;V%V!U=MO9.V>SZSJU
MJ*/%)L^DW=6;5S++AZ+#(U)24]1!404,+7IXXW5&7W7NE9A/BQ\>\5LG9FP\
MATUU/N?$;&P<.#PS9[JGK.RH9?O<I7QXC$;2Q6V<36;@S3RY"M3&T-#225T\
MDB0QZ@H]U[I18SX]=!86IP];ANC^H,36;>W%-N_ 5>,ZTV905.#W94X>/;U1
MNC#STN%BEQFXI\!$E"]; 4J6HU$)<Q@+[]U[KN/X^="11TD472'4,45!'314
M,<?6NS$CHHZ+/T>ZZ..D1<*%IDI-T8ZGR4032(\A!'4+:9%<>Z]U.W;T=TKO
M[-MN;??4'5V]=QMC:?#-N#=VP-J;DS;8>D?(24F).6S.)K:\XVE?+531P>3Q
M(:F4A09'O[KW3#5?&3XVUV)R.!K?CYTA68++Y+%YC+86JZHV'48G*9?!QU\.
M%RF1QTV >CK<CAX<I4I2SRHTM.M1*(V42/?W7NAEH:&BQE%2X[&T=+C\?04\
M-'0T%%!%2T=%24T:PTU+24L"I!34U/"BI'&BJB*   ![]U[J5[]U[JGSN5E/
M\\CX*( -:_R_/G<S'0X8J_;GQ'"!I"Y1U#(;*%!4DDD@BWNO=6S;HW-@-E;9
MW%O+=>6HL!M?:6"R^YMR9W)3"GQV%P&!Q]1E<QELA4$$046.QU+)-*Y_3&A/
MX]^Z]U7'LG^:KT9O[XR[=^6>'ZW[RI.I]\]AT&Q.L37;9VAE=U=MTE3@:_==
M;O/K#;&Q=][UR6Z\#C]M8+*U/VB+%FYGQ53#'0F5 I]U[I%Y;^<A\=]M[*K<
MONOJ;Y);6[7H/DK2?$R7XOYO96PZ;Y#5G<N0ZNQO=6.Q6#V^.SGV)N7$Y#J[
M,T>6AJ\=N*J$BU<-.JFKEC@;W7NA"^0W\T7ICXW;E[2VYNKJGY';V;I'KC ]
MJ]PY'J?JX;YQ_66RJS!5&Z]WYC>-5%G<?24$?6>T:C$Y/,002U-;+2YJG;'P
M5OAK/MO=>Z4^V_YEOQLW?W)D>E=L'L#/9IH.R:;8FZL5L]Z[8W<F\^GNNME]
MJ]G=7]29:FR$F5W3V/M#9._*&IEH):&CBJY(:Z"DFJ)L=7I3^Z]U$JOYH7Q0
MQGQ4^.GS!SVX-T;<ZN^5&[>K-C=-XK-;;:#?F;W1V]NNFVEMK&Y';=/6U46'
M7&U4TE5E9YJH4^/HJ>1WD+^..3W7NK#K\7/']?\ 8>_=>ZK@[&_FJ_$;JG>?
M;>T-\9_>6(I>G\=V:<GO5=G5E=LO>F].F,7L7+=I]2=9UU!45.7WIVKLVG[+
MPD<V+@H4CJJNJEIJ2>HJ:'(14GNO=.T7\RGHV39=)N:39/>T&Z(.^-R?'#>7
M3"]7UN6[LZ[[.VCUEENY-P4&X]@[;R&<J,SC*?K''T^8IZS;T^<@R%)E: TC
M3FHLGNO=(?*_S<OBMMOKK&]B;QP_>6RE_O#W-A=\;+W-U!N"EWUU#B/CIF]J
M[?[Y[![2Q-')78W!]:]45^^L+_$\Q25N0@D3)PFD%21*L?NO=/'R'_FJ_&7X
MS[P[!VEOS"]W[@INIH-J93M3>G5_3^Y^S-C=:[3W'M["[LRV_-\[@VFE>FW=
MF; VSN_;]?G*N>,204F?HY:>*IC%4U-[KW2MH_YEGQ<R7;79?3.,S&]LKNCK
M2@[EE;(X?8.X\OMGL+</QVP6S=Q=Z]?=29?&TE4_8W8O5^-W]B_XCAZ"%JF6
M:6:*D%2]%7+3>Z]U(H_YC7Q\SO6/Q/[(V51=F=AUWS8VOC=[?'CJW9&QJC,=
MK;LV=5;?Q6Z<SN[,;=DKJ/$[*VCLG!YRCDSF7S&1H<9CYJNGIC.U354T,ONO
M='U]^Z]U2S_+**?[/+_/" 1A(/G%U*6?7=60_$'I(1H$TC2R,&)-SJU#@6Y]
MU[JZ;W[KW7O?NO= =\DOD3U;\3ND.P/D+W3F:O ]:=:XRBR.XLAC\76YK)/)
MELUC-MX+%XS%8^.6IKLIG=QYJDH:9!I0SU">1XX]3K[KW18.K?YG/QO[2H/C
MC-#B>Y]C9CY/=K;IZ0V%MCL;J'=FV<MA>T=H]:U/;V0VOOFO^WK=J[?;+==T
MK9/#5:9&IHL]37?'S5*QRF/W7NEYW;\_OC?\?N_^L?C3V+GMS4_9_:4&P:S&
MPX79N>SVWMKX_M?L^+I7JW*;\W!C:6:CVOB^P.VIEP&/J)-<:UW-08(;2GW7
MN@@V'_-S^$W8NS^W]][<WMO*7;74)V"_W,O6>]7R';%+VSV!OKJ?J:JZ(P%%
MB:W<';C]H=H=:YK 8*DQ5++D*[)4904ZK)&[^Z]T-??GS?ZK^-'2>V^\^V=F
M=YT&$W#BZO.S[*VMTWO+L#M#:> PNW*S=^\<_O;96Q:/<-7MC";!VQCYJS-5
M51((*-4$09YY(HG]U[IJV/\ S#?BYV1W;M7HC9>\LSG-S;WPV$K]K;G@V=N>
M#KG+[@W%U+CN_P##=:Q[VK<92XNG[2K.B<O3;P_@<WCJTP4RS/IDO$/=>Z%G
MXZ_*+I?Y68/L7='1NZX]Z;:ZP[C[ Z(W+GZ2FJ(L1-V'UA64F/WC2X&NE18,
M_A:&NK%BAR%,7I:IE8Q.Z ,?=>Z,)[]U[KWOW7NJROYSE:E#_*H^?,KF$";X
MS]DX\&HYA#Y7$G%QZTT2";]RL%HR LA]!*ABP]U[JRN@A^WH:."Z'P4E/#>*
M)8(SXX42\<*$I"AT\*.%' ]^Z]U*]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW73,J*68A54%F8FP4 7))_  ]^Z]UX$, RD$$ @@W!!Y!!'!!
M'OW7NN_?NO=>]^Z]T4';M,O^S\]Q5=H=1^(/QLI@?._W&D=S_*V4@TWD\?AN
M1Z]-]7%[<>_=>Z-][]U[KWOW7NO>_=>Z][]U[K__U]_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$U_F,&W\O?YW'GC
MX:_)\^D7;_F26^/TC\G^GOW7NG;X#7_V13X676G0_P"RE_'*Z4CF6E4_Z'MF
MW6FD9(VDIU/",54E;&P^GOW7NC:>_=>ZHWWU_+T[*WCWW\E:G!;JR^T-R5OS
MC^-O\S_XU]NYK#G=/5YW_P!=]';3^-V]/C_V7A*#*X;/5.,EVYLC)%UIZBE>
M/&[IHJNCFEJ<=4P>_=>Z*!\O/Y8_>&\_EGU9W=E-M=<=Z=T_*#Y-YS.]NY'*
M=,;AW/\ %KX]="]9? GOKXX]3[;W+2U-=-N+<4[[[[8AR=1D)ZN@K<EEZT/3
MT]%18QID]U[H4MN?R.>PMC9/96TMJ=_[)DZFVE\B^AN^QN+*;&W)%\@6;K7X
M I\#-\X&FWY#NJKP<+[DPJ#<V)J10I-C\BIBJ&JPRS1^Z]U+V9_)6[-VWN'X
M_P"Z=R]B_'3L"NZ5VOUWL+)[?KNH=P8/9F^-O]%_#WM[XC]4;OJ-N/N+<N/P
M_:.1Q_=%1FLUD(XI8*<;>Q&.HHEBB-1'[KW0E]Q?R<\GVW\3/@MT-F-[],[A
MWE\-?C-V1\79:CL3J;(;SZIWEMWL_H/#=&U_8V*VA-N:CS>TNR-I3;1Q.=PM
M3'7S_;2BMHQ(HJ4JX/=>Z,K\3/BQOO87RZ[*[JW+D=WMLOK;X@?&3X#=99#>
MABCW3W-%T-D]^;XWYWYN6*FK*@R0;@W%V%!B\7)5*M5-+C\G4H!255-)-[KW
M5I7OW7NJ;OYQ*L?^&L66UD_G(_"%GN\2^EAV=$/2\B/*2\@XC5V'ZB JLR^Z
M]T:WY7_#?$_+;?O55-V73;$W/T#@MA=][%[8ZVW/M^NR.>WE3]P;:VYAL+D-
MI[AIZVGCV;E=F9';J5T%='&];'4&.6EEIIX(Y??NO=5AUO\ )&[1J-JT6PLO
M\OJ[L[#;LV1O3J+N#?/:NSJK*=MY+8N1^=$/S'V?OS9&Z<)GL7!A.]*3&QC;
MV:S+Q+!ELG2X[/\ CCJ<='2R^Z]TX?&W^2#FNJNPL/N7?'R!K,)@J/I?MOKC
M.57Q2KNS?B_V=NO=78_S)W[\J\7NK+]D["W[39[^";>H-]O@)\3KD3)-20U4
MLH2.*EC]U[I4Y7^43VS_ '0K/C3B^]^OLS\0W^>>(^;VV*#>6P=U5?>'7^-R
M'=2]Y=M?'FDW/B]Z4NWMZ;,[/W+E<[0C-UT-+D*##Y^KI:FGR@*.GNO=)/>'
M\D?<V]<'\A,AD>\MK46[OD)T9W3L[<^S*#9>;;I.;Y%=C9CO#:G7_P K,U@:
MS<M1NK.=A]2?'7O"KVG34OW]/1Y*LQ])D9A'-3T8I/=>Z.E\9_Y<>UNK_D3V
M]\F.Y<#TMVAV=NK,=/97J+=&/V%609KIL==?&SK#X\[@AVS+N/(9JEQ-5N6#
MK05\-;CHZ2LI*;*5% 9)(07E]U[I#?,3^7)VQ\JMW=K]I4W>.&Z_[9P68^-V
M4^%6YL;0;ZEV_P!$U?0_8]'VUD,SV5LFCWCC-O\ ;V8WGO?[H3>2.CCCQ+04
M0(\4DT_NO=%R[ _E#_(G?%+WWAJCOOXXUF&W[VINSOSJS+;C^-M?G.U=K]@=
MH_(7I+Y']A]8;[[=JM_ON;/] 4&\.G8:3#T.%CP.9DQR8NGKZRHI\1!!)[KW
M3AO#^2[N7L?96/H=W=X;3PW9/^SS?*/OW.]@=>=>5>!DR?Q6^<%?E(?EA\5:
M>BW%N#=L]%'V9M/.34"YE)Q)25%%0UD:+40%W]U[ID[A_DT]K;^R7?%9M'MO
MHO:M+WD_\RG:\V/RW4>X<W2[,ZV^>W4_Q[ZYQ$&W8L=NW;RIO;K2NZ AK6JQ
MXJ&I3*SQI3*4#/[KW0?8;^1-OK"UO=,60[)^/V_<1V*F'SV"S6?ZY[AVIW+1
M[AKLO\=\[NW:P[DV3W1C\IL/:VV\[\?:');.S&V<?1;AQF1BQ;5\F0I<0M+5
M^Z]U=]\.ND-V_&WXP=(]$[[W]0=I;OZOV'BMJ;@[!Q>SL+L"AW5D:)IWFRD.
MT]OQQ8K&%Q,$=D'DJG0U$UYI9"?=>Z,K[]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NJ?NV6\O\\[X71-0M)]M_+G^;M2E8U5(B0F?O#XDT[>.F
M4&.2154*U[76<&Y,8'OW7NK5M]T>[<CLK=E!L.KVK0;UK-NYBEVG6;YPN1W)
MLRFW#/03QXB7=>W\1F=O97,[=6N9/O*:FKZ.>:GU*DJ,0P]U[JJ/I;^7'V5T
MYO?<7;^WMQ=";=WSEMU_(GOW:W7&U=A;GH.@NL?E#W;UMT_TMB=V[:VI39K%
MYJMVKA^N.OLY-F_'4XROW!F]Y92H'V2RA1[KW0>5O\M+Y,[W^-O8WQF[DW]\
M.NR-N]^;LW=F.Y=]S]#]GP]C4N;WOMN@I\_\@-H9W</<6[?N_D(FZJ<SX@N,
M7@MN8_'X:CQD-/3XH0U7NO="EW!\"?D7N_J#/]4[*[;Z7FH>Z>].S>Y_E:O:
MNQ^R=P4O>N,RE338OJ;J>OK-D=C;%S^+Z[VUL/;.VL/N:".J%1NC';?&/:2E
MH*^NAE]U[I.]/_RT>V>L?D;M[N;+=K==;KV[UIVU\H?E/L3;>+VON;9]9N7Y
M*?+3J';O7/8,.[WES&[*7;W5FWLT=TY'%14)KJW[?<E/32(#AQ-D?=>Z ^J_
MDH;MW=\,_BMT-NKY);GV7W#\9<-L'8..WGU5701]7Y'8^V?E'UWWUN3<&/V)
MO'9V9KL1V-N'#]:XNGIYXZH04F0H:43-5T,4M//[KW5PNZ/CXFZ>X>K^X9.Z
M_D)@INL<.V(_T:;7[-GP?3O899<D/XKVAU_38LT&[,RKY+6)_)3V:"&RZ8P#
M[KW55W8_\HC(;_[#WA4[WJNL.Y^A*/L_YN=Y["Z.WCDM[=?U.[M_?.K;^&PF
M^]L=E=B;6QNYLIMS:W7E=D=UY'"Y3"TE1E99<W1(D=#)B8ZJI]U[I3= ?RR>
MY/C?N7>_<&,[7VMWMW+F=I]Q[OQ0[IW%VU4[=ROR%[YRNP-M;DJ,[N[)9?L'
ML3&===;?'3HW9>P-KUOGR^?>F3*U];Y)*L4X]U[HO-=_)/[,AZ^WGM39/9G7
M6QZ'O78/SEZ"[*ZXJ\KVEV%L'HWH3YU9OIG<&\:+X]9[=4Z;HS>[MD[BZEK<
MRJ9.#!T&>RV[:YI#004M-"_NO=#5O_X"?-.FZ"P?2O5&X_B?FZ/L/MSL;NGY
M747<=1W!)@>U<G-F\?'T;U;!)LG#T6:R74?7>Q=J[9PF<I:B6@JMT8K;-/C9
M'IJ*KK5E]U[IQZ]_EF]\;3[_ #V-N/L_JC<NPNO]Y?.#OSJV@Q&'W+M;>.Z>
M_P#YX;;QE'OVCWY4/29[';.ZXZTS5=N9,)/CY<WE*_&YNC2JCBEQ)?)>Z]T4
MO<G\BON'<O37Q&V++VEU!CNR.D/A)UI\),MVY21;W.[NCVZC[JVAVCMGY1?$
M[-+B*:OP/<><Q&V)L=DL=4C#HSU-+KR]328^2DR7NO=;-<2&***-I9)FCC1&
MFET>68HH4RR^)(H_)(1=M*JMSP ./?NO=4W_ ,LZCT?,S^=GD/ H^Y^>W7E'
M]UY)BTWV/PX^/,WVYA,8ID6E_B&H,CF1_*0X4*A;W7NKE/?NO=>]^Z]T7?Y7
M]=;P[;^/G976VQ]K=.;ZS6\L5082KV'\@,979;I_?>U:G.8O^_.R-[4V.Q6>
MK*>AW=LM:_'PUBT%<*"KJ(JEJ:=8C$_NO=4^_&#^6I\Q^K^EOY8VRNPNPNN]
MRU/PZ^6>>[\W%M?/]F;_ -S3=6=,9CH?L;I?;/QZZRW[DM@Y?-]I2]>CM"LK
M:>KRS8.B2"D3$TY^R6GG@]U[KV__ (._-?YG_)#XF_-#LQ^F.B>P/C;O;(8[
M8\.,GWI)N/8FR]M_)[.UV[=XX?;>3VO4T_8D?RW^*]'C\!7;;W954!V)DECR
M^+F6KFJJ?W[KW1=-A_R)^[=K0Y;)[USOQY[7CK?D;UQ\G^P>H,SF=]83J_Y+
M]U8&D^66U^PNT=R5E!UQ-6?':?=.TN_MNU>,VKMK'9[;N&SVTVJ(2IK7E3W7
MNC<T?Q=^;.\/BKV!_+;[#VUU[W3U/L+X_P#4?2F.^3G9_=7>73F].V-QY?I_
M<"[SSL#=?[-W!NC-TW5._(<#'"QR,,.;Q,SP5.1ER4%<J>Z]TPXG^47WC-E:
M?KC>?R4K\QU7DNYO]F?WE\@L)EJK"_*[,]XY/^7A2?!/=#X"DK-G9K8NVH<I
MF#6[WAS#UM:](]4F+3'$1"N/NO='(_EB_!SL3X);%^1&QM^=P/VSC^S?E#V'
MVWUXR8'8NW8=M=>9O#;3V_MB@R6*V+UIUMB:#>%70;:5\M3T<,N'AD2,8]((
MS(K^Z]U9E[]U[KWOW7NJJ_YX$?E_E,?/&/R0Q ]";@):>%9T(7(XAB@1F33-
M* 5CD!U12,'7E1[]U[JTZG01T\"+?2D,2+J9G:RHH&IV)9C8<DDD^_=>ZS>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K#44\%5!-2U,4=135,
M4D%1!,B2PSP2H8Y89HI R212QL592"&!L??NO=<XHXX8XX88TBBB1(XHHU5(
MXXT4*D<:( J(B@    #W[KW7/W[KW7O?NO=%LV]3P?[.!V[5K/5&I/QL^.E/
M+3%F6A2 =H?*26GGC45#))522-*KDQ(41%L[ZR$]U[HR?OW7NO>_=>Z][]U[
MK&3+Y5"B/PZ&+L6;RA]2:%5 FDH5+$DL"" +&]Q[KW7_T-_CW[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$M_F25%/2?R
M[?GM4U4GAIH/A?\ *.6>75HT1IT?ODNP?4I5@/IR#?W[KW3Y\ EF3X(_"A:F
M435"_$GXX+43!Q()9ATYLT2RB04]()!(X)U>**][Z%^@]U[HVWOW7NO>_=>Z
MUGMQ_.#Y&_'C^8_\W^M-O;BW/W)UM\@>QMN?'GXN[4SN1R&[=J_'+YK8'XP=
M#]KX_"YMJK<E75;&Z0[*V'V3N;>.;+146,H?]'^0%,4EJ&!]U[HN?P?_ )L7
MR"V?\;_C#ML;@P'?6ZL?T_\ %+M#M"3NG=&]=V_(WYF9;Y7?*[L7H;>U%\5L
ME+OZ?#19GH0X/'560QOV>8QL=77QXC1B8$2ND]U[H]G\L7YH9?Y>_+WY-=FY
M[N+KV;#[O^(OQ]WO@^FME[YW7457QU&)[S^7.R]R[0[/V%O/>.YL'M7NO:^.
MP6&3=U90X[!4U34M3^6@5!%/4^Z]T,O\L/>V1K_D9\_NO<9WCO\ ^0O4^W<O
M\=M]=4=DYGY%4/REV'F,=V)LK>,&Y,I@.PZ&DQU%L'?&Z,YM Y7.]?XRGBVY
MMBCJ\7/B0*;)%%]U[JYSW[KW7O?NO=4N?SE9'2O_ )2ZK)(B2_SGOA8DJ)^B
M55PO<4BK+^S)=5D16'JC]2CD_I/NO=71^_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[JJ[?4M4W\ZOXTP?:K]E'_+2^8$ZUD=3"LK5$
MGR5^'$4U/4TMQ.]-$B1M&W*F1VL!I)]^Z]U:C[]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJCOY:
MZ$?)S^<O)Z+-_,;Q""RD27C^$WQ'8ZGUE63]STC2"#?DW%O=>ZMQ]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW53'\]=U
MC_E&?.YV6F8?Z%*E+54<DL6J3<^VT4A(@7\RLP,3?190I/ /OW7NK8X?\U%_
MRS3_ *%'OW7NLGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[HMNWEC/R^[?;QJ)5^-OQQ7R@OK>.3L_Y3GQL-9CT
MQM'=;*&NYN2+ >Z]T9+W[KW7O?NO=>]^Z]U[W[KW7__1W^/?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T2O\ F3"F/\NO
MY[_>4RUM+_LEWRC-12-$\ZU,0Z/WR7A,4?[CB0"UEYYXM[]U[JL?X@_$W^:;
MG/B%\3\OM'^;SC-I;>R?QQZ7R6)VX_\ +ZZ+S_\  \'D>L-MU>!P468R6]X<
MADC@Z26&G>JJ$$U6D3.ZI(_I]U[H?A\-OYO?V\6K^<_@?O/%4"H9/Y;O00I#
M,='VC4\+=A-/'$GJ\JO*Y>XTE+&_NO=2$^&_\W$(_D_G-XEI?(?&4_EQ_'Y(
MQ%^SI$BMOMV:7_.:F5E4W2RBS:O=>Z2'_#>_\S5*S/5D'\V?KV*;=$_WFXJG
M_AK[XQ_?;@KY,?D,-45>>JDW;&<Q-)A<E-2:YP[_ &\\T98QR,OOW7NBS]\]
M&_*OX8;=ZQWQV_\ S;=@8%*3=>5P'4&W]A?R?^CMZ;SGW97[=W'O??D'6^R>
MM<AGM\01?W#VAD<MG9\5#$:?%XZJJ*J<(JE?=>Z,%U3\3/G?V'L_ =T=(?SA
MNN*K9/=&VL-V%A]Z=??RV/C/!BNP<#O*ABW%C=TMD3NA\CEDW!39(51>ID>1
MFE)<!RWOW7NE=L[X!_S)^O<<<+L;^;-M/9^#?(566FP>U?Y9_P 7MM8BHR5?
M(LN0KYJ#!;BQT#5N0D4&>8 2R$7+7Y]^Z]TIV^'/\UEI?*O\Y4(-,:^!?Y>'
MQR-/9/U, ^ZFG$DO]H^0C_4A??NO=<I/AW_-:>VG^<E##9Y6/C_EW?'8W$CZ
MUC/EW?)Z(%]*?VBOZBQY]^Z]U59_--^-G\PK:V1_EF#LG^9K1=HON#^:K\3]
MJ;!'^R5]0[&_N%V57X3MJ7;W:DJ[?W95)O%]NT\%0LF#K#38VM$H8M&\0#^Z
M]U:M'\/OYK"5'F;^<=331ZW;[23^7A\>A3V;5IC+0[RBJ]$>KT_NAO2+D\W]
MU[KU-\/OYK%/)KE_G'4U:NDKXJK^7?\ 'I8R2+:R:+>='+J4\BSA?Z@^_=>Z
MD'XA_P U0T_@_P"'A* 2VB'WB_R\N@_N;QP20NP5M]-2:IG<2M^T0)$72%34
MC>Z]U%J/AY_-9FE>2/\ G(P4B/IM!!_+O^.[11V4*?&:K>%3.=1%SJ=N2;6%
M@/=>ZXR?#K^:T[NR_P Y2.)68LL<?\N[XZ%(P>0B&7=DDA5?QJ9FM]23S[]U
M[K@/AQ_-<!O_ ,/+J1<&Q_EW?''D?TN-U V/OW7NN3_#G^:VSNR_SE8XU9F8
M1I_+N^.96,,20B&3=DCE4!L-18V'))Y]^Z]UV_PZ_FMO([K_ #E(XE9BPBC_
M )=WQT*1@FX1#+NV60J/IZF8_P"/OW7NNQ\._P":T%13_.3B)64R,Y_EW_'7
M5(A" 0L!NX((QH)NH#W8^KZ6]U[KF_P^_FL-$8U_G'4\;^>2;SI_+P^/1E".
MJ*M*!)O)X/MX=)*G1Y;L=3L+ >Z]UB/PZ_FME$4?SE8U92Y:0?R[OCIKDU$%
M0X;=IC CM9=*K]3>_%O=>Z[/PZ_FM&-4_P"'E(PP9F,H_EW?'36P;19&!W:8
M]*:3:R@^HW)XM[KW6%_AQ_-@M^W_ #F8M5S<R_R[/CFRZ=+6LJ;MC.K7;DFU
MK\7Y'NO=>7X=?S8S31I)_.6H_ND'JFA_EU?'E(IG:.+4)(I-YS$(DROH",I"
M, Q9AJ/NO==P?#S^;)#)'(_\Y+&U01KO!4?RZ?C^L$J^) 5D^UWS35('FU$:
M)%.G2+W!+>Z]U&C^'/\ -M$,*3?SF<4TGI:IFB_ER?']'+ %2E,K[[DBBB8-
M<ZUD;4!9@+@^Z]T]5GQ,_FO5!R+4_P#-WVI0&H> XZ.G_EV=.R14"12-)(K"
ML[6JI:G[H:8W+/Q'?1H<AQ[KW4]OBM_-4DIU@/\ -EV5 ZPP0FLI?Y>/58JW
M:.&F@FJF%5W%547W5087F-H1"LTK:8Q&$C3W7NL./^)O\U*D@AAJOYNFWLI(
MD$RRU57_ "\NEXIYJB4DK+IQ_9M#3)'3 VC41_@:R_-_=>ZETWQ4_FE0>7R?
MS9]LUGDJ8IT%3_+VZ@401QR1NU'%]GVK2$TTZH4<OKF"N=,BMI9?=>ZKBW5\
M?OYAL?\ -MZ+V3/_ #&MKU/9DO\ +N^2VX*#N)O@QUG3RT.RH/D1\6\9F-B-
MM:#LM<+E:G*YYZ+(I722JV/6GEB2!EK"\/NO=60Q?%?^:/';7_-AVI/:992)
M?Y>_4PU($B4TY\';</[#M&6)%I+NUG TA?=>Z[A^+'\T>(4X?^;!M2I,*0K(
MT_\ +XZF!JVC8,\E2*;MJG"O4 :7\/B4*?2%-B/=>ZZA^*W\T>*9)7_FQ;6J
M$4.&II_Y?'48@D+2^0%S3]L4]2/&G[:Z9%]'ZM3>KW[KW463XL?S64FB^V_F
MQ;!>EMKJ!7_R[NM):PRK44I2.GFH^[*&GBI7I%F60/%)*9'1ED55*M[KW37-
M\9?YPR2U"T7\U3X]-2&:8TK9+^6ICI\BE.Q/@2HGH?ECCJ*6>);79:=%8\Z?
MQ[]U[K$OQG_G(*JJ?YJ7QJ<JJJ7;^6;%K<A0"[!/F"B:V(N=( O] !Q[]U[K
ME_LM'\X__O:A\:?_ $V<G_W8?OW7NO'XT?SD+&W\U'XTW_'_ &+-3_[L/W[K
MW4I/C?\ SB%ED=OYH?QDDC?]$)_EJ3!8>?[#K\QUD?C_ %1/OW7NN,7QR_G&
M+,TTO\S[XO2)(2IH_P#AMBJ6"F5C820S+\Q14S/& "%=K$DW-@/?NO=99?CM
M_.*$B/!_,T^++K<B2&;^6[D8D"BF>-2C)\QY9&9JC2Y!( _''I/NO=1:KX^_
MSF_"*:C_ )DWQ%/G6)YLC/\ RZMP15U#)YECEAHJ=/E_44%3!]JS2!ID#F9%
M7A"Q]^Z]U%C^.O\ .@E:M>I_F9_$VD\DK/10T7\N;*5$<,<L50K1%ZOY;)*J
MTLGB:/5Y6<EM;6 #>Z]TR5OQ\_GB@U4./_F1?"YX"]--25M5_+[W/!7W6")*
MFDE@B^4%5114K3-(P:TLI*)ZD#,H]U[JM/X/])?S?<MWW_-#INLOG?\ %#:.
MX,+\Y,=C.W,IG_A;N#<6.WSV$?B=\::X;IVGBE[\I)=EX!-GUN)Q_P##9:C(
MNU70SU7W %0(8_=>ZLZQ72'\\3% -4?/WX';E>2!8Y8\]\">RJ6*GF235YJ5
M]M_++"22-*ALPENHMZ5!Y]^Z]TXQ]1?SOTJ*F=OFY_+QFCJ%IUCHI/@GW6M+
M0F!9%D>E>'YDQUCM6%PTGFEE *#QA!J!]U[J1_HI_G>?]YG_ ,NC_P!(6[V_
M^[2]^Z]U[_13_.\_[S/_ )='_I"W>W_W:7OW7NN"=5?SOR9-?S-_ERJH>T17
MX,]\,730A+.&^9R"-_(6%@7%@#>Y('NO=>;JK^=^"@3YF_RYF!<"0M\&>^%*
M1Z6)9 /F>X=PU@%)4$$F_%C[KW7%>K/YX5HB_P ROY<>HRVF0?!SOHJD5W]<
M;_[.4K2N0%])"#D^K@:O=>ZRQ]8?SOA4U0?Y@_RX6I9 R4S#X2=_":G\BLXG
M\7^SC!)9*>1514,A5T8L2"H4^Z]T\T^P/YU,,N.GG^4'\MVL2&AG@R-"WP[^
M1=-%5ULL:+#7)51?,%ZB/[234PC541[ -P>/=>Z=(-G?SETJXYIOD+_+:FI7
M,IGHO]E,^2Z+ )9@8UIYU^7PFG^U@O8OH\C?J ^H]U[IARFR?YW,O\.;%?(S
M^673F::K3+QS?%'Y,Z:"GEF>2EJ,8Y^5U4V4J::%EC\4PI$;3<N2??NO=5G?
MSA<%_-QH/Y9?RS;O3L[^79N;J%>IZ&?LRGZQZ4^26T>S)J!MZ;;&1QVQ<GN;
MO/=FTZ>JBBT-3UE?0R*[:E>F46?W[KW6T7#_ )J+_EFG_0H]^Z]UD]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW6,K(98V$@$2I(KQ: 2[L8S&XDO=?&%86M9M7^ ]^
MZ]UD]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%JV[&G^SA]PS6_<_P!EJ^-T
M>J[?H/:/RK:VF^C]0^MK^_=>Z,K[]U[KWOW7NO>_=>Z][]U[K__2W^/?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T1/\
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7?\
MS=9YZ7^57_,BJ*::6GGB^#'RI:*:"5X98V_T);U&I)(RKHUC^#[]U[H;/@V
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M]++>"?+O#*R_<")A[KW17?DC@_Y8/0,'4NP=V_$CK#MK<.^=O3==]9=3=2]
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M\>AKK_LF?Q6\ADU+I8/_ '<TA MP5TDDD&XM8^Z]U$B^)'\QT2R&?^;;NF2
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M.[\MO_K=,;7X>L>CP_>.*ZEQ^'>26=AAJO(MD*'[:<O(_NO=&U^"O9F0^:^
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MUGL;2YZIBIL=&@J#5JHT5"O[KW1\_G/W9\R,E\1O@I+CX]K_ !X[*^5_R/\
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M3=H? 7;WQ(R6$K=I+B\HQVV_8U#D=Y##39BMH$FR(-3_ !"IB,DGNO=)R/\
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MN;;D."VK04V?BKZ6OPE744F*Q=+D)L,U7'20"?0/=>ZL,]^Z]U[W[KW58?\
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M[]U[JOG8_P ]-X+_ #4_D5W$O\N#^9'55-9\!OBILE^MH>E^@4[(PE%C._\
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MWJ[I"BJMR8?%-#V6:2&">7;V0S%'09>&K6CH1D&K8S[KW2V[)_G._)G']O\
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M8JF;[B'X0;U>,K2B,NJPG-K6&659+Q)XM<NDA06%C[KW6%_YL&WTCC<_R_\
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M()X<?4S439"8U#U$CUM;,1*(O%%%[KW4M?YR7QO*K(>@?YCZ1,R@RM_+2^;
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MQE?=>Z(QTA_(_P"XNG*'I;'/\G^J=SP]1T_P/Q1J9^A=VX^LS>'^$ORH[O\
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M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ8]_P!?Y/\
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M_P Z)59H6F7_ $<_ Y=8C++*L6KXA21TXEBT#TK8,I8W+'W[KW3I_LA?R-E
M-3_-J^?;2+)5Z#2[8^"5$G@GE<P1R11_#-Q))30%4\A-V92X"WL/=>Z@2?R]
M_D#(J*?YN'\Q1=#(P:.B^#T;-HDED =E^&=W5C*00?JH4?11[]U[JM7.?"ON
M2;^<%L'K?_AR7YRIN1_Y8G:^XY>XUQWQ"A[!&WZ;Y5=18R/KZCJJ;XKP;1;
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M>L,/V/U;\ MM[QWOLG:>4K\'GNP,=L'+?'J7,KM?[JF>825-,DM' \;3K$=
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MHWT4J_NO=9F^%7\TC1*4_G3;Q$S:Q#Y/@)\0GI8 [>EO"F(BJ)'A0G03,!J
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M[OV!NS;NR:+9O:/<>?S.VNZM]]=U66H=QU>ZME[6[&V+M^' #[+=SUM++N+
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MXF@HL5BZ&CQN+QM)3T&.QN/I8*.@H*&DB2"EHZ*CITCIZ6DIH(U2.-%5$10
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3#_.G>J?9O\
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M#.>%/OW7NKA??NO=0<IDZ#"XS(YG*U45#B\30U>3R5;.VF"CH*"GDJJRKF8
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MJ6*&:)?2C*O'OW7NGB+^7+OZ&?[A/YH7\S8O]N*73+V;\:9X/&)Y*@/]M/\
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M/OW7NO?\-X]B?][/_P"99_Z'WQ:_^Y)]^Z]T&/7W\HZ#JO.=K[CZ_P#YB/\
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9W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exh1071_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1071_3.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X0P"17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#(Z
M,3@@,38Z-#4Z-3       Z !  ,    !  $  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   K,
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M<VAO<" S+C  .$))300E       0                     #A"24T#[0
M    $ $L     0 ! 2P    !  $X0DE-!"8       X             /X
M #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M           ! #A"24T$"@       0  .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #1P    8
M             X\   +     "0!E '@ :  Q #  -P Q %\ ,P    $
M                     0             "P    X\
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   X\     4F=H=&QO;F<
M  +     !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   ./     %)G:'1L;VYG   "P     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     $_\
M     #A"24T$%       !     $X0DE-! P     "N@    !    ?    *
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M5Y>=EN#E>ZS\[]+^9_-I#IUC,7(.;16X[6BLGTGZESM_\WB8>WZ5;?\ "?\
MI1*=-G3.FUV&UF)2VPDN+Q6T.))#R[=M_?;N2'2NEA['C#H#ZQ%;A6R6C7Z!
MV^WZ2YW'G>\W-:^=Y#36  !^DU_R/59^;M_/3>F2\EOZ1@>&AQKK:1,;P=_2
M?=L]1FU[/YS_ #TE/1CI?3 \V#$H%AD%_ILDR-KO=M_=.U"?@X7KT8OV>K[,
MVNUS:=C?3#@^BP.%<;-V_P!ZR,$5MR**LAE=@<=EC;*P#N=[6?S?3<=C^-W\
MY1_.+3R>EXC\JFNJMF.378=[*ZR='4>W;;78SW)*;0Z=T]KBYN+2'$$$BMLD
M'0CZ*9G2^F,<US,.AKF0&$5L!$#:W;[?;[56_8C=M@-\N>(8_P!''EAD>YOZ
M#:[_ *XGJZ*QEH>ZT/K'^"-- '^<REKTE,L;IV%=7ZM^/59:;'/+W,!=N:YP
MK?N</YRMOT'JY1C8^-6*L:IE-0)(96T-;).YQVLAON<LO'Z2+*VO98QE9?N%
M?HU.  )W5[W,W;+'?I/])_+5RGIF,RL,N:V]X)_2.8QI(G3VU-8SV_U4E)*O
MZ;?_ %*__1BL*IBU5U960VMH8V*]!XPY6TE+'MI.J=0>XM+/Y3H_ J22G__2
M]522224T,3.PJZ2RS(J8]MEFYKGM!!]1_(<5'/ZA@.Q7-;DU$DMT%C?WF_RE
MHI)*:W[2Z<.<JG3_ (1O_DDOVCT\?]JJ?^W&_P#DE'-'5"6?L]U#1!]3UVO=
MK+=FSTGL_-]3<@6-^L?^#LPOI/@.9;]"&^CQ;]/?ZGJI*;(ZETX\95)_ZXW_
M ,D@NSL(YU3AD5$"JV3O;&KJ/-#8/K)L/J.PB\\%K;0!]+L7'=_@OW/ST[1]
M8=GN.&7^[@6@#VM]+N[=^E]3?_P:2FU]OP9C[15/;WM_O4AF8AXOK/\ ;;_>
ML]S?K/OT^P%FUO(M!W;6^KW=[?4]3T_Y&Q*QGUC]P8S =^X7>J),_G- ?^;_
M "DE-G RL48E8]:N8D^YO<GS5C[5C?Z9G^</[U7PZNH%Q/4&8T%HCT0XG=)W
M2;1]#;L5DT4'FMI_LA)2+&>Q^3D.8X.$L$@@_F^7Q5E1:QC!#&AH\ (4DE([
M?I5?U_X.1$.V=U<1]/O\'(B2G__3]522224I))))2DDDDE*22224I))))2DD
MDDE*22224CM +J_Z^GW.4^ZA;&^J?W]/\UZ(DI__U/54DDDE*22224I))))2
MDDDDE*22224I))))2DDDDE([8WU3^^8_S'HB'9].K2?>?^I>B)*?_]7U5)))
M)2DDDDE*22224I))))2DDDDE*22224I))))2*V=]/]<S_F/14.SZ=7]<_P#4
MO1$E/__6]522224I))))2DDDDE*22224I))))2DDDR2ETDDDE([/IU:_GG_J
M7HB'9_.5:?G'_J7(B2G_U_54DDDE*22224I))))2DDDDE*3)TDE*22224I))
M))2.S^=J^)_ZDHB'9_.U?$_]25/NDI__T/54DDDE*22224I))))2DDDDE*22
M224I))))2DDDDE(W_P [6/C^13[IBR7M=/T9T^*DDI__V3A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
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M  8 ,0  86-S<$U31E0     245#('-21T(               $  /;6  $
M    TRU(4" @
M               18W!R=    5     S9&5S8P   80   !L=W1P=    ?
M   48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA96@
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M14,V,3DV-BTR+C$
M                     %A96B        #S40 !     1;,6%E:(
M              !865H@        ;Z(  #CU   #D%A96B        !BF0
MMX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T
M<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N
M8V@
M    9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO
M=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A
M=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M     &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I
M;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#
M;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M      !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@
M      !,"58 4    %<?YVUE87,          0
M  */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 >
M ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L
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MJ[M#<7;NX?Y67\YC>&X:Z? G%8C=NW/B7E:/%[=P';^S_D%4[.;<+]]P[\[
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M*=C?+RJ?!R8%_%BEJ^T^R,M3Y&&6"*GFQ30T,$=@LC^Z]T.L_:'4]7\==_\
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MM3;6T=P5]74;:>LV)\5S\0Z'>F32FZ=H,SC\]GNGJNC7(&6MAQLF3Q\<\-/
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M=^"787PKGZGIZ2ESN=AQ?QBK*G?0W3)CS7UV2BCI(\45J&!RK>Z]T5WXZ?\
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MDLTOW!T?U\;_ .IY]U[IQ_X=K^$__.Y^2G_I _SW_P#N9_?NO=>_X=K^$_\
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M?%3'V73[QRNWNC\)@:3)T>*J<8E+F7CS58LE35T6%@G]U[I$;T[7VYU5W_\
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M'/UX^O\ K_U]^Z]UT41K!D5@K*P!4&S*0587'#*0+'\6]^Z]UV% %@ !>]@
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MKCL/2&2. M)(SO),['W7NC;^_=>Z][]U[KHB_P#MP?\ ;$'_ (CW[KW50O\
M(BB1?Y7_ $7. /+D.Q?EODJMPJ+Y:RM^9'?\]3*5C5%!DD8GZ>_=>ZM[]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2?K=J;7R6X<%N[([<P==
MNK:]+F:#;6Y:O%4-1GMOT.XUH4W!18;+RP-7XRCSJXRF^\BAD2.I^VB\@;QI
MI]U[I0>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDIN;8VT=Y5>TZ[=6WL7GZ
MG8VYH-Y[2?*TJ5B8'==)C<GB:/<-!!-JITRU!09BI2GG9&>G:4R1E9 K#W7N
ME7[]U[KWOW7NO>_=>ZKP_FYS3T_\K#^8W+30Q5$R?"'Y0:8IJVHQT1#=-;Q5
MV>KI:W'SQB-"6LLR:[:3<,5/NO=&(^(=.:7XG?&"E.J]-\>.E:<ZUC1[P];;
M:C.I(9)8D;T\A690?H2.??NO=&']^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3U\NZD_\/ _R<Z/POI_T
M>?S+JS[BS>/4G5'1L'VY/Z-;+*7_ -59>.+^_=>ZN%]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4^?$.CIY?YO
M7\XO+2+(]?#L?^6U@HI3--XX\5#T]W%EHZ9*?R?;@C(92>0OH\AUV+:0 /=>
MZN#]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=%*^4F&H<UN7XAPU\9D2@^6NU,S3 :#HKL1U+W/74<GK1Q9)X0>
M+-_0@^_=>Z-K[]U[KWOW7NO>_=>Z][]U[K__U-_CW[KW7O?NO=8:F<4U/-4,
MDTJP1/*T=/#+43NL:EF6&GA5YIY2!Z412S'@ GW[KW6;W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK6XKH[Y/=W_P WW^;"OQK^>&[_
M (:KM+;G\OM-[87:G1/1O<_^D2JR_16\JC!9?)/W#M_/56WH<)2T<]-&,:U.
ME7Y7\P+11M[]U[H]M-\/OYHB3*U5_.'K9X#*7GBA^ 7QKII/'I@58J69\M5+
M!;1(2TB3$LX^@6S>Z]U!'PZ_FKFH5G_G)#[59G?P1_R\OCFD[Q$2+'$]2^ZI
M8R5U LPB745X !(]^Z]UR?X>?S5B9/'_ #CXT!C01!OY>7QU<I*&C+O(1NQ!
M+&R!@% 0@D'4;$-[KW7<7P^_FKH8_)_.-@E!73/_ -B\?CRC']\/KI2N\-,$
MG@&C]P3K<EM/T"^Z]USI?B#_ #5X7+S_ ,XF@K%NC)%+_+OZ!B34DJ2:)#3[
MZBD>"55*2!61RC'0Z-9A[KW4B3XC?S471D7^;]C(CXR(Y4_EZ=$&43,*:[R^
M3?SPR0H8I-"*B,!+ZG?2#[]U[J4GQ0_FGJJAOYMVV9"M1YRS_P O+IX%X_&Z
M?9N(^UHU^V+.&NH6;4B_N6U!O=>Z?!\:/YH(GJ)O^'1>N629H6BI&_E\;&^V
MI?$5+I"R=]K5O'46(?R2R, ?04-B/=>ZSQ_''^:$'0R?S->I70&,R(/Y?&VU
MU$1GR!3_ +,?=4:>UOJ0EQ<MZA[KW577\G_I?^8MO/\ EV]%;FZA_F!=,]:[
M)RVZ/DE48_:&1^"V,WP<?.OR5[E@KJF'<+?(7;$E3%F-U0U609/M(HX*6J6E
MA \(G?W7NK#IOC9_..+G[?\ FD?&58]$=O-_+2:242>)!,2R?,.)"AGU%!IN
M$L"6()/NO=.F.^/7\WRAEK"_\R+XFU=-.%^UHF_EN9RE@QS?N&:2G:B^:E/+
M,]1))K;RLXU#@"Y!]U[KE5?'[^<%.LX@_F4?%&B,L:)$\7\M[.S-2NLJNTL8
MJ?FK*LC2(-!#AE -P ;'W[KW7,]"?S@HX3X_YCGQ(J9Q]QI^X_ER[F@1O+3^
M*(,\'S5?3]M.!(I"&Y)#AELOOW7NH57TG_.<C8-C_GY\(Z@&4*\>1_E_]B0!
M8/,DADC>D^9,A\QC4QZ&!722=6JQ'NO=/K=1?SA14B1/G!\%WIWI:59*>3X"
M=LHL%6D]0:EZ=D^<)ED2:GD07D?]2 !5]3-[KW41>J?YS.A-7S2^  <R4XDT
M_ [NHJ(BJ_=F,GYO F5'U>($68 :K<^_=>Z;YNK/YUXJ]--\R_Y=ST'G(,E1
M\%^]4K13?<.%811?-9Z<U'V@5B-6GRDB^FQ]^Z]U%?JW^=X'<1_,C^7&T8=O
M&9/@WWX)#'J.@R!/FD55RMK@$@'\GW[KW3]A=@_SH\>Q;+_)_P#EN[B7\1O\
M./D9AP/3,.7HOF5,Q]4B'\?YNW]H^_=>Z43;6_G"MIMWE_+8CLZL2OQ7^3S%
MU!NT9U?,/TAQQ<<CW[KW7GVM_.%=;+WG_+8B.I3J7XK?)Z2ZB^I=+_,2WJ_K
M^/?NO=1)]M?SDXS"M-W3_+-J%\M(L\E3\8OE-3/X&D9:Z:..'Y;52//%$%:*
M,LBR,2K-& &/NO=-,FW_ .=>@!A[<_E<3LY1G6?X[_+&!8;QQB2.)HODY,TJ
MI(&*E@I8$7M]![KW7.3!_P ZP*J1=I_RN'<F5WJ).@OEG&BJL;B"G6C7Y(RL
MQEFTEYC.-"W B<V/OW7NH3XG^=['#(8]_P#\JNMG6:T8?J#Y<8N&2G6=KLY'
M=N7DAFDI2/2!(J2*>7!]/NO=9XJ/^=HDLIFW+_*RJ(3/3BG2+8WRVI)12JU6
M:IYY&[ KE-1,CP"- H6,I(2SZU6/W7NH,M#_ #QUDF:'='\J.2$2HU/%+L/Y
M>0RM"BQ"2&:=.Q:A$EJ65RLBQ,( Z@I+H)D]U[IZA3^=+'3**FK_ )7M75A6
M+208WY7XZGD8DE%$+Y3*2PJ!8$EY+GFP^GOW7NB'_P T1OYMO_#;7SV_THQ?
MRZ/]'/\ LHOR#&^/[@GY,3[U.S3U?ND;C?:J;BI3@1N9<0'-$M8#2BH*F5@B
MDGW7NATZ.J?YUE-T!\?UZ[P?\K/+[;;I3K$X]MW;P^6.'RU+CQLG C%Q3U&"
MV;N;'YBH:ATF:HC^VC,@)1"I!'NO="SC\K_/4CF)RNPOY3-73V73'C^V_F%C
MY@0X+DS5/2>30AH[@#QBQYY'!]U[I6T6X?YS*1,,CU%_+&JIC)='HOD7\J:&
M)8M" (T4_P 6\B[2>0,=0<"Q TW!)]U[K+4[F_G(I"7INE?Y:$\J$-X&^37R
MBC\Z"^J%)6^)H6"1C:SD.!;])OQ[KW4:;=?\YA9"L'17\M%XT5I-;_*+Y/*:
MBTD\0ID7_93!]N[(L<OD;6H#%--_4/=>ZP5.\OYST35 I_CW_+4JEC-H&_V:
M_P"3$'W/$QOI?XB.8.8T'JO_ )R_]DW]U[II/8/\[%/"?]E;_EKSB1JQ)4C^
M9'R-B:G\;RQT<^J3X=,LR5(5)60!616*WU"_OW7NO?Z1_P"==%&I?XG_ ,M^
MJE)J$*0?-/Y"TJK:21*:;5-\,IR49$5W4#4/)8&ZF_NO=0X.T?YV\B.9?AU_
M+FA?21&DGSA[[OK*!@[>'X83JT:NVDBX)*FW!!/NO=>I.V_YUR4<G\0^$W\O
MR>O,<_A:A^=?<T%,DO/V_FAJ?AK-(R+H.H+*-6M;%;-[]U[J(.W/YW4T!EC^
M$O\ +XI)"V0E%-6?.?N:6804Z:*.E9J/X?2TYK:Z=2Z.)/$(F42&)P??NO=,
M'^GC^>3'1I(_\O+X-5-6U-1ZH:?Y\[ZAT54\T\U2S+4?%HQ>*CI(TA>-96O/
M()$DDC#(/=>Z<(?D/_.L2TE3_+0^'TZM+(/MZ?\ F-;@IIHXEB306GE^(-3$
MS23,3<+PJD$"X8^Z]U-7Y&_SF=+ZOY8/Q1#V'C"_S*\F4)U#5Y"?AB&4:;VL
M#S_AS[]U[JNGO[MS^:=F_P"9%_+EW3N'^7?\<,9V9LKJ[YXU77VS:3^8#793
M;FZ\9F]L="87>62R^[G^+-'+M"LVLE5C_MHDPV2;*??R1F>C6%FE]U[JR&G^
M2?\ . CIIGR?\KKX[RU22U2108/^9!1U"3)_#P]!*)<O\4<1I0Y0^.HO9DA!
M=%=K*?=>Z<*GY4?S5*:F25/Y3FQ:^8O(CTM#_,2ZQ61?')31B77D.DJ" PS"
M9W3UZ]$+:E5BBO[KW3)4_+W^;%#43PQ?R=<#6112R1QU<'\QOHU(*E$8JL\*
M576-/4K%*!J421QO8^I5/'OW7NL/^SA?S9O^]-N&_P#3CO0W_P!K?W[KW7/_
M &<'^;%XU/\ PSAB?*78,G_#C/0NA8P$T.)/]'>IG9BUUT@  '4;D#W7NF[(
M?-;^:]1N5I_Y*F4RB10.T\E%_,-^,""6I2 3"''+78FC-3#([B)9)_M3Y%>Z
M! KO[KW3;'\Z?YKXDB^Y_D<[U$+-HE:A_F#_ !!JIXB849)!#55N-CDIQ4:U
M<^0.J!65'+%$]U[I15?S>_F3S4-5'3_R7^]*&LDBDIH:F+YB_!6K-+42PNJ5
M\,-1W#%#504LUF"R:&DL 4 )M[KW68_.#^9#3GP-_):[UKFA"QM60_,?X+1Q
M53*H#3I')W% Z"0\V*+;^EO?NO=98/G)_,8=R*C^2MW]#&(IF#Q?,3X)3L9E
MA=J>/QGNV$!)IPJ,^KT*2UF(TGW7NGBG^;GS[=W%3_)L^1U/&*M8XVB^57P.
MJ'>CU3ZZET/R#@$<X18R(@S EV&L: 7]U[IJJ/Y@'S=QYC&1_DP_,9S"?]R?
M\#[T^#&<6(:X.<2T?R4I1EV,4VJQ^W&I66_!(]U[H#OY8_96\NW/YCO\WK?.
M_NCNQOCGN?(XW^7I25?5':V2ZZR^]L-3X_I7M"*CR5?7]5;V[#V5)1YN%O-3
MK!E9ITC],\<,H:,>Z]U>U[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*M\E)WBW?\0XUA:45/RIQ,$CA@HIT7H[
MO6I\S B[JSTXCL+&[@_BWOW7NC4^_=>Z][]U[KWOW7NN#2QH\<;2(LDI81(S
M -(476X12;L547-OH/?NO=?_U=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3S\-(G3^;;_.BE'BDAGH_Y<'[
M\4RN8JJ+XZ[X6;'U,6@/!504YAJ+7(:&JC(L2??NO=7#>_=>Z][]U[KWOW7N
MB6_S#_D%V7\4_AGWW\C>I<-L+<.\^G=EU&^*;"=DOGUVMD\=B:JF;+TDPVU5
M4.5DR$U [K2*L\*-4%0[A;^_=>Z!SM'OSYI[.^??Q_Z-PN+^,,GQV[KR>[YE
MHJ^@[<R_R'I>O.INK(MT=I=H39/#92FZRV[@XNR]R;?VQC::LI99&FR<,LDK
M-4+%#[KW5FOOW7NO>_=>Z][]U[KWOW7NJ!/Y8_?^S?B'_(/VO\F=RXK-9_9G
M1'6WRY[=R>"Q+1G/YZ@VMW]WMN8X>@FKF6&/)9B6(0)+.1'&\NN2R@^_=>Z$
M[>G\T/L#X:[IZTI_YBNS.O=I;"[S^/\ V!WGL;>'QMH.TNRJO8&>ZFFZXG[
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M>>X?D=LN@[)^-_76U\_V5WGB>T]A93K_ *_WC)FJG<VSNE*#);'J-FY[L"'
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MECN2FWA\FNO^Y<!W#EJ7JW:T5-F-Q]U]I=&]A[RWCM;:T>YH:#;F)QM-\?\
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MW5!)4?SXO@@RR4R)C_Y?'S?K'65XH9IEF[5^-%#XJ:]I:N97J%?Q G1&LC@
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MRW_A21'Y-,H_F$;M\=1H;2HA!^*8E4S#E?(J6'ZK'CW[KW6!?D-_/',7D/\
M+5^&","X\#?S"MR&4Z4D=6!7XMM#ID*!1Z[ZG%[#45]U[J%5?)'^>=3U$D,/
M\L+X>UT:"/354O\ ,.R2P2ZXDD8(M;\:J.J!B=BC:HE]2G3=;,?=>Z]3_)G^
M>./+]W_*T^)TEXF$'VW\Q5HM$_&AYO+\;Y-< YN%LQ_!]^Z]T77YEUO\ZKY?
M_%3Y+?%NO_EM?&;8>.^073.\NIZ+>5'_ #!*3<%;L^IWEAGP]1N&MPLWQYQ$
M&X*:@2>5TI(ZFC=R4!F #$^Z]T8'KCO+^<7U[UQL/8"_RKN@<LVQ]C[8V<N5
M/\R7!T:Y.7;6W\;A$R9HO]E=G-)%634#S&#RR-&DBH'8J6;W7NGG,?+7^<YC
MUUT'\GSIO-BGAI99X<9_,RV"L]<\LD\-12XULW\>L%!%44VE)6-0R1>)K([R
M71?=>Z:9OFA_.?@2/3_)-V/6R&.(R_:_S/>D(D$CB42!16=/P&T;1 GD\2+8
ML=>GW7NL2_-;^<^RH/\ AD+::2-)H<O_ #/N@_#'&2@64O'U5)*P6[%P([@
M:=1-A[KW4U_F;_.8\L*Q?R4MD&*9Y5:67^9WTE&:5$56C>KC3IR8WEU:0(3-
M9@;V6S'W7NHC?-?^<U'(ZR?R0ML2IH98I*3^9UT#(&G9#X?(M3U=2/%2>6PD
MDLSHMRL;FP/NO=>7YJ?SF9()!+_)(V]2U GHS":?^9M\>JF%Z82.U>)7FZS@
M:.;QJJQ*$=7UL6>,JI;W7NEHOS._FI_V_P"2]F?HEO'_ #!OBPW.@>4-K@BX
M66X4B^I;$A22H]U[KQ^9_P#-2MZ/Y+V;U<6\G\P7XK*@Y&K4R12.++>UE-SQ
MQ]1[KW394?.+^:G2X^*ND_DD[TJI9#"#C\;\_/B345L?FFCBO(M56T, 6%9-
M<EG)"*U@Q !]U[IGG^??\U."ICIO^&+>UYP\;R&JIOGC\-7I(RD1E$4CR[EA
MG$LA&@ 1D:SR0.??NO=16_F#_P U @M%_(A[J*Z9#IF^=/PKBE+111N5T)O2
M9/W7<K&=7JTDG3[]U[K!)_,*_FKQI"X_D-]T2&52Q2/YW?"LR0V-M,X?>"*K
MGZ@*6%OS[]U[KJ3^89_-631I_D-=UR:XPYT?.SX5?MDLR^-]>\E]8TWXN+$<
M^_=>ZZ3^8=_-4.OR?R&.\$M&Q33\Z?A,^J0$:4:^^$T(PO=AJ(-N#?CW7NGR
MF_F"_P S%GH!6?R+OD3!')6RQY1J7YE?!JK>DQH5##58])NVJ%<E7.Y8/3RM
M21H ")GN0ONO=*?_ &?SY^?]Z3/EI_Z4U\ ?_NEO?NO=<6^?WS[16=OY)GRV
M(4%B$^2_P$D>P%SI1/DJSNUOH "3^/?NO=</^' OGSJ"_P##)?RZN75!_P Y
M)? C3J:+S E_]F2T! G!8G2']!.KCW[KW4FF^?WSO-5%%D/Y*GR]I*4@R5%5
M3?(KX$9&2&$:AJBIXODQ$*F8N /&'5['5]/K[KW1'OGUVE\\/F#UQT-L_;?\
MH;Y=;9RW4WS*^+/R8S;[A[E^$R8VMVC\?NX\-OG<6%Q%;C/DCD9JO<^>PN.,
M-#3R000F>75),D49=O=>Z/Y+_,%^5=*H>K_D\?/,HZUDD7\/WY\%\E)XZ5#,
MGFBA^6ZO!-4P#T(;DRVC%SS[]U[I.S?S+?DW"TT1_DS_ ,QV2:&M$%X<C\,)
M:62E0JE14Q52_+ B1U<-XD"E)5"MY%U6'NO=>A_F8_)0M+]S_)H_F31*&/A,
M%1\,*AI$XLTJR?+2E$+'^@+@?U_I[KW66;^9I\@XIO"O\G#^9I*#X]$B4?PU
M,9$A91J<?+LI'I9#JU$:18FP87]U[ILJ/YIO>='6?P^J_DW_ ,TI:O[>:M!I
M-G_%;*4'V5,FNI?^,8SY45>)%<H($5'YONZ@FT4;D&WNO=)FN_F[=T8^LJJ"
MH_DO?S:Y)Z.HEIIGH>J?CUDZ)Y(6*.U)DL;\D:O'U].2/3+!+)$XY5B.??NO
M=.>,_FX]E5$],N8_D]_S<<-23T4U0]6G1'2N7>GJ8ZJ6"*BDH\=\B)*@--%%
MY Y 4*P!^H/OW7NE%_P['N#_ +U3_P W;_TF'K'_ .Z$]^Z]UB?^;5G(TE=O
MY4_\WO3"RH^CXL==3/J?QZ?'%#W])+.O[HNT:LJ\W(TM;W7NL:?S<ZY5GDJ_
MY6?\WZAB@IWG\C_$';E>TK /XZ:&GPO<N4JY)YS&0O[8C7@NRAE)]U[I12_S
M68(*<SR?RYOYKFL1QN::+X8Y.IJ!(\22O3@4V]YH7E@U%697,3,I".WIO[KW
M4')_S::#$K.:G^7%_-IF,,LT:KC?A!N/+&H6*%I1/!_"]V5@,4Y0HFHJY>P*
M@%2?=>Z;5_G![:)(/\NG^;XH !#'^7EVT0W$I(4).[ @QJ.0/\XOX#E?=>ZE
M#^;YM,@$_P O?^;FI(!*G^7=W22I(N5)6!E)7Z&Q(_H??NO=$,V'\\<KMO\
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M(VCGD)F5N@ D>AH A);3KD4 D7*^Z]TB4_GJ? 5H7G?_ &;F%$GGIU\O\O\
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M+1PR(SAK:!(FJVM;^Z]T\?R==[;<[0Z-^37:^R)Z^OZ_[4_F&_-OL/K[.9#
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M_)?/O^:)\J_CSV=\I,O-@<GOKK#IOXY;JHZ/9?375M5E]LU>S]G;^[@QL_\
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MU-_CW[KW7O?NO=>]^Z]U[W[KW6-X]3Q2:Y%,;,=*M99 R.FB12#J4%M0^AU
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MU[HE/35(Z?-CYM5[05JI4;0^)U%'52A?L)?L=L]J5#4U&WG9_N*8Y'7.OC0
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:KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>exh1070_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1070_1.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X15117AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  'H2    G
M$  >A(   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#(Z
M,C0@,3@Z,SDZ,C0      Z !  ,    !  $  * "  0    !   #CZ #  0
M   !   $FP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !0;
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MG%EV4\G3\V65?G_]!)3OI+%HQ\.Q@).9N!)(:^_Z)<XUS+S^8B.QL"L;W_;
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MYES]KF?GI*;XP;(C8"-.<BX\?'X)OV>_<7>F),S^L7=^Z%NZ5$_;[8\?7?\
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M;W @,RXP #A"24T$)0      $                      X0DE- ^T
M !  R     $  0#(     0 !.$))300F       .             #^    X
M0DE-! T       0    >.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-! H       $  #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      UL    &
M          2;   #CP   !, 90!X &@ ,0 P #< , !? %  80!G &4 7P Q
M "  8P!O '  >0    $                          0             #
MCP  !)L                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P  !)L     4F=H=&QO;F<   ./    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   #CP    -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     $_\        #A"24T$%       !     $X0DE-! P
M    %#<    !    ?    *    %T  #H@   %!L &  !_]C_X  02D9)1@ !
M @  2 !(  #_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( *
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MIS7$"UF16[TA4US\G0F6M]3;2Q]?KN]OO?7_ %/\(AC*(L#/L>5<U\1)8V9
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M '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
M<  @ $, 4P R     0 X0DE-! 8       < !     $! /_A.6EH='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I
M9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL
M;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](C,N,2XQ+3$Q,2(^"B @
M(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P
M,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAA<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(CX*(" @(" @(" @/'AA<$U-.D1O
M8W5M96YT240^=75I9#HR-CDT149%138X1$)%-3$Q048Y1$9#-C!%-#$S13DS
M13PO>&%P34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AA<$U-.DEN<W1A;F-E
M240^=75I9#I#,C8Y,#1&0C8X1$)%-3$Q048Y1$9#-C!%-#$S13DS13PO>&%P
M34TZ26YS=&%N8V5)1#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.GAA<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @
M(" @(#QX87 Z0W)E871E1&%T93XR,#$V+3 R+3(T5#$X.C,X.C4V+3 X.C P
M/"]X87 Z0W)E871E1&%T93X*(" @(" @(" @/'AA<#I-;V1I9GE$871E/C(P
M,38M,#(M,C14,3@Z,SDZ,C0M,#@Z,# \+WAA<#I-;V1I9GE$871E/@H@(" @
M(" @(" \>&%P.DUE=&%D871A1&%T93XR,#$V+3 R+3(T5#$X.C,Y.C(T+3 X
M.C P/"]X87 Z365T861A=&%$871E/@H@(" @(" @(" \>&%P.D-R96%T;W)4
M;V]L/D%D;V)E(%!H;W1O<VAO<"!#4S(@5VEN9&]W<SPO>&%P.D-R96%T;W)4
M;V]L/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C
M.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O
M;&]R36]D93XS/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" @(" \<&AO
M=&]S:&]P.DE#0U!R;V9I;&4^<U)'0B!)14,V,3DV-BTR+C$\+W!H;W1O<VAO
M<#I)0T-0<F]F:6QE/@H@(" @(" @(" \<&AO=&]S:&]P.DAI<W1O<GDO/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z=&EF9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B/@H@(" @(" @(" \=&EF9CI/<FEE
M;G1A=&EO;CXQ/"]T:69F.D]R:65N=&%T:6]N/@H@(" @(" @(" \=&EF9CI8
M4F5S;VQU=&EO;CXR,# P,# P+S$P,# P/"]T:69F.EA297-O;'5T:6]N/@H@
M(" @(" @(" \=&EF9CI94F5S;VQU=&EO;CXR,# P,# P+S$P,# P/"]T:69F
M.EE297-O;'5T:6]N/@H@(" @(" @(" \=&EF9CI297-O;'5T:6]N56YI=#XR
M/"]T:69F.E)E<V]L=71I;VY5;FET/@H@(" @(" @(" \=&EF9CI.871I=F5$
M:6=E<W0^,C4V+#(U-RPR-3@L,C4Y+#(V,BPR-S0L,C<W+#(X-"PU,S L-3,Q
M+#(X,BPR.#,L,CDV+#,P,2PS,3@L,S$Y+#4R.2PU,S(L,S V+#(W,"PR-S$L
M,C<R+#,P-2PS,34L,S,T,S([,# S-C8R03=%.3<V1D0R.45!.4(U-S<V0T,Q
M-D8S,#8\+W1I9F8Z3F%T:79E1&EG97-T/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z97AI9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]E>&EF
M+S$N,"\B/@H@(" @(" @(" \97AI9CI0:7AE;%A$:6UE;G-I;VX^.3$Q/"]E
M>&EF.E!I>&5L6$1I;65N<VEO;CX*(" @(" @(" @/&5X:68Z4&EX96Q91&EM
M96YS:6]N/C$Q-SD\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@(" @(" @(" \
M97AI9CI#;VQO<E-P86-E/C$\+V5X:68Z0V]L;W)3<&%C93X*(" @(" @(" @
M/&5X:68Z3F%T:79E1&EG97-T/C,V.#8T+#0P.38P+#0P.38Q+#,W,3(Q+#,W
M,3(R+#0P.38R+#0P.38S+#,W-3$P+#0P.38T+#,V.#8W+#,V.#8X+#,S-#,T
M+#,S-#,W+#,T.#4P+#,T.#4R+#,T.#4U+#,T.#4V+#,W,S<W+#,W,S<X+#,W
M,S<Y+#,W,S@P+#,W,S@Q+#,W,S@R+#,W,S@S+#,W,S@T+#,W,S@U+#,W,S@V
M+#,W,SDV+#0Q-#@S+#0Q-#@T+#0Q-#@V+#0Q-#@W+#0Q-#@X+#0Q-#DR+#0Q
M-#DS+#0Q-#DU+#0Q-S(X+#0Q-S(Y+#0Q-S,P+#0Q.3@U+#0Q.3@V+#0Q.3@W
M+#0Q.3@X+#0Q.3@Y+#0Q.3DP+#0Q.3DQ+#0Q.3DR+#0Q.3DS+#0Q.3DT+#0Q
M.3DU+#0Q.3DV+#0R,#$V+# L,BPT+#4L-BPW+#@L.2PQ,"PQ,2PQ,BPQ,RPQ
M-"PQ-2PQ-BPQ-RPQ."PR,"PR,BPR,RPR-"PR-2PR-BPR-RPR."PS,#M#-#@R
M,#=%,48W,#1#,3E".3!"-S@W0T(W0S<T0D-$,3PO97AI9CI.871I=F5$:6=E
M<W0^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO
M>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\
M/WAP86-K970@96YD/2)W(C\^_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"
M$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-2
M1T(                  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
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M^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X #D%D;V)E &0
M ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,# P,# P0# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $'!P<-# T8$! 8% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@$FP./ P$1  (1 0,1 ?_=  0 <O_$ :(    ' 0$! 0$
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M\Y??]7CRU_P+_P#5#%7?HS_G+[_J\>6O^!?_ *H8J[]&?\Y??]7CRU_P+_\
M5#%7?HS_ )R^_P"KQY:_X%_^J&*N_1G_ #E]_P!7CRU_P+_]4,5=^C/^<OO^
MKQY:_P"!?_JABKOT9_SE]_U>/+7_  +_ /5#%7?HS_G+[_J\>6O^!?\ ZH8J
M[]&?\Y??]7CRU_P+_P#5#%7?HS_G+[_J\>6O^!?_ *H8J[]&?\Y??]7CRU_P
M+_\ 5#%7?HS_ )R^_P"KQY:_X%_^J&*N_1G_ #E]_P!7CRU_P+_]4,5=^C/^
M<OO^KQY:_P"!?_JABKOT9_SE]_U>/+7_  +_ /5#%7?HS_G+[_J\>6O^!?\
MZH8J[]&?\Y??]7CRU_P+_P#5#%7?HS_G+[_J\>6O^!?_ *H8J[]&?\Y??]7C
MRU_P+_\ 5#%7?HS_ )R^_P"KQY:_X%_^J&*N_1G_ #E]_P!7CRU_P+_]4,5=
M^C/^<OO^KQY:_P"!?_JABKOT9_SE]_U>/+7_  +_ /5#%7?HS_G+[_J\>6O^
M!?\ ZH8J[]&?\Y??]7CRU_P+_P#5#%7?HS_G+[_J\>6O^!?_ *H8J[]&?\Y?
M?]7CRU_P+_\ 5#%7?HS_ )R^_P"KQY:_X%_^J&*N_1G_ #E]_P!7CRU_P+_]
M4,5=^C/^<OO^KQY:_P"!?_JABKOT9_SE]_U>/+7_  +_ /5#%7?HS_G+[_J\
M>6O^!?\ ZH8J[]&?\Y??]7CRU_P+_P#5#%7?HS_G+[_J\>6O^!?_ *H8J[]&
M?\Y??]7CRU_P+_\ 5#%7?HS_ )R^_P"KQY:_X%_^J&*N_1G_ #E]_P!7CRU_
MP+_]4,5=^C/^<OO^KQY:_P"!?_JABKOT9_SE]_U>/+7_  +_ /5#%7?HS_G+
M[_J\>6O^!?\ ZH8J[]&?\Y??]7CRU_P+_P#5#%7?HS_G+[_J\>6O^!?_ *H8
MJ[]&?\Y??]7CRU_P+_\ 5#%7?HS_ )R^_P"KQY:_X%_^J&*N_1G_ #E]_P!7
MCRU_P+_]4,5=^C/^<OO^KQY:_P"!?_JABKOT9_SE]_U>/+7_  +_ /5#%4FU
M?5_^<K-*US0]&N=5\OM=^8)9X+%HXV**UO T[^H3"I4<$/'BK_%BJ<_HS_G+
M[_J[^6O^!?\ ZH8J[]&_\Y??]7?RU_P+_P#5#%6_T9_SE]_U=_+7_ 2?]4,5
M:&F?\Y?'<:OY:I_J2?\ 5#%7?HS_ )R^_P"KOY:_X%_^J&*N_1O_ #E]VUCR
MT?#X7W_Y(8JW^C/^<O\ _J[^6O\ @)/^J&*N_1G_ #E]_P!7?RU_P,G_ %0Q
M5K]&?\Y??]7CRU_P+_\ 5#%7?HS_ )R^_P"KOY:_X%_^J&*N_1G_ #E]_P!7
M?RU_P+_]4,5=^C/^<OJ5_2_EJG^J_P#U0Q5WZ,_YR^_ZN_EK_@7_ .J&*N_1
MG_.7W_5X\M?\"_\ U0Q5WZ,_YR^_ZO'EK_@7_P"J&*N_1G_.7W_5X\M?\"__
M %0Q5WZ,_P"<OO\ J\>6O^!?_JABJ3><-7_YRL\J>7+O7]2U7R^]E9>GZJP1
ML\A]658EXJT*#[4BU^+%4Y_1G_.7W_5W\M4\>+_]4,5=^C/^<OO^KOY:]OA?
M_JABKOT9_P Y??\ 5V\M?\ __5#%7?HS_G+W_J[^6O\ @'_ZH8J[]&?\Y>_]
M7?RU_P "_P#U0Q5WZ,_YR]_ZN_EK_@'_ .J&*N_1G_.7O_5W\M4\>#_]4,5=
M^C/^<O?^KQY:_P"!?_JABKOT9_SE[O\ [E_+6W7X7_ZH8J[]&?\ .7O_ %=_
M+7_ /_U0Q5WZ+_YR^_ZN_EK_ (!_^J&*N_1G_.7P_P"EMY:_X!_^J&*N_1G_
M #E]_P!7CRU_P,G_ %0Q5Z=^7\/GJ+R_&GGB>TN=?$DADEL 1 8J_NZ JF]/
MM?#BK)<5=BKL5=BKL5=BKL5?_]#U3BKL5=BKL5=BKL5=BKL5=BKJ#PQ5U!X8
MJZ@\,5=0>&*NH/#%74'ABKJ#PQ5U!X8JZ@\,5=0>&*NH/#%74'ABKJ#PQ5U!
MX8JZ@\,5=0>&*NH/#%74'ABKJ#PQ5U!X8JZ@\,5=0>&*NH/#%74'ABKJ#PQ5
MU!X8JZ@\,5=0>&*NH/#%74'ABKJ#PQ5U!X8JZ@\,5=0>&*NH/#%74'ABKJ#P
MQ5U!X8JZ@\,5=0>&*NH/#%74'ABKJ#PQ5U!X8JZ@\,5=0>&*NH/#%74'ABKJ
M#PQ5U!X8JZ@\,5=0>&*NH/#%74'ABKJ#PQ5U!X8JZ@\,5=0>&*NH/#%74'AB
MKJ#PQ5U!X8JZ@\,5=0>&*NH/#%7G'YAC_D)_Y8?\Q^I_]TV7%64Z'#):ZGK?
M*"9(;F]6:&1ZLC VD(9D)9J)ZB.M/A^+]G%4LOM(>XU2X^L64L]^UPL^EZJI
M CMHX^+(K/R#($D5C)#P99^7[7+X54GU71;R32Y([?2KJ*98D743%Q]6XNQ+
M$RSQ/S^-XN,TGUAN+?&O^JJJR[\H$O?7VIZ0NHZC)J-EZ=Q!$I,MLIMGGE:(
ML%CY>E*)5_GYJGP2XJK6FAS:5YEN[ZTTN9-,M98DC2WA7ZS*JVJQ I,TE9;?
MFC+-$R*W/TYN?'GBJ_38O.92ZCN[.1!K!6^9(Y6)A*3*9K5V81^BTUH%@BX%
MT62-G]5/4Q5;?^5-$F^K7L/ER=1/?0++;LBD);H*2/Z'/A!&:?%P^.3[>*J_
MG[1(YX+&W@TB;41;V=W!$8XUE]-G@]. %I&#5Y\2&_V>*IAI&GW:QWWZ(M6T
M6VDM/2@@EC6/_3:-2<1*6"J 5#'_ '9_+\&*H)=%C/\ I-OHUQ;^GP368&9:
MWL8#EPJ\R)V]4I(\K%?K$?[KX_L8JA7T>(:Q;3WF@3W6G>E<K9VRPQR-;1R&
MV]&)JN/3/J1W4J -^X27C^[^SBJB=%U%/,=K<WVF/J$L5M9)<7 MDF]6XB>8
MU6Z>2,PF'G;M)-Z;^IZ7'%7I*#;Z<574'ABKJ#PQ5U!X8JZ@\,5><?\ .1 '
M_*G?,'_1G_U'08JC=1TFY/G'4M5AT]A';06LRW$<(^L7$L!D9X;>7FJ_O4,<
M,OJ)\:<E_9Y*JAM-M?-Z63V&I6LDL=R8M2N/1=I%=97)N[/E((61RWQI#]GA
MRB]7%4IO/+EX;F&5='/U(W=S+!$;!9_2@>*-.#0O<41G=6X<>*+Q]7TOWF*O
M3]-4"Q@'H&V C0"V8@F.BCX"02#Q^SUQ5%4'ABK&_,5B\M_!-=V4FIZ8L3*M
MG"%8I<E@5E*LR?L517Y?NF_EY<L52+R[Y6OF\S2WFI6J<[=+9I+F6W5GGN$B
MXF2&ZY\AP:G.L7[W%7H"J  /#%6'>;]#EU/S'I@BM%XBVN8Y=3DA]18"[1M&
M4971DF7A(T+?%P;_ %\52^V'G1KR]N5MYH%U=)K:V+N6EM6@3A:SSIQX1J]'
M:4Q/-\<R_#^[Q5!ZKH-S+!K#6>C216=Q%91I9M;B25KF*X9WE/[_ (2A$+<Y
M?@:?GQ]5N&*N_05S(UD@T.<+&4_>+#%:PLYGYR2)$LC26#[!BZLZ3Q_NY4^S
MBKTZ@\,5< !T%,5=BKL5=BKL5=BKL5=BK__1]4XJ[%78J[%78J[%78J[%78J
M[%78J[%5*ZO+6TMY;FZE2"V@1I9YI"%1$459F8[*JC<DXJ@M8\R:%HME]?U:
M^BL;+O=3L$B%?%S\(^G%5S>8="31?TX]_ FC>B+H:BSJL'H,O(2^H3QX%34-
MBJ62?F-Y%CMK2ZDURT6VOV"6,QD 2=F^RL3=)&;]D)RY?LXJO;\P/)26]Y<R
M:S:QP:=Z?Z0=Y H@]8$QF7E3TPX5N!?[6*J]WYR\JVEO8W-QJENEOJ8!TZ;F
M&2XJ.0])EJ)*K\0XXJA;;\R/(5R0(=?L6#2FW#^L@7UE%3$6)"B4#_==>>*H
MR]\W>6+'6+;1KS4[>VU6\8):64KA)9F--HU:G,[C[.*KM8\U>6]%>UCU;4K>
MQEOF*644TBH\S+2HB0_$Y%1]D8JA&_,#R6M[-8'6+;Z];#E<6H:LL:_S.@^)
M5_RB..*JEIYY\G7=Y965MK5G+=ZE%Z^G0+,G.XB()YPBO[Q:#]C%5.?\P/)5
MO<36\VLVL=Q!.MK-$T@#+/("4B(Z^HX')$^TRXJWI?G_ ,E:M=PVFFZU:7ES
M<F1;>*&56:1H1RE5*?::)=Y%7['[6*ICJNN:/I%K];U2\ALK;DL8FG<1J7<T
M5 6IR=C]E1\38JHV'FGR[J%O=7%CJ$%S'8DK>^DX9H2!6DBCXD--Z,,52Z+\
MRO(,L/KQ:]9O;^J(#.LH,8E+!!&7^P'YD+Q)Y<L53?5==T?28XI-2NXK19Y!
M#!ZK<3)(03P0=7;BK-Q7]G%5!O-GEA=,N-5;5;0:9:,4NKTS1^C$P )5WKQ5
M_B7X3\6*MZ=YI\NZD]PEAJ,%S+: -=0HX,D:L.2LZ?;56'V6*_%BJS1O-_EC
M6KB>VTG4H+Z>U)6YC@;FT3*0"LE/L.*_8;XL56VGG+RK>:O)HUKJEO-JL/\
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M.4*K\>2H5:J.CJR_LMBJ-_Y4_P#E3_U)VB_](%M_S1BKO^5/_E3_ -2=HO\
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M[1?^D"V_YHQ5W_*G_P J?^I.T7_I MO^:,5=_P J?_*G_J3M%_Z0+;_FC%6
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M .5/_4G:+_T@6W_-&*N_Y4_^5/\ U)VB_P#2!;?\T8JU_P J@_*D?],=HO\
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MX8JK1>3K=&G+:C>2I+-+=)&Y@XQ7$I)]5 L2U:.O[L2^HB_:X<L50L/Y>:9
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M0Z8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J\X@_\
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M_.O_ )<G6_\ D1IW_9/BKO\ E6?G7_RY.M_\B-._[)\5=_RK/SK_ .7)UO\
MY$:=_P!D^*N_Y5GYU_\ +DZW_P B-._[)\5=_P JS\Z_^7)UO_D1IW_9/BKO
M^59^=?\ RY.M_P#(C3O^R?%7?\JS\Z_^7)UO_D1IW_9/BKO^59^=?_+DZW_R
M(T[_ +)\5=_RK/SK_P"7)UO_ )$:=_V3XJ[_ )5GYU_\N3K?_(C3O^R?%7?\
MJS\Z_P#ER=;_ .1&G?\ 9/BKO^59^=?_ "Y.M_\ (C3O^R?%7?\ *L_.O_ER
M=;_Y$:=_V3XJ[_E6?G7_ ,N3K?\ R(T[_LGQ5W_*L_.O_ER=;_Y$:=_V3XJ[
M_E6?G7_RY.M_\B-._P"R?%7?\JS\Z_\ ER=;_P"1&G?]D^*N_P"59^=?_+DZ
MW_R(T[_LGQ5W_*L_.O\ Y<G6_P#D1IW_ &3XJEZ^4]8:2XB7\V=2:2T5GN4"
MZ7RC5#1F<>A\(4G<G%4JE\@P6^LQ>8I?S5OX]4O+3ZE#>M^C09+6.4R<$!AX
M,J2L2Q Q5,I/+.IQWPL)/S;U%+UBBBV8:6)"9?[L<?0Y?O*_!_/^SBJ4?E]H
M7Y@>9[36IKG\PM7@.F:SJ&E1"."P^**RF]-';E ?C8?:Q5E7_*L_.O\ Y<G6
M_P#D1IW_ &3XJ[_E6?G7_P N3K?_ "(T[_LGQ5W_ "K/SK_Y<G6_^1&G?]D^
M*N_Y5GYU_P#+DZW_ ,B-._[)\5=_RK/SK_Y<G6_^1&G?]D^*N_Y5GYU_\N3K
M?_(C3O\ LGQ5W_*L_.O_ )<G6_\ D1IW_9/BKO\ E6?G7_RY.M_\B-._[)\5
M=_RK/SK_ .7)UO\ Y$:=_P!D^*N_Y5GYU_\ +DZW_P B-._[)\5=_P JS\Z_
M^7)UO_D1IW_9/BKO^59^=?\ RY.M_P#(C3O^R?%7?\JS\Z_^7)UO_D1IW_9/
MBKO^59^=?_+DZW_R(T[_ +)\5=_RK/SK_P"7)UO_ )$:=_V3XJ[_ )5GYU_\
MN3K?_(C3O^R?%6#^<?(GFFW_ #'\@6LWGK5;B>\FU06]Z\-D)+;T[%G<QA80
MA]5?W;^HK_#]G%65V'D[7M0>5+'\UM4NG@IZRPIICE.50.7& TY<6I_JXJB9
MORZ\WPA3+^9FLH&8(I:'3@"S&BJ*V_5B:+BJ#_PIK'Z0.F_\K9U/]( A39\=
M,]4$CD!P]#ENNXQ5L>4=;.GMJ0_-?4SIZ$A[SCIGI*5;@07]#B"'^"G\_P .
M*J%OY?OKA)Y+?\WM0E2V0R7#(-+81HIXLST@^%5.S$_9Q5J+0;R:&2>+\W[^
M2&)E261?T655I!5 3Z.Q8"JXJL_1,O,Q_P#*Y+TN 25!TH[ $D_W/@K'%6AI
M,Q56'YQWQ5CQ5JZ50FG*@_<_R_%_JXJB)/+6IQ7HL)/S<U%+XE%%JPTP25D^
MP./H5^.OP?S8JOT[RIK.ILZZ=^;&IWC1BKB!=,D(%:5/& ]]L560>6=4N%N6
M@_-O4I5LP6NB@TMO2"FC%Z0?#Q(^*OV<55K+R;K]](T5E^:NJW4B)'(ZPIIC
ME4F7G&QXP'X9%^)#^TN*J;^5-:CFE@?\UM56:!)))8C'IO()#02-Q^KU*QD\
M7*_9;X/M8JB;7R#YKNK6.[@_,S6VMI4$B2&WL%!4BM3RMP5_V6*NM_(7FJY>
M=(/S-UIVMI/1G40:?59."R<36W_D=&_U6Q56_P"5;>=*5_Y61KG_ "(T_P#[
M)\54(/(GFB>>:WA_,[6I)K?AZR+!IYXB1>2'_>>A#+TIBJO_ ,JV\Z?^7(US
M_D1I_P#V3XJAXO(_F2:ZGM(OS2U:2ZM2HN8%CTTO&9 2@=1!52X!*U^UBJ(_
MY5MYT_\ +D:W_P B-/\ ^R?%5*Y\@^:;6%IKK\S]8@A39I)(M-103L-S!BJZ
MV_+WS;=1>M;_ )FZS)'R9>2P:?3DC%6'^\_[+ C%57_E6?G7_P N3K?_ "(T
M[_LGQ5W_ "K/SK_Y<G6_^1&G?]D^*N_Y5GYU_P#+DZW_ ,B-._[)\5=_RK/S
MK_Y<G6_^1&G?]D^*N_Y5GYU_\N3K?_(C3O\ LGQ5W_*L_.O_ )<G6_\ D1IW
M_9/BKO\ E6?G7_RY.M_\B-._[)\50&A?DMK^@Z3;Z1I'Y@:S::=:@K;VZPV!
M"AF+G=H&;[3,>N*H_P#Y5GYU_P#+DZW_ ,B-._[)\54;O\O_ #59P/<7?YGZ
MQ!;QBKRR1:<J**TW8V].IQ5"_P"%-8X6SC\V=2*7C%+1PNED2LIXL$/H?$5;
MX33]K%5D7EG5);B>WB_-O4GN+;F;B)5TLO'Z7]YR4057A^W_ "XJQGSX?,FB
M^1]5\P:#^:5_JMUIRVS^@JZ<Z<;BX2$,WIPUH0[%/YN.*LY_Y5GYU_\ +DZW
M_P B-._[)\5=_P JS\Z_^7)UO_D1IW_9/BJV3\MO.D<;.?S(UPA 6(6WT]F-
M!78"WJ3BJ16^EZG=:/\ I:T_,_7[FT%R;&016-HTT=R)/1:&6$6OK1NLOP,K
MI\+8JB[OROKMG:ZI>7?YGZW!9Z."VH7#V]APC"Q"9NEN2>,;J=A^UBJ80?EW
MYON(8YH?S,UF2*50\<BPZ<596%0P(M]P0<55/^59^=?_ "Y.M_\ (C3O^R?%
M7?\ *L_.O_ER=;_Y$:=_V3XJ[_E6?G7_ ,N3K?\ R(T[_LGQ5W_*L_.O_ER=
M;_Y$:=_V3XJ[_E6?G7_RY.M_\B-._P"R?%7?\JS\Z_\ ER=;_P"1&G?]D^*N
M_P"59^=?_+DZW_R(T[_LGQ5EWEG1]2TG3%M-0U>XUNX5F8WUVL22D,:A2(5C
M2B]OAQ5-L5=BKL5=BKL5=BKL5?_1]4XJ[%78J[%78J[%78J[%78JQK7_ "]J
MEYK=KJ5G/P:WC].+E*Z+"Q?D\HC *3&6,>BR2<>*XJF6OVE[>^7;^SMHT-W=
M6TD"([E$#2H4W<*QHO+^3%6,3>5_,LT\TS6=BO)VF2,W$Y7D\R.6C81J]M<<
M58O/"W%YN$OI<\51EMH.OVT%M,D=O)>+'>031-*4%+V6.3U6E6+][*OH_O3Z
M2>LS\_\ 650-KY9\UZ?J$CVJQS6ZP06\8:\:.)Q# L1DD@$#_O3Q_=_OO@_R
MN.*IKY?T?6[=;&:^A@AGTVP^HQQ0RM()C2/XW<QQ\0IB_=KQ;CZDC8JEOEWR
MEKEI:7"ZC'',SV+6C6[W+3I)5BRHC&&(V\0Y.K?#+RY)_OKXE62^6;"[L-$L
MK6[55NXXA]:*.90TY/*5^;!&8R.6D9BO[6*IIBKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BJRXB]:"2+D4]1&3FNS+R%*CW&*L5'ES57MK.)
M[>T232!$MI*K,3<+"RMPD^ >C')Z:N5'K?ON#_[K^-58='\T1:Q!JL5I;2N\
MDTUQ;&Y:-8S)#'"JJWHOZA/I>I(_&/XF^SBJ&LO+'F:PUR*X@,;VD<<,7^]+
MQQ-22>20O;")N:1?6J6R>NO]S'R9<50'Y'_\<SS8/^_LUO\ ZB<5>D8J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%7G'GX5_-G\L!XSZS_W3FQ5F5CIU
MU!J%[=RA6-W(JIQ8_N[>&,+$E".ID,KM_+ZO[6*I9YO\OZWKLMK:P31VVGP!
MYWG/QRFY"E8>*$ *(^32+)ZG)9>'P?#BJ"71O-U]^D(M1M;.W&J06\,]S#<O
M*8FA1@\D<9ACJW)N47QKP;BV*I=/Y'\R26UVJQ6JQW-^^IM8>N_!KGZWZT<I
MD]+;C&?BC]+_ 'HBBEYXJJOY0\T7D_.>.WL9$343;W45R\Q5[ZY^L*C1F&+G
M"R_NITY_%]I?B5&Q5$#RUYF02*L%N>%S!-!,EU)%,%BL1:EXW6(^E)S13Q<3
M1R0O)&^*HFW\N:Q;-(B65EZ2Z5':PB)_1C^MH9&8K$(B(HRTS<75F?\ R/BQ
M5+(_*7G-K#3; S?5Q9RK(;X7K2W"4M9+<\*VZKZ8,BLL7_&3]Y\6*HNST#S5
M!K=O>1VL%K:P06MJMM#>R&#A!ZJLSPF#E)19N4*^JO[R->3XJCM$T370UB-0
M@M[1=/N+FY1X)FG>0W)E_=FL<7%%$W)_M<Y(X\50VB^6M>AUU]0O51(A/=RK
M&+DW">G=,3P2(PQ>D]>#/)ZC_P"[$X_O?A51&F:1K&G>4K^U2%;;4W6Z:V]"
M4S'DRL+8!Y%3XHHQ%$M5XKZ7\N*I*_E[UM4TS16M2;"WMK#T*^J2L%JS32M,
M>$<8DEG2&+AZKO\ [M9/BQ5&>;O*&NZY=2J?1FL3+$RI)/+$6M@JK+;%$4J
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M%7?XC_/+_J3=(_[C#_\ 9+BKO\1_GE_U)ND?]QA_^R7%7?XC_/+_ *DW2/\
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MQ?W:^K'Z4GP_83%4)/Y=L(H?,XM].O\ U$MO3T]J7):8RVP!X$M^];UQR/\
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MJUMO^<A[U[B9(4;RG:A6D8("?TC-L.1&*O0/TUH__+?;_P#(U/ZXJ[]-:/\
M\M]O_P C4_KBKOTUH_\ RWV__(U/ZXJ[]-:/_P M]O\ \C4_KBKOTUH__+?;
M_P#(U/ZXJ[]-:/\ \M]O_P C4_KBKOTUH_\ RWV__(U/ZXJ[]-:/_P M]O\
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MO?(6E6,5U+-;VTH6.8&6W,G-6HB</A@D=6^)?A^+C\.*H:?R1^4K:&VKZ?\
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MMJNH6M@LM1$UU-'"&*TJ%]1EY4KO3%76VO:+=6+:C:WUM<:?'R]2]BFC>%>
MJW*16*"G??%45/=6UO"9[B1(8@0#)(P506/%1R-!NQXC%4KO/.?E"RN9+6\U
MO3[6ZB-)8)KJ".13X,K.&&*IBM_9LT"+-&7N5,ENH=29$ !+)O\ &H#+NO\
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M^J">'43+Z/H)Z?J%9 O/C3GQ^'EBJ=^C_P Y%?\ +3Y1_P"1.I?]5,5=Z/\
MSD5_RT^4?^1.I?\ 53%6#P1?G8/SKNP)_+?Z>_PW 9&]*_\ JGU3Z]+Q 7GZ
MOK^KRY'EZ?I\?VL59MZ?_.1/_+3Y1_Y$ZG_U4Q5L1?\ .11Z7/E'_D3J7_53
M%7&+_G(H"OUGRC_R)U/_ *J8J[T_^<B?^6GRC_R)U/\ ZJ8JUZ?_ #D2>ESY
M1_Y$ZG_U4Q5OT_\ G(HBHN?*/_(G4_\ JIBK7I_\Y$_\M/E'_D3J?_53%7>G
M_P Y$_\ +3Y1K_QAU/\ ZJ8J[T_^<BO^6CRC_P B=3_ZJ8J[A_SD3_RT^4=N
MO[C4_P#JIBK?I_\ .17_ "T^4?\ D3J?_53%6O3_ .<BO^6GRC_R)U/_ *J8
MJ[T_^<B>]SY1_P"1.I_]5,5=Z?\ SD5T^L^4?^1.I_\ 53%7>G_SD3_RT^4?
M#^YU/_JIBK?I?\Y%?\M/E'_D3J?_ %4Q5KT_^<B:T-SY1_Y$ZG_U4Q5LQ?\
M.10_X^?*/_(G4_\ JIBK7I_\Y$_\M/E'_D3J?_53%7!/^<B"*BY\HD'N(=3_
M .JF*M^G_P Y%5I]9\HU\/1U/_JIBKO3_P"<BO\ EI\H_P#(G4_^JF*M&/\
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M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78JQK\SO\
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M5L5=_P J)\E_\M>M_P#<9U#_ *K8J[_E1/DO_EKUO_N,ZA_U6Q5W_*B?)?\
MRUZW_P!QG4/^JV*N_P"5$^2_^6O6_P#N,ZA_U6Q5W_*B?)?_ "UZW_W&=0_Z
MK8J[_E1/DO\ Y:];_P"XSJ'_ %6Q5W_*B?)?_+7K?_<9U#_JMBKO^5$^2_\
MEKUO_N,ZA_U6Q5W_ "HGR7_RUZW_ -QG4/\ JMBKO^5$^2_^6O6_^XSJ'_5;
M%7?\J)\E_P#+7K?_ '&=0_ZK8J[_ )43Y+_Y:];_ .XSJ'_5;%7?\J)\E_\
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M_P!6;RW_ ,&__91BKOTK_P Y??\ 5F\M_P#!O_V48J[]*_\ .7W_ %9O+?\
MP;_]E&*N_2O_ #E]_P!6;RW_ ,&__91BKOTK_P Y??\ 5F\M_P#!O_V48J[]
M*_\ .7W_ %9O+?\ P;_]E&*N_2O_ #E]_P!6;RW_ ,&__91BKOTK_P Y??\
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M\5=_RLC\P/\ RVFK?])FF_\ 5?%7?\K(_,#_ ,MIJW_29IO_ %7Q5W_*R/S
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MCC*W[.*HBX_*'4XX))!^8GFPE$9@#>6U*@5_Y9L51_Y3^999OR>T+S#YAO\
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MU9KV>V>\D]*_M7>9XDDB,($#VGK0\.3W'J_5$7]RG'BJ[4/R]\V2?E+I'E6
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MAQ5E/D[S/YKU.^UZ/4K6.,Z?-<1V]@(KB*1&CE=;=3))&L,J7%N(YN<<LO\
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M'@>9%DN%64NTD\LZQ>I3BOP\_P"\^WBJ*\QZG^5^I,@UV_T^1K4S1_OIU0@
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M]K%6,>;O)?F/6])FCM=-AL+BTT._T:RM(;A?3E>_CCA%&X+PM+=8N:<N,O\
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MWO8)II88XS('F:V]%&:6,^E(D_[#1MR53]/S#UM'\LSWUK;VEGJNG7^HZC&
MTTB+8(D@:!UD"%)XY1(@9>2?M?%]E5USY]\S6VDZ5J<MM:"/7K.>XLH4$CM:
MS163WZ)._-5FC>&%XVD3T.$OI_"ZMBJ8?EOYTU+S19W$]U%#Z<45I(EU;AXD
M,MS )I;<Q2LT@>WY)^]^Q,DT?#]K%4DU3S[YUT:;6_KZ:9.GE^SL+V\BACN(
MS-]>:=#%%(TC\.#P(%DDB^+G\2)QQ5E%CKVN0^9HM"U:*WD:\L9;^VGM!(BQ
MFWDBBFAE$C/RWN(S#*O'U.,O**/C\2J1'S)^88U75M,9](%QH]A9:A<,(+DH
MPNFN1(B$S@_NQ:_ S*OJ<_B]/%4GMOS6\TW.F3WB06L;0>5?\2,LUK<Q*TP4
ML84+RCE#M_?+BK-O*6MZWJ^GSW%V(HF/%;8FVFMR'],,W.&61F:,%TX,'3U/
M\G[6*L,T+\W-9N;?2;[4K>**RGT?4M9U+T[6X0A=.,7P6TDDI27FLU2WQ?8_
MXL^%5,=<\_\ FK1](MK^YMK/GJ>FW5]:1(LKBVGM+0WIBG?FOK1/&C1^LGH\
M9>/[IU?X55_F'SQYITORY>ZO&+&1[/0DU@PM#-1IC4M'435"47;;EBK(O)GF
M*\UNVOI+A8FCM;M[:VO8%:..X1%4LWHR%I86CD9X'21OMQ,Z_ V*I59_F!+J
M'F;7-"M/JZM:6CSZ5<-RDY2VTC072SQJP*B*;TJ+R1GC?E_JJI58_F9KU_IC
MRB"TT_5[+2+K4-4TF</,\<L"QO"Z2)+&&M;I)><4G']ED;]ZLB1JISY7\X:O
M>:CI^GZK';M)JND)K-I-:J\:HH:))H9$D>0U5KB,QR*WQKSYI'Q7FJE\/GSS
M%#/?W%['9RZ;8>8(M DCA22.<BY,$<,X9I)$)66Z3U(^*_NU=U?E^[Q5''S^
M\GGB7RS;+;L&M9Q:S,YY?7[8)(\4BK4K$8I:JU/]TSXJIZ%YE\WSZ[JUGJ4F
MFBST&:!-1DBBGC9HYK%;IGB9I9 /3D=5HZ_'%R;X7^'%4;Y!\[?XG351(D44
MVGW02-86YAK:>-9K>0G<<^#F.4 _#-%)BK'M5_,OS!81ZZMQ!:65]I]GJ-]I
M]C<QS'ZQ%8J)(GAG5Q#=I-$&:;T3'+9LR+)&_P!IE5.Z_,CS;#!83?4XOJUW
MJ LH[L6=TQGB;3I+UI(+4R)-6&2%K=N3-')R]5'7TW7%6167F7S#?Z@-(MUM
M(]0M;"VU#4)9$F,9%Y)*D$<<88,E1;R&5VD?TOA58Y?M8JQK4_S%\[:??W=K
M/#8*]E>Z/8S1QP7$[<M553(4XS*9/08D(%3]]_D8JLU[\R_.6F6=Q<I%8D0Z
M!-KZQRV]PCL(Y@B0NOKUC9HW4O\ ;X2<E^/%4WN?.'FR./1S']44:KK+:4KW
M%I<0NL:PS.9# T_)6]2V<*"_QQNC?!QQ5,++S=JEYY6UR[6*"+6-"DO+6>H=
M[:2>S7F74!ED$<JE?A9N<?+_ '9QY.JE&G_F9JVHZCY5T^*SMX+C4I;BV\P\
MV:3ZK<VL,[O!$%*\F9[2;XW^Q%Z4GIMZF*IM#Y]6X\^2^6(O1$1MIOJ]QR+.
M+RU*&:-XP1\'IS*4^QR]"XQ5;Y?\R^:+W5YM&OHK:+4-+G<ZLT<4@B:SD%;.
M6W)E8\KCX_M\N'HSHWV8VE52_4OS UVS\^R^74AM;B)9=.6WMPDJ3RQWQF$S
M"8N8%:U2!KCB4Y3QJZ)\>*M:=YZ\UW6N:Y816MM<?H>YO(8XO2EMTF2WMX9(
MU^N22/#'-)+<QH5]-E6-9)/A^%<50L?YE:_(+&%?J:W\NJ6.G7]I-;W,%Q +
MU7+%[>20,G%HG]&0/+#<)\:-BJ:S^;/,L6LZ99ULS!?ZW/I3GT90ZPPVLMT'
M!]:GJ'T/3^SQ^/EQ^'BRJMYDU_S98ZWI=M92:=]2UC4#I]J9(II98^%E/<.\
MA66):^K;F/TU'V&Y<^?P8JOU;S!YHL];\L:0OU)9]9CN5O7,<LB)/;6_JDQ?
MO(R8F?X?C'/CBJ7^4?S!UC7+S2K&\M[?3M2DMGN-5TX\I'*<4:"XMI Z_P"C
M7 >JLT;\&22!_P!ZC8JMT_S]KDWGBZ\NLEI.L&I26/IQ)+%*ELMC%>"[9W=H
MI/3DG2WDA3]Y\:3?"OPXJWY3\Z>:M:2_,J6L9LQ?H7^JW$<9>UNYK6%D=IF6
M8-]69YD7AZ?-5]3%4KLOS*\WW3^78UBL_4U_1;;55].UN95CGNIH8EB=EF^"
M!?K YSM]GA]AOLXJR>#S)YAU:35VT.*T]/2KM]/$5SZO*::%4:5N:E1$BE^*
M?!+ZG'[4?+%4CNO-_P"84$_F&"NDM)Y<L[>]NOW%SQD$UO-,ZQ_OZ_ \ 5"P
M^-6_8Q56LO/WF6^TC4M0MK>S_P!P5G;7-^'$H%Q--9I?R0PT<F!4MY8E29_7
MYRO_ ':^G\2J@/S-UHW,UI-;6]B;NXM!H%Y.K-'<1W202R6TD8D1DOK>.Y#\
M?4XSHKO$OP2<%64:OY@U!/,5AY=TY(A>WEK<7TUU.&>.*"V>*+:-61I'DEG1
M:>JG!>3_ !?9Q5A[_F;YI?4K.PBM;>*::._AG M[BY47FG:A%I[,&22+A9RO
M-ZOJR+RB1?VVQ5E7FSS%K&@+8ZI(MO\ H))$CUUN#O-"DGPB:,AU#1K(561?
M39^#>HO+[.*H:'S)YHGU6V\OA+2#67L'U.[FDCD,,,;3>E;P^DLO)Y&H_K.)
MN">G\//FN*I1HWYC^8-6O9XX[>UM8XM'N-0,<B2R.+FUNI;-UY"1.<#26[21
MMP1VC9?LXJLF_,;S);>98=(>.RN7EATF:*VCBFBEF.I23).$E:5X8S;);M<*
M)/[Y.4:_'\6*LJUOS#?0Z[IF@Z;'$;W48KJZ:YGJT<-O9^DKMZ:LC2.\EQ"B
MKZD?[4G+X.+*L/G_ #-\T?I&TL8[2!)6_25M>%+:XN0;K3+BWM_4CX2Q<;6;
MZT&Y2?W'!EY28JC;+SKYON/,&KZ04LU;2[AX3*+2Y,)5+&"Z),WK!/4#W/!8
MN/QHG/\ =\L52JU_-+S7+Y2TWS#)':017LVDP3+)9W2\#J?IF1HE]8M/'$LZ
M\)%X^JR.O']K%6?^3M;O-;\NVNIW<*0RSF3B8FY1RQK(R1SI4EE2XC59DC?X
MXU?@_P :XJ@?-OF36-)UKR_9V,4,\.JS7,4\<BGU:6]I+= 1/ZB(K/Z/I_O!
MQ7ES_9XXJQZ'SOYH;\O]#\T/%";G6[S2BMB(Q5+;4IXHFA1Q+Q:2DI,<S\./
M^[8N2XJF-G^:EC=7XL$TRZ2ZDY)!&[0#U)H+SZC=0I20\GM)OBFI\'H\949^
M>*IE>^=8(/,,V@&PGDO8UM98N!BI+'=F4<XPSAB(?J\OJ\N/V?AY8JQ.[_.2
M6T\JV]Y::9/J>H-H]GK#S,L-K!Z=Y*8070S2.CAU^**/U?\ C)^UBJ;7_P";
M^A:=+=I?V=U +&6\@N&"QR4DL8()V"A');U5NHUC_P OESXXJG,OG>RA\M_I
MR>TNH4]9+5;*6)HYVN)9UMHHU$G!:2S.BI+R]+BWJ<^&*I+#Y]U'6/,VE:1I
M5L;6*5;]]3FN DC1RZ7<PV]Q;<%D7]J?:>-G_P!ULBNOJXJD\OYO:G;:U.^H
M::8M"LCK*7(AX23D:5=VMN)PQD4<>-PW.'ASY<>&*IT/S*LK&SN;F\26;CJU
MYI<0X16X#6SD+'S>8Q,[_9A+R1-<?[[1O@Q5G8Z8J[%78J[%78J[%78J[%7_
MTO5.*NQ5V*NQ5V*NQ5V*NQ5V*I;<>7M+N-9M=:E1SJ5E')#:S"6552.8@R+Z
M8<1-S*)RY)^PG\BXJ@U\D>75O+F\6&83WDXNKH_6KKA).J+&LC1^KZ?-$2,1
MGC^[]./T^/!,5;C\D^78Y=)F2V82Z'%);Z6QFG;THIE"2(0TA$@=57EZOJ?9
MQ5+]3\J^1+6RBT:_3T;'5F.GVUE)<W 1_45I&MH$]3]TKHC<HX?33TTX?8^'
M%4V_PKHYL;RQ=)9;?4$]*\]6XN))'CX\>'JO(TJIQ)'%7X_$W\S8JA3Y \JM
MIEQIC69>SN[=;.Y5IIVD>U0$+!ZQD,PA%6_=!_3^)OAQ5;#Y2\KW05E5[F2U
MF)BN3=7$LT,T:-"0DQE:6-HU>2/BCKPY/^URQ5T?Y=^3HV<KIJ%)+46$D#M(
M\+6RL7$;1,QB/[QFEY<.?JLTO+U&9L55%\B^6UBN(Q!+_I0@6XE-S<F9UM26
M@4S&4R\(F9F1.?#DV*J-[HWDY-:AMITB@U75+A=1CC222*6YN-/10)F$;+ZO
MHH8^7J<E^QSY<5Q5=J'E/RI;Z=Y@EO(62RUE7GU\^M<<956+@[,%>JCT4]-U
MBX\XU]/[.*KW\F>7+M[*\*7'JVEJ;2SG2[NXW6VDXLR!DE5CSX1\F;XVX)R^
MSBJD?)GD^VU'UWMD^M7SQ-Z,DTK1RO:+6*EN\AB?T$3E'^[_ '7#EBJ93^7=
M+GUFUUJ5';4K*.2&UF]650D<Q!D7TU<1MS*)SY)\7!/Y%Q5+[S2_*3Z_%;W,
M<7Z6O0;T6A=U^L?5&C7ZP\(/I2M"QAXR2HS)^[Q5?;>1?+$#&2*U996NVU$2
MF>=I%NG%'E1VD+H9%/&0*>$B?!(K+BJ-U#RYI6H:A8:A=QL]YICM)8R++*@C
M=U*,>".J-R1F1N:M\#<<52X?EYY5$@E%M+ZBWQU0'ZU=?[VE>!G_ +W[?$E?
M]7%41I7DS0-*F$MC%+&5DFG5'N+B5!-<LSS2".61T]21G<L_'E\;_P V*K9?
M(_EN2:]G>U9I[^XCO+F5IK@M]8@4+%-&?4K#(B*L:M#Z?[O]W]CX<52@6OY>
M>7KN2V>;T9@9[F6UFN+JX0O<U:=_1D>6-II?59F7AZS+(S_8;%4</(OE*]TC
MZBUN\VES1H(X3<W+((5(=$C/J_NXJJC<(RJ? GP_ N*JMUY)\N.T-S.D[2VD
MK74-PUY>>HDIA,)D]7UN>T):,<F^!&?C]M\57>7](\KS>4;6QT1O4\MW%L%L
MQ%-*RFWD&PCE+^J$*GX:/]G%4QL]"TJTT6/1(;=3I44/U5+24M,GH <1&?5+
MEDX_#Q8_9^'%4BD\K>1=0DU'R^\:W,P@@34K7UYVF6UD+F"-G]3U$@9HY"D*
MNL?P_8Q5D-SI5C=6#Z?=Q+<V<D?HRPSUE#I2E'YEB_3JWQ8JQ_7_ "UY)MM,
MD_3*B.SN9[5)KB:XN \DJ3 6D;3>IZS!)W7T8N?!)/V<53B;RYI<^KV>L2I(
MVHV$4D%I/ZTP"1R\3(O .(WY\$Y\U;EP3^1<52AM!\GVNKWTK/)#?2/'J%^'
MN[I(VDD_<0S.IE$/+]SZ<7^^_3CX<>,>*M6OD#R/)IZ6,%BDMC;)<683UII!
MZ4KD7%N[>H6>+U!\<$C-&LG['/%47:6'E>SU.[T6W<1ZGJ,'UJZB]:5KJ2W2
MD ?U&<S"..HCCXNOI_[KQ5M?(WEI=/TK3UMY%L]#=9=*A%Q< 0-&I5"").3<
M$)1 Y;@GP+\.*M6_D3RQ;:A!J$%HT=Q:-.UJJ33B*/ZR>4X2 2>BJRD5D18^
M#?RXJAM+\N>2-3L9FTZ..>SI<:=6"67A$JOZ=S;P4?\ T=><?"5(/3^SBJJN
MD^4?+<^GR+PL9YEBTFP+2R\I@ S0VYY,WK&-0_H^IS:)>7#BN*HW_">A'4;_
M %%[;U;G5(5MM0]5Y)8YH4Y!8VA=FBXJ'>E$_P!V2?SMBJMIGE[2=,E>:T@X
MSR(L33.\DK^DA)2-7E9V6)"S<8U/!?Y<549?*>B2W^H:@T4GUO58$M+Z03SC
MG!'RX)Q$@5.'.3CZ81E]23^=L52\_EKY/]'T/J<GHFP_1/#ZU=4^H?\ +-_>
M_P!U_DXJFFG^7-,T^.5+42@31K"[///*XC0$(J/+([QA>1X^FRXJDO\ A?R)
MY<DT>1D%G]7)TO2%EN;AD!O6%;=$>1E?UF5?@96^PO\ (N*II:>4/+UH3Z-D
MG'T6M4CD+RQI;R4YP1I(S)%"_%>44:K'\.*J,GD3RS+H]QH\MJ\FG742V\T+
M3W#%H$%%AYF0R+"/]]*ZQ_Y.*HRV\N:7;7%S<P1M'/>1)#=2+++641KP5W^/
MXI@GP_6#^_X\?WGPXJDUKY8\DW\\%M: R3^5EDTZ'TKJX$EI]8A0R1,RR!BS
MPM$?C9V^QBJ\>7O)$U_+HPBB?4K?3!9S1B67ZTNF7#GC$\H;UO2=X6X\I/V6
MQ5,](\L:+HP+:?;^FXB2 2N\DTHAB_NXA)*SN(DJ>$?+@N*H'3_*GE&"275;
M:)9"US)>R3/<37$0N@/3DF"R2/$LRA/3]15Y)QXXJIZ5Y:\GZGI6BWEB#=:?
M9S'5-&N$N;AAZDX9C,KF3E)ZBS2?WA=>,CK]EL514_D?RY/^E?5@D/Z<*-JM
M+BX'K&,!4^S(.'%45/W?#]VOI_8^'%47#Y;TF'7)]=CB9=5N8([6XN/5E(>&
M$EHU,9<Q_ SN5;AR^-_YVQ5+I?RZ\GRV\UL]A_H\\<\+PB68*J7;<KD1@./2
M^L'^_:/BTOV7^'%45>^4-$O8].CN8YF726#Z<5N;E&B81F+ES2169_3=TYN6
M;B[?S8J@TT3RA<ZJ=-B-=4TJ!?5$-S/'<QP7;LX]:1)%ED2:2)W_ 'KO\:L^
M*H>Z\D^0VU"6:>,)=&>TEE O)X@)XCQLOW:S*JLA'&W7A_QCQ5':YY"\L:Y<
M37.JVSW$UQ;&RG(N+B-7MF;DT12*1$X,P#,O'XL5=<^1/+MTT+W$=Q)+;SBZ
MAF:\NS*LPC,2N)/6Y_"C.J#EQ3G)Q_O'Q5&CRUHXTB31TMQ%ILRNLT$+/%S$
MI)D)=&63E(Q8R-RY/R^+%4(/(_EH7UO?+:%+RUG-W%.DLRL9VA6W:60AQZTC
M0*(F>7FS)]K[38JELVE>0K/2;?4KAQ#I?E>XN;J"\EN;D"VG5Y$N'9W?E)\3
M2HWJ>HO%W3[+8JG=GY?TJUU2[UF"-EU#44C2[F,LK"1(J^F.#.8UX<FX<47C
MS;^;%4LM?+ODK77U+4X%6_:_?ZI?S+/,ZF2PE9551SXQR6LP?TWB"/$_+@V*
MKO\ E77E/TKN.2UDF@OG>6^@FN;J6*>22+T7>6.25D=VC 3DR_R_RXJIQ^7_
M "2U]=Z)Z:/J++;WUQ$TLK72QPL4MI5E+F:)(G1U@]-T]/X^'VGQ57NO*_EF
MZGLK:96^LZ>SWEFJ75Q',CR!HGG)259'=A(\?JR%V^-EY?%BJQ-$\H7FHV^F
M*W._\MNE[#;I<3B2W>Z$BI-)22LCS+Z_Q3>HS\I?YVQ5,=2\L:3J5_::A=I(
MUY8>H+.9)IHC'ZJ\).(C=%JR_"6IBK5EY6T.RELI[>U5;G3[=[.SN6+22I;R
M,K-#ZCEG:/DB'B[-QXXJACY%\M,]U(ULYDO;I-0GE,\_,7<:A%FC?U.4,@C5
M8JPF/]U^Z_N_AQ53M_R^\K6]L]K';S?5G,S>BUU=LH>X<RS.H:4\)))&9FD7
M]Y\;_%\;8JA]:\N>2;2YL[O4!]2DE2+1;)H[FXM5,<S!8K2..&2-.+LJ_NU7
M]G%4?<>7/+D-^+QXE@GNY(U=5E>&*>2,4B#PJZPS2*J_#SC9N$:_LQKBJDOE
M3RSJ!U&^5&F&OP)'?S1W,Q2X@"D(!QDX!.#,J^EQ^!F_9=L57_X&\L>BD!L@
MT*PI;.ADE(EABJ(XIZO_ *1&E?@6?U..*JTOE'0)C,;BU%P9KN+4&]=Y)0MW
M 5,4T8=F$+IP0+Z7#X5X_9Q59-!Y<UV\F@+I<7VCR^E*\#O'/;2RQK(4]6(I
M)'ZD3H657^)?M8JNM?*'EZTU*TU&UM?0N;&W>TM3')*J)!*P>1/2#>D>;JKO
MR3DSJK_:7%43KN@Z9KNGRZ;JD1GL9J>K 'DC#<3R%6C9&I4?9KBJ7ZQ;>6#?
M6%KJ#@:BRM#8.)9DN>+TY)ZT;"7A)P'+U'XRNO[3XJK2^3O+LGU6EFL0LX/J
MEN(&> "V)!,#")DYP?"/W4G*/_)Q59=>2/+=U=7UU<6GJS:C#%;7?*68HT5N
MQ: *G/A&8'9GA>)4>)V9XV5FQ5&7OE_3+U+9;F,R/:;VL_.19XR5X$I.K"96
M9?A=O4^/]O%4!'Y8\L6>JZ;<QQ+;7MHDUOIH2:2,!9OWTZK$'X2-(4]6;DCL
M_#F_V<55T\M:'8KJUP@>$:LQGU65KB<!V$8C,G(R?NJ1(J<HO3XHBK^PN*I)
MIOE'R!?P+86(:Y@T26W@2%+V[=;62W5)[=$_>_!Z:O#*BI_Q4W[*XJG]EY8T
M:QOFO;2 P2N\LI1))1%SN.)E80\_15I&0.Q6/[?)_MN_)53\P>7]$U&2VO\
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M>\^?%55?[QX_W2R*HJS_ #6G@GM8-5TP"2]U>\TR%[656"QP:F--CD9& ?\
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M]##_ )/_ /5]?_I!O_\ LGQ5W_0P_P"3_P#U?7_Z0;__ +)\5=_T,/\ D_\
M]7U_^D&__P"R?%7?]##_ )/_ /5]?_I!O_\ LGQ5W_0P_P"3_P#U?7_Z0;__
M +)\5=_T,/\ D_\ ]7U_^D&__P"R?%7?]##_ )/_ /5]?_I!O_\ LGQ5W_0P
M_P"3_P#U?7_Z0;__ +)\5=_T,/\ D_\ ]7U_^D&__P"R?%7?]##_ )/_ /5]
M?_I!O_\ LGQ5W_0P_P"3_P#U?7_Z0;__ +)\5=_T,/\ D_\ ]7U_^D&__P"R
M?%7?]##_ )/_ /5]?_I!O_\ LGQ5W_0P_P"3_P#U?7_Z0;__ +)\5=_T,/\
MD_\ ]7U_^D&__P"R?%7?]##_ )/_ /5]?_I!O_\ LGQ5W_0P_P"3_P#U?7_Z
M0;__ +)\5=_T,/\ D_\ ]7U_^D&__P"R?%7?]##_ )/_ /5]?_I!O_\ LGQ5
MW_0P_P"3_P#U?7_Z0;__ +)\5=_T,/\ D_\ ]7U_^D&__P"R?%7?]##_ )/_
M /5]?_I!O_\ LGQ5W_0P_P"3_P#U?7_Z0;__ +)\5=_T,/\ D_\ ]7U_^D&_
M_P"R?%7?]##_ )/_ /5]?_I!O_\ LGQ5W_0P_P"3_P#U?7_Z0;__ +)\5=_T
M,/\ D_\ ]7U_^D&__P"R?%7?]##_ )/_ /5]?_I!O_\ LGQ5W_0P_P"3_P#U
M?7_Z0;__ +)\5=_T,/\ D_\ ]7U_^D&__P"R?%7?]##_ )/_ /5]?_I!O_\
MLGQ5W_0P_P"3_P#U?7_Z0;__ +)\5=_T,/\ D_\ ]7U_^D&__P"R?%7?]##_
M )/_ /5]?_I!O_\ LGQ5W_0P_P"3_P#U?7_Z0;__ +)\5=_T,/\ D_\ ]7U_
M^D&__P"R?%7?]##_ )/_ /5]?_I!O_\ LGQ5W_0P_P"3_P#U?7_Z0;__ +)\
M5=_T,/\ D_\ ]7U_^D&__P"R?%7?]##_ )/_ /5]?_I!O_\ LGQ5W_0P_P"3
M_P#U?7_Z0;__ +)\5=_T,/\ D_\ ]7U_^D&__P"R?%7?]##_ )/_ /5]?_I!
MO_\ LGQ5W_0P_P"3_P#U?7_Z0;__ +)\5=_T,/\ D_\ ]7U_^D&__P"R?%7?
M]##_ )/_ /5]?_I!O_\ LGQ5W_0P_P"3_P#U?7_Z0;__ +)\5=_T,/\ D_\
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M11F!_:.*HBYTG3+JWFM[JTAGM[@@W$,B*Z2$  <U((:@1?M?RXJHP^7M"@$
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MG_57%7?]"K_D?_U8'_Z3;S_JKBKO^A5_R/\ ^K __2;>?]5<5=_T*O\ D?\
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M_P XU:>UR+S3&C2Q!-],+K4'B@HH<B:5':*(\"&XR.K<67^;%56\_P"<?_\
MG'.TG^KS:/(;@1K*\45QJ,S)&]>+R")W,2-Q;BTG'EQ;^7%6HOR"_P"<;I=1
ML].CTY6N]1@:ZT]1>WO"XA0 LT$GJ^G+Q4AF6-V94^/[.*H:\_)+_G&BSN9;
M:YTF=)X&D26,2:JQ!B19)#\):JI&Z.SK\'%T^+XUQ507\G_^<7C:?6QILOU?
M_12)/4U7=;YBEJRBM62X=2D3K\+-\/[2XJG&D?\ ..?_ #CUJ\4LNGZ.TRV\
MK07"_6[Y'CE0 M'(CR*\;@,K<75?A96^RV*K[;_G&W_G'ZZGNX+;1_6FL)1!
M>1I?7C-%*460(X$VS>FZ-_LL52V[_)#_ )QEM!*]QIYC@@D,,MT;G43;K*']
M,Q^N',/J>I^[X<^?J?!]K%4-'^4'_.+LCA5TV8$I;R_$^K*!'=N8[>1BU L<
MK@JCM\#8JC)?R*_YQIBOFLI--*W"W"69_P!*U#T_K4O$);^KZGI>NW-?W7/U
M/\G%5:[_ .<?O^<=+25X;G1WCG1UB]$75^[M(Z&41QHDC/*XB'J,L:MQ3XL5
M4KC\B?\ G&NWTF[U>;2V2PT\D7\AN=0Y0$ ,1-$']6*BL&/-/L?']G%6D_(G
M_G&QK74+D:5((]*4/J2-<:DLL",O-6DA9Q,$9/B5O3X\?]7%6]/_ "'_ .<;
M=0F@@MM)D]:[C]:T2:XU* S)3ERA]9X_5HOQ?N^7P_%BJA:?DK_SC+=R1)!I
M4[>O<M8QNTFJI&;E&9&A]1RJ+(KHZ%6;[:\<5;M_R3_YQDN+\V$>FN+H7+6/
M&2XU*)3=*O,P!Y'6,S<#R$?+DR_9Q56N?R)_YQJMKR2TGTTI-%+%;RGZWJ!C
M2><J(H6E$AB69_43C$7]3XU^'%4Y'_.+'Y''_IGW'_1Y>?\ 57%6_P#H5?\
M(_\ ZL#_ /2;>?\ 57%7?]"K_D?_ -6!_P#I-O/^JN*N_P"A5_R/_P"K _\
MTFWG_57%7?\ 0J_Y'_\ 5@?_ *3;S_JKBKO^A5_R/_ZL#_\ 2;>?]5<5=_T*
MO^1__5@?_I-O/^JN*N_Z%7_(_P#ZL#_])MY_U5Q5W_0J_P"1_P#U8'_Z3;S_
M *JXJ[_H5?\ (_\ ZL#_ /2;>?\ 57%7?]"K_D?_ -6!_P#I-O/^JN*N_P"A
M5_R/_P"K _\ TFWG_57%7?\ 0J_Y'_\ 5@?_ *3;S_JKBKO^A5_R/_ZL#_\
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MQ'*CN49B8TM)&MI)/Y()N7[38J]"OM"\DZCJND7,L-I->6P>33518VJI"MS
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M>Y];T2W#U?3IS]/G\'.G'EBJN/SPT8]/+/FC_N"7?_-.*M_\KOT?_J6?-/\
MW!+S_FG%7?\ *\-'_P"I9\T?]P2[_P":<5:_Y7AHW_4L^:/^X)=_\TXJ[_E>
M.C?]2SYH_P"X)=_\TXJ[_E>.C?\ 4L^:/^X)=_\ -.*N_P"5XZ-_U+/FC_N"
M7?\ S3BKO^5XZ-_U+7FC_N"7?_-.*N_Y7CHW_4M>:/\ N"7?_-.*N_Y7CHW_
M %+7FC_N"7?_ #3BKO\ E>.C?]2UYH_[@EW_ ,TXJ[_E>.C?]2UYH_[@EW_S
M3BKO^5XZ-_U+/FC_ +@EW_S3BKO^5XZ-_P!2UYH_[@EW_P TXJW_ ,KPT?\
MZEGS1_W!+O\ YIQ5K_E>.C?]2UYH_P"X)=_\TXJ[_E>.C?\ 4L^:/^X)=_\
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M?\KOT?\ ZEGS3_W!+S_FG%7?\KOT?_J6?-/_ '!+S_FG%7?\KOT?_J6?-/\
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M)9!96]6I1))/58R10EN03X&;^?%5>Y\KW5QY3M] :[0F%+>.2X>WYI(ELRL
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MKL5=BKL54Y_4],^G024/ FM.5-JT[8J\[$?_ #D30?O/*'_ :G_S7BK?I_\
M.1/\_E#_ (#4_P#FO%7>G_SD3_/Y0_X#4_\ FO%6$!?SL_Y78XY^6OT]_AI:
MGA?_ %/ZI]?:FW+U?7]6O_%?I_Y6*LW]/_G(G^?RA_P&I_\ ->*N]/\ YR)_
MG\H?\!J?_->*N]/_ )R)_G\H?\!J?_->*N]/_G(G_?GE#_@-3_YKQ5WI_P#.
M1/\ OSRA_P !J?\ S7BKO3_YR)_WYY0_X#4_^:\5=Z?_ #D5_OSRA_P&I_\
M->*N]/\ YR)_WYY0_P" U/\ YKQ5WI_\Y$_[\\H?\!J?_->*N]/_ )R)_P!^
M>4/^ U/_ )KQ5WI_\Y$_[\\H?\!J?_->*N]/_G(G_?GE#_@-3_YKQ5WI_P#.
M1/\ OSRA_P !J?\ S7BKO3_YR)_WYY0_X#4_^:\5=Z?_ #D3_OSRA_P&I_\
M->*N]/\ YR)_WYY0_P" U/\ YKQ5WI_\Y$_[\\H?\!J?_->*N]/_ )R)_P!^
M>4/^ U/_ )KQ5WI_\Y$_[\\H?\!J?_->*N]/_G(G_?GE#_@-3_YKQ5WI_P#.
M1/\ OSRA_P !J?\ S7BKO3_YR)_WYY0_X#4_^:\5=Z?_ #D3_OSRA_P&I_\
M->*N]/\ YR)_WYY0_P" U/\ YKQ5WI_\Y$_S^4/^ U/_ )KQ5WI_\Y$_[\\H
M?\!J?_->*N]/_G(G_?GE#_@-3_YKQ5WI_P#.1/\ OSRA_P !J?\ S7BKO3_Y
MR)_WYY0_X#4_^:\5=Z?_ #D3_OSRA_P&I_\ ->*N]/\ YR)_WYY0_P" U/\
MYKQ5WI_\Y%?[\\H?\!J?_->*N]/_ )R*_P!^>4/^ U/_ )KQ5WI_\Y$_S^4/
M^ U/_FO%7>G_ ,Y$_P _E#_@-3_YKQ5WI_\ .1/^_/*'_ :G_P UXJ[T_P#G
M(G^?RA_P&I_\UXJ[T_\ G(G^?RA_P&I_\UXJ[T_^<B?]^>4/^ U/_FO%7>G_
M ,Y$_P _E#_@-3_YKQ5WI_\ .1/\_E#_ (#4_P#FO%7>G_SD3_/Y0_X#4_\
MFO%7>G_SD3_/Y0_X#4_^:\5=Z?\ SD3_ #^4/^ U/_FO%7>G_P Y$_S^4/\
M@-3_ .:\5=Z?_.1/\_E#_@-3_P":\5=Z?_.1/\_E#_@-3_YKQ5WI_P#.1/\
MOSRA_P !J?\ S7BKO3_YR)_G\H?\!J?_ #7BKO3_ .<B?Y_*'_ :G_S7BKO3
M_P"<B?Y_*'_ :G_S7BKO3_YR)_G\H?\  :G_ ,UXJ[T_^<B?Y_*'_ :G_P U
MXJ[T_P#G(G^?RA_P&I_\UXJ[T_\ G(G^?RA_P&I_\UXJ[T_^<B?Y_*'_  &I
M_P#->*N]/_G(G^?RA_P&I_\ ->*N]/\ YR)_G\H?\!J?_->*N]/_ )R)_G\H
M?\!J?_->*N]/_G(G^?RA_P !J?\ S7BKO3_YR)_G\H?\!J?_ #7BKO3_ .<B
M?Y_*'_ :G_S7BKO3_P"<B?Y_*'_ :G_S7BKO3_YR)_G\H?\  :G_ ,UXJ[T_
M^<B?Y_*'_ :G_P UXJ[T_P#G(G^?RA_P&I_\UXJ[T_\ G(G^?RA_P&I_\UXJ
M[T_^<B?Y_*'_  &I_P#->*N]/_G(G^?RA_P&I_\ ->*N]/\ YR)_G\H?\!J?
M_->*N]/_ )R)_G\H?\!J?_->*N]/_G(G^?RA_P !J?\ S7BKO3_YR)_G\H?\
M!J?_ #7BKO3_ .<B?Y_*'_ :G_S7BKO3_P"<B?Y_*'_ :G_S7BKO3_YR)_G\
MH?\  :G_ ,UXJ[T_^<B?Y_*'_ :G_P UXJ[T_P#G(G^?RA_P&I_\UXJ[T_\
MG(G^?RA_P&I_\UXJ[T_^<B?Y_*'_  &I_P#->*N]/_G(G^?RA_P&I_\ ->*N
M]/\ YR)_G\H?\!J?_->*N]/_ )R)_G\H?\!J?_->*N]/_G(G^?RA_P !J?\
MS7BKO3_YR)_G\H?\!J?_ #7BKO3_ .<B?Y_*'_ :G_S7BKO3_P"<B?Y_*'_
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M5KSE1HHK4\OADB F,?J_S_R/Z6*H26"=_*=IH\6@7BM%=I<2-+;.R1TO5?\
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M[_E2R?\ 4\^;_P#N+O\ ]4\5=_RI9/\ J>?-_P#W%W_ZIXJ[_E2R?]3SYO\
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M3_J>?-__ '%W_P"J>*N_Y4LG_4\^;_\ N+O_ -4\5=_RI9/^IY\W_P#<7?\
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M3%4E&L_D>&U%_P!-:#RU<4U,_I"VK<#_ (M_>_%L./\ J_#]G%43H7FK\G-
MLA8Z+KV@Z?8JQ=;6"_M4B#-U*J)*+7_)Q5B:^??(W_*^WU'_ !%I?U ^54M_
MK?UVW]'UAJ+/Z?J<^'J</BX5Y<<59]_RL[\N/^IKT;_N(6O_ %4Q5C^HZK^3
M.IR7+:GYGTF]CNI[:Z>WFU.V:)9;-@T+1J)!PW7XM_C7X6^UBJ&2X_)I+B2Z
M7SC9"Z>_?5%G&L6X=+J6!K:1D(?X0\#>D5^S_+Q?XL54(8/R*@M8K6#S1I\4
M4,%G;1TUF(FFFS&>S<EI3RDMY&)1F_U67[.*J=S8_D3<VLEO)YJL:2M=M-(-
M:C]1S?S1W%P&;U?LO/#%+Q7]I?Y&=653_2/-/Y4:2VH/9^;M,#ZI<&[NVDU2
MVD)F,20\E+2?#\$48_V.*I;<ZC^4SZ9I5I#YTL$DT*5KK3+@ZO 9!.R.G*9_
M4Y3*5FD5U?[:MBK'M'B_+L1_4M1\YV,6F 1.]K'YACN(I+BWGCGADCCD*?5U
MBDAY*J\N2MP?X4Q5DDUY^2,_F&YUV7S)I3W=Z@2\MSJT/U69EC:$22VPE]%Y
M1"[1>HR?8Q5!:;;_ )'::EBEMYML_P#<<)5M'EUN.9E2: VW#E+*Y].*%F2%
M/LQ8JZ2V_(F73GT^7S1ISVKV%GIBJ=8A#)!ISF2T:-UE#)- [LRS*?4Q5=)%
M^2$D<Z-YMLB;J*VAN)#K4+2.+.Y:\B=G:5G,GUF225WK\?/XOA^'%4YTWS/^
M4>GVU[:P>:-(:TOYI[BXMI=3MI(^5T[23A5:0A5DDDD=E_R_Y>.*I0__ "I(
MVD-LOFVQ1;>2UD@D&LPM(BV$AFM(A(\KMZ-O(W.-#_L^>*ICY@UW\H->,+7W
MFO3!+!%<6Z2P:K;Q/Z-V@2="5DW#A$_X'%4JN;;\BKFUGMIO-.GLL\5A")!K
M$*2Q?HNOU22&1)5>*6/DW[Q#R?DW+%4RU#6/R>OO+0\N2^;-.73/AY\=6@]5
MRK^I5Y6D:1F:3]X[%N3MBJWS+JGY-^9+6&WU7S7IL@AAGMA+'JT$4C17<7HS
MHS)(*^JGVO\ A<54([C\ETM9K<^;;!_6OX]6]=]8@,JWD2)&LBOZE1^[C5./
MV<54KM?R/NK-;:3S78H8]1FU:"ZAUJ.&YBNKGEZQCGCE614E]1P\?+C\6*HN
M+4_R=A<O#YNL(G$,EM;2+J\ >WAE=7=()/4]2-"R)1.?%%7X..*LA'YF_EP!
M3_%>C?\ <0M?^JF*M_\ *SORX_ZFO1O^XA:_]5,5=_RL[\N/^IKT;_N(6O\
MU4Q5W_*SORX_ZFO1O^XA:_\ 53%7?\K._+C_ *FO1O\ N(6O_53%7?\ *SOR
MX_ZFO1O^XA:_]5,5=_RL[\N/^IKT;_N(6O\ U4Q5W_*SORX_ZFO1O^XA:_\
M53%7?\K._+C_ *FO1O\ N(6O_53%7?\ *SORX_ZFO1O^XA:_]5,5=_RL[\N/
M^IKT;_N(6O\ U4Q5W_*SORX_ZFO1O^XA:_\ 53%7?\K._+C_ *FO1O\ N(6O
M_53%7?\ *SORX_ZFO1O^XA:_]5,5=_RL[\N/^IKT;_N(6O\ U4Q5W_*SORX_
MZFO1O^XA:_\ 53%7?\K._+C_ *FO1O\ N(6O_53%7?\ *SORX_ZFO1O^XA:_
M]5,5=_RL[\N/^IKT;_N(6O\ U4Q5W_*SORX_ZFO1O^XA:_\ 53%7?\K._+C_
M *FO1O\ N(6O_53%7?\ *SORX_ZFO1O^XA:_]5,5=_RL[\N/^IKT;_N(6O\
MU4Q5W_*SORX_ZFO1O^XA:_\ 53%7?\K._+C_ *FO1O\ N(6O_53%7?\ *SOR
MX_ZFO1O^XA:_]5,5=_RL[\N/^IKT;_N(6O\ U4Q5W_*SORX_ZFO1O^XA:_\
M53%7?\K._+C_ *FO1O\ N(6O_53%7?\ *SORX_ZFO1O^XA:_]5,5=_RL[\N/
M^IKT;_N(6O\ U4Q5W_*SORX_ZFO1O^XA:_\ 53%7?\K._+C_ *FO1O\ N(6O
M_53%7?\ *SORX_ZFO1O^XA:_]5,5=_RL[\N/^IKT;_N(6O\ U4Q5W_*SORX_
MZFO1O^XA:_\ 53%7?\K._+C_ *FO1O\ N(6O_53%7?\ *SORX_ZFO1O^XA:_
M]5,5=_RL[\N/^IKT;_N(6O\ U4Q5W_*SORX_ZFO1O^XA:_\ 53%7?\K._+C_
M *FO1O\ N(6O_53%7?\ *SORX_ZFO1O^XA:_]5,5=_RL[\N/^IKT;_N(6O\
MU4Q5W_*SORX_ZFO1O^XA:_\ 53%7?\K._+C_ *FO1O\ N(6O_53%7?\ *SOR
MX_ZFO1O^XA:_]5,5=_RL[\N/^IKT;_N(6O\ U4Q5W_*SORX_ZFO1O^XA:_\
M53%7?\K._+C_ *FO1O\ N(6O_53%7?\ *SORX_ZFO1O^XA:_]5,5=_RL[\N/
M^IKT;_N(6O\ U4Q5W_*SORX_ZFO1O^XA:_\ 53%7?\K._+C_ *FO1O\ N(6O
M_53%7?\ *SORX_ZFO1O^XA:_]5,5=_RL[\N/^IKT;_N(6O\ U4Q5W_*SORX_
MZFO1O^XA:_\ 53%7?\K._+C_ *FO1O\ N(6O_53%7?\ *SORX_ZFO1O^XA:_
M]5,5=_RL[\N/^IKT;_N(6O\ U4Q5W_*SORX_ZFO1O^XA:_\ 53%7?\K._+C_
M *FO1O\ N(6O_53%7?\ *SORX_ZFO1O^XA:_]5,5=_RL[\N/^IKT;_N(6O\
MU4Q5W_*SORX_ZFO1O^XA:_\ 53%7?\K._+C_ *FO1O\ N(6O_53%7?\ *SOR
MX_ZFO1O^XA:_]5,5=_RL[\N/^IKT;_N(6O\ U4Q5W_*SORX_ZFO1O^XA:_\
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M,5=_RKG\O?\ J5](_P"D&V_YHQ5W_*N?R]_ZE?2/^D&V_P":,5=_RKG\O?\
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M57W_ )S\R1B2PMM5TPWUA;&[.HW$@MK:Y5;J6&KJ\;_NU2!5N#:M\,TO*/\
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M1BK?_0O?Y3_]6FY_[B6I?]E&*N_Z%[_*:M/T3<_]Q+4O^RC%7?\ 0O?Y3?\
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M;UY>7IW/%O@])L53K5-*UEM"D.C+/I]Y/JD;MH>I7SI]:BM@RO;0W*M,UO\
M6HXO6_=/(G)&Y_"\N*H+1M=MM1U+3M!MY=3LX]0U"[.K6%]*Z75F]G:1.NF\
M^3GT9@WUJ-H96]6#GZ;<&;BJBOS(T9M(\F^8;ZQOKN-&@M#:VPN9ZPR0W!#O
M"YDY)ZRS!''+C\'Q8JEMS>7<WDO\R+JVFNK&SL;6Y2PTZ:Z=[ZQO+.U=Y)"Z
M2.T"S/Z$T$2S2*T?^D<N%QZ:*H[S%%&GFK0;40ZC=V\_E^^;ZI87,ZRM+#+9
MB&2OK1J)$$LBI-(WPM)\;8J@K3RSJ5EJ7D73]?O;NXU34HK]]?87MP!+.ML)
M0O[N14 A=N,?I\5^'X<5:\W7NH^6-9U*;3KBXGFTKRD9K;ZQ++,IGCN/0%S+
M&3Z<DBQCD[LGQ\?BQ5/_ #3:-Y:T2QU33;RYEOX[W3[:9YIY)OKR75S':RK(
MC,4Y.DS3JT2+PD3X/@Q5(9KW4M"TS7=.O[F:;0=2?4UT2^DFE,UE>6[R\+(S
M$AQ%(L2RV<C2\O5]2V_WPN*LO\[75S86GE_3+&=[*'5=4MM-N;M&/JQVYBDE
M(61B2KS- EMZA//]]\'[WABJ7:Y%^A_,6C:=8RS?H_7(;^"^L7FED $%L9TN
M48LTL3(Z^@Y1E5O73E\:Q8JA/RGAENM)\N:E<6VHP7'Z%MII[ZXNVFAO)+F)
M/49H_5F'/DGJJS^G(OJ?8^UBJ._,_5M62Q-CH<MS'JD<+ZE$;6&:8N;1E>&W
M<Q))P2[E'I/S_P!U++BJ4>?M<O;S0_+/G'R[+.#;K^F1:1.X%U9I )IK:2,,
MJR%H&=D!')9HTXXJBI]8?6_S)\LRVUU*_E^>TU(6\<<CI%</'';N9RJE>?I^
MMZ,?+[++-_DXJ@/RTLOTGI6E2WD&I@A]1:357O9&AG"7,EJD#KZSN08Y:Q^H
MD3*]NK1XJA]/O]1M/+]OH&M7,]Q;WK6]QH&J//*)I$^MHMQ932@JYF@1_P!S
M^\=[BTY<OCMYFQ5/=&T2UU/SCYUM[F>["6MY9K9F*[N8S!ZMC#*QB"R!4_>,
MTE./'%6)KYGU^,>4_.4]Y-)#8)<6_F!$9A!=V)OOJ OGA4B/G'^[O.<:\?3>
M7C^[XXJG<]]>:GYYUN66ZF_1K^6Y)=.MDED2-1'<21?655&4<YZ<ED^UZ7I8
MJB?RXT_](Z'H]Q>6VI0--HEI]8N9[UWBO7O(E:5J)-*1*GI>HLE8IE]9OAQ5
M+]%U#4HM#TCR[Y@N9;F6=M-N]%U9Y9$FN[:6>$3P2R*4Y7%L)6C=:MZ]KZ<S
M?'ZV*HIO*MH?/B^7_KNH?5&\O/,9?KUUZOUGZVL?UCEZG]Z >M./^3QQ5=YZ
ML]9UC2;Z]T:\EM=4;48K?198I6C#-8AFX, R*T=S=++#*K?"\7^Q;%4/J7FZ
M;S/<>1;^PFFM]*N=1MAJ$".\7.>>RN)3:R\2I/U5H@9$;_=C1_R8JF7ER";S
M!Y,F\Q:C?W-GJ]W]<E6[29XUL/2EDC2-(N2Q<;98P)!,G[QO4];[38JE_E-V
M\T^8HKO5A.C:AY6T?4IK2*YN8(X[JZDN5E9$21.#%4C7^;X%Q50T_4-0N_,G
MEVRN[NXN(].\R:II:7)ED4W-M:6$UQ$)^!6.9H9@D;,P;G);_'\?J8JK>6;-
M[SS!K<$EOJ4J0^99(X=3CO)!%;10017"QE#,7,32+Z3IZ/I<9_M8JI>6[R=[
MFRT!KBY6UU/7O,"SW'UB4R-#IES(L%FLCL71&3C\,;*WI6[K_.V*LXCL[7RV
M-4U47-PVG+:HXL7DEN!&;;U7=H0[,U9O4165?M.BXJQ3RA>ZAJMUYB\KZY=7
MHEF^KZK;W!%Q:3"WNZ">VA9TBE6.VNH9(E9?]TS1\6_E51/D_P OVEYK'F-I
M;B\(TO79;>U07=P4%N=.MZPLK.P,?*>22G[,OQKBJ2?EQ=7FKVWE71[^ZN6L
M&\O_ *6N3ZTOJ7EU).(29)BWJLL ^/@K\><R,_V8\51>O6VHRZIK?EVQU6ZM
MDL9=%NM'OTE=I+.:_N6AD@)+'UX>,*R^C<<_@N&7[/I8JG?EC6)-8\RVKW\1
ML]<L;*YM]8T])93%'<QRP@.B$JKPR)(SVTS1\GBD_F7X56_/WFIM._2:M;M-
MIVB:6VJZDB'@T[LS):VO/]E)3%,TY_D5%;X'XNJE7FZVU30_)@U*[U*XN?/%
MS-;Q:6\<K1QMJ5PZK%:Q6RL(3;*25D1U?E!ZLLC,WQ8JC+?\U+V;1=0UTZ#*
MNCZ?->VYNTN(G$LEK<K:Q>F !6*>3U"]P3Z-O''SD?[7!56L/S+N;NZ;3DTU
M)-2:_?3;4P7*S6LLD, N+B83>FK"WM598IW]'E]9_<*G+%4!:?G%)<6]I,^C
MF!;K3;[6'=[A2L%I9S^E'++QC)]*Y3][&ZCE^PD<N*HB+S[YAN[J^FM-(>-M
M-T^PEFLKJ[BAMS<:B!,8G=()IEGMHU"<4Y^KZZ?N?C23%5]Q^9FJ6UQ::9+H
MGJ^8'A@N-0TJVN1*T"7,YBB1'](>K*56263DD,,,<3>I.O[OFJE_FK73YLN=
M*T.TMRNGWNM_4QJ N'B>2+3 ;B]DCCC^U;$P/9>HTG]Z_+C_ '3XJN_,77Y[
M#S7;:E;6_P!<@\I:5=ZUJ$'UAK=6:<?5[>/[+H\CQK=^C&R_WBI]GDK8JGLO
MGV=/,5[H0TXF]MX].GLU:7B;F&_E>.5E7@>+6JQ.[IR^/^:/[6*H?6;:34OS
M.T:S4W,=KI>GSZC>&.:6.&5Y95AM(I$1U62A6XF^)6^PF*I7JUQ=2><DL].N
M)[9]?O)-/DO5FDI#:Z=:^M=-;1N6A2YFF;ZOZBQ_!'$\G]XF*HWS;I5KY=T7
M5=:MKN[:"VTJX@CTI[NYD2:ZE*"WDJSO+ZS2!80Z'G^\^'XL55/R]T6:V5)+
MF+48+K2H$TV9[^YDF-W-Z<,D]TZ^K/$WQ_#%(K?\M"XJ[5?S1CTK6-9M+VR"
M6.B1K+<W'KH)W26-#;R16Y4"2.YN)#:1,)OAGBD]7A\')54L/S$OKL6]K^B&
M75;VXFAL8%FY02Q6T,<EQ=>LT:-]7ADE^JEUA;U+C^Y]2-TDQ5+=>_,GS'IU
M[>RC25&GZ1H4>JZG:M,HN_K=VQ2WLP0KQ"93%+55Y\^47'[2JZJ/;S]<6%BY
M:VDOX-)N++2]6O7EC$SWMPT4;I D48CN)(7GC];B+=.;,D/Q)PQ5K1_S.GU/
M4;.UBTIEAO=3OM,AG$ZN&33U?U;J.B /"KQ&-VY+\;Q^FTK-BJ5^:/-7Z.\^
M7VI00-?_ .'M,@MVM$=D#7>JW(X)6CIZS)%$D*\>3?6&]7TXEYXJG"_F?9OK
M]U8Q6Y?2M/>YBU+5O4^&V:RB:2XDD0(5$,<@6UY&597N.7IPM%&\N*H8?FI)
M%)<&_P!&FMK6+2H=67]XKW!:\F]&SLFAXKQO+EE?BGJ,J?"O+^15CUUKVK-Y
M[O;U;66&[:XL/+%NEE=K((YKH"^O+@":-H6-O;) DB"%OB2;[/\ >8JR+0OS
M5;59-.;]$R16NH2:CPF27UC]7TUF5KE%5/WD3L(T'[7J3(L?J_$V*H>S_-R[
MNK&_O(=":=+/2DUDI;W4<S+'-S,4$P5/W5TT<;2O$GJ\8_L^H_PXJS+RQK$^
ML:1#J,L4427')K<V\XN8I(>1$<T<@6.J3)^\2J\N#+R^+%6(ZW^9%WIGF/48
M4L)[FWL[S3=&@A2:$)<76H?O7:-?3,OJVT!5F1I>#+_OO^\Q5&V7YC37DPL[
M?36DU*:\O;2S@60&)X]/"BXN'EX52**9Q;?"C\[C^[YHW/%4@O/-MXOGA-6_
M1LS2V\&FZ(NG22A"E[JTBW-PI*^I&7M;=8F?A^SZO-TCX.RJ?P?F5;WKF+3[
M;ZR]SJ5UINF.)5$4L=C'RNKQY K".VAD#P\E]7D_I_M2\$58-I?GFY\NZ#'K
M9M9W76SJGF>YB%TG&.RM MO:VS&=)G*W"M:>F81&SR\N'+_=BK-+C\S;FVCU
M+U]&D2:P_1T8C]50/K.IMP2"9RO"W]+E'+-)618X9$Y?'^[Q5._)WFJ7S!:7
MES):"VBM+N:S2=)EGAN# Q1Y87"IRBY#B&95^+DO[.*I!I/YH7>I:@-.CTD)
M?SW4]G;6WUE6=)+5G^L?6U],&V6"-8969?6]3ZW:^CZGJ8J@AYE'FCS#Y>*P
M_5UTG]*ZGJ<9FK$6T^1M.C42CBCPRW#23PRNJ<DM_L_WBXJBO+?YA:IJ.F6S
MVNDW5YJ%Q:QZO=64DL >UM;Z=OJL =4C1Y6A5WCC8+QBB_?S<^/J*J&J^??,
MAFU%=&M0US)KEOY=TZ.ZD1H"R+ZEU=QB*/U/W:-)ZB222*K6_P"S^\C95%2_
MFI(;BT>VTP2:5>KJ4L6H23B,"WTM"9;HIP;_ $::7TXX'Y<G63U>*_#R52[3
M?S*UR**PG\PV<EO-'I"ZO?0V31NC2ZE<"#3]/]*1/6^L,3QC_>1_O%^/G^PJ
MF>J_F?=:5=2Z?=Z1ZFIQW>FVJVUM<+(&&J,X4*Q1?](A6"626#CQ]/TY/6].
M3DJJ[_&4>M6-TMU']0L+&YN_TI<^ISC-EII'KNK@(:23!K8[?[JN?39U56Q5
M%?X^O4M+:YN=%N(/TH;5-$@9T]6XEO/4812+_NB2&&)KBY^VL4/[;2*\>*H)
MOS0G35+71_T7ZNI2ZE<Z7.L%PK1J;6T6[:='9$YQ*LL4<W)8O0EYHW+A\:J2
MZG^<FKPVEMK%MI<1TJ'2+G6]1B:<B1XEF-M9I"[1A5^N-^_AYKZCJO#AR^TJ
MR>3SUJD,\5I<Z/\ 5;ZY66XMXIKE.*65O DDUU<LJL;=5FD^K+'Q=VD^+X4Y
M^FJH^6OS$U#7[:TFM="G5F2RDU.,RI6U_2"K(B5*CU)(;>2*YN5^#THI%7XY
M?@Q5'^1/,.M:Y;ZIJ&HQ006*ZA<6ND^BY?G;VCF!I68A:^I+'(Z-_)_PRJ1:
M9^:U]>:Q:V+Z,D$$]Y<6<\SWB>I:M:+,\_UB'TQZ;0QQ1RM\?HM'=6_I32,^
M*I'KGGB773Y=US3K,-:Z9!JGF.6"2Z>W62SL@]M:22.J,H6Z+_6(T*NO[O[3
M1>H^*IU<?FDEOJ%Q-):SPVMK9:>(+626!%GOM7^.&W?DG.&:W2.LK&7TXX9&
ME>)OW>*IA:_F'J-W!'#;:)--K+075Z; /P4VEM*88IEDD1&_TXK_ *$DD4;2
M?%ZGI)&SXJC= \QZ[JGG+7;!X(HM#T=+:W24,6FDO9HQ<2J=N $,3Q*P5OMM
M^U^PJRO%78J[%78J[%78J[%78J[%78J[%78J_P#_U?5.*NQ5V*NQ5V*NQ5V*
MNQ5V*I7KOEK2]<AMXK\2E+6XCNX1%+)"1-"P>)R8V7EP<<E#?#RQ55U/0],U
M2.".^A]9+>XAO(021QFMI!+$U5()XNH/$_#BJO:V,%KZQC:0^M*TS^I(\E&>
ME0O,MP3;:-.*+_+BJ7:KY6TC5=3M=4N'N$OK**2&UF@N)H>"3%3( (V5?WG!
M.1(_87%4//Y"\M3:<FGF&9(%NH[]W2XF6:2[A97CGEF#^K+(CI&RF1V_NT_D
M7%6IO(/ERXB=+I+BX=KB.\%Q+=7+3)/#&8XGCE]3G'Z:LW!495Y,S_;;%5:7
MR?Y=DLVM9H6<RSBZ^LM-+]9^LJG!9EN.7K+*L2\%97_N_@^QBJR_\C>7]0TR
MXTZ]2>X@N^ N9'N9S,ZQMR1#+S]3@K;\%;CBJGJOY?>6=4GNI[J.X]2_M!8:
MB8KJXB6YMP&4).L;JLK<79?49?5XMQY\<51<?E;28M5LM6K.U[I]LUE;2/<3
M,!!(5+JREN#\VCB9F<,W*-/Y<57WWE[2-0UFQU6<R-?Z67^J%)I$5#*M'Y1J
MP1N:;'FK?#BJV7RIHLNN/K4L;R7TML;&0/)(T+6Q-3$T)/I%2QY'X,54;7R7
MY>MI[258I)!I]#I\$T\TL-N57@IBBD=HT94^%&X\HU^QQQ5N3RAY<N=%O=#N
MX3?:9?N\EW;7,KS5>1_4:A=BR?O?WB\2O"3XEQ5,=1TW3=6LFM+V)+FUD*L4
M)_:1@R,I!JKHZAD=3R1OLXJE\'E/1(I9YJSRWMQ"UNUY-<32W"0M3DD4CL6A
M4L%9O2X<F^)L51FBZ'IVC:5::58*R65C$L%K&[O(4B041 [EGXHOPK5OLXJM
MMM L;;5;O5(WG-U>HD<W.>5XPD9)0)$S&./CR:GIJOVFQ5+M)\A>7M)2TCL1
M=)#8R32VT+7=Q(BM<5,OPN[<E8LQX-\*\OAQ5NU\@^6+.32FLK9[1=$@DM=+
MB@FECCABFIZBA%;BW/BO)GY-\.*K=,\@>7M-6UCM/K:P63R36MN]W<O$DDH?
MF_!G*EJRR,O+[+MS7XN.*HD>3_+[:3:Z3/;FZLK*>*ZM%N)'E>.:"7UHG61R
M7Y1R#X?B_P G[.*J$OD309+W4+PM=I+JKK)J(CO+F-)BJ"-0RI(H"B-5CXKQ
M7A\.*JUSY-\O7*F*6V/U,V+Z6;%7=+;ZG(O%HO04B, K\-0O+%5-O(WEWZVU
MW'%+#*; :4!#/-&BV:CX8D16"(%[,J\L5=IGD?0]-%L+4W02RMFLK)'N[B18
M(655I$KN0C!455D_O$7[+?$V*J_^$= ;3M-T^:W-Q;:1-#<Z;Z[O*\,UN3Z3
MK(Y+\D!X"K?8^#[.*JA\M:7_ (A7S!27])K;FT#^K)Z?HEN13TN7I_;'.O'E
MRQ5TOEK2WMK*V EBAT^19K98II$/-*D%RK5DK4\N?+E^UBJ"?R#Y7(M1%:M;
M+9W\NJP+;RRQ#Z[.6,DS!&'-F]20?'R7B[+BJI=^2/+ETUP)8)!;7CM+>V4<
MTL=M/(_VVE@1ECD]2G[WDO&7_=G+%6KOR5HMQJDVJ<KJ"]G@CM)'MKJ> >A"
M6,<86-U5%5I)&^ +\3MBK?\ @GRZLFDO#;O -$D>;38X99(T221621V56 E:
M19)!(TO/GZC\OM8JB='\M:5I#WSV0E5M2N&N[OU)I)>4[ *SCU&;A4*H^#^5
M<50</D/RU%ITFGB&5H)+J34 [W$[2QW4K,\DT4Q?U89&=W8M&Z_;?^;%5UUY
M)T2ZMC!.UVQ:2*62?ZW<"9C W.(-*'Y\$?XO3KZ?+]G%43=^6=*NM;LM;E]8
M:C8126]O*DTJ+Z4S*TB/&K".17:.-F]16^PN*M:=Y7TK3GU)[3UT?5IFN+US
M/*Q,S((S(A9CZ;>FB)^[X_83%4+:>1/+EIIFGZ=;0RQ0Z4&739EGF]>!''%D
M2?EZH1E^%DY\?^!7%55?)NA)9FUC2:-9+E+V>9;B83S7$9!22:;GZLI7@GVW
MX_ G[*XJC1H>E+K3:V+91JK6XLWNQ4.UNK^HL;=BJN2R_P O)OYL50\^B1S:
MG?27,<=SI^I6L=M<VLJ\@?3,@H01Q:-TE8,#_+_E8JHV?DS0+:>WN/2DN+BS
M1HK&>ZFEN9+='4(PA:9G:(LHXLZ?'Q_:Q5+_ ##Y+,OE*U\M:$([73(3%%<6
MC231&6SC^W"MS$3-%)(>+--^\9_C5_[UFQ5":/\ EQ;M8BW\P2S7_HB>&R#7
M#,T%K=(BSV_KQ):/-'*T:R_O(_@;@J_W:XJF"?EKY-32KG2TL2ME=VD&G7""
M:8$VML6,<0;GR5*N_/B?WG)O4Y8JIWGY8>4+J261H;J"2>X%U*]M>W=NQE2(
M0(>4,J-1(EXHM>*XJC[7R5Y=M+V&\M+=[>6"WM[0)'+*L;PVA8VXDC#<)3"7
M;@\BLV*J-A^7OE*QO[6_MK+C=6)G^INTDK"(7+^I*J*S%50R?&$IQ1OLXJK7
M7DOR[=:K-J=Q;-+<W!@:X1Y)##(UH>5NSP\O3;T6^)*K]KX_M8JHZ1Y:=]8'
MF/6XH#Y@^K"R0VS2-##"'9RL9D"LS.[,S2,BMQ_=K^US51U_Y:TJ^O%O9%DB
MODC]#ZW;RR02F$MS])GC*EH^7Q<3^UBK5WY7T2ZL;:RDMRL-FXELVB=XY(90
M&'J1RH5D60AWY/RY/S?GRYMBJ$O_ "+Y?O[1;:\%S*@GANG<W5P)));9Q) 9
M) X=UAD57CC8^FK_ !<<53_@*UQ5C0_+CRA]3N;1[-I8KJ/T7:6::21(_6^L
M!8I7<RQ4G_?+Z;KQEXO^RN*HFY\E:#<RV<\R3FYL1,(+H7,ZRE;GCZRR.KAI
M5E]./DLG+["<?LXJI7GY?>4[R2^DN;-G;4GMI+RDTRAC9%# H"N."(8T/IIQ
M1OVEQ573R9Y<2_:]6TI*TXN_3YOZ(N0GI?6%AY>DL_ <?5"<_P!K[?Q8JLLO
M(WEBRFTJ6VM"CZ)!):Z8/4D*Q1RE3(>):CR.44M*_*1OYL5=>>1O+-XLZW-J
MT@NKZ/5+G][*#)=0JJQNY##DJ+''QB_NEX+\&*M?X%\L^CJ5NUJSVFK^O]>M
M&EE,#?6Q2X*1EN$1FK\9C"_M-^TV*H<?EMY0]2]F-I(USJ#VLMU<M<3M*TMD
MRO;R"0OR22.2-).2?M_%BKH_RU\F17"W$5@8I4N9;U2DTR_Z3/%Z,DM _P!O
M@6XM^QR9D^UBJEJ?D&P2QC;R^J:?JVGZ<=+T:YD,LD5M"2NPB#@<CP7][_>_
M9;DW#%4K\N_EH]D/0O+FYCTV!DFL;"*^FF,-R@*^LMSZ=M<?W;>GZ<K3J_VV
M^/%64Z+Y?M]*N93:5@L1;P6EGIT?(00QV_,@JA)4.YD(=D5>2)'SY,N*J%OY
M&\LP:J=5CM2;XW<FH>J\LK_Z3+$8&DXLQ7:$F.,4XQ+_ '?'%4-;_EOY2MDL
MQ;6TT+V)N/1ECN;A9"+QP]RLCB3E*DSHK.LA;XEQ5?)^77E&2Z-T]FS3M>_I
M(N9IM[GT3;UISIZ?H,T7H_W7I_#PQ5J/\N/)\=K;6JV3>A:K=I&IGG-4OW$E
MRCDO5TFD1'97_;1<54_^58^22UB3I_)=.AM[:SC,LQ1(K687$2\.?%J2@,W(
M?O/A63DJKBJ"\T?EZM['<+I-(QJEXMYKR27%Q%)=>G&%C5+A/5:W]-TA?@L3
M12)%Z+IP;%4ST'RQ<P^6I]$UJYEOX)P\5'DJZ6SJ$] 31);.X5:_O.$;_%Q_
M9Q5</(/ED>FX@D%U'(THOA/,+IF>)8&#W <3.K0QQQ%7?[$<?^^TQ5W_ "K_
M ,I#ZSZ=CZ(NK :3(L4DD:K9KSI%&%8"+^]D^./B_P 7VL57VGD;RU9WD=W:
M6[P21P06Q1)I1%)':EF@$L7+TY#$TCE6=>6*J=O^7_E2WFM9H[1O4L[N?4(2
MTTS?Z5=<O5E<,Y]1CZCTY\N')N&*H(_E/Y$,9C^H/P^HMI2K]8N/ALG-3 OQ
M_"E/@'']CX/LXJC9?R_\IRR7DDED6:]BMX)B99?A2S/*W]+XOW+1./41XN#^
MK^]^W\6*HBW\G>7K>ZMKM+8M=VL[W:3O)([M<20^@TTA9CZLGHGTU:3EZ:?#
M'QQ52TWR'Y6T[2KW2K:R_P!!U%)(KZ*2224RI+RYJ[R,ST;U)*_%]IV;[6*N
M'D?R\-/@LBD[K:R1S6MP]S.UQ%)"I2-DG9S*O&-FC^W\2.ZMRYOBJZ/R1Y9B
M;E%9^FWU:XLPR22*1%>.)+DA@W(2S2*KR3_WS,O]YBJ$@_++R5#Z?#3SQBCL
MX41IIF41Z=)ZMLG$N5XI)\97_=C?WG+%45Y@\C^6?,#N^JVIG:2UDL92LLL7
M.VE8.T;^FR<EYJKK7[+?9Q5O3O)'ES3;V2[L;>2!YO3,L:SS>DSQ1"%)#$7]
M/U5B54]3CR^'%52P\G^7[#RZWEVUMC'I+1/"\'JR%BD@(>LI;U:L#NW/EBJ"
M/Y;^46N([F2UDENHUE0W+W$YED$\<<3^JW.LI].W@5&DY-'Z,?#[.*H6_P#R
MXT.*P1-)LHS/;VUM8PV]W-<-:R6UI(7BBG0,WJ(G.0IR5_C^VKKBJI9>0[*6
MWO?TQ_I%[J&HC5YIX'DB,5Q$$2W$,@82J((8HX^J\_WGP*DGIXJF$GDKR^^H
M0Z@8I1=PP?53(L\P]6'U#-PG >DP]4L_[WDWQO\ SMBJ*TGRYI&DSWT]C"8Y
MM2N&O+V1G=S),^Q/QEN(H**B_"O[.*IEBKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5?_6]4XJ[%78J[%78J[%78J[%78JP7S_ /F->>6-1@M+:PBNT.G:AJM[/),8
MQ;P6"*06 1MII)%C0U^)_@_RL506G?FIK$R7"WNA"WO@=+MK.P6?E(]_J<7K
MO:R,4 C:UA*SSM\7"+E_LE5"Z\_>;K^T@M=-@LX+V[\Q?H.VN@S2QRVULADO
M+E%(^'AZ-Q$/[WBR_P# JH*S_-#S-_I06U@U&^U"YU"70;.W60K^C],?ZMS/
M 22/)=W%/1_8X2>L[QQ1\<59+HGG3S1K'F'4M.@T6"*RTF[M;6^O'NBU#+:B
MXN%0+'QDF@>6*+@&X?;;U/LKBJ%\S_FC<>7=5UC3[O3DDDL[6RO=-].:OKPW
M5PUM*\I*@0"WD4<OM\OV6Y-BK'_,OFZ8^9DU@VL3MY6TS4-20;F-DNIVMK!F
M<CF);F"";TX$"LSSIQ=H^6*LDC_,;5+G7OT=9:4DD%A)';Z[.TK<+:5K;ZS,
MPE">EZ5L&C1FDXR3N[>C%^[Q5+K#\UO,$OES1]:O=$ALU\Q+%%H]OZ\DLC7$
MQDD!D18N7H)9Q_6.2!II6_=I#]CDJR"_\V:Q9_EQ>>9KRQCL=2M;2:Z-A<%J
M'TBWIJ1\#J\Z*I6)OCC>3TG^)<58AY+UN_TJ]BTN/2X[O5+=K>'SGJP:11]:
MEC:[N)BY7T@MLLU7:5D>9G]"!.,7PJIO;?F9KM[=V?U#2(9K;4=-O=5M+=YS
M'<^C RQV/-2I16U.21#"/]UIS_O'7%4-'^9%[?0>7[F>."/3[^2[O;B^M+F2
M,Q6.EPB69I8I8@RTN#]4N8)"GIM\//XL58_H'F;5?+OD[5;*[TV 7-SI$GF%
M/29RPO-8N9$M[2XB94XM([QQPHK<N,3Q?&Z>HZK)M!\Q7.C7FG>2-"T_](PZ
M$MEINK78Y)1Y(5DEE4JGI*(HB+B0RM'Z\DJPP)SY<562ZU=1)YI\NVZ F[GD
MNV/&FUM';'U2PK7CZS6J_P"LR8JR)?LC%6\5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BK__U_5.*NQ5V*NQ5V*NQ5V*NQ5V*I5J'E;0=1FN)KZSCN)+
MJ**"X9ZGG%;RF:.,[_864\Z?M_M\L54'\D^5WDN)7T^(S75T+^>;XN;7*KP$
MG*O('@2G%3PX,R<>+-BJG8^0/)]@+%;+2K>!=,DFEL512!$]Q3U&45IR-/M'
M['[''%70>0?*5O!906^G1PQ:<CQ6BH77C'*5:1'HW[U',:<TEYJW'%4VT_2M
M/TZ*6*RA6!)YI;F8+^U-.Y>1S6N[,<50NH>6-!U&2>2_L8;I[J*.WN3*@?U(
M89#+'&U>J+*S2<?YL54K[RAY=OX[Z.\LHYTU*2&6^#<AZK6W'T.5"-HO37BO
MV?\ @FQ5;+Y+\M2R7LCV*'](HT=Z@9PCJT(MR> 8(KF$"+U$59.'P\L51.H^
M7-'U"VMK:ZMPT-FZR6@1GB:)T4JK1O$4=*(S)\+?9^'%4NU?RM)J;V^FR2PQ
M^6HOJ\DFGI&1(\EK-ZT8$@8!8BR1<T*MR5&3_=N*HX>5]#&I7&HBU7ZW=FMR
MQ+%';TQ%S,9/I<_2 B]3AS]/X>6*I8OY8^1$9771X5D2.&%)09 ZI;,6@"N&
MYKZ)/[LAN2?97X57%45<^1/*5T$%QID,H2VELE#@D""X/*9:$]96^*23^\?^
M?%5TGDGRO+8/82V$<MK++%<3(Y=VDE@(,32.S%Y/3X+PYLR\5XXJKKY7T-=2
MEU);95NYPOK.&<*Q1/25B@;T^:Q?NUDX>IP^'EBJS1O+]M87 G(#S0PBSM*5
M(AM$(X0H6+,?LJTKLW*1_P#)5%55.,5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5?_]#U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5?_1]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_TO5.*NQ5
MV*NQ5V*NQ5V*NQ5V*H75E9M,NE21XF,3\9(SQ=3Q)!4]CBKQ(^9_-S_E^-7L
M-5U*0?X4.I:G?SQ\(XM46.&2 V\CQ+S,I-QZT*>I!Z:Q?9Y?&J]7U:*>.\\O
MPQWERD?ULPS<9-YD%I-(!*2/C^.%#^S_ ,-BK O)_F#7[CS!8Z?;ZC?W5XNI
MZNFIQWH7ZHVE6EW<6\3Q.R*9)XG2VC'U8LWV_K?PMRQ55N]7\R)YH\Q6FE7^
MH7.J66LV$.F6'!I;,6UQ;6LUREPWIE(X0)KA^9E6:/X/3_81E4\\OS:YYG\O
MRZ^FJS6%Y=278TN&+C]7MTAFDA@$D14_6"?3YS%S\3.RQ^FO#BJQNZ\ZZ_=Z
M?8>8M2N;O1M U;1[66UU33PDT&FWT\;O+)J$3+))Z!K#Z4SAK>-5;UO2Y>IB
MJ.U#4KU_-VNZ<^JZK]7%EI3:?+IH]2.&:_:>)YJ\6CX52*2DK<.*-_E8J]&M
M6U R313QA8X>"P7/,,9ZH"[E !Z?%^2\>3?S8JP!=*UT><I/+A\RZG2/0HKP
M7?./E];-R\32E.''B0@_=?W?_$L53N\_,""WD>X^JO)HD&I+H]SJ*2 M'=/(
ML%?1XU:!;ETMGD]3FLG)O2]->>*JNH><;RU\V_H"/3&DCBLUU&YOS.B(EMZI
MBD98Z.[M&17A\/+%4FU'\UY;2PN+]-%N);&W6UN'NV,L,0MKF80L\CO  LD
M9)Y8D]3]QSD67]VRXJC9O.$K>:].L)]/N$@>[OK:QO(+DF.4VELSRF2W 0ON
M'B16Y\)4Y<OL\E5NE_FAIVI:8VH6L0D1YTM;:-)&D?UV1Y6BN8DB-Q:20QQE
MIDD@;_BKU<53:V\US3>53KC:;<PRKR5M/D'IR!DE](MRD]/]QMZHF95_T;]]
MP_8Q5)+?\T/KUSIUIIVF-=W%_?WFF,XN%2".XLH&G8B1EYR0NB5618O]ABJ
MU/\ ,6?7?)ET^CVLUOJ$NBW.I75+E89+-8S+"A610WJ2//!-Z7%47C$[.\?P
M+BJ;/Y@DM=%\D-=I<W4FK364#7,4YBI/):-)RF%0TZ/Q?E&?AY?$V*J%G^:+
M//:O?Z3)86%Q>ZGI[7)GCE:.724GDE9HXP:QNEI-Q*ORY_L<?CQ5&1>?I?JU
MO<3:7- FIBT_0C-*A2Y:^)].-VI^YFC0>K.G&7A#_=M*WP8JA)_S)O5OXM)@
MT1YM:-_+ID]L;I(XDF6R>_A83,M7BN+=.2OZ7P-\$B8JHG\VDMK-=2U?2I--
MT=-1O-*NKUKB.5HI[,RCDT:#XHY6@9 RO\+<>2^G^\Q54UW\T+C1+>X>_P!%
MF%PFGC5;6WCG0B6V$L<,H:0JJQSP-/#ZD7QK^]7TI)/CQ5%W7G^>PU&ST_5M
M-:RGO+F*R0"=92TUP6$3(%2K0?"HEF;T_3D;TU23ABJ5Z+^96KOY>6[O[!9=
M3GGU+ZO;6KRNIAL;R2WH62!^+[1Q1\E_>_WC-'\7%5,?S"UJ_C_*[5-=T^6Z
MTV[CL!>VU5]*YB;B'"R1L&XN*\9(V_:^'%4!/K"Z?<13>IK-Q9SZKINF?5[N
M1K8Q3RR!EG4MPFE@D]=(YH3^[D]+_6Q5$0_F?.UPJRZ).D!U:ZT3DDT4LIN+
M6"6<%(E^TLJP,@_>+Q=D_P!;%5,_FQ%PD2'3'NKR&^T^PGAAN(S&AU1@D+"5
M@BN58\951?@=?MM]K%439?F//>2-IT.ELVOBZO[46!G A(TT(9I1<</L-Z\"
MQUBY^I+Q951'D55JT\[_ .G:W(VFWL%Q:1:6TD%W<*J*M\&XLZ<GCM!!\7UM
MEYM\'+C)Q3%4'I_FY]<\Y^5KNQN)XK&[@UNVO;+FWH/-ITT,/,+1>?&3U/2D
M95;TV^PN*IW/>W6L><-0T2.[GL[+1[2UFG6W(22::]:7@?4HS*D26Y^%>/-Y
M?B^PN*K(M4UG2KB/0_4.N:U=&\O;032);\;&&1%022+'3DAFBA6D3<V^)V^T
MV*I GYSQSV5]J-IHMP^G:;!97-W++-%'*$O)Y+=U$5&K+;RP2JR,RJ_#X9/L
M<U4K\UZMYEN=?UIVNY[*'0==T"UL3:7DL:O%>36HECG@5529)TN7,G-O@^!$
M_F=5E5EYUB2YU&V2TN/TE+KKZ1;6LUP71YULH[HNK_&MM;BW#2>FJ_:5_@]6
M3%6M(\W^9;_SM#H\VFBPLCI9O9XIY/\ 2$E^LM ?LH5=*Q_NJ.OJ1/ZW_%>*
MHC6_/\6F?I.Y^J/<:3H<\5MK-[&XYPO*D<C%(>),JP1SPR3?&C*C?NUDX8J@
M_+3:UK7F[7[B_GFMX=!U7ZK916UW)Z+Q?4(']*>W,:QR*S7!G]3^\63BB_!'
M\:J6Z!YOU?3GE@F2YUF34/,U]HMH\T\:+;I DDL0)(J4X0O6BL__  JXJK0_
MF7JEQJ>C2?44M-*GMM:FU97F,DL;Z+=);3>GPC;U$4EWCIP:;DO]UQ^)5%77
MYFW<"570;EV>[L+6!V9H86_24Q@CK)-'%^]B<?Z1%&DOIJ\;K(_+%43_ ,K#
MD6[B@?2;N6ADAOOJJRW!@N(86EE7:)8Y(5>-H!,)>3S<%]+BW+%4KF_,[4=0
MM-#N] @M+BWU+6(M-ED%V''%K>2=D-(O4AE4Q^G*DT221M]E75UDQ5./,WFK
M5M(\VZ)8+%$=)N[6_N]0F9V$BI9+$3P54>O%9>?&O[QOA^#]I5 W7YGW$,99
M-"NI0UQ800REFAB8:E<"VCY23QQTEBD*F:&,3<4='61\56:M^:&I:6VJI=^7
MY VB0Z?<:B$NX6^'4)&CI#\(YM&R-]OTN:_R?#R5;U#\V+?3+B]L]3LA97EG
M>"RK/<JEJ[R6L=U$#=%/2BDE641QI-Z:-*K_ +WC\6*L]MW9XU9AQ8@$J36A
M(Z5&*JF*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5__3]4XJ[%78J[%78J[%78J[%78JH7]LUS9S6XD>
M$S(R>K'QYKR%*KS#K7_65L52BQ\H:;;>4HO*LX>^TB*T&G^G<E2SVRIZ:HYC
M6*M$ 7D%Y?M?;^+%6[+ROZ%S:W-UJ%WJ4EBA6S%VT1$3%#&9!Z<<9DE:-BGJ
M3&1N+-_.V*I4GY9Z8EE;PI?7J7EG?W&J66IHUNMU!/>.\ERJ,(0GHSF602Q/
M&Z\6_P B/@JF^C^64TO4=5U".ZGN)]8FCN+M9S%Q$D4*0*4$<<?']U%&O5OL
M\OM8JA9_(]B\-Y:P75W9Z;J$DDU[IUM(B12/.:S\6*--")B6:18)8N3,[_:=
ML563^0M.:XNGMKBZL;>]M(K"[LK9XQ;/;0H8T01O&_I$(S)SB*/Q_;^%.*JF
MOY?V\%Y?7.G:G?:8;^UM[%XK0VRI%;VBND"0\X':,QB5Z-RY?\ N*L@L+!K1
MY*3RR1.$$<,C*R1+&@C"QT4-\7'F_-G^/%4$/+-M_BM_,GUB<W4EHM@;<F/T
M/15S(-N'J<O49FY>K_PN*H5?(^DQ7]U-$919WMVNHW6F$QM:O>*583\60R*W
MJ1QRLB2+$TJ>IPY\^:JL_E6VD\S/Y@DFF>>2S.G/:'TC;FW+^H05]/U.1<\O
M[W_A<50.E_EYI5CI]WIKW5]?:;<VC:?'97EP98H+1EX&&$ +0<:+SD]67BJK
MZG'%7#\OM."Z J7=W&GEV)XK(*\59/5A,$CSL8R[R21LW)D9/WG[S[6*J4OY
M9Z-,))Y;J\.JO]6]+65DC2]C^I"18"'2-4=E6>=7::.5IDE:.;U(_AQ5&WOD
MJPOO*LGER[N;N:WEXM)>O-RNC*DHG$ID8%>7JJ'X^GZ7^Z_2]+]WBJ!T_P#+
M73[+5X-46_OI;B"^N=4597@*&YNX#;S,0(5;B8V;BBLJK_L<54+;\I]&M=/^
MI6]]?Q*UG-IL\RR0^I+9SN\AB?\ =<#Z<DLKPR!/5B]1^,G%L53*Y\CVD^GZ
M%8_7+N.+R]-%<63AXF=G@C,4?JL\;\P$=A\/#[7^KBJ%B_+72T6R5[JZF%EJ
M%[J?&4P,LLNI+*MRDJ^B%:)UN9UX*%X^I]KX4XJJ=K^5NA6^E#3O7O9XK>2*
M32Y;BX]26P^K.9+=;5V7X5@8_#ZOJ\T_=S>K'\.*HV7R+:2:C8:DUY<_7K&[
M.H-./JX-Q<-;FTK/2&A5;9FA18_3XK\7]Y\6*I%Y<_+V2ZM]2C\T6\CVL^J:
ME?0:3)+%+:,FH2R%794',R+%,R<'E]-)&:2->7%\53.]_+33+[1GTF[OKV6%
MK9;&*X9X6GBM5=7]%)#%N&,47J/('F?TU_>8J[4/RTTR^U=]5EOKY+F6XLKV
M=8I(E22YTY2D,K Q$BJ&DB(5B_:5%?XL56G\LM,2&)+/4-1T^:WFNY;6ZM9T
M26)+^;U[F!28V5H9)OCI(LCJW#A)^[7%4UUWRE9ZSY9F\MS33P:=/ MM(T3A
MIC$H X^I,)34@;NWQ_Y7+%6]=\KIK5K8V]U>7$?Z/NK>]CEA]%7>>U<21M(&
MC=:<QR945.6*I->?E7H]YI\EE<7EZ\<VI7.K2D/"K-/=P26\JU$.T9BFDHJC
MFK-R]3X5Q52A_*72X9$D_2>HR.DNG3'U)+<AFT@@VM0(!L.(Y\>//_9-BJO+
M^5^D/=2WD=Y?6]\U_/J4-[;RQQS0R785;B*-A'O!,B(KQ2B3[".K+(BOBK<_
MY7Z/++=R"[O8_K1T]E5)(J0OI,@DM&BK$6)C8?%ZID63E\>*JFD?EQ8:9JUG
MJ46H7TDME-?SQQS/ Z%M4E]:ZY4A5J/( RT;X,53;4_+-M=ZK'J\%Q/8:FD7
MU=[JU,=98 2PBE25)8I%1V9XZISC9FX-\;\E4--Y,M)+NSOTNKJ'5;+UA'J:
MR(\[I<!1+'()$DA:)N$;</2^!HH_3X<<52RX_*S0IK75K59[J"WUB"UM9XHF
MA4)'92/+'Z9,1/-I)9&E:3U.?/%5U]^6MI>7.H3RZKJ .IW=G?784V@!GT\Q
M&V9:VYXA#;Q<EK\?[7VL5;N/RRTJXCOO5O;[ZQ>:BNL17J2113VMZL2P>K;,
MD2A:PH(GCD$L;Q\U9?WC\E4QLO)FGV6KV^JV\URMU!;-9R,T@<3QO*TY,W(%
MB_K.\G-&3DS?%\.*K;CR1I<VH7UURE2#56BDU;3U*&VN9(0%22171F5BB1I)
MZ3IZJ1QK)BJOHOEE-)U#5;R&[N)CK%S]<N8IO1*+-Z4<-4X1HZJ(H8TXL[?9
MY?;^+%4LM?RXL8+FWG_2%[)]7U:7751VM^)O)T>-^7&%3Z?":3X ?VL56VOY
M9:+"(%DGN;A(&U+X)6B*O%J\PGO(9 L:\HI)5Y?[\7^[]3T_AQ58OY8V?U.&
MUDUC59DMKFTN;5I[B.5HA82"6WB7G$R^FCCDSLK3S?[NFDQ5%R^0-/?4[N^B
MOM0M8KYI)KC3[>X]*U-S)'Z1N JCU%EX_%3U/1]7]]Z7J_'BJD_Y;:-)<&]>
M:Y.IM=V]^^I!HEG::UB>"'D%C$3<8I94Y-%S;ER9^2)Q53+6?*MAJ]_8WMWZ
MGJV,=Q"@5EX20W819HI%96Y)((TKQXO_ )?Q-BJ2C\K[$6$=B=7U5X()K2:T
M]6XCE]%;"59[:&,21,OII*B,SNKW$O'A),Z?#BJ(UC\N=.U:?6IKF]O%_3T5
MK#>I&T "I92&2'TJQ,5(9GY<B_+G_J\5777Y=6%S=ZK=27UX6UH!=2AY0&&5
M?0CMF5HVA9?BBA3_ %6Y-'PY8JG^D:1%ID1M[>27ZHB116MJ[!HX(X8UB5(M
MN="$Y-ZCR-SQ5'XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%7__4]4XJ[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%7_U?5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5_];U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_7
M]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_T/5.*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]'U3BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5?_2]4XJ[%78J[%78J[%78J[%78JQ/SAYLUS
MR_'<7D6E176G6YLX_7DNC"SRWER+;@B+#+M#SCD=F;XN7PXJA+CS]J&E>8[+
M3?,=I:Z5974%_,;TW1D!%D;<JRUCB^"1;AB>7QIZ3_#P^/%63S>8=$A:T66^
MA0WW'ZF2XI+ZGV.)Z'G7X/Y_V<57:GKFD:7"LVHW<5I$Y(629@@V%3N>P&['
M]G%5LWF+0X=0BTZ6^A2^G($-NS@,S,"RJ/\ *95+*OVF7%4"GG[R2[A(]=L7
M=C*J!)XVY/ >,J+0_$Z'[2+\>*K&_,/R(L0E/F"P],PI<\OK$>T$I*I*=]HR
M13F?AQ59I'FQY]5\RVFH1Q6MOH%S#"EPLA<21SVT=PKO55XO^]X\%Y?ZS8JH
M7GYB^5H=0MK%-2@]2]L[B_M[AGI;".W=(SZDO1?CDH?Y>#\L53)?-6C6VG:?
M<:EJ%I"][#'*DB2?N7YA?CC=J?N2S#A(W'[2XJY/.7E-]0&G)J]HU\;@V?U=
M9D+_ %E5YF$@':7A\7#[6*N\T>8[/0]/DN)KB"*X9)#9PW$GIK+)&A<K4!VH
M /B8(W'%4+Y;\ZZ7JFC:9=W-Q#;W]]I]OJ$UFK\C&)H%G9??BK5I]OA\>*K-
M%_,'ROJ>@6VNK?);Z?=,5B>X/IFJG]JOV?AXL?Y>7Q8JG]Y?6=E;/=7<RPVZ
M4Y2N:#<T ^;$T4?M8JQ37_S"T^V?1[72;BVN;O7I9X+">5W^K*UO&[OZAC#-
M]N/T>/VE=OB^QQ95$7_G2/3KO2]'OECB\R:I:2W$=FLCM;K+"J<T,XCY</4D
MX(_I<F^UZ>*M^3//^C>8/+EEJ4EW;0WLFGV^H:A:)*'^KBX3D:DT/%7#Q\OY
MDX_:Q5D%AJ5AJ-J+JQG2YMR67U(SR')"593X,K#BRXJA8O-'EV:*ZEBU&!X[
M(@7;*X/I\C1:_P"N=D_G_8Q5#/YX\GHD+/K-HGKK*\*-*H=UMSQFXH3S/IML
M_P /PXJ@7_,OR;%JK6,NIPI&M@FIF^9U%M]7E)",)C\'Q*O,?%]G%4TMO-OE
MFZ>%+;4[>9KAF2'@X8,R,4(J._,%%K]IOLXJAM<\[^6M(L]3GN;Z/GI-O)=W
M=NAY2B.( M1!N3\2K_DLZ\OM8JONO,]B-#M-2@N[:%+V6WCMWO9#$CF:54,:
MFG)IBI98D ^.7C^SBJ.BUO27OVTU;N-K]%9VMN0]3BM.1I_D\TY?R\EY?:Q5
M"7_G/REI]W+9WVL6=M=0>EZ\$DR*\8G;C$9%)J@=ME+8JKOYET!+]]/:_A%]
M&K,UOR'.D:\W%.[*GQLH^+C\6*H;RKYLTCS)HD>LZ?*392<Z-(.! 0G=@:4^
M'XL52G6OS!L;.71I;&XM+O3K_4AIM_<F;B;<M;2W",% H2WI#[3+R5UX<^6*
MIY!YJ\N3I:/%J5O(M\*VCK(I$GQ</A/^O\'^O\'VL54X/.?E*XO4L;?6+2:\
MDF>V2".9&8SQKS>*@)_>*H+</M8JNM/-WE:\N7MK75K66XC#,T2S)RXQU#L!
M7XD7@W)U^'X<57#S5Y=;3GU%=1@^I))Z+SEP LI(41D=1(690L=.;<L52'2O
MS&MCY)U7S3JZ)!;:5/J$4HMF:=72QGDA5HV*HS&7TZ_87[6*IU'YM\O!+,RZ
MA#$U\$-LLC!2WJ-P3K_._P "5^V_V<54/./FR+R[%II=8^>IWBV4,MS*+>VC
M=HWDY3S%9."D1E(_@_>3/%%^WBJ^W\S+;V$UWY@C711#/) 1-*&1EC.TJ/1:
MQNO[RI5>"?WG'%51_.GE%+PV3:S9B[$T=LT'KQEQ--3THV /PO)R'!3]O]G%
M4)I7Y@>6=2M]1NXKL1VNFW4EE<22@J/4B/$TJ*T+*_'_ %>6*HBX\]^2[=V2
M?7+&-T2&5P;B/X8[DTA=OB^%)/V';X<52G6_S(TJTN])^H75I>6-SJ7Z,U2<
M3_';,UK+<QG@JMR+B(<>3+R5UX<\53Y_-7EM-.@U)M2M_P!'W)I!=B13$U-C
M\8/&BD?&?V/VL5=:^:?+EWJ<NE6FI6UQJ4)<36D4JO(AC"EPRJ30KZB<O];%
M4/9^8I9?-^H>7I;;TQ965K?1W?J!A*MU)-%QX4JG!K=OVOBQ5+O*_GD^8?,6
MJZ?:0VXLM+=HI)#<M]=YAN*E[)H4,<,E':&;UF61%Y+]KX54[UV_U*TLJZ78
M_I&_D=8X+=I/0CWJ6:2;A+Z:*JM\7IMR;C']I\58K8_F3J&H65F+/0W;7)5U
M W>DR7")Z/Z*F^KW'&4*WJ^I<<(K=O357Y\Y/2XXJF9\[Q22^56LK<W-AYI+
M""[]15,5+.2\2J -SY+"4^%_AQ59=^9?-L.O6UHNA0?HJZNA;0WLE]PG*A2T
MDHME@<<%5'9:W'Q+Q^SSQ5EF*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O__3]4XJ[%78J[%78J[%
M78J[%78JQC\Q=%U36/+$FGZ5"DUW)<V<M))/24);74=RWQ4;<B+BOP_:;%4/
MKVC:]>>;]'U2WM4:SLM/U&WG+S!6$U[Z!C"KQ-0OU<JS<O\ =G^MBK%-'_+K
MS1;6.D6-]IMA?VXL-+M+Y;B[N EM+IBA&D6&)1'>1R>FDT"OZ+13?;Q5D_FG
MRYYAF\QV.MZ3!9WZ_4KG2K_3M0=HXO0NW20S*RI,&*M$J2PM'^^B;[:XJEDO
MY?ZQ);ZMH4_I3:5JFH6NI0ZA&1%+;?5OJY,*PD,/W9M%%LR-QC23CQ7TOC54
MM)\H>:8+S1+F>Q@06'F'5M6N$6X#4M]26Z$?#X!RDC^N+S7_ (K?B_V<58KY
M?T36[#7;_P K^A92ZM<^79+:XC:Y'IQ+=ZG>RAVHA:0+#.KR1A>7V?V7YXJR
M&+\O?,]L-52VCBEC2\TVZTWZQ=.ANXM/L8[)TFDA7U+>241M,DB^IQD]/DOV
ML51 \E>9(3;W=MIEE TNFZQ:76G0W4A$<VJ3P3B0SRHQN'K"_KR<4YRO]CCB
MK>E^2?,]G91V\UO;W<-_Y>M-!O[627:VDM$DC,B,5*RP3K.S2)Q1_P!W']OE
M\"J#L?R[\S6&G+9PP1S"V\QZ?J4+2W YR65A:6]L6=N%/7<VW/C_ )?V\59/
MYDT'S#)YA_2VG1Q7D4VF7&E26L\IA])I7$BSH>$@(:G"9?A?BL;+SX\<58?Y
M<_+WSY83>6Q?6]DR:+>V4[-;W3+'Z,.D'3Y2T?H)ZUUZOQ^O+R;T.$".JIBJ
MK:_EUYML]$TW3WL+'5$M["71[NUGO;BWB:-I2RW%8HR9(G5G6>T=?B7T_P!Y
M]K%6:^:/+^J7>G:*=,:(7.B7MO>_4VJD%PD,;Q-#6K>G\,GJ0LWJ<)HHN7\V
M*L=7R9K]OYKT_7;6RC$<FJW.K:C:^NJ^D;C3UL L=$I(Q*_6)3_,S_:;%4\\
MR:'K4_F31]9L(4N$L+74;2>!Y?18F\$!1U/%Q\/U=MO\I,584OY<><Q8^685
MMK42Z-H=OIUPK73JCW%K=6\Q7G&@D$<R6K 2K\<3R(WIMP;%6;Z%Y:NAY6U/
M3[NT@T>ZU<W+3)932W31M<1^GZCW$H1II]N3/QC_ &4_9YLJQRU\E^=&T;2U
MN8--M]3\O/8);_5F<KJ$&FNU$E=HU:V21']2"'_2%@N?WGQ8JKVGDK6XO/\
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MJO3SW<+J/F".\U&**PM=2TJVTJ\M[5YU,>HQP2+')P9_[YIO26X)2-/45_\
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M7+C\07U>=/\ )XXJC_*7D.30M=O-5]:*/Z[%PN[2RC:"VN)RX?ZW+!5HTN0
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MNCWMI!>6MY%+;W,7KP.''Q1; O0FM 3Q;^5L57KJVEL0JW<+,Q4*!(A)+UX
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M9/A]/X>3*JV@ZM^7ND:K;7L7G;RYZ5O;K;>@D]JAXB""-BC?6"(^36W+[+?
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MW_*N_P O_P#J6=)_Z0;;_FC%7?\ *N_R_P#^I9TG_I!MO^:,5=_RKO\ +_\
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ME+F]CFAA1FOR6]:X5H@O&.4%>-O]B+C\'VL53+SUY$B\TVUHT=_/I.L:7/\
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M78J[%78J[%78J[%78J[%78J[%78JZ@Q5V*NQ5V*NQ5V*O.//M?\ E;7Y8?\
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M\4?X7XXJG.B_DO\ D_K-B+VQM-0:'U9H&#ZGJD;I-;RM#-&RM< AHY8W1O\
M5Q50U7\H_P F],O$LI;+5)[UXFN#;6NH:K/(D"&AE=4G/"/E\*\O[QOACY<6
MQ5!#\O/R),RH(=2,):".2\^OZM]7BEN5#PQ33&?A%*X>/X'/P-+$K\6D3%5.
MU\A?D3=VJW-I:ZK< 7,UC<0QWVK&:WN;96>6*>+U_4B=4C=J,OQK]CER7%4(
M_E/\ATD>)],UU9([E;%U-SK%1<N\,:Q']_\ :+W=NO\ +^]7_*Q5,Y?RW_(:
M'0&UZX%]!IJ3_5)GDU'5@\=P)OJ[121^OZBO'+\,@X_!Q9V^#XL55M5_*G\E
M],NWM)K+5)KF* W=S%;7^K3M#;@D>I*(YSP5N+>F/MR\']-6X-BJ!_P%^1@U
M)]/>QUB*2./UY)I+W5TA2#U3#Z[2-.%6'U%8>H?AX_O/[OXL54[CR1^0UM87
M%]/::Q%#;P+>%7N]861[5V""XCC:8/)$&*\^(Y1\X_45?43%4=%^6'Y)2VDE
MU]7U")8+KZE=QS:GJ<4D$RJ)&$RR7"\%2$_6&<_#Z'[Q>7PXJ@;CR3^0MMI]
MQ?SVFKQ06]N+ZCWFL*\EH6X_6(D:8/)$I*\^(Y)SCYJOJ)R5;E\A_DG%??49
M-(UY;OTYI?3^M:ONEOZ?K,&^L<#Z9GB5OB^T_'[7+%5-/)GY%-:75Y^C=<6W
MLC.+IVNM8'!K1/4G!4S\OW:"K;?Y/V_AQ5%0_E]^1$MI-<>AJ:20O!$;-[_5
MENFDNEYVZQP^OSD,Z_%'P_ED_P!]R<55*?R)^1<+6\?U#69+BYFGMA;17FKO
M,D]M&9I8I(Q/R1UA4RJ#_>1_'%SYIR59!8?D=^4.HV%MJ%C!>7%E=Q)/;3QZ
MMJ95XY%#(ZGZQT93BJI)^0OY3QL%DMKQ';[*MJ^HJ3\@;G%50?\ ./OY7G_C
MROO^XKJ7_91BK?\ T+Y^6'_+%??]Q74O^RC%7?\ 0OGY8?\ +%??]Q74O^RC
M%7?]"^?EA_RQ7W_<5U+_ +*,5=_T+Y^6'_+%??\ <5U+_LHQ5W_0OGY8?\L5
M]_W%=2_[*,5=_P!"^?EA_P L5]_W%=2_[*,5=_T+Y^6'_+%??]Q74O\ LHQ5
MW_0OGY8?\L5]_P!Q74O^RC%7?]"^?EA_RQ7W_<5U+_LHQ5W_ $+Y^6'_ "Q7
MW_<5U+_LHQ5W_0OGY8?\L5]_W%=2_P"RC%7?]"^?EA_RQ7W_ '%=2_[*,5=_
MT+Y^6'_+%??]Q74O^RC%7?\ 0OGY8?\ +%??]Q74O^RC%7?]"^?E?_RQ7W_<
M5U+_ +*,5>=>4OR^_+--)\VZIYF34&L]'\R7^F6\D=]J;&.VBDC2!"L,M2%+
M_P!X_P#LWQ5EES^57Y)6VM2:/-#?K=P6IO;M_P!)ZIZ%O *_'/-]8].&O%BO
MJ,O+%5VC_E+^3FK3+%;:=J\;20_683<7NKP"2&H42(9)UV/(?#]O_)Q5OS!^
M47Y.Z%':O?6&J,+RX2TMQ!J&JRDSRFD:'C<;<SL*XJAI_P M_P A[;09]<NE
MO[?3[27ZO>&74=6$L,_,(8I(?7]17!933C_=_O?[KX\5=K?Y8_DQHU]!976F
M:S)-<LL=N;>\U>9'D:.241JRS\2_I6\K\?Y5_P I<56:)^6_Y+:S<K;VFF:T
MK--+;EIKS5XE$T K(C%IQQX]*GX>7P?:;%5&\\B?D-:VE_>/;:M)9Z<)VN+F
M*]UAXBMI((;DQN)N,GH2MZ<O#[+*W\N*HJX_+'\E+<R>I8:N1 T<=TR7NL2+
M#+,$*12E)F"R'U4Y+_NOE^\X8JAK7R#^1=Y:1W-C9ZM=A[F>QE@AOM6,T-U;
M!FE@GB-P'AD58W;BX^)5Y+^SBJ@GDS\BGL+6_73=<-K??5/J<GUK5_W@OV"6
MQ4>OMZK,@'+C]M>7PXJGVC_DQ^3^KQ2O9VFH<[>5H+JWEU/5(YH95H2DD;7
M9#Q*NO\ /&R2)R1EQ5,/^A?/RP_Y8K[_ +BNI?\ 91BK"/.'Y,>0++\Q?(.E
MP6MVMGJLVIK>(VHWSLP@L3)'Q=IB\='^UZ3)S^RWPXJG/_*M?R*%E?WK1Z@D
M&FW9TZZYZAJZO]:HA$4<9F]25F]5.'IJW/\ 9Q5#2>0?R/AOWL;G3M:MYH39
MBX,MYJZI$=1D]&UYMZY ]68&+_)?[?'%62O_ ,X__E>BEC8WYH*T&JZF2?D/
MK&*L83R'^2$FEPZI%I>N2VD\ES#&8[K6&?G9\_7' 3\_A]*4=/C]-N&*K+SR
M9^0-MI<6K)!JEWI,]H;^._M+_5IX3;A@C-R2X-&1F572G-?Y<577'D3\DH+Y
M[!])U[ZW'$9VB6YU@D1"7T"^T_V1-\%?]G_=_%BJFGDO\BGLK2]73=<-M?&U
M%F_UK5_WGU[_ 'FH/7V]7;[7'CR7GQY8JF1_+'\C5T6ZUF2+4(K2QD,%XDFI
M:JLT4_)4$+PF?U!*[.@C3C^]]2/T^2R)BJ%O/R]_)&T@MYI=-UOC<S+;(%NM
M8)6=YS;)$_[\<7><<%_X/['Q8JC[?\J/R3GU"QTU8=0CU#4;5[ZUM)=1U9)#
M!&5#%@TXX,ID7]V_Q_:_D;%4J;R3^1BRWD;:9KH:PB%Q=UN=9'")HY)D8_O_
M -N*&5U_U?YN.*JL?D'\C7B@<V.L(]V8Q9P->:OZLWJQ/./203EFXP1/-)^U
M''\3?:3DJF%Y^4WY+VMK83FTU*5M4 .G6T.HZJ\\P*>H2L0GY@)'\<C-Q6/]
MO%4L?R/^1 DACALM8N6GMI;Q/1O=7:D5O(L,X8>N"DL,SI%)"W[Y9&X<.6*I
MOJWY0_DKI$%I/J,5];QWUQ!:6I.IZJ2TURP6):+.2M6.[-\*?MXJHC\JOR2_
M3.H:/)!J$%_IMNM[<I+J6JHIMFJ/5C<S\9$4K1^!^#]K[2XJD]CY2_(:^6)K
M33M<E2>UCU")Q=:P UK*Q2.45G!H[#BJ_P!Y_D8JB+;R-^1,[SQK9ZNDL)NT
M$<E[JR-))8&EU'%6?]Y)#^TJ_L_$G+CBK</D/\BI[..[@L]8G@>T34)3%>:P
MYAMI06BDG"SDQ>J@,D:-^\:/X^''%4WC_)W\EY-?ET!(KTZO!;K>2VOZ4U2H
M@=R@;EZ_#[0^SRYKR1OVUQ5,?^A?/RP_Y8K[_N*ZE_V48J[_ *%\_+#_ )8K
M[_N*ZE_V48J[_H7S\L/^6*^_[BNI?]E&*N_Z%\_+#_EBOO\ N*ZE_P!E&*N_
MZ%\_+#_EBOO^XKJ7_91BKO\ H7S\L/\ EBOO^XKJ7_91BKO^A?/RP_Y8K[_N
M*ZE_V48J[_H7S\L/^6*^_P"XKJ7_ &48J[_H7S\L/^6*^_[BNI?]E&*N_P"A
M?/RP_P"6*^_[BNI?]E&*N_Z%\_+#_EBOO^XKJ7_91BKO^A?/RP_Y8K[_ +BN
MI?\ 91BKO^A?/RP_Y8K[_N*ZE_V48J[_ *%\_+#_ )8K[_N*ZE_V48JPO\Y/
MR?\ (_EO\M]8UK1X;ZVU&T^K>A.=2U"3CZEU%$WPR3LAJCL-UQ5D$GY0_DM%
MK<NBRP7\=]#:'4)1)J6JI$+97",_JM.(OA8_%1_A_:Q5!)^6_P"2$MK:W,%E
MJTPOY&CTZ)+W5_5N0B\GEAC,X=H%7<S$+']GXOC3DJF^F?D=^4NI64=[:V6H
M^A)R"^IJ6J1N"C%&#(\X92&4]1BJ2W7Y>?D;::G>Z?=6>K0OIQA%_<M?:M]7
MA6YKZ+R2B?@L3\3^\^PG^[.&*HZX_*7\DX-6FTAX;\ZG!9-J4EJFI:J[_5D;
M@6'&<AFY?[K!]3[/PXJDTGD_\B(K:]N9=-UR.'3I#!>,USK'P2AHE*']_P#:
M!N(?^#_R7XJIH_Y6?DO#I<^I7-CJEM!;SK:M'-J&JK*T\C(D<4:"X)D>225(
MT"?[L_=_:5L50Q_+S\C%NDMI;35H6>VNKUI)KW5XT2"QD]*Y:1FG' Q2%4*G
MXFYKPY8JI:CY%_(;2UYZI:ZOI\0,7J3W-WK,44<<\GHQ2R2--PCB>4A.3G]V
MW][PQ54O/R[_ "5M+];&32];:>2Y-G"8[S5G1YEMS=%5<7'&GU96FY_8X8JH
M_P"!_P BA+,DMAK4*6L,%S>32W>L+'!!<LZQRRL9_@CY12\W^S'Z;/)QC^+%
M64I_SC_^5KBJV=ZP(!!&JZD10]/^/C%5W_0OGY8?\L5]_P!Q74O^RC%68>5O
M*VD>6=+72](CEBLD=Y%2:>6X?DYJW[R9I)/^&Q5.,5=BKL5=BKL5=BKL5?_2
M]4XJ[%78J[%78J[%78J[%78JQO7?+NHZAYE\OZK!-%%!HLT\LL,BNTDHN(&@
M(5@P5.*OR%0WQ8JQ_5_RQN+ZVF$0TZUGO-0L-0OXHH)%MIOT=()%K&'KZL]!
M'*_^^U3[7'%4_P#)_EG4M A:U:YADL9);BY-M'&R"&2XF]01P$L>-NBE_A<,
M[2OSY(G[O%5^H^7=2'F8^8-)N8HKF>S33[V&YC:2-HH9'EA>,HR,LD;S2\@>
M22*W['#%4FO/RZN[A-2TX7R#1-9OHM2U&-HC]9]5#&TB12*PC6.9X(F^*-FB
M_>JO+DGIJK]/_+VY@U^QU^2[C@OH;BYEU&&UCI!>I-ZY@]7F2XFM&N9/2EY?
MW7*-OM? JPCS7Y1U@0ZO?27EO';VOFBWOM0*K<"EG*MC-(O[MU>L<D5JYD7X
ME1)F3]G%66WOY;:I>Z.= NKZ!]$C@O8X1%'+!<237:E$EN7B=5E94DF6>BK]
M::5IFX/BJ0^9?+WF?1I]/OX=<5-9_1JOJ<JI(D5W)H:EHJ(KU_>QW4[3P2-)
M&_'E_NK%67:SY%GU?S!J=W>7"'2=4T5]"GMXU*W'IR,[/(LA)C#?O6 7T\52
MOS#^6OF#7M.FAO\ 5+4W@TQ]'M)8[>1(Q#/+%)/-(GJ%FED^JP!$1U2+]Y]K
MG\"J.@_+J26SO-*U*Y2;2+J.\7C"A6YYZA%Z,K23.6]9HHFEBAF=?5]-D];U
M&3FZJ \P_EIK^NZ3+:7NIVS72:7-HUE,MNZ1B*Y>)IYYD]0EY76U@"1HRQQ_
MO/M<_@51MU^6MK<:UHEPT%HNE:7!>+)8!):FXOIHKAY87Y?N^$L'P+3_ '8V
M*I>OY9:XL'F)([G3UN/,+:AZUYZ,QD2+45 ,5/4XN(V5&#?Y/'X.6*JUE^6>
MI6EK:QQWT GT^YM]2L9C"[L+N"%K9HYG9_4GM7@>18@[^M;\^*2/%'&F*J.K
M?E9J.IW\5]<:DB337\^H:E)"DD;<IK :=&EM1CQ$-NL;'UO56>56]2/TI/3Q
M5$:*=6U%(].U74!86MK>R:/#9:-&;3F]K"T@>63DSP1R11F2.&U9?31HU]9_
MB5%63+Y(\HI#+&=(MI?6!$TDT8GD>I)/*27F[;LQW;%4!^65E=V/E9;&[U&X
MU.>SN;FV::[H9%$$K1!*A4/"B<TY<V^/CZC)QQ5E>*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*O&/*7EV]\Q^5/S$T:TGBMI;OS?JBM/,K.JJDT,A^%2I
M)/"G7%6;:YY"A\P7T\^J);QB:RN;!KBTC,=VT5[;^A/&\K$AHP?WD0X_:6+^
M3XU4STVR\V6\%O%<WEG*T)CCD=+>1?4B39VH9/@F< <=VC3_ "_V55#SEY=U
M76XM,6QGAMWT_4+?46,ZNX<VS<E0!"M.1^TV*I%=_EIJ%]#?0WU_'+!J\EW>
M:I'$LT'*[N+9+.'TV20,MO#:IZ3QMR>9F:7DGPKBJ-_PAYDDL/)T-UJ%M/=>
M6YX[B]N3%(OUHQ6LMI55Y_NV=)VE:O/]XO\ +BJSRMY%U/1=<O=3DDLG>_O+
MNZN)XXI5G,5VXD] %G*<4=(_WA7EQ7X>/+%4KUC\JM6OH=<2WU&VLVUJUNK6
MX6&&6.&9[J0,+FXA601M<6\:^FDD:QO+ZDCS.WPHJJ*U#\MM5N;34+"/4(8[
M'5M1BU:Y5HW,L%P'B>X6WD5TK#/Z3+QD7G'ZLGQ.GP8JJ6WY<ZA!J=MK,5Y#
M;ZE&UTU];PQD6MYZRSBW:6I]42VOUEU616^.']W_ "<%4NT_\K-;L/+>F:):
M7&G0KI\VF7$LZ03@W,NEO$RR.OJ41I1;HC</YG?X\59EY:\O7&F7&J7]Y.MQ
MJ6LW0N[QHD*0J8X$MXDC4EFXI##&&9F^.3F_P\N"JI[BKSCS]_Y-K\L/^,^L
M_P#=.;%5TWY::K/-=W-Q<V4[R:U)K=O:S0226S>M9&Q:&XC+@R<8_P!ZCK_N
MW]CCBJ"'Y/ZCZZA]3BE5+32K*'4I(G:_B&E2/)Z\<A<Q^M,TG[2\(^*?WN*O
M2K%;X0 7SQR7 9B7A5D3B7/ !69VJ$XJWQ?$WQ?#]G%6'V?D35+/37TR*]A>
MTMY;^?37>-Q)SU!IF83D-Q98OK,G'T^#/\'V?BQ5*M1_*.^GTW5;6RU&*T76
M+ 6MQ9^D3:Q73O&UQ=0JI1U^L")/4C+?%+^]^T[\E4_O?*NN7'F>;7%N;5?5
MT=M*] I(:2._JF3D&^QSVX4Y<?VL58_8_E;KEAY>TG1K2YTZ!-+N=-O'D2&?
M_29]-$:^HX,E$:98(U/#[/Q-\;8JGZ^2KIM)UF"YDMKJ^U^[6\U+UX!)9L%6
M&'T! S%O3^JVZ0\F?GZG[_X?A154 ?R]UE/+.GZ1#J2R/9:M!JJ&Y$TL<45M
M<+<1VD)9VE]). B5I9'XK_L455?J7D37KSS#::_^DHDU"RU074(XSF$Z>+=[
M?ZJ8_4X^J5FD;U_YF_N\55[[R7K4]_YNN([NV1/,ME%90*T<A:'T8Y(@[D-^
M\JLS'BO#XE7%4K7\L-0&@0:.1I?U>W,<@B^KST:X2 0"Y619%FMYEX1LOU=D
M_P!V?%^\YJJG<ODW4(U\NW=OJ+7.L^7X'MA>7RF07:3QI'.TX0JPED,4<BR*
MWV_M*_/%4IL/RJ,6OZ=J%_/!?06BWLUPK1NDC7U_?1ZA)/"0Y$21W$06*/XV
M])OCD;]I5'^??(NI>:X;NT^O):V;V,D%AP]57BO)6'^D2<'198T"IPBI]K]O
MB^*H:\_+_6M0UB'6+V]MUOH5B1C;QR*MQ&L?[ZWFYL_^CS7"0347]XOH\>?Q
M-BJ4Z)^4^NZ=/I4TUUIUW)I&FV^FV<CP3@J]M.9TN123[7(_W5>/^5BJ+T[\
MM=>L+C4;V.^LY;O49K]I%EAE>-(]0<R$Q5?E#*C'@YB_=W$?'U4YHC8JC/*G
MD/6_+4<:V=_;NT]G96FI,\+GX]/@%M'/!\?P\X%7G%+S7U%Y<OM+BK<'D77X
M_-.F>96U&(W\,U[^DT"S>E-:W814AB1I"L+1+!;UDHWJ- GP_$V*LZ6M!7KB
MK>*NQ5V*M,P45/08J%*"Y28D+7;Q%,64H&/-136M'DDGBCOK=Y+:HN465"T?
M$T/, U2A_FQ8HF2>&->4CJBU Y,:"K&@%3XDTQ5MY8T4N[!54$LS;  ;DFN*
MM1W$$E3'(K@&A*D'<=ML5<T\*%0SJI<\4!(')J5H/$T&*M^HGCBK?)?'%5BW
M5LY4+*C%Z\*,#RX[-3QX]\5>>?\ .0[ _D[Y@H?^6/\ ZCH,51GFOR/<>8M6
MU&[.I16VG7FC7&B2&)29XS+(':7GRX? Z<6C*_9Y?%BJCIGY?W]E?1:Y9WUJ
MNJ+/<2I:QQ,NFK;WL5O'+%#&'+Q\FLX;GU0_Q3/-\'[W%646]_/:70MM4U&S
M]2X""SB%(9GDZ2?"[GFI<J(E1?A_;YMBK%/,7DR]N+_S$]]JUG9:/YJBM;"Z
M#JRSK!"DB,D3NXB]:=)74-Q_=_:X28JB!Y%UK_%.G>8SJ,(O[2\N6NT"SF*2
MQN(A"MND9DXI(B1PLTO'XY(%^#XWQ5#:A^7FL7GEWS-I#7UH/\1:D-0#F*0K
M&A,1:)EY_&3]73XJK]MOAQ5-I/*5U+Y9GT61-.%O),)%LC \MKZ1E$LL;+(Q
M:LCF1ED7CZ/)/27X,58U'^5LVIVT5O)KR7FG+I]_IK30EY9HFN[N*[1899'F
M'IV3VT4,4<WJ.T?]Z^*II>>0-?OM9DU:^N=/GFFAM;6XM_0E]"6.VN#/([1M
M(X]290D)7XE]/^;X<50<_P"4=P+:TL(KR&^TNTU.74(K348W<K;O8&PBLP\3
M(?3MT<F.1OWG%(D_R\51-S^7WF6\FUI;C4+-+;7].MM(O/2@E]2.V@-P)/1+
MR%>;QW;QHTG+AP21O4^),59[:0+;P1P("(XD5$KUXJ*#\!BJMBKL5=BKL5=B
MKL5=BKL5=BK_ /_3]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78JQA;:W
MNX?-EM.P2">X>.9SQH$?3;=6)Y578']K%4U\M7,EUY=TJXE8-+-9V\DC+L"S
MQ*Q('TXJQG\R[D)'8VJAGN;PW-O!$H/Q/<0&U0DT(5?5N8@6/\V*LX!J*XJ[
M%78J[%78J[%78JXBHIBK'];*IYA\NHS,D)N;AA0?"9A:2A%8T/[#3,/YN.*I
MKJFJ6&EZ=<ZC?3+#:6L;2SR'>BJ*[ ;DGHJC[38JEGDE+\Z&+N_@-K=:A//>
MO:-]J%;B0O'&_P#Q8L93U/\ BSEBJ?8J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J\Y_);['GG_P "_5_^)QXJ]&Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O
M.//O_DVORP_XSZS_ -TYL5>CXJ[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%5*Z#&!PIH>)P%GC^H*-@ZLJ!:;1*3\R3@BG(-
MV%W6AZ]/9-!:Z?\ 5;VRN=0GBOG:#]Z+EY^$<=&=N,@FCD?UN"_NOL,V2:VO
MK.O7OF&ZM;62XF]!W-W\49M5 O[=H B-\22+9K/SY*GJ/S=/4_=R8JA[G0?.
MB:58Z;:K<N(XIH+QY[A)5D61Y%?ESD!XE&4PLRS-_D6[)\:J(6RURTO[?3H)
MW@DU.XE-Q#'( T=K&T<C72T#4;X6M?\ 6GC_ )<53"\L_,_Z9N)(?4:T$JRQ
M33,C1(H@D'%(E9F91(49F]..;]C][]O%4GT;_$^K37$UK=WXL(HV:)WFB*R7
M@C6@5E!K!ZO+X/LK]EU5/W6*HM;7SX;R=[J:9K=SRFM[81(#%4<8[:5KBL<Z
MK]O]S$LG[S]]_=-BJV/0M<ATW0 UM>M)91W:WJ6D]LERIN&#1\I&9$:M/WGH
MLO\ P'PXJPG\Y/\ $#_EUYEM[V\-S!I\5E)=-&U4-[<7-J'MJ4'PP<'F1?V?
MK,/\F*LZ72O-=)A'#)#'=2SS0P^I%Z<:SW,LDZW2AFYO) Z+#Z7J+'+^TGVL
M576?E[S5;QV-BEW=)86]HC.XFC]3ZT(2IC+4KZ2R+&RJO[O_ )Y?!BJ+:SU]
M?,.F:A);2.IL(H;[T%MV03AR[!C+(KHBEJJT//%4;J-O?-J$&HOIS7\+VIMV
ML*Q%HI'8,6/J.L95A^[D9#R^'[,BXJD3:/YS72FT']_*&$B?I))DCC6%M-:)
M8PQ;ZQR%[Q?^[_R^7[.*N&F>>VFEC%S=QV\BPK"H,)9(1)%R#3M/(?K*Q^MZ
MC+;_ +QO]W-^[Q5/X=/UE]-GLKEEDB$TT?&X4S//9&H5"ZR1\9'0\?5?G_EH
MV*K_ "I9WEII_H7,;1+&W&V640B?T5157U_0K"9/A8<D_P!U^GR^/EBJ=\E\
M<5;KBKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_4]4XJ[%78J[%78J[%78J[%78J
M[%78J[%78J[%78JD'ER$3G6Y)R)!<:E.&0J.(2*..W"T-:@I$.5?YL54O)D9
ML!J&@5)AT>X]*QJ"*6<R+- @KL1#S>V6G[$"XJE/Y@RH=<\MV;\@=1N#:Q,L
M9D^-;BUNB*T*H_HVLTBLW[,;M^SBK.5^SBJBU_8K=I9M<Q"\D4NEL77U&5>I
M"5Y$#%5\]Q;V\+S3RI%#&*R2.P55 [DG88J@-0\S>7]/M(;V]U.UM[*X!,-Q
M)*BQN%4L2C5HP"@LQ_97%4?!,DT:R(P>-U#(ZFH(85!'L<55*BM*[XJ[%78J
MQOS_ "6MIY=DU6X;BFE3VU^9"P4JMO,IDXD_M-#ZB<?V^7#]K%4"D<WFC4K:
M\OXQ:>7;"5;BQLKCX)[JYC:L5S-&:>E##02V\,@]5I>$TJQ>DBXJS%:4J#4'
M<'%6ZC%75&*NJ,5=BJU)(WJ$8,5)5J$&A'4'WQ5=BKL5=BKL5=BKL5=BKL5=
MBKL5><_DM]CSS_X%^K_\3CQ5Z-BKL5=BKL5=BKL5=BKL5=BKL5=BKL5><>??
M_)M?EA_QGUG_ +IS8J]'Q5V*NQ5);GS?H=MYHL_*\UQQUN_@DN[6UX.0T,)H
M[%P."TIT+<L53D," ?'%6R=ML52#R5YVT7SCHIUC2/5^IB>6V/KIZ;>I W!_
MAJVU<53_ !5U1BKL58OYR_,GRGY-:P7S!<R0/J;2)8QPV\]R\C1!2X"P)(VP
M=>V*H/R]^;WDOS#JT.DZ7)>O>W 8QB?3[ZWCHBEVK+-"D:_"O[38JS0&HKBJ
MG<7$%M;RW$\B0P0J9)99&"HB**LS,:!54;DG%6 /^?\ ^4R7"QG7XS"7],WZ
MP7#60??X6NA']75MO]^?\2Q5GEC?VE]:1W=I/'<6LPY0SPNLD;K_ #*RDJPQ
M57J/'%6BR@5)%/'%7)(DB*Z,'1@&5E-00>A!&*MXJZHQ5U1XXJ[%78JP_P S
M_FKY$\N7SZ9JVIA=36,2OI]M%-=7(C?8,8K=)&4?ZW[/Q8"D([R1YBT3S%I0
MU71;M+[3I24BN8PP!*$AEHP5@5/4$8(MN8VQS4]>UNUTN:^M]5,MW<2ZE%]5
M>.!Q EN\ZQ3(JHK\86BB1_5:17]1?BY9)I3[0-?U*\U:^L[I$62T>*":*O#T
MY?0]1_3!'*5)#1TW_NVQ59/YW:*SCO'M85M;AV6VYW<<4I"$@F1)514:H^PK
MR?Y?'%4,WF._FM;J:WGC@F;4+.&U5O3D"07$-N[GX?[Q TDS>H#]E6XM\&*I
MAY>UHKI4QU&X>6_MBXN8G]$N7CA65U@] *DT?%PR4'/BW"3X\50I\]K%!ZDM
MI&KUC-/K40C*2Q^I'223TU,G'^\C7['\SHRMBJE8^9KNZ6"4RH@FU7T#&#&_
M&U^KF6G)=B/VO5'[/[6*HZQU*[C\S3VUY>%K:8%M.1/0,!0"($.5_?+.))/V
MCZ4BNG#XL5>=_GYJ-U<_E_YI4SRI#97%K;FRA^K\.!GMY?5N/4'KTD+4C]$_
ML_Z[8JSVY\\26D3M/9)SC>2W/IS\T:Y,*SV\2/P'+UU;ARX_NI?@^/DN*J47
MG^YDO5MQH\RQO/+;K<NQ2.MLDK3&K(*FMN_I*G/U$^-O2^QBJE+^8=W%;Q.^
ME+Z[VOZ0>(7(*K:^BTX//T_BEI&Z>GQX\^/[W@W-55>X\^W,#) =(FGOO6DC
MFM[9C,%2*.&5BKA!R<K<Q<498TY>I^]X+S959=>>-36V+P:=$)99C'9B6X/%
MXX=0BL9VD*QGTC^^5XZ>K_E?9XXJFFL>:8K".*2&-+M7BFN&=90J"*VX^KP>
MC"2;XQZ<7P\_C^-..*H&Y\_VL*6[>@O*X^MT26>.$J+.X6W);U*?WA?E3]G[
M.*I9J7G?46M]3N+.UD=(M-2XAD@:VGB@E,MPC/(Y=>:_N4^%%DX\6^'EBJJ_
MF37I72U@C:VEDNM6@BOKA8#;-]5^L+ /A?U (_33ER1.7!N38JR#RQJ:75CZ
M4EQ))>1,ZSQW!A]92C<6KZ 6)T#?"LD:\6_U^6*ISBKL5=BKL5=BKL5=BKL5
M=BKL5=BK_]7U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL50^H:A::?:37EY
M,D%K ADFFD-%55ZDG%6'^5?-$4.DM>2:;J9M;Z>[O8[WZLT@>.6X=HSZ49>X
MC_<E.*20(W%?Y\55[36M*G\V6VI:;=0W%KJ-K)9Z@$8!HI;4M/ 958J\9"-=
MHP=.7V<52J>76-4O-/\ .SL8](M+F(:1I9(!>UNB;:6\EJ/[Z59TDMD_W5;Q
M\>7J74J*JRWSAJDVD>3M<U6%:SZ=I]U=1*#2KP0O(N]#3=?#%6+:A^6'D>3R
M#+:#2XH62R,\=]$.%ZDX3U?76Z'[_P!;U/C9R_Q_M\EQ5,-1M9E\CZ-:F3Z[
M,LFCH9;OX_59;FW!>:G5FIS/^7BJIH/EG0['S=K+6EHD2"VM_2A&\40N6E:<
M0QGX(5G:-'F6,*LKKR?XL51OD:*6WT>6Q)9K;3KJXLK"1R"S6UO*4C!I_OJG
MH"OQ.L7/]K%6.'36M(KWS=;O_N9@U6X6]<? EQ9)<_5C;.HJ"(X$1X&;DT=P
MG+X4EE5E7H@% !X8J[%4A\]1)-Y6O;9H5G^LF&W2)PI4O/,D:%N6U%9PV*J_
M^%?*[*6_0]C7?<VT/_-.*L(TW4=6LI_,NG:9>P:=HGEB5I8'FM7N XG'U@Q*
MJNA%O;,)K9?1^/G^[3AZ'&15E-IK]U?>2&UOT?J=^;&6:6V:K&"YB1O4B;FJ
MGE#,K1MR3]G%6-ZYYRU[1_(]U-&WZ4\Q137$-GQC1'G2T4W$DDD:@I5;=&5^
M"<7DX<%C]1<591Y5U2^O;*ZAU%XI=0T^;T9I85]-9%:-)X91'R<Q\XIDYKR_
MO.?'%4C\K6<%K>^7+MIG:^UK3[FXOIW=JSSR^A<;K7A^[YR^DM/W<7PI\&*H
M?2'MO+GFC4+Y0(=*US59;2]XBB)J#!#;S&GV?K/)[>1S]J7ZMBKT1345I3%6
M\5=BKL5=BKL5=BKL5=BKL5><_DM]CSS_ .!?J_\ Q./%7HV*NQ5B\WYC^64\
M^VOD:.8W&O3P2W,T45&6WCC4,/6-1Q>0'X$')N/Q-Q7CR5:\Z?F/Y9\H3:7:
MZK,3?ZU=PV6FV,5&FD>:18R_$D<8H^=9'/\ J_;95Q5-?,?F"TT#0[[6+U6:
MWL8FE:./XG<C98T!I5Y'*HG^4V*I1JOYE>6],\V:)Y2N'9O,&N%C#8Q\7:&-
M8GD,DY!HB_NS&OVN;_9^#DV*K?-GYCZ=Y?U*WT:#3[W7-?NHFN8](TR-99EM
MD;BT\I=HXXHN7P*SO^\?X4Q5=Y>_,C0=;\KWWF&-)[*WTHSIJUI=IZ=S:RVJ
M\IHI8P6HZKO\);E^SBJ477YQ6JW MM.\MZSK-S;PPS:O'I\$4OU%KB,3+#,S
M2(KW C;DT4!E9?\ 98JB=0_-_P L0Z#H^KZ9%=:XWF!VBT;3M.B]2ZG>,$S
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M::&(*K^O.M>".BI \G/D_I\9%4\C\L:S(=.AU#4X;FQTV9;A(X[4PR2M"K"
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MKL5=BKL5=BKL5=BKB0!4XJ@)-?T*.1HY-1M4D0\71IHP01U!!;%5O^(_+_\
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M1\7_ #5BKO\ $7E[_JYVG_(^+_FK%7?XC\O_ /5SM/\ D?%_S5BKO\1^7_\
MJYVG_(^+_FK%7?XC\O\ _5SM/^1\7_-6*N_Q'Y?_ .KG:?\ (^+_ )JQ5W^(
M_+__ %<[3_D?%_S5BK9\PZ" "=1M0K?98SQ4--MOBQ5H^9/+_P#U<[0_\]XO
M^:L51T$\-Q$LT$BRQ.*I(A#*1[$5!Q5?BKL5><_DM]CSS_X%^K_\3CQ5Z-BK
ML52^YT#2;K6K'6;BV634M-2:*RN26Y1I<A1*  >/Q\%^T,5:UK0-+UJ"&#4[
M=;F""XANXD8L.,UNXDB?X2-T<<OY<57-HNGOJ\.L/"K:E! ]K%<DMR6&5UD=
M%%>(#O&A;;E\"XJUJ.@Z5J-]I]]>6ZS76E2M/I\I+ Q2.AB9AQ(!K&[+\6*I
M;YO_ "^\G^;XH(O,6E0Z@MLQ:W=^22(2*'C)&4D"M7XDY<6Q56L?)?EFP_1@
ML=-@MDT594TJ.)>"0"X7C*41:+R<?:=AS^)_B^-\52+6OR1_*_7-5NM6U;0T
MNM1O6]2ZN3/<JSL %!(655V44V&*HZ7\K/(4WE>#RK-HT$N@6SF6VLI#(_I2
M,S.721F,J/5V^)9/VOY<53+RSY0\N^5]-_1GE^PATVRYM(T4(/Q2-0%W9B7D
M<@ <G9FQ57TCR]I6CK=KIELMJM]=2W]V%+'G<W!Y2RGD3\3D=OAQ5Y1YK_+[
MR7I?YS^0+^QT>VM[K4[O5)K\JGP2206+2QR>D3Z2R++^\YHB_O/C^UBJ)\L^
M1M4;S%%/J&D.EA)J&NR7EM>+:&U^HZI*[QA!"6EEFD_<\XI^<*1--]EUCQ5E
MOY;:)>V-C.=4LYH;NUEDL=.ENC%)+^C()&%FO.-I/B]$KZW(\WD^WBK)=8&B
MM9F+6%MGLY#Q,=WZ9B8TZ$2_"=L50UIJWE*SMTM[.\L+:WC $<,,L"(H&P 5
M2 ,54=2NO(^J1+#J<NF7T2'DD=RUO,H;I4!RPKOBJ*CU[RU&BQQZC9HBBBHL
MT0 'L V*J5EJ?E"PA]"QNM/M8.1?TH)((TY,:LW%2!4GKBJR&^\EP17$,$^F
MQ0W;/)=QH\"K*\@H[2 &CL_[9;[6*JMMJ_E2UMDM;6]L(+6->$<$4L*1JO@J
MJ0H&*K;'5/*%A;):V-WI]I:QU].""2".->1+&BJ0HJ37%5'4Y_(FJK&NJ/I=
M^L53$+DV\P4M3EQY\N-:;XJA;2Q_+&RN8[JSM]%MKF(UBGA2TCD4]*JR@,,5
M3./6O*T4LLT5]8I+<$-/(LL(9V50H+D&K$* N_[.*JG^(O+W_5SM/^1\7_-6
M*H$3>0QJ#:D&TO\ 2+"C7M;;UB.E#)]OMXXJCO\ $7E[_JYVG_(^+_FK%4+'
M>^2H[V2^CGTU+V4 2W2O;B5@O0,X/(T^>*JEIJWE.SMTMK.\L+:WCKZ<,,L,
M:+R)8T52 *DUQ53L;WR5IYF-A-IMH;AO4N# ]O&9'_F?@1R;W;%5.:;R'/?I
MJ,[:7+J$8XQWCFV:91OLLA^,?:/?%5:?4?)UPUNUQ<Z=,UHXDM3(\#&)QL&C
MJ3P8?S+BJZZU'RE?B**ZN;"[$<BRPQRR02<95^PZAB:.*_"P^+%58>8_+_\
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MXOCX/QQ5./+OZ.U :F&M[>5;._GM(Y!"@J(^)*G8;QLS1?[#^;%4W_16E_\
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MN"?#RQ5,[#SG_P Y-6%I':V_Y;69CC!^)K^)G9B:L[L;CXG=B6=OVFQ5$?\
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M)T/_ &48J[_E87_.47_EMK'_ *3H?^RC%7?\K"_YRB_\MM8_])T/_91BKO\
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MJ&;T="F?ZL[PW,0B8M]:>%3+=P_:C:""3^Z].9U67Z-J%VL'Y<W4,<]O<:I
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MM3(T@=;D>E>UE_TGT?KCFTX^CZ#0V_POPQ5GGE?2'T;RUI6CO.+E]-LX+0W
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978J[%78J[%78J[%78J[%78J[%78J[%7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>exh1070_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1070_2.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X1G?17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  'H2    G
M$  >A(   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#(Z
M,C0@,3@Z,SDZ,C0      Z !  ,    !  $  * "  0    !   #CZ #  0
M   !   $FP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !BI
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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ME-@I<\SNKJK! T_1[O3]S/;^>B?9<O\ [F/Y)'LKX(]K3[/S4XR[21^J7:N
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M>6DAQ!;V.)8)/TO]-]%S4E-:N@"W7%K+00Z&X+FF6'=[;#?L_,_1)VT;)?\
M9ZP^L@[FX3M9!]S0+M_YK58MS<S?['N:PMW#]3N<X G=7[M^WZ'Z.UG\YO\
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M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24T$"@       0  .$))32<0       *  $          CA"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #6P    8
M    !)L   ./    $P!E '@ :  Q #  -P P %\ 4 !A &< 90!? #( ( !C
M &\ < !Y     0                         !              ./   $
MFP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $
MFP    !29VAT;&]N9P   X\    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !)L     4F=H=&QO;F<
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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M;U(N9(!^RVQ#B&N_[3_R5)O5:G&-O41H"2<5X G;[9^S_P I)3I;<W_25?\
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M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %,
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M1T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M          #VU@ !     -,M2% @(
M                                $6-P<G0   %0    ,V1E<V,   &$
M    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H
M  (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U
M960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M)'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\
M   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R
M9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M        $G-21T(@245#-C$Y-C8M,BXQ
M                                      !865H@        \U$  0
M  $6S%A96B                      6%E:(        &^B   X]0   Y!8
M65H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M       6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT
M=' Z+R]W=W<N:65C+F-H
M                     &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F
M875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V
M,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                      !D97-C         "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                        =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03
M"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                   "CP    )S:6<@     $-25"!C=7)V        !
M   %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M
M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L
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MCP,!$0 "$0$#$0'_W0 $ '+_Q &B    !P$! 0$!           $!0,"!@$
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M_HK\_/\ J8/+O_<-NO\ LIQ5WZ*_/S_J8/+O_<-NO^RG%7?HK\_/^I@\N_\
M<-NO^RG%7?HK\_/^I@\N_P#<-NO^RG%7?HK\_/\ J8/+O_<-NO\ LIQ5WZ*_
M/S_J8/+O_<-NO^RG%7?HK\_/^I@\N_\ <-NO^RG%7?HK\_/^I@\N_P#<-NO^
MRG%7?HK\_/\ J8/+O_<-NO\ LIQ5WZ*_/S_J8/+O_<-NO^RG%7?HK\_/^I@\
MN_\ <-NO^RG%7?HK\_/^I@\N_P#<-NO^RG%7?HK\_/\ J8/+O_<-NO\ LIQ5
MWZ*_/S_J8/+O_<-NO^RG%7?HK\_/^I@\N_\ <-NO^RG%7?HK\_/^I@\N_P#<
M-NO^RG%7?HK\_/\ J8/+O_<-NO\ LIQ5WZ*_/S_J8/+O_<-NO^RG%7?HK\_/
M^I@\N_\ <-NO^RG%7?HK\_/^I@\N_P#<-NO^RG%7?HK\_/\ J8/+O_<-NO\
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MW6*-Y6 YR2&B1H.KR.=E1/C;%4)_C'RM_AU?,@U2W.A,GJ+J(<&(K4KL1WY
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MXA5>YN#=,9:?!!-R_N^;8JE'E^]_+CRA^2L5PMUIVL3VK7-G:7LW'ZF^IZF
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M_P"4HQ5=J7EO0=4=9-2TZUOG1#&CW,$<Q"-NR NK? U/B7%4P2)(XEBC4(B
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M_P"3K_+K_F$U[_DS;XJ])Q5V*NQ5V*NQ5V*NQ5V*O__6]4XJ[%78J[%7F_\
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M?-._[@@_[*L5=_A;\\/^I\T[_N"#_LJQ5*1^5_YM#S4WF@>>;#]+/8KIA?\
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M'_95BKO\+?GA_P!3YIW_ '!!_P!E6*N_PM^>'_4^:=_W!!_V58J[_"WYX?\
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M7F"?\L=;N)K/1CY?-H][9""6T:O(OQB#B1B?V'5?\G%5'2(O.&G^3KWR=/\
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M0;".[LM3O(M.GL[J1H9H+B60Q,"460'TG5J_SKQ9<53Y_/FJ:9Y]TKRAKMC
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M%LI96G,$TIE ED)9V4D<OC;[6^*MWOD+R_/KS>8;=9=.UR5!%<W]E(8I)XU
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M2)Q/-#'R3]K%5DWY@>4(M,AU0ZE$VGSP/=QW$8>1?J\1XRS,$5FCBB8\99)
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M,H=>5W;_ !"M=Q]I=L58'IOF#7KK\M/R\NI/,5\EWJ'FIM.O[E;D>I/ ]]=
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M,K=#\.*I%>ZO;7.J^;[2ZUB73=-T71;6Z\J3V]Y)&K))%(\UXCF1EN9$NU6
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M*M7.CZ3=3K<7-E!/<(.*S2Q([@;[!F!/?%5'_#?E[TA%^B[3TE8NL?H1<0Q
M!8#C2IH,5;7R]Y?1$1=-M52-_4C001T5]OB4!=F^$?%BJN+#3HYC,MO$DQ<R
MF4(H8R%>!?D!7F4^'E]KCBJD-,T0F2,6EL2[-+,GII4M(I1G84W+H>+,?M+B
MJ^SL])AMS!9P01V[U8Q0HBH>6Q/%1Q-<5=9:/I-@7-C906AD #F")(^0'2O
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MZ)82:; EMY@TC].VES%.S&&WY*IAE3TZ-,OJQ?$'2-F]1?V/C55_-FHWM_\
MF!Y<\I^K+;:5<VMYJFHM"Q0W/U0QQQVK.M&6+E/ZLP5OWG!(V_=L_)5">8FG
M\K^;?*ZZ!6.TU^XN-,N]+JQM>8MGN(;H**^F\30\)#'Q]6*3X_L)BKRN>/6K
MK\H#YDN/JDFJ3Z[+;3ZI687CI<:S]3EBDD6G.!X/W'IOR3ZOQ7CR5<5>C:5K
M6A^6O./G)KC0+72Y](TBVU/4M1L78_6H?WQ"K!Q"Q</2?;[3M\;?:Q5DU[YQ
MUW1[&XO=:TE%@/U--/:TF,WJ7%],(%M7'#U \<CQ\IEC:-T?X?B7ABJ2>8OS
M1\S:#Y<U/5KORT['3[RSMH9))3;17,5ZZQ"6,2*95:&5Q%)&R_\ %B/PQ5E-
MS?:XGEC4;G5M-MWO(8[D_H^"X+130IRX S/&A0R1CX_W?P?Y6*L$\N?F+J:6
M'D;1?+GEJUAB\Q:(][I\4EXT<%M]6CC/H&D4DC(@EC_>4Y/_ "XJS/R+YXC\
MT>1K#S4]L;%+F&26XMRWJ>F8'>.7BP YKRB<H>/Q+^SBJ36_G#4_,MB\4NB3
MIY>UC2YKJ'45,L1B!B#1QRDB)B9XWY)) WP,OI_RR8JQ_P#+?SG=:?\ EMY.
MT?3;-K_5Y-"CORA29E$:$1@$Q(YY2R'C7]C[7Q?9Q5EX\Z>8;Q1:Z9H@76X-
M-@U2_P!*O9Q$\9N&=([17563U7>"9?59O33@G+^\^!5(+CSYYMM?.?G4-;P7
M.F^6M'LKZ'3.9BD)E6XF<F6DB>IQC"O]I.,:^G^UBJ(TO\SO,EZGEJ*72K2W
MO/.$,=UHB_69)$6W2T6ZNY+@B)>+1<T2*).7J^I]M.#XJA_^5Q:PU_I^E0Z#
M')J<NN7/E[45:[$<,5S;P&Y62)O39GBFAXRBJ*T?]VRM)BJ"@_,C].W_ )4&
MJ^7(#?IYDOM&DN!<L\=I?6,4JM-;_ C3++&'"F18^.*LUT[S3K6IWHET[3HY
M]$CO[G3;FX,P6XC-HSQ27'IL%5HQ<1M#Z:MZO']]]GX,58Y^=UUK":9Y<M[.
M2);/4/,.EV=]%)SI-'+<"L,@79K>3C^^7]M?AQ52;SB?+]AYJN- T6U;3O*;
MF?7XHY7@,MT84N+H6D;*418H"KCE\,TGP*J?WC*HY/S)\R:EYJNM%\O:);WD
M%O86&JPW5S>& SVM\[ E4$+^G(JH>".?]?C\.*I/Y?\ SI\RZPGE69/+EO'#
MYO\ KD6F@WWQ)/9<G8S?N:"#THW^).<O-?[KXL53.S_-+6K[R;!KD&E6UO="
MXOK/45N+K_1XIM/,B,(BJ?6+CUY8N,2QP\U5FD?['QJH&U_,;S'KOF3\NVT]
M(;+2?-&FW>IW5G(6>0>C'$>!D %0HFY)15^/[>*O5A0@"N*O(M?\K:'IWYJ?
ME_H\%O73Y[/6#=Q2.S^NT$,!C>>I_>NA9F#/_-BJ1+J$WY>^<_S&O=#L!?Z?
MH^F:/=W,%U>2AE@47#R")G6<L_$MZ:?NX_AQ5Z#J_P"8VH+/=6_E_1Y=6NK"
MWMKJYM@KJS_6E,B0HZJT22>D.7.1^'+X?\I54N;\V-935/-"S:)%;Z1Y0DC;
M5;A[DM<-;S6;72O%"D94R_W2-$TGP\_MMQQ5.K/SAYG=M4%QY>E"VEG]<LI^
M7U>*:0<N5HSW(B].1**WKE?1:-^7P<..*L.US\S-?U7R5^8D-HMO9:KY6LBW
MZ1M)I'B<7%DTX>W8I&ZR1'X5?XHV;XU^'%4'HU_J/EWS3Y6B2&PL=/NO+D^H
M:L;5) TT-DL)5I!^U,BS2LK?:=F_>,W%,59?:_F)YBEM9M03RY+)IATQ]3M+
MCFT*\D4.MO*TJ#XI(V]198U=/A9./V695-/R]\T>8/,VB6FMZCI]M86&I6=I
M>:>(;AIY#]8BYRK*&CC$?!N/#B7YJW[++BJGY[\ZZIY<U#R[9V.F1WYU_4!I
MHFEG]!89&B>520$D9U(C:M/LXJEUW^8?F6(W%I:Z =0UC2H[8ZQ8VC22*9[B
M-96AMYS&L?P1.)%DEX<_L?!]K%4HU;\X?,M@OFF^_P /0-I/D^^C@U8_7/\
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M['Q5K3/)\\7F31+F;R[(+2'R,^FSL]IR"ZCS4F)@0?WK*LWQ?M<^/+]]\2J
MT30O-&EZ+H-IJGE/4M<TR^\N6FB7NG6T[VKVMU;&598[F,S0(UK=+.H>3XU_
M=8JF&N>2KU_,?FEE\OF1;CR4FEVLT-NTD3ZC&DRF.*60%W/!XHTE=N3+\'/X
M,5;T/R[Y@BU!'OM O;FRNO(%KHLT0XPDW=MZHGM6=F#12/S"Q-Q;ESYK\.*L
MJ_*O0_,FCW.K6VHR37FF*EI'IVI7]O';:BWI(ZM;7!B/"Y6V7TUCNPO[SFZ<
MI$C7%6):[Y5U*XL?SCMH-!G==?\ 1;1(Q:GA<3+9K"SQBE PN>3^H>/^_O\
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M@R23QVL6F7%3<'U%4O*?M*B2EE"(O)OM?9RW4@B<R#']Y]7J8:?>,;$OW?\
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M"^K_ #9<;"6,CC _C_WPX5^HS1V=I8^6+G3]3N=.T^VMQ=7-K9RS1W1@4<8
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ML=<TK3/)%Q<Z5=R66F+>07]BD#&:">8GT9_28!F55Y1\T^PLO^MEN:<)')1
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M ,Y1I,0Z*@_+GR;_ -6R.G^O+_S5@_.YOYQ0-'B_FM_\JZ\F_P#5L3_@Y?\
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MXL)U^;O^YC^0Q=R+'Y<^3  !I<8 V #R]/\ @L UN4<I,ORF/J'?\JZ\F_\
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MSU5H8?T?J$\=I9W(:X*O/-)Z21T!+*WJUC;F%X/]OCA_/9OYWW+^4Q=R=_\
M*NO)W_5LC_X.7_FK -;F'\2_D\7<T/R]\FDD?HQ-O\N7_FO!^=S=Z?RF/N;_
M .5=>3?^K8G_  <O_->'\[E_G(_*8SS#O^5=>3?^K9'_ ,'+_P U8/SN8<I(
M_)X_YK3?EWY- K^C$V_RY?\ FO"-=FN^+=/Y/%7TM#\O/)IK33(ZC8CG+X?Z
MV/YW+_.7\IB[DHU#2ORJT^]-E>0117*^EZHK<,D?UA^$/K2(6CA]5QQC]5DY
M_LX_GLW\[[E_)XJJDY'Y=>3?^K9'_P '+_S5C^>S5]2_D\0Y1=_RKKR;_P!6
MR/\ X.7_ )KQ.MRG^)?RF/\ FM?\JZ\F_P#5LC_X.7_FK'\[F_G*='C/,-_\
MJZ\F]],C_P"#E_YKQ_.YJ^K[D?DL7\UW_*NO)M?^.8E/]>7_ )JP_GLW\[;X
M)_)XOYKO^5=>3/\ JV)_P<O_ #5@_.Y?YR_E,?<EFJ^7ORPTF[T^RU&&VMKO
M59OJ^G6[RR\YY?Y44,2:5^(_97#^>S?SON7\GB/.*9_\JZ\F_P#5LC_X.7_F
MK!^>S?SON7\GB_FK5_+SR820-,CJ.OQR_P#->/YW-_.^Y?R>+N;/Y=^3!_TJ
MT^7.7_FK!^=S<^)?R>+^:@-(\K_EQK,,L^FV<=Q#!/-:RN&G7C/;N8Y4^(C[
M#CC_ "Y+\]F_G?<ITF,\PB;[R1Y T^RFOKVR@MK2V0R3SR2R*B(HJ69B^PQ_
M/9OYR_D\7\U!Z1Y<_+;5VG6PLEDEMB@N89!<PRQ^HO./G'-Z<BAU^)#Q^+$:
M[-_.^Y?R>+N3/_E77DW_ *MD?_!R_P#->/Y_-_.^Y?R>+^:[_E77DW_JV1_\
M'+_S5C^>S?SON7\GB_FM?\JY\F_]6R/_ (.7_FO(G6YNDE_)XOYKC^7GDU02
M=,CIV^.7_FK#^=S?SE_*8SS" TCRQ^7&KK='3;..<65S+8W9#3CA<0&DL9Y%
M:\">J_#C^>S?SE_)XNY,/^5=>3?^K9'[?'+_ ,U8/SF7K)3I,?*FO^5=>3?^
MK7'_ ,'+_P U8?SV;^<OY/%W._Y5UY._ZMD?_!R_\UX_G<W/B7\GB_FICI/E
MO1]',OZ,MEMA-3U>)9N17I]HGQRK+GGD^HV6W'AC 5'9-,J;'8J[%78J[%78
MJ[%78J[%78J__];U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL58[<V
MWF W,IB:Z](L>'&>V5:5VH&A9A_LFRX2C73_ &7ZV@B?XX?^)83^:VI.VAO9
M7MM>'ZH]D\<A@>2%YS/&79IT40DJG[M!\/*5F^#[&9W9T?WE@QW$_P#<EP];
M/8 W]463^:M"U+7[.VU32]1?3I[>)Y+>VO($:W?F 2+J&9?479>/[+1?%F'I
M\L(W&4>,'^._7#^JY.?%*0N)K^A_"G?E;4I=0\O:9>7$(MKFZMHY9+==@A91
M4*#0\/Y?\G*9@"1 ;\9)B"6*^<M$U"Y\[V>L>6-5BM_-VEZ=(ITJ]4O:7=A/
M.I96*_O(&,T*K]8BY\/@YQLN19L;\O\ GJ&;3_+NBZ#;+Y<&K7&L+<VT\Z1&
M"_L[D&>UAE]"YA;U)IY98OW?QQQ\?A;X<53!/-WFVXN=&\M2:K8KK%Y87EQ+
MJUO)Z$%Q<6EU]6X6_K6\ZLT8_>3(L:\O]U_NL59IH-]>7OE"VNKZX@N[V:S)
MN+JS#BWED"$-)"' ;TW(Y+BKR_\ +/RMJ_F/\M_RU:Y>VLM)T%H-7]>.222Z
ME>V#B*+B8TCAC?FWKGU)>2+P7^;%4PT#SQYFO_.-G8VNMK?Z5K6CZEJ%I?&U
MA2W$MM=+' ]K$&^L>@B2^F?K$O\ I'I^HG#EBK&9-5\YZ[Y!_+[S%JOF*XD;
MS!K>BQ7%E;PVT$:,;J1F<$1L[D^G#\#GT^4?V/BXXJ]5_,7RMJWF#R]9P:3.
MAOM-O[/5(HKDD0W9LI1*()V0?"DI%>81N+JGP8JPG3/,>J-YK\Y^9+*SN?T9
M<_H[21)IT3ZB&O;<2BZN4$"'UC;1%+=W167U42)V^!N"J*_YQ]U/3OJ/FVQM
M;:ZM8(/,>HR0_6K>:!1'(ZJB,\JK^_7C^]B)]5/]V+\6*HO\T_+_ )CL7N//
M>C:HDLVEVZ&7R]J%O#-97$,#%S'"Y3UH;J5F;TY$?XY/3C^SBKT^&42(IIQ8
M@%D/521T/N,5>4?FS:WMEK8\[Z7$TNI^48+.\D1*@RZ;)-=1ZA"=CR'H?OA_
MEP*R_%\.*H7\P[J#6=?\AZY;2"?3AYGL;;3)T^PZ-;7$D\J^(=Q'%7_BAO\
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MF_)FX'X>3,Z_%BJ,A_+SR;!<Q74&F)%/!9'3(6C>5.%F5XF!0K ",_:I_/\
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M:SW>YN;KU&CAU%6)D$MTLK_OD:2&9N'V),53CS5H6BV7YH_E?:6=C!!;*VM
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MY.7#%4XUKR5KGF/1KJRNDMM">SO;;4?+0M2;D07=K*;CUY_AA#^M,S+) O\
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M_%RQ5E7Y7?EY/Y!L-6T:&[6ZT2:_FO-&@H0]M#/0F!BQ/((1\+C[6*KORO\
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MN[\E><HM#MH3_ACSAK.G:Y8A=DM[^"8)>(H\)1(DG^KZ?\N*LQF_+^R\X_\
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M6-1%QX\ !QX]*4Z4Q59##:VZE(8TB0'EQ10HKXT'?%5YA@:43&-3*HHLA Y
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M!Y3MB3=>C)JVF0W*6#3)<R027L22Q1&W9)N4B$IQC;DV*L=G\]:7Y4TRSL]
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M\JJLG&5:LN\;I(KJ[(\;JZ-QQ5-C/ (O5,BB*@/J$CC0]-^F*N>>",$R2*@
MJ2Q %*TKOBK;RQQH7=PB#JS$ "O3<XJT9H0H<NH5A56J*$4K4'Y;XJXSP"+U
M3(OI4KZG(<:'WZ8JE.M>89],FJ-.FN;);2XO)[Z-XA'']74,(RK,'+RBO JO
M#X?C;%45H>KP:MI5GJ$0],7EO#="!B"\:SQB15>AZT;%4/Y9\R6NN^6].U]$
M-K;:C;QW,<<Q4,BRBH5B#QK\L538D]!UQ5A&B?FUI&JOI;/I>I:;8:VPCTG4
M[V&);6>1P6CC#Q2S-&\JAO2]9(^?V/M_#BK-8YXGV5U9J!J @['H<5<D\$B&
M1)%=!U=6! IOU&*N$\+(KK(I1J\6!%#2I-#]&*MK+$R<U=60BH8$$4'OBK2S
M0M'ZJR*8J$\P05H.IKBJ7ZKYCTC2SIXNYPGZ4N!:61%6#RM&\@!(V5>,;_&?
MAQ5NQU6ZN=4O[26QDMK:T:);:^=XS'=>K'S;TE5F=?2/P/ZBI_D<EQ5,#)&.
M56 X#DU2-AXG%7"1&0.C!E(JI!J#](Q5BEY^8]A#J%S:VNEZGJ=O8N8=0U*Q
MM?6MH)5)#QD\EEF>*G[T6T4_I_9;XOAQ5E"74)**756DWC4FA8>(!WQ5<\\"
M&CR*IJ!N0-STZ^-,52^?S#ID&MVVBRS!-0NX);J&(@T,4#QQN>70-SFCXK^U
M_L6Q5,%GA9@HD4N1RX@BM :$T^>*N2>!T,B2*T8ZNI! IUW&*I=J_F32M)BM
M9KR=4AO;F&RMW +!IKA^$8V_9Y?:;[*XJCS<P+&KO(BHVRL6 !KX$]<57/-#
M'4R.J4W/(@=33O[XJVLL3,RJZLR?:4$$BOCBK;,JJ68A5&Y)- ,5<'0D ,*D
M5 KO3QQ5)T\SV;>9KG0BI5[:RAOVNBR^D5N)IH50;UYAK=JXJBIM2NX]:MM/
M6PEEM9XI)9-15HQ%"T94+&ZEA(6DY?"41E^'XL50VO\ F2VT>RCNVC-TDE[:
M6'&%E)62\N([92:G]AI0S#[7'%4UBFCE7DCJZUI52"*CY8JYIX%(5I%!)X@$
M@$L>WSQ5S30H0'=5)( !(&[=!]-,5=ZT/J^EZB^K2OIU'*GC3KBKO7AYA/47
MFU>*U%3QZT'MBK<<L4@+1NK@&A*D$5';;%5*2^M$MY;CU4,4"EI64@A0HJ:T
MQ5#Z1KFF:MH]KK%E.KV%Y#'<PRM\/[N9 Z%@U"AXL/A;%48T\"H':150THQ(
M ->F^*KZCQQ5 :MK%OI^D7^I?W\>GP2W$L<9!8B%"Y4;T#$+WQ5=I>JP:CIU
MK>P_#]9ABG])B"Z"9 ZAJ5WWQ52TC5Y[S3Q=WUF^E,9)8_J]R\98".1D5^4;
M,E)0O-?B^RWQ?%BJ822Q1KRD=44=68@#?YXJ@)_,&EPZY!H<DX74KFWDNX8C
M6ABADCB<\NE><T=%^TW^QQ5O1=4N+^T,UU92:;,))4%M.\;.4B<HLH,;.O"0
M4=?VOB^+%6KK5;F'5K2RCLI)K6X29[C45>,0VYAXT612PD)DY'CP1E7C\>*M
M:!YATK7M*M=5TV82V=[&);=B"C%6%=T:C*?\DXJC9I^$<C(/49 3P!%20*A=
M]JGWQ5":3JDEYIEM>WMLVF33Q"66SN'C,D5:?"[(S(2*]5;CBJ/#H5#!@5(J
M#7:GCBJU9X&Y!9%/$ M0@T!%03]&*N]> Q>J)%]+_?E1Q\.O3%6VFA6/U6=5
MCH#S) 6AZ;XJU)-#&O*2147^9B -_GBK;RQ(*NZJ*5J2!L.^*M>O#S5/47FX
MY(M14CQ Q5*_+_F2UUJ*XDB0P?5[V\L?3D*\G:QN'MW=0#]AFC++_DXJUK_F
M.'1FTT2PM-^D[^'3XBA'P-.&(=JD?"O#>F*II'/$\:N'5E<T5E8$$^ /?%5_
M)>7&HY=:=Z'_ &L5;Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]'U3BKL5=BKL5=B
MKL5=BKL5=BK _-_EK3M=_,+RS#JM@+_38;#5FEBE0R6YD+V0C$RD>F]?C9$E
M^'DG/[4?PJO.M>\KFZ\YZY9ZM?2Z?J=S>Q?H*2'1'OIDL^$:VS6%\@*VPAX-
MZJKZ7IR)(\GJ<N;JN_,BUT"*P_, >8=+GN?-DXGFT/4$MII*:>+=1!Z%VH$4
M$$%)?K<7JQ<OWOJ)-ZO[Q5D_F[4%T?6?.\5S:W<TWF#1K=-&CM;::X^L/#;W
M,4B!XT:-'1G7DLKI\#<L52S7]-U!]"\PQK:SN\GY?6=M&$C<EIA];K$M!4RC
MDOP?;^)<57?F)Y0TK3+[R^D,$6F>5#'=->L-+.K0OJ3+$(I;VW%6ED>%)E2Z
MG$W[S_+?GBJ,A\GV4^D^0-*NEGU?2#J][<RK<6DEFBPR6=[)'$]J?[FU5F2*
M.&7X'CX1MR5^.*I9?^2-,L_+GG2^L=&$>I:5K8;RV\<+%[2)#:3#Z@M#Z,9F
MDGD;ZLJQNW/GRQ5"7_EI[WSQJT&L:C-9Z]<:P)M-DCT1[RY6T$B&T>TU(!E@
MA2%56;^Z6)DN/51O[R15-M;\CZ5?:5^9^LW&E&?7HKB]?1KQDD:>-HM,MGA>
MS[HWKK]N#XI'7@W+CQQ5$7^BZ!'YYUFZU73I;?4=;\OVXTW6K2R>6Z%Q%!>)
M?/!/%&YBO%@>"G)D>7]W&G/[.*H_\F&MH;;4M.T^PMDTRS%L(=9M+"?2DO)"
MCAEDM9Q7ZQ BQ>M,A9)?5_99&7%4HU:U\II>^9XO..C3ZCYEO+NX;1KA+&XN
MII+5HU%DMA<Q(5@:->,9].6WX7"O(_\ OYE4VT#RS,/S$T34=;T^*?7;?RO"
M+[5#"KG]()*D4K";C_>\3(HI\7I?Y&*H?\U-'\ZW=SJNH6^E6VIZ/8Z-=PZ7
M']=DAFBN;FW=+FX^KK!*)YO2I#;+S7X?5_W]\*JEJ!\JR:=H;>;[;5-)\R+I
M20VQT:35&/HL:")9[*.)))2T:2-!,G[MV3[2_%BK,=&L?,FI_EA'8:[*T.O7
M^F207,[J%D22:-E1I%3BHF564RA.*^ISXXJEWDWSYIZ:9I/EVXT[4;37[6&W
ML;O3#97%('C14=S.$%LULM.0G6;@R?9^+X<54/RZ\N:XGUV_DUN_MK3]-ZO)
M^A##:K;LAU"?B>3P?6N$FTH83_ZOP8JP[R]Y<U'2-(\I:]=OJ5_I9U>6+4]
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MI'K#O\3._/C\.*H:7\PO,ITF[\TVVCVLOE"Q:X,LCW;IJ$EM:2M'-<QP^B8
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MG6_ES1TEU:[MIKN\M]0N?JT5HMM<&TD1Y8H[DRNUS'+'%Z4?!EC]1F3DG)5
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M42ZC-I<$L[VD<F[F!"[QU02$2<5/%>/VL51VGZK8WFD6VJP2@V-U!'<PS/\
M #%*H=">5./PL.N*HCUX^06H+$<@H(K3QIBK&_,GG=]#M]4OGTR2YTO3=/%_
M]>BFA*RN9&0P*G+U P5>?J,OI-]GER5L53'3?,4-]K^LZ,D+))HWU;U)B05D
M^M1&4<0-QQ H:XJCVO[19%C>:-9&;@J,ZABU >(!->7Q+MBK<U]:0LBS2I$T
MAXQ"1@A8^"\J<NO;%4!-YHT6'S#%Y?EN%34YK=KN.)B #&LBQ=3^V6=>*?:;
M%5FI>9[73]?TS2)XR#J4%W<BZ+*L<:V?H\@]?Y_K"\?]7%4S>[@2#UVD18*!
MO5+ )Q/0\OLTQ54CD26-9(V#HX#*RFH(.X((Q5)?*WFRQ\P:5;W\2?5Y+@S4
MM)'4RA8)W@+T!^RQCJ,55]-UJ:>&^FU"S.F16EW+;1O-+$RRQ1D*DX9&8(LI
M.T<G&5?VUQ5&O?VB0"X>5$@-")F=0A!Z48GCOVQ5=->6T"JTTB1(S<59V"@L
M=P 33?%727=O$R++(D9D;A&'8+R8_LK7JWMBJ5:!YI@UGRA;>98[=X8;FU-V
MMLY!<*%+<21M7;%57R]YCL];T:PU*&D;7MI;WK6K.K21+<Q+*JR ':@?%4Q%
MS">%'6DE/3-11JBHX_S5'ABK5Q>6ML%-Q*D*N>*F1@@)\!R(WQ5J:]M8 3/*
MD0458NP6@)I7<C:IIBJ\7$98+R'(CD%J*\?YO]7WQ5#:CJ]K8:7>:E)62WL8
M99YA%1F*P*6=5W Y_"10G%5EIKFGW.G6U_ZBP074,4\8F948),O).53U.*HP
MSQAN!(#@ E:BM#T-.O;%5DE]:1HKR31I&[<$=G4 MTX@DT)]L5;>\MTDCC>1
M4DE)$:,P5F*]>(.[4]L52:3SGIDDFN6FG#Z]JVAK^^T]7CB:20P"=(T>1E3X
M@RJ78\(W^W]G%4QAU: 6=K-J'#3IKB-7:VGDCY(Y4%H^0/%S&3Q9D/'%59]0
MLT]/G-&OK[05=1ZG3[%3\74?9Q5!1>9]'EUZZT%9U_2=I##<30D@?!<&0(%W
M^)OW#\E_97C_ #8JCEO;5IVMUD4W""KPA@74;;E:\@-QBKEO;1I1"LJ-*06"
M!E+4#<2: UH&''_6Q5BU_P#F Z:_JFC:5I3ZG/H]H+F]D6XMX!ZLB,\4""5U
M+,_'XY#QBBYKS;%63)J, BB:X9+>5^"M#(Z<ED<5],[T+?+[6*KYKVU@9%FE
MCB:0\8P[JI9O!:G<[XJZ>^M( 3-*D06E3(ZI3D2!7D1U(-,5;FN[>#CZTBQ<
MVX(78+5CT45I4G%4'%JMT^LW=C)9-%9VT,<J:BTD921W+<X_3!]5/3"UY.JH
MW+X/LXJA/,?FZPT7RY=ZZH^O6]H4#);NAY%Y$CH&KQV]2N*IU),D:L[D*BCD
MS,:  =22?#%5/Z]:F#ZP)4-O0MZP8%*#OS^S^.*N6\MWC25)$:*3:.0,"K'P
M#=#BJ6>8O-NDZ%Y;O/,%PXFL;.-I#Z#(Q<C8(AJ%+,WP_:Q5*;3S[?SPZE$=
M#D&K:=I]MJ+:>EU;N)/K4EPD<23\A#RI:\N9;T_CQ5E"WT/*&.4K#<3+R6W=
MEYF@JP K\7'_ "<50.F^:=%U*\U*SM;A6N-)G^K7J$@<7$4<Q(W^)%29*O\
M9Y\D_9Q5,H;B&>$30NLD3?9="&4TVV(J,56?7K7ZP+;U4^L$<A 67U"/'A]K
M%4BTWSFFI^;-2T*SLS);Z0%COM1,T7$7+1I+Z*0AC,X6.5.<O%45_P!W]I6Q
M5,+/6+F;4M1M;BQ:UM;-X8[2]>6)DNC+&&;@BL7C,;GT^,JIS_8^'%6M7\SZ
M-I.A7NNW=PITRPB>>XFB(D^&,58+Q/Q-X*/BQ5&#4K(VWUH3Q_5N\_-?3ZT^
MW7CUVZXJNDO;6-.<DJ(G$OR9E XBA+5)&VXWQ5S7UJK1(TT8>?\ N5+J"_\
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M%7__U/5.*NQ5V*NQ5V*NQ5V*NQ5V*NXBM>^*M!0.@Q5L* *4Q5HE0?GX8JX
M4VQ5P"]A].*N 7>@^>*M\1X;>&*M<12E-L5:JO(#N.F*N)0-[XJV*$;=#BK?
M$>'3IBK1*KUZG%6AQ-13YC%7?#TI]&*K@!M3Z,5:XK2E-O#%6S3%6AQ)J!N,
M5;H,5:/$=L5:Y(*_CBJ#UK2-.UK2[C2M1A^L6-XABN("64.AW*DJ5:A^>*HM
M>"H$I0 ;*!L /EBJY0O4#VQ5N@ \*8JMYJ-NF*KN(\,5:XC?;KUQ5OB/#%7
M =!BKN(\,5=08JZ@.*NH,5=08JUQ'A3%7!5'04KUQ5O%6BH(IBJ7Z5H&E:7/
MJ$]G!Z<VJ7)O+Z0NSF2<HL?+XRW$!(T547X%X_"N*IC0>&*NH#VQ5+M:T'2]
M8BMH]0@]=;.YAO;=.;H!<6[<XG8(5YA&^+@_).7[.*IB!L,5=0>&*NH*U[XJ
MT% Z;8J[B!T&V*MT&*L7UK\N?*>LZC-J-]92-=7$:Q79AN;FV2X2.H1;B."6
M..<!6*?OD?\ =_N_L?#BK)+>VM[:WCM[>-88(46.*) %1$0<555&P"@4&*KP
MH'08JXJ"*$;8JW08JZ@\,5=BKJ#%7<12E,5=08J[B/#%74%:]\5:XKX8J[B*
MUIOBK=!6M.O7%74 Z#%74'ABKJ#PQ5U!X8J[B/#KBK7$4I3;PQ5NE,5=0>&*
MM<5I2FV*MT%:]\5< !TQ5U!]_7%74&*N  Z8J[%74&*NH*U[XJZ@WVZ]<5=0
M>'OBKB >N*NH,5:*J>V*MT&*NIBKJ8JUQ'ABK9 /48JUQ7;;ITQ5N@Q5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5__5]4XJ[%78J[%78J[%78J[%78JP_\ ,#SC=>7(
M;4P7FCV1N&<-+K5T]NOP 46*.)'>3ER^)ZJL?^5SQ5+-&_-4WI\J75W:I::5
MYHL+J=;KU"_HW=FHE:&O$(T<D"SR1R'BS>E]G%4DU3\Y]9LO+%AKTR:'IWUV
MSDU.+3;^^D2[FMR[M D4:1'B\MLL3<Y/A]:7T^'[O%5OG_5+/4+'S9>PVCP7
MO^"4NH;T32B017;W+>CZ2MZ*F-H0_JJ/5^+CSX8JFGYB_FE<^3YG*S:,;:UM
MUN9;&ZO'CU&X4;ND$*QLB/Q%(?5;C*_\BKBJR;4/.L7YB>:?\-6=I>%+#2II
M(]0N)(4V6ZI#$(TDI)+_ +];]VG'XN7[*J$D_,.PMM7OO.BQS2::?*%AJ,%G
MN&9IKNX]-*?$%=F98^7'%4[\@?F+JGF'6Y]+O[)%XVS7<=W:PW\<*<9$0P2M
M>V]MRE_>!D:+ES59/@3A\2JA^9?YGW7D^YD9)]%$%K;&[DLKV\DBO[@)5FC@
MB2-E1BJ\86E;C+(W['!L55]%U;SE=?FGJ]J7M&\N16&FSK [S>O&+@75&C4+
MZ?JO)'2?XN/I)%P^+EBKO/6H^=+?SSY3L]!DM5M+P7OUJ"Z>95E,4(;XQ$K5
MX+\47_%F*L<TKS9YO\OV/FG5TT^VNO+6F:[J+7CRW+B]DC-X5D-O'P:)5MU:
MH223][Q94X? V*HK6?SJO+77M0M;#3OK5AI-V;&XC$-_)=W+QE1,UN8;:2T3
MTV9E59I_WGI_[J5E;%4^_.I]97R!<II3QQR7%U96MRTDDL58+F[BAD17A_>+
MZGJ".3C_ +I>3C\?'%4/INJ>;HVGT/RII6EI:^6Q!9WXN;B>.-[IK>.X>"T"
MQR,L:)-'2:;[7J?8_=MBK$/,GF7]/:+YRUNU]6VCO/)=G<)"7/**7U]05P"M
M!R1TX<U^UQQ5G]]YE\X7NN:GIWEBQL)(-$DBM[Z?49Y8FEN)84N/2A6*.3B%
MAEBK-)^U)]C]VV*I0WYPQ1#3=0NK06^BZGHM]J<3EN4RWFF$-<VAH K!8^3)
M(OV_3=OL8JD>I_FS-K'DCC<Z1$US<Z%K%]YDTJ2>:%[8:?6U>WY($F1Y;H^E
MR^!HU23C\7Q8JR6;S)YS3S!?>6_+&E6$UKHEE93M<7US,C,LZ2A8%"I(S2?N
M-I9&XK^WRQ5)-?\ SJO(;'3[O38]-L4O-"77ZZW=-;B0/4"TM_35O5G7C\?^
MO%\'Q_"JR[5X-8\S?EM/"LDFG:SJFEEXGMFDAD@N98.:<"2DB\)>(*L4;]EL
M5>97_P"8&MZQJ7DGS+IUY)#I&D6>GWOF:VC8K$YUFX_1S+**T_T1HKB2C._#
MCS_W5RQ5.1Y]O-%7S#YE=9;M];\P-HGE^VE>=[:.'3X6B>81P)<.(_4@O)7]
M&'U)N*+_ )2*J6I^>=;U_0=/F6PIJ=AYETR&(QBZM;6[]0AU*-=PPSJ@+&.?
ME$_]W\'/EQQ5GOE;S%KESJ>I:'KUM;V^KZ:EO<E[*1Y;>:VN_4$3KZJI(CB2
M":-XV'["O]E\52W1//VIZEY\U'R]/'8V$%E))%%:7$LJ:E,B+5;N*)HUAEMI
M3RX^E(_%/B=N7[O%6(Z1JWF@6?Y<IY4AM-/T_5OK\MQIUU<74J%C'+,RM(WJ
M2.BGE)'R;X9>*_W>*IBWYTWLGF"6"TTX3Z5#J)TPHL-^]Y(4N!:RW$;I;&R6
M..3FW![C^[B9O41FX8J](M)=;;5[R.XBMQI"QQ&QG1V,[R'EZPEC*A%5?@]-
ME=N6*IABKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BK__UO5.*NQ5V*NQ5V*NQ5V*NQ5V*L8\P^28M6UFVUB#4[W2
M-1MX)+-KBQ,7*6UE=9'B;UHYE7XT5EDC"2K_ #XJEFJ_E#Y>U+R'9>3I;J]C
MM-/*M:Z@DB"\4@MS/J<./[U)9(I?@^.*1UQ5?K?Y7:=J5U>RVNI7^CQ:G91Z
M?J=MI[0JD\,"M'".4L4LD1C21E_<NG-?MXJB+W\N=(O+2_MGFN%CU#18?+\Q
M4H"MM 9>,BU3^^_TAZ_L?9^#%4)YA_*JPUF?62-7U+3;7S!$D6LV=D\"QSF.
M$6ZR%I(I)4/HJD;I'(D4BI\:?$_)5$:Q^7*7^KWNJVNN:GI%WJ5O!9WOU!XE
M5X+<2!5 DBE].3]ZW[^/C,G^ZY%Q56E_+?RS()XO0=;*?28=#%DAXQQVMN[R
M1F,@>HLRM)\,G/X>*/\ ;Q5'>6O+E]I#R->:]J.M,T:1QF_, 5%3P6"* ,Y_
M;D?D[8JDWF7\KK+6[O69EU?4=,@\P0+;ZS:6+P*EP(XC"CEI8I94/I$(RQ2)
M&ZK\:_;Y*IO%Y1AA\S1:_:WMS:R_5H[.^M$,;0744 ?T/5#HSJT+32,K0/%R
MY?O.:XJN\S>5(=;N=.O%O;G3=0TJ5Y;.]LS'S E0QRQLLR2Q/'(GVN2<OVD9
M<50=QY!TR?RWK6@O-.MKKMQ<W5W("OJ*]W)ZL@C/$J%#?8Y*WPXJTWD7T]:G
MU&PUG4=-M;VX2[OM)M6A%M+.M.4E7B>:+U>"^NL,L:R_%R^*23DJF_F70;77
MM+.F73R1P/-;SEHJ!^5K<1W"#X@PH7B4-_DXJE&J>1C<ZG=ZCINM:CH<FH\#
MJ<-@T'"X:-!&KTGAF,4WI 1^K 8WXK'R_NTQ5#3?E=Y=?3K_ $Z$SV]GJ&D0
MZ"\<;*2EM;M,ZNK.K,9F-S(7=^?-O\KEBJ*U7R.;G5;G4M.UG4-#GU$(-32P
M,!2X,2^FKD3Q3>E+Z=(_5A].1D2/_?:8JAM<_*SRSJV@:+H3">UL-"GAN+,0
M/21O2#*T<KL'+I.K-]8_;E_FQ51;\I/+;7'FV<27*OYPA:WO_B0^@DBL)/JW
MP?!ZC/ZK\_4_>8JR&R\NVUIK>I:Q&\C7&J0VT$\9IP5;02",IM6K>LW.I_EQ
M5YEK?Y::YI^H6=MH]GJ%[I-II=GI]G<V%_;6=PLED9%5[L7*%9.*R+Z+VZ?!
M^]YQ-\&*O4O+EMK4.A:?#KLT=QK,=O$NH7, XQR7 4>HZBB[%O\ )7_5Q5C%
ME^4?EJST/S/HD;W4EGYHEFEO#+(':'UP:);DCX$A8F2(-SXOBJ.'Y=:7'Y2T
MOR_;W=W;MHQCET_5HV07L=PG(-.6*&-Y)O4D%QSB9)EEE]1/CQ5;??E^NHZ-
M#IFI:UJ=Y)#?1:BNHM)%'<B:"AC"&&*.**-2OV8XU_X9L51_EORE%HSWMW-?
M76K:IJ#(;O4;XQ>JR0J5BB584ABCBCY.51(U^.221OB?%4&WD19O,MOK=[J]
M_?1V-S)>Z=I4[0_5K>>6)HBR,D27#*L<DJI'),\:^I]G[.*J"_EMI\6C:%IU
ME?WEE-Y<9FTS4HC$9P)%:.1762-X'61'*M6+_4XMBJM:^1?J6L27=AK6I6FF
MRW37TFAQ-#]3,[MSDH6B:=(Y9.4LD*3+$SO)\/QXJG=IIDT.L7NH-?7,L=U'
M%&EA(RFWA,/*KQ*%#!Y>7[WD[?97%4QQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__U_5.*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]#U3BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5?_1]4XJ[%78J[%78J[%78J[%78JU7(\71+=<-HIU<;5
MKE@)6G<MNF&TH?\ 2-IZ!N/6C^K#;U^:\*UX_:KQ^U\/^MA((-5NNR(Y9'C"
M'5QX@KN0Q$A\UIU<>)7 ^V(D$TZN&T.Y"M,'$+I:<&]L;4.J?#'B5W+VPVKJ
MXDA7%P!@XNG5-*4=U%)))&C*SQ$+*H8$J2 P# =*J0V_[.$FD!5Y8.+JFG<O
M;'B5W+$R13JX\2NKB)*IO=0I*D3NJR2U]-"P#-Q%3Q'4T'7#9HFN2:5.6-HI
MW+!Q*[D?#'B5W+VPVFG<O;!Q(=R]L3-7!J]L(-I;PH=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_TO5.*NQ5V*NQ5V*N
MQ5V*NQ5IJ]L!5@GG*^\P6_GORY'HENEU<S6.I*T-Q.T%NJB2SK+*561FX"H1
M4C9^3_LKS;-GI(8CIYG*>&,9XO5$<63Z,OIC]+ DWLE6K><_.-Y#H1TJWMK2
M_P#T]-I&K6L\[^B\L$$Q"+(D3LUO*$];EP65/W:</[S+<>CP0,Q,R,?"CEQR
MA&/TSX?KXI1]45LHE/,GG2U\S^;FNH[.;2-&LH+I8!/+S0_5990(QZ-#ZSI2
M7F_P+]CED?RN">/$(F7B99\'JC'@^H1_G_[U;(1^A^<_,$VH:+%K6DPV-IY@
MA9]-DM[@SR1R) ;@Q7*E(U7E"KLCPO*O)>#_ &ERK-I,7!(XYF9PG][Q0X.+
MU<$9XM_YW^J<$EXCLJ^:/,?F+2_*&KWDUK#;ZJ9GLM"CBD,XE>XD6"R=ZJG%
MW>16DB^+C_,V5Z3#CGFB+)A7B9.+T?1ZLD?]CZ64C22ZEH$5M%Y+_+JUH]I$
M4O=68K4/:Z64<\O>YOGAY5^W^\S)QYI'Q=1+G+]W#^OG_P"(Q<3$CD%M_P#G
M#]02&*\T\#41KLNC:A!&[,EO;Q,I-Z6X\O2]&:WEW5?[WA_E9/'V,<ED2J,<
M/CX_]LG7]U_L<L?\Q!R4F!_,>Y&H0,;*,:%/KTGE\:@93RYI&567CQ"\7O5>
MU^W_ )7Q<LH_DX<)J7[V.(9^'X_[W'^\29T@]"_-O]-PP_5-/X7=YK8TFSMI
M792]IZ?UD7OV:\6LU:95^S]G]Y\67:CL@X9'BD.".+Q>7TY>+PY8?ZWBIC*U
MD7YQ /HEK<Z=PU"_U6YTK5X4D9DLOJTXMO5+\:E7EFM G-8_]Z/]7">QS60Q
MEZ80CEQ?[;QQX_\ <QG_ *1CXC*_+'F<ZSI-_J[Q+!IT-W=0V<JN7,MO:.8C
M.10<>;QR\4'+X..:_/I?#F(7Q2J/%_1GD]7#_LF=L3\I?G =?UG3K464:6FK
MEOJ@B>Y>YA7TFE1KD/;QVX614_W5<2<'=%^+,W5]EQPPEZB9XSZ^+@X)>K@_
M=>OC_P!-"*!/?R3OR_YH\TZXBZC:Z3:#0[P3'2[E[IQ-1.0ADN(O2HD<[K]F
M-Y)8E9>:?:S'U&GP8Y"!E/Q<9_>QX?1ZOJX)<7JE#^GPK$EA_D76_,VF^6_+
M[16%O?Z[YNGN9)+F:]G*GTHFF]:8R(W"E'4Q6Z?"G#T_\G8:V&')EGZI0Q8!
M&,(\$>+_ #.'_=9),(DT] \T^8;OR[Y0N-;NH(Y;JVCB]6!)2L/JRND6\KJ"
ML"._)Y2GPPJS\,U6DT_BY1C!/"3_ #?7_I?YW^^;)&@QNP_,S5&CUA;JSL+N
M?3[FQL;$:7>/-#<W6H$".,SO$B1<2Z^I]KA_P'+-R:#'<>$SC&499)>-&,9Q
MCC_H0E/^;Z6(D>JKK/GOS5H%M>)JVCVDU_%8SZE8I8W4LD4\5DT?UF)O4ACD
MCECCE$B? R2?8P8M%ARR'AS/#*0Q_O8QC*,I_1]$IPX/\[B7B(YIK9^>+6\U
MF^@MU271--TR'4;S50^P:Y#21Q!*=/JR&9WY?M)\.8IT4A&-G][.9AP?U/\
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M_P"EQ'A2)+M"\WW>K30$:'J%II]Y";BTU*?ZOZ+I162JQS22Q-(C<D]6-/\
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M'DR9>L./P?Z4\GIC+_,CZO\ 2LB#0"&_,KR]YVN9->U&TL;*_P!/31KBQTF
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M/3DE_E(X_P"?_$Q%F)3_ ,Q^2UT^^L8_)VG+IMU<Z-K%H]Q:)Z:^M)#$UO\
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M,[WB)#S_ 'R\LZ(9<$R,>24(X<1@<,HRXO%C'_)9\?U_SO7_ )+U_P #28R
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MZN=U6UN8H$D7ZLWH6T$#"-3SD_??\9V;)C/IY8YCBG&(P^'BA*,?K\3'.?\
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MP_O4?X/@^QF;AU^;'#@@:C[HRX?ZLICQ(?YC$Q%VR".&-%5$7@B@*J+LH V
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ME)(L;VWIR>DC.J3<_LJV*I;YSU9/-OENUCT6/4;>-=;T@)J/U22!P!?1-)-
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M*6VN%7U;RW"PO];C^%WE7[,BXJR_1[#R_J/FS3)-'T@0^69_+FI6WU5[%K2
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M97Y7\Q7GF+RFFJPVJ6FHO]9@:TE?G&EU:S26[J9$%6B]:)OC5?BC_9Q5Y?\
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M&&*-''+^7XOVL53W3?+5KI^L3ZK%)(\]Q96FGO&U. BL6F:-A05YL;A^>_\
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M-O*B%$9'>'U5?XN?QOR51PTKS##K6AVT%U<2:+IUO<2:E=SR(\UW,RB*&*0
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M^5BJ5V'G?RU?>8[OR[!?1-JEI%!,T/J1GU%N%=U$5&+.RI$7D^'X$9&_:Q5
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M(F$A=&>421#X[?T0%^*7^\5N2_9Q5&6NK:5=QPRVMY!<17/+ZN\4J.LG#[7
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M](B2WM8X9FDA1;E/BY<V].;BO[O%66^;?,E[I7Z-L-+LTOM9U>X-M8PSRF"
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MKZX>]G>VMH8%D$2U:..>1WE?D$5$^'ARD;[/)5A'G#7?,GF6+0M&2R@MY/\
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MJ'M;H,MQJS/Z=XDLO!_@C]&63@_)>,?)5,;7R+9VWD)=6@T3T_-0\Q"Y^N+
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MOU$NKB?T86M+J3G.6/JROZG$NT2_M-P3TT^RJM\Q^<?/EYIEC%9"ST[6M/\
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MS Q)&YD=X8 H4Q1-)/-+QK_>R._VL53'RWY4N-%E+S:_JFL 1""&/498G6-
M0:_NHHC))M_?3>I+_EXJA->_+^#5==DUR#6=2TC4I;2/3WET^6- ;>.223CP
MECE3D6F/[SCZB<5])H_CYJJ=Q^6ND^GI2Z7>WFB/I%LUC!-82())+20HSPRM
M,DQ;D\:R>J.,WJ<G]3DS8JAI?RIL/\.VGEZSUO5;#2K:"XM)H()HC]8@N7+N
MLQEBEJWQ,BRIPFXM_>8JB[O\M/+UQ!J5N&G@M]4M]/M98XG%(XM+8M;B,LK$
M?:XORY\L51VO>2M%UV^:[U$22A]/N-+D@#<4,%U)%*["@YK*KV\9BD5_@_UN
M.*J.E^3;BSM+NWN/,6KZBUU!]62XN9HA) E" \)@BA43#E7UW5Y/\K%4#:_E
MJEO'J$J>8=6.L:D]LUQKGJ6XNN%F&$,(58%MO27U)>2M;MS]1N?[/%5,](\D
MZ-IOEVXT$^I?6=\;EM2>[8/)=/>LS7+R\ BUE+MRX*B_R*N*I;H_Y:6>G:MI
MNIR:SJFHS:.DT.F1WLR21Q0SH(S'18T,E%"_O92\_P /QRMBJAI7Y4:5I=WI
M<L.JZG)8:%<27.D:1)+$;2W,D<L10*L2R2*J3OZ?K2R21_LO]ODJA?*/Y="S
M\T>=]=GB:PD\P7 @L6@F!>.T6$%YHF7:"2XNGEG*\>2NJNV*I_Y9\E0:'>7F
MH2:E>:OJE]'#!<7]^T32>A;<S%$!#'!&%5I97KZ?-FD;D^*H34ORXM;J[OI;
M76=3TJVU5S)JMA8S1QP3NR"-W'..26!Y$4!WM98&9OWG]Y\>*IMIGE72M,U9
M]2LU:)FL+72TMEH(8[>R>5X0BTJ#^_=3\7V53%4G\Q_EGIVMZAJ%X-4U'3#J
M]LMGJ\-A+'&ES%&KK'S+QR.C(LKK6%X^:_#)SQ5-]2\JZ?J'E&?RM.\JZ?<6
M1T]Y$*B7TC'Z502"O/C_ ).*J'F#R=#J]S9WL.HWFD:G8K)'!J&GM&LIAE ]
M2&19HYX9(F9$?B\3<9$5TXMBJ&U#R#!=0::T>LZG::II:2QPZS#-&UW)%/0R
MQS&6.2&5'94?BT7[MXX_2X<<52GR_P#ER?\ "4VB:A/<6LT&LWFI:;J$,RRW
M<1:]DGMY_5D656E>)_WOJH_+U)$?%49'^5ND"QU.WFU'4+BZU6Y@OY=4DF7Z
MW%>6T:)%/ ZHJ1,OIK\ C]'_ '5Z7H_N\51O^"[S]$RV1\SZPUW+,DXU3U;<
M7"&.@"(BP"V$3*/CC^K\7^VWQ_%BJ$/Y8Z4NAV>FP:A?V]W97TFJ0ZS')']<
M^NSF3UYFY1M;MZRSS(\9@]+@_P *+\.*L@T[1WLKN^N&O[J[^NR)(L-PX:.#
MA&L?"!55>"-Q]1E/+]XS8J@;#R3H5HVIN\(O)-7NY;V\EN@LKEY56/@I('&.
M.*-(HU_91?YL54]/\E0Z=Y-M_*UEJE_!!9Q+!::BLB?7(TC?E&%D*%"(U"Q4
M>)N47P2<\50NF_EMI-C]6EDO+N\O(-4.N3WUP\9EN+PVS6E90B)$$6W<(J11
MQ?W:?Y?)5@_E?R3^8&EZW8>C%+IZVM\[WMV-0272Y;!IG=X+>P*M-'ZD;CTE
M?AZ,GQ^L_']ZJS]_(&COY;F\O&6?ZC/>OJ#N&7U?5DOOT@0&X\>'K_#3C_=_
M#]KX\5<WD#2#!/"9I^$^L1Z^YY+7ZW%+',JCX?[GG"M5^UQ_;Q5;J/Y>Z/?K
MJQ>>YAN-5O(-2^MP.J36UW:P1012VS<3PXI O)7$BORD1^4;\,50UQ^6EO.M
MC.VO:L-9T^6>:#6O5A:YI=1K'-'Q>%K81.L<?[M+=>#)S3BW/DJK:%^7&CZ-
M/IMQ!=7=Q-ICZC+#+=2"5Y'U6437#3-Q#.>:_ ?^"YXJJ7GY>Z/=:;JU@\]S
M&-7OUU9[B*0)+!>1^D8I(&XT7TGMXG0.LGQ?;Y+\.*H_4/+<6I>5[KR]?W<]
MS#>V<EC=7C>FMPZRQF-Y"418A(0:_#%PY?L8J@M7\A:1JLFHO<RSJVIZ0VA3
M^FRBELQ<EDJII+^];XOL_P"1BJKKWD;1-=-FNHB22&SMKNR]$-Q62&^@^KS*
MY Y?W?V2C)QQ5+=*_+*TL;U+RXUK4]3FAT^;2H!>RPLD=M<&,L$2**)1)^X3
M]Y3FW^[.?P\54R3R3I2:?Y=L/4E:W\LF-K$,5)D]*TDL@)OAHP,4S\N(3X_^
M!Q5++;\K]/@TZ\TLZOJDVD7-E<:=;:;+.C06EM=+Q980(P[&-?@@:Y>?T4^"
M/X>6*J6L?E-I.HO>^GJNI:=#JEG%8:M!92Q1K=101M%$SEXI'1UC;C^Y>-9%
M_O%;%4^T7RI8:1?WM[:R2M+?QVL4JR$%0ME$88^- .JGX_\ *Q5"7/D+2;B>
M[FDFG#WFJV>M2@,M!<V*P+$J_#_=$6L?-?M?;^-<55=6\D:-JUSJL]\9)%UG
M3H])O85;@GU>-YG'#B ZR$W,GQ<OY,52^;\NFD^I7">8]6@U>TA:UDUB-[7Z
MS<V[.9%BN%:W:WD$3']R_H++'\?Q_O).:J;+Y5L_TCH^H/<7$USHEO/:VSRO
MS:1;E8E=YF8%I)/W"?'5?VL50$7D&&WUF6_LM9U*RL[BY%[<:-!+$MF]P2&=
MJ&)IT65QSFBBG2*1^?)/WDG)5N+R%!_B6'7;O5M0OVLYI[C3;"YDB-M:RW*-
M'(T7&-)32-Y(XTEED2-'^!?LXJC-#\IV^BW^I7%I>W36VI3O=MITK(]O#<3,
M7GDA^#U5]9R7=&E>/DW[M4Q5"WGD#2+O2]=TV2:<0>8;KZ[>LK*'63A"E(B5
M(5:6Z?:#_M8JOUSR)HVM7UY>7S3&2\L4TYQ&_I\$BG-S'+$RCFD\<Q#QR!O@
M9$Q5"2_EW#>:)?:3K&N:GJR7I@87-U)"LL#VL@E@D@$$4,22)*JR<FB?U&5?
M4YI\.*J(_*W3I;76X=0U?4M2F\P6T%G?W5U)"9!%;-(T?HB.*.*+^^:JK'P_
M:X\V=F53C6O*=MJU_'?M>7-G>0V=W803VCB-XTO6A9Y%8JU)4:WC]-OL_:Y*
MV*K/+/D^VT&2_N?KUUJ6I:I(DM_J%ZT9ED]&,11+QACAB5(T%!QC_P!;%4G'
MY4:4M]',FK:FFGPZF-9@T=98A:)=^O\ 67-/2]9T><M)PDF=59OW?#X<59)K
M/E^TU:?2YKAW1M)O%O[8(0 95BDA >H-4XSOL./Q<<52VZ\A:3<SWDTDTX>]
MU2RUF4*R@"XT]8%A5?A_NB+6/FI^)OC^-<56^8?R^TC7KNZO+J>XANKF"S@2
M6!E0PMI]R]W;31<E;]ZD\G+X^<;<55H\50=M^5VF))=3W>J:CJ-W>76G7EQ=
M7<D3.9=*F]> *$BC1(R_]Y&B*O\ )PQ5':YY!T;6KR^N[R2<2WUG!8LT+^F8
MA:SO<P30LHYQW$<TG-).7["?#BJE%^7]N4M/K^KZCJEQ::A#J:7-W)$6,MNC
M1QIPCCBA2+BWQ+'$G-OC9N6*H&V_*;2;:\M)(M5U,:?I]^VJ:?HYEB^IPSO(
M\K@*(A*Z,\KMQEF?A_NOCBK)M"T&TT6WNH+5W=;N\N;^0R$$B6[F::0+0+\
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M!%R7U2.0CY#EQ\:=:8JX74)D,0=3*H#-&""P![E>M,572S1Q1F21E1!U=B%
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M+F&-#)(PCC%*NQ 45-!N=L5;$\9"FHH^Z4(^+:NWCMBJU[NW1&D=U6--G=F
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M  W'IBZ-./S9$ZL^I_49_K'UX709[LZCZ?IFSI^]_O\ TOJW[OT/]T8JS?\
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M %9+:ZT31[V.&QMH99?K'J3VMK]6@0/&(D29YE:9V?\ =SR2?[J7EBK(=/\
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M:3Y733]0U#47NYKN]U2WM+>\FE$:\OJB.BR!8U15>3U&:2@X<OL*BXJD=O\
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M7\O;%;:S0:EJ(NK'3)='M]1%P!=""62&0R&4)\4ZM;14D(^)>7J*_+%5&/\
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M*5(I[".SG9=3N&OXKC39[*K_ +BTM.!N(@:QFW$IC:!5_>22-_>JL^_Y5]I
M\FV?E19[A+33HX5L+U'"W<,EL0T,R2!>(E1A7['%OL,G!F7%4D\W>2-?D\IR
MVEGJ-YKVI&]M;QI+R>*WG"6\JLRV;PQPV]M-P'[MVBX<_M_%\6*H#RYY UW4
M-.O]/UV6]T[2Q/:7F@PRW<%Y?V=Y:NSO.LR1F'@S"$QP/]87X96?^\X8JGL?
MY6:6=/UJTO=4U&_FUU[::[OYY8Q<)-9\6@DA:*.-(_3D1)%3T_3Y+]CA\.*J
MMU^7C2W27L'F+5;*_DMTM=3N[9K9&O4B)X/,I@:-)E#.JS6Z02<6X_L)Q51.
ML>1+?4-3AU2VU2_TK4$MULKJYLI$5KFU5BZQ3^JDJU1F=HYHQ'/'ZDG"1>>*
MH/2?*FH:'>>6M&TF>:/RSHL%RUS))*K27,CCA!!(M 65/4DG]3^>.+^9L53#
MS!Y-35=3AU6TU6]T74XH3;275@T-9H"W,1RI<13Q-P>K1MP]2/G)Q;]X^*I?
MK7Y6:#KDC/J]U>WO'3/T5:^K,&,"LRN]U$Q7D+UWCB9KDGE^Z3%574/R\BN[
MF*\CUS4["]-I'8:E<V<L4;WT,5>!N*Q,%F7E)QGM_0F7U'XO]GBJOG\@1G6;
MC4;'6M2TN*^DCFU#3[.2);>>:)0GJ'G%)+$\B(BS&"6+U>'Q_%\6*MW7D&-]
M9N=2LM:U+2TOY$FU*PLI(DMYY8U">H><4DL3NB(DK6\L7J\/C^+%4%Y@_*K3
M-8DU=?TKJ6GV&OHPUC3;*9$MYY&C]+UOCC>6.0H$$GHR1QS>FOK))\7)5%ZK
M^7UOJFI07-YJ^H/IT$MK<C1.<7U,SV15H7_NO76DB1RLD<Z(\B?$OVL596!0
M8J[%78J[%78J[%78J[%78J[%78J[%7__U_5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5":MJ=KI6F7>IW9*VEC!+<W#*.1$<*%
MW( W)XJ=L58GI'GCS"VG:YK6M^7YM/T6UMGU+1Y1+;R236<=NLA298Y9/3N6
M;U&7_=?I\5Y<T;DJFOE7S)KNL@2W_EZ?1[22%9K>XFN;6?U.="%XP.[*>)Y?
M%BJ[S)YL?2KNTTVPTV;6-9O5DE@L+=XHB(8.(EEDDF=$CC4R(B_M/(_%?VN*
MJ5C\S(;FULTTO1[R]UN[DNHFT4M!#- ;"01733O)((8TC<HJ-S;UO4C]/X6Y
M8JO/YE6DNF6DMEIEU<ZS>W5Q81Z%6&.Y2XL^7UD2L\@ACCB"<O5]3@ZR0^GR
M]:/%4X\K^9HM>MKHFTFT^^T^X:TU'3[GAZD,RJKTY1LZ/&Z2(\4B-Q=&Q5?K
M_F*WT5M+6:%Y?TI?Q:=%PI\#S*[!VJ1\(]/MBJK%YDT":\2QAU&UDO9%,B6J
M3Q-*R*2I94#%BH966M/V<57C6M)DU%]+COK=M3C4226(E0SJAH0S1 ^H%-1O
MQQ5 >4/-5KY@\O:1JG!;2?5;1;R.Q,BO(J&G*FREU0NJLW#]I<51EWY@T.UL
M#?76H6UO8\C'];EFC2'F&*%?49@G+DK+QK]I<52[0?.>GZCIFI:C<&.QL]-O
M[NQ>XEF3TBMK(8_6,C<%59/M=?A_FQ5,GU_1%TO]*M?VZZ65##4#-&+?BQXA
MO5Y>G0L:?:Q5!^6?,]MKMQK*6RJ8-+O%M([E)!*DZO:070E4J*<:7'#JWV.7
M+%49_B#0SJ8TK](6QU0CD+#UH_K% .1/I<O4I05^SBK:Z[HQO5L%OK<WSEQ'
M:":,S,8O[P"/ES)C_;V^']K%5VGZYHVHRSQ:??6]W+:L4N4@FCE:)@:<9 C-
MP:HZ-BJS4?,&AZ82-2U"VLJ<2?K$T<7]X6"?;9?ME'X_S<6_EQ5O4]?T32HX
MY=4O[:PCE/&)[J:.%6:E:*9&6IIX8JB$OK1Y)(DE1I(55YD#J617!*EA6JA@
MK<:_:Q5 S>:O+4$<4D^JV<4<_I^B[W,*J_K F+@2PY>H%8QT^WQ^'%41!K>D
M7%[<6-M>P3WMI3ZW:QRQO+%7IZD:DLG^R&*M6^NZ/<WUQ86][;S7UK3ZS:1S
M1O-'7^>-6+I_LABJRU\QZ#=W8L[34;6XNS&)A;0SQ22^DP!63@K%N!Y"C4XX
MJE>A_F+Y.UF#4)[34[81:7--!>M)/"/3$$AC,K4=N,#L/W<K<>:XJGUI?6=Y
M:1WEI-'<6LR\HIX762-U/=64E6'RQ5#6?F#1+V[GLK._MKJ\M?\ >FU@FCDE
MCWI\:(Q9-]OB&*M6WF/0+J\%E;:C:SWC)ZRVT<\3RF,]) BL6X?Y5,52KS#Y
MYTC2[FVM(9H+S4);^SL)[&.>,3PB]F6(2O&.3@)S#<2J\OYL59!>WMI96TEU
M=S1V]M$.4L\KK'&BCJS.Q"J,50W^(-$_1GZ5.H6PTL+S-_ZT?U?B3QY>KR].
ME=OM8JW#KFCS0B>&^MY8&:-%E26-D+3A3$H8-3E*'3TQ^WS7C]K%4)YBUY]/
MTJ_GT^*"_P!2LTC86$MU':@F5N*"25^2P\_BX,Z_']E<50D'G_RH=?U#R])J
M,$.IZ7%%-=1RS0H.,BNYXU?D?12(M-\/[M>+8JGDE[:K-%;O*B3W 8PPEE#N
M$IR*+6K!:CE3[.*I6-<ECUN]M;F*"WTVTMX)OT@]S'R]29W7TY(31HE' <)7
M;C+]E/L8JJS>;?+B:?J&H)J-M/:Z6KF^DAGB<1&,597(:B/M3B_'%5#2_//E
M;4O+D/F*#4K9-)E2-WN99X46)I55A%,W,I'*O-5:,M\+8JCY]?T6"U2[GO[:
M*UEC,T5P\T:QM&HY%U<MQ9 #4MBJV;S'H,$EI'-J-K$^H -8(\\2F<&E#""W
M[T&H^QBJH^MZ0FHQZ6U[ NIRH9([%I4%PR"OQ+$3ZA7X3\07%4JT#\P/*FO#
M4CI^H0/^B9IH;T&:*J+;GBTWPNU(#^S*W'%4WLM6TR_M$O+&[ANK.4\8[F&5
M)(V(/$\70E3\6W7%47BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5?_0]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%4#KC0KI5V9K-]0A,,@EL(D61YD*T:-4<JC<U^'BS?%BK
MR3RK/8B_O$\J:5K,_P"7B:;?1:OI=[%,T+7,3B%+338+MEG60<;F*>%/]%^S
M$O&7%4Z\BZ38VOF];KRMI&HZ%Y;6QEBU6*^BGM89[GU(S:^C;W)]4/!'Z_JS
M*B1LDD<?-^'&-56FU]9]>T3S[9:;?WN@W^EW5C(+:W::XA+7,4L,K01%Y9(Y
MO2=0T2OQ^!V^!\52G1;+6= \R+YRO-(OI;+6&U7ZS:6T!N+NS6ZN+:2T,T$1
M:5_4CMCS6)&]!GXR?S8JNL=+UO2M6L?.MQI=Y)!<ZEJ\]WID,7JWMM;:C'"D
M$CPH2\C?Z#%ZL,:M)']9_P"*6Y*LA\K7M[:ZGJ>LW6DW\<?FO5HQ9P>@?4MH
M+>RCMUN+Q25:WCE-LS ..:>I$C_&WPJIAY_L+Z[E\KFU@DG%MKMI<7!C4MZ<
M*1RAI&IT1>2U;%6$:9Y&2U\@Z7/'H/H^88_,4%[.ZP<;P)^FZR2LX DX?4F:
MN_'ZO_D8JFODJRMM/U5=,U3RS<R^88=3O[N;S";1?083O*\5V+T[-SMY([7T
ME;UT_NVB6*/EBJ6^6(-4\MV?D'4[[2+^9+/0+G2KRWM+:2>X@N9WM)4$L2#F
MB$6TBF0_"C\.?'EBJ$T;3-1TZR\J:GY@\MWEYIUI)KOUO3$M_KD]I=WNH-+;
M7#6R<VD'H">+UH1)Q^L<O[N3GBJ7/Y0U5?+NGR#2M1TG1K'S)J=[+I%E9V]S
M=0P7!D6SF2SECN(98XF?=8XY619/4B_N\536/RVNGZ?HNJ?HW5M9T--9N=1U
M;3KVR@6Z#RVOU:"YCTVWCA7THY5];TU@]=6DDN&BYXJRO\J-/^J_XJGBT6;0
M;'4-9:\L;*>(0,T4EE:@S",;)ZLJR,5^TC\D=5DY+BK!=5LO-6H><+)I-%EM
M9+;S);W$T5IHZ+ +:.['&\;5>?*5IK;XY_27]MX98TC5WQ5D4/DJ_G\M_F#]
M2LA9>8]8OM4&FW\B".9UEB"0M'*PJ(W^)48'A]K_ "L56_EAY>L8]>M]0ABU
MVV>PT][5(-3TZRTVWC25HOW!-M;VS7+Q^DO!E,T"_'QD^/XE6O-=QHMM^;5Y
M/JOEVYUZ(^7;6-3:V?U]HN5Y=U1H1R8>N!3U./#X/WCIR^)5(KC1_-NF:)Y>
MT6ZTAC'#I;*MU%I4>N7"S2S,?T:[22"*VBA@,"^H[>A*Z_WRI#\2J7:MI'FO
M1/+7DT:=;R1:KYJT*U\G:K!*3');W#1B2*ZD4]7M(?KRGE\7Q(OV<59E<>0K
M#]+^<$_0B3VL?E^PT[16D@$BL(H;M6AAYAJE3Z'(+\7V,54]-\HWUBWD?]%:
M>=-NUT2]MM3O$B*&.XEM8"GUIU'(M]95G_>?%ZJ_SXJE?Y7^41::AY?2[BUV
MVU'08I/K,=SI]E:V2S&%H9@;V&"*6\CE9WDBX7$_J-Z<L_Q8JK^7_(WZ,\C?
ME\]KH9L];M-1T^XU-XX.%U'S5X[IYV $G'TWX2\SQX?#]G%5&Y\N6B:'YDTB
M^T74[2ZAUZ34[6]TW3DNE>&6[]>TD12KQ7D,7)?7M>+R1\?[I>//%6>>0;G7
M9/**R7^G)8W:27 M+80?4?6B61O1FDMB7^JR7 _>2Q<O@9_]CBKSKR3I_F2?
MSWY7U"[TB;3TM8[U=1@BT9=-M;.26WH8$N0[/=1>J (Y/BAEXK)SY_#BJ.T+
MR,=/\@^2GM]#-KKUMK%A=Z@\<'"Z0-<%+F29@/4X_5W9)>?P^E\/V<52^VT2
MX%EY<TFX\IW;>:=+\Q6M[JVN?5 8F'UWU)KQ;V@^L+/&_P 00\XU;][''Z7P
MJLT_.#1+_4;?0+B,7DFG:;J(N-1ATZ"&\N0IADCAF2VGCFCG$,[HSIZ4DBK^
M\C7FF*L9B\LQV6F:9JHT_5M8T=-=?4M7TN]L8([EPUF;6&XBTZWCA7TX9Q%/
MZ?H>OS]2?TF?%4-86@N++S;=:1H=Q:06?FK1]6;1U@"71@MHK"XF9+9?B$LJ
M(\RP?#)\7'@LOP8JB=;MM:U^/SS?VVB7\$.I)H*Z;%<V[Q37"VMRS3,L3?&O
MIU^)'"R*OQLOQ+BK(9O+]C+^8GF.VU31I)M/\S:;;6]OJ*6WJ0?NX[F.[269
M0?0=TE0+ZO'UOV>6*I+^35OK]_JUY>:^O*;RA;_X2M+@MS^L2V\G.[NA7<>N
MJV:[_%^[;[.*J_G_ ,O:MJ#?F D.GS7,>I:;HMO:A$+"=HKBX,R)3[1C21>=
M/L\L5335_)-M#YL6/1](BM]/N?+>I6$P@A6.V:;U[8VL<E (^0#3F/E_Q;BK
M#)M#NYM&\DW#Z;J^FV6AVDMAJEK9Z9#<7,6I&"!!<FUN(;A9X66.XA^MV\4G
MQ2K\?I^IBJ>:7Y&M_KODB-K"]O=,@N=7OIQJMO"C0272%HS)!"B6\"O(S-#%
MZ:<>7V$D^'%4I\T^3'F\U>98-2BULV^N&!-/;2-.LKR V8MD@$'UB>WF>RD@
ME6=OBFMXT]1)8OCYXJF\NGWNF?F<)M&TZ]OFO[RV_2KZAIZ/:I$EJD3WMIJH
MXM&T<2!/J[O)ZDWJJD*>KZF*J)\NV(T+SOH.I:'J,)N-2FODN=.LEE::UEN8
MYH#;L5:&X]-ARFLVY/P21/1?]M5,/+]S;/Y7AM_-VC\K6?7+:UT>MB-/FNI"
MT9AO)K'E6!TG60M_Q3!]8])4Q5ZCBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5?_]'U3BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5:8K^U]&*J-K965K"8;6!((2[RF.-0B\Y'
M,CM0 ?$[LSN?VF;%6[NUMKJUFMKB,207"-%-'O\ $C@JPVWW!Q5JVMK2UMH;
M6VB$5O;HL4,2"BHB *J@#H% VQ549HEW.P/[1V'WXJXF+J:#:I)Q5M0C;C?P
M.*KB >N*M<5\,5;H/#%6N"^&*N"*.V*K?W0;CMRZT[[[8JV0E:&E<57  "@Z
M8JUQ7PQ5W!?#%6PH&],50JZ7IZZG)J@@0:A+"EK)<T^-H8G>1$)_E5Y9&_V6
M*HG@OABJ#N]%TJ\U"PU&YMDEO=,:5K"=J\HFG0QR%>WQQGABJ,X)X#%7<1X8
MJ[@OABK15 -QBKAZ9'(4(;H1O7%6A)"2*,*L?AWZT\,57$(H)- !U)Q5PX-N
M-_?%6B$!%1OVQ5<0#U&*M<5\,50MOINFV=Q=W4$*0SZA*LUY*-C+*L:PJS?Y
M7IQHG^QQ5%!5ZTQ5HB-06- !N2>V*H32='TK2K0VFFVZ6ULTLLYC2M#).YEE
M?>N[R,S-BJ,X+6M,5<W']K%5G*$$ D M]D$[G%5P$9/3?%6^"^&*NXKX8J[@
MOABJ$O-.TN>YM+N[A1Y]/=I;.5_]U.Z-&S+VJ8V9*_Y6*HM65A4&HQ5O%5OJ
MQ\N/(<J5X]_NQ5I9HG-%<,=Q0$=NOW8JOQ5V*NQ5P(/3?%5AGA!H74&H!!(K
M4[@4Q5?BKL5=BKB:8JTKJXJI!%:5&^XQ5Q=00I-">@Q5Q= P4D!CN!WVQ5O%
M6@P)IW&*MXJ[%78JT6 -#WZ8JWBKL56K(C$A2"1U'?%5Q( J<5<#7?%5ID0-
MQ)'+L.^*N$L9) 8$C9@.WS\,5<9$'5@!XGWQ5=BKL5=BKL5:#J20#4C8_/%6
M\5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?__2]4XJ[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%5"^A]>VD@]1X?51D]2)N,B\E*\D;
M]EEK56_9Q5@'EG1-/T[\P9H_+ N5TJTLI8?,4TMS-<0S7[O&UN@,TDG*\AC6
M9[J15^S-$DCL_P *JLS\RZ2-:\N:CI+2/#^D+66W$L3%70RH5#*P*D%2:]<5
M>$W_ )RUW4].\F:S%--#_@ZQ@U7S1 E56207JZ9=1RBC;1I!J,H^UQX<OY<5
M9+<2Q:A=^8]<OK5-0T_4/,^D:%96MTSM"L%E=0VTDT2KZ=)%O'N75OC^.-.7
M)4Q5&F?S=+>?F?'?W]M-HUJLT<-LL4_K1A])ADC$;-,T:(%?]\OI?O)_4E7T
M^7#%45Y+\P>=-/@\FV.LPZ>=,UZV6VLELS,;BV:"Q-S'ZTDAX7'J10OS].*'
MTI./]ZOQXJG>J>8/-\OGK_#>BK816L6G0:C=7EXDTCCU+F6$Q)'&\?+FL55<
MO^[_ )9.?PJL9T[\V/-&I:Q%+9:1+-HLNHG3T@33=0>4P+<FV:\-^%%B%3BT
MSP\>*QKQ^L>I\.*K3^:GF:Z\Y1:/8S:4JMK<FDR:.8KF;4UM;<L)+TLLD<0B
M?T^8;TO2B1UY222KZ6*HF[_-/4+;SK9Z4E[I=_87>IC3#9VD5V;B(.659&O3
M6S:6-U'KVP3X?C3U>:8JJV?G[SJWEB]\SW-OIQL_K,VFZ5I\0F$LMT=2_1UM
M)/.S%(H6>GJQI#(Z_P!XLG^ZE57^7_\ %2_FS.GF%[&6Z70$]"?3UEBC=3>G
MD&BF:5D9&V_O'Y_:^#[.*JNI7_FV'\VQ'#?6Z:%#HHN[FQDBF=S&ES21DXS)
M$+@T_=RF/X4^!D;[6*J5OYY\[QZ'IGFZ^ATW_#FIM9,=-A$_UV"WU*6.*"3Z
MPS>C-(OK1-+#]7A7XI%2;]W^\53[\P?--QH%G:-;:CI^GS7,C*&OXKBZ=E1:
MGT+6U*S3$5'/XU6)?C;^7%6,V7YE>;=7T7RO)H]OIQU/7[S4+":6X^LK:K^C
MUG!N$2B3A7-MZBV\G[SB_I-(G]YBJ(_Y6-YDTZ9(=:M;1A8:_!H6MW=KS6+T
M[ZVCDM+F)9&8Q#UKFWCGCD>7CR^%L59%Y0\SW^OV.J:DT<26$5_=VVDO'4F6
MWLV]$RN:D'U)TE*<>/[KA_K8JQ?RYY^\^S67E36=<MM,72?-3V]O%;67K_6(
M'N;5IXY6DE;TY%9XR'A6-6B5_P"^EX?$JJ/Y\\ZR>7;SSK;0::?*]F;F;]&R
M"?Z_)9V<CI+,)PWH1S,D3RI!]7D7[,;3_%S153U/S[Y_B@\U:Q9VVEMH7E.X
MG26"7U_K=U%;V\5Q)Q96$4#JDC<699?5;X?3B^TRJ=^9OS)TO3M,UY;"7UM=
MT?3KF_6SF@G$1:" S!6EXK$P^S7A+BJ!?SEYUTF_@M]>M]/==5L+R\T[ZEZP
M-O-91"9H+CU6/KHR.O&>+T/B1OW/Q<E51VG^=-2NI_(Z/#"%\S64EW>T#?NW
M2TCN (JG[/*0CX^7PXJQ+\M?,'FS1_)ODF34(K%_+>HBVTV&*+UOKL3S@K;S
MO(Q]&19'7]Y"L:-$LG+U9>'QJK?*]]8VMOY0^M6<5Q34_,]Q%=.&,UN8+B\8
MM#1@O)T+1MS#?#BJ8ZCK7G;6ORRUS6-2CTY-$U7R]?7EI!;>N+JW2:U:2W25
MW)CG9X7_ 'K(D'I2+Q595;DJJI>?F5<>6H+^ROK>,BS\O6VK:"5)#7+T%O);
MO4_WGUIK95],?8N$_;Q5,OS-O/-%M^4VL7D%S%9:[!IWJ7%Q$) B2*@,WH%'
M#HU>7HMZC\?VN>*M76N_F(GF/3_+,$FD-?RZ=-J%]J+P7(A7T[I8E6*W$Q=N
M22 'E<?"_P"\_P"*L52S5_S3U"P\XV^F17NE7ME-JD&EO86\5X]TGUB00\VO
M!6S6:%VY2VK)]E>'J^IBJ6Z[Y@\X^8=*T76?2L(_*]WYCTQ;6WI.+^.&+5(X
MXYI'Y&%VEDC^*!8T]*.3^]D9/B514OYK^:9M;NAI>CS7.E6>I/IOU:/3=0FE
MG6"<6]Q.E\BBQA]-Q*RQ.)/AB^.:-G_=JJ7YD^8?.6K^4_/BZ1%IXT+2+:[T
MZY2Y$XO)W6U#W,L<B'THEB68>BC1R^LT;<GAY_"JS;SEYJE\K^4I-6AM6O;A
M/J\%I:*')DGNI4@B!]-9)*>I(O(1QO)_(G+%6'G\S_.=KH'F"]NM+]:;2[>"
MXL+R73[_ $JVFDFF])[=H[PF7F@XOZL3LG&3["\/C53#4O,'G^V?4="U4Z:F
MH76BWNIZ9>V*W C@:U:..2*57D$DA7ZQ&T<Z-#R;E^Y3C\2J7>6KK6)T_+<:
M\ECJ6JW=G<7-CJ7ISB2WIIT15CSF?U)I!(ZW$G^[%^PD;8JAO*_G'SIH7DBR
MUS7KFSU+36UN2ROIE29)X+:74;BT:4R2S2*RQW)M_36B^E:\H_C?B^*L]\H>
M9;S7I]:G>.--,L]1FT_3'2O.9;0+'/*YJ5_WJ$T:<0OP1_Y6*K?/GF:;0=*C
MGM[^PL)YIEB234$GG!'%F816]L5FN)-A\",O%.<C-\&*H?\ +OSE>>9_*\^I
M31Q27=K<W5F6MEDBBG-LY59(XYQZL/J"G[N7DR-^TV*L+E\_ZEK'Y=^:Y]?@
MTV:]M=.>:X\KR07=M/ &#!X+M)V5YX_V/K5OZ44K<_3Q56\^?F;KOEW5[_1=
M$?2K0Z5:VAL+"^CN)[K49+@D+#9I#)#\484(J?O79V^/TH_CQ5/+[S)^8MQY
MEUG2-$CTD0Z);6EQ+/>+<%II+B*1S"B1N!&K-'_?,S^FO^Z9L52&[\Q2:W;Z
MKKVEV=OI^L3>2;74K749!(\\4=X]S*T!*.@X1F'G$R\667X_B7X,50?EZ[T[
MR=I^C75YI-@9=,\IWVM-=V$3P2&DEL70!Y) 6G1D^L2R<WDF3U/A^QBK-#K?
MGS2M"O=1\QSZ%;<((Y+>X5KF*WAG=N)AFYF1Y@*KZ<D7IM/)^[]"/%6,VOYO
M:XWEWS5=(+'4[[R^ME):W$,%W903B]<H(Y(+DM-&T;(_[Q9'C;FG\KIBJ::I
MYC_,"U_2NAZFVFQZC<:)>:IIM]8K<".$VK)%+%*KR"21E]>-HIXVAY?%^Y3C
M\2J??EQ)YCF\B:5-J]U;W6HSV4$L5Q''*H*O;H4];U))'DEKO*X=.?\ *F*O
M./(>G>G9>6KS6;'3=0U'6_-%\[ZDD,J7"RVB:BR3/(\KM+)&T+1P<_@BMG]/
MAR_>8JR&R\_^?FTN+S)=6NE_X?;51I;6D/K_ %PH^IMIRW =F])65S&WU?@_
M+XV]9/[M56K[\T]1L_.EII27NEW]C<ZFFEM9VL-XUQ$)&,8D:]WLS+$]/6MN
M"\?BC]3GBK5Y^8/GV"Q\P^8$M=,/E_RYJ%S:2VQ]<WES!:S!)'1^0A@=$-55
MEF]9T_W0K8JGNF^8?.6LZY>OID>GKY=T[4#IDT=P)A>RF!@MU,DB'T8Q&S,(
M8FB?U?3^*6+G\"K'K7S:FC>4Q=Z;)I.@S:AK.K+*EQ%=7/JM!?31/+%:P-Z\
M\LGIH\["1(XN?/[/P8JN\K^:;CS1YE\E:Q<)&D\ECYB@E]#U!$[6MW:6YDC6
M4+*B2^EZBQRCU(^7!_B7%4V\W:Q%IWG&>Z2PMY;[3?+.HZA;7L@<R@Q2Q5AV
M8+Z,AHS[<_A^UBJCI'F[S\;OR^FLPZ6D7FF&7ZBMH)V:TG2T:[C$[2,!<QNB
M/S]-(/3?X?WG+U%58]Y;\\><-"_+#3]4U.2+6M1U.]^H:6L,%W)*&DN)A(]P
M%>YGN!&D3O&D"(_%%B_XL55,X_S)\ZKH5[,^E*^H6^H:9965Q=6=[I5M=+J5
MRD#@177.>-X"Q#.#-'_=O_-$JJW6_P P_.^FZRWEY8;>YU*QMH[O4K^UTK4[
MVW8W,D@@@CAM6E>#]W%R>>:=OB_NX&_855]5_,GS-;2>7GGLX/+MCJ=C'=WU
MUK,%T\4=T[#E8-+#Z:6<B(&;UKOX?L\8OA?%4;I%UYOE_-GS! VH6KZ!;V>F
MRBR:.9I%68784Q-ZWI)(TD=9W])O5C])?@9.6*J/G/\ ,37M/\SOY?T6T+/:
MVD5[>7;:=?ZFM;AY$AA$=@ 8N7HR,TTLG^2D,GQ,JJ7ZW^;/FC25T,76CQPW
M7FVTACT*PFY136^KLR))!>AV5OJZB59?41(W_=O"_P"\DBQ5=JGF+5-%U/SC
MJ&F:1;3ZS;2:1:WVHPP7$I:%X [W,]O"TDTL=HLDA2&#]YP^T_[>*NU[S#YN
MU.S\C76AZWI;2WNK2V]W<017+6LSK:73(C1">.1441MZUM*[.ESZ?Q_N?C53
M;0_.^NW'GJ[T'56LM-@AD>*RL9H;F.ZNXTC#+=6]P[?59DD8/_HT2O+%%\4D
MG)>.*HWS&8Y/S \NP1VEM)J'Z/U:?3]0G5W>WEC^JQ44*Z5CE$_[X?:^!>#)
MBJ4?D5I=S!Y$@U"\6U>^U622YNKRVB>.6<F1JM=22/*\TW+G\=57AQ3C\.*L
M2U6Z\Z3>2_.[ZG>6M_;VVO)#96Z)/'()8]0M"B>K)+,L=O0\0BQ?!]OXOLXJ
MRG5_S%\V>5#J,'F6ULKZYBTS])Z?^BUGC5I/K,=I]5=9#-(W[VX@XSQK\:L_
M^CJR?&JC_(WG3S5JVL3Z?J^GR+ +;ZS#J"Z;?Z;$L@D"&V9;_>9RK<TDB*_"
MK\XH_AY*H?S-^9NI:#J7FG3YK6&2ZL+"TOO+42EN5VUXYM!'**]5O^$9]/\
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M^$_*]UHL^ER2OJLTFFOIXBL_J<L36CRNJ+=/+,85586N$Y1>IZGV7=52\O\
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MVMK&Z1W,2%?4-S'*SV_/UN7[[A^WBJ8^=/(CVU\UMY*TY=,EO/+FL61FL8Q
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M?ESXXJ]B2N^*O.[KSKYVET[5?,FEV6GMY=TF6]0VMQ).+VY339'BN9$D4>C
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M?U.3*LL'#XH_[KX_A51_EWSIYVFN?+,VO6%A#I_FI:6:64LKSVTGU-KQ1,9
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MN="N;>[2XO+*UGB$9MI;F6%H[FO[SESBDX)Z:)(WI<\531?RNTB/18M,AO\
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MJA;C\M]/>RMH;74;RQN[+4;O5;+4(&B]:*>^DE>=>,D<D+QLMS+%QDB?X/\
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M^3%4Q&MZ1^D3IGUVW_207F;'U4]<)_-Z5>?'WXXJU'KFCRW?U**]MWO.+O\
M5EFC,O&-S&[< >7%'!1OY7^'%6K/7]$O89YK._MKJ&V)6YDAFCD6,J*L)&5B
M$XC<\L52W5_/_E/2](MM7GU&WDTV[NH+*"ZBFA>-I9Y1"/CYA.,9;G-\7[N-
M'?\ 9Q5/+6ZM[NWCN;:1)K>50\4T;!T=6%0RLI*LI'<8JJXJ[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78JZ@Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5__7]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%4A\_6MQ=^1_,5I;1-/=7&F7L4$,:EG=WMW544#JS,>(&
M*L5T;R=97GG4WNM:,EPD'EW2K6VN+N .B2K)=_6(T]0%1(JM'ZG[:J_^5BJ0
M>7=$N=,A_+J^U?0[FYCT^QOM,NO]%:YFMGEF@-EZJ4:9(D2"0++QX0_M<.>*
MH+RGY+GBUNSL]9.N#6+/6)-0N)HM-LULI)%G><7'Z3^KB9[>=&5'C^M_6.,C
M0/'Q5^*J<'R'>2?EIYLAL--^J>8=4O\ 5Y&D$:1W4\$NI2-P1Y!TN;1>$7(^
MBW-.7PXJEEGY/T6^T?7IY8_,LEO)IB64UNVDVFGR,GK+,%AMHK:U^MRP%/LO
M'-%Z4DL,?J>HZ8JB?J.LZAY N%O-!-U#I>N:?=VW'2UL;N]M+2XMI;J<Z<VZ
MS<$GA"J$:YCC^"+]YQQ5Z;H^N6=Q.+"UTV\LX(K2"ZBEFM6MX.$U0L*\N)6:
M(+^]@9%:+DN*ISBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_]#U3BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=2N*M<%\,5=Q7PQ5W
M$>&*M\12E-O#%6BJGMBKN*^&*NXK6M,5;Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*O_T?5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]+U3BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_3]4XJ[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%7_U/5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5_]7U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5?_6]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_
MU_5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]#U3BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_1]4XJ[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%7_TO5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
..5V*NQ5V*NQ5V*NQ5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>exh1070_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1070_3.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X1G717AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  'H2    G
M$  >A(   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#(Z
M,C0@,3@Z,SDZ,C4      Z !  ,    !  $  * "  0    !   #CZ #  0
M   !   $FP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !BA
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M%_G/W(_:M#Z>6RPL9^D)S&  RYCS_,?F;ZO?_I$CG/=[_M+&B-Q RJ8 D?\
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MV;_WU'[47,W^L[LP1;AG=I[K-6;?=_Z/_FTE)&YCG/9.5#+"22+\?VM;ZFZ
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MTFM<_=;_ .!(S<?I@<XCII!?%CB:6\@[8_K-5=V)2\-#L9AW%Q>1B6"=NUS
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MV;?I?3_X/V)*4*&.,^FS<V0TG#NT:[]&X:V^[=^C_L,2&/7/MKK:0-NF%>!
MEVGZ5K?I?0478["![!+FF#]ER28<=_O=ZF_^O4Y3]!KJMNV.><?)Y#FVM_PF
MY)3!]=0N]4,]Q?H3AY!,ZN]WZ7W?\9M]-3?2WTFL+&D:%H&'>0!&R"SU?Y-/
M]BO_ +;BUH8'%@$@'G$R?SAZ?T2__A??_P!N)#%J9$,_1MB&_9\J1N'L'\X[
M<UNUN]B2EVX]3RR&-#?4W .P\B1N.W1YL;L]OTW_ ,W_ (3Z"@<>A[!MJ;))
M/NPL@:D>[_"-V?HF,_ZXQ390UMC#6V(U,XV2-2-K_=ZNW_._P:CZ%9#1LAP
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M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M! H       $  #A"24TG$       "@ !          (X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300(       0     0   D    )      #A"
M24T$'@      !      X0DE-!!H      UL    &              2;   #
MCP   !, 90!X &@ ,0 P #< , !? %  80!G &4 7P S "  8P!O '  >0
M  $                          0             #CP  !)L
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !)L     4F=H
M=&QO;F<   ./    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   2;     %)G:'1L;VYG   #CP    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  $_\        #A"24T$%       !     $X0DE-! P     &+T    !
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MNWNGZ?\ I#ZO]=/]B<PC]7<W;+BX58@D[2UP^G[?5<YW_;OZ1,W#>'APQW
M.+F^CBR1+O:8L^E;L_J>])2_V>"3Z-CB0X6C9AS.NSU/<WWM:*7,_P"#]+>H
M#%=6UCG,=O<!7[:\-I,26M]S_P WZ.S<GJQGN-=C\9SFPTM)IQ1H0'._PIV_
M0VI#"M%9:<=Y(VM:X4XL0/;MCU/YO_OB2F8I&QK?1?[7-=Z.S$X]OZ.-_P"Z
M/5^EOV(;L:T#:&6%I]VE>'(<"S=9[GAOM:VMGT?W$2S$L?:6FA\;B6S5BF)/
M\X/TF_\ -3'&<T ,H<14U[1LJQ=ID^_9-@VN=]#_ *W^D]Z2F36Y-)+*1?6U
MH/T&XC6DD_SNW>'?NM8B>IFBM^ZVX;9_2$8P!#7>YS??M_,V^_\ TBJC!(W#
M[)O<QSBQS*,4 !PV5N8UUN[V_P [N?\ SG_@:=^%;N!=3] D,)HQO:UK8.KK
M?HV?R/\ KB2FQZV:QS1.0_C3]5 =/OV_SC7?1W)-?GL?$Y-XK,F!B@/ C@;V
M6-]3\W^;0'8=AK?Z>.\-L^DP4XA$M]A_PFW>[^6]:&#3116USJV4WO:0[VL8
M\@'3<*7/;[=W[Z2FVTD@$@M)'!Y'W)TDDE/_U/54DDDE.-DXP?EVN&+O<'AW
MJ?9Z7 B(]MEEC;+'?H_Z_P!!0=CWFML8Y$B#^KT'L6,EOK^W8Q]G^>C9.,WU
MWO;CAWO)M)QF/]0#:6[7[V/W>YK/4L_T2 <4;"T8; '.!(&(R)AS?HF[Z?O_
M )QZ2F3L1SG.<<71[G[0,>B6[C._W6GZ7YV[^<3'$,LL&)#O:Z/LU,[VQ6'S
MZOMV[-_TT2MN1C1Z% K+VD37C-;W]@=&1]%FU_M_X5$KR>I/W.AX:T%VTXX:
MYT1[&;\CZ?[FYJ2D#<."/U2'!X/J?9J-8]K'.BS\Q[&6[FJ#<9[8=]D_2/>X
MM+<6D;?9[-WZ9VUS7?X3U/I_HT<Y?4W>U@L:XLF78T@$1S&2W_MK?O1/6ZE(
M(+P'1(-#3!EM?:_Z'T[?STE-08EP,C&#8(+2,6G1U8+V\7_O_P T].,%^A9B
M^D=S T?9L<[-H#/4&VS^3_+_ .#5AV1U/32WVF'$4,UCVN=[LCZ#_I,V)W9'
M41H/4#H!GT&D0 W=]&_Z3W?RDE-9N,7%K!B"O;6X.W8M1! .[:W;<=GJ.V?H
MT]6&\;F#'%8?,G[+2!M((<SVVN_G&'TO=_Y[5@Y'40T"+2XZDBAN@(!#-KLC
MZ3?Y*3KNJ-D2YTEP!% /!?\ ]V1^C^AM_/\ ^W4E-=V(XV OQ/4+@TV3C4PX
M1O>S=ZO[SG)-QW@BXXSK'L?N=^KT!SH.U_\ A&^]WI;_ %:_])4COOZE,--@
MW@EA..#!EVUKRV]K588WJ%S!8V_T09BM](W#L-_Z1)3=23"8UY[ITE/_U?54
MDDDE.+EXP?=9:W'K<'/<'N=A[W: -^GZM;['OGV7?S6QBB:0UC2W#K&Z0\?8
MI) /L&T9 _T;43,J8ZXAU#7N%CG5DXC[!!V;OTC+&LW/>SW/=_.?Z+_2"% +
M; RBMK0_< <*P&275A^M[=^W^0DI>VA@!=]EK(K]K9PBXP/!K;F[_P";_=3'
M%8Z=N(S<T@']3'!F?I6MW;OY'\W_ (93=C4N+:QCL$O=M)Q'ENI%>[^<V,_F
M?<Y_\Y7Z2B*&ZL;0W0E^TX=D<B[9N-_I_2_ZWZB2F3J-UA8ZAKFFSWAV'(+'
M$?G^K])K7/W6_P#@2,W'Z8'.(Z:07Q8XFEO(.V/ZS57=B4O#0[&8=Q<7D8E@
MG;M<P"+MU7M:]O\ PO\ Y\0QPZMI&.P[0=#AO;'T-YVNO;[';_YO_P!)I*;&
MWIPW']FOEP!=^A!D-.]O_4?S:<,P'EE3NG.V"!6YU32V"-O]9C6,_?5;TJFO
M!;0 US#I]BM+HF6^\V[?;8SU?2VIW8S-A?Z%<@!SQ]C?+B'^W8T7?]'_ *\D
MI.QO3F0ZOI[VET:"G;,0_P!W#?8ZIGTTC1TW<T?LTG:'.;%+8EI(+?ZWMW,5
M=U%1:7/H87N=VP;>?SG.:VP_RT[:F.W X[38/TFXX;Q+Q#P?==]-OJ7?G^])
M39JIZ=:\4GIQK#X?+Z6ADEOYQU]_YBM5X&#4]ME6/6Q[)V.:T B=\[8'_"V_
MYZRW8PW//H5\-,##?+I#8U]?;[7GZ#OH)_LPL])GHU@. @NP[-H));_I_P!#
M_-U;M_\ QG^$24[:2%C4BBBND!K=C0(8-K9[[&2[:W^TBI*?_];U5))))3C9
ME%+[K0VN23-A=BW62=3[;&65[V[/W/9O0W8['DRQI<XE[W/P\@@F/4&W]-['
M?^JOY"-EU%][PX2T;]OZO>X\;_YVFUK7?2?L_P# 4-F/6'-VLA@(<!]FR X.
MCVO:Y]FWZ7T_^#]B2E"ACC/ILW-D-)P[M&N_1N&MONW?H_[#$ACUS[:ZVD#;
MIA7@0)=I^E:WZ7T%%V.P@>P2YI@_9<DF''?[W>IO_KU.4_0:ZK;MCGG'R>0Y
MMK?\)N24P?74+O5#/<7Z$X>03.KO=^E]W_&;?34WTM])K"QI&A:!AWD 1L@L
M]7^33_8K_P"VXM:&!Q8!(!YQ,G\X>G]$O_X7W_\ ;B0Q:F1#/T;8AOV?*D;A
M[!_..W-;M;O8DI=N/4\LAC0WU-P#L/(D;CMT>;&[/;]-_P#-_P"$^@H''H>P
M;:FR23[L+(&I'N_PC=GZ)C/^N,4V4-;8PUMB-3.-DC4C:_W>KM_SO\&H^A60
MT;(< &O)Q<DSJ#MGU/H;OY=B2FSA8MP!OQ_1J<XD2['MK.W4N!KMO:[W.V*X
MUG4 ?==41Y5.!Y'_  _[FY9CJ6EOIAIYW:X^26[_ *)=_._G-]-3KIQ6.><B
MHN;;.E>->W@[BYVMW^C]B2G2I9F!Y-]M;V$:-966$&?WG6V?F_R$997H=)T9
M]GN@Z:UW_G?O>WS5[%]"'^BQS-SM[][7M)<[\[],&[DE)TDDDE/_U_54DDDE
M.-?3NR;=NCG61(IR=NO\YN-5C*7/_F_TS/Y:@*1:6[1+6EH&^G+!CZ#-N]W[
MOTW?YZ)DMC(L+G607'?M^U_1]NW9Z+O28[V/_F_IH,.A[3N)D%[ W-//JL;[
M)^@[_,_\"V)2[F&2XC0'<"*<O<2_W-D-=[O;NW_Z)2?CR&M&X!T^D=F4(8=_
MMM<VQKO5;^_9Z?\ (2L)V;6[B'Z .&69$_GG\W?;ZG_&5IW-.Z&;@2T N(R]
M6#W5&0?Y[8VO=[O5_G4E,:ZPT@'?H"&GTLPF1 W2Y_\ *^DHMK:]E8;OVZN:
M6LS"(>X?NO;N^C^?_P"!L2:[]'6T:ML+BZ?M9T/Z/:R?I^W?O9^_[TX#G.8'
MGQ @Y?TOI5^_^M;3[W?\3_@TE+BMWI%K@9:=A(JRSQ]/;[M[]KF^RY,* YHD
M.X%8_1YC?<?<=YW^ZK<Y_P"D_,_FTS38UC2!P2 "W,(X^CK_ (-S?S?YO_MM
M3<V"XUN<#8QP$C++I#BUN[:[=^8S_A?SV?HGI*8.K)W!@]Q.]H]',:"[WL&[
M:[]'])3%0,4DN-#7.8UIKRPZ'!\;K'//J[G,_GOH?]N,47G]7!8[?4\L>"W[
M6000Y[?YMS_9L^G^9_I6)R7>LVH$^V 1^MCZ7TMWYEGZ1[OYQ)2\PT@[B"-#
MZ&8-7#]-N]SG?F>S]Q3QL4/RVU&2*C+G!N2R0![=F399Z5GN<SV;WH1!<6-!
M/OFKWG,'(K:[<''V[[K&?3_,_P *K]73R+RZPDUB#7MLNW @[MK]UKF/24W*
MZV55MKK$,8 UH\@I)))*?__0]522224XN4\_:K02[Z4 -LRP(C\[T6NH8[3V
M[5"QVRMC&A[CO,[K<S\S<P%M@8]W^D_XWZ:W4DE.)6XELDNV/?Z;7!^88DL#
M@YA^A^C=^C]WTU /D_I"6M<8>*[,P<[GO]+:&MW-]_T/_ EO))*<%UNX%Q<3
M)?ZA:_,#06Z?18-M?N]1GIJ=EA)>U\BPM:=HMR_HCTQN;M:W:[^;_F_?_.?\
M*MM))3A>HUV^Q[CMC0M?EG1P=_5_=_,3BPNVU!QW$^_WY@,R[\_]UU;O^M_]
M:6XDDIPQ8[8[5V[:"TE^9PY['#WN;O\ I;/H?^>?T:37/? 8XEX :!ZN8 3[
MMG];VL]ZW$DE.)7>TLV[G_1]WNS"8#FP6DMW^WU/=_VQ_-JQAY.4?2HK%>PP
M07>M.P$>H[==7]+W?HVOL6FDDI22222G_]D .$))300A      !5     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P R     0 X0DE-! 8
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M0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8
M,0  86-S<$U31E0     245#('-21T(               $  /;6  $
MTRU(4" @
M           18W!R=    5     S9&5S8P   80   !L=W1P=    ?     4
M8FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D
M   49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P
M ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E12
M0P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M        $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V
M,3DV-BTR+C$
M                 %A96B        #S40 !     1;,6%E:(
M          !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4
M !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO
M+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M
M9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ
M  !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@
M  !,"58 4    %<?YVUE87,          0                        */
M     G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ",
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@$FP./ P$1  (1 0,1 ?_=  0
M<O_$ :(    ' 0$! 0$           0% P(& 0 '" D*"P$  @(# 0$! 0$
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MO^RG%7?HK\_/^I@\N_\ <-NO^RG%7?HK\_/^I@\N_P#<-NO^RG%7?HK\_/\
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MQK^SPXTQ5%XJ[%78JQW\Q_\ R7GFC_MD7_\ U#28JL_++_R6_E3_ +8VG_\
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M\B\:E>*-4UY+BJ9@4Q5#Z?IFG:;;_5M/M8;2W!+"&WC2).3&K'B@5:L=SBK
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M'_95BKO\+?GA_P!3YIW_ '!!_P!E6*N_PM^>'_4^:=_W!!_V58J[_"WYX?\
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M_P!3YIW_ '!!_P!E6*N_PM^>'_4^:=_W!!_V58J[_"WYX?\ 4^:=_P!P0?\
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M_A;\\/\ J?-._P"X(/\ LJQ5W^%OSP_ZGS3O^X(/^RK%7?X6_/#_ *GS3O\
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ME\_>6X=>;0FEF:]26*VFDCMKB2VCGG ,4,MRB&".9PR$1O)R^-/Y\5=;^?\
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M$\%G(%'***3AS1#^RK>E'R4?R+BJE!Y?T."6.:&P@CEA-P8G6-05-[();FA
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M3+&H4-+,Q>1VIU9V/)F_:Q5*]+\B>2])OOK^EZ'8V5[R=Q<P6\<<@,HI)1U
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M&S^4_/NM:G?ZEK2:;:-<>7[W1K>TLYII@L]T\;B5Y9(HOW;</LK'RC_XMY?
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MLQZ;:)K$@*OJ2V\0N64@+0S!?4(X@#[6*J?E;R]#Y?T:/3DF:YE]26XN[N0
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M[%78J[%78J[%78J[%78J[%78J[%78J[%5&\:Y6WD:V19;@(QAC=BB,X4\0S
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M)-Q<1M:W4MTUU=2VDUFE \,/H0*MQ*[!O5D_N_Y7Y*JVE^3-8MA^7_JM"?\
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M4B)_JIBJ::EIWGB;4=!\S0:98MK%G;WME?Z2]ZZPJEX\+B6*Z%NS.4-JGP-
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MOXK>))SR^U615#?%WQ5,+.PLK& 6]G EO I=EBB4(H:1B[F@VJSLSM_E-BJ
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M_<W1(B$21N_+E3=SQB3XN<B^G)Q52_S#^:ZVGDS5=<TS2[MM1TJXAM;K2KN
MI/#)*R$&5 X'!H9%='CD;[:?Y6*II<_F-9P_5X4TC5;G4YH?K,NDP6P>ZMX2
M[1J]P.8BCYLC>FOJ\W_97X7XJJ5Q^:GEU1IXLK>_U.XU2&XFL[2SM7>8_4Y4
MAN$D1_3]&2%Y/C6;T_LM^WQ5E45^8/G"[\K^7H-4M=/FOY9KVRM3!%'ZA5+J
MYCB<L.:?%Q<I%\7^]#1*WPXJI7?YC64$T=M%I&JWFH&".YN["UM?5FM(YJ^F
M+GXQ&DC<&_=+(\GP_8XXJG$'FC0IO+?^)%NU&C"!KIKMU90L2 ERR, ZLE"K
MQE>:O\''EBJ3VWYE:,^EW.HWMGJ.EQ6PA(AOK.6.:873>G!Z$:\S*\LG[M8E
M_?*W]Y&GPXJI/^:>A6]EJ-QJ=GJ&DS:9:OJ$]G>VWIS/:QD*\L/%GCE"L>+J
MLG-/AYK\:<E5$_FUI'UJ2Q72-9?4?3%Q:V L7$US;<BIN(06"^DIIS]5HI%Y
MQKZ?-U7%45=_F=Y?AMM&FMH;S46U^WEN=*M[*W:6618/3,BLI*^FZ";XA(4X
M\)%;XL509\^+JNJ>4CI$S1V&J7M]::K:SQ>G/&]K932&"5''.&6*>->8_P")
M1MBJ-TW\R]!U"_MK:""]6TOI&@TW59;=H[*ZFC5F,<,K$$EA')Z;.B1R\/W3
MO\')5*_+GYL1WNBW^I:QI5[IJVM_/8VX:W)-PZWLEK!!"B/+))=?NU6=*<$D
MY_%Z:\L59+Y<\VV6N_6HH[>YL;ZQ*"\T^^B]&XB$H+1,5!=6210>#H[+\++]
MM'7%6.P?FDT6L><+?4])O(-,\K\I#J"PCTVAAM([B3D3(:R2%F:!53XXO3Y?
M%BJ:KY_@DTHZE!HNKSQ/,(;2%+-O6N%9.8FC0L.$!7_=D_H_R?;95Q5"MYQM
M]97RY/IE]<:<M]JDMG<6DMJK2O):PSO/9W D-;9E:!^4L?)N4?%?@DQ53LOS
M<\MW=Q$B6NH1V4MV=/&JRVCI9"\]=K80&8G[32KQ5U5HOB16DY_#BJC%^85C
MH]K=W>IWEYJRW6NWFEZ=!;V(]:.6!7(LTCAJTZ@V\OIW#?$_->?%<51W_*S]
M &D75_+!>PW-G=16$VCR6Y%_];N I@A6$$AFF61&C97]/C^W\#\54?Y4\XVW
MF1+XV]A>V$FG7'U2YAOX1!()>"R4"AWVX.C5_:5U9?AQ5+[7\T?+MQ#J-WZ-
M[#I>E_65O=4EMV6V66TG,$D*,"7EE+K^[6)']3[/]Y\&*KX/S+T+ZOJ,NHP7
MFCMI=J;^Y@U"W:*5K1209HU4R>HO(<"J_O%;CS1>:<E5+3OS-L[V74(&T/6;
M2ZTZVBNY;:XLB)I$G<QQ"*-'D9V=U<=.*<']1EX-BK8_-+R_'H^J:G?6]]IW
MZ%>!-3LKJW*7,0NF589/34N'C?G]J-G^R_[2\<57W/YD6-O!:%](U8W]\\JV
MFDK:5O'B@ ,EP8^=(X!S0<Y71N3JG'G\.*I)Y8\YW^NVF@W1U.6W.IZ[JUM#
M$;-0;BULWNS%;RB0)):E(8%)?AZWJ1\'^VV*ICIGYN>6K^>V2*UU"*RNKGZA
M#JD]J\=F;LR-"L'K$_::1>"NJM#S^#U/4^'%527\U-&76HM,BT_4KA)M0.DI
MJ<5M_H1O$)62/U7=#^Z9)%D8)QYQNB<VQ55\[^>+SRYJGEZS@TFZU./5[J:"
MX^J1"5U6*UEF CK)&/5+QJWQ?#Z"S-]I5Q5);3\U8=-U3S+;ZS!>SVFE:D\;
MWUO:%[:QLQ;6\B_695X_MR2N>/JR*G]YQ3CBJ>ZQ^9.AZ7>W-N\%Y=0Z>JOJ
MU]:6[36UDC() T\H(_W4?5;TA*T<?QR</AQ5$?F#K]YHGDC5-;TTQM=6D'JV
M[2#G&264;@$<A0^.*H+6?S0T/2M6U#2FLM1O+G25274WL[1YXK>"2/U1+(ZF
MG'A^PO*9N+<(FQ5$P_F'HMUK<.E:=#=ZD9([>::^M(#+:0)>)SMS-+4<?53X
M_A5^*-SDX+BJ2P_F1>WG^-K6?3[W2HO+INE@U?ZLKQJD%G%/R*M(PDGY2M-%
M%Q5)(/2Y<>38JJ^7O/>IR>;$\K7%C>7T<>EZ?<G71;)%'++<K,9)I0LG&*)_
M141JB?#/ZT?V47%4[L_/>B7>F:)J,7K?5O,%R+/3^24;U2DK_O!7X%XV\F_^
MKBK$/^5F:EJNB>9P\%[Y<DTN_-C:ZQ]3CG10;B&! 8I)&62<F7]XOV%C^/%6
M2ZM^8^E:=?W=HECJ.H+II"ZK=V%H]Q!:G@)")&!!=EC82.D"S.B_:7E\.*H>
M_P#S7\O6U_)96MKJ&JRQ6T%]*^G6KW$2VERC/'.9 0O#BA^'^\;_ '7&^*J<
M_G&2VU&X\S373-Y!70[:]MIXXE=9KFXG?="!Z[2&'ZNJ1?9_>_SXJR70M;.K
MV7UKZC=Z<>3(UM?Q>C,"*$'B"ZE6!V96_P"&Y8J\VC\Z^9=3U'S/+)J%]H-G
MI^K6>C:<IT^VEA#37%M'R)=FEDFF:9D>KK'#;RI,B>KBK)=0_-GR[I]]J5K)
M::B\.C3&'6+^*T=[2THB2<Y90:<.$H;]WS=5Y-(B+BJ.U[\P]+T.Z].\L=1:
MQC]+ZSK$5J[V,(F(XL\M1R0<EYO$LBQ_M\?BQ5#ZQ^:.AZ7JNH:6UEJ-W<Z0
MJ2ZH]G:/-%;PR1"82R."!QX'["\IO@?A&W'%56__ #)T*UN88+>"\U17MHKV
MXN=.MGNH;>VGJ899F3_?JAG1(Q))P7GPXXJM@\S26ESYDNI)KS5XK&_BLX-,
MM;(-+!(;:&4Q1&,UG1_660S3&-8N7!FX)RQ5 3^?6U&;R\=,6>Q:?7OT5K5C
M>P"*XCI87%UZ3JW+B6XV\R21M\4;?;^+%60^9/-ECH"VL<MO<WU[?.8[.PL8
MO6N)2B\Y&"U552-?BD=V5%^']IEQ5 7?YCZ5$EFMM8ZCJ%]>0FY73;6T<W4<
M*MZ9>=)3$(1ZG[NDC*SM_=JRH^*H>Z_-;RW##IS007U]<ZH;F.TL+6UD>Y]:
MR=([B&2)N+0R1-)\7J\8^*,_/CQY*I'YS_,RYFT+1W\LI?17&JZJ=*O)(;2.
M6[LW@#M<0F"=A&MT?3XIZ@DB]/G*O/\ =\E45=^9-82?S#8S:O):&QUK2-+L
M+Q+6&=P+R"R9T:,A4_?S7$@>3_=*R<H_[M5Q5/&_,/2CK4^EP66H70MY3:RZ
MA;VKR68NE7D;?U@?[P?89N/I))^[>57^'%4C\M?F]'>>4(]=UC2;VSGENOJ5
MM:QV]6NYI)Y(HH[5/4<NX6/]]S9%1N?Q<,59SIVII>Z9%?M#-9K(I=X+Q/1E
MCXDAA(I)XTIUKQ_:5N.*L:L/S0T*^N;11::A;Z=J,BPZ=K-Q:/'97$DG]T$D
M/QKZO^ZGFCC23X>#?O(^:J"_+/S-KWF.^\P7^H?6[:SM[^:RL=.GMH888X[>
M5XAQD0O-+/\ N_\ 2?4?TT=^$28JS[%78J[%78J[%78J[%78J[%78J[%7__4
M]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%4J\V
M:5-J_EC5])@94FU&RN;2*1Z\%>>%HU+4!/$%M]L58QH_E;SB^JZ+<:_-I[6_
MENWD33VLC/SN;F6#ZOZLRR*%@C6(O^ZC:;D[\O47AQ95EFBG6?T7;'6A;C5>
M ^N"R]0VXDKOZ1E DX?Z^*L&L_RRU2QT#RJ+6XMH]=\O73&XNAS"3V-S(XN[
M;D%Y?O(9 Z<TXK<0QM_E8JA?)'Y4MY?O[&*;0_+WU72P\=MKEO%(-3E0(T<+
MLIC6.&?@5]>59YO4_><43U/@50D^@^<]''DG1+LV4^A:-K-K;V-Q:K.UU+!%
M;SI ;A&416_I1!1*R/,LLG^^?LXJF5SY&\ZDMI5O/IRZ"NOQZ\+ES.UY(AU%
M=0EMS&$$495_46.99'Y(L:-&G-I%51K>0=5-X\XN( K>:4\P@5>OU9;98#']
MG^]Y+7^3C^WBJ%\Y_EM-JGFJ37K;2=%UKZW:16MQ;ZXLE8&MW<QRV[QQS55U
MF<30LJ<N$;+*OQ8JR/6_)EKJGD*?RI2"RAFLA:*MM$%MXF51QX0D_P!RKJ/W
M7+^[^#E^UBK%=+_+C5[?2M76TT[0?*FLWEBUI9ZIH4<IF61R&9VD:.W:.)F5
M?W:<W3[?K<N.*H#2_P GM5DEUW](?4M,M]9TG]'I%97-[?-',LIE69Y+WBSK
M6C<$]+^3_BS%62:AH?G[7M EL=;?2[>X^LZ;/ MBUPZ$V5['=7$CO*BLOJI%
MQAB$;>FWVYGY? JG7Z!N_P#'@\Q<T^J#2CI_I?%ZGJ&Y];ETX\./^5RQ5(_.
M'D35-;E\UM;3P1_I[1;72K7U"XX2V\MU(SR<5/[LBY3CQY-\+8JGFL^7)-0\
MU:5JDAC;3[.QU&SNK=ZEY/KS6W&@IQ*A;=P_+^9<5>>Z?^2FK)Y9U72]2O;2
M_N5DL8/+PN%DFMAINCRF:QMKU&"L_-GD2Z]+]EN4>*I]I7D*YL_+^M6\?EKR
MS97NI1I$EA;QRO:3)&2>%Y*8HG<'DWI\8/W+?%^\Q5#6?Y>^:8O)\^G&ZM8;
MV+5+35-&TWUKJYL;5+"6&6.T%Q,/K)BF>!G=O3_<^M^[BXIBJ%\_^7M8BT3S
M3J]^D3KK,&C0W%M;+-<I']4F;ZTTO%$G-HHEY-+;JMTL*/)'Z<O'%4@\N:3K
M>O6.LV&C3Q7#23V-Y=ZZ)M6ABU%$,D<FESW-TTUZ@CC ?E;/)&JR<&B^.3FJ
MR#3/RHUJ'RCYLTB66RLKG7[B&ZL4@DNKJ&!H(855)9+D^O(#)!\;@_8;DD<?
M]WBJ>?H7S[:ZS+YAL(M*?4=4M+>VUC3II[E8$>S>5H9;>Y2%G8%)V62.2V3]
MEO4^'BZK?E?R+JFD:[8ZI=7<-Q(+;5?TB8E>,-=ZM>P7C>BAYT@C]%T^-_4^
MQ_E8JG?GG0KW7/+<MC82Q0WR3VMW:M.&,1ELKF.Z1).'QA)&A]-F7XD5N7%L
M52-=&\^:?K%[K.EQZ5)<:Y';-JME=37*1P7=O%Z)>WG2%FFA:,(OIR0PMR3E
MS^/BJJ+C\@AORWN?*-S><IKV&Y-S?1IQ7ZU=RO<22)&6-(Q<2LR1\^7I_!S_
M &L505[Y?\_:[I/IZS+I5GJ5E<6=]I1LQ<3P&ZLY?59[CU/1?TIZ!/1C^*'[
M?KRXJ@?,?DCSIYJL]1?6)-.L;QM*NM+TNVM))YX@U\\3S33SR1PO3_1HE2..
M#X?C;F_)515E3:#=GSY'YB]1/JBZ4^GF'XO4]1[E)@W3CPXI3[6*L!B\N><?
M+VI>0],TKZG<ZAIVG:RET;CUUM9$DEM6X"9$9X7-596:)_[MTX?M*JGVE>0-
M7AN]%U&^N;=[V/4M0U;6UA]01F2_M)+<16O(%BL7.->4G'U.#R?#R]/%4N\C
M_E4WES4=/670_+QM]*Y);:Y#%)^DY452D+.IC6.*?B5]>43S>I\?!$]3X%5V
MI_EIKE_H^H:/<+IEY9P:Q)KNB_61*T<SW%Q+/+;7\' JL8%Q)$DL,DG[$OH_
M!Z;JLD\A^51H5M=<M'TC19[J12T&BJW I&M$]61XX3*]6<C]TG!6X?%]ME4I
MU_R/YDNYO.UI9S61TWS?8LJRRM*D]O=BQ6R52JHZ20,(TD9^:2)\:^G)\.*H
MSS]Y5U_7+72H].FBE@LW?](:3<7-S9P7:M'Q0M/:!I@8)!ZB)P:.3]KXE3%4
ML\J?EQK&CV/EZ"XGM.6CZWJ&JW"P-.4,-Y#=1I'$9N<I=3=)R]61OLO^\?%4
M9%Y$U5/(5OY<,\'UN+58]1:6K^F8DUD:B5'P\N?HCA]GCZG^3\6*NLO(FJ6]
MWI\S7$)6T\RZAKL@!>IM[V*ZC2-?A_O5-TG/]CX7^+%6.?F?Y?O;(ZGJTLBB
MQU75M+G]94N'6U2SMFC]6Z-MPN8D6=8VBDM'5_5]+U72%IL53K\F9G.F:K$M
MLK0+>>JFMQF\*ZB\L2&28M?L]R[PD?5W=I)$_=JL?V."JHN7\NKB\_+C4/*M
MY/"9[JZO+N*0JTD'*74I-0MUE1N!>.K1I.G[2^HJM^UBK&-8\ESZ/Y$\SSOY
M:T;3+BYLDM_2\OP23R21&0&?UF>*%VM^)J\<,331Q)))"[3>EP52CRQINLZR
MFMZ9HES'<S7,-I/)YB276$CE6VN*G2);B\DFN8XI86?BUG+^Y221FB^-?453
MW3?RGUZ#2?,EJ38V<FMSZ7-;6\$]Y<1PBPG664/-<AI79@OP,JJG_%:8JS#S
M)H'F+_$EAYE\O/:2WD%K/I]U9:@TD43P3R),'26%)726.2%?A:)TD1F^PWQ8
MJE6@^0]>LF\ORZA=VL]SI>LZMJU])")$61=36["")&Y%65KM.2L_[+?&^*JU
MGY#U6#R)I/E]YX&NK#5+:_FDJ_I-%!J@OF5?AY<S$."_#_>?Y.*O-O+\DD/G
M>"1K?](WPUVXDDT&9-3CN8&N+EXVU%HE9M)62*&3UO52!4>#[,OKOS95ZYYT
MT37-0ET34=$:V.HZ)>F\CMKUI$@F62VFM71I(ED>,A+@NC>G)\2<67%4ON/)
M6J2^6_/6FB:$7'FJ2\DLFJ_"+ZU816BB4\:_#)$S-P#?!BJ0:E^4\TOF&_O!
MHOE[6;;57AGGNM7BD:YMY%AC@E1%6-UN(&6%'B1I;?TW:3ESQ5FWGSR]<Z_Y
M-U+0K)XX)[V#T8'EJ(U((._$,:4'9<54+3RU?0ZQYLOC+&8M?%N+11RY)Z-H
M(&]3;NXJ./+X<58?'^6GFF&;RVEJNF6<VD6FF6EQYAMI;N+4#'9K&+F Q(JP
MW<,_I>G']8=?3CE;]US7%4[OO)WF.1O.ME!+9MI?FN":2":1I4N(+N6QCLA&
MZ!'C>WI")/5#K)\7#TF^UBJ+T_RWK^F^;+34[9[2?3YM+M-+U2.1I$FC:Q:9
MXY+<JK+*)&N&5TE]'APY\OV,52/2O(?G.T;RYI<L^G_H'RSJ3WD$J-,UW<PE
M+A(PZE%BADC%P.81I5E_FBX\'55;_P A>9IK/S+I$4UDVF:SJ<6K6ER[2K/'
M)]8MYI898PC(4"P/Z<J2?%R3G&OV\51S^7_/.E7NLQ^6VTR33]:NI+WUK]KA
M)[2>:-$E(CB5TNDY)ZJ)ZEJW^Z^?[>*HCR9Y'E\LW=ZL=PLUB^FZ7IMD342T
MTV*6)FD%.(Y^HI'%FQ54T_RKJ-A^5UCY7,5AJ%_::;!8O%>*[V$SQ1JC"0!>
M?I/QZ\.2_:X8JU^77EG6M TV\M]1DB2*:X]2PTNVFN+JWLH%C2,0Q37(69U=
MU:8KP1(VDX1KQQ5!7'D35);+68%G@#:CYDL]<A)+T6WM9K.1T;X?[UA9R<:?
M!\2?%BJO<>2-3E\M^?--6>$3^:9;V2Q8E^,8N;"*U02_#44>)F;@'^#%6*><
MORG\V:]=:@%GLKF"Z,#6%U=W6H(]FD21JUM':P_Z*Z%XGE69_BY2_O(7XXJS
M>W\LWT6J>;KPRQ^GKXA^J*.7)#%9BW/J;4^V*_#R^'%6/Z%Y*\\>64@CT*?3
M)?K6G:?:ZH]X9_W-UI]LMKZUNL:_OXI(U7]S*T'Q)R]3]YQ155UWR%YCNK?6
MQ8WD*_I/6X]5:S::XMH[FS6QAM'M)Y[<>M#RDB];E$)%^"-'^%WQ5!^6/RPU
MK2S:O,]G$(?,?Z<:"WEN946W_1C6/I+)<\Y7E]5N?)VX,OQ+Z?\ <JJR?S5H
MFO3:MI.O: ;5]3TQ+FV:UOFDC@EMKSTS(/5B25XI4DMX71O3D7CS3]KFJJ G
MT/SW;:K'Y@L7TN\U>ZL8['5[2=KBUMCZ$TLT#V\J+<2+P^L2HZ21?O?@?G'Q
MXLJI>7_(>JZ=Y@T[6[NZ@FN0VK7&K"$.J&?5'MFC6W5N1]*)+7@QD?DWV_VN
M*JM+Y!U47B3FX@XKYI?S"15Z_5FMF@$?V?[[DW^IQ_;Q54U+R-JEU>ZO<1SP
M*NHZ]H^L0AB]5ATT68E1J+_>/]4D].GP_$G)EQ57T;1/.>C:O<VEE)I[^6KC
M4)]1,TOKF^47DC7$]N(P/1/[]W,<_J_#'\'H,WQXJE$7D3S)%Y-NO*UQ9:-K
M%G#>/)8"]>XC6:WFN))V,O"-VM;F+U%]*6'U_L\OW>*LC\K>6-1L_)K:+KMW
M]<FG%RLICDEE6*&X=REO%-/6:1+>)Q#'+-\;\.38JD-MY0\\3Z9I/EK5)M,&
M@Z3+9.U_;&X^N7,>FR)+;I]7=1%;L[PQ>J_UBX^%7X1_'^[591Y.T&ZT6TU*
M&YD21KS5+_4(S'6@CN[AID5JA?C57^+%4^Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5__5]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M5"^O;6PLY[V[D$-I;1O-<3-]E(XU+.S>RJ*XJUIVH6>HV-O?V4JSV5W$D]M.
MFZR12*&1U_R64AABJJ9HA*L18"1P2B$@$A:5('4TJ*XJOQ5V*NQ59+-%%0R,
M$!(4%B "S'BHW[DF@Q5?BKL54[B>*W@DGF8)#$I>1ST55%6)^0&*I=9^:- O
M;^VL+6]BEO+RR&IVD*D\I+,LJB==O[ODZC%4UQ5V*NQ5J1TC1I'/%4!9F/8#
M<XJA-(U?3=8TVWU/3+A+JPNT$MM<1[HZ-T9:TVQ5&8JLEEBB4-(RH&8*I8@5
M9C10*]V.PQ5>#45Q5V*NQ5V*NQ5V*H?4=0L]-L+C4+V58+.TB>>YG?98XHU+
MN['P503BJZRO+6^LH+VTD6:TNHTFMYEW5XY%#(P]F4UQ56Q51OKVTL+*XOKR
M58+2UB>>XF?94CC4L['V517%5NGW]IJ-A;W]G(L]G=Q)/;3INKQ2*'1U/@RD
M'%41BKL5=BKL5=BKL5<305Q5#:9J5CJ>GV^HV$RW-E=QK-;7";J\;BJLI\",
M51.*NQ5"VVJ:?=7MW903K)=6#(MY"/M1-*@D0-_K(>0Q57EEBB3G*P1*@<F(
M JQH!4^)-,57@U%<5<>F*H73-4T_5+"'4-.G6YLKA>4$\>ZN 2*CZ1BJO#/%
M/&)(G62-OLNI#*?D1BJ_%78J[%78JA=0U73=.C22_NH;2.61((GGD6-6ED-$
MC4N0"[G[*_M8JO:^M%NTLVF07<B-+';E@)&C0JKN$^T55G16;_*7%5&'6M)G
M%H8+R"47ZM)8E)4;UT4!F:*A_>*JD$E,55X[RTDN9;5)D:Y@5))H P,B)*6"
M,R]55^#\"?M<&_EQ5 ZAYGT+3M2L=,O;R.'4-28K8VI-9)>) )"J">(+*"S?
M#BJ:8J[%4-J6IV&F6AO+^=;>V5XXS*YHO.:18HU_V<CHB_ZV*HD&N*H74]3L
M-+L+C4-0F6VL;2-I;FX?94C459F]ABJ)4U%:8JWBKL56RRQPQM+*P2- 6=V(
M50!N22=ABJX&HKBKL5<=A7%5D4T4H8QLKA6*L5(-&4T933NIZXJOQ5V*H75-
M3T_2M/GU'4)UMK*V4R7%Q(:*B#JQQ5%8JMEEBAC:65UCC05=V(50!W).V*J5
MW>6MG9SWMU((;6VC>:XE;[*1QJ6=C[*HQ5?;7$-S!'<0,'AF59(I!T96%58?
M,'%53%78JL2:)W=$8,\9 D4$$J2 0"!TV-<57XJ[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J__UO5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5(_/-[<V'DO7[^TD,5U::;>3V\H )22.!W1@&!4\6'[6*L/
MA3S/Y@\U#38O,=WI.G6^@Z7?2164=MZDES<R7:,WJ2QR!$_=)SC5/CXK]C]M
M5(]&?5?-'F'\NM9O]8N;/4+G2-3^L"S,$4<LEM/:AR$DCD(^L]9T5OLQIZ?I
M\?B57>5M=_-36=3LM;^*/3[G4WMKFVEO+);2.TCN7CDA%J(/K8NXHD_:N?4]
M9/C14_=XJB9-;\WV/DGS-YQ_3%Q>7=E=ZK9Z;IKK EG!%%J4EM%++^[YR-;(
MOJ&1Y4C]%>,B_"TF*MV9_-^&RUJ!;KTI)K 2Z?/J=[8W,R7;RJH:(V]O!''%
M)%ZHC]=)8_K"Q_L^IBJ"UVXEU;R1%83ZOK%GJ6D>9-'@U$7K67UN"6:[M75'
MEAB:VE5!.EQ!(@^WZ?J?8:/%6:_F-?ZIY=_+74;JQU*2._L((1'JEQZ;N")4
M1I91Q2,GB29/A1?]3%6,^8/,7F?RC/J\-KK4FOQMH<VKI)>)"[6<Z7$4*2CZ
MNL2_5)(YI9Q%*O\ QZ/QFX>IP516O#6-!>RMCYDN==M_,%OJ$5U;7HM318["
M:Y%U;&WBA:.-7C6)E_>1?Z1'\7+AS52>#S;KFA^7H&L7YQ6'D6QO[>%D#*EP
M3Z9G;;D5CC =TY<.,?[/VL53W7E\S^6_*5_J&F>9[GS#>::EGJKVUPMJTLEO
M%(6NE7ZO$A]&[MUD]%>'PR1?NY?MXJFWY?\ F2X\T7>O:];WIN/+;W:V6A(H
M7TS':1A;B=& Y-ZUR\B?$S?#"O#%6'7NO^:H]*\U>9H/,TK77EW6KJTL="X6
MYMI(TG58K2=>'UB22=9.,#)+')\47%9/]V*LGTQO,&H>9?-EY+KEREAH5\;>
MPTJ)(%A(;3;>9O69HWED'J3<XU5X^#?S\N*JI3Y;U#S!YH30-+GUVYTD'RSI
MVK3S62VZ75[<W8*3-REBE58X/34ND,7V[E.?#X%95"Z=K7FW7]9TG0?\03VU
ML)=>M[G5;2.W$M[%IL]JD$J%DDAC=3,\4CQQLC<)?@1F_=*I[^;NF23^7M#B
M_25U9>GKFD(;F%H@[%[V*,.YDC=.2,?53X>/JJO['P8JV\.MZMYMN_+/^(;_
M $RUT2PLIHGM_JHO+UYS*LES-)+#(O!/2$96&)$]7E_DHJJIIWG#6Q^56J^8
M&*:GJ>EQ:F+:Y1 L=[^CY9HX;@)'5>-PL22TB^#XO@^'%6.Z+?\ YG6EO=W^
MH7+RZ?+H]Y>/<37MA<UG2)7@GLH[6"+A#4O4.\\?%XO]DJB]$OO-&DMY,U/5
M/,=QJD'F6-QJUO<PP)!%339;Y9+<0HLD7IF#BX9YO5YXJQ_RAYM\T7$MOKVJ
MZQJJZ?9Z5>:GYF]5;+ZC$WI!X391PHUQ+&@+NL;GEQ6/U_WG[ME4S\O^;?,E
MAYBNX+VZU/ZA)H%YK"MKWZ/;]Y:R1".:)-.)DA@=)G]6*9>7PIZ7V),5272=
M>\\R:+K.L-J^KL=/\LWMWJ(O_P!'""/5C#SB^JI A9X4I,WQG@G"'ESY.N*L
MS]#S/K_G*]TV'S)=Z1IUAI.EW:PV4=MS>XNC=JS%YHY:1_N4Y1*OQ\5^)/VE
M6'7_ .8'FK5-*T&1]0U"UDN- 6]N/T&EH)7U&9S'"TPNP56W?TI&58OA5N?J
MLB^GBKTG49]?TG\I+VYO+ASY@L="FFN+DM'(PO([1G9N041OQE'P_N^+8JDD
M<?F?S!YM?3(O,=WI&G6NAZ7?-%91V_J27-R]VC-ZDT<O%/W2<XU3X^*?$G[2
MJ-T[S3K-[^3$GF2:8+K T:YN6N(E"CZQ!"])50U5:NGJ</LKBK'-8N_/UG;^
M6-.LM6O=3OO,T4EW?7 ELK)D-O;QO]7LFE@DBB]1IC+P<3SM';OQ?^\=549.
M_P":DGE/3X9)9?KB:C-'>KI]U8MJDMA&K^F(YI8TLFNHY./UD"*+G'&WV';%
M4HF\X><O,FH1V_E>ZNYM*M-*M+V.\2XL;"YGDE:5))[A;FWF5DC:'TY(X4CB
M]3G\7V."J<>9-=\Q36VE:8]YJD7F.+28]1UBV\OG34A0N#&9WN-1XQF$2QRJ
MD<;?%]M_AXXJI^4]7\U>;=3T07&N7&GVTOEG2]8O(;&.!/6N[B:8.>4J3>G&
MP2CHGVOAXNG'XU4T\DW.L:O(GF*^\QS1&ZOKZT;RXRVWU9%MWEB2V0<%N1<Q
MB%9Y']7DW[S]TL?V%6,>1?\ $FA>3_R^U4:[<7=MJ\EAI\^CR10+:1VUQ;L$
M$7%/7$T3(C^LT[^K\?P*K_"JS7SQ-KD_FORQHFG:M/I-MJ:Z@;Z6V2)I62"*
M-D"-*LBQN&;9^#_M?#^TJK"SJ_YK7^KZG-I,DC0Z-J9TVV2>\L8;9H[=DCK>
MPO;M<O+=J3-R26#^_B]!>/%G5334-833->\^M]:NK6XO+_1[.S:P2*2Z>>>T
MB1(H1< P*\FZ>I+\$?\ >?LXJQG5K[7=5\J>8M*U34M3M$T77-"$,MY)IYO5
M6YNK8LD\MJLMJRQROZT.RR(RIZOV>&*LE\U7GGP>:(?*VBW-[/;:=ID-Y+=Q
MW=C:7MS)+-)$7D>XMY8WCB$0]18($7G,GJ?[K7%56QOO-^LZG9Z/JWF#] 7^
MG:%:ZI>OIWU5UN;F>66-Y6>>.1&M8%MU9TB5$9KGXG1?3Q5.?R?B:X_*308A
M<,K2V3*+N'BK59G'JQU#(.O--F7%6#^1?TMI_D7R9IEGK]W!!YDNY;:?4)/J
MSM:K#'<2>A:5B")+<O%PY2B9U;EZ:\OLJL_\I76JV?FO6/+-SJDVM6EA:V=W
M#>70A^L0R733*]M,\"1(YXPI/'RC23TYOVDX-BK#]8\X:TGF>UU'2K[5Y],;
M7X-&E,RZ;'I-#=BSN8$B/'4'>)N?"=1_>K_OE<57:KJ/G/\ 17GKS/!YDN8!
MY7O+P:9I:PVYMF2TACF:.XY1F659*LB\9(_2^U\38JN\R^=?,VG>8-6\FK>M
M%JVO76GMY2NN*%X[6]^"^X@IP;Z@+>XFY-S_ +V+G^SBJ=?G+HFG:[I'E[1=
M20RV&H:Y:VUR@/%BCQ3"H8?993\2M_-BJ3>1=8U*?\R++0M<</YB\N:+J-AJ
M$G_+1&;FP>UO!7M=0_$W\LZS)^QBJ5Z"NNG1_P HAH;6J:C^BKO@U\LCP\/J
MD/*HB9'Y>'Q8JR+0M0\V:;YV\USZII\>LZJ+#1@MKHH6$&(R7]"?KTT:\E/+
ME^]_EXKBJI96=W>?G/#JDT]]8.WEZ*:32)&MRJ<KEXS#)Z:R5"M^\/IS_P![
M^WP^'%5+0O-^L3^7_P M'N=1KJ.NWA34E/IB2XCCL;J24%* @)-'#SX*O!N*
MM]K%4NM=1\YQ^6QYQE\R7,SIKC6*Z0T5N+0V9UQM/*/2/UFD])JK-ZJ\>*?!
M_,J@/--SJNL^6+O7[GS'+''_ (D@TY?+X%M]6$=IK,<"04*?6/K+K"MX9/5Y
M<7X^EZ6*HK5-<_-34_,.O3Z)RBAT?4#8V5NUY906@"K'3ZY#-!)<R?6>?-66
M:+]W)'Z'^_'50OYB7NJ:SY3_ #"U*3S)+IT&C23Z7'HJK;&V,<<:"DXD0SM-
M>^H?2=98^'.+TE?C\:KT?\QM7U#2_+32V%R+&>ZN[.Q;4F"L+2.\N8X)+FC_
M +O]RLA9?4_=\OMXJD.KOK6E3:5Y<A\U7$RZMJGU2XU6=;5KVTC^IR7(M^:Q
MI#ZUS)&!!)+#ZB)+\"R?!BJ4:[J_FW1[N_\ +5CYBGN7BN- -OJMS';S7-L=
M3U$VTUO,(TBBFK$OK1JZ1R<)/Y.#8JA?/,.NV?E_SWY6O-?O=2LXO+(U2*\N
M1;K<J[-<QS0L\<21M!,+=>2^GS16?A)^UBJ?3V'F!O,NA^6;;S3J,=A+H][?
M7=Z/JKW<S1W-LL5)3#Z2</7*\EA^*+X?M?O,52;S!YRUJ/S"FHZ/?:Q-80Z]
M:Z+,T@TU-)#-=I:75OZ3%-0ED3G(5G1?[W_BF-L59#H=SJ^K:UJ&K7'F273X
MK'6)M*CT'C;?5C%;OZ:)('3ZP;B\7_2(Y!*GP2Q^G&Z?$ZJE^3^D2V4'F"9M
M5O+Y3KFJ0-!<M"8T:.]DK*!%%&PED^U)5N'\J)BJ1^:/.6M1:\VI:-?:O+8V
MFMVFD3\UTU-(5FNHK:YMS&_'4)G7U)"LT?+]YQ_W5$V*NO\ 5?.D.@^:O-Z>
M8[D?H#5;V+3]($5O]4:WM;KBT4]8S-+ZD?)$=98_1^#[;+\:J!_,&\U76O)_
MGK5)O,4MA;Z7=S:5%H:K;&V,4+(@6;U$,[7%YRYQ.LL?#U(O31_]V*O4//FL
M1Z7Y<DD-U=6D]U-!9VDEBD4ERT]Q,L<<<0G!A#R$\.<OP1\N?[.*O)]9U+7]
M1_+S\R='U2\U*&/1[>*2W-^]B]\JRP&26&:2S$ELT3,G3^^5&96;[.*O3?,U
MB]C^6.OVKWUQJ+1Z5?\ ^FW9C:9PT$C L8DBC-*T7BGV<58#=:UY^O;^#1M"
M,]O9Z3HNFW2FVNK*T=WGB>LTIO(+CU8$],1\8^"<E?F_+X555?.7FKS0FF2"
M*]U1/,&B:+!>ZS%HQTU=/M[J:)W62>6^XM<12/$U(K?_ '4G\\F*H[4O,GF>
MWU72=?U6]NK;RLUGILDC:6;5HHKJ[<+(-0@F5KIH9VDC2%[9_P!TO+E_/BJ9
M>2=(DB_,;SU=_I:\E"ZA;A[!WA,!];3K9U9E6(2UB'[J']Y_=I\?-_CQ5)_-
MVL_F/?\ F[7;#0&EM[;08K8VQAN[*U0O-!ZQGNDNX)WFM^9]+]V8H_W$WQ\^
M7IJK/-/GCSEY>U'4=,NYU_2?F'2K)O*\2!#%!JTDBV-U#"S+^]5)9X+RDA?]
MWZK?W>*H74]5_-6ZU?6[71[F9_\ #;Q65K*UU86L4DOU2*3ZQ?0S6\DLB7,C
MU_=/ G#X8?C^+%65:6OF/6?/'F.&?7+JRT_1Y+)+;3[58 G.>QCDD]1Y(Y)'
M3FW)$!3XOVV^RJJ3>0_._F+S!K>B^7KB[*:GY>@O#YT5%4>I/!*;*U5JJ"GU
MHB2^^#A\*I^PV*O6<5=BKL5=BKL5=BKL5=BKL5=BK__7]4XJ[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%5*[M+6\M)K.[B6>UN8VA
MGAD 9'CD4JZL#U5E-#BJE;Z5IMM<FZ@MHXKEH8K5ID4!C! 6,4=1^Q&9'X+^
MSS;%4#/Y.\JW%E96,VDVLEIILHGT^!HD*P2J20\0I\#5)^SBJV/R3Y0BUU]?
MCT:S76I&+OJ A3UBY 4OSI7F5%.?VL53"#2M,@M)K.&UB2TN&FDGMPB^F[7#
MM),66E&]5W=I*_:Y8JE%E^7GD2QTZ\TVST"P@L-07T[ZW2WC"3(.BR"GQ*O[
M*_L_LXJB+;R9Y2M=#FT&WT>TBT6XY_6-/6%!#(9#5BZ4HQ/B<50_F7R;9:MY
M/F\KVI33[%XHH(@D8=(XH71@@C)4%>*<*5Q5%:/Y0\JZ+'=QZ1I-I8QWQY7B
M00I&)=B*. /B%"?A^SBJCI7D3R9I#W,FF:)96;WB-%<M# B%XW^TAH/L'^3[
M.*HZWT#1+=D:"Q@C:.U6P0K&HI:)]F#I_=+7['V<50%EY+T'1])O['RS86>B
MR7L;KZL%NG .4*H[HO#U%CY5]/E_D_#RQ55\H>6;7RSY6TOR_:D/#IMM';B0
M*$YLB_')Q%>)D?D_^RQ5*=%_+#RO8ZI<ZQ>65KJ&L2ZC<ZE;:A+;H)H3<.75
M%<\F;TJ\4?\ X'CBK)H=,T^!KMH;>.-K^3U;TJH!FD]-8N4G\S>G&B;_ +*+
MBJ6ZEY(\GZGI]GIVH:-:75CIZ+%8V\D*,L**H0)'M\"\55>*XJC;;0=$M6LV
MMK"" Z?%)!8^E&J>C%,5,B1A0."N8TY!?M<,55-3TO3=5L)M.U.UBO;&Y7A/
M;3H)(W7P96J,52S4_(?DO5+2SM-1T2SN[?3T6*RCEA1O1C44"(2*JE!]G[.*
MIQ;VEK;6T=K;PI#:Q*(XH(U"1J@% JJ %"@=L52;2?(7DG2/K7Z+T.QLOKT;
M0W?H01IZD3_:C:@_NV[I]G%4=<:#I4UK:VX@6$6"LNG21 *]J6A:WY0&G[ME
MA=D4C]G%6">6/R;32=3TR\N[NQN$TE)(X?J>F165Q=++"T#"_G$DIN@R/ZCK
MPB62?]Z^*LCA_+;R?8V5Y!H>F6^AW-W:S6?Z0TZ)(+F..X #>G(HJ.)5'3]E
M71<58]Y<_)NVT_4(;K4I=.N(8+*?3S9Z=ID6FQW$-RBQR"]XR3?61Q3X4_=H
MK,S<<5>@6^F:?;W4EW#;QQW4T44$LRJ [10%C$A/=8_4DX#]GFV*L&\Q?E/#
M?:C;W&EOIMO906:V$>F:CID6I6T,:.SAK5&DA^KN_/C-]M9?3A^']WBK*=#\
MJZ?I?E.U\L2%K_3[>T%C)]:I(9HN'!A(*<2&4TXTX\?AQ5'V^EZ=;W374%M'
M%<O#%;/,J@,88"QBC)'[$9DDX+^SS;%5D6B:/%I)T>*SA32C$\!L50"'TI 0
MZ<.G%@QJ,54=6\K^7=8TR/2]5TVWO=.B*&*UGC5XT,8HA4$?"5&PIBJ%O/(?
MDJ]T>VT6ZT.RFTFS;G:630)Z43T(+(M**QY-R8?:Y-BK6I^0?).J1V46H:%8
MW4>FIZ5@DL$;+#'M^[C%*+'\*_!]G%575_)?E'66M&U;1K.^-B.-GZ\$<@B7
M;X%##9/A7X/LXJBM/T#1-.:-K"Q@M6AMH[&(Q(J<;:$DQ0B@VCC+MP3]GEBJ
M'A\G^58==EU^+2+2/6YJ^KJ*PH)V)7@27IRY%!Q+?RXJB$\OZ(EE8V*6,"V>
MF-&^GVX1>$#0@K&8UZ(4!^&F*J\VG6,]Y;7LT"27=F'%K.R@O&)0!)P;JO,
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M:58^7KNP2SO-6T.[U21K2:>2""6#5)I9-IEAE=98P\7^Z>/]XO\ *V*H2?\
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M4:5"@8@$$@5Q5CITGS_%JT/F:"QTQ]7N+!=-U727O)U@"V\\DMO+!="W9O\
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M3^*']YQ_W\V*J-Y^6&H77Y<>6="NHK+4-3\N-!,;.Z:3ZC<M'%)!)&TBKZB
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M;O[2WU&[OKN&]MVNK>*1K62"VBMU]%V#,O\ <+)R_FQ5/&T^)7N)[=4@OKE
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M42RL#R-O!ZC_ ,J8JI77GH1^8I[R*Y];RW'Y7.O1($^W24L)1\/J_%"/L?\
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MT_2[*2/4_,6H-IL%_J%W9VB-)'!(HXW%S'&RHCS$.RV]OZLOP2>G%Q7%4O\
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M5E'E_P P6.NZ-#JUH)(X)N8>*=?3EBDB=HY8I5J>$D4B/'(*_:7%4CTK\SM
MU+4;2VAM[R.SU&5H-+U::)4M+J5%=^,+<_5^-8I#$\D,<<W#]TS\DY*JUEY_
MLKC78-(N=+U+36O3,NGWE];B*"X>!3(Z(>;2(WIJ\BB>.+FD;\<52V?\R;?4
MM'U672;+4($CLKV?2M9FMJ6=PUM&W[R%ZM\/(<HS/'&LZ_%%ZB8JWY+_ #*M
M=6AT2RO;2_MKS5+57L[^[MO0@O98H!+/Z&_,;<I%]2*'U$Y/#S3%6<C%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%7_];U3BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL58;I7EWSEH^LW5O87-@?+-W?S:D[3+,;Y#=R&:XMU5:0L
MK3,[1S,W*-']/TFX\\59%HRZZ+1OTTULUYZLO#ZF)!%Z/J'T:^H2WJ>EQ]7]
MGG]CX<58-I?D_P#,BUT.X\L+=Z79Z3/+>_[E(3<37JPWEQ+,>$++%"LP$W$/
MZKJC?'PDQ5"7GY.I!K=U+INB^7=0TN]-NP;6;1I[FT]"".V,<1"GUX?2@C:.
M-I(/3?U/B;EBJ9W_ )"UZX\_6NN6JZ;IEI;SQ22ZC9_6(]1N;6*.GU.YC6EO
M-&S[>I(S<(N/IQ+(O/%6)>=O+EYH>G^7+*\N3#'#>ZS=G5(X+^:WADO+EYX5
MY:<\%['<-#.\:-ZJVWPW'J<W]#%4_P#(6@ZA?Z?Y3OTLXM*M/+USJ*B$)<1?
M6X)XY(8KJ*.YY7"?6&?ZP_UEVE;DS\WY<L55O,OY;^8;^;5)K2YMI8;_ %A=
M2ETNXEN8+>YMQIT-GZ-Q);_O 8YH?K$?$21M\'-?Y54-I?Y6^8]*\M6UM97&
MGKJVG:])KME#2X%DRR1O";=BQDG3]W,_Q_O?C5?V<55-=_*V\N_,U[K$>D^7
M=4_3'H27CZU;-<2VL\4*P/Z!"5F@9(XV6%W@_><_C_>_ JRSSEY=U'5O*TND
MZ1<)8SUA,2\I(H7CAD5FMG: I+'#/&IA=HCS1'^'^7%6#:9^3^MV^D>9K7EI
MUC)KITUH+>S:Y>&'ZC,9) SSEI)"Z_9<!%_XJ3]I5GL^@7<GG>TU\2H+6WTR
MZL&A->9DN+B"96&W'B%@8'%4ED\M^>=*U/5W\LW&FFQUNY-](VH+/ZUK</$D
M4C(L54N8SZ2R+&S6_%N2>IQ;DBJ(T#R&VB:KY?DMKA9+#0]$FT:C@B61I);9
MUDV^$"ELW+?]I<50ND^0=2LK/RM!)<0LV@ZK?:C<%>5'CNTO51$J/M+]<CY<
MOY'Q5;Y?\I>==+TH^66N]/?RW:6T]II\P6;ZY)$R,ENDP-(HS"&422)ZGK<?
ML18JD&M?E)YDO++2K(3V%_:VFC6NEF"^DO5AM;BVC*/<V\5N\:S>OR =9O3=
M?1CXR?;7%4X@_+.^^I):7-U&8CY27RS,8BP?U>/%I4++3A_+4<O\G%6.P>3O
M,OFCR!Y6AM;&PT^_TW3AI[WM\+J'4M.O+8"T>:TE@XEU!B=UC8QQR\8W]1X\
M59+9Z9=77YOG4"LK6^@Z E@U[(.*SW-].)F !4!O3CMU=V1N*M+PQ5-=9\L:
MU-YQL==L)+9K9K*32]5M;CU%;ZO+,LIEMW0-^]'$KZ<@X-_.N*I%#Y#\Z2Z+
M8>4+Z[TYO*^GM:(+Z)9Q?S6VGRI)!"T1_<Q.WI1I+.LLGV6=85]3]VJFWYC>
M4]6\PVEI#86>E7C0N[\M3-Q')!(0/3FM9[;][$ZGES"\?47_ ':G'XE4';^4
M/.^AW27VBWUGJUY=6%E9ZN^K&:)I9[%&1;M)(1*>4JNWJQ.GVOC]7^95#VOY
M8:K;^HSW\,\USI&L6=W-P:(-?:Q=K>/(D=7X0*_,!.;/QX_:Q55@\E^=-%NX
M;KRY=:=ZEUI=EINJ"^69A'+8(R17-OZ=/4'&63G!)Z7/C'^^3XL55M:_+W4M
M2LO.5N+R**3S'+:SV<I5F$;VEM!&/53X:J\MOOP;^[;^;%4XU?2?,^L>3+O3
MY+R+2?,%W;M']<L6E:**4G8QN?2FXD?"S#A(O)N'[.*L%TS\GM:@@\T573-.
M;7]#DTB&WLGNYD29_5I+++<\G=?W@^PB?R\7^VRK*O-WD&;S&^F0RW(AL[>Q
MU&PO2M?5(U"T%MRBJ"M4^)OCQ5":5Y5\^S>8O+^I>8+O3&M] CN80EDLX>X,
M\(B6=O4^&)OAW@7FJ\O[U\59%>:!<S^<],UU9$6WL;"]LY(C7FSW<MM(K#;C
MQ46S<O\ 67%6&2_E.T?F>_NX]'\NZEIVIWOZ0EO=4M6FU"%I6#3Q+1>,R<U+
M0,TL7H^I]B3T_C51VL?EI>7OYD6?F."ZCCT1GM[S5].8OSFOM/25+*5=N'%/
M65I:GXF@@_DQ5!:S^4]W>VLLI33=0O(M=N]8M;+4HFFLI8;Q3&\,Z\699%0\
MTE1)/3D1?A9<51MS^7%W<?E_>:);6FDZ)K$DZ7]C^BH6ALX;VWD26VD?X>4I
M5XD663TTYQ_#PQ5*M"_)B\TOS1Y>U(7L/Z-TRTADU2UC5T:YU>WBGB6[ KP"
M,+R5BK?%\$>*LM\V>7=>NM4TG7= FMAJNDBXA%M?<Q;S07@C$JEX@TD<BM#$
M\;JKK]I&3XN2*I)I_P"7GF-%MY=0O;26\'F8^8;EH5D2,Q-;F+T45N1Y(312
MS?$J\OM8J@X?RKUB[U76FOSI^DZ3K%G?6=[#HWUA/KK7E$CN+B"4^A%-!&*\
MH_4>221^4G'%4QU+RQ^8FN^5M1T;7+O2DDFC@CMI+19Z.\4R2/-+S_N^:I18
M(U?@W^[GQ57F\N>>M*U75Y?+$^F-9:W<F]D.HB?U;6X>%(79%BJMS&?2218W
M:WXMR3U/BY(JDJ?E1K%GJ>@QZ8VGVUIHL=C -?3ZQ%JSV]IQ,UO(L9%O/'<%
M#'^]?A%%*_&)G7GBJO??E]YS=KO2K2[T^/R]<:Y%KOJR"9KQO].BOIK<J!Z2
MCU$?TY@S?#PC:/[4N*L@M_)1DLO-]A?R@VGFBZGDK"2'C@N+&&T8&H_O!Z3M
MM_DXJD/E+\M]2TCUC/HOE:VN8K.2UMK^QLG66XE9> >X6D?IPN!^_@1Y?4Y_
MWR\?C53'\N/)6L^79-2DO?J=E:7?HBTT32WN'L;=H^9EFC$_'TWN#( T44:1
M(L,?VFY8JIR^5?/.FS:Q:^7+G31IFM7,]Z9KY9S<6DUVH$W!(_W=ROJ<I8U=
M[?[7I-_-BJ8^6?)1T'6#-!,'TV+1M-T:U1B3-_N.:X^-S3C\23IT_:5L52KS
M=Y%\PZQYKLM3L!IMBMLUN1KB?6(M6CBCE$DT ].D-Q%,J^F%F;@BR2?NWQ5C
M7Y@>6;W2]+_TF7_1;_S+/JIO(H;J>*U26W80O.+-HKY)%E 6*2VE15F9/5?T
MN2XJC/RZT.]U!-)NXK:*UL]!U>]N!>B.\B.II>6+H;E5OC)=>IZ]P8Y7GD?G
MZ#-&_#@N*I_>>0=2G\Q3:HMQ"(I-?L]9"'GR$-KIJV31]*>HSKS7]GA_E8JM
MU'\O]4N?+OFC3([F!9M=U4:C;.W/C''RMVXO05Y?Z._V?YEQ5$VWEKS?I7F3
M4)='N+#] ZQ>IJ-Y]968W<,A2..XCB"'TI4F2%>#NT?H,[?#-Q5<58M#^47F
M4^:K#5KRYL+HV&K?I!M6EDO)+^X@YR,L+1LWU:'T4=8EX*Z,B?#Z.*LBA\@Z
MFGD2T\NFYA-U;ZI%J#S#GZ9CCU<:B4&W+D8AZ?\ QD_R<53+0/+VN:3YDUV8
MR6TVAZQ<_I%&_>+=QW+0PP-&5H8FAX0<U?DK_%PX?M8JOD\KWC>8/,.I>M'Z
M.L:;:6$$>_))+<W7)GVIQ;ZTG&G\K8J@?*ODC4='U/2+N>XADCT_R]:Z)*L?
M*K36[AFD6H_NS3X:_%BK&K_\I_,LMO86_P!9LM0M(9-2>?3KV2\CME>^OY+N
M*Z46S(TTT44OHM%+Q7[7IS1_M*IUY"_+S5/+=QHTEU<P3+IFA_HB580XY2_6
M1-S3F/[OB./Q'GBJ'L_(7FW1)[34]$N;";4XY-4ANX+SUE@DM-0U&2_B*/&"
MZ3P,ZJWP<)>3_9^%L51.M^1?-6H_I>XCU>.UU/4M&L-.%Y )8?\ 2;.>>>5J
M(WJ107 F]+]W-ZT:,_%^7%L58_8?D]K<>G>;8*:9IK>8M(CTVVMK)[N6**6-
MISZDLEQ5Y*^NOV$C_E]/X?4=5G_GCR]<^8/+-QI-M(D4TTELZR2UX@07,<S5
MXU.ZQD#%4$_E&_8>=1Z\7_.S-6S^U^Z_W'16?[S;_?D1?X?V,52R+R#K4&H6
M#I-:S6$^A0>7]<C<R1RB.W#D36KJ&!9C-(I24)^PW/\ 9Q5"^0ORSN?+M];&
MYT?RY&NG0M!;ZO86C1:C/\/II)(2JK [1_W_ !>?U&;]C%5:\_+&XNORQT3R
MM.UG<ZCH26<D(NHVFL9I[, <)HS1F@E7FA_:3EZG%N''%5)/R[OE\K:AIZ>7
M?*L%Q?RQ&;38;>5;.6&+;][,JI(9UJSPRB#]S_*W]YBJZ#R%YNM?+F@I%?VM
MQKNA:E+J4$-RUP]F(YXYX19K,Q>Y]*WAN>,$KAV_=)R3CBJI:^1/,"_F$OF+
MCINFVBRR274VG&YCNM0C:)HXX;V(D6[>FS^J;C]Y*S0Q\/25FQ5D>L^7KF^\
MS>7]6BDC2'2&NS/&U>;_ %F#TEX4%-CNU<528_E_>3>6M=TB6\2*?4M6GU:Q
MN44R+"_UM+NV]1&X<^$L2>J@;XU^'GBJ UKR1YU\T1S'S!-IMK);V.H6VEPV
M!N)%:YU"V:V]:=Y50JD<;O\ N8T?[?+U/@XXJR"+RO>IKWES43-'Z6C:;=6%
MP@Y<G>X^J\63:G$?57KR_F7%41Y2\NSZ/H4^FW<B2M->:C<EHZ@>G?7DURJ[
M@?$J3!6_RL58?Y(_*NX\NWUI%)I/ET6FF*\=IK=M:%=5D4*8X7<\52.<(5]:
M422^K\?P)ZGP*H+RQ^4?F'3_ #/HNKZE-83R:4]R+W4DEO9;[4!-:R6ZRR^N
MS0PR,9%>2- Z_P"^Y41?395.](\G^>;3RY-Y4FO-.;0;;3Y]-TV=$F^M2QM$
M8;7ZP#^[B]&/B)6C]7UV^+]U]G%4U'E&^">3%]:+_G6C6[^U^]_W'2V?[O;_
M 'Y*'^+]C%65CIBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_ /_7]4XJ
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%5"&_LIY[BWAG22>T94NHE8%
MHV=0ZAP-U+(RN*_LXJK<ABKN2^.*MUVKBJF]S;QM&LDBHTK<(E8A2[4+<5!^
MTW%6:@Q5"66N:3?7VH6-I<+-=Z7(D.H1*&!B>2,2HK5 'Q1LK?#BJ.!7MBJR
M6YMXE5I9%C#LJ(7(6KN:*HKU9CLHQ5?R&*NY#%7<E\<5=R&*H72]6T[5;*.^
MT^=;FTE+".9*\24<HW6G1U9<517(8J@M7UW2='BMY=3N5MH[NYBL[=F!(>XN
M&X11B@.[MMBJ.!!Q5KD,50OZ6T[]*G2?77](B 79MM^7H%S&'Z4IS''%4467
M>O3%7<EQ5JJ5I_GOBJ"T77M(US38]2TJY6[L9FD6.= 0"8G,;CX@#\+HRXJC
MN0Q5W-<561W-O*I>*19$#,A9"& 9"59=NZL"K8JOY#%7<ABK9(&*M<UQ5+M4
M\RZ#I6E/JU_>QPZ;&Z1-= ETYR2B%5J@;<RL(_\ 6Q5,>0Q5 Z1KNDZQ;/=:
M9<"YMXYI;9Y%# "6!S'*GQ ;HZE<51]=JXJIR7,$;1K)(J-*W"(,0"[4+<5K
M]IN*LW$8JOY#%4%K&N:5HUJEUJ=PMK;R316Z2,"099W$<2?"#]MV"XJC>0Q5
MO%6N0KBKN0Q5 WFO:19ZGI^F7-RL5_JIE&GVY!Y2FWC]67C04^"/XOBQ5'<A
MBKN0Q5LD#%6N0Q5+M1\R:%IUI#>7E['':W%Q'9P3 \U:XED])(P4Y?$9/@_R
M6^UBJ8\ABJ!T37M(US3(=4TFY6[L+@N(;A 0K&-VC>G( _"Z,N*H[FN*K)+F
MWB:-99%1I6X1!B 6>A;BM?M-Q5C08JA++7M(O=1U#3K6Y66]TIXX]0A :L33
M1B6,-4 ?%&0WPXJCN2XJY2IZ8J@M.UW2=2GOH+&Y6>;3)_JE\B@@Q3A%DX-4
M#?@ZMMBJ-# XJLGN;>WC:6>18HEIRD=@JBIH*DT'7%5 :MIQU1]*$ZG48X%N
MGMM^0A=VC5^E*%T9<517(8JV"#BJ60>9_+EQI#:U!J=K+I"\N6H)*C0#@W!J
MR \!Q;X6WQ57GUG2;=KM9[N*)K"$75ZKN%,,#<Z2R5^Q&?2D^-OA_=O_ "XJ
MOGU+3[>&":>YCBBN7CBMY'8 223&D:(3]II"?@ ^UBJW5=7TS2=.N-2U*Y2T
ML+5#)<7$IXHBCN?U ?M-\.*MZ=J=EJ-C!?V;F2UN4$D+LKQDJ>GPN%=?]DN*
MHGFN*NY#%4-IVJZ?J,#SV,RSPQRRV[NM:"6WD:*5-P-TD1D.*HGD,50MCJVG
M7[72V<ZS-93M:W06OP3HJLR&HZA74XJBN0Q5W(8JV#M7%6N0Q5W(8J[D,50U
MGJFGWDUY#:S"66PF^K7B &L<OII+P-1_ON6-_P#98JBL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK__T/5.*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5Y%KU_JUIJ'GEM*O6T^]FU_P NVL=VB+(46YCL
M(7^!_A:J2,.)Q5=K?^-]'?S#Y?T;7;W4[RVT6#7--FO/1>Z-S!=2"6W#)$J-
M%=I"L7IF/X.3<./+%4IU/\PO-&OLVK^6+XIH6IWMAH=C26&! S6KWMW*MQ)'
M,D5Q)*\.FH623A*K+&OK_953A5_-)/)VIV9OHTODU"WCL@=1MIK\VQ5&N+87
MAMXK=+J0EOJQE@Y*DGQ-]AU506K&U\Q6/D0QZWJ]H]KK]UIMQ/+-;QW:7,5G
M>(XDD1'@DFB:/T(Y8^2R1N_VW?EBJ*\S>:=>M=/\R0Q:C.AC\R6FF0R1&%;E
M+(V-I/<I;R3!8(YBAN)$><\>;?"WJ-&N*H'3=8U== :*75->N9M=U:2+RY#'
M<Z:VH26MM:^I)').W^B6W[Q9I/[SUGC2)?M.ZXJ@;F\U+S'Y!TXZGJ=[;/8>
M<+:P2Z$]L;@1+?(D9GFA62WDEAY_#)'\/-5Y<L59?';ZCJVMZ[87/FJ_TF'R
MU]6M[1(9+:-Y(FM(YFO[II8F]82R-(G1(/\ 1I>/^[,52[R=J?F?S?K&GO?:
MS=6%LF@Z=J,UK8K'$+F>2[NX_7+,CE8;B*!':*/[:LG%_@^-5D/YF:Y?>6FT
M'S)]:>'1;'4%@\P0U B:TO$:$325WI;3M#)\/[//X6Q5@WDGSSYXU35M'\L:
MO=20ZU>:G^FKIH@A":'+:_7H;<DJOP^NZ6+_ +7P2?'PQ54\I0:[I'D_0?,-
MOKUT8Y]:BL7T=EA^HBUO-6:U=. 3U/5'JF7U_5Y<OAX\/AQ5&7.L:[)Y-U?S
MTWF6ZM-6T^:]$.A5M_J226MP\46GRP-'ZKRSA4BY&3ZQZDRNG^ZTQ5FWGG5-
M1LT\LFUE:W-[K5G;7:"GQPR+(7C:HZ'B,58_Y-U?7+7SG-8>9+^[N+W56O7T
MKTIK:?29H+:4$>@D:K<6LMO$R1R+/\,C^I^\D;[*K>N-?:IY]UW29/-MSY?L
M]/TFQOK>*V>WC8.[W2RW+-,KUACX1^JG]W]CFV*I%IOG"87*>:M>E:RF;R1%
M=WEQ;0@LCO=.?4BAD#K6I#HC\D_F^#%5&V\S^:M./G*PDN=3A-GY:N-5M/TK
M<V%W<Q7,8D"2QO9%EC1AP;TY?VDY(N*IY'+YFT'4] :?S#=ZL/,%G?-?Q7:P
MK&DT-I]9BDM5C1#!P(9/3Y2<T;XOC3EBJ%\KS^:K&Q\@:Y>>8[S59/-!MH-4
ML[I81;<;C39;I6A6-%>.1'@7X^;>KR?GBJCH6H>:?,=GY$LF\PWE@-5TW5+K
M5;FV$7KSFVN+41@.Z.L3?O&'-4Y<.:_M<U50>I^;]?MM.MM)N]7O6AM-=U*P
MO+ZS-K#J4UE9)RA_>3A+;FLLMO'/QX33)\2)_>XJS_\ +%-9/DVVDU>\N+N[
MN9;B6.>ZFAFG%N\S?5P[VX]'U!!Z?J+'R1)>>*L \N"_T/RLRV6OWJC5?--Y
MI-[>W$D,HLHCJ5URF0-&$CN+IECB9Y>2^M<+(B?81E6:>7I-0TGSQ+Y9_3%S
MK=@VF'4)7OFBEGM9A<+$BF2)(_W=RC2,B2#_ (]I/3_;XJL=U_4=5EUCS_,O
MFZ?2?\+_ %>YTZPC-L(DY:=#/RN%E5GE@FFYIZ?*-?[WB_)O@52SSWYX\P'3
M;_5-/GU:UU30M-MKK4;:WDT^VT^TO)K9;I(YX[PK=78DY*LD2<_A_=1?OF;%
M671PZWKGY@ZK9MKE[8Z7IMCI5S'8V9CC#37)N>;,[H[^F5B'*,?:_P!CBK%?
M**7FA?E9#>6.L7DTUQK]O;.L\D<@B1O,'U>=$ 1>)N(W?U^7VF;X>&*LFT2X
MO]4U[4M5O?,D^FM8:U)I<6A VXM3#$X2*-XY$]5IKU#]823U%?C+'Z7P+\2J
M06^O:_J47DVRG\PSZ8-9U'7K6\NHS"DLR6MQ.MM"CR*RHX6-5C95Y\5_F^+%
M54^9]3_14_EXZMJ>I7BZY<Z9HUYIK645Y>P6MJES(LMU<!;53;N\D,LR>E)(
MUMZ?'GZV*I-#-J7F72_*+:GK.H6<MKYKOM-BN4GM1<>G':W8B:6:)9+>6X0)
MZ/JQ? ZN_P!IWY8JCK[5?S.U'7];FTFZ$"Z+J(L+**;4+>WMU15C"&\MGM9)
MIOK?/U%;UX^2S)]7X?"[*O0?S U*_L++2'LYF@>?6]+MIBM/BAGNTCEC-0?A
M="5.*L#U2]\VKHOG7S7'YEO(W\MZA>C3-+58#:>E:<',4ZE#),LBDI_>+Z7[
M'Q_%BKV%+B!Y7A216EB"F6,$%E#?9Y#J.5-L5>;R3:EK5_YIO;OS3=>7AY>N
MY+>VM8'MHX((8[>.5+FZ2:-C,LQ8R_O&6+TO@3]IL54?)FH>9O-?F#ZUJ&JW
M>G6]MIFAZB^D6H2-#<W<,LLR2LZ-)Z1X<6BJG^MBJ?\ FO4]7MO-^@6-C=K;
MQW=CJ\DBS4,!F@C@,#R]^,3.S;'[.*I=^5VI:HLUWHNOW=]<>8HK>WO;I;N:
MUNK9HY6>/U[.6V5.,$SQM2&94DC^'X/VF52?7=0U6XU[SZ_^+Y]'7RPMM=:=
M91M;B.,-I\<Q>X656::WEF#+Z?*-?[WX^3? JE?G?SSY@DTB[U2PGU>UU70]
M)MKS4K:VDT^UT^TO)[87*)/'>E;FZ#DJKQ)SXK^ZC_?.V*LMT :YK?G;7S<:
MW>0:?I4EA]5TVV]..(M<6$<DOJ,R-(R%WY+'R7BWQ?%^RJQ3R:E]HGDS1I;+
M6+V<W_FHV5U#<21R*D7Z5NHY44*B\3/]N>OVG^)>&*LI\H7&H:I?MKU]YFGM
MYY-5O=/;RZ6M_JJK;22PQVHC*>L+@QQ)>&3U/5;E]GT<58]HFM:[KD/D"QO/
M,MQIHUS2-1GOI86@2XN[B"2V,:H[HP615:1_W:<O3]3_ %E57)YJU:\T2ST9
M]2U2_P!2:_U.WTZZTA[&VFO[+2Y5C,\US=<;=>'J*)&@*>M(K?!_>8J@6DO_
M #/Y4_+Z\U/6+VUN1YBN['ZY!-;)*PB6_@AD>2-9()+@1P+'ZL7[N1I)>']X
MN*IUKNM^9@-=LK+5YK6:'S1HVE6EWQCD>*WN8+'U1Q9>#\VFE=N7[3_['%4/
MYDU7S3Y6@\S:+::Y=7[QV&F7.F7M]Z#744U_>S6DR+-PCA^)(>4+3JL,,O\
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M-4,LRH&*K;J9%XR2R)R^S]O%60Z3KUAK6DKJ5BSFW?U%I(C))')"[1RQR1N
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M=7GF74M4G]6W%O=Z99VMO#<(TB&ZL;]KY!.@IRMI#Z<<H5^?#U,51?D+R?\
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MUS"D]O,I2:&10Z.C"A5E:H92.QQ53L]+TRQ4+96D-JJQQPJ(8UC BBJ(XQQ
M^"/DW!?LIR^'%4->^6/+5]906%[I-G=6-M3ZM:S6\4D4=!0<$92J;;?",577
MGESR]>R6LMYI=I<RV-/J3S012-#2A'I%E/I_97[&*MWOE[0+^]@OK[3;6ZO;
M7:VNIX(Y)8Z&OP.REDWW^$XJC9(HY8VBE021N"KHP!4@BA!!Z@XJ@+#RWY=T
MZSFLM/TNTL[*YJ+BUMX(HHI.2\3S1%"O5?A^(?9Q5,$1$18T4*B *JJ*  ;
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M6D6)M8GM-1GO;J!;LZ=;64\]U! Y(#W$4:MZ/Q IQ?X^7+BC<&Q5-QYAT;]
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M=T^WZ:+S7@JF\'D36D\@6?E]G@-];ZM%?NW)O2,,>LC4" W'ES] 4IQ_O?\
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MB:QDU%N3%&6UL9;9_1/&K'U)%X\N'P8JM_+JS,WFSSWYC$<D4&JZI%:6PD%
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M<7,+RP<6X\7X8JEUWY;\Y>8=074-;MK+338V%]::=:VES+=F2>_C6,RS2/#
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M47J@NVT'S0MG)'%=GSU8"WEF4R1+(;K3^!=%9&=0WVE5TY?SKBJ;7Z^=K/\
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MO;,:M".&I6R00)J\4NHO!Z+27%FFH26\*QSR-Z<T*R1<_1]5/61&1HU5"_\
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ML.0X^HS<0V*HJ?RIY?O/J#ZCI]KJ%SIJ!+.YN8(Y9(R  61G#%.7']G%5?\
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M,R,=U+(S(>/[+8J@'\I^67U*356TFR;5)BC2WQMXC.QB96C+2\>9,;(C)O\
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M,<MIJ/FB=I;[5XK"[MK2'2+>T1G@D>UBE*PNA#3)+ZZ2/+<,B0_%\2QKRQ5
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MYI5\]K/IL=U<3Z7<0F03LEW<2W+K<1L."M&TO!#&[\U^+X/LXJEFK^0=3O=
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M.2"&3]W^]DXR+]O%4W\H_EQJNB1^44GN;9AY>CU2.Z$/J!7^OR!XQ%SY-QC
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M-2N%L[%6K^]G96<1K0'XBJ.=\57Z9JVG:I:"\L)UN+5GDC65*\2T,C12#?\
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MY8JFLOYB:0='L=6TZSU#6+?4!(8$T^TEFD40MPD]52$]%DD_=M'(5DY\N*_
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ML?I\'^#%4%Y5\T^9]3O;'RW<:C<#4_)UMJ3^:I@:-/+$6M=.]9NM+F%FOO\
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MD>&:.1'BFBFB/&2*6*0*\<B'[2LO_"XJP?RW^9VLW?FSS%H6K6L%O%;RWO\
MAJ\CJ!<KI[>G<PRAB?W\):.7X/MQ2?\ %;8JC/+?GO6-3ET5)XX%_2/E>/7I
MN"L*7+F(%%JQ_=?O#\/V_P#+Q5+C^<FE/^7^E:O;:OI4WF2^BTPRZ8EQ$Q$U
MY+"DZ+ LOJUC$LE%KR3A\6*LL_,7S/<^5_).L:]:V[7-S86TDL$*QO*#(!\!
M=4HWI*WQ2M^RF*J7E37W:/3M(U*\N+O7;FSEU O<V9L9#"DRQ'G#TA9&EC7@
M3RX_%BJ&NOS4\J6]EI=USNI_TU]8&EV]O:S33SM:2".55BC5GY M7?\ 8Y/]
ME<55I/S,\K#1H-2C>YN&N;E["+3H+::2^^MPU]: VH7U5DA".TO)>*(O+EQX
MXJE/EO\ ,ZSN=,UO5M1ED:T@UJ72]*MX[6874A6&(K;BW">NUQZK2JPX?L_%
M\"\L539OS(\N)H\FI2?6XFBN4L7TV2UF74/K4H5XX!:%?69Y(W61>*\?2_><
MN/+%5'R)YRE\RZMYF5?46QTVZM[>T@N('MIXBUI'+,DJ2!7Y"5VZK_J\EQ5%
M1?F!H,NN7>C1?69+G3I'AU*<6\OU:U9(5N*SW%/2C5HV^ EOBQ51L/S.\K7?
MJ,\ES8VZVTM]!=W]K/:P7%K H>6:WDE15D1(RLA_;]-N?'CBJM9_F#H5QH<^
MMS1WMA8P&,?Z;9W%O+)ZQ A]&)T]2;U68)&(U9F?X>.*NLO/^BW5A?7(AOX9
M].$9NM.FLKA+T"=BL)6VX&2196#*CQJR?"_V>#XJH+^9_E8:-J.K73W-A!I$
MT,&IV]Y;2P7,#7+(L)>%E$G"3U4977X>/^KBJVY_-#0+9(/6M=4$\ZR2_5!I
M]TUQ';PL%:YEA5#)';U;X)&7X_V.7%L52J3\U;33_-NN6&H?6;G3[6WL;NS%
ME9SW#16\T+R33SF)&X15"_WGQ?:XKBK-SK>F?H;],I-ZVG& 7230(\Q>$KS#
M(D8:1^2[JJ*S-BJ00_F7Y=;3]7O;E;S3QH=M]>U&UOK2:VN%MJ,1,D4BAI(V
M]*10R?MQLN*KM)_,KROJ5U-;I+<69C@EO(I+^VFM(Y[6 @2W$#S*@DB3DI9A
M^RRM]G%4IT[\S(M:\ZZ#I6EI=065]:7UW<)?64UJTT<0@^KS0M,J<HV]1_L_
M[)5Q5FVKW7U32KVZ]7T/0@DE];AZG#@A;GP%.?&E>'[6*O/%\Z^89_,7DWR_
M;WD\J:AIJZIJ.L1:8Q2["F$!:%C':12"5GF?XV@;T(_]V8JR_P Q><]*T&XM
M;2ZCNKF]O%DDAL["VENYO2B*B29DA5BL4;21JSG]IT7%5'6//FCZ7?BP,-]?
MW@B2>>#3[.>[:&*7D$>;TD;T^?!^*M\;<?LXJCG\TZ)_AB3S/%<^MHL5H]^U
MS$"Q,$<9D9@M U0JGX*<N7P_:Q5)Q^9_EQK**[BBU"5;I^&G0I8W)FO5">J9
M+6+ASEA6/XVFIZ?^5\2XJI/YW-]KOE:/29:Z?JLVH0:A%-$T<R26<#-Z3I(%
MDADCF7C(K#%49IWYAZ'?ZNFE)%?6US.LKV37=E<6T=T(!RD^KO,B"1E7XN/V
MN'Q+BJ6>5OS5L-4\N7^M:I:7>D6]A<3P227%K.B.%NY+6%8:J7FG;TT62&-6
M=)W]'[6*IE%^9/EK]&:A?W?UO3_T8D<EW9WMK/!=!9F*0E(&7G+Z\BM'#Z0?
MG)^[^WBJ"\J^>V\P>=-5TR".XM[/3].LIWL[VUDM+F.YN)[E6Y+*%8H\44+)
MQ^'_ &7+%60^9O,FF>7-*?5M4=HK"%XDFE12_#UI%B5F Z('=>;_ +"_%BJ7
MWGY@^5K.[U^TN+SC<>6+6.^UE CGTH)4:1"" >;%$KP7XOL_S8JQU?S9LM/\
MP^8K/6%NVM=.DMY8C;V,\OU2SDL(+B26\:-&$2B264_'\7%&^']WBJ?:Q^8O
MEW2[GT'-U>&.%+J[EL+6>\BM[>4%DEGDA1UC1U1W7]K@O+CBJ%3\Q$?\P!Y7
MCL;F>UEL;>\@U.""22$FX=Q4R*/3$'!5I-7^\Y)^SBJ5^3/S:T^]M;6WUIIT
MOYKZXL&OEM)DL!<"\EAM[8W''T?6:-(UX\_M_P"7\.*I^_YC>6_TJ=/5KHHM
MQ]2?4EM9S8+=^IZ7U=KKAZ/J>J1']KCZG[OEZGPXJJ:3Y[T75M8N=*T]+N>:
MRGGM;RX%M*+:&>V;B\<DY7T@Y^TB\OB5E_FQ5DF*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5__]?U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5>1ZY^7/GG4M?
M:>=XKR!-:MM1MM1FU.^0)8P7D=PMJNF1I]3]2%%9%E=I/5_O/AD;X%60W7DK
M6)?+?G[35:'ZQYGFO9--)9N"BYL(K5/6/'X?WD;<^(?X,53?S7Y>OM6\L6VF
M6IC6XAN],G8N2$X65[!<2T(!WX0MP_RL52NZ\FZQ+H'G_3U:(3^9Y+Q].)8\
M5%QIL-HGJGC5/WL3<N//X/\ @<52CS!^6&L7_FS1[ZTE@CT6YBL8O-]NY8/-
M^AY?K-D80%H_*8M',9&_N>/#%4+<_E*Q\RZG)+Y>TG6-.U:_-^^HWUQ/'<0B
M8AYHFMDB>.?BP?T&]6+[:>I]AF=5-K?RAYFB_,+],6EI::1ISW,DVHW=I>7#
MG483"RQQSZ>T:VT<_J.LCW2R-)^YX_MXJI0>2?-2Z<NC2):&SLO,<6M6=ZLS
M\YK=]3>_F22$Q_NI8@_IIQDD6;_BK%7GXOX[?SM.\O#49D\QM,?++7-Y!>O-
M]9$<=X-.1&M6]!/3NHY.?I2P1)=2,L[-Q59;?_EUYYO?,<-U=217<5MKD&I1
MZG+J=\*V,5XMPMLFF*GU)'@B_=*[,_J</4^"1_A53:Y\B>8KFS\VZ*S6R:?K
M5X=6TO4@[F2.YY0R)#/;\ /226W^*2.?E)'\/!'^+%6]9\M^>O-#1'6+6PTQ
M-.M[[ZFEM=2W1N+N[LY+-&<O! (8$2>1BM)9.7I_R-S59EY>T^XL/+^G6%SQ
M:XM+2"";B24+Q1*C4) JO(8JP[R#Y0\S:-K=Q//:VNBZ(UN4_0MA>7%Y;27;
M2AS=11SQQ+9*$5D]"'X7]7DW]W\2KM>\G^9KGSQ#JVD6MIIJ^M:-=:]#>7"7
M,UK"5::VN+%8_J]T9 IABEDEY0QOR3XDQ5BGGO2;_0+#38[R\BL%N/,6K:E#
MJ+2SV]M +OUY(#+>0+ZUO,8YFC6/CZ4S-)&[_9YJII^6^DSZFV@ZI:V\4-EH
M=YJR75X)[B<:@UY&C"]@EN$62=9I&;U9'_W8C^ESCXXJGJ>1]97S$NH\X?JX
M\S/K9')N7U5M'^H 4X_WOK[\:\?3^+G^QBJR7R-K;^6-6TP-#]8OO,(U>$EV
MX"W_ $I%>48\:B3T8V^&G'G^U^UBJ*TG1?.6AZY?VNG06,_E_4M1?4WOIYI5
MNH1<L'NH!;K&4D;F&]"7UT55=?4C?A\:K&=+_+KST/,^AZCJSQ7;:5J,MU>Z
MM)J=],]U&T-Q%&8].=!96K*)HU*)RX_[KD^US53JQ\AZY!Y#\L:#(T!O='U"
MPN[M@S&,QVMX)W"-QJS</L JOQ8JG'E#1->T;6->AN8[>32-1OIM3L[Q)6$X
M>YX<H)("G$<"K<95F^/X?W:XJA=0\H:M/>>>)D:+AYCT^&TT\%F!$D=M-"QE
M^'X5YRKNO/X<55O+?E;5--\P)J%PT9MUT'3M*(1B6^L6<L[R&A 'ITF3@U>7
MVOAQ5AH_+;SY!INEZ>'AO;.WM9X9+%=4OM,BANI+N69;KG9();H-#*L;0N8^
M'I_!_>8JR+R!Y(UK0+K39;]H&6T\N:=HTHA9F_TFSDF>0K55K%25>#?:_P G
M%4!I/DCSAY>@T/4--ALK_5-/BU*ROK&>>2"*2VO[P7:O%.L4I66-HXN:O"R.
MK2?Y+8JB=3\H>>[C]/WUM>6UIK&J66D1+):RRQ*TMA+-)=Q+)Q:6".=)O0CG
M7G+'S:3C\.*I)!^5WFE])\WPM#;6<FOVVGP6-LVHWFI&,VDDK2>M<W:>KN)!
MQ6-?3_R>7)F5>@>=]#O=;T*.RLR@G6^TZZ/JDJO"TOH;F05 ;XO3B;C_ )6*
MI-=>3-7ET#S]IZM#Z_F>6[DTTEFXJ+C38;1/6/'X/WL3<N(?X/\ @<54+[R5
MKDVKZA$! ^C>8=#AT75)A*T=Q:-;I<J)8$]-TN!)];IQ9H?3X<OC^SBJ$_+_
M /+R;1=4MKJ^\M:/83V$#1)JEC<W$\TTC (7CBEC06Z.G/FIEF?X^'+%5.Z_
M++4[C\M?+V@W,5I>ZGH$T5W]3GDD6SN602QO$TJ+ZB!HIW].01_!*J<D=.2X
MJM_Y5U*OEFXMXO*&C1W=U>Q7$VG1W]U'\$491)5OTA$R7<;,WIO'$O&)N'+E
MBJ*B\I>>K?2O*MY)/;ZKKV@W5U/<6]U<2JDD-Y'-"L2W9BD=WM8ID1998>5Q
MZ7)^#/BK)O->@WNJW/EV6V*!=*U6._N>9()B2WGB(2@-6Y3+M\.*L=\F^4/,
MNE^;)[YK6TT3172Y^LV%A>7%S!>7$LBF*X6VFCCBL61$8N(2WJO-\7V<59%%
MH=_'Y\O=>)0V-QI=K8QJ"?4]:"YN)7)6E.'"=.)Y?:Y8JP;R[^4S:5KD2S^7
MM)O+2UOWO;?7I+B?ZV4:9KB/E:"/TOK,,C!1+ZWI_!SX+]G%43J'D3SFNG1P
M6DB7%N=8U:_OM*CO[G31<P7]Q+-:DWELC3(\'-6>%5X.W[?P+R5:T_\ +SS7
M8>2[*SB%I)K6F:])KD-L]Q<26\J-<RRB$W4JO<!O3F_O9$E;U%^/EBJ%U/\
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M'#X_3?8-RQ5'5&*H#7=;TO1-)N-6U2<6VGV:^I<3E6<*M0*\4#,=SV7%4:C
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M%N3Q\U5EC^:GEZ[L;S4OJM_!I%D)!+J4ML1"\T4_U8V\(4M+-,TNR+%&ZO\
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M*D1Q336P]97A?C+15>)W3XL5=Y._*_6-#FT:2>:S"Z;JVHZE+#;&<IZ=]:O
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M3EC?=6X.CC]ED=77X<52L?F%I UV/2)K/4+9KB:2UM+VXLYHK2>>-69HHI6
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MW?>9_+6J1/&MOHTUU+=*Q(=EN+5X$X  @_&XY<BOPXJD%EY$UB'R)Y<\OO-
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MTK45L],AN=7-E%"G&/TC/8"UE%TMWSYJTMQR?U.$'H\5Q5GOYO\ _DKO-/\
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MGX1_#PQ50LQYH\R3>9[^^US4]&N-,L[&XMM,LY!%%;7<VEQ7,A=2I:55F/\
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MY+BK*M7_ #3TK3-2U6P.F:K>#0J'6+RUM5DM[>,P1W'J,Y=>8]*7EZ<*R3_
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MKH^E+ILFF+9PC3IA(LUF(U]%UF):4,E.)$I=S)M\7)L5121JB!% "J** *
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MUO1_N;9I8T56:!Y/D\TZ-(+?3;#46T?5?KT%[J:WSV&L?6K;T;@RM>^O=^M
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MJV=W RW^NOJLNGO/<VL-U:O9QVWU>>>W'K1E9$]?]VLB-Z:(_P +-BJ'\O\
MY6ZWI^EPVLLEE$Z>98=>,4#W,D:V\<,<9B5Y^<SR\D/Q.W%O^*_[M%65></+
M^M7M[H^M:$]M^E]&EE,=O?&1;>:"YC]*:-GB5Y(WV1XY DGQ)P9/C^%5+;CR
M]Y\CU.T\QVKZ7<:Z;.2PU*RF:XAM&B,YG@,,RK-*KP5*.7A;ZQ]K]QBJCH_D
M#7(/,.G:]?W5L]Z;^^U+5XX ZQA[NSCLXHK?D"S+%'!%S>3AZC<Y."\O355?
M>^0=6GN[V9;B +<^9K'7D!+U%O:0VT;QGX?[UC;/Q_8^)?BQ5UYY!U6:[U"9
M+B +=^9=/UV,'G46]G%:QR1M\/\ >L;9^'['Q+\6*HCR]Y?\YZ'J$FG6TNG/
MY8:^N;Y)W]8WPCO)7N9+<QT]&HN9GXW'J_W/P?5^?[S%4IG\A>9?\/ZEH$EE
MHNL:=)J<^H6"W[W,3-'>7$UU(',<;FVN+>28+!/"9.:K]B)L59!H'E/4(O(K
M>7-?O6O9KF&Y@NID>1^$5TSTACDFY2NMO%((8Y9?WCK&KR8JD]MY3\]W5MHV
MBZU-I@T;1I[.X:]M#/\ 6KHZ<RR6X,,BB*VY2QQO+^^N/A5D3[?-%62>3]!N
MM%TVZM;ETD>?4=0O5:.M E[>2W"*:@?$J2!7_P K%6/G\O\ 5C=F;ZQ!Q_Q2
M/,%*O7ZL+;T?3^S_ 'O+_8<?V\5;\S?E]J>L2>;6BNX8?T[9:=!8LP9O3FT^
M2:7]Z!Q_=NTB#X&Y<>>*I3Y@_+76]7UM/,%YHWEW5=0O+**TU&SU+UIH;>2W
MDD,4MI-Z!=T=)F]:&2&+DR1\9<593HOE&?3?,L.I1+:V]A%HUOI26=JIC1)(
M)GD/IQTXI %?C&O+EBK%M&_*1M+\P>I^@_+UY8)J$E_#K-Q"YU55DF-P$*B/
MTVFAE<K%<?6/L+'^YY8JF7E[R/YBL//$VMLFG:5ITC73W=OI<ES34'F8>A)<
MVT@6WAEB4<GEB]6227E\?!L54_+Z>:O)^D:!Y5>*TOI#>K8VES#ZWQ:;$KRS
M7$ZLJK!.D2\5422QO*R_S?"JR7S'H%WJFH>7;F"2-$TC4_K]P'K5X_J=Q;\4
MH#\7*X4[_LJV*I*WD35CY"?R\+B#ZXVJMJ(EJ_I^F=9_27'[/+GZ/[O[/]Y_
MD_%BJOH&@^==%U*33[>;3G\L/?W-^L[^L;X)>2R7,EOZ8 A^&YF;A<>K_<_!
MZ'/]YBJ4Z?Y"\VZ+IGE632Y+"YU?0(+VSN(;J2:*VDAOG21G22..2021M!%0
M-'Q96D_R6Q5;I_D#SII-KI%_9W>GW?F#3;G5WN(IA+!9W$&L79N7 9%EF@DC
M*0LOPS+]N/XOAE555TW\OO,B+:RZC=6<EXOF9_,-R8!(L?I/;O#Z488%N:%Q
M]KX65>7^3BJ*NO(.K3>1=5\O+<0"[OM3N;^*4E_36*?5#?*K47ER$1X-1?[S
M_)Q5YM>230>>[^;ZM^D+Z/7_ *RGEN:/4X[B<B5$BNE2%_T4WHPA9[:=[=OW
M,4<EQ+]8YNBKU'\P_*>NZ^FG#3Y8I;6VED:_TFYN;FS@NE=*1L\]H&E#0..:
M)Q:-^7Q?$J-BJ5^4_P M=9T>R\N03SVO+1]9U'5+A8#,4,-[%=QI'$9N<I93
M=)R]61OLO^\?%4/Y^\IR0>7_ #]JUU.%^M_5=5TEH%=YH;K3+:+T#Q5>7(W5
MNOPQ_:C;%64?EMH5YHODZQM]0?U=7N@]_JTQ !>]O7-Q<&B[;22%%I^RN*I2
M/R_U86<<'UB#DOFE_,!-7I]6:Z:<1_9_ON#4_DY?MXJZ]_+_ %6?R3YIT!9X
M!<Z[>W]U;2DOZ:)>3^J@D^'ER4?;XAL52#S'^4_FO5]>N;N2YL[N-]4MM0L]
M0NKJ^$\%K#<13FR2T3_1%$?IN(Y?BY_MP^H_JJJRNX\F:G+I7GJS6>$/YH>=
M[%B6XQB;38;,>K\-?[V%G/#E\&*H73O*_GC1-3N/T-/IKZ=JAM)K][OU_6@N
M(+:*TF,*(.$Z2PVT7#U'@]*3D_[U?@Q5+]7_ "X\SS6-W%:75O+'<ZY=:I<:
M9)<75I!=6MS'P2&:>V7UXWB?C-Q19(W9%5L56^3OROUK1)]'DN)K,+I^L:AJ
M<L5NUPR^E>V;V\:(T_.1G1WJ_J2?9_:_9Q5D7F;0/,;>8]/\R>7#9R7UO;3Z
M?=V>H-+'%);SNDH9)84E9)8Y84ZQNLB,Z_!]K%4$_E_SYI^L2ZWI;Z7?WVIV
MEK!K$%VUQ:1"XM.=)K=XUN6$;"5E]"1/V5?U_P!G%7>5/(6IZ-KMEJ=U=PW+
M+9ZDNH-&K1\[S5+^.^D:)#SXP(RR(O*3G]C%5MAY#U:VOM)N'N("MAK^K:S*
M 7JT&HK=B)%^'^\3ZW'ZG[/PMQ;%5DGY?ZLUW+,+B#B_FF+S  2]?JT=ND)C
M^S_?<DK_ "?Y6*HGRKY=\YZ!=#28Y=/?RM#=7-S#.?6-^T5R\D_H-'00*T<\
MO^] E;G$G'T%=N:JI/'^7_F9/(5EY5N['1-9CTJ:.*S-W)=1"6UA5A'-SCC>
M2TO58IO%ZR_WG%TY_ JS+R9I&K:1Y:L=.U>^.HZC K?6+LEVJ6=G5 TA:1UB
M5EA1Y#ZCI'SD^/%4ZQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O\ _]3U3BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5:Y#%4JE\TZ+%YAA\O&61]6FB]<PQ0RR+
M%$>7%IY$5HH!)P<1^LZ>HR_!RQ5->:CKBK=12N*M<U\<50>IZUINF);O>R^D
MMW<PV<!XLW*>X;A&GP@TY,?M'X<51G-?'%7<ABKN:^.*J5U?6=I:RW=W.EO:
MP*9)YY6"(B+NS,S4"J.Y.*JO)<5=S7%7<ABJC:7UE>6ZW-I/'<6[E@DT3!T)
M1BK ,M1\+ J?\K%5;FOCBKN0Q5#:;JFGZG86^H6$ZW%E=();>=-U=&W#+['%
M43S7QQ5W-?'%7<ABJ@=0L1/-;^NAN;>-9YK<$&18W+!7*#XN+F-PAI\7!L54
MM'UK3]8TNUU.P=GL[R,2P-)&\3%3TK'(J2)\G5<51G)?'%5(WUF+M;(SI]<:
M,S+;<AZAB5@I<)]K@&95Y8JJ\E\<5<&&*K+F>"VMY;F=Q'!"C22R-T5$')F/
MR Q5"Z'KND:[I<&K:/=QWNG7()@NHC5'"L5-/DRD8JI:#YFT'7[66[T6^BO[
M:"9[6::$\E6:*G-"?%:C%4RYKXXJ[FOCBKN:^.*NYKXXJ[DOCBK55)'X'%6P
M5Q5W-?'%5);VS:[>S69#=QQK-);A@9%C<LJ.5^T$9D=5;_);%57D,52W7_,N
MCZ!8"^U29HH&D2")8XY)I9)I31(XHHE>661NR1HS8JCX9XY88YEY!)%#J'5D
M8!A4<E8!E/\ DMBJ_DOCBK8(/3%4!I^N:=J%U?VML[M-IDPM[P-'(@61D60!
M6=560<'7XHRR_LXJNM-:TV[O[ZPMYN=UIK1I>1\6'!IHQ+&*D!6Y1L&^'%49
MR'7MBJG<7=M;6\MS<RK#;P(TDTTA"(B(.3,S&@5545+'%4'/Y@TJ'5-/TQY6
M-WJB32V02.1XW2!59R954QI\+KQYNOJ?L<L52W3OS#\JZC/;Q65S+.+NZDLK
M6=;:Y]"6:)&=_3F,8B>,"-QZROZ//X.?+%61<UQ5!ZGK.G:9%!+>R^DEQ<06
MD)XLU9KF011+\(-.3L!R/PXJMUW7M*T+3)-2U2;T+2(JI8*\CL\C!$CCCC#2
M222.RHD:*SNWV<54='\S:3J\]U;V;3>M9+ US'/;SVY3ZS$)HQ^^1*MP/QJ/
MBC;X).+_  XJFG(8J[FOCBKN:^.*H#6]=TW1=.?4-0=TM8WCC9HXI)FY32+$
MGP1*[_;==^/P_:;X<51_):TKBJ$TO6-.U6.XDL9?52UN9K.<\67C/;2&.5/B
M KQ=2.0^'^7%47R7%6O@W]^N*M\EQ5CQ_,#RJ-2GT\7;M/;74-A.ZP3M"+NX
M=4C@]<)Z+2\G3U$5^47^[>&*IG8Z[IM]J&H:?;N[76EO''>*T<B*K2QB5.#L
MH23X&ZQL_'[+?%BJ)EOK.&>"":=(Y[HLMM$S -(R*78(IW;B@+-Q_9Q55YKX
MXJH7^HV.GV-Q?WLRV]G:QM-<SR'BB1QKR9F/@H&*I?%YLT>3RW)YCK<1Z7%#
M)<.TMM<13>E$"6;ZN\:W!V6J#T^3_L8JF5M=6]U;17$1)AG198RP925<!A56
M 9=C]EABK1O;-;M+(S(+MXVF2V+#U#&C*K.$^T45G16;_*7%5;DI[XJU5*]=
M\5<&0=#BJG=7UG:0^M=3I;P\DC]25@B\Y6"(M6I\3NRH@_:9N.*JO-?'%7<U
MQ5W)?'%7<U\<50.L:YIVCVBW=^[I TL4 ,<<DI]2=Q'&.,:NU"["K4XK]IOA
MQ5'<EK2N^*NYKXXJV"#TQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5__U?5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5Y!J.H6]S;>:]7
MU3S7=Z-K6C7=]%96,-Z+>*VCM@?JA-F?W=S]9C].X_?QS>KZ_%/AX*JJ8^1-
M/FN?S)UK6+Y[J#4I=%T2:[L#<3?5XYKA;KU$] MPI$T?[M2/W;>HR_WCXJD'
MYQ>;Y+6[U[]&7=]:ZAY>L4E,GZ6ATRUBFDC::!X[5OBU#F>*R)*K1OQ^KQ?'
MZN*O0?.LNJR^0[AM/U.'2;^>*WXW]Q*+6,>I)'S03E7]!YU+0Q2\&:*21'1>
M2XJQ#2O-J'3_ "X8KN[M+>Q\R2:9KCWM\MY'4Z?/((C?!BMS;^O);K&TC<O7
MXPLJR)PQ5+/,_F*WU33-9N#K932[;SMIEM;:E'(K);0K#9F3T7<-&JI*\K5H
MR*_)\55]1UJ?2H?,.E:3YBNKKR_#/H\=UKTMT+J;3EU"=HKY$O).9'I6ZP3A
MI6?ZM]9]3[/#@JF6JW5A8C2]&LO-=V^A7VJM:ZKJC7RRSVQ^I&:*R%\W*6,7
M,H1N32>NOJ>G%+'SCXJI7JNI7MO=WV@Z%YFO;C3%U#R_%'J@N%N[BVGU"]:*
MZM5N7$AD!@6&;TY_6]/U_P#??!,56>>M+NK'0?/WE@ZKJ-]IL'ER#5+?ZU=2
MS7*3.]U'(OKD^J\$OU9#)$YX?;7[#<<53PZ;%?>;]&T"P\QZD^@?H6[O6EM]
M1EDDN9%O851GNPS3,(_48#A+]G]U_=?!BK'=;\XS_P",[6ZTN]OHD_Q%;:1+
M]9U>%8R/K:VMS FD -SB*&1HY7"W'_'SR]-4Q5D7DJXM-5NUO]4\SWD7F*]O
MK^TNO+XO0L4?I&9%M4M!_<M!#&EPLR!9V9/5>9DD^)5C7E22+1?RQLQ9:U=6
MRW>M"QUZ\DO&F?3K=K^>-F7UC(EFTIX122<%^*;U?M_'BJ(\VZI<Z);ZYIOE
MGS)>7EH-(6[FN9+PWTMA=_7H88"EPY>1?K,3W'[F21D_T;X57]YS5>N:)HL>
MD69MEN[N^+R&5[B^G>XE+,!6C-]A-JK&@6-/V$7%7DGDVUO=8TS\N]&&KW^F
MZ=-Y;N+N[CTZ<V[3-!-9*@:11S0#U6^*)DD^TG/@[8JN/FO6/+UKIOF'4M5N
M;CR]H.N:KH.MR2MSK9&5X[2XN3MSEMYHH(?6^WQF_F9L50,E]Y]E7RWI^IZE
M]5_3-A=:U=)=ZG/HY:XN)UD6SCN88IYN-A!(BBV4Q?:YR<^/#%41KFI^8--T
M?0]4UOS)%?V5A8W-SJ$&CZNMK<RHLQ:&]B<K"-3"6ZI T3^C%+/R;@_/ABJ>
MBUTT_FSK6I?I*[M[R;0;"[L;1KR6))23>HZ_5BP618E"/Z?%EAE=I?MR8JQ+
M7O-]^-$\GKJ6K7R0W'E>"[E:VU2#2)IM0GCC"3O=74ENMS0+(9(TDE]%G22:
M!_5CQ5-/,VJW%CI6C:)<ZE?3ZO8Z)#?:A>0:ZFF6KF4,C7"W<I,UX_JQN5#<
MX4B:-I?B>/%53RVL6K^=?(^NZQJES'J&I>58;HE;M[:*XNO5M6:,1(R1NLG-
MGE@5>$GP\D^'%5.;6ICY1O\ S7+YGNX?.=O/<K#H@O (%NHKIHH=-_1W]VXD
MHD%61KA_4]7UN7!U591Y3//6?-'F#6-;NEM-&U:\@A@FNC%86]M';Q,YD2JQ
MLJ\V?E.66'_=?I_%BK*O-DT,WDO69X762&33;EXY$(965H&(92-B",5>-:;K
M.J^4M/B\IZ26CO//EE8W?E68*?3M[RYAC@U(U&P^K #4O\MI'Q5$6]QIGEVS
MU#RM9&\BY^89[;3XK.^CTM'2RTRT++/>'BT=1^\X0_O)9/\ BKU<57>6-3US
MS-#Y3TR;7K^WM;F]U^WGFLKU99IK:QD MXVO4'[_ (K1?K4?[UU^S)R?EBJ,
MO?,-Q96=[Y9N;_4KV>+7[BPTF9=033Y7@@LH;ST;K49/WG[OZPWI\#]8F]-.
M?-?6;%4K7SMJA_+S2I+S5+GZHWF"]L[NY@U&&.:33[0SF.%=7<PP&3FL'&5I
MX9+M$:-9/B;%55-1\TP>3] BMM9Y6>OZS>^IJ-WK19DM0LC6EE)JD*W@BE?T
MPK?5?]V1^FDW-W9E4VB7S0^E^7]-N/,=([_S*]HMUI5^]]*MB-.N)'M)+V2.
M-Y9!-$_QLGJQ?N_C]:/U,50VJ1ZSIVA>>-0B\Q:K(_DR\IHD4MTS* MK;7C)
M=&G.]1Y)VCXW32\8/@CX-\>*J6KZEYXU'S1KY@UNRTFZTW45M-+@O-7FLEAC
MXQ^BTFG);O%=I=\^:M-,S2>IPA]%D^%5D=[I6H:]YW\V6[Z_JEA:Z1;6+V-I
M87)@B2::WD8RL%')]U7]TS>@W^[(GQ5*/(1M]5\^:7KVJ:G<)JVJ>5=&U 6P
MO)8H)YI#<K,JVP<1R1I\,GHA62*23U/MRXJR;SK=B?SAI&AZCJ\^BZ'=6=W<
M^O;7/U)[F[ADB"0&Y4K(H2)Y)O3B>-I./Q\HTXXJPK4H!K$^EV#:S?:AI.F>
M;XK#2=5CO)%EDB>P,LJ&XA*&=[6X]6W29N4R\71Y&?U,59[^9VKPV&DV-H9+
MM)]2NUMK46=XFG<G6*28K->2?W$;)&V\?[UY.$<?VL58!H^NZ_JGE2ULDUJ[
MM"_G :0E[;WL=[<):-#ZC0_7>+)<<6=U62179/A^T\6*L^\F"\TWS9YC\N'4
M+K4-/L8-.N[,W\S7,\9O!<+*GK2$R.A-LKKS9N')^/P<555C&J:_J#W.HZ=>
MZQ<:=I-SYO.F76I1RF)[6T&F17$<$<__ ![+<702#F"C?Z0RQLLDF*I!+JE[
MHUKYV_PWK;7D;:WI%E-KEW=!C;6\MO"DO.]].;B(Z_5_K+QS21\^3\I%YXJF
M<DGFVQ\J:VJ^8(EC:_T6WL9+'5)=7NK-[B_BCN>=S<Q1/QFBDC].&42+_>?[
MK?ABJKYNTJ\TZU\X>5DU?4M0L)O*<^I(+NYDGN5NH6E0F.:HD$=P JRP+^Z^
M'BB(KNK*IQH'U<:KY4T?3=8NKO1]1T/5)99?KTMPSR![%599R[-RA$TGHE6_
M<\_@Q5(/R\:\TCR]^6]O87EU+%J0U&:XMIKB299#'92&.,!V-(E>-72-?@5_
MCQ5K\MK[SEJFH:!JUWKUE)-J!>76+)M7EN))%]&0RVT>EFWBAM9K6;@&]*3E
M%Z#^J\WQ-BJ >_MM3L/+>M7WF2Z;S#?>9[%+[R^]S6&-H]1"_518G_>?ZJJ(
MWJ<4E;ARE=_5^)5G_P"<>EPZAHFBQ2W%S;C]/Z0@:UGDMV_>WT49^*,J:J&Y
M1_R2<9%^)<52+S!J6MU\R:?;:M=VGH^9]!TVTN8Y.4L,%S#IXE5#('7]X99&
M?FK*[2-SY<L56ZM?OY/O=?T>?6-5N]+.G:7/;22W:O>175]?369X7ER:0PRM
M'%ZKR'A O.2/ABK'K7S/KZ>6_/EK;ZG<VS:8=*-C)^DEU>:UENYBDO&[H6^(
M(C>A+SX?'^Q+QQ5/O-$_F#R9>:E:Z5K%_?I/H%UJ#MJ$OUR2">VNK>%[N+F*
M)P@N9)7@5/J_[F/C%]ODJB[^>PTC0BOE[S9>:N3J.@"8RW_UUXX[G4HXF;UM
MW5+R/FKQ<O2XI^[1.3<E4@\S^<9_\6B\TJ]OX3!Y@M-(D^L:M#%"6^MQ6UQ!
M'I KZT3QO(T<L@^L?%]87]TD>*O0?RO(_1VO?^!#K/\ U'28JQ'R]K$S>79O
M,<?F&YO/.L]KJ,TGE>2Z$D/UR".1OJ:V/^Z?JDB+'^[X2/Q_?/)ZF*JME>VM
ME)Y4O]$\UW>O:EK-W;0WUG/?"ZCN;>>)GN91:_8MOJZ@W'^CI"J</3?X/@Q5
M >6WUZT\J>3/-<OF'4KW4-7U&QM;Z&ZN#):O;7DA@:(04$8*5619_P#>CU$^
M.1D9DQ5"Z?I4%AIMR\=S<S&3\P+>(BYN)9U BU%:%1(S!7;E^\8?%)\//[.*
MIWKVNZG]9U^RGU6>PTN3S39Z;=ZBDOIM96,NEV\Q6*4_[SB:Z*0^H/L?6F9.
M$GQXJ@O,&E>79=>\F#_%-_=:=!J>H6K7_P"DY%,+_4)'$#7,;(7D#CB&D=IF
M1VA9VQ5FWYE:C<66E::D=Z^F65[J5M::IJL3*CVUK+SJPD<%8O5E6*V]7]CU
M_AXOQ;%7GGGD0QZ'YQT#3=<O=6T2/RY-J-RSWSW<EK=QR$0Q_6>32^G=QB3U
M+>61T9(/LJCOS5>A>>%GT'\J=>;3[RY6YL-*NI+6^EG>6Y5UA9E<SN3(SJ?V
MRV*I+/I6H>8?/GF"SEU[5+"STVQTV6UM;"Y:W19[A+GE,W$<G_NU_=EO1?\
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MRQ52M/+GE^SLI+"TTVTM[&4\I;2&"*.%FVW:-5"L=AU&*I@0#MX8JAX=-T^
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MS%Q!CD23F.?/@R?Y>*KM6\OZT?.VF>8],DMFCBM9-.U&VN?45OJ\LT<QD@9
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M0\OK 3G(G[;8JRNZU[3?,7GN]TG3=7-[IK>6IWGBL+EN EDN55'62!OAFX5
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MK'U&Y)R696_>?#+R^+%6!:NNO:?Y=\F^AK4_I>8XHY=<U/5=4NK2.29+,/#
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ML57MIMBS3LUO$6NE$=TQ1294 ("R&GQJ :4;%5:&&.&-8HU5(T 5$4 *JJ*
M #8 8JOQ5V*NQ5V*NQ5V*NQ5V*NQ5__1]4XJ[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%6):G^9FB6%Y=P_4]1N[33F:/4]4M+1YK2V>-0\@DD7XF])3
M67T4E]/]KXE;%4LL?->LZM^:MUHUNUU;Z#I=C;W-8[:%K>[>[$I#R7+%Y%C
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M".:65[AO4+KPBX.C1I_>_!BJ(A_-C1C;ZE+=V%Y82:;I\^K_ %><6[23V=L
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M+>K*P2L<O+]Y\,G[6*O-?+/F.3],ZW;Z??@VDGE>]OY(H->EUP^O$\8BG=Y
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MU/\ ,?S"VI:C>2_H?]%M;64-S-#:+.]L6DD]&-E#\V']W+SB_P"*^7Q8J]$
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M.WF[2-(U33-,URQ\T.NE3WFF:W:JGUNT2)HT+WJ0>K;L/2D>6&>.-/4>!O\
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M*JC](UG1]*\_^;8M;NHK&_N7LYM.FNY$A$NFK:HBK"[D!DBNQ=\T'V'EY/\
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M:_6((H8TCDY#B>:JH5ZC;XL5136D#2QRF-#+""(9"H+(&V;B:56M-Z8JAI-
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MD,-JC>7M3.JZA)*-.T>EL+F6"!59[EB9O1MX1ZB*?K,L4BR,L7I\V7%4//\
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M%X/S#UO4/)WFN^U>QO\ 0X],NKVUAU*T^IO*JPW1@18D,LP-Q$ /5:1/1?\
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M#R12027$$B_$8Y1SYQ>HG)5YIBJ8S>;[32-4\S7$MQJ&HO;WMEIUIHJI"?\
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MDTV>5I6E]2[DF^KW3WBQ,BQ,LK^BG']Y&_/%6:>8M6\QZ3^54FHO<Q/KL%A
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M.9392PQO"9&8N7]-E*<B[,Y:GVFY8JOAT72($C2&R@B2&4SPJD2*$F*E3(H
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MS'+[/VL51[(K"C"H\#BJ7Z7Y<\NZ0>6EZ9:6!HRUMH(H31R"P_=JOVBJEO\
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M%-PX?9X*I+Y*>QTO\L_+2Z1J4POFUW2[36(?KLTKQ.=0]*2W>-Y&^KAUJLD
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ME;ZQ^[YJS1<.7Q8JDGDG\UA<Z=81:Y!?&:XO);!M:-IZ=@;EKN2&" 2#C\1
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M)(O55/5A8-^[F3]W)^PV*IKBJ%U/4['2["YU"_G2VL;2-IKFXD-%2- 2S'Y
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MGZ_ZJK#9:?>6+0$$NS74UM*&!Z47ZLP/^MBK5GH$]OYOU;73*K0ZC9V-K'
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M(E9+>.1N+)^V_'%4\\V^9KC3-!@N],$<U[J-Q:66F-*&,/JWTJQ1R2!2K&-
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MV[7MM9VI@CDCMHZ!Y9FGDBBCXR,L-/4_>2?W?+BV*JMUY^G-W'8Z3H.H:KJ
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4*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>exh1070_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh1070_4.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X0M<17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  'H2    G
M$  >A(   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#(Z
M,C0@,3@Z,SDZ,C0      Z !  ,    !  $  * "  0    !   #CZ #  0
M   !   $FP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   HF
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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ME/\ _]G_[1 ,4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M        .$))30/M       0 ,@    !  $ R     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))300*       !   X0DE-)Q
M      H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -;    !@             $FP   X\    3 &4 > !H #$ ,  W
M #  7P!0 &$ 9P!E %\ -  @ &, ;P!P 'D    !
M      $              X\   2;                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    !/_         X0DE-!!0
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MDDDE*22224I))))2DDDDE*22224I))))2DDDDE*22224_P#_V3A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, ,@    $
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M  #VU@ !     -,M2% @(
M                        $6-P<G0   %0    ,V1E<V,   &$    ;'=T
M<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M%&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
M    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@
M  0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E
M>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP
M86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M$G-21T(@245#-C$Y-C8M,BXQ
M                              !865H@        \U$  0    $6S%A9
M6B                      6%E:(        &^B   X]0   Y!865H@
M    8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6
M245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W
M=W<N:65C+F-H
M             &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!2
M1T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M              !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X
M   !6%E:(       3 E6 %    !7'^=M96%S          $
M           "CP    )S:6<@     $-25"!C=7)V        !      %  H
M#P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\
M ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L
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MMGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#
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M5=^BOS\_ZF#R[_W#;K_LIQ5WZ*_/S_J8/+O_ '#;K_LIQ5WZ*_/S_J8/+O\
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M^I@\N_\ <-NO^RG%7?HK\_/^I@\N_P#<-NO^RG%7?HK\_/\ J8/+O_<-NO\
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MMI-3TL);P,/L1I$6E85_W[.7W_;CCA_R<5>4^3_+VF^8OR3_ "TTX:W)Y?\
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MC6T"5X^B$ CXU_9X<:8JB\5=BKL58[^8_P#Y+SS1_P!LB_\ ^H:3%5GY9?\
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M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7G$?_K1<_\
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M_P!3YIW_ '!!_P!E6*N_PM^>'_4^:=_W!!_V58J[_"WYX?\ 4^:=_P!P0?\
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M#_LJQ5W^%OSP_P"I\T[_ +@@_P"RK%7?X6_/#_J?-._[@@_[*L5=_A;\\/\
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M6AS7^HZ<EY$UWI7H_I*$FGH_65YP^H6HH]1=UQ5,@:C%78JT[JBEFV %23L
M!BJ6Z%YET37[1[S1KM+ZTCE:$SQ5X%TI4*Q #CXA\:<D;]G%56YUO2K6"WGG
MN8TANYH[:UDY<EDFF;C&BE:@EVV&*HX;C%78JA$U;3)-0FTV.ZA?4+=%EN+-
M9%,T:2;([Q@\U5Z'BQ&*K8M:TB5H5CO(':XEE@MPLB$R2V_+UHTH?B>+TY/4
M4?8X/R^SBJ]-5TY[66[CN8GM8#*L]PKJ8T,#%9@S T7TF1EDK]AE^+%5:">*
M>))H662*10\<BD,K*PJK CJ",50&D>9=#UF>]@TN\CNY-.E]"\]*I5)02"G*
MG%F4JP;B6XM\+8JF>*M(B(*(H4=: 4Q5#1:G82ZC<:=%,KWMHD4MS /M(DY<
M1,?]?TI./^IBJ*Q5"G5=/_29TKUU.HB 71MOV_1+F,2?ZO,<<516*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5_]?U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M>?>1H]%NY_.,^I1V\FKKJ][#K#7*)ZBVB&EDLG,?[S?41$T?^ZF_>/\ ;]7%
M6&Z7HWUJV\A+8ZA>6.D+YDU9=#%J\80Z>8;Z2U9/5CD;T_03TX?^765N/VHG
M15%2#5-"T'\TM8L=7O#=1:NRP+,87CC<V]F_J*OI#XN,GI?%R7TD3X>?QLJR
M:&XU;5?-6O7$OF271+?R_?VUE;:6@MO0>*2*&4RW*S(9'^N/.\$/%XE3T_W7
M.3%6-Z5K7YJ:OK4FK6[&&SBUF2P^K/>V<=HEK!>&%XI;4VYNC<O K2*WUE)&
MDDCXKZ7PXJRSR(NNZIJNM:I?ZW=2V]CJ^H6%GI8$*6ZPQ2<5]0B/U9'7]AO4
M7C_*WVF52/S5>>:I=3\^7%IYAN].MO+%E!>Z=9VR6_ SBR>=A*TL<C20NR#E
M$.'^O_*JB['5]8T'6--N=8UZYOK#5]$OM6U%9HXA%;/8BVD+6D<2"1$XW,@]
M*22?X4C^)G^TJD&DZUYUO-9&DV6IZQ"?,&AWU[I]WJYTQB)X_1-K<VT5ER>W
MC8SMZD5Q'QX\$3XXWQ5D'Y<>?-1\[ZY%=Q2FWT_2M*@36K!0 !K5TQ,T#%AS
M_P!#2&G&O_'Q\7V<52_SU=ZGJZ^?E_Q)+HMOY:L_0@L(A;>E(L]@+AI[H3([
MR),TIMH@CQ*OHMP;U/LJI=<:QY[O;RQT30S/:V6EZ#IMX!;W=I92.\\;AI9#
M=V]R98(O2$95 B<_[QOL\54[AN_-FL:JUCJWF,^7+G1M$L;^X:P-L89[JY$G
MUBY<W".LEG;O $XIZ<?QOSD^SQ54M>\V:W#J.OZ<FIFSAN-<TG2+?4E6.MG!
M>V$,LLD?-2G.21F6)I>:I+,OVOAC95)[_4=<\K:C^8$NF:LVL:G;P>7[:&\O
M3;B2U%U-/$?K#JB0_N%E:XYS1KQ1D]7]VG)E69?EVGGR#5-0MM?9VTX00R6Z
MW=[;7MVD[.X?XK:"U"P.@7@'1OC1^+8JA](TAS^=/F2]_2MXOIZ?I4IT\/%Z
M$BN;V,*R>GZGIQ,OJ1TD_O9'Y,R\555BWD;_ !%H7DOR)K$>NW%S;ZG<6.GS
M:/)' MFEI=!HPL85/6$T;<)/7,S<_B7AP?X543IGG#6;OS9Y>N["_P!7FT+S
M)?7-M'/?'34LY;=;:XE5K2WBI?1/%)!&$DF3BR<O5^*5<53_ /)72GLO*T\I
MU2[U!9M1U*/TKIXF2)H=2NE9D$<<9#S?WDW,M\?V."_#BK']0\X:T/-.G:EI
M5]J\NE76O1Z1(US^C4TME^LM:SP10 KJ)>)PW"?C]M.;_NL59E^9NHZC:)Y;
MM[+5FT8:IK45A=7JB(MZ4MK<'@OK!DYO(D8B-/[WA\+_ &&58Q-YCU;2TUWR
MY<:UJ.H&#4;+3]&U"U2T;4I9[R%KB2Q,LBI9B2-$)]9TB:**1>7Q<&=5 V?F
MCS@WEW4K!=2O+2_LO-&FZ1;7=\+*YO(X+QK1I4G-J6M92&N)57C\2IQ23XU;
M%4VUORM/%^8WDJW;S'JC2)9ZK2=Y;;U93');2E6(@"GU%?TY.*K^ZBCX\?C=
ME5&#7=?U>73-%;5I],CU/6O,$4VIVPA6XX:9>2K;6<32(\:L\>_+@\OHVS_Y
M<BJI]IFJ:A;><M)TJ?6_TII[:-J$\UVPA19I[:]MXP[&(!/4AB>2.3AQ7[;,
MBXJQ?R]YCDO[OR)KVI79N%-MYCFEO-FY0PRH%8<!1E$2+QXCXEQ5!Z;YP\RQ
M:O;/#>ZO+IVM:/J&H0S:N=-XR>E DUM<6D-I^^MA\3?!<)PX\4_O$Q5Z'^6M
MMJQ\LV&JZKK%SJU[JUE:7,WKB)(HF>$,1!'&B% W/X^;R<N/+%6"6T>I:)%Y
MUU"TU:[DEE\W:=:-'.87C"7$VFK*0!&IY/#,UON?[I4_W9^\Q5%ZS<>;Y;;S
M_K]OYFN[-/*L]R=*TV**W:W/U;3K>Z*S\XVDFC=F9>'./AR?%4!Y^\ZZ["-2
MU?1+S5A)HGU9;F.(Z='I4%P\45PT,R7!6\NO4CF7EZ')EY\8OC7%4]U"/S3J
M_FWSA#;>9;S2K+0HK5]/MK6.W9?7DM/5+2F6.1I(N0WA^#E\7[S^55!:)K^O
M^;9!=W7F*7RRFGZ+IFI+';"W$4LE_;F>:YG%RCE[:-U]!45HT^"7]YS_ +M5
M%ZKYIO8V\SV<M]?1SR:_;Z3HL>FI;?6F,NFVUS]7B>Y'H1\SZ[>M,?W?[+?8
MQ5(M(UG6KZZTFRU2:ZE?2?.D=I!]?:UDO%C;1Y9RD\ED6MI&229PO#XE3@DG
M[Q6Q5G/G2ZU.XU_R]Y=MM3FT:UU;ZW+<:A;>D)V:T1&CM8GF62-6F]1Y6^!W
M].WDX_M.BJ5\M8U7S%:^6!YJN8[2VTSZ\-3L1:QW-_,;J2!@7,<L7&T2)!,L
M$?Q23JTGI_"K*I+9:QYNUO6])\O1^8I[>V6ZUNTN=8M8[?UKV#3VMO28$HT,
M<J-*]O)+&G'G'+\"NW[I50U\:QJ_E&;3;[6+LS:)YQT_38=1A]&.XFA%]:F%
MIOW;1M+"+@4=8TYRPQRNGVTQ5&W5[?:3J?FTVMRXF'F/RW:23N$9Y(IXM.AE
M#_#Q_>QNP:B_M?#QQ5.-!N-5U;6M0U>Z\RS:>EEK,^EQZ#2V^J^C;R>G'&ZN
MGKFXNUI<I()5;C+'Z:-']M53_)_2'LK;7Y?TK>7P.MZK UO</$\:-'?25D C
MCC82RUY25;C_ "HF*H6XN]<U2T\TZ\WFFYT1_+]W?6]M8Q"U^J0)9K^Z>[2:
M-I)?K  N/BEB_=3(L?\ OQE5WD:&_P!1_,74]=NKJ\MI[O0=$NKC2'9/0C>Y
M%WRA93&):0,K&/X^7J22\^7PJBKO/WF77M.?SR+"\:W?2]#TZZTY@J-Z,\\]
MXKN 1\7(0QU5CQ^']G%5]_9^8],UI_+]SYDOM2MM;T74[J6:5;:.6WN+5X%#
M6ICB58XV6Z8>E(LO'@OQ8JQRRNO,^C?EG^7^EZ!?W-W)YBCMD>YEN+:)X8QI
MWJBTM9I('ABY-'QB]2.6;BLG'D_Q(JFGUK\Q8]+T73=0U1]/NKWS&-.6[CEM
MKVZ%@;":5XYG2&*#UQ-&_!O1Y)QB=^?Q*ZJ UJ]_,V37-;TS1+ZY>#RTD$-I
M<S7UA;&1Y+99_K5\DUK(T\3R/Z?[OT(N,$JI^\Y\54[\Q:QYHTSS7:ZEK%Y<
MVWEJ%+&*1=*DM7AAN[B412I?PS(UU)%/(Z1P2VS?NT^+CR^/%45Y&TAX?S \
M]7?Z6O)N.IQ*]A))$8?WVG6DBNRK&L@:,?N8?C_ND7ES?X\52;\PO,_G'1_,
MFJ>7]+O^-]YJL[1?*+3<?3MKP3BVO E 681PNEZP9)./"3_C'BJ7Z?\ F/Y@
M\P1QZI:W<MM96<OES2[RWX1\6U&^OXCJ2M5/M1Q,EO\ #\*^H[)^SBJ.\P"F
MJ>;O_ L\K?KTS%60_F?&\VK^28(]1.E-/K,L0OD$9D3GIMVO&/U08Q+)7TXF
M97XNWV'^SBJ4R:]Y@T_2-:T_]*RZB=&\PZ3I]OJ\HB,TD%Y<V9GMY3&@B:2%
M;B2!W5%?C_+)\6*H'S+YPUB/S#^D]'O=7DT^VURTT><O^C8])#-=1VMS;>BY
M74)G422%9D'][Q;^YBQ5.O*FKZ]:^=)K#S-?7;W.JR7QT>.-[2;29H+:0%?J
M_I(+JWF@@*I,ERW[R3U/C;]E55\R:1)=_G!Y8F&K7EE32M1806\D*H_HW5DS
M1\7C=BLX;]^%;EQBCX>GQ;DJQG1(_,6D>4QYGM=?N5A37Y[=-$].#ZE]7N?,
M$EK,KU0SM*WK.XF]9>'P_!BJI9ZS^:6K:Y<:G92>G9V^M2:>EN][9QV:6UO>
M>@\4UJUNUTUQ+ K2(WUE).<L3)^ZX\E6:^>]1U-+[R]HUG?OI4&N7LEK=:I$
M(S+&L=M),L41E5XTFN'141RK-]K@G/[*K!?.=YJEE)=>79O,#W=MINI>7+JW
MUF]%NT]G+=Z@RO%,R+%%)Z:PI<IZJ(W"9>7./CBJ8ZYK'F'R]I?GS2X-;N-4
M;1]&CU*QU*Z]![FUN)UG5H)&BC2)J"".XC]2+GQF_;3CBJCYKU?\R+_S5K]G
MH$CVUMH*6XL_3O;.TCYRVPG^L74=S;W$DT#2-Z7PO%'^XE5?WG/BJG"7>OZM
MY@U<WWF)_+I\OK8H+.W^KFV<W%O'/+<3_6$9Y89)GDM(>+Q*OH-Q9I?L*I#>
M0W^CW'YO:Y9:U>_7+!'GAM6>!H5D?2()HY"GI<N4-/2AJW'TX^+^HW)L51?G
M3SIYE\NZ[J^CQW9,WF+3[,^3.:QA8=0DE6QGC2JCU.#36]ZR/S^#U6^&/%4!
MY^;5+ORG^8&F7NJW#1Z+/I445POI([*;6UDEYG@1QDED>9_\K[/%/AQ5,?.'
MG#6/R]OS'<ZA/JFFZAH\T>BRW?IM*VM6TI]&$M''&A-ZMRG[/_'M]G[>*LD\
MR:AKWEO\N8I'OP^L01V5K=ZQ.B,J23S16]Q>.GPQ\81))/Q;]U\/Q_!BJ1Z]
M;:QI&H+Y?7S'J&J6NN:9J4D_UDVK75K]6B5DN87BACXQL6]!EDC=.<B<6Y?:
M53[\L=+DB_*[R_:?7KF1KC2K5DNG:/UHA-;*0L1"! (>7[GDC?9^/GBKS?1M
M(O(OR<\FK:ZQ<R3WNK:3]7GG]&=;1_K7#]RBI&I",*\)?4^/[7\N*IUYDU_S
MCY3&NZ-9ZM-JTD2:*]CJ&H?5TGM_TI>3VLY>41I;E%] -$\T7")Y/BYK\.*L
MH_+E?.\%WJ5IYB9VM(U@:R%U=V][=K(WJ>J)'MH;91$5](Q!X^?]Y\7'%6'^
M9-.O[3\R/,WG;2(C-JWEF/3GGME)Y76F2V\AO+8 =7HBW$'_ !?"J_MXJN\G
MWMG?S^1;ZRE6>SNO,?F:>UG7=7BE_2+HP_UE-<54K>'S\?('FQM.GTE=%^M^
M9*QW$-TUUP^NW?J_&DJQ<C\7#]W_ "XJSKROJ>IRZ9I&D+HU[%8OIELHU])+
M00J3:*:JAE-QS5CP%;;CS_XKQ5AGY;2:CI&@>1;>+4[J>UU75]2CNTN#$PX)
M!>LD0*QIQ4S0I+_.TO\ D_!BJ(U#S/YCOX;J#2]<:V:7SF-&@OHEBF]*T^JJ
M9(E5E*-QDY_:Y<9/M<N/#%5NK:]YET*_U/RJ=?GD@DN]&M[;7;L0&[M(M6:=
M)JL(XX';E:\;9Y(O@>X_W9Z:*ZJ!O]0USRKJ/Y@2Z;J[ZQJ5M;:!;PWEZ;<2
M6HN9[B)OK#HB0_N%E:X]2:-56-E]7]VG+%47)K'YD>7=$UJ;5+HVMJRV$-K>
M7]W:7]Q:2WMXMM+<GT(+6,6\<,GK*LZLOJ0M\?I\\537ROIT^G?F_>V<VMW&
MMF/R_ RO>&!KB$/>.>+M D082?;3FG)?]7%7IN*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5__T/5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5(];\C>3==N4NM
M:T2RU&YC'%9KF".1N(W"DL#R7_);%4R?2]-<V9:UB/Z/;G8? O[AO3:&L6WP
M?NG>/X?V&XXJI2Z!HDUM>VTMA ]OJ4GK:A$T:E9Y.*KSD%/C;C'&M6_D7%5"
M^\H^5K_5[?6;[2;2YU:U %O?2PH\R!22O%V!;X22R_RM]G%5-O)7E!]=_3[:
M-9-K=0WZ1,$9GY* %;G3ER   ;[6*IG9Z?8V0F6T@CMQ<2O<3B-0O.:4\GD:
MG5W.[-BJC+HFD2F_,EG"_P"E$$6H\D4_6(PAC"R[?&OIDI\7[.*KCI.F&:WF
M-K$9;2)[>U?@*QPR\.<:?RH_I1\E_P A<52W1_(ODW1+D7>C:)8Z?= .HGMH
M(XGXR%2Z\E /%N"?#]GX<54_)?E&/RU8WL/K+<W6HZA=ZG>W*1B$/-=RE]HP
MS\>"<(_M?%PY_M8JB=7\G>4]9O8;[5M'L[^]@0Q0W%Q!')(J-6JAF!/'<[8J
MLU7R/Y.U=;-=4T6ROET]?3LA/!'((D%/@3D#Q3X5^'[/PXJOU;R;Y3UA[-]5
MT>SOFT\4LC/!')Z0V^%.0/%?A7X?L_#BJ(N?+VA74&H07.GV\T.JT&I121JR
MW'%%B7U01\=(T1!R_95<50^G^3O*FG6<]E8Z/9VUI=1""ZMXX(U26(<Z)(H%
M'7][)]K^=L57Z!Y4\M>7H98="TNUTR.8AIEM8DBYE=ARX@<N-=JXJK7/E_0[
MK5K76+BP@EU6Q5TL[YHU,T2R AU22G(!@>F*N30-$2RL[%+"!;+3WCDL;<1J
M(X7A-8VC6E$*?LT^SBJ!M/(?DJSU0ZM:Z%8P:F9FN/KL=O&LPF<,KN' Y!G$
MC\B/M<L51UAY?T/3[Z]O[&P@M;W4F5]0N(8U1YW0$*TA4#FPJ=SBJ!/D3R4=
M7?63H5B=6>5+AKXV\?K>M&05DY\>0D!4?']K%5OF[RA8^9ETJ*^$<EIIU\+V
M:UFB6:.<"WF@])E8T _?\^7Q?$F*JB^1_)RZ"WE]=%LAHC-ZC:=Z$?H%^7/F
M4I3GR'+E]K%5]CY.\J6%I]3L=(L[6U]>*[]"&%$3ZQ!P]*;BH ]6/TH^+_:^
M!<51.K>7]#UA8%U6P@OA:RK<6WKQK)Z<R?9D3D#Q<?S#%5"_\I>5]0TV33+[
M2K6YT^6=[N2UEB1HS<22&5Y>)%/4:1F=G^UR9L54[[R3Y/OK&SL+S1;*XLM.
M;E86TEO&8X3T_=K2B5[\<515MY>T*U-J;;3[>'ZB)EL^$:KZ0N#RF$=!\/JG
M=Z?:Q5 :?^7_ )&TZ>2>PT#3[6>42K)+#;1(Q6<<95Y*H/!Q]I?LXJG5K:VU
MI;16MM$L-M BQ0PH JHB#BJJ!T55%!BJ&?0=%>.>-[&!DNKA+VY4HI$ES$4,
M<S[?%(AABXO]K]VG\N*MMHFD-;W]LUG"8-5+MJ411>-P9(Q"YE%/CY1(L;<O
MV%XXJEVH^0?)&I7OU[4-!L+N\]-8?K$UO%(_IILJU93]G]G^7%4U32].2>[N
M$MHUGOPHO9 HY3!%X+ZA_:XI\(K^SBJ67OD;R9??H_ZYH=C<_HJ-8=-$L$;^
MA&@ 5(Z@\47BM%^SBJ(O_*WEO4;6\M;_ $RVNK;4)5N+Z&6)'6:9%1$D<$?$
MZK%&JM]KX%Q53T_R=Y4TV**'3]'L[2*&=;R)(84C5;A8O0$P"@?O?1_=\_M<
M,51&M^7M"UVQ-AK-A!J-F663ZO<QK*G-?LL P-&'CBJ%U'R3Y/U+3[;3K[1;
M*XL++:SMG@C,<(Z4C6GP?['%49;:#HEL;,VUA;P'3HY(K#TXU3T(Y>/J+'Q
MX*_!>07[7'%6CH&B,DJ&Q@*3W27\R^FM'NHV1TG;;>56BC97^U\"XJZ70=%F
M>=Y;&!WNIX;JY9HU)DGMN'H2MM\3Q>E%Z;?L^FF*J$GE'RM+KJZ_)I-H^MJ
MJZDT*&<!11?WA'*JCX0?Y<55[7R_H=IJEWJMK800:E?A1>WD<:K+,$V7U& J
M_'_*Q5!ZEY'\FZGJ::KJ.B65WJ4?'C=S01O)\/V:LP)/']FN*II'864=[-?1
MP(MY<)'%/<!0'>.$L8U9NI5#))Q_EYMBJ'O-!T2]-V;NQ@G-_$EO>F2-6]:&
M(LT<<E1\2(TDA53_ #MBJ(DL+*2]BOI($:\@CDAAN"H+I',5:1%;J%<QQEA_
MD+BJ5'R+Y,.E7.D?H2R_1=Y.;JYL?0C]%YR0?5*4X\ZJOQ8JB++ROY;L;2TM
M++3+6VM;"7ZQ90Q1(B13<63U$ 'PR<'=>?VOBQ52U?R7Y1UF^@O]6T:SO[VV
M4+!<7$$<CJH/(*&8'X0V_'%6[SR=Y4O=:@UR\TBSN-8MN(@U"2%&F3A4I1R.
M7P<CP_EQ5$_X?T/]-?ISZA -8]'ZL=0$:B<PUKZ9DIR*U[8JON]%TB\O;.^N
M[.&>\TYG:PN)$5G@:5>+F)B*H64<6XXJA[?RMY;M[:2UM]+M8;:6Z&H20I$B
MHUV)%E$Y4"GJB1%?G]KDN*JTN@Z+,\[RV,#O=3PW5PS(I,D]MP]"5MOB>+TH
MO3;]GTTQ5K5] T3684@U:P@OX8RS1QW$:RJK.C1L0&!H3&[I_JMBJE:>5O+=
MGI46D6FF6T&EPR)/%91Q(L2RQRB9) @%.:S*LG+^?XL50UQY#\E7.KMK-QH5
MC+JK/'*U\]O&TWJ1,K1OS(Y<T,:<7^U\.*JNF^3O*FEZI<:KIND6=GJ5WR^L
MWD,*)*_J-S?DZBOQO\;_ ,S8JB=4\OZ'JK6CZG807CV$RW-DTT:N89E^S)&2
M*HP\5Q5LZ#HIL#IQL8#8F;ZP;7@OI^MZ_P!9]3C2G/ZQ^^Y?[]^/%4))Y+\H
MR:Y^GI-&LWUJJO\ I%H(S/R4!5;G3ER4 !6^UBJ.U71]*U>QDL-4LX;ZRE_O
M+>X19(S3I\+ BH[8J@;;R5Y0MM+&E6^C64>F^JMP;-8(_2,J$,LC+2C.I ^)
ML52O5?RXT:3RK=^6=!BMM!TS4F*ZFMK;)62&1>$H2A14F=>(2=_5]/C_ ';X
MJF>L>2O*.M7L%]J^C6>H7EJ L%Q<P1RNJ@\@H9@?AY;\<55-2\H^5M4U&VU/
M4M(M+S4+,4M;J>&.22, \@%9@3LWQ+_*V*MWWE/RS?WTU_>:7:W%[<VSV-Q<
MR1(TDEK("'A=B*M&U3\!Q57O="T:^NK&[O+*&XN=-<RZ?-(BL\#L.):(D50E
M=OAQ5<VBZ0_U[G90N-4H-1#1J1< 1B("4$?O/W2K'\7['PXJQ_5/R\TFZ?RQ
M;VB06.C>6K[](PZ9% O%Y4CD6'@P(]$1R2F4\5;G]GX<591/;6]Q#)!<1)-!
M*I26*10R,K"A5E-05([8JE.C>2O*&B+<+I&C6=@+L%;GZO"D9D4]58J*E?\
M)Q5-+2SM;.TAM+6)(+6WC6&"",!42- %1%4;!5447%4NM_*'E6V:5K?2;2$S
MW2ZA-PA1>5VC<EG-!_>JWQ<_M<L51-WH6BWANS=V,%P;^!;2]]6-7]:!"Y6*
M2H/.-3+)16_G;%5/0O+/EWR_;O;:)IMMIL$C<Y([:)8@S>+<0.1^>*HJ+3K"
M*[N+N*WC2ZNP@NIU4!Y!$"J<SU;@"0M<50EAY7\N:?#906.F6UK#IKRRZ?'#
M$B+ \X82M$% "&022<N/\[8JB(]'TJ.RGL$M(ELKDS-<6X0".0W+,\Y9>C>J
M[NTG\W+%5>"W@MX8X((UBAA54BC04554450!T &*I;=^4?*]YHPT2ZTJUGTA
M7]1;"2)&A#\S)R"$4#<V+5Q5=;>5?+5K#%!;:7:P00W"WD,4<2*J7"((UE4
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MJ_U:[2PO)D!XGFR3&[&_^ZO]GBJ>>?#-J'E?SG!?:C<QVFD>9=)C@D2<Q&*
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M]*N]1\@:J;(#])Z>B:GIY-12YL)%NHZ$%2.1BX?:_:Q5Y:_F?3H-:B_.TO\
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MT+49;6;4-.M;R6Q;G927$$<K0MMO$74F,_"OV,54[GRIY:NH[..ZTFRN(].
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M ,C[?PXJLT[\QO+&H:C%96[W/"Y=XK+4)+6XCLKB2,,SI!=.BPRL%CD/PO\
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M\<31\.?Q_9Q51U#REYM3\NO+>AZ=.JW^E0V,.K6T5U+9K=PV]MZ,T"7D2--
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M&)H)956-I0T:27$L4=K&[#DK2_N_WG#%7GGYAQZE#H?F[RP-=O=3TZSTRSU
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MV,<SVL9"O+#Q9XY0K'BZK)S3X>:_&G)5/=$U]=7M);N.QN[2%'*Q"\B]%YE
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MI\CJZ*Z[JP!!]CBK>*NQ5V*H"VUW2KG5+S2H+A)-1T]8I+VU4_'$MP"8B_\
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MC]M_A5<53K3OS%\M7\^EV\$TRW&K375I;Q2PR1M'=6*E[BVG# >A.BJU$?\
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M1LH"K!)Z<JR_'\'*-/M8JC//WY=WGFK4KE_6BBLY]&FT]?4#,?K+7EO=0ET
M'*#_ $?C+1U?C]G^;%53\OO);:+?7%]<>6]'T.X>!;='TN:6YD<$\I.3RQ0<
M(BRQ\8PK?$GQ/BJ<KH-\OGN\U[E']2N-)M]/C6I]3U8;B>5B12G#C,M/B^UR
M^'%4C\F^1M9T6?RN]W)"RZ+Y>?1KOTF8UN&DM7#1U5>4=+>3XFXM]GX<52C4
M/R[\XE52!X;JQDU'5[NYTO\ 2%YIJ/\ I"\^L6L[3V:>L\EO'R1[<_NV]7^\
M^#%4;Y0_+S7=&C\GK=26Q.@#5A?")Y7#?I"0O%Z32KS?C7XS*W/_ %VQ5UQY
M%\SVNN7/F+2S:3ZBFLW%_:6=Q+)%#+9WEC;VDL<DJ1NT,ZO;^I&RQS)Q7C^W
M^[53"\\M><=2O[75)[JUT_5$T;5=/,]ISD6"YOI8'MI(A(J^H($@_>,WI^I)
M_NM5;X56(VWY5><9FOYKN.TMY[OR]J>CM(VIZAJ3S7E\(N,[M=(%AB9HV9UA
M3E_QD^#@J]!\Q^6+O5O)7Z%BF2"_C2UDMIF!:(7-E+'/%S HQB,T*^IQ^/T_
ML_%BJ4ZCHWG_ %FTL[V]BTRRU;1[^'4-+LHIIYX'*12P3)/.8XG7U8[B3TFC
M@_<MPY^M]G%4MUKR-YP\QRW6J:HEC8:@8K*TL;*VGEGC6&#48;ZXDEG>&(M)
M((%6)$A7A^T[<_W:J<>;/)NJ:MK&HWEL\*Q7?EV^T:,.S!A<73JR,:*0(_A^
M)OM?Y.*H/4/(>LW+ I) /^=5N= W9O\ >J;T^+?9_NOW;?%]K_(Q5;:^5?.V
MA7XN] 33[EK_ $VQLM0%]+-&(+BP1HTGB]*-_7B9)&Y0MZ#\D_OEY_"JF]KH
M>O67GV_UB%;>?2-9MK6*\+2/'<6\MDLH7A&$=)DF]8<N4D7I\?\ =F*J>N:)
MYFM?-(\R^7H;2]EGL5TZ]L+V:2V!2&9YH9(IHXKBC*9IED1XOC^#BZ</C52[
M3/(>MPZCI&J7DMNUZNMWFMZND3/Z2?6;"6RCBM^2\G]-6@Y,_I\_WDGP_#%B
MK(?,.A7FH:WY:O;<H(='OY;NZ#DABDEC<6P"  @MZDZ'<K\/+%6/P^1=;3R#
M9^7C+!]>M]6AU!W#/Z7I1ZP-0(!X\N?H#C3C_>?Y/Q8JA=;_ "\U[4H/-ND,
M+*32==NX=7LKB9Y.0NX!;<;6XMPE&MG:S'J2QSK)PDX>GR^+%5.P_+FZ7RWY
MGM8_+VC:!J>L:9-IUJUA--<<C)%(H,\SPPD1<W3BB1-Q^/[6*HOSQ^7MSK3Z
M!?+IUAK$^CP2VD^F:E))%!+'<+$7DCEC25HYHY+>/ARB='C:1?A;BV*H?4?R
M^NO\)Z7IECY9T4S6US)=2V45U=6,=O*_(K+:7D,37 FW43/PC]7X_L_9Q5'0
M>5O.ME<>4-0:ZMM9U/1[.?3M:EN7D@,J79@:2XB=4EY21-;"B2(OK<OBDB;%
M4WUOR[?WWFG2]5A:-;:RT_4K.56)#F2]:V,94 $<1]7?G\7\OVL52NU\E:Q'
MY<\A::[PFX\L2V4FH$,Q5A:V$MJ_HDK5JR2*5Y!/@Q51_,3\OI->US3-;ATR
MPUMK.WFLY],U262"(QS,DBRQ2QQS%)8WCXE6B=7C?]CCBJ$U;R!KXT'0]/T>
MVL[:SLFN&U;R]9WMYIEI,\YYI(EW;H;G]S+R?@R<9FD9FX\$Q5"^6_('G7RS
M;Z9?V$>GWFJVAU6WN[&:YN5@:UU&]^NQM%=/'/<>K$Z1A_727U%9_P!YS^/%
M65Z3H&NQ^;7U[4WMV:?1[2PN!;<P/K4%Q/-(45ZD0_OE$?)^?\V*H/3M OM!
M_*V^TJ]*RW45KJ3N82S ^N\TR@%@I)XR#M]K%4G\CZ+YSU*S\F76N1V%OIN@
MV<5U:R6DDSSW,\MB;9/4BEC1;=(X9Y?47U)F>7AQX+RQ5WE_R3YXLY?*&G78
MTY-$\H7#^G/%+-)<W<0L[BTAD*-'&D#A9D,L7.;DS-PD3T^,BJS3O(_GL:79
M^6;_ /1PT&+5#J<]_#+,;KTH]1;4(;=8&C$?,RB(/.9>/I\U]#G\>*IC8^1-
M9M[O3YG> I:^9]1UR0!FJ;:\BNXXU'P_WH-S'S7[/VOCQ5%>2M#\Z>7X;3R_
M,E@_ES3 \5M?K+,UY- *_5U: HL44D=5$TGK2++Q^"./E\*J6Z^_FJ/\UH)O
M+]K:7<@T%Q<0WTLMNC W@X<)HXY^+*?B96C;FO\ )BJ-\M^1=5TG4O+]U-/#
M,;"TU<:FZ<EY7>K7<-XWHH>7[E9$F YOSX^G]KXL52*\_*3EYFU.Y;R_HNLV
M.JWWUYM0U&29;J 2\3/"8$B>.< JWH-ZL/V^,BMZ?)U4S_P5YC;S\VKVUM9:
M3ITL[R:E>6=U<F;4+<P-&D-Q8F-;43>HZNUUZCR?N5X_:Q5+_(OY5/Y>U'38
M[CR]HABT<,L&O0R3->S!$,<,GH-&(X9V4KZ[_6)%_O/35>?PJII9^1-;A\AZ
M%H#R0&]TS4[.]N'#,8S%;:B+MPA*U+F(46JK\?[7[6*M3>4/.L-OYOT_2[NW
MM(];GDU'2M5261+F*>98E>"2,1D(E(G'UJ*7U%Y_##S7%4ETW\JO,$B>:END
MMM+C\P:(-)MHDOK[5FBDK/6226\".4_?*W"+@O\ L_C95.K_ ,D^8/,;A]>2
MUL/K7E_4M#OH[*9[@))>RP%)(FDBAY+Z<+,W-5XOQ3X_MXJJ_H+SWK-WHD/F
M&'3;6QT6[BOI+FQGFEENYK>-UBXQ211K;1\V]1U:6X;C^[5O]V8JLLO(FLP>
M3?)>BM+";OR]<Z?-?N'?TV2T5@XB)6K$EOAY!<53;S/HNOG7]-\QZ MM<7UC
M;W-C-8WLDD$4MO=M%(2LT:3&.6.2VC(Y12*R<T^%N+XJDD_D3S'?:;J]S>O:
MQ:UK>J:5?RV\+R-;06^F3VS"(2L@DEE]*WDK)Z<:/(Z_!&OQ8J]$IBKL5=BK
ML5=BKL5=BKL5=BKL5?_2]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%4#?ZYI-A9W]Y<W4:6^E1M-J3 \S B1^J2Z)R<?N_CX\>3+BJ,CD5T5U-0P#
M ^QZ=<5;HM:UZXJW48JZH\<5=4>.*NQ5+M,\PZ-J=I9W=G>12V^HAC8M7@9N
M%2W!'XNW$*Q/PXJF.*NJ/'%4I\P^:=$\OV\5QJMSZ"7$JP6ZK')-++*P+!(X
MH5DED;BK,W!/A1>3?#BJ837=M!&LD\J1([I&C2,$!>1@B(*G[3L0JK^TWPXJ
MAX-9L)]3N],BF#7UBD,EU#1@42XY^D22.)Y^F_V3^SBJ.J,5=48JMHO6OSWQ
M5<".E<5=4>.*NJ/'%75'CBJV66.*-Y7:B(I9CX "I.V*H?3-2L]3TZVU&RE$
MUE>PQW%K. 0'BE4.C , 1R5@=\5151XXJZHQ5HF@Q5!Z=K%AJ+7:V<PE-C</
M:75 PX3QA69#R K0.O3X<51$-W:SF403)*87,4P1@W"0 $HU#\+ ,/A.*JM1
MXXJ[%75'CBKJC%75&*NJ/'%75&*J5O=6MS'ZMO,DT?)DYQL&7E&Q1UJ"=T=6
M5A^RV*JM1BKJCQQ5V*NJ/'%4'::O87EY?6=M,)+C395@O4 (,<DD23JI) !K
M%(C_  _S8JTNL:>VKR:0LRG4(H$NY(*-402N\:/6G'XI(Y%IRY?#BJ-J/'%7
M5'CBJ"NM8T^UU&STZ:8+>Z@)6LX2&)D$"AI*$#B.*L/M'%4;48JZH\<5=4>.
M*J<5U;3-*D4R2/ _ISJC!BC\0_!P/LMQ96XG]EEQ54J,5=BKJCQQ5U1XXJZH
M\<52_2->TO6%NGTZ?UULKJ:RN3P=.-Q;MQE3XPO+BW[2_ W[+8JF%1BKJC%4
M'<ZQI]MJ5GILTP2]U 2M:0D,3(( K2D$#B. =?M'%4948JZH\<5=4>.*H&ZU
MFPM=0LM/GF$=WJ!E%G"0Q,A@3U)*$"@XI\7Q8JW>ZO8V4UG#<S"*74)_JMFI
M#'U)O3>7@*#;]W%(WQ?RXJLT?7M,UB":?3IO6B@N);25N#IQFMW*2I1U4GBX
MIR'PM^SBJHFK6$FJS:4DH:_MX8KF>"C56&=I$C<FG'XFAE'VOV,51E1XXJZH
M\<50>EZO8:I;O<6,PF@CFFMG<!A2:VE:&9/B ^Q*C)BJ,J/'%75'CBKC0]\5
M:J!M7%6ZCQQ52N;NUM8'N+F9(((Q6261@B*.E69B ,55:CQQ52^M6OUGZKZR
M?6N'J^AR'J>G7CSXUY<>7P\L50FC:WI>L037&G3^O##/-:RMQ=*30.8Y5HX4
MGBZD<J<6_9Q5,*C%75&*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*O_T_5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5X?KVD
MVT$GYR7/Z3NFN$L9G%A)<<H2D^CHW-H#U],AHXF_81.'[&*IKJLWF7R9<V+6
M6KWNNS:GI&K7,EE?E)(VN[*V2XMS;QQJGHCD6B]&/X6C?]IT5\55/RVD\[2Z
MWIUW>:M;WNFW]D]Q> ZLNHM<$A#'<6MNMI:K;(KO\8B=H>,JIPY<&Q5.M;@U
M+5?S.31_TQ>Z?I4.C)>R6UE((3)-];9%9I*%U7B*,J<?4_:Q5B&DZK^8.JZ]
M)JBZE;V[1ZW)8?5)M66***V@O/2:U?3!:'G<2VR\XV:Z]=WECE63T^$>*IIH
M>L:M9>;-1LM7U*ZO+_5?TD=%DM+N&ZTYXK4EE1;5%6:SN+6/A$^SI++ZO*7F
MZIBJOY>\VW-V_P"5UL-6$]WJ=@\^L0B16DF*:;R9YE&_PW/7_BW%6*:1I-M?
M:3^4\EQJ5WIT;F_A]2UN3;@'ZO.XH?YWX\/\I.28JROROK&I67Y@S6>N:C<7
MD^L7%\FCO:WD-QIK0VS%_2:T55FL[BUB01R-\:23>ISFYR+'BJ:>9)9=4\\K
MY?N]:N=$TZ/3$OK9;*=;6:[G:=XIOWQ',I:HD-8XS_Q]?O?]UXJQ"!;SS!KW
MD\W6L7EQ#8^8-6L+#4X)A'];MK:SG=)6,*B*1PR-:R2H/WB)+^U(V*LM_.>P
M@N?+6FF>\GL8HM;T@R3V\WU>BOJ$*%G?_BOEZB,?L2*DG[.*I/;^59M2\_>8
MK:W\PZE8PV.F:.$GM)D]6>3A=".:XE96:;C3EP^&.1FY2<L58\GFGSUYE&D*
M+Y+>/_#VGZK)PU-=&::XNA)Z]Q7ZK=F:*$HJM'\$$;2?O$?FG%5Z!KM_K]G^
M3NI:C<WD9\P6V@SW$NH635B-TEHS^M"U%!4N.:,%Q5CGFY?-6C6WE_2]/UBZ
MNY/,%S(VI:A>WRV)+I;<UMK><03I:"=^4B1PP\OW3)&ZXJ@[H>?O\/6,,^LQ
M2QQ:E<^M:V&L0IJ$UE%$JK$NH2PP)+-:S&5IT9(&>-8EDFY<_454M4\S^8?,
MFJZ;#HE_)#H3:'::I:M/J2:-=W#3O(LDTCK:W7K>@L<?JQIZ<"//R=7YQ<55
MWFCS#K1TNQLKO4KV3S!8:-#J&J7.D:C9:=8?OQ(L=T)K@(;GFT+?"B_5^/VH
MU]1<5331[O7?-6N>6X;K6KRRMKORM::O?0V#K;^M=22)5JA2R+\355./+[/V
M<57^4;MM1TU->U'S-<?IC4A?I=^7'GB^KH\2RJUI';E1)$]F(_B=?WK>FS3?
M;Q5+O)=KK&A:!^6NHQZ[>W::ZME97NGW#(;18)=*EFC6")57TFA:"/BX;G)\
M7J\^6*I_^9NLA+ZQT6VEU-;YX)[YX=.O;73$-O$R1M)+=7)4GTV?X8HF_:9Y
M?LIBK'M U+S)YJL?R^MKC7KRQ&JZ;J<^JSV3Q)-<_5);98JRJK(K?%\4T*KR
MY2>GP]3%6[;6M6NM1L_*.H^8+JTL$U?5;(ZPDJPWLZ6$<,MK:/<\:>HPN)"[
MKQFF2T_RIL59'^3GI_4?,PCU ZK&OF&]5=0<HS2A8X15FC"HQ6G#DJ_%QY8J
MQ"R,OEZT\]:C8ZW=PW7^(EL[J6XG6:.SM;J2S6:_,,@,8>&&1V661>'IK\7P
M8JR_26ET?SSIVBV&NW6MV.I65W<W]M>W"7CVQ@:)8;A9 /4C24N\/!F])F^P
MO-7Q552UU+5OS.UBUEUB]M],TBTTJZ@TZVD$<;S3/=<S*0"[(ZQ*KQ<N#_M?
M97%6(^1=3_,/5]1T;6[C4;=/K]W(NHV<NJAT](>IZMG%I@M8_1N;7A3:Y]96
MA?UGD_>8JML-:U22S\I:Z_FFZ_3&OZU;P:MH1FB," R2">SBMP.</U3AZ<O[
M3\&];XGQ5-+WS??6WEC5!-JQAU5?-R:=:(\@6?T'U>$+ JGXN+6;-Q%/[AN?
MV<52N_U3\Q-4\QZY<66H6]@^EZJ;&P@N-5%I!%&K1K$+BP^J2?6/KBMZB,]S
MS?UT]#TN*8JG>G:IJ=G^9$T.M:G<W-OJ][/9:*;&]@DLD58&D^K3V0"SV]Q
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M],M3RMK&2UA>",TI5(RI1#0_LC%574_*OEO58K>+5-*L[^*T-;2.ZMXIEBV
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MEU-#M=;2^273[\QI8R0@R-/),>,<<2*"[RLVWIA>2_%SX\&Q58?.OEH:+#K
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M 5.P\<5?._Y/6\T0U?7+[58+?RIIWF/S#^E[.X])(OWL:HD[RL02J@M'Z?\
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*78J[%78J[%7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6844829408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOCRYST PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">bcrx<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,576,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,078,490,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6850470880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember', window );">Collaboration Receivables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 6,243,000<span></span>
</td>
<td class="nump">$ 3,849,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember', window );">Trade Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,641,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember', window );">Deferred Collaborative Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 2,163,000<span></span>
</td>
<td class="nump">1,481,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredProductSalesMember', window );">Deferred Product Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,605,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,899,000<span></span>
</td>
<td class="nump">54,540,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">1,612,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">22,664,000<span></span>
</td>
<td class="nump">18,232,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,612,000<span></span>
</td>
<td class="nump">683,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,870,000<span></span>
</td>
<td class="nump">6,172,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred collaboration expense</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">65,990,000<span></span>
</td>
<td class="nump">89,343,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments</a></td>
<td class="nump">47,683,000<span></span>
</td>
<td class="nump">41,116,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,149,000<span></span>
</td>
<td class="nump">207,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseAssets', window );">Deferred collaboration expense</a></td>
<td class="nump">265,000<span></span>
</td>
<td class="nump">177,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">5,468,000<span></span>
</td>
<td class="nump">6,031,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">124,555,000<span></span>
</td>
<td class="nump">136,874,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,307,000<span></span>
</td>
<td class="nump">2,849,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">16,237,000<span></span>
</td>
<td class="nump">11,329,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">6,746,000<span></span>
</td>
<td class="nump">6,029,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Non-recourse notes payable</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">64,453,000<span></span>
</td>
<td class="nump">57,293,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred collaboration revenue</a></td>
<td class="nump">9,674,000<span></span>
</td>
<td class="nump">3,552,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">329,000<span></span>
</td>
<td class="nump">$ 394,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease financing obligation</a></td>
<td class="nump">2,375<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 73,355 in 2015 and 71,955 in 2014</a></td>
<td class="nump">734,000<span></span>
</td>
<td class="nump">720,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">558,113,000<span></span>
</td>
<td class="nump">542,943,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(206,000)<span></span>
</td>
<td class="num">(130,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(510,917,000)<span></span>
</td>
<td class="num">(467,898,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">47,724,000<span></span>
</td>
<td class="nump">75,635,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 124,555,000<span></span>
</td>
<td class="nump">$ 136,874,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deferred collaboration expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LeaseFinancingObligationNetOfCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Financing obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LeaseFinancingObligationNetOfCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3-4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a(1)<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774050896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">73,355,000<span></span>
</td>
<td class="nump">71,955,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">73,355,000<span></span>
</td>
<td class="nump">71,955,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6850402896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">$ 6,291<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">2,386<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
<td class="nump">$ 2,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopment', window );">Collaborative and other research and development</a></td>
<td class="nump">39,580<span></span>
</td>
<td class="nump">10,550<span></span>
</td>
<td class="nump">14,769<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
<td class="nump">48,257<span></span>
</td>
<td class="nump">13,608<span></span>
</td>
<td class="nump">$ 17,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of products sold</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">72,758<span></span>
</td>
<td class="nump">51,796<span></span>
</td>
<td class="nump">$ 41,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">13,047<span></span>
</td>
<td class="nump">7,461<span></span>
</td>
<td class="nump">6,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">87,701<span></span>
</td>
<td class="nump">59,379<span></span>
</td>
<td class="nump">48,048<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(39,444)<span></span>
</td>
<td class="num">(45,771)<span></span>
</td>
<td class="num">(30,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5,200)<span></span>
</td>
<td class="num">(4,998)<span></span>
</td>
<td class="num">(4,778)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain on foreign currency derivative</a></td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">5,487<span></span>
</td>
<td class="nump">5,294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,019)<span></span>
</td>
<td class="num">$ (45,189)<span></span>
</td>
<td class="num">$ (30,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding (in shares)</a></td>
<td class="nump">72,901<span></span>
</td>
<td class="nump">66,773<span></span>
</td>
<td class="nump">55,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available for sale investments</a></td>
<td class="num">$ (76)<span></span>
</td>
<td class="num">$ (134)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (43,095)<span></span>
</td>
<td class="num">$ (45,323)<span></span>
</td>
<td class="num">$ (30,131)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and other research and development during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51677171&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6850284480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToReportingEntityAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,019,000)<span></span>
</td>
<td class="num">$ (45,189,000)<span></span>
</td>
<td class="num">$ (30,108,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization</a></td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="nump">177,000<span></span>
</td>
<td class="nump">304,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss (gain) on disposal of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="num">(47,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,705,000<span></span>
</td>
<td class="nump">10,177,000<span></span>
</td>
<td class="nump">4,368,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Financing Costs</a></td>
<td class="nump">439,000<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssets', window );">Change in fair value of foreign currency derivative</a></td>
<td class="nump">564,000<span></span>
</td>
<td class="num">(5,487,000)<span></span>
</td>
<td class="num">(5,294,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="nump">3,247,000<span></span>
</td>
<td class="num">(7,375,000)<span></span>
</td>
<td class="nump">$ 2,447,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(929,000)<span></span>
</td>
<td class="num">(683,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,207,000<span></span>
</td>
<td class="num">(1,943,000)<span></span>
</td>
<td class="num">$ (620,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities', window );">Deferred collaboration expense</a></td>
<td class="num">(102,000)<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="nump">5,133,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">14,393,000<span></span>
</td>
<td class="nump">6,818,000<span></span>
</td>
<td class="num">(2,049,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">1,199,000<span></span>
</td>
<td class="nump">4,429,000<span></span>
</td>
<td class="num">(1,103,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities:</a></td>
<td class="num">(13,116,000)<span></span>
</td>
<td class="num">(38,551,000)<span></span>
</td>
<td class="num">(26,530,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisition of property and equipment</a></td>
<td class="num">$ (5,122,000)<span></span>
</td>
<td class="num">$ (106,000)<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfFurnitureAndFixtures', window );">Proceeds from sale of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td>
<td class="num">$ (1,462,000)<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">157,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(53,830,000)<span></span>
</td>
<td class="num">(73,875,000)<span></span>
</td>
<td class="num">(23,974,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">42,410,000<span></span>
</td>
<td class="nump">34,000,000<span></span>
</td>
<td class="nump">20,330,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities:</a></td>
<td class="num">$ (18,004,000)<span></span>
</td>
<td class="num">(39,980,000)<span></span>
</td>
<td class="num">(3,467,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">106,600,000<span></span>
</td>
<td class="nump">23,633,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 5,124,000<span></span>
</td>
<td class="nump">4,997,000<span></span>
</td>
<td class="nump">1,333,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Employee stock purchase plan sales</a></td>
<td class="nump">$ 355,000<span></span>
</td>
<td class="nump">$ 310,000<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral', window );">Receipt of foreign currency derivative collateral</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,180,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities:</a></td>
<td class="nump">$ 5,479,000<span></span>
</td>
<td class="nump">$ 111,907,000<span></span>
</td>
<td class="nump">30,270,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">(Decrease) increase in cash and cash equivalents</a></td>
<td class="num">(25,641,000)<span></span>
</td>
<td class="nump">33,376,000<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">54,540,000<span></span>
</td>
<td class="nump">21,164,000<span></span>
</td>
<td class="nump">20,891,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">$ 28,899,000<span></span>
</td>
<td class="nump">$ 54,540,000<span></span>
</td>
<td class="nump">$ 21,164,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deferred collaboration expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the receipt or payment of foreign currency derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 8<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51824106&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToReportingEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToReportingEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfFurnitureAndFixtures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfFurnitureAndFixtures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774005296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2012</a></td>
<td class="nump">$ 509<span></span>
</td>
<td class="nump">$ 391,611<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="num">$ (392,601)<span></span>
</td>
<td class="num">$ (454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,108)<span></span>
</td>
<td class="num">(30,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">23,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">420,988<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(422,709)<span></span>
</td>
<td class="num">(1,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,189)<span></span>
</td>
<td class="num">(45,189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">106,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,177<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">720<span></span>
</td>
<td class="nump">542,943<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="num">(467,898)<span></span>
</td>
<td class="nump">75,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,019)<span></span>
</td>
<td class="num">(43,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">5,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,705<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 734<span></span>
</td>
<td class="nump">$ 558,113<span></span>
</td>
<td class="num">$ (206)<span></span>
</td>
<td class="num">$ (510,917)<span></span>
</td>
<td class="nump">$ 47,724<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6773908352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parentheticals) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares (in shares)</a></td>
<td class="nump">1,359<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan sales, shares (in shares)</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">7,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares (in shares)</a></td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777431792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note&nbsp;1&nbsp;&#x2014; Significant Accounting Policies and Concentrations of Risk</div></div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash, restricted cash and investments of $100,858, to continue its planned operations through mid-2017. The Company&#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017 it will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources; (4)&nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on one or more research and development programs; and/or (6)&nbsp;restructure operations. The Company may issue securities through private placement transactions or registered public offerings pursuant to a registration statement filed with the SEC.&nbsp;&nbsp;Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on November&nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Beginning in March 2011, the consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;). Royalty Sub was formed in connection with a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 3, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). Such consolidated financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Long term deferred rent as of December 31, 2014 has been reclassified to conform to the 2015 presentation.</div>    <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Restricted cash as of December 31, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $59 in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note 3) and $1,403 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</div>      <!-- Field: Page; Sequence: 58; Value: 3 -->      <!-- Field: /Page -->          <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>    <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.<div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At December 31, 2015, the Company believes that the costs of its investments are recoverable in all material respects.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair value of the Company&#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair Value</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">26,557</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">88</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">(99</td>      <td style="width: 1%; font-size: 10pt; text-align: left">)</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">26,546</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Corporate debt securities</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">21,820</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">184</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(41</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">21,963</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,884</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(72</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,838</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,261</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">293</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(212</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>    <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2014</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair Value</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">20,307</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">22</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">(23</td>      <td style="width: 1%; font-size: 10pt; text-align: left">)</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">20,306</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Corporate debt securities</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">27,152</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">151</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">5</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(47</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">27,261</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Commercial paper</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,838</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(63</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,781</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,297</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">179</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(133</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#x2019;s investments at December&nbsp;31, 2015 and 2014.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 67%; font-size: 10pt; text-align: left">Maturing in one year or less</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 13%; font-size: 10pt; text-align: right">22,664</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 2%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 13%; font-size: 10pt; text-align: right">18,232</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">28,395</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">25,459</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,288</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">15,657</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>      <!-- Field: Page; Sequence: 59; Value: 3 -->      <!-- Field: /Page -->          <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>    <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivable from Collaborations</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At December&nbsp;31, 2015 and 2014, the Company had the following receivables.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt; text-align: center">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 52%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 13%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 13%; font-size: 10pt; text-align: right">5,536</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 13%; font-size: 10pt; text-align: right">5,536</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Shionogi&nbsp;&amp; Co. Ltd.</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">469</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">469</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">210</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">238</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">679</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,564</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,243</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>    <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt; text-align: center">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2014</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt; text-align: center">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; width: 52%">U.S. Department of Health and Human Services</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 13%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 13%; font-size: 10pt; text-align: right">2,778</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 13%; font-size: 10pt; text-align: right">2,778</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Shionogi&nbsp;&amp; Co. Ltd.</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,071</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,071</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,071</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,778</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,849</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Product Sales</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</div>  <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Inventory</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">At December&nbsp;31, 2015 and 2014, the Company&#x2019;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">During 2014, in connection with the FDA approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company&#x2019;s inventory consisted of the following:</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31,</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt"><div style=" margin: 0">Work in process</div> </td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">1,612</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">267</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished goods</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">416</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net inventories</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,612</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">683</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>      <!-- Field: Page; Sequence: 60; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the remaining lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period of ten years equal to the term of the related lease</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patents and Licenses</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;">       <tr>     <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">&#x2022;</div></td>     <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</div></td>    </tr>    <tr>     <td style="padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>    </tr>     </table>  <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;">       <tr>     <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">&#x2022;</div></td>     <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</div></td>    </tr>    <tr>     <td style="padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>    </tr>     </table>  <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;">       <tr>     <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">&#x2022;</div></td>     <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and</div></td>    </tr>    <tr>     <td style="padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>    </tr>     </table>  <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;">       <tr>     <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">&#x2022;</div></td>     <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td>     <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">professional fees.</div></td>    </tr>     </table>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</div>      <!-- Field: Page; Sequence: 61; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; text-align: center; margin: 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">Accrued expenses were comprised of the following:</div>  <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 67%; font-size: 10pt; text-align: left">Compensation and benefits</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 13%; font-size: 10pt; text-align: right">424</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 2%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 13%; font-size: 10pt; text-align: right">2,105</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Development costs</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">10,398</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">4,232</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">Inventory</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">549</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">397</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Professional fees</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">242</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">238</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Duties and taxes</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">102</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">75</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; padding-bottom: 1pt">Other</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,522</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,282</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; padding-bottom: 2.25pt">Total accrued expenses</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">16,237</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,329</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">As of December 31, 2015 and 2014, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</div>  <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accumulated Other Comprehensive Loss</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During 2015, realized gains of $13 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded during 2014.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#x2019;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &#x201c;stand-alone value&#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&#x201c;TPE&#x201d;) and (iii) best estimate of selling price (&#x201c;BESP&#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&nbsp;</div>      <!-- Field: Page; Sequence: 62; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; text-align: center; margin: 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, the Company entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting Seqirus UK Limited (&#x201c;SUL&#x201d;) and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&#x201c;EU&#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&#x201c;Health Canada&#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Product Sales</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be primarily responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales, and the Company&#x2019;s commercial sales will be minimal.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&nbsp;</div>      <!-- Field: Page; Sequence: 63; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-style: italic;">&nbsp;</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-style: italic;">Rebates and Chargebacks</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#x2019;s selling price.&nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Discounts and Sales Incentives</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#x201c;IMA&#x201d;) Fees. Per contractual agreements with the Company&#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Product Returns</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the years ended December&nbsp;31:</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 61%; font-size: 10pt; text-align: left">Product sales, net</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">6,291</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">33</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Royalty revenue</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2,386</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">3,025</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2,562</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">U.S. Department of Health and Human Services</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">16,337</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">9,366</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">13,585</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Green Cross Corporation</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">132</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Shionogi (Japan)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,184</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,184</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,184</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Seqirus UK Limited</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,927</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,580</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,550</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,769</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">48,257</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">13,608</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">17,331</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Advertising</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred. Advertising and product promotion expenses were $103 and $290 for the years ended December&nbsp;31, 2015 and 2014, respectively.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Expenses</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.&nbsp;</div>      <!-- Field: Page; Sequence: 64; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; has occurred.</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Interest expense for the years ended December&nbsp;31, 2015, 2014 and 2013 was $5,200, $4,998 and $4,778, respectively, and relates to the issuance of the PhaRMA Notes. Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other non-current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $439 for each of the years ended December&nbsp;31, 2015, 2014 and 2013.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the years ended December&nbsp;31, 2015, 2014 and 2013 resulted in a loss of $564 and gains of $5,487 and $5,294, respectively. Mark to market adjustments are determined by a third party pricing model which uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. In addition, a realized currency exchange gain of $1,654 was recognized in 2015 related to the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of December 31, 2015 and December&nbsp;31, 2014, no hedge collateral was posted under the agreement.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the years ended December&nbsp;31, 2015, 2014, and 2013 does not include 3,524, 3,991 and 1,430 respectively, of potential common shares as their impact would be anti-dilutive.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&nbsp;</div>      <!-- Field: Page; Sequence: 65; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Significant Customers and Other Risks</div><div style="display: inline; font-style: italic;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Significant Customers</div></div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Prior to the SUL Agreement, the Company relied primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company&#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Risks from Third Party Manufacturing and Distribution Concentration</div> &nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Credit Risk</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6745181680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Furniture and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"><div style="display: inline; font-weight: bold;">Note&nbsp;2&nbsp;&#x2014; Property and Equipment</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Property and equipment consisted of the following at December&nbsp;31:</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 67%; font-size: 10pt; text-align: left">Furniture and fixtures</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 13%; font-size: 10pt; text-align: right">718</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 2%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 13%; font-size: 10pt; text-align: right">542</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Office equipment</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,122</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,115</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">Software</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,427</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,423</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Laboratory equipment</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">6,004</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">5,786</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Leased equipment</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">63</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">63</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Leasehold improvements</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">5,610</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">5,303</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Construction in progress</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2,821</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; padding-bottom: 1pt">Building</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,589</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">19,354</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">14,232</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation and amortization</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(14,205</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(14,025</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Property and equipment, net</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,149</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">207</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>        <!-- Field: Page; Sequence: 66; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Depreciation and amortization expense for the years ended December&nbsp;31, 2015, 2014 and 2013 was $180, $177 and $304, respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6772121568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Royalty Monetization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationTextBlock', window );">Royalty Monetization [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"><div style="display: inline; font-weight: bold;">Note 3&#x2014; Royalty Monetization</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 6pt"><div style="display: inline; font-style: italic;">Overview</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 6pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, the Company completed a $30,000&nbsp;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691&nbsp;from the transaction after transaction costs of $4,309&nbsp;and the establishment of a $3,000&nbsp;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">As part of the transaction, the Company entered into a purchase and sale agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#x201c;Currency Hedge Agreement&#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#x2019;s collaboration with Shionogi was not impacted as a result of this transaction.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 6pt"><div style="display: inline; font-style: italic;">Non-Recourse Notes Payable</div></div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#x201c;PhaRMA Notes&#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&nbsp;per annum, payable annually in arrears on September&nbsp;1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. &nbsp;&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In September&nbsp;2013, Royalty Sub paid $1,844 of interest on the PhaRMA Notes from royalty payments received from RAPIACTA<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">&reg;</div> sales from the preceding four calendar quarters. This payment resulted in an obligation shortfall of approximately $2,356 associated with accrued interest due September&nbsp;3, 2013. As stipulated under the PhaRMA Notes Indenture, if the amount available for payment on any Payment Date is insufficient to pay all of the interest due on a Payment Date, the shortfall in interest will accrue interest at the interest rate applicable to the PhaRMA Notes compounded annually. Accordingly, commencing in September&nbsp;2013, the Company began accruing interest at 14%&nbsp;per annum on the interest shortfall of $2,356. In March, June and August of 2014, Royalty Sub paid additional interest of $446, $1,882 and $70, respectively, bringing the 2013 shortfall down to $222 as of September 30, 2014. Under the terms of the Indenture, Royalty Sub&#x2019;s inability to pay the full amount of interest payable in September&nbsp;2013 by the next succeeding Payment Date for the PhaRMA Notes, which was September&nbsp;1, 2014, constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the December 31, 2014 balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&#x2019;s future results of operations or cash flows. As of December 31, 2015, the PhaRMA Notes remain in default.</div>      <!-- Field: Page; Sequence: 67; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of December&nbsp;31, 2015, the aggregate fair value of the PhaRMA Notes was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Foreign Currency Hedge</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950&nbsp;will be required if, on May&nbsp;18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark to market adjustments in 2015, 2014 and 2013 resulted in a loss of $564 and gains of $5,487 and $5,294 respectively. In addition, a realized currency exchange gain of $1,654 was recognized in 2015 related to the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of December&nbsp;31, 2015 and 2014, no collateral was posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of December 31, 2015, the maximum amount of hedge collateral the Company may be required to post is $9,750.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMonetizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6607795200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Lease Obligations and Other Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"><div style="display: inline; font-weight: bold;">Note&nbsp;4&nbsp;&#x2014; Lease Obligations and Other Contingencies</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company has the following minimum payments under operating lease obligations that existed at December&nbsp;31, 2015:</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 87%; font-size: 10pt; text-align: left">2016</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">651</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">2017</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">871</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">2018</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">870</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">2019</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">820</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">2020</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">651</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left">Thereafter</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,045</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total minimum payments</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,908</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>      <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">The obligations in the preceding table are primarily related to the Company&#x2019;s leases for buildings in Birmingham, Alabama and Durham, North Carolina. The lease for the Company&#x2019;s headquarters in Durham, North Carolina expires June&nbsp;30, 2020. The lease for the existing facility in Birmingham, Alabama currently expires on June&nbsp;30, 2016; however, in 2015, the Company leased an additional approximate 32,000 square feet in Birmingham to house its new research facility. The Company began construction on leasehold improvements for its new research facility in 2015 and this lease obligates the Company for $4,839 of lease payments into 2027. Rent expense for operating leases was $664, $633, and $526 in 2015, 2014, and 2013, respectively.</div>  <div style=" font-size: 10pt; text-indent: 0.25in; margin: 12pt 0 0"><div style="display: inline; font-style: italic;">Lease Financing Obligation</div></div>  <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 12pt 0 0">Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of $1,589, representing the Company&#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company will not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease and or construction in process.</div>        <!-- Field: Page; Sequence: 68; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</div>      <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">At December 31, 2015, the lease financing obligation balance was $2,375 and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease financing obligation are $4,839.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6609271616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"><div style="display: inline; font-weight: bold;">Note&nbsp;5&nbsp;&#x2014; Stockholders&#x2019; Equity</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Sales of Common Stock</div></div></div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company intends to file a post-effective amendment to this registration statement, which will allow for its use by the Company when declared effective by the SEC&#x2019;s staff.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">On November&nbsp;6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows us to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. On June 3, 2014, the Company issued 11,500 shares of common stock for gross proceeds of $115,000 under this $125,000 shelf registration statement. Net proceeds were approximately $107,800 after deducting underwriting discounts and offering expenses. The Company has $10,000 remaining under this shelf registration statement</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In August 2013, the Company completed a public offering of 4,600 shares of its common stock at a price of $4.40 per share, which included the underwriters&#x2019; over-allotment allocation of an additional 600 shares. Net proceeds were approximately $18,500 after deducting underwriting discounts and offering expenses. Shares of common stock in this offering were sold under the $70,000 shelf registration statement declared effective in July 2011.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In June 2011, the Company entered into an At Market Issuance Sales Agreement (the &#x201c;ATM Agreement&#x201d;) with McNicoll, Lewis&nbsp;&amp; Vlak (&#x201c;MLV&#x201d;) pursuant to which the Company was able to sell $70,000 in shares of its common stock at current market prices under a Form S-3 registration statement with MLV acting as the sales agent. During 2012, the Company sold an aggregate of 4,516 shares of common stock at an average per share price of $4.08 pursuant to the ATM Agreement for net proceeds of $17,805. During 2013, the Company sold an aggregate of 2,883 shares of common stock at an average per share price of $1.85 pursuant to the Agreement for net proceeds of $5,218.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6756001680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"><div style="display: inline; font-weight: bold;">Note&nbsp;6&nbsp;&#x2014; Stock-Based Compensation</div></div>  <div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock Incentive Plan</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">As of December&nbsp;31, 2015, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;) and the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), both which were amended and restated in March 2014 and approved by the Company&#x2019;s stockholders in May 2014. Stock-based compensation expense of $9,705 ($9,485 of expense related to the Incentive Plan, $220 of expense related to the ESPP) was recognized during 2015, while $10,177 ($9,963 of expense related to the Incentive Plan, $214 of expense related to the ESPP) was recognized during 2014, and $4,368 ($4,253 of expense related to the Incentive Plan, $115 of expense related to the ESPP) was recognized during 2013.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">The Company accounts for stock-based compensation in accordance with FASB authoritative guidance regarding share-based payments. Total stock-based compensation was allocated as follows:</div>  <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 55%; font-size: 10pt; text-align: left">Research and development</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">7,580</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">8,906</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">3,664</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,125</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,271</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">704</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total stock-based compensation expense</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,705</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,177</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,368</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>      <!-- Field: Page; Sequence: 69; Value: 3 -->      <!-- Field: /Page -->          <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant. Commencing March&nbsp;1, 2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of December 31, 2015, 75% of the August 2013 grants have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which vesting occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014, and (3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of December&nbsp;31, 2015, 25% of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5 to 10&nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.<div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Related activity under the Incentive Plan is as follows:</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Awards<br /> Available</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options<br /> Outstanding</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br /> Average<br /> Exercise<br /> Price</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 55%; font-size: 10pt">Balance at December&nbsp;31, 2012</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 12%; font-size: 10pt; text-align: right">2,815</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 12%; font-size: 10pt; text-align: right">8,073</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">6.09</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards granted</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(310</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards cancelled</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">53</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(3,277</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">3,277</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">3.05</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(563</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2.37</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock option awards cancelled</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,801</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,801</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">7.22</td>      <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">Balance at December&nbsp;31, 2013</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,082</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">8,986</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">4.99</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Plan amendment</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">3,750</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards granted</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(593</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards cancelled</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(1,965</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,965</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">10.99</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(1,258</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">4.78</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock option awards cancelled</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">88</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(88</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">8.83</td>      <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">Balance at December&nbsp;31, 2014</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2,362</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">9,605</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">6.21</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards granted</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(163</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards cancelled</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(2,217</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2,217</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">11.52</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(1,118</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">4.36</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock option awards cancelled</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">33</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(33</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">9.87</td>      <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance at December&nbsp;31, 2015</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">16</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,671</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td>      <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">7.50</td>      <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>    <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">For stock option awards granted under the Incentive Plan during 2015, 2014 and 2013, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during 2015, 2014 and 2013 was $7.72, $8.02, and $1.28, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following explanations describe the assumptions used by the Company to value the stock option awards granted during 2015, 2014, and 2013. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the volatility over the most recent period corresponding with the expected life. The Company has assumed no expected dividend yield, as dividends have never been paid to stockholders and will not be for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining term equal to the expected term.</div>      <!-- Field: Page; Sequence: 70; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"><div style="display: inline; font-weight: bold;">Weighted Average Assumptions for Stock Option Awards Granted under the Incentive Plan</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 55%; font-size: 10pt; text-align: left">Expected Life</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 12%; font-size: 10pt; text-align: right">5.5</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 12%; font-size: 10pt; text-align: right">5.5</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 12%; font-size: 10pt; text-align: right">4.7</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Expected Volatility</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">81</td>      <td style="font-size: 10pt; text-align: left">%</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">87</td>      <td style="font-size: 10pt; text-align: left">%</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">84</td>      <td style="font-size: 10pt; text-align: left">%</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">0.0</td>      <td style="font-size: 10pt; text-align: left">%</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">0.0</td>      <td style="font-size: 10pt; text-align: left">%</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">0.0</td>      <td style="font-size: 10pt; text-align: left">%</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1.6</td>      <td style="font-size: 10pt; text-align: left">%</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1.6</td>      <td style="font-size: 10pt; text-align: left">%</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">0.7</td>      <td style="font-size: 10pt; text-align: left">%</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The total intrinsic value of stock option awards exercised under the Incentive Plan was $10,117 during 2015, $8,522 during 2014, $738 and during 2013. The intrinsic value represents the total proceeds (fair market value at the date of exercise, less the exercise price, times the number of stock option awards exercised) received by all individuals who exercised stock option awards during the period.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The following table summarizes, at December&nbsp;31, 2015, by price range: (1)&nbsp;for stock option awards outstanding under the Incentive Plan, the number of stock option awards outstanding, their weighted average remaining life and their weighted average exercise price; and (2)&nbsp;for stock option awards exercisable under the Plan, the number of stock option awards exercisable and their weighted average exercise price:</div>    <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>        <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td>      <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td colspan="9" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Outstanding</div></td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Exercisable</div></td>     </tr>     <tr style="vertical-align: bottom">      <td colspan="2"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; text-decoration: underline;">Range</div></div></div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Number</div></td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Weighted <br /> Average <br /> Remaining <br /> Life</div></td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Weighted <br /> Average <br /> Exercise <br /> Price</div></td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Number</div></td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Weighted <br /> Average <br /> Exercise <br /> Price</div></td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 1%"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">$</div></div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"><div style="display: inline; font-size: 10pt">0</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 3%"><div style="display: inline; font-size: 10pt">to</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"><div style="display: inline; font-size: 10pt">3</div></td>      <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1,826</div></td>      <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">6.4</div></td>      <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td>      <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1.51</div></td>      <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1,322</div></td>      <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td>      <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1.55</div></td>      <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">3</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">to</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">6</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">2,792</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">6.1</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">4.63</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">2,329</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">4.53</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">6</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">to</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">9</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1,153</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">4.5</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">7.10</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1,070</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">7.13</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">9</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">to</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">12</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">3,728</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">8.1</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">11.07</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">714</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">11.45</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">12</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">to</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">15</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1,077</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">6.4</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">12.44</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">374</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">12.65</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">15</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">to</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">18</div></td>      <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right; padding-bottom: 1.1pt; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 10pt">95</div></td>      <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">9.5</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">15.39</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">&#x2014;</div></td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">&#x2014;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">$</div></div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">0</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">to</div></td>      <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">18</div></td>      <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right; padding-bottom: 2.25pt; border-bottom: Black 2.25pt double"><div style="display: inline; font-size: 10pt">10,671</div></td>      <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">6.7</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">7.50</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">5,809</div></td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td>      <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">5.70</div></td>      <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td>     </tr>       </table>  </div>    <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The weighted average remaining contractual life of stock option awards exercisable under the Incentive Plan at December&nbsp;31, 2015 was 5.0 years.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The aggregate intrinsic value of stock option awards outstanding and exercisable under the Incentive Plan at December&nbsp;31, 2015 was $28,511. The aggregate intrinsic value represents the value (the period&#x2019;s closing market price, less the exercise price, times the number of in-the-money stock option awards) that would have been received by all stock option award holders under the Incentive Plan had they exercised their stock option awards at the end of the year.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The total fair value of the stock option awards vested under the Incentive Plan was $4,492 during 2015, $2,844 during 2014, and $3,483 during 2013.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of December&nbsp;31, 2015, the number of stock option awards vested and expected to vest under the Incentive Plan is 9,633. The weighted average exercise price of these stock option awards is $7.51 and their weighted average remaining contractual life is 6.6&nbsp;years.</div>      <!-- Field: Page; Sequence: 71; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following table summarizes the changes in the number and weighted-average grant-date fair value of non-vested stock option awards during 2015:</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-Vested<br /> Stock Option<br /> Awards</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<br /> Grant-Date Fair<br /> Value</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 67%; font-size: 10pt">Balance December&nbsp;31, 2014</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 13%; font-size: 10pt; text-align: right">4,385</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 2%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 13%; font-size: 10pt; text-align: right">4.27</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Stock option awards granted</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2,217</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">7.72</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Stock option awards vested</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(1,711</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2.63</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Stock option awards forfeited</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(28</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6.39</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance December&nbsp;31, 2015</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,863</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6.40</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">As of December&nbsp;31, 2015, there was approximately $18,607 of total unrecognized compensation cost related to non-vested employee stock option awards and restricted stock units granted by the Company. That cost is expected to be recognized as follows: $7,023 in 2016, $6,010 in 2017, $3,891 in 2018, and $1,683 in 2019.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Employee Stock Purchase Plan</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company has reserved a total of 1,475&nbsp;shares of common stock to be purchased under the ESPP, of which 497&nbsp;shares remain available for purchase at December&nbsp;31, 2015. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">There were 41, 49 and 89 shares of common stock purchased under the ESPP in 2015, 2014, and 2013, respectively, at a weighted average price per share of $8.65, $6.29, and $1.39, respectively. Expense of $220, $214, and $115, related to the ESPP was recognized during 2015, 2014, and 2013, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option were determined using a Black-Scholes option pricing model. The weighted average grant date fair values of shares granted under the ESPP during 2015, 2014, and 2013, were $4.93, $4.41, and $1.27, respectively.&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777008032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note&nbsp;7&nbsp;&#x2014; Income Taxes</div></div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company has incurred net losses since inception and, consequently, has not recorded any U.S.&nbsp;Federal and state income tax expense or benefit. The differences between the Company&#x2019;s effective tax rate and the statutory tax rate in 2015, 2014, and 2013 are as follows:</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 61%; font-size: 10pt; text-align: left">Income tax benefit at federal statutory rate (35%)</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">(15,057</td>      <td style="width: 1%; font-size: 10pt; text-align: left">)</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">(15,816</td>      <td style="width: 1%; font-size: 10pt; text-align: left">)</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">(10,538</td>      <td style="width: 1%; font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">State and local income taxes net of federal tax benefit</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(819</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(1,286</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(839</td>      <td style="font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Permanent items</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">560</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">258</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">738</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Rate change</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,012</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">22</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,892</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Expiration of attribute carryforwards</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">330</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">373</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">242</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Research and development tax credits</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(10,454</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(748</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(1,206</td>      <td style="font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Orphan drug credit</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">4,307</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">Other</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(218</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(115</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,144</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,339</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,312</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,567</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Income tax expense</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company recognizes the impact of a tax position in its financial statements if it is more likely than not that the position will be sustained on audit based on the technical merits of the position. The Company has concluded that it has an uncertain tax position pertaining to its research and development and orphan drug credit carryforwards. The Company has established these credits based on information and calculations it believes are appropriate and the best estimate of the underlying credit. Any changes to the Company&#x2019;s unrecognized tax benefits are offset by an adjustment to the valuation allowance and there would be no impact on the Company&#x2019;s financial statements. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months.</div>      <!-- Field: Page; Sequence: 72; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 70%; font-size: 10pt">Balance at January&nbsp;1,</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">472</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">284</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Additions to current period tax positions</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2,616</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">176</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Additions to prior period tax positions</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">12</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Reductions to prior period tax provisions</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance at December&nbsp;31,</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,085</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">472</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><div style="display: inline; background-color: white">The Company&#x2019;s ability to utilize the net operating loss and tax credit carryforwards in the future may be subject to substantial restrictions in the event of past or future ownership changes as defined in Section&nbsp;382 of the Internal Revenue Code of 1986, as amended and similar state tax law.</div></div>    <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows:</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Deferred tax assets:</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 10pt">Net federal and state operating losses</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">142,836</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">135,922</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Research and development credits</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">48,551</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">38,096</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Fixed assets</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,054</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,073</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Deferred revenue</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">4,240</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">3,798</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock-based compensation</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">8,605</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">7,086</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">Other</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,590</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,178</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Total deferred tax assets</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">207,876</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">187,153</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Deferred tax liabilities:</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Foreign currency derivative</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,668</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,285</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,668</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,285</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(205,208</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(184,868</td>      <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net deferred tax assets</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The majority of the Company&#x2019;s deferred tax assets relate to net operating loss and research and development carryforwards that can only be realized if the Company is profitable in future periods. It is uncertain whether the Company will realize any tax benefit related to these carryforwards. Accordingly, the Company has provided a full valuation allowance against the net deferred tax assets due to uncertainties as to their ultimate realization. The valuation allowance will remain at the full amount of the deferred tax assets until it is more likely than not that the related tax benefits will be realized. The Company&#x2019;s valuation allowance increased by $20,339 in 2015, $17,312 in 2014, and $8,567 in 2013.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of December&nbsp;31, 2015, the Company had federal operating loss carryforwards of $386,219, state operating loss carryforwards of $373,454, and research and development and orphan drug credit carryforwards of $48,551, which will expire at various dates from 2016 through 2035. The federal losses begin to expire in 2018, the state losses begin to expire in 2016 and the research and development contracts begin to expire in 2018.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company&#x2019;s federal and state operating loss carryforwards include $15,655 of excess tax benefits related to a deduction from the exercise of stock options. The tax benefit of these deductions has not been recognized in deferred tax assets. If utilized, the benefits from these deductions will be recorded as adjustments to additional paid-in capital.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Tax years 2012-2014 remain open to examination by the major taxing jurisdictions to which the Company is subject. Additionally, years prior to 2012 are also open to examination to the extent of loss and credit carryforwards from those years. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as components of its income tax provision. However, there were no provisions or accruals for interest and penalties in 2015, 2014, and 2013.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6772125584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Employee 401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefits Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"><div style="display: inline; font-weight: bold;">Note&nbsp;8&nbsp;&#x2014; Employee 401(k) Plan</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In January 1991, the Company adopted an employee retirement plan (&#x201c;401(k) Plan&#x201d;) under Section&nbsp;401(k) of the Internal Revenue Code covering all employees. Employee contributions may be made to the 401(k) Plan up to limits established by the Internal Revenue Service. Company matching contributions may be made at the discretion of the Board of Directors. The Company made matching contributions of $366, $361, and $313, in 2015, 2014, and 2013, respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49170332&amp;loc=SL14450702-114947<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e2410-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6414199&amp;loc=d3e39622-114963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6771701600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Collaborative and Other Research and Development Contracts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"><div style="display: inline; font-weight: bold;">Note&nbsp;9&nbsp;&#x2014; Collaborative and Other Research and Development Contracts</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">U.S.&nbsp;Department of Health and Human Services (&#x201c;BARDA/HHS&#x201d;). </div>In January 2007, the U.S.&nbsp;Department of Health and Human Services (&#x201c;BARDA/HHS&#x201d;) awarded the Company a $102,661, four-year contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir program and to increase funding by $77,191. On February&nbsp;24, 2011, the Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to $234,852 and provided funding to support the filing of a NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired on June 30, 2014.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">On March 31, 2015, the Company announced that the Biomedical Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This BARDA/HHS contract includes a base contract of $13,314 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $36,169. As of September 30, 2015, a total of $16,300 has been awarded under exercised options within this contract.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;).</div> In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this contract as of December 31, 2015 could be up to $34,002, if all contract options are exercised by NIAID/HHS, over a five year period. The goals of this contract, including amendments, are to file IND applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human clinical trial. As of December 31, 2015, a total of $29,875 has been awarded under exercised options within this contract. BCX4430 is the lead compound in the Company&#x2019;s BSAV research program.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Seqirus UK Limited (&#x201c;SUL&#x201d;).</div> On June 16, 2015, the Company and Seqirus UK Limited (&quot;SUL&quot;), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &quot;SUL Agreement&quot;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &quot;Territory&quot;). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the U.S. Food and Drug Administration in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion.</div>      <!-- Field: Page; Sequence: 74; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In December 2013, the Company submitted a New Drug Application (&quot;NDA&quot;) for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency (&quot;EMA&quot;) until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company received an upfront payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement (the &quot;Royalty Term&quot;). The Company developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;).</div> In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Green Cross Corporation (&#x201c;Green Cross&#x201d;).</div> In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;).</div> In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#x201c;PNP&#x201d;) inhibitor, for use in oncology (the &#x201c;Original Agreement&#x201d;). Under the terms of the Original Agreement, Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a $10,000 up-front payment.</div>      <!-- Field: Page; Sequence: 75; Value: 3 -->      <!-- Field: /Page -->        <div style=" font-size: 10pt; text-align: center; margin: 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company deferred revenue recognition of the $10,000 up-front payment that was received from Mundipharma in February&nbsp;2006 because the Company was involved in the continued development of forodesine. Amortization of this revenue commenced in February&nbsp;2006 and was initially scheduled to end in October&nbsp;2017, which is the date of expiration for the last-to-expire patent covered by the agreement. The Company also deferred revenue recognition of a $5,000 payment received from Mundipharma in connection with the initiation of a clinical trial in 2007. Amortization of this deferred revenue commenced in 2007 and was initially scheduled to end in October&nbsp;2017. Under its agreement with AECOM/IRL, the Company paid sublicense payments related to these upfront cash payments received from Mundipharma. Expense recognition of these sublicense payments was deferred and recognized under the same term as the related deferred revenue.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">On November&nbsp;11, 2011, the Company entered into the Amended and Restated License and Development Agreement (the &#x201c;Amended and Restated Agreement&#x201d;) with Mundipharma, amending and restating the Original Agreement. Under the terms of the Amended and Restated Agreement, Mundipharma obtained worldwide rights to forodesine. Commencing on November&nbsp;11, 2011, Mundipharma controls the development and commercialization of forodesine and assumes all future development and commercialization costs. The Amended and Restated Agreement provides for the possibility of future event payments totaling $15,000 for achieving specified regulatory events for certain indications and tiered royalties ranging from mid to high single-digit percentages of net product sales in each country where forodesine is sold by Mundipharma. These royalties are subject to downward adjustments based on the then-existing patent coverage and/or the availability of generic compounds in each country.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>    <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Amended and Restated Agreement is a multiple element arrangement for accounting purposes, in which the Company is required to deliver to Mundipharma both the worldwide rights to forodesine in the field of oncology and the transfer of product data and know-how to permit Mundipharma to develop and commercialize forodesine (the &#x201c;Knowledge Transfer&#x201d;). The Company accounted for these elements as a combined unit of accounting as they do not have stand-alone value to Mundipharma. The worldwide license rights were granted to Mundipharma on November&nbsp;11, 2011 and the Knowledge Transfer was completed during the first quarter of 2012.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#x201c;AECOM&#x201d; and &#x201c;IRL&#x201d; respectively).</div> In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &#x201c;Licensors&#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000&nbsp;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach by the Licensors.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments the Company may receive in the future under its license agreement dated February&nbsp;1, 2006 with Mundipharma and (ii)&nbsp;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In consideration for these modifications in 2010, the Company issued to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally, at the Company&#x2019;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination of cash and shares.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On June&nbsp;19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.&nbsp;</div>      <!-- Field: Page; Sequence: 76; Value: 3 -->      <!-- Field: /Page -->          <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company&#x2019;s common stock, or in a combination of cash and shares.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#x201c;VUW&#x201d;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">The University of Alabama at Birmingham (&#x201c;UAB&#x201d;).</div> The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months&#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6756001680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"><div style="display: inline; font-weight: bold;">Note&nbsp;10&nbsp;&#x2014; Quarterly Financial Information (Unaudited)</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt; text-align: center">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">First</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Second</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Third</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fourth</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; font-weight: bold">2015 Quarters</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="width: 48%; font-size: 10pt; padding-left: 10pt">Revenues</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">6,826</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">25,842</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">10,987</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">4,602</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Net (Loss) Income</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(15,164</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">4,901</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(14,621</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(18,135</td>      <td style="font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Basic net (loss) income per share</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(0.21</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">0.07</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(0.20</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(0.25</td>      <td style="font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Diluted net (loss) income per share</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(0.21</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">0.06</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(0.20</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(0.25</td>      <td style="font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; font-weight: bold">2014 Quarters</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; padding-left: 10pt">Revenues</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">3,458</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">1,466</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">3,238</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">5,446</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Net Loss</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(10,137</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(14,649</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(8,731</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(11,672</td>      <td style="font-size: 10pt; text-align: left">)</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Basic and diluted net loss per share</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(0.17</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(0.23</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(0.12</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(0.16</td>      <td style="font-size: 10pt; text-align: left">)</td>     </tr>       </table>  </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e765-108305<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e725-108305<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section G<br> -Subsection 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 302<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6615140592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 0pt"><div style="display: inline; font-weight: bold;">Note&nbsp;11&nbsp;&#x2014; Recent Accounting Pronouncements</div>&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">In November 2015, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2015-17, <div style="display: inline; font-style: italic;">Balance Sheet Classification of Deferred Taxes</div>, requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as noncurrent on the balance sheet. The classification change for all deferred taxes as noncurrent simplifies entities&#x2019; processes as it eliminates the need to separately identify the net current and net noncurrent deferred tax asset or liability in each jurisdiction and allocate valuation allowances. We elected to prospectively adopt the accounting standard in the beginning of our fourth quarter of fiscal 2015. Adoption of this standard had no impact on the Company&#x2019;s consolidated financial statements.</div>  <div style=" font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In April 2015, the FASB issued ASU No.2015-03, <div style="display: inline; font-style: italic;">Simplifying the Presentation of Debt Issuance Costs</div>. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect this standard will have a material impact on its consolidated financial statements.&nbsp;</div>      <!-- Field: Page; Sequence: 77; Value: 3 -->      <!-- Field: /Page -->      <div style=" font-size: 10pt; text-align: center; margin: 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In August 2014, the FASB issued ASU No. 2014-15 &#x2013; <div style="display: inline; font-style: italic;">Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern,</div> which defines management&#x2019;s responsibility to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management must assess if there is substantial doubt about the company&#x2019;s ability to continue as a going concern within one year after the issuance date.&nbsp; Disclosures are required if conditions give rise to substantial doubt.&nbsp;This standard is effective for all companies in the first annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact this standard will have on its financial statements and disclosures.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">In May 2014, the FASB issued ASU 2014-09 &#x2013; <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers</div>, which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=6507316<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Direct Effects of a Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=6510796<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=56949863&amp;loc=d3e22583-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Indirect Effects of a Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=6515603<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=56949863&amp;loc=d3e22580-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Accounting Change<br> -URI http://asc.fasb.org/extlink&amp;oid=6503790<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56949863&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Retrospective Application<br> -URI http://asc.fasb.org/extlink&amp;oid=6523989<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e765-108305<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774430352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DescriptionOfCompanyPolicyTextBlock', window );">Description of Company [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash, restricted cash and investments of $100,858, to continue its planned operations through mid-2017. The Company&#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017 it will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources; (4)&nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on one or more research and development programs; and/or (6)&nbsp;restructure operations. The Company may issue securities through private placement transactions or registered public offerings pursuant to a registration statement filed with the SEC.&nbsp;&nbsp;Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on November&nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Beginning in March 2011, the consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;). Royalty Sub was formed in connection with a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 3, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). Such consolidated financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Long term deferred rent as of December 31, 2014 has been reclassified to conform to the 2015 presentation.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Restricted cash as of December 31, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $59 in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note 3) and $1,403 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.<div style="display: inline; font-weight: bold;">&nbsp;</div></div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At December 31, 2015, the Company believes that the costs of its investments are recoverable in all material respects.</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair value of the Company&#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">26,557</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">88</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(99</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">26,546</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,820</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">184</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(41</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,963</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,884</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(72</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,838</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,261</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">293</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(212</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">20,307</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">22</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(23</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">20,306</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">27,152</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">151</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(47</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">27,261</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Commercial paper</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,838</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(63</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,781</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,297</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">179</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(133</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#x2019;s investments at December&nbsp;31, 2015 and 2014.</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">22,664</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">18,232</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">28,395</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">25,459</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,288</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">15,657</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivable from Collaborations</div></div></div><div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At December&nbsp;31, 2015 and 2014, the Company had the following receivables.</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">210</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">238</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">679</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,564</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,243</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; width: 52%">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">2,778</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">2,778</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,778</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,849</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Product Sales</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Inventory</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">At December&nbsp;31, 2015 and 2014, the Company&#x2019;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">During 2014, in connection with the FDA approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company&#x2019;s inventory consisted of the following:</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"><div style=" margin: 0">Work in process</div> </td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">1,612</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">267</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished goods</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">416</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net inventories</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,612</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">683</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the remaining lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period of ten years equal to the term of the related lease</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&nbsp;</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patents and Licenses</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"> <tr> <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</div></td> </tr> <tr> <td style="padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td> </tr> </table><table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"> <tr> <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</div></td> </tr> <tr> <td style="padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td> </tr> </table><table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"> <tr> <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and</div></td> </tr> <tr> <td style="padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td> </tr> </table><table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"> <tr> <td style="width: 5%; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; width: 2%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</td> <td style="vertical-align: top; width: 92%; padding-right: 0.8pt"><div style="display: inline; font-size: 10pt">professional fees.</div></td> </tr> </table><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</div><div style=" font-size: 10pt; text-align: center; margin: 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div><div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">Accrued expenses were comprised of the following:</div><div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt; text-align: left">Compensation and benefits</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">424</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">2,105</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Development costs</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">10,398</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,232</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Inventory</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">549</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">397</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Professional fees</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">242</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">238</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Duties and taxes</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">102</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">75</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,522</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,282</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Total accrued expenses</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">16,237</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,329</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">As of December 31, 2015 and 2014, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accumulated Other Comprehensive Loss</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During 2015, realized gains of $13 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded during 2014.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#x2019;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &#x201c;stand-alone value&#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&#x201c;TPE&#x201d;) and (iii) best estimate of selling price (&#x201c;BESP&#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&nbsp;</div><div style=" font-size: 10pt; text-align: center; margin: 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, the Company entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting Seqirus UK Limited (&#x201c;SUL&#x201d;) and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&#x201c;EU&#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&#x201c;Health Canada&#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Product Sales</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be primarily responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales, and the Company&#x2019;s commercial sales will be minimal.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-style: italic;">&nbsp;</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-style: italic;">Rebates and Chargebacks</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#x2019;s selling price.&nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Discounts and Sales Incentives</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#x201c;IMA&#x201d;) Fees. Per contractual agreements with the Company&#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Product Returns</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the years ended December&nbsp;31:</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">Product sales, net</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">6,291</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">33</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,386</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,025</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,562</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">16,337</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">9,366</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">13,585</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">132</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Shionogi (Japan)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,184</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,184</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,184</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,927</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,580</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,550</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,769</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">48,257</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">13,608</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">17,331</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Advertising</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred. Advertising and product promotion expenses were $103 and $290 for the years ended December&nbsp;31, 2015 and 2014, respectively.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Expenses</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; has occurred.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock', window );">Interest Expense and Deferred Financing Costs [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Interest expense for the years ended December&nbsp;31, 2015, 2014 and 2013 was $5,200, $4,998 and $4,778, respectively, and relates to the issuance of the PhaRMA Notes. Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other non-current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $439 for each of the years ended December&nbsp;31, 2015, 2014 and 2013.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock', window );">Currency Hedge Agreement [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the years ended December&nbsp;31, 2015, 2014 and 2013 resulted in a loss of $564 and gains of $5,487 and $5,294, respectively. Mark to market adjustments are determined by a third party pricing model which uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. In addition, a realized currency exchange gain of $1,654 was recognized in 2015 related to the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of December 31, 2015 and December&nbsp;31, 2014, no hedge collateral was posted under the agreement.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the years ended December&nbsp;31, 2015, 2014, and 2013 does not include 3,524, 3,991 and 1,430 respectively, of potential common shares as their impact would be anti-dilutive.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&nbsp;</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock', window );">Concentration of Market Risk [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Significant Customers and Other Risks</div><div style="display: inline; font-style: italic;">&nbsp;</div></div><div style=" font-size: 10pt; text-indent: 13.5pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Significant Customers</div></div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Prior to the SUL Agreement, the Company relied primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company&#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Risks from Third Party Manufacturing and Distribution Concentration</div> &nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB.</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Credit Risk</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued expenses policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents concentration of market risk policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ConcentrationOfMarketRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents currency hedge agreement policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CurrencyHedgeAgreementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DescriptionOfCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of company policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DescriptionOfCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest expense and deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph k<br> -Article 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02, 03<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 206<br> -Paragraph b<br> -Subparagraph i, ii<br> -Chapter 2<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section M<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e4975-111524<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3-5<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6616140352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale Securities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">26,557</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">88</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(99</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">26,546</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,820</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">184</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(41</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,963</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,884</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(72</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,838</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,261</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">293</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(212</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">20,307</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">22</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(23</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">20,306</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">27,152</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">151</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(47</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">27,261</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Commercial paper</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,838</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(63</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,781</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,297</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">179</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(133</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock', window );">Available For Sale Securities Debt Maturities Fair Value [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">22,664</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">18,232</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">28,395</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">25,459</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,288</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">15,657</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock', window );">Schedule of Receivables from Collaborations [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">210</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">238</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">679</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,564</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,243</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; width: 52%">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">2,778</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">2,778</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,778</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,849</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"><div style=" margin: 0">Work in process</div> </td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">1,612</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">267</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished goods</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">416</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net inventories</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,612</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">683</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt; text-align: left">Compensation and benefits</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">424</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">2,105</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Development costs</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">10,398</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,232</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Inventory</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">549</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">397</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Professional fees</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">242</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">238</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Duties and taxes</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">102</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">75</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,522</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,282</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Total accrued expenses</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">16,237</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,329</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock', window );">Schedule of Revenues from Collaborations [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">Product sales, net</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">6,291</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">33</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,386</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,025</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,562</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">16,337</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">9,366</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">13,585</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">132</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Shionogi (Japan)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,184</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,184</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,184</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,927</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,580</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,550</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,769</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">48,257</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">13,608</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">17,331</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available for sale securities debt maturities fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure representing receivables from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of schedule of revenues from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 2<br> -Paragraph 6<br> -Subparagraph a,b,c<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6766512112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Furniture and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt; text-align: left">Furniture and fixtures</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">718</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">542</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Office equipment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,122</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,115</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Software</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,427</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,423</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Laboratory equipment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">6,004</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5,786</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Leased equipment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">63</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">63</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Leasehold improvements</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5,610</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5,303</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Construction in progress</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,821</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt">Building</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,589</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">19,354</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">14,232</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation and amortization</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(14,205</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(14,025</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Property and equipment, net</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,149</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">207</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777540816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Lease Obligations and Other Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; font-size: 10pt; text-align: left">2016</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">651</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2017</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">871</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2018</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">870</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2019</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">820</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2020</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">651</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left">Thereafter</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,045</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total minimum payments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,908</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6768435376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt; text-align: left">Research and development</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">7,580</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">8,906</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">3,664</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,125</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,271</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">704</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total stock-based compensation expense</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,705</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,177</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,368</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Share-based Compensation, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Awards<br /> Available</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options<br /> Outstanding</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br /> Average<br /> Exercise<br /> Price</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt">Balance at December&nbsp;31, 2012</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right">2,815</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right">8,073</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">6.09</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(310</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">53</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(3,277</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,277</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3.05</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(563</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2.37</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,801</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,801</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">7.22</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Balance at December&nbsp;31, 2013</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,082</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">8,986</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4.99</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Plan amendment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,750</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(593</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(1,965</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,965</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">10.99</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(1,258</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4.78</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">88</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(88</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">8.83</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Balance at December&nbsp;31, 2014</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,362</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">9,605</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">6.21</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(163</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(2,217</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,217</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">11.52</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(1,118</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4.36</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">33</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(33</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">9.87</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance at December&nbsp;31, 2015</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">16</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,671</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">7.50</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt; text-align: left">Expected Life</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right">5.5</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right">5.5</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right">4.7</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected Volatility</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">81</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">87</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">84</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.0</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.0</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.0</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1.6</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1.6</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.7</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="9" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Outstanding</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Exercisable</div></td> </tr> <tr style="vertical-align: bottom"> <td colspan="2"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; text-decoration: underline;">Range</div></div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Number</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Weighted <br /> Average <br /> Remaining <br /> Life</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Weighted <br /> Average <br /> Exercise <br /> Price</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; border-bottom: Black 1.1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Number</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt; text-align: center"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"><div style="display: inline; font-size: 10pt">Weighted <br /> Average <br /> Exercise <br /> Price</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">$</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"><div style="display: inline; font-size: 10pt">0</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 3%"><div style="display: inline; font-size: 10pt">to</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; width: 5%"><div style="display: inline; font-size: 10pt">3</div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1,826</div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">6.4</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1.51</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1,322</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 2%; font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1.55</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">3</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">to</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">6</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">2,792</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">6.1</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">4.63</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">2,329</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">4.53</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">6</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">to</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">9</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1,153</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">4.5</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">7.10</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1,070</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">7.13</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">9</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">to</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">12</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">3,728</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">8.1</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">11.07</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">714</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">11.45</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">12</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">to</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">15</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">1,077</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">6.4</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">12.44</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">374</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">12.65</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">15</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">to</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">18</div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right; padding-bottom: 1.1pt; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 10pt">95</div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">9.5</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">15.39</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">&#x2014;</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 1.1pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">$</div></div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">0</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">to</div></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">18</div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right; padding-bottom: 2.25pt; border-bottom: Black 2.25pt double"><div style="display: inline; font-size: 10pt">10,671</div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">6.7</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">7.50</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">5,809</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; padding-bottom: 2.25pt"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">$</div></td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-size: 10pt">5.70</div></td> <td style="font-size: 10pt; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-Vested<br /> Stock Option<br /> Awards</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<br /> Grant-Date Fair<br /> Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; font-size: 10pt">Balance December&nbsp;31, 2014</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 13%; font-size: 10pt; text-align: right">4,385</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 13%; font-size: 10pt; text-align: right">4.27</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,217</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">7.72</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Stock option awards vested</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(1,711</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2.63</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Stock option awards forfeited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(28</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6.39</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance December&nbsp;31, 2015</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,863</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6.40</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number of fully vested share options (or share units) and share options expected to vest at the date of the latest statement of financial position, weighted-average exercise price (or conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term for both options (or share units) currently outstanding and options (or share units) exercisable (or convertible).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6749332720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">Income tax benefit at federal statutory rate (35%)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(15,057</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(15,816</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(10,538</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">State and local income taxes net of federal tax benefit</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(819</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(1,286</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(839</td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Permanent items</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">560</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">258</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">738</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Rate change</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,012</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">22</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,892</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Expiration of attribute carryforwards</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">330</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">373</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">242</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Research and development tax credits</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(10,454</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(748</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(1,206</td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Orphan drug credit</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,307</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Other</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(218</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(115</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,144</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,339</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,312</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,567</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Income tax expense</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt">Balance at January&nbsp;1,</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">472</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">284</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Additions to current period tax positions</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,616</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">176</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Additions to prior period tax positions</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">12</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Reductions to prior period tax provisions</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance at December&nbsp;31,</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,085</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">472</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deferred tax assets:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 10pt">Net federal and state operating losses</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">142,836</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">135,922</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Research and development credits</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">48,551</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">38,096</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Fixed assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,054</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,073</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Deferred revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,240</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,798</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock-based compensation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">8,605</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">7,086</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,590</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,178</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Total deferred tax assets</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">207,876</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">187,153</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Deferred tax liabilities:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Foreign currency derivative</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,668</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,285</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,668</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,285</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(205,208</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(184,868</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net deferred tax assets</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=51663037&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6772041856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Information [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">First</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Second</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Third</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fourth</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold">2015 Quarters</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-size: 10pt; padding-left: 10pt">Revenues</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">6,826</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">25,842</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">10,987</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">4,602</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Net (Loss) Income</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(15,164</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,901</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(14,621</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(18,135</td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Basic net (loss) income per share</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(0.21</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.07</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(0.20</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(0.25</td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Diluted net (loss) income per share</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(0.21</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.06</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(0.20</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(0.25</td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold">2014 Quarters</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-left: 10pt">Revenues</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">3,458</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">1,466</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">3,238</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">5,446</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Net Loss</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(10,137</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(14,649</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(8,731</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(11,672</td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Basic and diluted net loss per share</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(0.17</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(0.23</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(0.12</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(0.16</td> <td style="font-size: 10pt; text-align: left">)</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6852912304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 06, 2013</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Mar. 09, 2011</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember', window );">Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,654,000<span></span>
</td>
<td class="nump">5,487,000<span></span>
</td>
<td class="nump">$ 5,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityOfInvestments', window );">Maturity of Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities', window );">Maturity Period of High Quality Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities', window );">Average Maturity Period of High Quality Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AveragematurityForPortfolioInvestments', window );">Average Maturity for Portfolio Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LongtermInvestmentMaturityMinimum', window );">Long-term Investment Maturity, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember', window );">Royalty Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember', window );">Collateral for Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember', window );">Laboratory Equipment, Office Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVABMember | Contingent upon EU Marketing Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVABMember | Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVABMember | Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,223,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVABMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,777,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember', window );">RAPIVABMember | Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="nump">4,998,000<span></span>
</td>
<td class="nump">4,778,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Investments and Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,858,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SecuritiesOffered', window );">Securities Offered</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,612,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,257,000<span></span>
</td>
<td class="nump">13,608,000<span></span>
</td>
<td class="nump">17,331,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,000<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="nump">$ 4,998,000<span></span>
</td>
<td class="nump">$ 4,778,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,524<span></span>
</td>
<td class="nump">3,991<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AveragematurityForPortfolioInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity for portfolio investments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AveragematurityForPortfolioInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LongtermInvestmentMaturityMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents long term investment maturity minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LongtermInvestmentMaturityMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maturity of investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityperiodOfShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of short term investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityperiodOfShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition royalty and milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SecuritiesOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents securities offered for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SecuritiesOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 8<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=bcrx_ContingentUponEuMarketingApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=bcrx_ContingentUponEuMarketingApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774359360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Fair Value of the Company's Investments by Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 26,557<span></span>
</td>
<td class="nump">$ 20,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (99)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">26,546<span></span>
</td>
<td class="nump">20,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">21,820<span></span>
</td>
<td class="nump">27,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">21,963<span></span>
</td>
<td class="nump">27,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">21,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">21,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">70,261<span></span>
</td>
<td class="nump">59,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 70,347<span></span>
</td>
<td class="nump">$ 59,348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents available for sale securities accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6746483024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Scheduled Maturity for the Company's Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 22,664<span></span>
</td>
<td class="nump">$ 18,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">Maturing after one year through two years</a></td>
<td class="nump">28,395<span></span>
</td>
<td class="nump">25,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears', window );">Maturing after two years</a></td>
<td class="nump">19,288<span></span>
</td>
<td class="nump">15,657<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total investments</a></td>
<td class="nump">$ 70,347<span></span>
</td>
<td class="nump">$ 59,348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents available for sale securities debt maturities after one through two years fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents debt maturities after two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6773891056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Summary of Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 5,536<span></span>
</td>
<td class="nump">$ 2,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">5,536<span></span>
</td>
<td class="nump">2,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 469<span></span>
</td>
<td class="nump">$ 1,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 469<span></span>
</td>
<td class="nump">$ 1,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_CSLLimitedMember', window );">CSL Limited [Member | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_CSLLimitedMember', window );">CSL Limited [Member | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_CSLLimitedMember', window );">CSL Limited [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">5,564<span></span>
</td>
<td class="nump">2,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 6,243<span></span>
</td>
<td class="nump">$ 3,849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_CSLLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_CSLLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6748046496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">$ 1,612,000<span></span>
</td>
<td class="nump">$ 267,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">416,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Net inventories</a></td>
<td class="nump">$ 1,612,000<span></span>
</td>
<td class="nump">$ 683,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section BB<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section BB<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6752940720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bcrx_DevelopmentCostMember', window );">Development Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedDevelopmentCosts', window );">Development costs</a></td>
<td class="nump">$ 10,398,000<span></span>
</td>
<td class="nump">$ 4,232,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">424,000<span></span>
</td>
<td class="nump">2,105,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedInventoryExpense', window );">Inventory</a></td>
<td class="nump">549,000<span></span>
</td>
<td class="nump">397,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">242,000<span></span>
</td>
<td class="nump">238,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Duties and taxes</a></td>
<td class="nump">102,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">4,522,000<span></span>
</td>
<td class="nump">4,282,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 16,237,000<span></span>
</td>
<td class="nump">$ 11,329,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedInventoryExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued inventory expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedInventoryExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bcrx_DevelopmentCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bcrx_DevelopmentCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6850340896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Summary of Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">$ 16,337<span></span>
</td>
<td class="nump">$ 9,366<span></span>
</td>
<td class="nump">$ 13,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">132<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">$ 1,184<span></span>
</td>
<td class="nump">$ 1,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember', window );">CSL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">21,927<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">6,291<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">2,386<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
<td class="nump">$ 2,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">39,580<span></span>
</td>
<td class="nump">10,550<span></span>
</td>
<td class="nump">14,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 48,257<span></span>
</td>
<td class="nump">$ 13,608<span></span>
</td>
<td class="nump">$ 17,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative and other research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueServicesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6750085136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Furniture and Equipment (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6773894560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Furniture and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 718<span></span>
</td>
<td class="nump">$ 542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">1,122<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">6,004<span></span>
</td>
<td class="nump">5,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LeasedEquipmentMember', window );">Leased Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">5,610<span></span>
</td>
<td class="nump">$ 5,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">2,821<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">1,589<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">19,354<span></span>
</td>
<td class="nump">$ 14,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(14,205)<span></span>
</td>
<td class="num">(14,025)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 5,149<span></span>
</td>
<td class="nump">$ 207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LeasedEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LeasedEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6852307280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Royalty Monetization (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 09, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 03, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | JPR Royalty Sub LLC [Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAmountOfCollateralRequiredToPost', window );">Maximum Amount of Collateral Required to Post</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | JPR Royalty Sub LLC [Member] | Shortfall 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | JPR Royalty Sub LLC [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PrivatePlacementOfSeniorSecuredNotes', window );">Private Placement of Senior Secured Notes</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="nump">$ 1,882,000<span></span>
</td>
<td class="nump">$ 446,000<span></span>
</td>
<td class="nump">$ 1,844,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,356,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Currency Hedge Agreement [Member] | Japan, Yen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Derivative, Forward Exchange Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Payments for (Proceeds from) Hedge, Investing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RequiredForeignCurrencyHedgePerDollar', window );">Required Foreign Currency Hedge Per Dollar | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1', window );">Percentage of Carrying Amount in Excess of Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | Royalty Monetization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet', window );">Revenue Recognition Royalty And Milestone Revenue Recognized, Net</a></td>
<td class="nump">22,691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_TransactionCosts', window );">Transaction Costs</a></td>
<td class="nump">4,309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Interestreserve', window );">Interest Reserve</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember', window );">Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,654,000<span></span>
</td>
<td class="nump">$ 5,487,000<span></span>
</td>
<td class="nump">$ 5,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_Interestreserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest reserve established as part of the royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_Interestreserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAmountOfCollateralRequiredToPost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum amount of collateral required to post.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAmountOfCollateralRequiredToPost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of carrying amount in excess of fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PrivatePlacementOfSeniorSecuredNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents private placement of senior secured notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PrivatePlacementOfSeniorSecuredNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RequiredForeignCurrencyHedgePerDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RequiredForeignCurrencyHedgePerDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents revenue recognition royalty and milestone revenue recognized, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition royalty and milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents transaction costs associated with royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeForwardExchangeRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual rate at which a foreign currency can be purchased or sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeForwardExchangeRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=bcrx_Shortfall2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=bcrx_Shortfall2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=bcrx_JapanYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=bcrx_JapanYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6844783792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Lease Obligations and Other Contingencies (Details Textual)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember', window );">Birmingham Research Facility [Member] | Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 1,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember', window );">Birmingham Research Facility [Member] | Long Term Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="nump">2,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember', window );">Birmingham Research Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
<td class="nump">4,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 5,610,000<span></span>
</td>
<td class="nump">$ 5,303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating Leases, Rent Expense, Net</a></td>
<td class="nump">$ 664,000<span></span>
</td>
<td class="nump">633,000<span></span>
</td>
<td class="nump">$ 526,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">19,354,000<span></span>
</td>
<td class="nump">$ 14,232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="nump">$ 2,375<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LeaseFinancingObligationNetOfCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Financing obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LeaseFinancingObligationNetOfCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bcrx_LongTermLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bcrx_LongTermLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6747895104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Minimum Payments under Operating Lease Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2016</a></td>
<td class="nump">$ 651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2017</a></td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2018</a></td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2019</a></td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2020</a></td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">3,045<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum payments</a></td>
<td class="nump">$ 6,908<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6773938656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Details Textual) - USD ($)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 03, 2014</div></th>
<th class="th"><div>Aug. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
<th class="th"><div>Mar. 03, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Nov. 06, 2013</div></th>
<th class="th"><div>Jul. 13, 2011</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAggregateOfferingPrice', window );">Maximum Aggregate Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares (in shares)</a></td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,883<span></span>
</td>
<td class="nump">4,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 115,000,000<span></span>
</td>
<td class="nump">$ 18,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 106,600,000<span></span>
</td>
<td class="nump">$ 23,633,000<span></span>
</td>
<td class="nump">$ 17,805,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 107,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RemainingAggregateOfferingPrice', window );">Remaining Aggregate Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter', window );">Stock Issued During Period Shares for over Allotment Option Exercised by Underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CommonStockToBeIssuedValue', window );">Common Stock to be Issued, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 734,000<span></span>
</td>
<td class="nump">$ 720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CommonStockToBeIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of equity to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CommonStockToBeIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RemainingAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the remaining aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RemainingAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents stock issued during period shares for over allotment option exercised by underwriter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6852807056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stock-Based Compensation (Details Textual)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2013 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Vest 25% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate', window );">Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Stock Options and Restricted Stock [Member] | Vest 50% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | August 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NumberOfMilestonesAchieved', window );">Number of Milestones Achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | December 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,485,000<span></span>
</td>
<td class="nump">$ 9,963,000<span></span>
</td>
<td class="nump">$ 4,253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.72<span></span>
</td>
<td class="nump">$ 8.02<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,117,000<span></span>
</td>
<td class="nump">$ 8,522,000<span></span>
</td>
<td class="nump">$ 738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,511,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,492,000<span></span>
</td>
<td class="nump">2,844,000<span></span>
</td>
<td class="nump">3,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 219 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="nump">$ 214,000<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum', window );">Percentage of Salary to Purchase Common Stock, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesBeginning', window );">Percentage of Common Stock Shares, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesEnding', window );">Percentage of Common Stock Shares, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount', window );">Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan sales, shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased', window );">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.65<span></span>
</td>
<td class="nump">$ 6.29<span></span>
</td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="nump">$ 4.41<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NumberOfStockbasedCompensationPlans', window );">Number of Stock-based Compensation Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,705,000<span></span>
</td>
<td class="nump">$ 10,177,000<span></span>
</td>
<td class="nump">$ 4,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,607,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear', window );">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,023,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,010,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,891,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,683,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">2,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfStockbasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of stock based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfStockbasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares beginning.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares ending.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of salary to purchase common stock maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award first vesting period after grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of performance awards that remain unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average purchase price of capital shares purchased through an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest50PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest50PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_August2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_August2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_December2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_December2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755674960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stock-based Compensation Allocation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 7,580,000<span></span>
</td>
<td class="nump">$ 8,906,000<span></span>
</td>
<td class="nump">$ 3,664,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">2,125,000<span></span>
</td>
<td class="nump">1,271,000<span></span>
</td>
<td class="nump">704,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 9,705,000<span></span>
</td>
<td class="nump">$ 10,177,000<span></span>
</td>
<td class="nump">$ 4,368,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6773782816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stock Incentive Plan Activities (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available (in shares)</a></td>
<td class="nump">2,362<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">2,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">9,605<span></span>
</td>
<td class="nump">8,986<span></span>
</td>
<td class="nump">8,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted (in shares)</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(593)<span></span>
</td>
<td class="num">(310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock awards cancelled (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Stock option awards granted (in shares)</a></td>
<td class="num">(2,217)<span></span>
</td>
<td class="num">(1,965)<span></span>
</td>
<td class="num">(3,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option awards granted (in shares)</a></td>
<td class="nump">2,217<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">3,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option awards granted (in dollars per share)</a></td>
<td class="nump">$ 11.52<span></span>
</td>
<td class="nump">$ 10.99<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option awards exercised (in shares)</a></td>
<td class="num">(1,118)<span></span>
</td>
<td class="num">(1,258)<span></span>
</td>
<td class="num">(563)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock option awards exercised (in dollars per share)</a></td>
<td class="nump">$ 4.36<span></span>
</td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Stock option awards cancelled (in shares)</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock option awards cancelled (in shares)</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="num">(1,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Stock option awards cancelled (in dollars per share)</a></td>
<td class="nump">$ 9.87<span></span>
</td>
<td class="nump">$ 8.83<span></span>
</td>
<td class="nump">$ 7.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available (in shares)</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">10,671<span></span>
</td>
<td class="nump">9,605<span></span>
</td>
<td class="nump">8,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="nump">$ 6.21<span></span>
</td>
<td class="nump">$ 4.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease', window );">Plan amendment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share based compensation arrangement by share based payment award options grants in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeitures in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6616866048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life</a></td>
<td class="text">5 years 182 days<span></span>
</td>
<td class="text">5 years 182 days<span></span>
</td>
<td class="text">4 years 255 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-Free Interest Rate</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section D<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6850427536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange01Member', window );">Exercise Price Range 01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">6,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life</a></td>
<td class="text">1 year 186 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">1,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange02Member', window );">Exercise Price Range 02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">6,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life</a></td>
<td class="text">4 years 229 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">4,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange03Member', window );">Exercise Price Range 03 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life</a></td>
<td class="text">7 years 36 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">7,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange04Member', window );">Exercise Price Range 04 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">8,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life</a></td>
<td class="text">11 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">11,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange05Member', window );">Exercise Price Range 05 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">6,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life</a></td>
<td class="text">12 years 160 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">12,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange06Member', window );">Exercise Price Range 06 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">9,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life</a></td>
<td class="text">15 years 142 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">6,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life</a></td>
<td class="text">7 years 182 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">5,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange01Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange01Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange02Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange02Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange03Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange03Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange04Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange04Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange05Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange05Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange06Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange06Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6764506880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested stock option awards (in shares) | shares</a></td>
<td class="nump">4,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">2,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">$ 7.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Stock option awards vested (in shares) | shares</a></td>
<td class="num">(1,711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Stock option awards vested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock option awards forfeited (in shares) | shares</a></td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Stock option awards forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested stock option awards (in shares) | shares</a></td>
<td class="nump">4,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774102720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 386,219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">373,454,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">48,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</a></td>
<td class="nump">20,339,000<span></span>
</td>
<td class="nump">$ 17,312,000<span></span>
</td>
<td class="nump">$ 8,567,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions', window );">Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options</a></td>
<td class="nump">$ 15,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the aggregate tax benefit realized from the exercise of stock options and the conversion of similar instruments during the annual period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6595422528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at federal statutory rate (35%)</a></td>
<td class="num">$ (15,057,000)<span></span>
</td>
<td class="num">$ (15,816,000)<span></span>
</td>
<td class="num">$ (10,538,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes net of federal tax benefit</a></td>
<td class="num">(819,000)<span></span>
</td>
<td class="num">(1,286,000)<span></span>
</td>
<td class="num">(839,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent items</a></td>
<td class="nump">560,000<span></span>
</td>
<td class="nump">258,000<span></span>
</td>
<td class="nump">738,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Rate change</a></td>
<td class="nump">1,012,000<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">1,892,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards', window );">Expiration of attribute carryforwards</a></td>
<td class="nump">330,000<span></span>
</td>
<td class="nump">373,000<span></span>
</td>
<td class="nump">242,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(10,454,000)<span></span>
</td>
<td class="num">$ (748,000)<span></span>
</td>
<td class="num">$ (1,206,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount', window );">Orphan drug credit</a></td>
<td class="nump">4,307,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(218,000)<span></span>
</td>
<td class="num">$ (115,000)<span></span>
</td>
<td class="nump">$ 1,144,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</a></td>
<td class="nump">$ 20,339,000<span></span>
</td>
<td class="nump">$ 17,312,000<span></span>
</td>
<td class="nump">$ 8,567,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents orphan drug credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation income tax expense benefit expiration of carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32059-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Subparagraph 2<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Subparagraph 1<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6772176016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at federal statutory rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6772168080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at</a></td>
<td class="nump">$ 472<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions to current period tax positions</a></td>
<td class="nump">$ 2,616<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Additions to prior period tax positions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at</a></td>
<td class="nump">$ 3,085<span></span>
</td>
<td class="nump">$ 472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777441216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net federal and state operating losses</a></td>
<td class="nump">$ 142,836<span></span>
</td>
<td class="nump">$ 135,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">48,551<span></span>
</td>
<td class="nump">38,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">4,240<span></span>
</td>
<td class="nump">3,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">8,605<span></span>
</td>
<td class="nump">7,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2,590<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">207,876<span></span>
</td>
<td class="nump">187,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains', window );">Foreign currency derivative</a></td>
<td class="num">(2,668)<span></span>
</td>
<td class="num">(2,285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(2,668)<span></span>
</td>
<td class="num">(2,285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (205,208)<span></span>
</td>
<td class="num">$ (184,868)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Liability<br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Subparagraph b(2)<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, before jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6595456864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Employee 401(k) Plan (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 366<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6775968976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Collaborative and Other Research and Development Contracts (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">50 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 16, 2015</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Feb. 24, 2011</div></th>
<th class="th"><div>May. 31, 2010</div></th>
<th class="th"><div>Sep. 30, 2009</div></th>
<th class="th"><div>Jan. 31, 2007</div></th>
<th class="th"><div>Jun. 30, 2006</div></th>
<th class="th"><div>Feb. 28, 2006</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 24, 2011</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Nov. 11, 2011</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractValue', window );">Collaborative Agreement Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementAdditionalContractValue', window );">Collaborative Agreement Additional Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementAdjustedContractValue', window );">Collaborative Agreement Adjusted Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">National Institute of Allergy and Infectious Diseases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts', window );">Expected Receivable From Awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementPeriodOfcontract', window );">Collaborative Agreement Period of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborationAgreementAdditionalPaymentsReceived', window );">Collaboration Agreement Additional Payments Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember', window );">UAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PeriodOfAgreement', window );">Period of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RenewablePeriodOfAgreement', window );">Renewable Period of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember', window );">Base Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember', window );">Additional Development Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember', window );">ASPRBARDA Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember', window );">Mundipharma [Member] | Upfront Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember', window );">Mundipharma [Member] | Clinical Trial 2007 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember', window );">Mundipharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_UpfrontPaymentsReceivableAmount', window );">Upfront Payments Receivable Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PotentialMilestonePaymentsReceivable', window );">Potential Milestone Payments Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember', window );">AECOM and IRL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMinimum', window );">Milestone Payment Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMinimum', window );">Annual License Fee Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMaximum', window );">Annual License Fee Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement', window );">Advance Notice Period for Termination of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement', window );">Stock Issued During Period, Value, for Modification of License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PaymentsForModificationOfLicenseAgreement', window );">Payments for Modification of License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember', window );">CSL Limited [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">$ 33,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyTerm', window );">Royalty Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents advance notice period for termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual maximum license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent minimum annual license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborationAgreementAdditionalPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaboration agreement additional payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborationAgreementAdditionalPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementAdditionalContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement additional contract value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementAdditionalContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementAdjustedContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement adjusted contract value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementAdjustedContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement contract value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementPeriodOfcontract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement period of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementPeriodOfcontract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents expected receivable from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PaymentsForModificationOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents payments for modifications of license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PaymentsForModificationOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PotentialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents potential milestone payments receivable based on possibility of future event payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PotentialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents proceeds from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RenewablePeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents renewable period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RenewablePeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between the date of the Agreement and its expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents stock issued during period value for modification of license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_UpfrontPaymentsReceivableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents upfront payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_UpfrontPaymentsReceivableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51666815&amp;loc=d3e55295-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_UpfrontPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_UpfrontPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_ClinicalTrial2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_ClinicalTrial2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6747986000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Quarterly Financial Information (Unaudited) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="nump">$ 4,602<span></span>
</td>
<td class="nump">$ 10,987<span></span>
</td>
<td class="nump">$ 25,842<span></span>
</td>
<td class="nump">$ 6,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,135)<span></span>
</td>
<td class="num">$ (14,621)<span></span>
</td>
<td class="nump">$ 4,901<span></span>
</td>
<td class="num">$ (15,164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MENW)4] '_K,- \]YEE<>QW8OG*\M"_V/Z'D4X$G1H>)%]2-F Q+M*;V"^GH
MA3&^.R6:E((C-Z."N[_8_ )02P,$%     @ MH):2+>K)I[H 0  V1\  !H
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M=ZU^:!X>E]?D[1N$[_\!4$L#!!0    ( +:"6D@2U8$'DP(  *0)   8
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M]UK\-;9UI]MA_!.CB68GH(F 9@+*G(1P(H0S 49.0C01HA=!>P)&5_1&G+#
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M]7>_/(,9&]PU53=])KO7KF_J6\@JJ<N?\_?I/'U?YW_R; F+!\ 2 /< I<4
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MY$<4&A+^WI%3QVL(GESA4%+@CTCI4DP+C^:0(]$,:F:XY@PLK$^"$XIV4/'
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M7_KYXJ<(;Q/D/8'&J6QD..($M[ F84/^@,24SV\0:S=XZQJ49880BO,+H+\
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M\Q>/^:)O+K</./>O2)O_ %!+ P04    " "V@EI(DA['H38"   &!P  &
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;(V5VXZ;,!"&7\7B =9@CAL1I$U0
MU5Y46NU%>^T0)Z UF-I.V+Y];4R(B;QL;^(#WS_SCR'C?&#\7=2$2/#1TDYL
MO5K*?@.AJ&K28O'$>M*I)R?&6RS5DI^AZ#G!QU'44HA\/X$M;CJOR,>]5U[D
M[")ITY%7#L2E;3'_NR.4#5LO\&X;;\VYEGH#%CF<=<>F)9UH6 <X.6V]EV!3
M9IH8@5\-&80U!]K[@;%WO?AQW'J^MD HJ:2.@-5P)7M"J0ZD$O^98MY3:J$]
MOT7_-E:KW!^P('M&?S='62NSO@>.Y(0O5+ZQX3N92HAUP(I1,?Z"ZB(D:V\2
M#[3XPXQ--XZ#>9+YD\PM0), S8(@616$DR"\"Z)5030)H@<!-*6,!U%BB8N<
MLP%P\_)ZK+^18!.IHZZ JEYX^M%XOIHH\FL1A&D.KSK0@MD9!AEF)J"*/J=
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M*L+.SE2!Z>/3L:3!2;MT>&MV?9WW1;R3=WA=C;R'W]ST0EMR0.=O-MY-A^C
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MX]VTB Z\B>QJ0TGO_\\22&A=6%[[M4E/*@4.A],'67YI]0902P,$%     @
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MOS;I2:6-P_'\0=9?6OT'4$L#!!0    ( +:"6DC()%E\I $  +$#   9
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M1D'MPG+CUR8]J;1QV)\^R/Q+BP]02P,$%     @ MH):2#/#-FVB 0  L0,
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M_Y]E(Z%U87GKUR8]J;1Q.)P_R/)+JW=02P,$%     @ MH):2.W<W&RD 0
ML0,  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&UL?5/;3N,P$/T5RQ^
MT[2T595&HJQ6RP,2X@&>W6226-B>K.TT[-^O+VDHJ/#BZSEGSLS8Q8CFS78
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M$\P#!'-',+L39-XM0DSN%UD$1!: H/"* $R>^D66 9$E("!>$8A!OG<6$,D
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MHQXG#3]J.\S,6 X]YC#1XO)HF<>^O?H/4$L#!!0    ( +:"6DBQ=]0QY@$
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M_@3S0D!E_73GYGJ\'./"JNYRU>?_3?X%4$L#!!0    ( +:"6DCH:4&QI0$
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M^V8\VHX-*<[S2?WV=\'F'U!+ P04    " "V@EI(:X\.L]\!   9!0  &0
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MGZ[M!MM.;B6+9IO? &<#?!CB9-. 9@-Z,@!'9NOZ1A0I<L&G0+BS&(DY\OB
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M?I5UU;+7+A#7IJ'=OS6K^6T5@O ^\5:=SE)/1&41C7&'JF&MJ'@;=.RX"E_
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M)M/X'#F73.F+GU3^GE7_.PYJ=I3Z-57O7=\1]@/)+_<&=^RRR_]02P,$%
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MV\SLI9\,;VC17^=\_MD4_P%02P,$%     @ MH):2)M7GYNK @  !0L  !D
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MWKZ'%7XFT&2(..TL86PION8';+E9:#KPM3^LZ?\)-.U\"LCMQXH @I8<^4(
MK!18W!1?#,":' "SQW&.P1W.%M72]^8+ C"3 !=+?GQ1 &NR *P^3_+"[2=;
MX\<7!I"O$9.;8@J2N-MY@J5S-BU]O[YP 2M=4N=*6S"3XY-:"B5N10\XA!>R
M'_LR!IL9$SO_+;<39NH5B NG'@N%4?8@)C(.+!=Z8C]H?ZH[$;QRJ<X^P^GE
MR+EDB@H]J4_YK,ZD\Z1A1ZF'F1KWXREMG$A^N1\ZYY-O]0]02P,$%     @
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MQ#(5G)N$?61(H.=2(@]G.@%=-Z/^V>>91&8:>B(+YSH!;&=P\$,1Q3G!F5,
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MPDIG1,FC..(I0#R+W[9#D:,&CF.3 FQR^.W93$3419K#D@98<OCV-A-1>3B
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M02#S!7+T:+)U21T&.I/Y*M:_*=S.QZV>8SB#V_NX%,+,QST8SQ>,YP_)T;0
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MHJ_=H!A!)LD(LFBV^1!@(Z*-'G0GRKPTSO0?W0,])/52VC$0E7B<&WI@\SA
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MCK;A253Q4ZN&BSY%IY[Z$IOO_":^T;UV:(U7F2+OR!%^$7%L6HEV7.DN8OO
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MXV*D[)77A COO6M[?O!K(88] +RJ28=Y0 ?2RY,K91T6<LEN@ ^,X(LVZEJ
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MU+QHR56H:2;GS+1LLQ!T>+Q \S-8_@-02P,$%     @ MH):2,*2'.Y5 @
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M4G?<.U(A&ZUNE6=*!9$1PR?Y'U;RQ)PF#3D+-4SEF)DSQ$P$[>]'XG0N%_\
M4$L#!!0    ( +:"6DAOW> IW0(    +   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;(V676^;,!2&_PKB?L6?0"J"U 1-V\6DJA?;-4V<!!5PAIVF
M^_>S#:%V9J/=!&S>]YS'!\><XLJ'-W%B3$8?7=N+=7R2\OR8)&)W8ETM'OB9
M]>K)@0]=+=5P.";B/+!Z;TQ=FR  TJ2KFSXN"S/W/)0%O\BVZ=GS$(E+U]7#
MGPUK^74=P_@V\=(<3U)/)&61S+Y]T[%>-+R/!G98QT_PL8)(2XSB9\.NPKJ/
M-/PKYV]Z\'V_CH%F8"W;21VB5I=WMF5MJR.IS+^GH)\YM=&^OT7_:I:K\%]K
MP;:\_=7LY4G1@CC:LT-]:>4+OWYCTQJH#KCCK3"_T>XB).]NECCJZH_QVO3F
M>AV?Y&"R^0UH,J#9 --% YX,^-- %@UD,I [0S(NQ12BJF5=%@._1L/X]LZU
MWB3PD:A2[R*U>A'K1Z:^6E$6[R6EH$C>=2!'LQDUR&C@K$A4]#D%"J?8(,N.
M? FVM@)#GZ2R)5GJA\ +Z\3&CZ=UWN7H1]!1DQK-%T@!S0  /N7V3IG#-*"L
M7"6@.+>5#CY9P"<./O+BCQHZILKA*@3OZ"#*@^QN0+P*DM,%<NJ08R\YM1)1
MC>,'MV6(YB%L6Y8MU#M=H$X=:N*E3JT\$$ 4PK9U**2JG&CY"@6QLP7LS,&F
M7NS,2H1QL-B.+,,A;%N&2)@Z7Z#.'>K42YT[FQ802D+@N?V/RTAPFS@Z]?;2
M(/MJ@7WEL&=>]I7%3C#X]U29CD$[%DZ]QV! XN#JKUWXO =V!))[@2?15&T$
M0S7<3L);$=69&2BV(X20D&"QX>+7"MKE#M%#*Q<"& =/0D<),QS\#U>.,J=I
M%N9?^!0^0>1LE]SWCC>.R+\/MO^AJ4*:$3>Q^H2.#4?3<(EHQR^]'#^T\^S<
MU#V9GNYN?J.;/=-_?(8IBW-]9#_JX=CT(GKE4G4QI@\Y<"Z9@@,/ZI0^J79T
M'K3L(/5MINZ'L4$;!Y*?;_WFW/26?P%02P,$%     @ MH):2-YNBR+( 0
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M26/;QS= ):4!6UQTM\:HL;^!R>!0&;>]MWL5)B,81G:7.9]^-OE_4$L#!!0
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MP5';[<KLI1\>_J#%<!V%\SRN_@)02P,$%     @ MH):2'$&_52" @  ^@@
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M@T*E[79G]M)/AC>TZ&YS/OUL\G]02P,$%     @ MH):2+N&A_LO!   SA4
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M/_''U0N+//,>6-Y!HASD(KA&(G\#6-Y!(2/IR<%2"AKE4%03'\#E%*0$#V3
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M)!FRDGP+5V$4.WU-80C#T&G,AJ$U<((.4ZTXQ,CM+'[B++:<88B<U@QF;?*
M!70[FZ.<OFP06( EF'S<-N?"H=LE?N(23UPZZ\_PEUS.44Z7>.H2.VW-E>:V
M NL9JBF_] U >#F[-M+\1<?HV&->H'[&9O%,]1[3*AXR:=*2"_U%^*5LA'=D
M4CV2_3-W9DQ251Y8J&,O5'<<%Q4]2SU=JCDW#<,L)&OO[6_LP>D_4$L#!!0
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M,WD-EL S.1,;^V@9;N(8J([H6]^Q)LG.UA0QX5W3* JYL4>:AMB15]7*H<J
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M'@\9)XVF-^W/&6V+)CV )Y@[<&'# _=\#M!A%NZ<\62,ST"PB@L"?M0S==7
M@'</9&N*2']3\'FTW,)_J>I(N$3:[C0K7M7AT.:J;7F2*CGZQ%HAQ,F@/^(+
M3X;G_8<(NU$KH/:SIM!U^L[;RF29)3\B?. !KNK(PP+>VFL[,$JD?0F,QC:?
M=_/-M4B6?T&;MF81G O;IMMKQM0SX047*<-"-U-GV'5CW&U<^<#R7-)^^1Z3
MKM"9,6V#L,W<3H=FLM2V'38EL!&;#9:ZF>\3Y/@X. ?U?_F90%X9YJ/W*<#Q
MEF8)L5<;RSOD&QG$5J5>R*_*J=5&F[M,657LQ2#C1A5BHX@4H@,5;K$K\]-
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M-(EG\ZE ??ICGX[POPX$T$D\'?3IOZ/^B$\N-\O6S%P.1,/2&\;SH4"&/S<
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ML-MZ!P^ L?V<>#V9/4*VM!_O/^QI!L@7".#6!\?<Z3F4DC?BN+HR'GJ1C4T
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MT <5,:9HD*"WCD8^Z'IR)-Z#APOX60MOLBO;G"U+&@<3[X$@K+*RVM50^X:
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M34HY['6P.IM6;OVU7G4_::^;%+VJ)04_9R.'O=$26EBCKI<I@0V]9.O53RO
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M\? <HQK,SLTB#48R*OIM-)X_I@&@*Z^V'-B4BG8JCVVM-15]<]SSH/C?)()
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ML,R$ ?L-]!J*MW$ OC2O>,1"-NYI3]Q+<REURK7H [85#D43VL*!X]#96 K
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MTFGG$D^MYM-NW_R5$8X_*I;=?S $>\HU/4AO2^O4<2/EO+O*;8MG@]?F9=A
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M[-'-9J$Z6$83@8 #9Q">G].K5)7Y!XQMJ*A<IOG:6%[1>EN56+L)G5'1I+B
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MI:6OJ^K^W_X/4$L! A0#%     @ MH):2+P-6 +O 0  +2   !,
M     ( !     %M#;VYT96YT7U1Y<&5S72YX;6Q02P$"% ,4    " "V@EI(
M2'4%[L4    K @  "P              @ $@ @  7W)E;',O+G)E;'-02P$"
M% ,4    " "V@EI(MZLFGN@!  #9'P  &@              @ $. P  >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "V@EI(U<E3>*@#
M  #6#0  $               @ $N!0  9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( +:"6DA+(H,)/@$  &D#   1              "  00)  !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( +:"6DB97)PC$ 8  )PG   3
M          "  7$*  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MMH):2&UK9U%9 @  T@H   T              ( !LA   'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " "V@EI( :5II^X$  "*$0  #P              @ $V
M$P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ MH):2!+5@0>3 @  I D
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M965T-2YX;6Q02P$"% ,4    " "V@EI(.F@R'-P#  !1$@  &
M    @ %'*P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
MMH):2)(>QZ$V @  !@<  !@              ( !62\  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( +:"6DB2]-QWI $  +$#   8
M          "  <4Q  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " "V@EI(._P'.:0!  "Q P  &               @ &?,P  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ MH):2#F=DE.E 0  L0,
M !D              ( !>34  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " "V@EI([%I]5Z0!  "Q P  &0              @ %5-P
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( +:"6DC()%E\
MI $  +$#   9              "  3 Y  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ MH):2!_H(&2D 0  L0,  !D
M ( !"SL  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "V
M@EI(,\,V;:(!  "Q P  &0              @ 'F/   >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( +:"6DA5NR4(I $  +$#   9
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M970Q.2YX;6Q02P$"% ,4    " "V@EI(L7?4,>8!  "J!0  &0
M    @ $+20  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M +:"6D@PW.69I0$  +$#   9              "  2A+  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ MH):2,7S*P:C 0  L0,  !D
M             ( !!$T  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " "V@EI(XGYM0-D!  !%!0  &0              @ '>3@  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( +:"6D@$GOD@O@$
M 'L$   9              "  >Y0  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ MH):2.AI0;&E 0  L0,  !D              ( !
MXU(  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "V@EI(
MA 5_'*4$  #;&0  &0              @ &_5   >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( +:"6D@<O\=5: ,  #H0   9
M      "  9M9  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ MH):2&N/#K/? 0  &04  !D              ( !.ET  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "V@EI(",H'&ZH"  #6"P
M&0              @ %07P  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( +:"6D@;,([OQ0$  ) $   9              "  3%B  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ MH):2**[$G\D
M @  %P<  !D              ( !+60  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " "V@EI(0BE,[=\"  !Q"P  &0
M@ &(9@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( +:"
M6DA;]9H T $  '@$   9              "  9YI  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ MH):2)M7GYNK @  !0L  !D
M         ( !I6L  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M    " "V@EI(-D;A,;P#  "\$@  &0              @ &';@  >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( +:"6DB,/?#+EP(  %D)
M   9              "  7IR  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
M4$L! A0#%     @ MH):2,!W'RC@ 0  704  !D              ( !2'4
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "V@EI(T!8D
MU-L"  "V"P  &0              @ %?=P  >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;%!+ 0(4 Q0    ( +:"6DC?YM-_004  "T<   9
M  "  7%Z  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
MMH):2*,D50XC @  > 8  !D              ( !Z7\  'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    " "V@EI(MK?&<WD#  #[#@  &0
M            @ %#@@  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( +:"6DA',4*<!@(  '\&   9              "  ?.%  !X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ MH):2)3:4DRB P
MW!(  !D              ( !,(@  'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    " "V@EI(&LVG,SD"   2!P  &0              @ $)
MC   >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( +:"6DC"
MDASN50(  *,'   9              "  7F.  !X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ MH):2&_=X"G= @    L  !D
M     ( !!9$  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +:"6DB[AH?[+P0  ,X5   9              "
M 0V=  !X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ MH):
M2'"\>7=1 @  CP<  !D              ( !<Z$  'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    " "V@EI(CML>"2*<   *2 ( %
M        @ '[HP  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P4&     #T /0"=
)$   3T !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.1.900</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>220</ContextCount>
  <ElementCount>332</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>91</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-comprehensive-loss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-stockholders-equity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 2 - Furniture and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment</Role>
      <ShortName>Note 2 - Furniture and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 3 - Royalty Monetization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-3-royalty-monetization</Role>
      <ShortName>Note 3 - Royalty Monetization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 4 - Lease Obligations and Other Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies</Role>
      <ShortName>Note 4 - Lease Obligations and Other Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 5 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-5-stockholders-equity</Role>
      <ShortName>Note 5 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 6 - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation</Role>
      <ShortName>Note 6 - Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 7 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-7-income-taxes</Role>
      <ShortName>Note 7 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 8 - Employee 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-8-employee-401k-plan</Role>
      <ShortName>Note 8 - Employee 401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 9 - Collaborative and Other Research and Development Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-9-collaborative-and-other-research-and-development-contracts</Role>
      <ShortName>Note 9 - Collaborative and Other Research and Development Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 10 - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited</Role>
      <ShortName>Note 10 - Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Document - Note 11 - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-11-recent-accounting-pronouncements</Role>
      <ShortName>Note 11 - Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 2 - Furniture and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-tables</Role>
      <ShortName>Note 2 - Furniture and Equipment (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 4 - Lease Obligations and Other Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies-tables</Role>
      <ShortName>Note 4 - Lease Obligations and Other Contingencies (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 6 - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-tables</Role>
      <ShortName>Note 6 - Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 7 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-7-income-taxes-tables</Role>
      <ShortName>Note 7 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 10 - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited-tables</Role>
      <ShortName>Note 10 - Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Statement - Note 1 - Fair Value of the Company's Investments by Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details</Role>
      <ShortName>Note 1 - Fair Value of the Company's Investments by Type (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Statement - Note 1 - Scheduled Maturity for the Company's Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details</Role>
      <ShortName>Note 1 - Scheduled Maturity for the Company's Investments (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Statement - Note 1 - Summary of Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-1-summary-of-receivables-details</Role>
      <ShortName>Note 1 - Summary of Receivables (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Statement - Note 1 - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-1-inventory-details</Role>
      <ShortName>Note 1 - Inventory (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Statement - Note 1 - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-1-accrued-expenses-details</Role>
      <ShortName>Note 1 - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Statement - Note 1 - Summary of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-1-summary-of-revenues-details</Role>
      <ShortName>Note 1 - Summary of Revenues (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 2 - Furniture and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-details-textual</Role>
      <ShortName>Note 2 - Furniture and Equipment (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Statement - Note 2 - Furniture and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-2-furniture-and-equipment-details</Role>
      <ShortName>Note 2 - Furniture and Equipment (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 3 - Royalty Monetization (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-3-royalty-monetization-details-textual</Role>
      <ShortName>Note 3 - Royalty Monetization (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 4 - Lease Obligations and Other Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-4-lease-obligations-and-other-contingencies-details-textual</Role>
      <ShortName>Note 4 - Lease Obligations and Other Contingencies (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Statement - Note 4 - Minimum Payments under Operating Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-4-minimum-payments-under-operating-lease-obligations-details</Role>
      <ShortName>Note 4 - Minimum Payments under Operating Lease Obligations (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 5 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-5-stockholders-equity-details-textual</Role>
      <ShortName>Note 5 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 6 - Stock-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-details-textual</Role>
      <ShortName>Note 6 - Stock-Based Compensation (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Statement - Note 6 - Stock-based Compensation Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-6-stockbased-compensation-allocation-details</Role>
      <ShortName>Note 6 - Stock-based Compensation Allocation (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Statement - Note 6 - Stock Incentive Plan Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-6-stock-incentive-plan-activities-details</Role>
      <ShortName>Note 6 - Stock Incentive Plan Activities (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Statement - Note 6 - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-6-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details</Role>
      <ShortName>Note 6 - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Statement - Note 6 - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-6-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details</Role>
      <ShortName>Note 6 - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Statement - Note 6 - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-6-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details</Role>
      <ShortName>Note 6 - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 7 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-7-income-taxes-details-textual</Role>
      <ShortName>Note 7 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Statement - Note 7 - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details</Role>
      <ShortName>Note 7 - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Statement - Note 7 - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-7-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals</Role>
      <ShortName>Note 7 - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Statement - Note 7 - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-7-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details</Role>
      <ShortName>Note 7 - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Statement - Note 7 - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-7-components-of-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 7 - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 8 - Employee 401(k) Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-8-employee-401k-plan-details-textual</Role>
      <ShortName>Note 8 - Employee 401(k) Plan (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 9 - Collaborative and Other Research and Development Contracts (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-9-collaborative-and-other-research-and-development-contracts-details-textual</Role>
      <ShortName>Note 9 - Collaborative and Other Research and Development Contracts (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bcrx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Statement - Note 10 - Quarterly Financial Information (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20151231/role/statement-note-10-quarterly-financial-information-unaudited-details</Role>
      <ShortName>Note 10 - Quarterly Financial Information (Unaudited) (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bcrx-20151231.xml</File>
    <File>bcrx-20151231.xsd</File>
    <File>bcrx-20151231_cal.xml</File>
    <File>bcrx-20151231_def.xml</File>
    <File>bcrx-20151231_lab.xml</File>
    <File>bcrx-20151231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0001171843-16-008207-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-16-008207-xbrl.zip
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M6'(=!;X[OP,,W@>1^V<)'>\/N6M:IK)$ JYVJV?;IGWRR_\*TG>>?V\DZ3P
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M7N>5R/1:@_;)+]?=U@<)] 8@J9B$8>8$E_ .8/B)L<\.<'8VU=^F7AO2^D4
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M "B0$5/#YUT;8N9/A]AH6#:-D)("B?K^_'_:;;NE=C(NRI: >1["'N"=*["
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M&N\[I4:;1U?9CKL1E?;-+!5;&*P"7H!!'O0+;T!Q'-\@DX"N'&LS O7NW+U
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M"S[$R_=%IZP4>.IOQ2+.:,7##.@AJ8-_4HT@Y%N8QN&M(G/KIGC93(A]Z?H
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M6+.K[5#8M#K=]CJ8U(.U3X0V:.]J]K25#&W;[G6?!3X;-&LU>_J>"3W[L-C
MB=.=Y_)W@PJ&[5;/QAX&!ZIB>!SQ..)>1EPT<:9.//;!O($_C!;]VS1/.YO
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M=D.=DS,W30(V05;2#J59LA2320JW\(%DMD8I;#Y%_?C7B"3Z182-4A)-C9R
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MZV5L,$(^/Z>!EP/<UA[X#_%YJ=:L5895%1IBOB9WX&&2]G5>)L%<1VW^L3#
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M(%..7]BJ04\\Y;2G VHML;CVS.V:F77[<K.9K^3M2\R!.7?B>#Z*8FP8FWP
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M>CS7;==SV7/>^=3!DE(E=E.DADN5:W[] Y#)36**I$2MQ1-SW"6)S,262"2
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M!8X/+R3$P^ZYB.D5]L](7[.C*'#N8IIAP:*Y/Q7 4"<)WG%D"1RU.2FG+)S
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M/#]['@=-'^$HSNT'RLO@L3:1]L!#;F)TI A&,^&?B,9%5%\:?42< $>6"<C
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M Q'2#>G&.!BM[^Y[!KR!S.B&?/\P-&M-*^T&>>*G22J#[R8LTDU"U\=5@*]
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MB'W'[J)O3TMV_<,)KV[F]M??KS_#:@U_IWN#DIRZP; O-;#Z=/ IP4 2$J\
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MNOD1AN^]VY[R6P[X$ER><H.HRL+WV).8AAY?Q!&0C5B8EU)X$C;BB;,45U(
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MCW4U?X^#Y^]0QH["$HPSX5& H%[Q4E.>'(7+33P3YY8GM&88B>?%78"/F-N
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M;S[^Z_J-> 0OD7R9Y6Z5\#R0>D')H;RNJVE22$A"GQ)\3Y$X:;+,+4!@@P'
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M-['$#K4N\8GO+16IE"*/Y$GS_+R$IM*-:L6/HSQZI%52F5F!(E>4I]Q?O4X
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M_Z:.;*Y<G9 (D3E.D9CPZ Q,XUPP ?Z'4A"[W-DVQ^41)B&(#-YD# 'WBF3
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M>0] M5K[>GO;U)S"^[MX<(V,,F\(7#BXVGI_6ZN0P\%UYAJ&>[HD@]7^8/>
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MJV&01LM3 'YN %N/#MZ!,)W@>C)QL3>R\TA]A"WF1U/*\I_?-[K&8-P^P4R
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MQSAQ JSK4.F$I61T;&I&3=&C!9I&4LJ(%[/O@ >9!DK#K43HFES$KE0\F(J
MY!XU6F#T.9E:B= \V% 8M">CT*<]K&=]TLZR2D2ZDX8>YI]"K,HA%*I4"K\,
M'<#5$K[C*6&IHQQ7)LH>7$*[ M:EN10)8A#<\ *>Q@@>82-7#^;D&T;4E,T
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MWD$48I_&YC:+Z:;L=3:/2RO_D'/!]JX5Z:("+=D9Z/W^L.R-E@""^H%R-&K
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M[^QLA]CD8LZ#F[X^V-GQLXG]-['_"[A(V6#HT@)E\A?;AI".3S>$E)_./MK
ML)/N)\]C].7&/'MF\4$K-(+D!J-9#ZYWO.'VI48ZTU>/#R7F&$T2IXJF"M&
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MIC)2M[PX?+9*FJS"_@K1$?PK=./&P[A#OKCP+_E$5I$C0$>2YN)P;1(;<NK
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M29II:_&F\I#0B$CZ, JZ3V<(ZFZ",]/D$[0!'PPMI2O[#\,<NCU=-OTSA!,
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M=886!E$8F)R/( 8-./^J3NC)NIW96W);'C8T?3]T$&N6YCRM L0CK8HOF^
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MS/C(G8)0/9@:R]D@J-Z#(D*2(34N6/1]#2RMW[8M/'W$*2B+//!W$D'AGV]
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M SWKJ^UV'V_*2ON9@FX/=;5-4J /">6ND$\4U6S*1!<RT7?.55V99I-Y3#
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M"A:KS"7S#D"M'2@%K&Y!VP:S$(K'7#ZVANF+MUR"72RI1Z<>XT"\K-#UU@"
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MU1=75Y3=499-.4/H]GW$0\&N0T_]I):Q1K?3WZ+9G&_=F/^J?,Y#[-1M;4D
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M8]0N0..'/)1M"#_RX<0._-AQV\GUGORN9,6 ;U JYRNBD] Z@P0EOJ*SE?2
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M8_0YXHOG;/6-GSN[DQ)P+.5IU_(\YH"?LL"X!659]*]BP?(Y7F>Q%<=F$P,
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M)]L3&@4^K:+BU\5+NJ^ENI]!\PPGNG>>:'B87]C21Y\8@D!YAJIB)U!9&KK
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M84G@UZ"03IF*\YCO#G50^)$E!\/G,PX'-7@,0D.'W )CQYP7:N7['JR0=U\
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M546QI08TE!H%^A:HEDHTG$<XLC  <ACAB".Q0WA7146EM_,J90Y%%6J+NK$
M9HLCK16)%X[/\\0BOSA/U#AUY&3T3(H8R=CT,4[V_L1E66YP<L8WJD5^Y]U3
M1(5/P\?K9^KFLHR(I'3^3,5Y_>X$FZ?9NZ&?B[0:7B%9[QST^*<M$%[.B*RA
MU7^S,YR<((^4,K1(P$4";Y.)+A#SA1NAF%$+&@G4J(6-'K;HE8K,_'E4+L!4
M"+ ^HZI3V,L] 4:M ,4[-0CW!;CIV CQKJIU%T/<#JZAOSZK2X;WDF(971&6
M\G!TR!&K?P7QL-.]>W&=TS"T#=P%9U1M'HBNNVN ]%.]N2%JU^URQI>Q1TI&
M>0S@6S2LA@ %:^@-K@0-4FQ9N,BS1N7[U9.-(;8O[=2UR7>$44L9OEUMD0V8
M'5QVE1'9-,PVHGG6"$%9QRANL 4PAFGM(7JR-%5]'-&)5D7MQQJ"5'ZH0^?J
MSHE:474[\*VKN6 PJ(J/:@I1EY_Q*>1J17(>?]Z3$RQBT)';C5.M8>>0LEX]
MW5V4D0><1-KC!'0SD9%'8KU*]?P!UZO6(_!51'O\&,=L+*M1U#\A2VZ[U;9F
M4JPL@YR33MH#T12EW\W\X=M XV6)E;X!;MZ/]NT\D49R$RS(OJZ:E E(='YU
M[#*GK@R7$UHE:074H[W>?-W7VB,+.?J (_])(,_Q([L HS=S-%0AJWQK,@?,
M>"WND'6Y9:I+%&7CUQR;;8/[Z$7L$O#C98E5CC<&&N=PIZYME!,)HA\30B1Z
MD@FL+5?=>Y$?L"SY1/$K6_JSV[LO9S\! ^)"K7,&N'M(Z73;HU7T$C*#1E6/
MQDQH3(16:P75B3K#<=CP:EK[<_-:0:-DO"3^=L5CVF0M60T&P]HYEGFU4MYS
MDN=97.*#J.9P#1V-,0@SLUWF,5EAZBYZCF)B6AO[Q'!.&^K:]X0VA,%D-C/D
MR61=(R[2[TQGF2I3CN>T424:F-"FI1@X,ORY(.64Y0PWMA4'\DZ#A7^<NI6H
M#\@'N-#$;,.]72T9B_(&1!;&'.KG1)I2UE,&(6MN:!+[W?HVBGWZ)F9AS@M@
M8ZE-@JFI'R%%7AR;AE1?!HQC7'!^S>/G*,VOJ(E>YV=IN29E*JHG">-]*S$2
MM8^ IC+>N2^#&4<!,1MK?.W&7??Z-L10H*\?*9YO$,E1PN'0Z88LV75?=B0O
M'I]JS^&#6):BDA&8A /'9.R D2]76?;HYRB/9<<O&E_:BM8.*00+W0ZA6(GC
MC#@T6?:TA'D^M0)#O@*Z$:T:B^ZF!!DVU"L**GM>I>6>XEB\I*I!G_Q#2^'?
M(0'7)K8?-Z$>!L1 H$\,1IAJ/1KR'PFGIH3J5QGY'8$3EB9V2E;L<%'820?R
M9-LUN8FVO)XU*P8KKA&4OV!6V7J1\_NFK(3!/6&_NMY4944G9W8CFOV-7S9@
M=5GN^7\F:EO- Q30B,*"=VV@'/KQ T^ [/.W8Z@/6]1O5S.).)=']=6F\@@)
M3GD,U_#*,K+8KVFKCM^Z1<LQ^L1Y1J&K=\U$3<E<$ 7U8SBC?3[^C'-63(2B
M7"2K-$]9"09VCC">/*3W,=0O*!%Q;K\"Q1%Z%#BX;44[2,+8DMX0$#.YSBG@
M.R.LG \HY-O]U$G0)TAX#_L^";ISC//VA*X<Z0U)TJ\>*L5>5F,AO['),%7(
M4MP4-V#'^ -ACP5RPF&VB*>C"QNSO>P!&Q&+L,O*[TF2+M.XKH]_E<;\0F+S
MELY0(HSVQY T&&4B?MZG446C_QZ+.SXA+]'4:/@-_SX>M@M<(T*S9-;\Q9D^
MZZL>NI+QGM6\MR]HA7AE1MONB)G</5>JHDNH C^QLLK/6*1/W! J]ZWX[]1$
MJOLYM%Z5(AGWN7D]'$@ .4("!/I4_S_TBEU[3(BIH/VJ['E4L$NJY0TN^#I?
M35,5OP(JZ$3OSI]TJ<FSDCMB5VIV6JDJ?P(4JINZ6_SR(2A>L]*AQ?I::H1#
MUM120VBK*)0K>5BMG57?23YR%!EZ%HW+&EGBTO-^%#F7(-*.,YBHA 49-CLO
M8=SC8C7D P?^;/#B!>O&BW_JT8,^;0'#"O =S;,<_L'"K+E[G;Y*5Q@]X.HS
MQCF_R)%$%2];P'[N7HQF6_?L11O\LDY%^:9P+W3L*#*9$J*A;2V29Y;$\8%4
MU(*%V*AQ,S)I7MOV:  "^1YBG3ITO)BO#B#]9\^<<@MYXDT 0@)14W.3380]
M4,RLYLJS<500U1+(A036G02J70F$C ! UDB,!R!P:N7NO1S5M,KAKVRE5.[V
M[NW0KQ#G9?-(,91(>"R]<$QLONOQ<$G*$@CW_PRNLB.Z\76>U]"#G.3!L4(B
M3B6@SBK^[ TNF9*"7]V\*6HSX6LT49NXEU@D45G%KX":/-&[A_=':A?(E^]'
M33EKTLM]^SK-ZU]_$^H5$J4!($"I>C_3:<JHJ6J@RB?PLQMIUQ[.:UBQO_DJ
MGI+<"428,ZJ1)_;MI=.U\I<NZN4)"EZKYO5 -"6Y9G=:HS,JJO7UAD1M6ESF
M[NHJ7:453D:>A92T 96)V>O+N?^ZNT(UP:; L'ZY%V/,QBOT/AN?GU)J!RE=
MMB.ZD%A'^191:E&>_D;_R-^NX!N 6?29IX L-BS'-4NC$ 5>9)I#E$3K.3><
MS0E/)*,"+,]YX5>6;*?^U+KV]] ,<54ZSI/$>T#^%Q)0V"X:GM7CZ?K#0HQE
M'7C3Z*:^]WQ#AZMB5S&:J\^J^T>3'=C:2I(2<JV[%^D+NU,THRHDTS(?VUQ2
M%*3OFKQU,2&U!*.IYN JO</=NE8Q01=1PK,+3B<E373%YU>Q%G%<;'!"E7Z)
MRY+&5%%V@?'$6[5J'P&5;+QS7UN@XR@@&Z.V^8(D=_=HHR4.M&^JJ#T$)CK?
M>ZPDQC@I+RB'=U&&KY<7FR)/*QK0T*F#3HWL)]GI@-['X!U7%2+N-UX%"L14
M 944Q\RJRFB.!3$3L%\E%>]1"QOJ%2,<]_%J'P&5<KQS7SY^' 7$Q]OF"^#C
MPY5-5]08 A.7]SWDJDC9A?SA9Y<ECS'+2\F8=PC?<082]K 172-#[8O=_(<>
MCI#59RP,&;$_#H$W1.@/I_3?J7AV?$D*5LRB;/;:57=%U'JQM34R3BW4*T4H
MYIAFLF>B.")C&R<Z8IY#S251@H7:'%V7T_%(GS';\BE'3P@->K):W6B48JB2
M1$VE(:[I+3#$D<UMW\9D("?K_VB,SFL(:P;/,VUVZ36T\71:*H]H0E9:L3):
MQE%-^!/*@;O%'W!UO:1SF#PK:>H+>Q?*FYY]K81'($"6P58Y E3)W[T:GTV6
M^?=W^?U 9<;ONP]+S<Y%N?<DQU7Z&Y^P9.=)RNT-KM(-]NL\**^OJO6):QRP
M.^<&F.92<[7J@0AW0VU<88BVW/S.$+W]*#J!'68O+!Y8,E LVS[5_1PX=ZB2
M<6U/5Y>+D\NKR_O+\SNT^'"&[NZO3__CK]=79^>W=[__W9_>O?WQ+^C\/S]>
MWO\]B"?6'@UB*F+/I[A\ 2X[K=WY(_14EG?B[?15(9O$+D[P6SP!$U_V!I:,
M2\&T8!R_ZC=QSU?:"%0 ;K\S/X7>]JGJUS@SQPTYVV\OLP=%;EZ%K>4C:*4U
MJ2(3-5F%WZ9O?E=GO._4I\Z3$YSC95J5PQM8IZ14SG"T2,KBAK\I)"\9O_4>
M:MRC/9O3 &MC.G%D8'>@3)?&E-QG5G15:;:;;@U:%DM[]5-P1DI>?TELD1/0
MY>":/+(Q-]IDQGB2+%K6YC%=*E@"T92CYSR^NC[J/5G$=%57X)N"))N8OX@\
MMK92_@Z:O3?5OZ\5V200R&+-)G<FSV]QZN)9N+FE)2KK%P&+U7#._+BFD/.J
M(7J+8YP^,P-?K,AF>.)4_ 0R>TYT[64*G<"@/?58YPDPF=884%L?O$.!YL*6
M\;2ZJ9EL*X$7+:8 DZJJE1"(/*T:O?S"\U@[<_/V<Y2_I_K-Y6?](R([X&%:
M?IDO2;$2YUQL<HM25LYX7^.#:[GD<O.TY SUN;V:1:V& DZSE(NJ_76].JV7
MH^=M_<?K)4]VNZB3W89,P'+7$*NQ!,'+Y&D)J[9Q!I,18#+NJ/.%7U45Z<.F
MPBCN)UZ^'@E /1J_%%I%+VR:[@%&:?<7+#"C!P&Z5[F526Y'7@%\GVW70%R.
MI*&'?9]FN*Q(CALG'KVDJ\U@J>:)IA /*.G2BT>3T-:V3VL\ #Q.2[N-@H)S
M81SMKUJ>ZN@'K026 )Y@2N6)CO0";YTMGJ,T8^L.ZD?8A<@['&\*GC]QAA]D
MQTK 7FQMJXU3"[;)-@[+RI:;-<Y--N!NZ.^?HA+S,DMI_DQUG*.<QYZ;HBJ.
M[<#I2-G[#?;A<B<?L-16%3Z!WU:7=NWACOK MN\1RG&P*^G38B80V7F^="(R
M/.N2N!*=&FX$O1BRTYFO7&*EJMIN !L\UA&R%KADT(F:8$SK-=(F:1QE]T4:
M913YCR-E&\>;@JHW#G?I_%I2319QNH@1AN]G6N/!ZI9F1=  ER%*-DYH#=$1
MHZ&R?^!BBK++O*S2:E/AZ^4BRW#QN.6W%)<XIG_?E&=IB5D8)C<%HXX@A@(B
MZ-J,&E"H1<632P2N^OIK@PPUT."&YDD&QBMJD%@"6*:9$A-[HV*:DTTJ=KTX
MRO:W!7J'?T-&K/,=*'-;H7\_R=P*0/2SI)UP!TGY;H"@@^VY_OG\3!@TSPQO
MV3W8N>N?U".15,N" E*6*;^[LV5^:+EAE;@0"R6[(_X0N>4ZUD? 8V+H6^Z>
M2%$MHXQ&)&__((\'1II!/,= =^ZK6=0D$:,)GZ2M0+<=";/RY9RM-*<.ABH.
M*AN8(9X>'5$6HBK&F6R/_5Q0[Z*[0;;SD>TM,MZYMZWJ412@G6G+?,'JHW((
M1[QFC7CO\[S;"%1@S?=6X*Y"J6P&#DC3>\7AS6J3L4.",S:YQ^)PFOZ<X?K6
MQV)%?4!]&5RW KOM[N%5C*W \%COV I>8&5DW[(R.:RZPF6)H@XS2GJ@N<^(
M>FA#E5BV:P3$]6AY+@@7T2"ZWE26GW-)6D$+N>WVYLNP]\A"[-,8.?AR?6'P
M$*4YZE?V'J5,78FB3&PG>-%%B&J"UVY3*PE>HLLP"5Z"MGEJ%)0'.PE>H;EP
MD> EL,PAP6M/Y:4)7D/2\SM9WE-JU\M%45 Q\XN:(V6N1]L")\[!/ET;-B/*
M#R\ZLCRT^T#RXZCWNWOZ8QFQG?X\:+'J<<$3+6D:3@3G+[B(TQ+?%&F,;QF9
M-V_E&XC3K2'3@;Q7UXK34$:<-.*TT9NW\'U%FZRXV%Y<ID7)$NMKMKE>!7"P
M"GI$-"5JFF!",MH=$:GU[2WW19*DXMQP=P,?)X.9)\ ^0"DIFK2\Q%:ZH/23
M6)QS#8C&=D!U12M0!VO_H&^6G!M'</&.'-H*%RCJY+!W HB3$)D^4"LE5H8B
M<*VI:SHG4.#YXQ4IRYW:_V=D18/9-)8$BP8]V:H4-4W1>2H1KM 2)Q1&Q@/,
MDEH+C3P;7+QZ<: -!9/Q&:OZI"MTXWATC5F%\NZ@G#W5M> $+T@Q_$[X*<EY
M5<_!*[UV>H3%M2:4O<S89A !X;%?B<"NZW*(_9H9#"02*!'5?K3S2DP/*7H]
MDC&>[7$CIUXR#W\O,.KD5$A?TVF !UE[6/$'Q,' V5_+_Z"UEO_!R5K^AY!K
M^1^LKN7!K+A9RR^KIUFNY??U:&0M/RA1^W;PO98=?._$#KX/:0??6[4#,"M.
M[(!^-E-#V%>D$4,8%*E]0QC)#IUN;<D0/.6*#AN"0=*H359<&$+UE!;)+.U
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MSE@:!/"IS#Y7+B:T,=X#F(FRFA&0E#U7M9IX^5JR<E']#%KY:J)[7[=.IG"
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MCN'YFL)<\P&9!><G6^@K2?7[(7'_G1'\PGX.$Y%Z,RH2:C0#3.]4.:)LD='
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M6YIC7GV:7Y2D*T->W%64?2U8(>J"IPA$Q;;?:+$BF[$@ST*G\&#0@+C'H-$
M)3"X]"H76!#*(*(^>;Z6.T(-3+2#<[>EBFS<1:XV-)ZX&:[0T]+HUL14<VM3
MDY]-B.')*>2NPZ2 1R>H\/L+O.+8(D^NJ ID_[XITC))8Z;JHY&PXE<F=>+D
MO3M/^&+D^?X6!X#Z",+&SZIBWZ\HIRI+ST>^FR)/JTW!X%VD+^RG\37]] ?0
MHUUIQ\Z/<QO*7-\:VH&38:;%3/1EYSGRIHZVK-+XE,W7Q794K4;;0N/DH3Y=
M*U-#=']^#*E,X\(E6A(+5"WU>GF1YE$>IU%V0\J4QX'CM]]U/C6MI3I"PLM$
MR>\"DB5J4: &!OK4  E<=55E%(:*L"J+-E02OZ3 V"W)L@M2L$>'-9/ZH1T:
M)_GK$O:9]"\M9X<8/%3CF]\] /!@#MX+,!NA4!9RL6$!R?LT3U>;U2U+S\CJ
M-[E+BKJM_L!/)71OP%CHV]AN###X-"$!$]4XD0#:/&5?\H27KE*> #L_>[(Q
MWH.F96T0_5K9*>%OV?/5Y&5^4Y!'J@U3CX%/?P*TB;&N7:MZGS8KP--0#_T2
MN(*P"42"GKTY>ZOGA#UR=TI6:YR78]>$QQM#_>U@I[Y.,X:I0TXI;/$!.'W@
MKRX=/S#:*.X11_B%_1PF)69"68B>Y/Q:Q7]NHH*.0[9MURB7.9U'5QS85!"C
M]S'0:M2(N+:B%D5OA=K#$?ZM8\VQ(&8"#A6(CV/5"[P!?1D'VAHT?0;6T]H]
MLR :,G:#03-X0)Q=UV#/>;V/JOI?[96FZ>I%EKJT>[5#B;3S"Q_MG0B*#]WM
M/9W+(*(.(^K=<+=0Y\B[:&P6/1J_3)(PP:TZP2V9X)X9#[.Z5J*G_=.730#C
MYLE9+);4E5WG^/ZI()O'I_O/Y.\X*CJ()EY#M6^7[F,*@VL_(I"P@K@,""(Y
M1EL* %4"#ZH^$_X+_6*&X23@^,+9OH_H)'<@M-?A/Y3M0->1Z VMQ7J),4Z?
M&3[CDHG:'9E6350FZ+=P8@O+1^U$AS*P%DD4C;=@OK/8E\^LZB?JZ_!0"47@
MH,SDINK'$B\WV56ZW \8 %_:OJG:4?"U;ZH !;*)ZH1#P([JQ(5<@09-<^G[
M.NZ JJE<QY5)-UA2$'M.X"(CGZ>>PE#YQ#P)Z*!KK\D_C#KBY&>4]".7]G"R
MSX0(O?OX&..$ST-7:<R.2"XP+L4,)7VE4_$KN&\?Z]VC7Q^# ?3I=CF#^7..
M0<16-0K$8" UUMPY<B6=(D!Q&BZ(;IZBV_>+#Z22)(^/-X(L9 XZ<UYZ@Q-$
MG"*"/O5F ;7QCD/-2,Y !%@NR+6 J DI6*S!3\_9K7GJ5EA$-/GTJM:WYM&'
MG(;7,*0/XW\A 61& 8G"2 Q')JKB]:N?(U6=1+ESEBQQ4+8,^#501Q6I.#_'
M:H@A1BW,4VR:\B:&0C2<UO_]YO:6;*.LVMYM'JZN3N5S^WA+R 0_W*-K':%4
M44T64;J($H8_[&J+!>,I?X"K #/_A(X0#:G-QL?&=&0V&9TCDI\+4I8L/S_*
MF"VRUPY/\)(4[*JQOO?5Z]>^7U:C[VNQ:0P4LASU*9V?A'1R_,@ZU5NR<@BH
MPX 8B$ /\MK3:+69#S(0\_<=/T=I[L)W#/;KT7?LT'?M.P[,@E%_/58Q/%:&
M5C$R 'ZM0G*/[0S'!;]?<XO+3<;..]GFU4V1DN(&T_^RMLTE4%D5,)M= VW#
M!@1?4ZL-K)#9-8R, #O"BR01U-@KWVL&!*TY$E1%+VBM)@-'CL6JKA.7@^.[
MY-M#=<GO4;%E4U/7^I9Z1+Z?DU"T,5M//<J.Z/4[ )=R4R7DKVR;*B)8B39W
M_(+*L3U4J,-SU!:U1PS2$1*@D"K/SDJO:6LC,1>Y7Y/EV_TWT99%-./UM4=:
M HUPH$=?UC9 &F)65C@ V,\'DA^SJ6)#OQ0G2F@M4 0QE#'5(!K2FD4P?)D/
MS;8U7M-P&-BYW8!8$T3@D%@3K<6@V+F<3,/B6$"9?6 ,U?KIT-AHB Q/:7H9
MLL]X\5A@?F IB%XO8U8Y]?",&O EY!1'C8)KR]: HGW(XXI#@$WN0$$M%B3
M\!3!N7%I?+05[_ <M3RO6YX;< %.O#3MBQ@(>Q8ABUX,XB:H"!PE6)SV]3D1
M2D^7=46EYSE.(OK/F-H/:/5A&?]YKGD"IHK>;["A$3V$-&4:L&!*ZVFT9-1P
M(Z#A[G;FVEX;:KQHX&F!:=B*3J.BV"Z;DH$ART-)!$O4I.574Z@ A?SZXAMY
MCV6R/5!_I/VZ5B6I!H5[F&5:QD1;<#/0J@_1:ORU1\6O;&I8UWL@/3M"#$+8
MEQ94Y3ZE=3)A^M6]\ZC(Z5*]I*$UKRUVEF:;2GJO9Z(U4-<DO?H*8R7D(6&@
M-4X@!SF"%LIQA;[.2%E^@U+Q3 F-*5')X*"OTQPE;&E5E-UOOPEB1E.J1#2E
MZOOYFXK*/GW(\*(L<55>I'E:X2MVJ^B&9&F\E1B0\G?@!W$F^G?_,DX#  D$
M1TA@..8@CI" @3[5_P]=$4Q]0 A8RMY5DQ]OWD2IS(T/-8$K7-N5+X?=IPGQ
MTF:8 :ZY/5*?1NQ.S0]'G*B(Q-[./,E[=2WD]RC4OC#<B1_HV7UQYA[UG2(O
MX-L5MADRWHJ>*,W""SP5.%T];(J2%[$IFJT)5C4BP<\X([S* OVPK$+<S534
MOH%]ZLD1\)QUG5=IP@(E.BMUB;'G+W&V27 BRLJLUALQUM?+_1AK].E/JWU#
MLZ]M8/!V>\,&6- -CC!2@IRF]Y#VBVLV6)M26"U:=K#5X&7G>X@C/@KY0*A=
MNR!.A]&O-_H;3A^?Z)IM\8R+Z!%_V##W>+VL5W(<9'F]J4H:5[-GMR5^!]@+
MT,-H4G/M2QHX*!)XQ.*]1*2#P-?WXM=A%O70 2*6I!YJI:60LSG>V'CUY3-S
MLUW.A$QTG)#GX-K&/-U15OREH'%?A6^R*&Y*)> \)07WU3CAV99#:QV=[T E
M8A3Z]Y)YI )$OY2,$^Y )9,X$-0BX45 .!94@T%S8M%XG;>N&5[W&2X%PV7-
M<+#J.CHV1<!R-O089WB)J1]*=A*=;ND".-]@^=Z(^E<0;S'=NVM?T2! NWE\
M-0;X1HD+SBQLE@BNDH;I39[09<Q>.E]1T,^Y3H8P)@V%(T!9!WC$BUI[++OW
M=MC Y+$NWI'7![HX1?"C7$"\D(>X^(&D EI7]; .QWG_G:T!85CR^C<%239Q
MQ2ZMC^R$3[<V\?*'O7KS[C5I_I"*P?:W34Y@WKSEJ/'E!>9%!\1%:<$D>] @
MI.L>T9Y]ESTE2,\[V'%<;'!RE48/:<8WO,97V)/MH3O-LGZ=5VL3A)NG"4&)
MU1;!5Z2*,CTG?\\^09$6'Z[V9B>U@VA+S7.JUFJ=D2VFL13W,<IVH?P=-'UK
MJG]OB5Q30$ I7?:Y ]UKZCU5RLY*'Y0N6[C*W5+6* (69-@TR).H3.-%GNBE
M0TJ^LI06N=>[:ZOBY,2Y?"^SD"46\M3!F*Q6)#?(*_3$-,#8)CB??2JE3 U'
M4BI'Q3R#;/C1= 2%+ZS>L_":.C " 6)?5CD"V)8TL3_@L;V*_DS>(0E^Q$YC
M5@9!K8+,>&/X0FF@4P^K)$XUZ&GDA#R)GI!\'V.S6P)4J\_%^JR^DBD]QQYM
M#3[('NS57T;Q('E8<K$E3D!YQOR^!RL^4J^U QW-CZL(T926X:9K??9P*ZX=
M\T1-45R;QCOOTPR7%<GQ;J/?</(!#]8+,>X,LF4+)NKE;!^,3GO#UZ,< -;7
MG%+VX+4EYRE U")$>RU_8_=B9BX/:Z>=14\Z12T=MM1:M=+9:\FE0Q=@ ;;0
MS8V=V!TISP4)<<7>HKLIR'.:X.1D^['$R65^D>91'M/5XR*NTF=1;WG\%2!X
M1]!RAMH$77O*EC2*6MI_#E,A$#X8Q)Z$O8>XO#994[[W,K^E)E>D<843QH8\
MUE7Z#![TCG;O,?H=Q0$,@VWQ9O(RQ.D3RYY!:<YN&M7D43S)D[O 6$V?"%20
M]K/22%Z'YD*4Y65^O<;L#]3&^>57.H/U]O+'\AC,>[64U:9)W4L4;0[31E:<
M.\GL6O$]I%!UG6NQ<Z=0;:$;FGE;070R*H-YY ="37LD?]!H8(QW#V*<KMGE
M 9$7?$$*G#[F8M\NWIYAGCF</F..ERX;HVS(!QIT ]LQT";GO@H9A\0RQ9<"
M35TT-]Y2O6[P",WF@ #+80],&]MP]83%/6DFBX+M6C<)]"-B"9% 9J*RQ-:0
M."D,W-2 _27*-OMYP+J?V2L)O--]P'K .S@LE<DUY,UB)> &"9H1>\Y* #>%
M<M$S S:;\K_#AC1>^W=$Q#-(%=))$'*1%A2J5AHG;BW/QV-VSRNMDK:K0%,)
M/8'3>!1?LQEI"4_;"?6:S0!I8)I.D-=LSC:\Z 8[D*D8A%#Y."IOV$S*R#!V
M?!^]I*O-2F3V7"^["/46_W.3TA7J/;DY?%<>\BDDAE0DX26.5,2B'6PYXQ%@
M&366.D]-O"31P$$-'G;O9UZ<&H>6JYKOJ.6[6Z'3=6S']YKB"Q!AZIH:,9&X
MWRFT7C67=-%\4Y 8XZ1DI7[^BI-'?)D_X[+:.6B33*_ 7H!3KR8U7].R)BS(
ME.V<<TAABAH3+[SW=0.+E]+Z!G%D[+W'&AM2Y=_1M ]55&)I#'P_.K&?$2)*
MQ[*"N+P>KL2<E;\#/TTQT;_[?>*#-*K950U6'P0"EJQO=6QK5ZKJX=0'8 64
M=>SEA$)0GJ'&38J;Z,O0=Q8.\\#,0=]3NB//IL@;@C-M]CMT7R.MH8@8R9 /
MI(Q(DZB+R'.9%O8N,]_VS:*RO%[>551W1S1FLCVTB(NL7^?5HAD]7D:,40RI
M/M.B)=KR\JQ,*9UOEVD<Y55]^X9&@=POTAAP:I[3^QBJ9DI$7.M<#P7J8* &
M!_H4>A+4' MB)N @U_=ZL":2JJ<_,+O&-]"QIZM\NTK7$ ^C<@I2/KS<-RDZ
MOZK%TD07.<\6/?_GAL:%&5LCJX7Y6M\"%4Z)AO,)EU+GYQ[\AQZ.V2T%](:$
M&,EY#HJZF^\L8T!+?_6ZM*K6:J0#:GL'$+UVF] <YDE3@8R=7PMJ\V*O2%GV
MZQ/(%D[3'P"U7]ZQKSU_.0+(]KY-?@ [^2UYQ.@C#78<69R"XA!]Z?FU%G8N
M0#&=X9(N#_@)Z>B+JU/-@98BZ]:UG=1T48]PV)=5)^5+=(5FG/O/NF1'1H^/
M!;^X<KU<XH*%]P,5A'4^@>7TCW;MZ:[_* 9 RKYEGD#W]FL,J 6!&A0J!8I]
ML&7IUD'#:-0R2AI&UPR82.\0A=W8SMT1_75SY:C^18+7I$RIUF[KEV:.Q%_0
MFH)XBDK<)AW3OWSFY<LKD5"VR=,@-<Q539) !L_SC7R2)[7'P\E@X6B%EM [
M]8<]NG8Y'TC5SD[LX:,2-7/694XC<6X1BN6C75VF'Q$ST9!=R(.X4PKJD13I
M;]RYC&J5^H=6#NJ&"/@[N"O#1D,:LI8>XTT+T%*.K')\I/2!23YLN-AH% $X
M(S1<7-1FO-J*BBRS9"4F:M-;_V^*B-2,<#]3UF(T)+NM65\+Y?EZ[<VOD:>B
M%=J#[F>.].M\9[:Y_,N)]RXNPE^)MLJ-%:N3,ED1],1_%>.BBEC9EK3\E1I+
M69(XY4'@Y[1Z0K&H \#JNK#N^.U&9JGL'_\>K:.<TD);G(OW.-B=2-HQ^^/'
M;^^^K>]VA;@-J:*O1'O80F^:C>3EC#>VMF'F(R-G<+LL7%K.A&1'M\J")^3$
MU,@W&9U)FKN*.*E3MQ=L4YAG#5VO^9OQ[+ZO %V6FY7XW3W+;)Q,W'%"!)K@
M8Q6,\T2@&BW//V-XCQ\88%0C1@M1LENDIM6HCU"+&_6 HT\<>O #0D?:0/P,
M<7CS[#] 4E^@V(+-4+TSB^8V33246?61'36W<+9SMAR- 9RP$-U1F9<E]&W:
MJE6H=^S(0J8!S,-:]N:@UV8\&N.L84BZ@^<]TW6SVO!'H*[IFJQ@R O\1,'3
MA9HH"#^Z":W]/3P/5HV.\[38Z]-+M*BJ(GW85%RMV37SJ A^^J$_$L18O,9'
M^N)V]UXA,K[(OL'%&=\:&#[8U_@0=KRO0,#3(;\"$L"9N!/^0 ?^==6"&LK^
M=A1%@^;%)&S3[9[MM%&KBO(M2LN=8@WL6(OOKT6'50?%!APK?"0VRNIWR=GV
M65M9K$2/Y!GSDD/\#S=/T>W[!?I JD"E"G6,D\ 'R^],60,[?Q'[G4T)M-'9
M4>D;X(PXVK?S"OJUGC;4NTI^0>= -7D3D! -Y[K+G#I'EK*,2UP\#Q['2II
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M?*^RZ/L<S8LKP/'TNWO6I$/>TNDEW^ /5+;\WF8EV3>;; _<,9/VZVNO3 H
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MQW)E5<ALI8K9F:[ (G,I],QT<P<F]?M8K629*TA)79?;@;V*'(+1LCQFJ6-
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M.<2 ,#U7E&H;BH%.OM:ZKP7:AHK&6J!V0N)K\OFD'OMJ\EF.B_#&%64MN +
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MQ(# +@]7-I&<70R3WUVQKGL/N/> :SQE828'5XY7I=-$2;IUQ7WI'5?><36
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MK;=&$DSH:9G@^!Y%:9CGE:1964;B_R[KU7*@'_ XZ_@8$PSC-2+%AO4@+*B
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M8%Z2+*$')ZH$?K0-G.OFEX ^;D2G@QI)O3P*7&4+2@/(BJO&D!5%&SJ7:[#
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M0U^M P6JMTE*38$14PX,G2QBG2%2CH6T#B(='8GA,N;T!?(Z.>.92N)478/
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MUG^C$XL+>C[VP$7]9?HA.3FHY%^O%DJ^-"+*?L%SD=#X#OU!D8TE8I;%]ZP
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M!U>E1DUIN)UF+7KZK=[#'>/6@@BWI0]W4ED+CH(1#8S.] -%1_.,CA\P\4N
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M"G0+2E%^[HC!*1UIZQ6D4I5@/3LNP3HC),P6J+[:]D.:%K(SJL7'34GEW^C
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M0^\(?D[H^CG;?*$'T.%WB2@O]9$IZ3P_X*L, +?"I$C^7:W97>N5;%&=GSP
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MTH<Q2/I!B:0?QB#IHQ))'\<@Z4<EDGX<@Z2?E$CZ:;RN-:,<&<"J7J,=7MZ
MI\9":TA)]==\5A9+3)A#_ N]#L@#^W"WU7=CH4[YV>9T>8LL:<.]:5*PG;(B
M7C/#O6GBL'VNCI3;^>7^\*C'#[ "5=YNU*4P!(NW94'/\RRFNH<!@$_?[@S
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M,C Q-3$R,S$N>&UL4$L! A0#%     @ MH):2!QJTJVJ&   ]18! !$
M         ( !*50! &)C<G@M,C Q-3$R,S$N>'-D4$L! A0#%     @ MH):
M2 ;LPI>("P  G9X  !4              ( ! FT! &)C<G@M,C Q-3$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( +:"6DB.Z4)/0EP  ,%F!P 5
M  "  ;UX 0!B8W)X+3(P,34Q,C,Q7V1E9BYX;6Q02P$"% ,4    " "V@EI(
M*"X,:OUY   J 0< %0              @ $RU0$ 8F-R>"TR,#$U,3(S,5]L
M86(N>&UL4$L! A0#%     @ MH):2(IZ&$H070  7[8' !4
M ( !8D\" &)C<G@M,C Q-3$R,S%?<')E+GAM;%!+!08     !@ & (H!  "E
%K (    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
